Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT04425538	A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).		Recruiting	No Results Available	COVID-19	Drug: Infliximab	Time to improvement in oxygenation|28-day mortality|Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|Qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|Incidence and duration of mechanical ventilation|Incidence and duration of vasopressor support|Incidence and duration of extracorporeal membrane oxygenation|Duration of fever|Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|Duration of hospitalization|Secondary infections	Tufts Medical Center|National Institutes of Health (NIH)	All	18 Years and older   (Adult, Older Adult)	Phase 2	17	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000564	June 1, 2020	September 2020	December 2020	June 11, 2020		June 11, 2020	Tufts Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04425538
2	NCT04333550	Application of Desferal to Treat COVID-19		Recruiting	No Results Available	COVID-19	Drug: Deferoxamine	Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay	Kermanshah University of Medical Sciences	All	3 Years to 99 Years   (Child, Adult, Older Adult)	Phase 1|Phase 2	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	1398.1224	April 2020	September 2020	March 2021	April 3, 2020		May 4, 2020	Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04333550
3	NCT04432987	Dornase Alpha for the Treatment of COVID-19		Recruiting	No Results Available	COVID-19	Drug: Pulmozyme	Response|Survival	Acibadem University|The Scientific and Technological Research Council of Turkey	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8820	May 25, 2020	August 25, 2020	September 25, 2020	June 16, 2020		June 16, 2020	Acıbadem Altunizade Hospital, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04432987
4	NCT04445272	Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19	Drug: Tocilizumab	To calulate the time of intubation|To calculate the time with oxygen therapy|To calculate the time with Non-invasive mechanical ventilation|To evaluate mortality rate|To calculate respiratory function parameters|To evaluate radiological lung extension|To evaluate radiological evolution|To describe the duration of hospitalization and ICU use|To evaluate the requirement of additional organ support|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers|To calculate the number of adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To assess time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory|To calculate the number of serious adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To calculate the number of adverse events of special interest in patients with COVID-19 pneumonia treated with Tocilizumab|To evaluate respiratory function	Fundacion SEIMC-GESIDA|Roche Pharma AG|Dynamic Science S.L.	All	18 Years and older   (Adult, Older Adult)	Phase 2	500	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BREATH-19 (FSG011-20)	May 22, 2020	August 22, 2020	August 22, 2020	June 24, 2020		June 24, 2020	Hospital Universitario de Cabueñes, Gijón, Asturias, Spain|Hospital Universitario Central Asturias, Oviedo, Asturias, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Sant Joan de Déu de Manresa, Manresa, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Hospital Universitario Marqués Valdecilla, Santander, Cantabria, Spain|Hospital Público General del Tomelloso, Tomelloso, Ciudad Real, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera, Cádiz, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra Señora del Prado, Talavera De La Reina, Toledo, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Clínic i Provincial Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital San Pedro Alcántara, Cáceres, Spain|Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitario Clínico San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Poliectenic La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT04445272
5	NCT04361422	Isotretinoin in Treatment of COVID-19	Randomized	Not yet recruiting	No Results Available	COVID-19	Drug: Isotretinoin Only Product in Oral Dose Form	Clinical clearance	Tanta University	All	18 Years to 40 Years   (Adult)	Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9469305c	December 1, 2020	August 2021	December 2021	April 24, 2020		September 23, 2020			https://ClinicalTrials.gov/show/NCT04361422
6	NCT04388683	Inhaled Nitric Oxide for Preventing Progression in COVID-19	NO-COVID-19	Recruiting	No Results Available	COVID-19	Drug: Nitric Oxide	Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with "Do Not Resuscitate" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level	Tufts Medical Center|Bellerophon	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	42	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000554	May 12, 2020	April 30, 2021	July 31, 2021	May 14, 2020		May 18, 2020	Tufts Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04388683
7	NCT04421534	Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Lactoferrin	Time to clinical improvement|Rate of virological cure	Cairo University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2|Phase 3	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CUKA-001	June 2020	September 2020	November 2020	June 9, 2020		June 9, 2020			https://ClinicalTrials.gov/show/NCT04421534
8	NCT04452669	VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation	VPCOVID	Not yet recruiting	No Results Available	COVID-19	Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)	Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes	Aerogen Pharma Limited|Ohio State University	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	APC-VPCOV-CLN-001	August 15, 2020	December 1, 2020	February 1, 2021	June 30, 2020		July 31, 2020	Ohio State University, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT04452669
9	NCT04291053	The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Huaier Granule	Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function	Tongji Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	550	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TJ-IRB20200205	April 1, 2020	August 1, 2020	September 1, 2020	March 2, 2020		March 17, 2020			https://ClinicalTrials.gov/show/NCT04291053
10	NCT04534673	Pegylated Interferon Lambda for Treatment of COVID-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Lambda 180 mcg S.C	Viral shedding in days since initial diagnosis|Rate of adverse events and severe adverse events|Time to clinical recovery|Rate of non-invasive or mechanical ventilation|Length of hospital stay|All-cause mortality|Undetectable COVID-19 virus levels	Soroka University Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0129-20-SOR|SCRC200006	August 5, 2020	December 31, 2021	December 31, 2021	September 1, 2020		September 1, 2020	Soroka UMC, Be'er Sheva, Israel		https://ClinicalTrials.gov/show/NCT04534673
11	NCT04363346	Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia		Recruiting	No Results Available	COVID-19	Drug: FT516	Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge	Masonic Cancer Center, University of Minnesota	All	18 Years to 76 Years   (Adult, Older Adult)	Phase 1	12	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IDIM-2020-28708|2020LS083	May 14, 2020	January 2022	January 2022	April 27, 2020		May 18, 2020	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04363346
12	NCT04324489	DAS181 for Severe COVID-19: Compassionate Use		Completed	No Results Available	COVID-19	Drug: DAS181	Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death	Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	4	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DAS181-SARS-CoV-2	March 6, 2020	April 16, 2020	April 30, 2020	March 27, 2020		May 5, 2020	Renmin Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04324489
13	NCT04335123	Study of Open Label Losartan in COVID-19		Recruiting	No Results Available	COVID-19	Drug: Losartan	Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg	University of Kansas Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00145514	March 25, 2020	September 2020	October 2020	April 6, 2020		April 24, 2020	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT04335123
14	NCT04464395	Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: CPI-006	Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19|Immunoglobulin Anti-SARS CoV-2 Levels|Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests|Duration of symptoms|Time to discharge|Rate of medical procedures	Corvus Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	30	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CPI-006-002	July 1, 2020	March 31, 2021	August 31, 2021	July 9, 2020		July 20, 2020	Icahn School of Medicine at Mount Sinai, New York, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04464395
15	NCT04527133	An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: Aprotinin	Time to elimination of SARS-CoV-2 virus|Time to CRP normalization|Time to D-dimer normalization|Time to body temperature normalization|Change in absolute neutrophil count (ANC)|Change in white blood cells (WBC)|Change of CRP|Change of D-dimer|Change in fibrinogen|Change of Quick's value|Change of international normalized ratio (INR)|Changes of lung injury on CT scan|Frequency of clinical status improvement by 2 scores in accordance with the WHO-OSCI or discharge from the hospital|Frequency of deterioration of the patients' status|Frequency of AEs and SAEs	Aviron LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-APR-01	June 11, 2020	August 11, 2020	August 31, 2020	August 26, 2020		August 26, 2020	Regional State Budgetary Healthcare Institution "Clinical Hospital №1", Smolensk, Russian Federation		https://ClinicalTrials.gov/show/NCT04527133
16	NCT04329611	ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease		Terminated	No Results Available	COVID-19	Drug: Hydroxychloroquine	Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)	Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of Alberta	All	18 Years and older   (Adult, Older Adult)	Phase 3	148	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	ABCOV-01 version 1.5	April 13, 2020	July 20, 2020	July 20, 2020	April 1, 2020		July 31, 2020	University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT04329611
17	NCT04306497	TCM Differentiation and Treatment Protocol of COVID-19	TDATPOC	Completed	No Results Available	COVID-19	Drug: TCM prescriptions	The relief of main symptoms/ disappearance rate of time|Chest CT absorption|Evaluation standard of comprehensive curative effect|Virus antigen negative conversion rate|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score	Jiangsu Famous Medical Technology Co., Ltd.	All	18 Years to 80 Years   (Adult, Older Adult)		340	Industry	Observational	Observational Model: Cohort|Time Perspective: Other	JSZYJ202001	January 22, 2020	April 30, 2020	May 30, 2020	March 13, 2020		June 4, 2020	Huai'an fourth people's Hospital, Huaian, Jiangsu, China		https://ClinicalTrials.gov/show/NCT04306497
18	NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients		Recruiting	No Results Available	COVID-19	Drug: Baricitinib (janus kinase inhibitor)	Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events	Lisa Barrett|Nova Scotia Health Authority|Dalhousie University	All	18 Years and older   (Adult, Older Adult)	Phase 2	800	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAIL-004	April 17, 2020	February 2022	March 2022	March 26, 2020		July 24, 2020	Nova Scotia Health Authority, Halifax, Nova Scotia, Canada		https://ClinicalTrials.gov/show/NCT04321993
19	NCT04323332	Traditional Chinese Medicine for Severe COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Traditional Chinese Medicine Prescription	Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events	Xiyuan Hospital of China Academy of Chinese Medical Sciences	All	up to 85 Years   (Child, Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020XLA015-1	March 2020	March 2020	April 2020	March 26, 2020		March 26, 2020	Hao Li, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04323332
20	NCT04375202	Colchicine in COVID-19: a Pilot Study	COLVID-19	Recruiting	No Results Available	COVID-19	Drug: Colchicine 1 MG Oral Tablet	Rate of entering the critical stage|Trend of White blood cell count|Change of the "Sequential Organ failure Assessment" (SOFA)|Rate of biochemical criterion (CK, ALT, ferritin) recovery|Rate of disease remission|Toxicity of Colchicine	University Of Perugia	All	18 Years and older   (Adult, Older Adult)	Phase 2	308	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001475-33	April 18, 2020	June 30, 2020	October 31, 2020	May 5, 2020		May 5, 2020	Associazione Italiana Pneumologi Ospedalieri, Milan, Italy|Società Italiana di Reumatologia, Milan, Italy		https://ClinicalTrials.gov/show/NCT04375202
21	NCT04375046	Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2	Bacterial ACE2	Not yet recruiting	No Results Available	COVID-19	Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)	Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events	Kafrelsheikh University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	proposed by Mahmoud kazazzaz	September 2020	September 2020	October 2020	May 5, 2020		September 30, 2020			https://ClinicalTrials.gov/show/NCT04375046
22	NCT04364022	Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland	COPEP	Recruiting	No Results Available	Prevention of COVID-19	Drug: Lopinavir/ritonavir	21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|Severity of clinical COVID-19 on a 7-point ordinal scale	Calmy Alexandra|University Hospital, Geneva	All	16 Years and older   (Child, Adult, Older Adult)	Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CCER 2020-00864	April 23, 2020	March 2021	March 2021	April 27, 2020		September 2, 2020	Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland		https://ClinicalTrials.gov/show/NCT04364022
23	NCT04287686	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19		Withdrawn	No Results Available	COVID-19	Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)	Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events	The First Affiliated Hospital of Guangzhou Medical University	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIRH-APN01	February 2020	April 2020	April 2020	February 27, 2020		March 17, 2020	GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04287686
24	NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	TOCIVID-19	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Tocilizumab Injection	One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms	National Cancer Institute, Naples	All	Child, Adult, Older Adult	Phase 2	400	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOCIVID-19|2020-001110-38	March 19, 2020	December 19, 2020	December 19, 2022	March 20, 2020		July 13, 2020	Azienda Ospedaliera "SS. Antonio e Biagio e C. Arrigo" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy		https://ClinicalTrials.gov/show/NCT04317092
25	NCT04443270	Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients		Not yet recruiting	No Results Available	COVID-19	Drug: Chloroquine phosphate	Negative Polymerase Chain Reaction assay at day 0|Polymerase Chain Reaction assay at day 60|Clinical improvement related to COVID-19|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic Use|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic|COVID-19 symptomatic onset rate	CMN "20 de Noviembre"	All	18 Years to 59 Years   (Adult)	Phase 1	200	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	01	July 27, 2020	October 31, 2020	January 31, 2021	June 23, 2020		July 14, 2020	Centro Médico Nacional "20 de Noviembre", Mexico City, Benito Juárez, Mexico		https://ClinicalTrials.gov/show/NCT04443270
26	NCT04348071	Safety and Efficacy of Ruxolitinib for COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Ruxolitinib	Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)	University of Colorado, Denver	All	18 Years to 89 Years   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-0869	November 2020	August 2021	October 2021	April 15, 2020		August 25, 2020			https://ClinicalTrials.gov/show/NCT04348071
27	NCT04340232	Safety and Efficacy of Baricitinib for COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Baricitinib	Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)	University of Colorado, Denver	All	18 Years to 89 Years   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-0738	November 2020	August 2021	October 2021	April 9, 2020		August 25, 2020	University of Colorado, Denver, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT04340232
28	NCT04428008	Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients	Ta1	Not yet recruiting	No Results Available	COVID-19	Drug: Thymalfasin	Reduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets (CD4, CD8)|Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parameters	Inova Health System|Nephrology Associates of Northern Virginia, Inc.|Davita Clinical Research	All	60 Years and older   (Adult, Older Adult)	Phase 2	240	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ACW-1221958-1	September 2020	March 2021	August 2021	June 11, 2020		September 3, 2020			https://ClinicalTrials.gov/show/NCT04428008
29	NCT04497948	Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Acalabrutinib	Acalabrutinib and ACP-5862 plasma PK parameter: AUC12h|Acalabrutinib and ACP-5862 plasma PK parameter: AUClast|Acalabrutinib and ACP-5862 plasma PK parameter: Cmax|Type, frequency, severity, and relationship to study intervention of any treatment-emergent AEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study intervention|Proportion of participants alive and free of respiratory failure at Days 14 and 28|Percent change from baseline in CRP at Days 3, 5, 7, 14, 28|Time to improvement- clinical improvement of ≥ 2 points(from first dose date)on a 9-point category ordinal scale Or live discharge from the hospital Or considered fit for discharge(a score of 0,1,or2 on the ordinal scale)whichever comes first,by Day 28	AstraZeneca|Acerta Pharma B.V.	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D822FC00005	July 31, 2020	September 28, 2020	September 28, 2020	August 4, 2020		August 4, 2020	Research Site, Baltimore, Maryland, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04497948
30	NCT04355793	Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection		Available	No Results Available	COVID-19	Drug: Ruxolitinib		Incyte Corporation	All	12 Years and older   (Child, Adult, Older Adult)			Industry	Expanded Access:Treatment IND/Protocol		INCB 18424-MA-COVID-19-301				April 21, 2020		April 24, 2020			https://ClinicalTrials.gov/show/NCT04355793
31	NCT04330586	A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19		Recruiting	No Results Available	COVID-19	Drug: Ciclesonide Metered Dose Inhaler [Alvesco]	Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure	Korea University Guro Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	94	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KUMC-COVID-19	April 1, 2020	December 31, 2020	December 31, 2020	April 1, 2020		September 16, 2020	Korea University Guro Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04330586
32	NCT04380688	Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.	CALAVI US	Active, not recruiting	No Results Available	COVID-19	Drug: Acalabrutinib	Occurrence of Adverse Events and Serious Adverse Events|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Change from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (SpO2/FiO2)|Time to clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale|Time to SpO2 > 94% on room air|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862	AstraZeneca|Acerta Pharma B.V.	All	18 Years to 130 Years   (Adult, Older Adult)	Phase 2	61	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D822FC00003	June 13, 2020	November 19, 2020	November 19, 2020	May 8, 2020		September 18, 2020	Research Site, Anniston, Alabama, United States|Research Site, Escondido, California, United States|Research Site, Fullerton, California, United States|Research Site, Newport Beach, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States		https://ClinicalTrials.gov/show/NCT04380688
33	NCT04346199	Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.	CALAVI	Recruiting	No Results Available	COVID-19	Drug: Acalabrutinib	Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Chnage from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)	AstraZeneca|Acerta Pharma B.V.	All	18 Years to 130 Years   (Adult, Older Adult)	Phase 2	140	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D822FC00001	June 12, 2020	November 26, 2020	November 26, 2020	April 15, 2020		July 27, 2020	Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Bobigny, France|Research Site, Villejuif Cedex, France|Research Site, Frankfurt, Germany|Research Site, Gauting, Germany|Research Site, Hamburg, Germany|Research Site, Köln, Germany|Research Site, Muenchen, Germany|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Madrid, Spain|Research Site, Mérida, Spain|Research Site, Pozuelo de Alarcón, Spain|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04346199
34	NCT04390594	Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal	SEN-CoV-Fadj	Recruiting	No Results Available	COVID-19	Drug: Nafamostat Mesilate	SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation|Clinical status on the seven-category ordinal scale	Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal|Institut Pasteur Korea	All	18 Years and older   (Adult, Older Adult)	Phase 3	186	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-002	August 13, 2020	February 12, 2021	August 12, 2021	May 15, 2020		September 7, 2020	Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal		https://ClinicalTrials.gov/show/NCT04390594
35	NCT04355936	Telmisartan for Treatment of COVID-19 Patients		Recruiting	No Results Available	COVID-19 Drug Treatment	Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.	C reactive protein|Admission to intensive care unit (ICU)|Occurrence of mechanical ventilation|Death|Composite occurrence of admission to ICU, mechanical ventilation or death (what occur first)|Time from randomization to discharge|Proportion of patients not requiring supplemental oxygen at day 15|Significative differences in serum lactate dehydrogenase	Laboratorio Elea Phoenix S.A.|Carlos R. Rojo, MD|Facultad de Medicina, Universidad de Buenos Aires, UBA	All	18 Years and older   (Adult, Older Adult)	Phase 4	400	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001	May 19, 2020	October 1, 2020	October 1, 2020	April 21, 2020		August 6, 2020	Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital Español de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04355936
36	NCT04362943	Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults	COVID-AGE	Recruiting	No Results Available	COVID-19	Drug: Baricitinib or Anakinra	Mortality|X-ray changes|Disability changes|Ambulation changes|lymphocyte count changes|C-Reactive Protein changes|Ferritin changes|D-Dimer changes	Complejo Hospitalario Universitario de Albacete	All	70 Years and older   (Older Adult)		576	Other	Observational	Observational Model: Other|Time Perspective: Retrospective	PAS-BAR-2020-04	April 20, 2020	May 15, 2020	July 31, 2020	April 27, 2020		April 27, 2020	Complejo Hospitalario Universitario de Albacete, Albacete, Spain		https://ClinicalTrials.gov/show/NCT04362943
37	NCT04381884	Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19		Completed	No Results Available	COVID-19 Drug Treatment	Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.	Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2	Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes	All	18 Years to 69 Years   (Adult, Older Adult)	Phase 2	45	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IVM-AR-1	May 18, 2020	September 29, 2020	September 29, 2020	May 11, 2020		October 2, 2020	Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina|Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04381884
38	NCT04389359	PROphylaxis for paTiEnts at Risk of COVID-19 infecTion	PROTECT	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine Sulfate 200 MG	Time to confirmed diagnosis of COVID-19|All-cause mortality|Severity of COVID-19 disease|Incidence of COVID-19 complications	Cambridge University Hospitals NHS Foundation Trust|University of Cambridge	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	A095590	September 2020	August 2021	August 2025	May 15, 2020		July 13, 2020			https://ClinicalTrials.gov/show/NCT04389359
39	NCT04394442	Hydroxychloroquine in COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine	time to viral clearance|% of mortality|Length of stay|time to be afebrile|need for mechanical ventilation	Samah Lutfy|Zagazig University	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SNH1352020	March 21, 2020	August 2020	August 2020	May 19, 2020		May 19, 2020	SNH, Mecca, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04394442
40	NCT04535869	Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)	CCOVID-19	Not yet recruiting	No Results Available	COVID-19	Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg	rate of virological cure by Rt -PCR for COVID -19using the triple therapy as compared to standard treatment|resolution of pneumonia BY high resolution Computed tomography	Mansoura University	All	18 Years and older   (Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MS.20.08.1214	September 4, 2020	January 1, 2021	September 3, 2021	September 2, 2020		September 3, 2020	Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt		https://ClinicalTrials.gov/show/NCT04535869
41	NCT04389567	Famotidine Outpatient COVID-19 Treatment Study		Completed	No Results Available	COVID-19	Drug: Famotidine	Symptomatic improvement|Peripheral blood oxygen saturation	Northwell Health|Cold Spring Harbor Laboratory	All	18 Years and older   (Adult, Older Adult)		10	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	1605914-1	May 12, 2020	May 25, 2020	May 25, 2020	May 15, 2020		June 4, 2020	Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States		https://ClinicalTrials.gov/show/NCT04389567
42	NCT04361214	Leflunomide in Mild COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Leflunomide	Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol	University of Chicago	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-0622	May 5, 2020	September 2020	September 2020	April 24, 2020		August 25, 2020	University of Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04361214
43	NCT04304313	A Pilot Study of Sildenafil in COVID-19		Recruiting	No Results Available	COVID-19	Drug: Sildenafil citrate tablets	Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GST-G1	February 9, 2020	March 1, 2020	November 9, 2020	March 11, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04304313
44	NCT04365699	Cardiovascular Effects of COVID-19		Recruiting	No Results Available	COVID-19	Drug: AT-001	Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization	NYU Langone Health	All	18 Years and older   (Adult, Older Adult)	Phase 2	500	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-00416	April 8, 2020	December 31, 2020	December 31, 2020	April 28, 2020		April 28, 2020	NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04365699
45	NCT04477642	Abatacept for Patients With COVID-19 and Respiratory Distress		Withdrawn	No Results Available	COVID-19	Drug: Abatacept	Mechanical ventilation-free survival|Duration of days on a ventilator|Days until pulse oxygen is > 93% on room air|Days until supplemental oxygen is no longer required|Duration of fever >= 38°C|Overall survival|Infusion reactions|Secondary infections|Change in Clinical Status, based on 7-point ordinal scale|Viral load|Radiographic Improvement	Beth Israel Deaconess Medical Center|Boston Children's Hospital|Bristol-Myers Squibb|Brigham and Women's Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-P-00XXX	August 2020	October 2020	December 2020	July 20, 2020		July 20, 2020	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04477642
46	NCT04365725	Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections	REMDECO-19	Recruiting	No Results Available	COVID-19	Drug: Remdesivir	Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	APHP200522	May 5, 2020	June 2020	June 2020	April 28, 2020		May 13, 2020	Hôpital Cochin, Paris, France		https://ClinicalTrials.gov/show/NCT04365725
47	NCT04389710	Convalescent Plasma for the Treatment of COVID-19		Recruiting	No Results Available	COVID-19	Drug: Convalescent Plasma	Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma	Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20D.379	April 15, 2020	April 14, 2021	April 14, 2021	May 15, 2020		June 25, 2020	Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04389710
48	NCT04380402	Atorvastatin as Adjunctive Therapy in COVID-19	STATCO19	Not yet recruiting	No Results Available	COVID-19	Drug: Atorvastatin	Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death|Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement|Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement|Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7	Mount Auburn Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MountAuburn	May 20, 2020	December 31, 2021	May 8, 2022	May 8, 2020		May 22, 2020			https://ClinicalTrials.gov/show/NCT04380402
49	NCT04462757	SCIL-1Ra in COVID-19 Feasibility & PK/PD	SCIL_COV19	Active, not recruiting	No Results Available	COVID-19	Drug: Anakinra 100Mg/0.67Ml Inj Syringe	Plasma IL-1Ra levels|Plasma IL-6 levels|Plasma markers|Safety Endpoints related to the Serious adverse reactions of the IMP|Safety Endpoints related to the anaphylactic reactions of the IMP|Safety Endpoints related to neutropenia caused by the IMP|Safety Endpoints related to any severe laboratory abnormalities|Feasibility endpoints related to IMP and deviations|Exploratory Data on Clinical efficacy by time to recovery|Exploratory Data on Clinical efficacy|Exploratory Data on Clinical efficacy of the ordinal scale	University of Manchester	All	18 Years and older   (Adult, Older Adult)	Phase 2	5	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	282110|2020-001636-95	May 28, 2020	August 31, 2020	September 30, 2020	July 8, 2020		September 9, 2020	Manchester Univesity NHS Foundation Trust, Manchester, United Kingdom|Salford Royal NHS Foundation Tust, Salford, United Kingdom		https://ClinicalTrials.gov/show/NCT04462757
50	NCT04354805	Administration of Chlorpromazine as a Treatment for COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Chlorpromazine	Clinical improvement	Cairo University|Noha Mahmoud Nasreldin Hassan	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Medical	August 1, 2020	October 2020	November 2020	April 21, 2020		July 8, 2020	Cairo University, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04354805
51	NCT04356690	Etoposide in Patients With COVID-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Etoposide	Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)	Boston Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	H-40102	May 8, 2020	December 2020	December 2021	April 22, 2020		September 4, 2020	Boston Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04356690
52	NCT04412785	Cyclosporine in Patients With Moderate COVID-19		Recruiting	No Results Available	COVID-19	Drug: Cyclosporine	Safety-oxygen, ICU transfer and ventilation|Safety-changes in absolute lymphocyte count|Safety-changes in creatinine clearance|Safety-secondary bacterial infections|Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions|Laboratory measurements-D-dimer levels|Laboratory measurements-ferritin|Laboratory measurements- IL-6	University of Pennsylvania	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	842998	June 22, 2020	September 2020	December 2020	June 2, 2020		June 29, 2020	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04412785
53	NCT04383002	High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)		Recruiting	No Results Available	COVID-19	Drug: Nitric Oxide	COVID-19 PCR status at completion of treatment (day 7) from tracheal aspirate	University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-5449	September 2, 2020	December 2020	December 2020	May 11, 2020		September 11, 2020	University Health Network, Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04383002
54	NCT04427865	Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: prophylactic lactoferrin daily	Incidence of SARS-CoV-2|Severity of disease in confirmed infected participants	Cairo University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CUKA-002	July 2020	September 2020	November 2020	June 11, 2020		June 16, 2020			https://ClinicalTrials.gov/show/NCT04427865
55	NCT04362085	Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care		Recruiting	No Results Available	COVID-19	Drug: Therapeutic Anticoagulation	Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|Renal replacement therapy|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of organ support-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia|Changes in D-dimer up to day 3	St. Michael's Hospital, Toronto|University of Vermont Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 3	462	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RAPID COVID-COAG	May 11, 2020	November 2020	December 2020	April 24, 2020		September 4, 2020	St. Michael's Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04362085
56	NCT04351620	High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine	Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol	University of Chicago	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-0572	April 2020	June 2020	June 2020	April 17, 2020		April 17, 2020	University of Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04351620
57	NCT04363216	Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment		Not yet recruiting	No Results Available	COVID-19	Drug: Ascorbic Acid	Clinical Improvement|Patient status upgraded to ICU level [Clinical decline]|Oxygen supplementation|Days with fever|Days to discharge|SAEs	Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Phase 2	66	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JT#15681	May 2020	May 2021	May 2021	April 27, 2020		May 5, 2020			https://ClinicalTrials.gov/show/NCT04363216
58	NCT04552951	Effect of Vitamin D on Morbidity and Mortality of the COVID-19	COVID-VIT-D	Recruiting	No Results Available	COVID-19	Drug: Cholecalciferol	Mortality|Admission to Intensive Care Unit (ICU)|Time of hospitalization|Clinical changes|Radiological changes|Calcidiol changes|Inflammation markers changes (CRP)|Inflammation markers changes (IL-6)|Inflammation markers changes (Leucocytes)|Inflammation markers changes (D-dimer)|General biochemical parameters changes (Creatinine)|General biochemical parameters changes (Ferritin)|General biochemical parameters changes (Bilirubin)|General biochemical parameters changes (Albumin)|General biochemical parameters changes (Haemoglobin)|General biochemical parameters changes (HDL cholesterol)|General biochemical parameters changes (Procalcitonin)|General biochemical parameters changes (Protonin)|General biochemical parameters changes (Calcium)|General biochemical parameters changes (Phosphate)|General biochemical parameters changes (pO2)	Fundación para la Investigación Biosanitaria del Principado de Asturias|Hospital Universitario Central de Asturias|Instituto de Investigación Sanitaria del Principado de Asturias	All	Child, Adult, Older Adult	Phase 4	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	2020-019-PF-CAANJ	April 4, 2020	September 14, 2020	December 30, 2020	September 17, 2020		September 17, 2020	Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain		https://ClinicalTrials.gov/show/NCT04552951
59	NCT04374903	Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients	COVID19-HOPE	Not yet recruiting	No Results Available	COVID-19 Patients	Drug: HCQ & AZ vs HCQ+SIR	Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance	King Hussein Cancer Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	58	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20 KHCC 74	May 1, 2020	August 1, 2020	September 1, 2020	May 5, 2020		May 5, 2020	King Hussein Cancer Center, Amman, Jordan		https://ClinicalTrials.gov/show/NCT04374903
60	NCT04354597	Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients	MOPHYDA	Not yet recruiting	No Results Available	COVID-19	Drug: HCQ & AZ	Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate	King Hussein Cancer Center	All	25 Years to 70 Years   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20 KHCC 67	May 1, 2020	August 15, 2020	October 15, 2020	April 21, 2020		May 5, 2020	King Hussein Cancer Center, Amman, Jordan		https://ClinicalTrials.gov/show/NCT04354597
61	NCT04492254	Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients	ETHIC	Not yet recruiting	No Results Available	COVID-19	Drug: Enoxaparin	Hospital Admission|Death|Bleeding (as defined by ISTH criteria)|Diagnosis of VTE	Thrombosis Research Institute|Sanofi	All	55 Years and older   (Adult, Older Adult)	Phase 3	1370	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TRI-08892|2020-003125-39	July 2020	January 2021	July 2021	July 30, 2020		July 30, 2020			https://ClinicalTrials.gov/show/NCT04492254
62	NCT04333225	Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers		Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine	Rate of COVID-19 positive conversion|Time-to-first clinical event	Baylor Research Institute	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	228	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	020-132	April 3, 2020	July 30, 2020	July 30, 2020	April 3, 2020		May 5, 2020	Baylor University Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT04333225
63	NCT04377659	Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Tocilizumab	Progression of respiratory failure or death	Memorial Sloan Kettering Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-185	May 1, 2020	May 1, 2021	May 1, 2021	May 6, 2020		August 21, 2020	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04377659
64	NCT04474457	Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age		Recruiting	No Results Available	COVID-19	Drug: Favipiravir	Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oximetry from baseline|Changes in fever from baseline	Ministry of Health, Turkey|Hacettepe University, School of Medicine|Prof. Dr. Cemil Tascıoglu City Hospital|Umraniye Training and Research Hospital|Istanbul Training and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital (Application and Research Center)|Derince Training and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital	All	15 Years and older   (Child, Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-19-PMS-FAV	June 11, 2020	September 30, 2020	September 30, 2020	July 16, 2020		July 20, 2020	Hacettepe University, School of Medicine, Ankara, Turkey		https://ClinicalTrials.gov/show/NCT04474457
65	NCT04348448	Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia		Not yet recruiting	No Results Available	COVID-19	Drug: Canakinumab 150 MG/ML [Ilaris]	intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event	AUSL Romagna Rimini	All	18 Years to 100 Years   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CANASCOV	April 2020	July 2020	September 2020	April 16, 2020		April 16, 2020			https://ClinicalTrials.gov/show/NCT04348448
66	NCT04432766	A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients		Not yet recruiting	No Results Available	COVID-19	Drug: BAT2020	Incidence of adverse events (AEs)	Bio-Thera Solutions	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	174	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BAT-2020-001-CR	October 20, 2020	January 20, 2021	August 18, 2021	June 16, 2020		September 29, 2020	Snake River Research, Idaho Falls, Idaho, United States		https://ClinicalTrials.gov/show/NCT04432766
67	NCT04429711	Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19		Recruiting	No Results Available	COVID-19	Drug: Ivermectin Oral Product	Viral clearance at day 6|Viral shedding duration|Symptoms clearance time	Sheba Medical Center	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SHEBA-20-7156-ES-CTIL	May 12, 2020	September 30, 2020	October 31, 2020	June 12, 2020		June 16, 2020	Sheba Medical Center, Ramat-Gan, Israel		https://ClinicalTrials.gov/show/NCT04429711
68	NCT04536090	Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Isoquercetin (IQC-950AN)	Changes in viral load from baseline to end of treatment - Mean viral load|Changes in viral load from baseline to end of treatment - Area under the viral load vs. time profiles|Changes in viral load from baseline to end of treatment - Time profiles of viral load|Changes in viral load from baseline to end of treatment - Time to viral negativity|Time to clinical recovery|All-cause mortality|Progression to supplementary oxygen requirement|Incidence of mechanical ventilation|Incidence of ICU admission|Time to hospital discharge|Changes in serum C reactive protein levels (CRP)|Changes in D-dimer levels|Changes in soluble low-density lipoprotein receptor (sLDLR) expression and proprotein convertase subtilisin/kexin type 9 (PCSK9) and soluble angiotensin converting enzyme 2 (sACE2) levels|Changes in LDL-cholesterol|Changes in creatinine|Changes in liver enzymes	Institut de Recherches Cliniques de Montreal|Pharmascience Inc.|SCiAN Services, Inc.|Quercis Pharma AG	All	18 Years and older   (Adult, Older Adult)	Phase 2	150	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRCM-IQC-001	November 2020	April 2021	May 2021	September 2, 2020		September 2, 2020			https://ClinicalTrials.gov/show/NCT04536090
69	NCT04345692	A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients	OAHU-COVID19	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine	i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality	Queen's Medical Centre	All	18 Years to 95 Years   (Adult, Older Adult)	Phase 3	350	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RA-2020-018	March 26, 2020	December 31, 2021	December 31, 2021	April 14, 2020		June 4, 2020	Queen's Medical Center, Honolulu, Hawaii, United States		https://ClinicalTrials.gov/show/NCT04345692
70	NCT04433910	A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19	CAPSID	Recruiting	No Results Available	COVID-19	Drug: Convalesscent Plasma	Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions	Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	106	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAPSID2020-DRK-BSD|2020-001310-38	June 2020	December 2020	February 2021	June 16, 2020		June 23, 2020	University Hospital Ulm, Ulm, Baden-Württmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany		https://ClinicalTrials.gov/show/NCT04433910
71	NCT04434131	Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19		Recruiting	No Results Available	COVID-19	Drug: Convalescent Plasma	Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples	University of New Mexico	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20-227	April 28, 2020	April 28, 2021	April 28, 2025	June 16, 2020		June 16, 2020	University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04434131/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04434131
72	NCT04371926	Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk	PREVENT	Withdrawn	No Results Available	COVID-19	Drug: Hydroxychloroquine Sulfate	Time to reach normal body temperature|Development of COVID-19 symptoms during HCQ preventive therapy in staff|COVID-19 test result at follow-up in patients|Worsening of symptoms in COVID-19 patients	Texas Cardiac Arrhythmia Research Foundation	All	18 Months to 85 Years   (Child, Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention	TCAI_PREVENT	June 2020	June 2021	July 2021	May 1, 2020		June 4, 2020			https://ClinicalTrials.gov/show/NCT04371926
73	NCT04576312	Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19		Recruiting	No Results Available	COVID-19	Drug: UNI911 INHALATION	Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency	UNION therapeutics	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	44	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Investigator)|Primary Purpose: Other	UNI911-101	June 29, 2020	October 31, 2020	December 31, 2020	October 6, 2020		October 6, 2020	DanTrials, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT04576312
74	NCT04308317	Tetrandrine Tablets Used in the Treatment of COVID-19	TT-NPC	Enrolling by invitation	No Results Available	Corona Virus Disease 2019,COVID-19	Drug: Tetrandrine	Survival rate|body temperature	Henan Provincial People's Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TT-NPC	March 5, 2020	March 1, 2021	May 1, 2021	March 16, 2020		March 16, 2020	Tetrandrine Tablets, Jinhua, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04308317
75	NCT04431453	Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)	CARAVAN	Recruiting	No Results Available	COVID-19	Drug: Remdesivir	Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Plasma Concentrations of Remdesivir (RDV) and Metabolites|Change From Baseline in Oxygenation Use|Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Clinical Improvement on a 7-point Ordinal Scale|Time (days) to Discharge From Hospital|Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result|Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load|Bilirubin Concentrations in < 14-day-old Participants|Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale|Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)|Proportion of Participants With Concomitant Use of Medications other than RDV for Treatment of Coronavirus Disease 2019 (COVID-19)	Gilead Sciences	All	up to 18 Years   (Child, Adult)	Phase 2|Phase 3	52	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GS-US-540-5823|2020-001803-17	July 21, 2020	February 2021	February 2021	June 16, 2020		October 7, 2020	Children's Hospital of Alabama, Birmingham, Alabama, United States|Ronald Reagan University of California, Los Angeles Medical Center, Los Angeles, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Tampa General Hospital (Inpatient Visits), Tampa, Florida, United States|Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Minnesota, Minneapolis, Minnesota, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|NYC Health + Hospitals/Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Northwell Health-Cohen Children's Medical Center, New Hyde Park, New York, United States|Carolinas Medical Center-Levine Children's Hospital, Charlotte, North Carolina, United States|Lehigh Valley Hospital/Lehigh Valley Health Network (LVH/LVHN), Allentown, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04431453
76	NCT04568018	Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19		Recruiting	No Results Available	ARDS Due to COVID-19	Drug: Surfactant	Mean duration of oxygen therapy (days) in the treatment group and in the control group.|The proportion of patients who required ALV within 5 days after the start of treatment.|Change from baseline in PaO2/FiO2 ratio dynamics within 5 days after the start of treatment.|Change from baseline in SpO2 dynamics within 5 days after the start of treatment.|Proportion of patients who achieved an oxygenation index (PaO2/FiO2) of > 300 mm hg.|Proportion of patients dead of any reason within 30 days after the start of treatment.|Time to patient transfer to mechanically ventilated.|Change from the baseline in the severity assessment of the patient's condition according to the NEWS-II scale within 5 days after the start of treatment.|Change from baseline in leukocytes within 5 days after the start of treatment.|Change from baseline in lymphocytes within 5 days after the start of treatment.|Change from baseline in CRP within 5 days after the start of treatment.|Change from baseline in ferritin within 5 days after the start of treatment.|Change from baseline in D-dimer within 5 days after the start of treatment.	Biosurf LLC.	All	18 Years to 75 Years   (Adult, Older Adult)		120	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	Sur/ARDS-2020	July 3, 2020	December 31, 2020	December 2021	September 29, 2020		September 29, 2020	FSAEI of Higher Education I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation		https://ClinicalTrials.gov/show/NCT04568018
77	NCT04374279	Trial to Promote Recovery From COVID-19 With Endocrine Therapy	RECOVER	Not yet recruiting	No Results Available	COVID-19|SARS-CoV 2	Drug: Bicalutamide 150 Mg Oral Tablet	Percentage of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COV2003|IRB00249425	November 2020	November 2021	November 2021	May 5, 2020		October 2, 2020	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04374279
78	NCT04371965	Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19	KILLER	Recruiting	No Results Available	COVID-19	Drug: Povidone-Iodine	Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures|Thyroid tests at Day0 and Day7|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|Need for ward or intensive care hospitalization	Poitiers University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KILLER	September 1, 2020	November 1, 2020	December 1, 2020	May 1, 2020		September 16, 2020	University Hospital of Poitiers, Poitiers, France		https://ClinicalTrials.gov/show/NCT04371965
79	NCT04381962	A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)	ATOMIC2	Recruiting	No Results Available	COVID-19	Drug: Azithromycin Capsule	Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability	University of Oxford|Pfizer	All	19 Years and older   (Adult, Older Adult)	Phase 3	800	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATOMIC2|2020-001740-26|282892|20/HRA/2105	May 29, 2020	September 13, 2020	October 13, 2020	May 11, 2020		June 9, 2020	Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom		https://ClinicalTrials.gov/show/NCT04381962
80	NCT04343976	Pegylated Interferon Lambda Treatment for COVID-19		Enrolling by invitation	No Results Available	COVID-19|COVID	Drug: Pegylated interferon lambda	Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs placebo with symptomatic improvement|Percentage of subjects on Lambda vs placebo with improved clinical outcomes	Raymond Chung|Eiger BioPharmaceuticals|Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2020P001083	June 22, 2020	March 1, 2021	August 31, 2021	April 14, 2020		June 24, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04343976
81	NCT04382625	Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial		Not yet recruiting	No Results Available	SARS-CoV-2 Pneumonia|COVID-19	Drug: Hydroxychloroquine	Change from Baseline Oxygenation on Day 1 to Day 5|Change from Baseline Oxygenation at Day 5|Intensive Care length of stay|Required Mechanical Ventilation|Required Oxygen supplementation|Hospitalization length of Stay|Mortality|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc	Kootenai Health|Washington State University	All	18 Years and older   (Adult, Older Adult)	Phase 4	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18244	October 2020	January 1, 2022	June 1, 2022	May 11, 2020		September 2, 2020	Kootenai Health, Coeur d'Alene, Idaho, United States		https://ClinicalTrials.gov/show/NCT04382625
82	NCT04389411	The COvid-19 Symptom MOntelukast Trial	COSMO	Not yet recruiting	No Results Available	COVID-19	Drug: Montelukast 10mg	Emergency Room Visits and Hospitalizations|Emergency room visit count|Hospitalization admission count|Time to ER Visit|Time to hospitalization|All-cause mortality|Inpatient Length of stay|Time to ICU admission|Time to intubation|Time to other serious COVID-19 complications	McGill University|Lady Davis Institute	All	40 Years and older   (Adult, Older Adult)	Phase 3	600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	443807	October 1, 2020	September 2021	December 2021	May 15, 2020		September 1, 2020			https://ClinicalTrials.gov/show/NCT04389411
83	NCT04346355	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients		Terminated	No Results Available	COVID-19 Pneumonia	Drug: Tocilizumab	Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count	Azienda Unità Sanitaria Locale Reggio Emilia	All	18 Years and older   (Adult, Older Adult)	Phase 2	126	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RCT-TCZ-COVID-19|2020-001386-37	March 31, 2020	June 6, 2020	June 6, 2020	April 15, 2020		June 22, 2020	Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale "Dell'Angelo", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy		https://ClinicalTrials.gov/show/NCT04346355
84	NCT04394117	Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease	CLARITY	Recruiting	No Results Available	SARS-Cov-2|COVID-19	Drug: Angiotensin Receptor Blockers	7-Point National Institute of Health Clinical Health Score|Mortality|Intensive Care Unit Admission|Respiratory Failure|Dialysis Requirement|Hospitalisation Days|Ventilator-Free Days|Dialysis Days|Acute Kidney Injury|Hypotension Requiring Vasopressors	The George Institute	All	18 Years and older   (Adult, Older Adult)	Phase 4	605	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	11052020	June 19, 2020	January 30, 2021	April 30, 2021	May 19, 2020		July 16, 2020	Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal prince Alfred Virtual Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia		https://ClinicalTrials.gov/show/NCT04394117
85	NCT04353596	Stopping ACE-inhibitors in COVID-19	ACEI-COVID	Recruiting	No Results Available	SARS-CoV-2|COVID-19	Drug: ACE inhibitor, angiotensin receptor blocker	Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic/diastolic blood pressure > 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)	Medical University Innsbruck|Ludwig-Maximilians - University of Munich|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)	All	18 Years and older   (Adult, Older Adult)	Phase 4	208	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	EudraCT 2020-001206-35	April 15, 2020	May 15, 2021	May 15, 2022	April 20, 2020		June 11, 2020	Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum München, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|München Klinik Bogenhausen und Schwabing, Munich, Germany|Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik für Innere Medizin Weilheim, Weilheim, Germany		https://ClinicalTrials.gov/show/NCT04353596
86	NCT04305106	Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT	BEST-RCT	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Bevacizumab	The time from randomization to clinical improvement	Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	QLEmer	March 17, 2020	June 30, 2020	July 31, 2020	March 12, 2020		March 26, 2020	Qilu Hospital of Shandong University, Jinan, Shandong, China		https://ClinicalTrials.gov/show/NCT04305106
87	NCT04534478	Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19	NORCOVID	Not yet recruiting	No Results Available	COVID-19 Pneumonia	Drug: Prednisone	Change in pulmonary diffusion.	Hospital Universitari Vall d'Hebron Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 4	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-003651-15	September 7, 2020	May 2, 2021	December 15, 2021	September 1, 2020		September 1, 2020			https://ClinicalTrials.gov/show/NCT04534478
88	NCT04363736	A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia	MARIPOSA	Completed	No Results Available	COVID-19 Pneumonia	Drug: Tociliuzumab	Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA42481	May 5, 2020	August 12, 2020	August 12, 2020	April 27, 2020		September 11, 2020	Mayo Clinic - Arizona, Phoenix, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States		https://ClinicalTrials.gov/show/NCT04363736
89	NCT04455815	A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home		Recruiting	No Results Available	COVID-19 Infection	Drug: Camostat	Number of participants who require hospital admission and require supplemental oxygen.|Rate of COVID-19 related hospital admission in patients with SARS-CoV-2 infection.|Number of supplementary oxygen-free days at 28 days (from randomisation).|Number of ventilator-free days at 28 days (from randomisation).|To evaluate overall mortality.|Time to worst point on the scale or deterioration of two points or more (from randomisation) on a 9-point category ordinal scale.	Cancer Research UK|Latus Therapeutics	All	50 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	389	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRUKD/20/002	September 25, 2020	August 31, 2021	August 31, 2021	July 2, 2020		October 6, 2020	The University of Edinburgh, Edinburgh, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT04455815
90	NCT04376593	PET/CT Imaging in COVID-19 Patients		Enrolling by invitation	No Results Available	COVID-19|SARS-CoV-2 Infection	Drug: 18F-αvβ6-BP	Administration of 18F-αvβ6-BP|Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage	University of California, Davis	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	1592298	May 1, 2020	May 2021	May 2022	May 6, 2020		July 7, 2020	University of California Davis, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT04376593
91	NCT04428268	Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Chloroquine Phosphate Tablets	Overall mortality|Clinical outcome assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Time to negative SARS-CoV-2 test	Hospital Universitario Dr. Jose E. Gonzalez	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IF20-00003	March 10, 2020	June 10, 2020	August 30, 2020	June 11, 2020		June 16, 2020	Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico		https://ClinicalTrials.gov/show/NCT04428268
92	NCT04354870	COVID-19 PrEP HCW HCQ Study		Completed	No Results Available	COVID-19	Drug: Hydroxychloroquine (HCQ)	Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time	NYU Langone Health	All	18 Years and older   (Adult, Older Adult)	Phase 2	130	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	s20-00390	April 3, 2020	September 15, 2020	October 1, 2020	April 21, 2020		October 2, 2020	NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04354870
93	NCT04325061	Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19	DEXA-COVID19	Suspended	No Results Available	Acute Respiratory Distress Syndrome Caused by COVID-19	Drug: Dexamethasone	60-day mortality|Ventilator-free days	Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001278-31	April 3, 2020	October 30, 2020	October 30, 2020	March 27, 2020		September 2, 2020	ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain		https://ClinicalTrials.gov/show/NCT04325061
94	NCT04567173	Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19	Co-CLARITY	Recruiting	No Results Available	Covid19	Drug: Anti-SARS-CoV-2 convalescent plasma	Incidence of serious adverse events|Quick SOFA (qSOFA) score|Cardiopulmonary arrest|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Dialysis-free days|Vasopressor-free days|ICU-free days|28-day mortality|Anti-SARS-CoV-2 antibody titers|SARS-CoV-2 RNA by RT-PCR	University of the Philippines	All	19 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	136	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PHRR200824-002868	September 21, 2020	June 30, 2021	June 30, 2021	September 28, 2020		September 29, 2020	UP Philippine General Hospital, Manila, Philippines		https://ClinicalTrials.gov/show/NCT04567173
95	NCT04414098	Ruxolitinib in the Treatment of Covid-19		Not yet recruiting	No Results Available	COVID-19	Drug: INC424 / Ruxolitinib	Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinib	Marcelo Iastrebner|Novartis|Clinica Zabala	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZabala	June 1, 2020	August 15, 2020	September 15, 2020	June 4, 2020		June 4, 2020			https://ClinicalTrials.gov/show/NCT04414098
96	NCT04577534	COVID-19: Salvage TOcilizumab as a Rescue Measure	COVIDSTORM	Recruiting	No Results Available	Covid19	Drug: iv Tocillizumab (TCZ)	Clinical status at day 28|Time to clinical improvement|Time to decline of at least 2 categories|Incidence of mechanical and/or non-invasive ventilation|Number of ventilator-free days to day 28|Organ failure free days to day 28|Incidence of ICU stay|Duration of ICU stay|Time to clinical failure|SAPS II|CCI|APACHE II|SOFA 6|Mortality rate|Time to hospital discharge or "ready for discharge"|Duration of supplemental oxygen	Jarmo Oksi|Turku University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EudraCT 2020-002039-31|2020-002039-31|T124/2020|KLnro 36/2020|dnro 68/06.00.01/2020	August 14, 2020	December 31, 2021	December 31, 2021	October 7, 2020		October 8, 2020	Turku University Hospital, Turku, Finland		https://ClinicalTrials.gov/show/NCT04577534
97	NCT04539626	Estrogen Therapy in Non-severe COVID-19 Patients		Not yet recruiting	No Results Available	Covid-19	Drug: Estrogen Therapy	Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients|Clinical improve to estrogen therapy in non-severe COVID-19 patients|Symptomatic improve to estrogen therapy in non-severe COVID-19 patients|Biochemical improve to estrogen therapy in non-severe COVID-19 patients	CMN "20 de Noviembre"	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	03	October 1, 2020	December 31, 2020	March 30, 2021	September 7, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04539626
98	NCT04335201	Defibrotide in COVID-19 Pneumonia	DEFI-VID19	Not yet recruiting	No Results Available	Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure	Drug: Defibrotide Injection	to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival	IRCCS San Raffaele	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DEFI-VID19	April 6, 2020	September 30, 2020	December 31, 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335201
99	NCT04461340	Efficacy and Safety of Sirolimus in COVID-19 Infection		Recruiting	No Results Available	COVID 19	Drug: Sirolimus	Time to clinical recovery|Viral clearance|radiological lung extension|drug adverse events|28 day mortality|intensive care unit (ICU) admission rate|Duration of hospital stay	Alexandria University	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	sirolimus in COVID 19	August 15, 2020	October 30, 2020	November 30, 2020	July 8, 2020		September 9, 2020	Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt		https://ClinicalTrials.gov/show/NCT04461340
100	NCT04366960	Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients	X-Covid 19	Recruiting	No Results Available	Covid19	Drug: Enoxaparin	Incidence of venous thromboembolism detected by imaging|In hospital major complications|Number of deep venous thrombosis events|Sequential organ failure assessment|C-reactive protein|Interleukin-6|D-dimer|hs-troponin levels|Acute Respiratory Distress Syndrome|Hospital stay|Right ventricular function|Number of pulmonary embolism events	Niguarda Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	2712	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001708-41	May 14, 2020	August 2020	November 2020	April 29, 2020		May 15, 2020	Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy		https://ClinicalTrials.gov/show/NCT04366960
101	NCT04280588	Fingolimod in COVID-19		Recruiting	No Results Available	Coronavirus Disease (COVID-19)	Drug: Fingolimod 0.5 mg	The change of pneumonia severity on X-ray images	First Affiliated Hospital of Fujian Medical University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MRCTA, ECFAH of FMU [2020]027	February 22, 2020	July 1, 2020	July 1, 2020	February 21, 2020		February 21, 2020	Wan-Jin Chen, Fuzhou, China		https://ClinicalTrials.gov/show/NCT04280588
102	NCT04357535	Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives		Completed	No Results Available	COVID-19	Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)	Severity of COVID-19 Infection|Degree of severity of respiratory disease|Septic shock as defined by sepsis-3 criteria	Hakeam Abdulaziz Hakeam|Buraidah Central Hospital|King Khalid University Hospital|Princess Nourah Bint Abdulrahman University|King Faisal Specialist Hospital & Research Center	All	18 Years and older   (Adult, Older Adult)		314	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2210061	May 10, 2020	July 1, 2020	August 1, 2020	April 22, 2020		August 4, 2020	King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04357535
103	NCT04475601	Enzalutamide Treatment in COVID-19	COVIDENZA	Recruiting	No Results Available	COVID-19|Corona Virus Infection	Drug: Enzalutamide Pill	Time to worsening of disease|Time to improvement of disease|Adverse events|Duration of supplemental oxygen (days)|Admission to ICU|Laboratory assessment of Hemoglobin concentration day 0, 2, 4 and 6|Virus load assessment day 0, 2, 4 and 6|Hospital stay (days)|Re-admission to hospital due to rebound COVID-19|Mortality at 6 months|Hormonal status at 6 months|Serological immunity for COVID-19|Laboratory assessment of CRP concentration day 0, 2, 4 and 6|Laboratory assessment of liver function day 0, 2, 4 and 6|Laboratory assessment of creatinine concentration day 0, 2, 4 and 6|Laboratory assessment of D-dimer concentration day 0, 2, 4 and 6|Laboratory assessment of platelets concentration day 0, 2, 4 and 6|Laboratory assessment of IL-6 concentration day 0, 2, 4 and 6|Laboratory assessment of B- and T-lyphocytes concentration day 0, 2, 4 and 6	Andreas Josefsson|Umeå University|Sahlgrenska University Hospital, Sweden|University Hospital, Umeå|Uppsala University Hospital|Skane University Hospital|Jonkoping County Hospital|Sundsvall Hospital|Helsingborgs Hospital|Göteborg University|Astellas Pharma Europe Ltd.|Norrlands University Hospital|Västerbotten County Council	All	50 Years and older   (Adult, Older Adult)	Phase 2	500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVIDENZA	July 15, 2020	July 8, 2021	May 8, 2022	July 17, 2020		July 17, 2020	Anders Bjartell, Malmö, Skåne, Sweden|Ryhovs Hospital, Jönköping, Småland, Sweden		https://ClinicalTrials.gov/show/NCT04475601
104	NCT04435808	Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine	SARS-CoV-2 Infection|Symptomatic vs. Asymptomatic Infection with SARS-CoV-2|Occupational Health Exposure|Impact of Hydroxychloroquine use on Need for Hospitalization with SARS-CoV-2 Infection|Impact of Hydroxychloroquine use on Need for ICU Care with SARS-CoV-2 Infection|Adverse Effect Profile of Hydroxychloroquine|Seroconversion Following SARS-CoV-2 Infection|Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates	University of New Mexico	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	350	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20-206	April 14, 2020	April 14, 2021	April 14, 2025	June 17, 2020		June 17, 2020	University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04435808
105	NCT04337359	Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness		Available	No Results Available	Severe/Very Severe COVID-19 Illness	Drug: Ruxolitinib		Novartis Pharmaceuticals|Novartis	All	6 Years to 90 Years   (Child, Adult, Older Adult)			Industry	Expanded Access:Intermediate-size Population		CINC424A2001M				April 7, 2020		July 9, 2020	Novartis Investigative Site, Curug, Indonesia|Novartis Investigative Site, Caserta, CE, Italy|Novartis Investigative Site, La Spezia, SP, Italy|Novartis Investigative Site, Cirie, Torino, Italy|Novartis Investigative Site, Torino, Italy		https://ClinicalTrials.gov/show/NCT04337359
106	NCT04345991	Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort	CORIPLASM	Recruiting	No Results Available	Covid19	Drug: Transfusion of COVID-19 convalescent plasma	Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale ≥6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs	Assistance Publique - Hôpitaux de Paris|Etablissement Français du Sang	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-10|2020-001246-18	April 15, 2020	May 15, 2020	June 1, 2020	April 15, 2020		May 20, 2020	SMIT, Saint Antoine hospital, Paris, France		https://ClinicalTrials.gov/show/NCT04345991
107	NCT04451174	Early Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia	PREDCOVID	Recruiting	No Results Available	COVID-19	Drug: Prednisone	Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation or All-cause Death by Day 28	University of Chile	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 3	184	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2092	June 23, 2020	September 30, 2020	September 30, 2020	June 30, 2020		July 13, 2020	Hospital Santiago Oriente, Santiago, Peñalolen, Chile		https://ClinicalTrials.gov/show/NCT04451174
108	NCT04343742	Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19		Recruiting	No Results Available	COVID-19	Drug: chlorine dioxide 3000 ppm	negative testing of covid19	Genesis Foundation	All	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Genesis AKCOVID- FG-1	April 1, 2020	April 7, 2020	June 1, 2020	April 13, 2020		May 27, 2020	Hospital Fhsj, Bogota, Cundinamarca, Colombia|San Carlos Hospital, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04343742
109	NCT04360980	The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Colchicine Tablets	CRPxN/R ratio change|Clinical deterioration by the WHO definition|PCR Viral Load|CT severity involvement index|LDH change	Shahid Beheshti University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SBMU.IR.REC.165423	March 20, 2020	September 1, 2020	September 30, 2020	April 24, 2020		July 28, 2020	SBMU, Tehran, Iran, Islamic Republic of|Nooshin Dalili, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04360980
110	NCT04382794	Sitagliptin Treatment in Diabetic COVID-19 Positive Patients	SIDIACO-RETRO'	Completed	No Results Available	Covid19	Drug: Retrospective case-control analysis	Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease	University of Milan|Papa Giovanni XXIII Hospital|IRCCS Policlinico S. Matteo|Humanitas Hospital, Italy|Ospedale dell'Angelo, Venezia-Mestre|University of Pavia	All	18 Years and older   (Adult, Older Adult)		338	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	5/2020	May 14, 2020	June 15, 2020	June 15, 2020	May 11, 2020		July 9, 2020	ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy		https://ClinicalTrials.gov/show/NCT04382794
111	NCT04334044	Treatment of SARS Caused by COVID-19 With Ruxolitinib		Recruiting	No Results Available	COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Ruxolitinib Oral Tablet	Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate	Grupo Cooperativo de Hemopatías Malignas	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HAL 345/2020	April 15, 2020	June 1, 2020	June 1, 2020	April 3, 2020		April 17, 2020	Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico		https://ClinicalTrials.gov/show/NCT04334044
112	NCT04443881	Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)	ANA-COVID-GEAS	Recruiting	No Results Available	COVID-19 Pnemonia	Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]	Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Mortality 48 hours, 7 days, in ICU and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Viral clearance / viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.	Fundacion Miguel Servet	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANA-COVID-GEAS	May 8, 2020	December 2020	March 2021	June 23, 2020		June 23, 2020	Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Cataluña, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT04443881
113	NCT04365127	Progesterone for the Treatment of COVID-19 in Hospitalized Men		Active, not recruiting	No Results Available	COVID-19|Sars-CoV2	Drug: Progesterone 100 MG	Change in clinical status of subjects at Day 7 based on the following 7-point ordinal scale|Change in clinical status of subjects assessed daily while hospitalized and on Day 15|Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization	Sara Ghandehari|IBSA Institut Biochimique SA|Cedars-Sinai Medical Center	Male	18 Years and older   (Adult, Older Adult)	Phase 1	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000611	April 27, 2020	August 20, 2020	April 17, 2021	April 28, 2020		September 15, 2020	Cedars Sinai Medical Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04365127
114	NCT04328493	The Vietnam Chloroquine Treatment on COVID-19	VICO	Recruiting	No Results Available	SARS-CoV-2 Infection|COVID-19	Drug: Chloroquine phosphate	Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|fever clearance time|Ordinal outcome scale|Development of ARDS	Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID	April 7, 2020	April 1, 2021	April 1, 2022	March 31, 2020		May 29, 2020	National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam		https://ClinicalTrials.gov/show/NCT04328493
115	NCT04452435	Safety and Efficacy of C21 in Subjects With COVID-19		Recruiting	No Results Available	COVID-19	Drug: C21|Drug: Placebo	Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.)	Vicore Pharma AB|Orphan Reach	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	VP-C21-006|2020-001502-38	July 21, 2020	September 2020	September 2021	June 30, 2020		September 1, 2020	Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India|Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India|Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India|First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India|Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India|Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India|Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India|Respiratory Medicine, University College Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04452435
116	NCT04504240	Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients		Recruiting	No Results Available	Covid19	Drug: Famotidine 20 MG	Symptomatic improvement|"Clinical status (Stable or Deteriorate clinical state)"|Adverse effects	Chattogram General Hospital	All	16 Years to 80 Years   (Child, Adult, Older Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10000753/980	August 1, 2020	October 30, 2020	October 30, 2020	August 7, 2020		August 11, 2020	Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinājpur, Bangladesh		https://ClinicalTrials.gov/show/NCT04504240
117	NCT04568031	Study of AZD1222 for the Prevention of COVID-19 in Japan		Recruiting	No Results Available	COVID-19	Drug: AZD1222	Proportion of participants who have a post treatment seroresponse|The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination|The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)|Biochemistry; change from baseline for blood chemistry measures|Haematology; change from baseline for hematology/hemostasis measures|Geometric mean titres	AstraZeneca|Iqvia Pty Ltd	All	Child, Adult, Older Adult	Phase 1|Phase 2	12	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	D8111C00002	August 23, 2020	September 6, 2021	September 6, 2021	September 29, 2020		September 29, 2020	Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Toshima-ku, Japan		https://ClinicalTrials.gov/show/NCT04568031
118	NCT04478019	SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding	SHIELD	Recruiting	No Results Available	COVID-19|SARS-CoV 2	Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse	Number of Participants with COVID-19 diagnosis|SARS-Cov-2 Viral Load|Fidelity of the treatment regimen|Feasibility of the treatment regimen	University of Wisconsin, Madison	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	94	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2020-0540|A534265|SMPH/MEDICINE/INFECT DIS|Protocol Version 6/1/2020	July 7, 2020	April 30, 2021	April 30, 2021	July 20, 2020		July 20, 2020	University of Wisconsin-Madison, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04478019
119	NCT04345445	Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression		Not yet recruiting	No Results Available	COVID-19	Drug: Tocilizumab|Drug: Methylprednisolone	The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay	University of Malaya	All	18 Years and older   (Adult, Older Adult)	Phase 3	310	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TVCS-COVID19	April 15, 2020	October 31, 2020	October 31, 2020	April 14, 2020		April 14, 2020	University Malaya Medical Centre, Kuala Lumpur, Malaysia		https://ClinicalTrials.gov/show/NCT04345445
120	NCT04393805	Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto	HETHICO	Recruiting	No Results Available	COVID-19|Hypercoagulability	Drug: Low Molecular Weight Heparin	Bleeding|Thrombosis|Mortality|Worsening|LOS	Quovadis Associazione|University of Padova	All	18 Years and older   (Adult, Older Adult)		877	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	HETHICO	June 1, 2020	December 2020	December 2020	May 19, 2020		September 17, 2020	Giuseppe Camporese, Padova, Italy		https://ClinicalTrials.gov/show/NCT04393805
121	NCT04470531	Role of Co-trimoxazole in Severe COVID-19 Patients		Recruiting	No Results Available	Covid19|Severe COVID-19 Patients	Drug: oral co-trimoxazole	Length of stay in hospital (in days)|In-patient mortality|SpO2/FiO2 ratio|respiratory rate|C-reactive Protein|Fever|Ventilator support|Proportion of drug adverse reaction	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Anwar Khan Mordern Medical College and Hospital, Dhaka|Mugda Medical College and Hospital, Dhaka	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	94	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BSMMU/2020/6969	July 12, 2020	October 12, 2020	January 30, 2021	July 14, 2020		July 16, 2020	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh		https://ClinicalTrials.gov/show/NCT04470531
122	NCT04476706	Canakinumab MAP in COVID-19 Pneumonia With CRS		Available	No Results Available	Cytokine Release Syndrome in COVID-19-induced Pneumonia	Drug: canakinumab		Novartis Pharmaceuticals|Novartis	All	18 Years to 100 Years   (Adult, Older Adult)			Industry	Expanded Access		CACZ885D2001M				July 20, 2020		July 20, 2020			https://ClinicalTrials.gov/show/NCT04476706
123	NCT04530422	Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment		Completed	No Results Available	Covid19	Drug: Sofosbuvir plus Ledipasvir	Therapeutic success (cured)|28 days in hospital mortality|Percentage of clinical failure of treatments|Length of hospital stay|Incidence of side effects	Almaza Military Fever Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	14	April 15, 2020	July 8, 2020	July 23, 2020	August 28, 2020		August 28, 2020	Almaza Military Fever Hospital, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04530422
124	NCT04501796	A Trial of NT-I7 in COVID-19 (SPESELPIS)		Recruiting	No Results Available	COVID-19	Drug: Double-Blind NT-I7|Drug: Double-Blind Placebo	Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.	NeoImmuneTech	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NIT-116 (SPESELPIS)	August 2020	October 2021	December 2021	August 6, 2020		August 6, 2020	Nih/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT04501796
125	NCT04347915	The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19		Recruiting	No Results Available	COVID-19	Drug: Clevudine|Drug: Placebo	The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load	Bukwang Pharmaceutical	All	19 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BK-CLV-201	May 6, 2020	September 30, 2020	December 31, 2020	April 15, 2020		June 30, 2020	Korea University Guro Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04347915
126	NCT04470622	Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)		Recruiting	No Results Available	COVID-19	Drug: Aprepitant injectable emulsion|Drug: Saline Placebo	Proportion of subjects alive and discharged from the hospital.|Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).|Time to discharge from hospital.|Change from Baseline in Interleukin 6 (IL-6).|Incidence of treatment-emergent adverse events.	Heron Therapeutics	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HTX-019-202	July 20, 2020	October 2020	November 2020	July 14, 2020		August 28, 2020	Helen Keller Hospital, Sheffield, Alabama, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States|Ponce Medical School Foundation, Ponce, Puerto Rico		https://ClinicalTrials.gov/show/NCT04470622
127	NCT04359667	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	UHID-COVID19	Not yet recruiting	No Results Available	COVID-19|Severe Pneumonia	Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]	serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab	University Hospital for Infectious Diseases, Croatia	All	18 Years and older   (Adult, Older Adult)		30	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	UHID-04	June 16, 2020	April 16, 2021	May 15, 2021	April 24, 2020		June 9, 2020	University Hospital for Infectious Diseases "Dr Fran Mihaljevic", Zagreb, Croatia		https://ClinicalTrials.gov/show/NCT04359667
128	NCT04456049	Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19		Not yet recruiting	No Results Available	COVID-19 Infection	Drug: Enzalutamide	Efficacy of Enzalutamide|Disease progression|Tollerability of Enzalutamide	Ricardo Pereira Mestre|Oncology Institute of Southern Switzerland|Institute of Oncology Research|Institute for Research in Biomedicine|Ente Ospedaliero Cantonale, Bellinzona	Male	50 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID_ENZA	July 2020	December 2021	December 2021	July 2, 2020		July 2, 2020	Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland		https://ClinicalTrials.gov/show/NCT04456049
129	NCT04393038	ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19	Mir-Age	Recruiting	No Results Available	COVID-19	Drug: ABX464|Drug: Placebo	Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive|Rate of patients hospitalized|Percentage of patients reporting each severity rating on a 7-point ordinal scale|Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs|Rate of patients requiring oxygen supplementation|Time to hospitalization|Time to assisted ventilation and oxygen supplementation|Change from baseline in microRNA-124 levels|Change from baseline in CRP, Troponin I & T and D-dimer|SARS-CoV-2 viral load|Number and rates of participants with Treatment Emergent Adverse Event	Abivax S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1034	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	ABX464-401	May 1, 2020	December 30, 2020	April 30, 2021	May 19, 2020		July 20, 2020	Centre hospitalier Saint Pierre, Brussels, Belgium|Hôpital Erasme, Brussels, Belgium|UZ Gent, Gent, Belgium|Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema, Manaus, Amazonas, Brazil|Centro Oncológico de Roraima - CECOR - NAP, Boa Vista, Roraima, Brazil|Hospital das Clinicas da FMUSP, São Paulo, Sao Paulo, Brazil|Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro, Rio De Janeiro, Brazil|Conjunto Hospitalar do Mandaqui, Sao Paulo, Brazil|Hôpital Nord, Amiens, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|Centre Hospitalier Universitaire de Nice, Nice, France|Hôpital Saint-Antoine, Paris, France|Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid, Mannheim, Baden-Württemberg, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases, Milano, Lombardia, Italy|Ospedale San Paolo, Milano, Lombardia, Italy|Ospedale Luigi Sacco, AO-PU, Milano, Lombardia, Italy|Ospedale di Vittorio Veneto - Medecina generale, Vittorio Veneto, Treviso, Italy|Ospedale A. Manzonidi Lecco - ASST Lecco, Lecco, Italy|Ospedale Niguarda, Milano, Italy|Consultorio médico, Mérida, Yucatan, Mexico|Centro de Prevención y Rehabilitación de Enfermedades Pulmon, Nuevo León, Mexico|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|H.G.U. Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Royal Free Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04393038
130	NCT04303299	Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19	FIGHT-COVID-19	Recruiting	No Results Available	SARS-COV-2 Infections|COVID-19	Drug: Oral	SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment	Rajavithi Hospital	All	16 Years to 100 Years   (Child, Adult, Older Adult)	Phase 3	320	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TH-DMS-COVID19 study	August 19, 2020	December 31, 2021	December 31, 2021	March 11, 2020		September 1, 2020	Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT04303299
131	NCT04401423	TXA127 for the Treatment of Severe COVID-19		Recruiting	No Results Available	COVID-19	Drug: TXA127|Drug: Placebo	Change of serum creatinine|Number of participants requiring intubation and ventilatory support|Change in number of deceased participants|Number of participants requiring dialysis|Number of participants requiring a vasopressors|Change in blood inflammatory markers|Percent change in supplemental oxygen requirements	Columbia University	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	AAAT0535	August 2020	June 2021	December 2021	May 26, 2020		August 20, 2020	Columbia University Irving Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04401423
132	NCT04514302	Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Placebo|Drug: Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS)	Proportion of patients with improvement in clinical status|Time to clinical improvement|Proportion of patients that reach a score of 6, 7 or 8 in the NIAID 8-point ordinal scale|Duration of hospitalization|SARS-CoV-2 PCR negativization rate|Proportion of patients with clinical improvement at day 7|Proportion of patients with immediate adverse events (< 24 hours)|Proportion of patients with late adverse events (1 - 28 days)	Hospital San Jose Tec de Monterrey	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	51	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	INOSARS-CoV-2 TecSalud	October 20, 2020	February 20, 2021	June 20, 2021	August 14, 2020		August 14, 2020	Hospital San José, Monterrey, Nuevo Leon, Mexico		https://ClinicalTrials.gov/show/NCT04514302
133	NCT04392141	Colchicine Plus Phenolic Monoterpenes to Treat COVID-19		Recruiting	No Results Available	COVID-19	Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions	Mortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|lymphocyte count|serum lactate dehydrogenase|serum Interleukin-6|erythrocyte sedimentation rate	Kermanshah University of Medical Sciences	All	10 Years and older   (Child, Adult, Older Adult)	Phase 1|Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	1399.062	April 1, 2020	June 1, 2020	October 1, 2020	May 18, 2020		May 18, 2020	Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04392141
134	NCT04409925	DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)	DISCONNECT-1	Not yet recruiting	No Results Available	COVID-19 Infection	Drug: rhDNase I	Safety of inhaled rhDNase1 in non-ventilated COVID-19 patients by reporting of adverse events: rate of all adverse events, rate of serious adverse events, rate of grade 3/4/5 adverse events, drug-related adverse events.|Time to first study participant enrolment|Enrolment rate|Eligible patient consent rate|Completeness of drug delivery|Completeness of study-specific tests or procedures|Completeness of data collection|Hypoxia rate|Supplemental oxygen requirement type|Progression to mechanical ventilation rate|Duration of mechanical ventilation|Radiological progression|Renal dysfunction rate|Renal dysfunction extent|Time to hospital discharge or in-hospital mortality|Overall safety of health care workers and study personnel|Daily safety of health care workers and study	Exactis Innovation|Jewish General Hospital|Hamilton Health Sciences Corporation|McGill University Health Centre/Research Institute of the McGill University Health Centre|Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 1	25	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DISCONNECT-1	June 2020	August 2020	January 2021	June 1, 2020		June 17, 2020			https://ClinicalTrials.gov/show/NCT04409925
135	NCT04370262	Multi-site Adaptive Trials for COVID-19		Recruiting	No Results Available	COVID-19	Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo	Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity	Northwell Health	All	18 Years and older   (Adult, Older Adult)	Phase 3	942	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	20-0268	April 7, 2020	September 7, 2020	April 7, 2021	April 30, 2020		June 16, 2020	Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States		https://ClinicalTrials.gov/show/NCT04370262
136	NCT04434248	An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: Favipiravir|Drug: Standard of Care	Rate of viral elimination by Day 10 [pilot stage, dose selection]|Time to viral elimination [pivotal stage]|Time to clinical improvement [pivotal stage]|Rate of viral elimination|Time to normalization of clinical symptoms|Duration of oxygen therapy|Change in the level of lung damage according to CT|Rate of transfer to the intensive care unit|Rate of the use of non-invasive lung ventilation|Rate of the use of mechanical ventilation|Mortality|Peak plasma concentration (Cmax)|Time to peak plasma concentration (Tmax)|Area under the plasma concentration versus time curve (AUC0-t)|Trough plasma concentration (Ctrough)	Chromis LLC|Chemical Diversity Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	330	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-FPR-01	April 23, 2020	July 2020	July 2020	June 16, 2020		June 16, 2020	Republican Clinical Hospital, Makhachkala, Russian Federation|"K+31" Clinic, Moscow, Russian Federation|"Khaven" Llc, Moscow, Russian Federation|Central Clinical Hospital with Polyclinic, Moscow, Russian Federation|Central Research Institute of Epidemiology, Moscow, Russian Federation|City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital named after S.S. Yudin, Moscow, Russian Federation|City Clinical Hospital No. 24, Moscow, Russian Federation|City Clinical Hospital No. 51, Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|City Hospital № 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Ryazan State Medical University named after I.P. Pavlov, Ryazan, Russian Federation|Military Medical Academy named after S.M. Kirova, Saint Petersburg, Russian Federation|Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation|Clinical hospital No.1, Smolensk, Russian Federation|Regional Clinic Hospital, Tver, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yakutsk City Clinical Hospital, Yakutsk, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl, Russian Federation		https://ClinicalTrials.gov/show/NCT04434248
137	NCT04350593	Dapagliflozin in Respiratory Failure in Patients With COVID-19	DARE-19	Recruiting	No Results Available	COVID-19	Drug: Dapagliflozin 10 MG|Drug: Placebo	Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:|Hierarchical composite outcome measures including time to death from any cause, time to new/worsened organ dysfunction, clinical status at day 30 and time to hospital discharge|Time to hospital discharge|Total number of days alive, out of hospital, and/or free from mechanical ventilation|Total number of days alive, not in the ICU, and free from mechanical ventilation (as defined in the primary outcome measure)|Time to death from any cause|Time to new/worsened organ dysfunction|Time to acute kidney injury (defined as doubling of s-Creatinine compared to baseline)	Saint Luke's Health System|AstraZeneca|George Clinical Pty Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	900	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	D1690C00081|ESR-20-20653	April 22, 2020	October 2020	December 2020	April 17, 2020		August 27, 2020	Heart Group of the Eastern Shore, Fairhope, Alabama, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Centro de Pesquisa Dr. Marco Mota, Maceió, Alagoas, Brazil|Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Hospital de Messejana dr Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil|Hospital Coração do Brasil, Brasília, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espírito Santo, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Clínica do Coração, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, São Paulo, Brazil|Centro Integrado de Pesquisas, São José do Rio Preto, São Paulo, Brazil|Fundação Pio XII, Barretos, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04350593
138	NCT04366830	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection		No longer available	No Results Available	Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19	Drug: Remestemcel-L		Mesoblast International Sàrl|Mesoblast, Ltd.	All	18 Years and older   (Adult, Older Adult)			Industry	Expanded Access:Intermediate-size Population|Treatment IND/Protocol		MSB-MSC-ARDS001				April 29, 2020		April 29, 2020	Mount Sinai Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04366830
139	NCT04386850	Oral 25-hydroxyvitamin D3 and COVID-19		Recruiting	No Results Available	COVID 19	Drug: Oral 25-Hydroxyvitamin D3	COVID-19 (SARA-Cov-2) infection|Severity of COVID-19 (SARA-Cov-2) infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Serum levels of calcium|Serum levels of phosphorus|Serum levels of creatinine|Serum levels of albumin|Serum levels of the blood urea nitrogen (BUN)|Serum levels of the parathyroid hormone (PTH)	Tehran University of Medical Sciences|Boston University	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	IRCT2020-0401046909N2|IRCT20200401046909N1	April 14, 2020	November 15, 2020	March 15, 2021	May 13, 2020		June 12, 2020	Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04386850
140	NCT04372979	Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.	PLASCOSSA	Not yet recruiting	No Results Available	COVID-19	Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.	Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics	Direction Centrale du Service de Santé des Armées|University Hospital, Grenoble	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-A01166-33	May 2020	October 2020	May 2021	May 4, 2020		May 15, 2020	HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Bégin, Saint-Mandé, France|HIA Sainte Anne, Toulon, France		https://ClinicalTrials.gov/show/NCT04372979
141	NCT04427254	Study of the Sars-Cov2 Neuroinvasiveness - COVID19	CORONEVRAXE	Not yet recruiting	No Results Available	COVID19	Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies	Percentage of patients with COVID-19 positive samples/biopsies	Fondation Ophtalmologique Adolphe de Rothschild	All	18 Years and older   (Adult, Older Adult)	Not Applicable	500	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	PBN_2020_16	January 2021	January 2023	January 2023	June 11, 2020		October 5, 2020	Fondation A de Rothschild, Paris, France		https://ClinicalTrials.gov/show/NCT04427254
142	NCT04425629	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19		Recruiting	No Results Available	COVID-19	Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo	Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Proportion of patients with at least one COVID-19 related medically attended visit|Time-weighted average change from baseline in viral shedding measured by RT-qPCR in saliva samples|Time-weighted average change from baseline in viral shedding measured by RT-qPCR in nasal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR|Change from baseline in viral shedding as measured by RT-qPCR in NP swabs|Change from baseline in viral shedding as measured by RT-qPCR in saliva samples|Change from baseline in viral shedding as measured by RT-qPCR in nasal swabs|Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Time-weighted average change from baseline in viral shedding|Proportion of patients with at least two COVID-19 related medically attended visits|Total number of COVID-19 related medically-attended visits|Proportion of patients admitted to a hospital due to COVID-19|Proportion of patients admitted to an intensive care unit (ICU) due to COVID-19|Proportion of patients at least 1 outpatient or telemedicine visit due to COVID-19|Proportion of patients requiring mechanical ventilation due to COVID-19|Number of days of hospitalization due to COVID-19|Number of deaths due to any cause (All-Cause Mortality)|Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only)|Duration of symptoms consistent with COVID-19|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987	Regeneron Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	2104	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R10933-10987-COV-2067|2020-003690-21	June 16, 2020	December 19, 2020	December 19, 2020	June 11, 2020		September 21, 2020	Regeneron Study Site 1, Tucson, Arizona, United States|Regeneron Study Site 2, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site 1, Long Beach, California, United States|Regeneron Study Site 2, Long Beach, California, United States|Regeneron Study Site 3, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Ridgewood, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04425629
143	NCT04359212	Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19	VTE-COVID	Completed	No Results Available	COVID-19 Disease|Thromboembolism, Venous	Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux	the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism	Quovadis Associazione|Azienda Ospedaliera di Padova	All	18 Years and older   (Adult, Older Adult)		90	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	VTE-COVID	May 1, 2020	June 30, 2020	July 31, 2020	April 24, 2020		September 17, 2020	Giuseppe Camporese, Padova, Italy		https://ClinicalTrials.gov/show/NCT04359212
144	NCT04432298	Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease		Recruiting	No Results Available	COVID-19	Drug: Pamrevlumab|Drug: Placebo	Proportion of subjects who never received mechanical ventilation and/or ECMO and alive|Proportion of subjects alive, discharged home, and not on supplemental oxygen|Time to recovery based on a Modified 8-Point Ordinal Scale|Days in ICU/CCU (either on or off mechanical ventilation and/or ECMO)|Days on mechanical ventilation and/or ECMO|Time to death from any cause|Changes in PaO2/FiO2 ratio, both as categorical and continuous variable|Change in (non-invasive) oxygen supplementation requirements	FibroGen	All	40 Years to 85 Years   (Adult, Older Adult)	Phase 2	130	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FGCL-3019-098	June 20, 2020	December 2020	January 2021	June 16, 2020		June 24, 2020	Research Center, Greensboro, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04432298
145	NCT04325633	Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection	ENACOVID	Not yet recruiting	No Results Available	COVID-19	Drug: 1: Naproxen|Drug: 2: Standard of care	Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 3	584	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200387	April 13, 2020	May 13, 2021	July 13, 2021	March 27, 2020		April 14, 2020			https://ClinicalTrials.gov/show/NCT04325633
146	NCT04374591	The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia		Active, not recruiting	No Results Available	Pneumonia|Covid19	Drug: Sodium Bicarbonate	Time to clinical recovery|Pulmonary recovery status	Mansoura University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	180	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sodium Bicarbonate COVID-19	August 1, 2020	November 1, 2020	November 1, 2020	May 5, 2020		October 6, 2020	Gomhoria Street, Mansoura, Outside U.S./Canada, Egypt		https://ClinicalTrials.gov/show/NCT04374591
147	NCT04550338	Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure	TXACOVIDPREV	Not yet recruiting	No Results Available	COVID-19	Drug: Tranexamic acid|Drug: Placebo	Conversion from negative to positive COVID-19 test	University of Alabama at Birmingham	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	TXA.COVID.3	December 1, 2020	December 31, 2022	March 31, 2023	September 15, 2020		September 15, 2020			https://ClinicalTrials.gov/show/NCT04550338
148	NCT04465695	Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19		Recruiting	No Results Available	COVID-19	Drug: Interferon beta-1b|Drug: Clofazimine	Clinical alleviation of symptoms|Hospitalisation|Time to negative viral load|Inflammatory changes|Mortality|Adverse events	The University of Hong Kong	All	18 Years and older   (Adult, Older Adult)	Phase 2	81	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW 20-463	July 14, 2020	June 30, 2021	September 30, 2021	July 10, 2020		July 15, 2020	The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong, China		https://ClinicalTrials.gov/show/NCT04465695
149	NCT04377750	The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation		Recruiting	No Results Available	Covid19 Pneumonia	Drug: Tocilizumab	Survival	Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 4	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0224-20-HMO-CTIL	April 8, 2020	April 29, 2020	May 8, 2021	May 6, 2020		May 6, 2020	Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel		https://ClinicalTrials.gov/show/NCT04377750
150	NCT04464408	Favipiravir Therapy in Adults With Mild COVID-19	Avi-Mild	Recruiting	No Results Available	COVID-19	Drug: Favipiravir|Drug: Placebo	PCR negative|Time from randomization to clinical recovery|Symptoms progression based on clinical evaluation using simple scoring system.|Rate of daily requirement of using antipyretics, analgesics, or antibiotics.|28 days mortality.|Rate of requirement of hospitalization, ICU admission or Mechanical ventilation.|Incidence of Treatment-related Adverse Events [Safety and Tolerability]	King Abdullah International Medical Research Center|Ministry of Health, Saudi Arabia	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2|Phase 3	576	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RC 20/220/R	July 23, 2020	December 2020	June 2021	July 9, 2020		September 9, 2020	Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia|King Fahad Hospital - Madinah, Al Madīnah, Saudi Arabia|King Abdullah Medical City - Makkah, Mecca, Saudi Arabia|King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04464408
151	NCT04364984	ARB, ACEi, DRi in COVID-19	BIRCOV	Recruiting	No Results Available	Hypertension|COVID-19	Drug: Angiotensin converting enzyme inhibitor	BP (hypertensive efficacy)|COVID-19 course	Medical Practice Prof D. Ivanov	All	18 Years to 90 Years   (Adult, Older Adult)		10	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID20	April 1, 2020	April 1, 2021	August 1, 2021	April 28, 2020		April 28, 2020	Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukraine		https://ClinicalTrials.gov/show/NCT04364984
152	NCT04333420	Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia	PANAMO	Recruiting	No Results Available	Severe COVID-19 Pneumonia	Drug: SOC + IFX-1|Drug: SOC + Placebo	Mortality|Treatment Emergent Adverse Events|Safety Parameters	InflaRx GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IFX-1-P2.9	March 31, 2020	May 31, 2021	August 31, 2021	April 3, 2020		September 18, 2020	University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands		https://ClinicalTrials.gov/show/NCT04333420
153	NCT04341688	A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients	GARGLES	Not yet recruiting	No Results Available	Covid-19	Drug: Gargle/Mouthwash	Intraoral viral load|Salivary cytokine profile	Aga Khan University|University of Karachi	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	2020-Sur-ERC-4926	August 1, 2020	January 31, 2021	March 31, 2021	April 10, 2020		June 26, 2020			https://ClinicalTrials.gov/show/NCT04341688
154	NCT04433013	A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Lianhua Qingwen|Drug: Placebo	Proportion of participants who test negative for COVID-19|Time taken in days for relief of clinical symptoms|Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness|Proportion of participants who test positive for COVID-19 with Ct value>30	Nanyang Technological University|Ministry of Health, Singapore	All	21 Years and older   (Adult, Older Adult)	Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	IRB-2020-05-029	July 2020	December 2020	February 2021	June 16, 2020		June 17, 2020			https://ClinicalTrials.gov/show/NCT04433013
155	NCT04426695	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19		Recruiting	No Results Available	COVID-19	Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo	Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Proportion of patients with at least 1-point improvement on a 7-Point Ordinal Scale in clinical status|Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in saliva samples|Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in nasal samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR|Change from baseline in viral shedding as measured by RT-qPCR in NP swabs|Time-weighted average change in viral shedding|Change from baseline in viral shedding as measured by RT-qPCR in saliva samples|Change from baseline in viral shedding as measured by RT-qPCR in nasal swabs|Correlation of RT-qPCR results over time between different sample types|Concordance of RT-qPCR results over time between different sample types|Proportion of patients with at least 2-point improvement on a 7-Point Ordinal Scale in clinical status|Time to no longer requiring oxygen supplementation|Number of days of supplemental oxygen use|Proportion of patients initiating high-intensity oxygen therapy|Number of days of high-intensity oxygen therapy|Proportion of patients initiating mechanical ventilation|Number of days of mechanical ventilation|Number of Ventilator-free days|Number of days of hospitalization|Proportion of patients re-admitted to hospital after discharge through the end of study|Proportion of patients admitted into an intensive care unit (ICU)|Days of ICU stay|Number of deaths due to any cause (All-Cause Mortality)|Overall Survival|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987|Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933|Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987|Assessment of PK parameter: Clearance (CL) for REGN10933|Assessment of PK parameter: Clearance (CL) of REGN10987|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987|Assessment of PK parameter: Mean residence time (MRT) of REGN10933|Assessment of PK parameter: Mean residence time (MRT) of REGN10987	Regeneron Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	2970	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R10933-10987-COV-2066|2020-002537-15	June 10, 2020	January 25, 2021	January 25, 2021	June 11, 2020		October 1, 2020	Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Chandler, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Mission Hills, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pensacola, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Glenview, Illinois, United States|Regeneron Study Site, Urbana, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Chesterfield, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Englewood, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Pennington, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site 1, Buffalo, New York, United States|Regeneron Study Site 2, Buffalo, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, West Islip, New York, United States|Regeneron Study Site, White Plains, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Sugar Land, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04426695
156	NCT04542694	Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19		Completed	No Results Available	COVID-19	Drug: Favipiravir|Drug: Standard of care	Time to clinical improvement|Rate of clinical status improvement|Rate of viral elimination by Day 10|Time before the end of fever|Change in the level of lung damage according to CT|Rate of transfer to the intensive care unit|Rate of the use of non-invasive lung ventilation|Rate of the use of mechanical ventilation|Mortality	Promomed, LLC	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FAV052020	May 21, 2020	August 10, 2020	August 20, 2020	September 9, 2020		September 11, 2020	State Clinical Hospital №50, Moscow, Russian Federation|Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation|City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation|Medical institute Ogarev Mordovia State university, Saransk, Russian Federation|Smolensk clinical hospital №1, Smolensk, Russian Federation		https://ClinicalTrials.gov/show/NCT04542694
157	NCT04502069	Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen	Opaganib-RHB	Withdrawn	No Results Available	COVID-19|Lung Infection	Drug: Opaganib	Time to breathing room air|Adverse Event Grading and Coding	RedHill Biopharma Limited	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	0	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABC-112	August 2020	February 2021	June 2021	August 6, 2020		August 11, 2020	Shaare Zedek Medical Center, Jerusalem, Israel		https://ClinicalTrials.gov/show/NCT04502069
158	NCT04359615	Favipiravir in Hospitalized COVID-19 Patients	FIC	Not yet recruiting	No Results Available	COVID-19	Drug: Favipiravir|Drug: Hydroxychloroquine	Time to clinical improvement|Mortality|oxygen saturation by pulse oximetry (SpO2) Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events	Shahid Beheshti University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Favipiravir in COVID-19	April 20, 2020	May 3, 2020	May 5, 2020	April 24, 2020		April 28, 2020	Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04359615
159	NCT04355247	Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm		Recruiting	No Results Available	Covid-19	Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension	Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria	Auxilio Mutuo Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CCAM 20-01	April 14, 2020	July 31, 2020	April 30, 2021	April 21, 2020		April 21, 2020	San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT04355247
160	NCT04511819	Losmapimod Safety and Efficacy in COVID-19	LOSVID	Recruiting	No Results Available	COVID-19	Drug: Losmapimod oral tablet|Drug: Placebo oral tablet	Day 28 Mortality|Clinical Status Assessment|Respiratory Failure Assessment|Treatment Survival|Treatment-Emergent Adverse Events	Fulcrum Therapeutics	All	50 Years and older   (Adult, Older Adult)	Phase 3	410	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FIS-001-2020	August 28, 2020	November 2020	November 2020	August 13, 2020		September 16, 2020	University of California Irvine - Irvine Medical Center, Irvine, California, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil|Irmandade de Santa Casa de Misericordia de Porto Alegre, Centro Histórico, Porto Alegre - RS, Brazil|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|JM Research Cuernavaca, Cuernavaca, Morelos, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada, S.C., Culiacán, Sinaloa, Mexico		https://ClinicalTrials.gov/show/NCT04511819
161	NCT04359316	Azithromycin in Hospitalized COVID-19 Patients	AIC	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events	Shahid Beheshti University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Azithromycin in COVID-19	April 20, 2020	May 3, 2020	May 5, 2020	April 24, 2020		April 24, 2020	Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04359316
162	NCT04364815	The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures	Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection|Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)|Time to COVID-19 infection in patients receiving study drug (in days)|Safety and tolerability of study drug (to be reported as absolute number and frequency of events)	University of the Philippines	All	18 Years to 59 Years   (Adult)	Phase 3	960	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	RGAO-2020-0339	May 2020	May 2021	May 2021	April 28, 2020		May 5, 2020			https://ClinicalTrials.gov/show/NCT04364815
163	NCT04504032	A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: Rivaroxaban|Drug: Placebo	Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs)|Number of Participants With AEs Leading to Study Discontinuation|Number of Participants With Serious Adverse Events (SAEs)|Proportion of Participants With Disease Progression|Median Time to Disease Resolution|Proportion of Participants Who Achieve Disease Resolution|Mean Gates Medical Research Institute Ordinal Scale Score|Change From Baseline in Gates Medical Research Institute Ordinal Scale Score|Mean World Health Organization Ordinal Scale Score|Change From Baseline in World Health Organization Ordinal Scale Score|Incidence of Hospitalization|Number of Days of Hospitalization	Bill & Melinda Gates Medical Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 2	600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Gates MRI - COD-01-T01-01	September 2, 2020	December 2020	December 2020	August 7, 2020		October 6, 2020	Woodland Research Northwest LLC - ERG - PPDS, Rogers, Arkansas, United States|Science 37, Los Angeles, California, United States|Adult Medicine of Lake County, Mount Dora, Florida, United States|Providea Health Partners LLC, Evergreen Park, Illinois, United States|Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States|South Texas Allergy and Asthma Medical Professionals, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT04504032
164	NCT04329832	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19	HAHPS	Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score	Intermountain Health Care, Inc.|University of Utah	All	18 Years and older   (Adult, Older Adult)	Phase 2	85	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1051355	March 30, 2020	December 18, 2020	December 31, 2021	April 1, 2020		September 2, 2020	Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04329832
165	NCT04523831	Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection		Completed	No Results Available	Covid19	Drug: Ivermectin and Doxycycline	Early Clinical improvement of the patients|Late clinical recovery|Percentage of patients having clinical deterioration.|Persistently positive for RT-PCR of Covid-19	Dhaka Medical College	All	18 Years and older   (Adult, Older Adult)	Phase 3	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ERC-DMC/ECC/2020/117	June 1, 2020	August 22, 2020	September 10, 2020	August 24, 2020		September 30, 2020	Dhaka Medical College, Dhaka, Bangladesh	"Study Protocol and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/Prot_ICF_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT04523831
166	NCT04386239	Study on the Use of Sarilumab in Patients With COVID-19 Infection		Not yet recruiting	No Results Available	COVID19	Drug: Sarilumab Prefilled Syringe	Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction	ASST Fatebenefratelli Sacco	All	18 Years to 84 Years   (Adult, Older Adult)	Early Phase 1	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-SARI-001	May 2020	December 2020	December 2020	May 13, 2020		May 13, 2020		"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04386239
167	NCT04487444	Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection	Ta1	Recruiting	No Results Available	Covid19	Drug: Thymalfasin	Time to recovery (free of respiratory failure)|Lymphopenia|Survival|Hospital length of stay|Requirement for high flow oxygen supplementation|Duration of high flow oxygen supplementation|ICU admission|ICU length of stay|Mechanical ventilation|Duration of mechanical ventilation|Change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections (other respiratory, urinary tract, cellulitis, etc.)|AEs/SAEs|Changes to vital signs|Changes in laboratory parameters	Rhode Island Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCN-16130571-2	September 10, 2020	March 2021	June 2021	July 27, 2020		September 14, 2020	The Miriam Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT04487444
168	NCT04372589	Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )		Recruiting	No Results Available	COVID-19|Pneumonia	Drug: Heparin	Intubation and mortality|All-cause mortality|Intubation|Hospital-free days|ICU-free days|Ventilator-free days|Non-invasive ventilation|Organ support-free|Myocardial infarction|Ischaemic stroke|Venous thromboembolism|Major bleeding|Heparin-induced thrombocytopenia (HIT)	University of Manitoba|University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	3000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATTACC|OZM-113	May 20, 2020	January 2021	January 2021	May 4, 2020		June 4, 2020	University of Chicago, Chicago, Illinois, United States|Ochsner Clinic, Jefferson, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States|Deborah Heart and Lung Center, Browns Mills, New Jersey, United States|Albany Medical College, Albany, New York, United States|Mount Sinai Health System, New York, New York, United States|Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of São Paulo, São Paulo, Brazil|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Center Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier de l'université de Montréal (CHUM), Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Quebec-University Laval, Québec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT04372589
169	NCT04475107	The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Pyronaridine-Artesunate|Drug: Placebo	Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*|Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline|Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*|Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Time to achieve normalization of body temperature, post-dose|Time to achieve normalization of respiratory rate, post-dose|Time to achieve normalization of oxygen saturation, post-dose	Shin Poong Pharmaceutical Co. Ltd.	All	19 Years and older   (Adult, Older Adult)	Phase 2	76	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SP-PA-COV-201	July 2020	December 2020	February 2021	July 17, 2020		July 29, 2020	Korea University Ansan Hospital, Ansan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyungpook national university hospital, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04475107
170	NCT04273321	Efficacy and Safety of Corticosteroids in COVID-19		Completed	No Results Available	COVID-19|Novel Coronavirus Pneumonia	Drug: Methylprednisolone	the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days	Beijing Chao Yang Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	86	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Methylprednisolone in COVID-19	February 14, 2020	April 15, 2020	April 15, 2020	February 18, 2020		May 11, 2020	Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China		https://ClinicalTrials.gov/show/NCT04273321
171	NCT04500626	Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients		Not yet recruiting	No Results Available	Covid19	Drug: Oxygen	7-level COVID Ordinal Outcome Scale|Length of hospital stay|Days with oxygen supplementation|Daily oxygen flow values required to obtain saturation values ≥90%,|ICU admission|ICU length of stay|Days on invasive mechanical ventilation or high flow oxygenation|Major arterial and venous thrombotic events|Sleep quality|Fatigue|Mortality|Incidence of any adverse events related to HBOT	Ottawa Hospital Research Institute|Climate Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	234	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	OHRI-HBOT-001	October 2020	August 2022	August 2022	August 5, 2020		September 16, 2020	The Ottawa Hospital, Ottawa, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04500626
172	NCT04397328	COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo	Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.|Requirement for admission to acute care hospital and/or ICU admission or death|Asymptomatic PCR+ SARS-CoV-2 test result|Time to clinical recovery (TTCR).	Lawson Health Research Institute	All	40 Years and older   (Adult, Older Adult)	Phase 3	336	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	9881	May 19, 2020	April 30, 2021	April 30, 2021	May 21, 2020		May 21, 2020			https://ClinicalTrials.gov/show/NCT04397328
173	NCT04555213	A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19	NOXCOVID	Not yet recruiting	No Results Available	Covid19	Drug: NOX66	Incidence of Treatment-Emergent Adverse Events|Change of National Early Warning Score 2 units from baseline|Change in WHO-9 point ordinal scale	Noxopharm Limited	All	18 Years and older   (Adult, Older Adult)	Phase 1	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NOX66-007	September 2020	March 2021	June 2021	September 18, 2020		September 21, 2020			https://ClinicalTrials.gov/show/NCT04555213
174	NCT04355026	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia		Recruiting	No Results Available	Covid-19	Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet	Duration of hospitalization|Duration of disease|Hospital-aquired pneumonia|ICU stay duration|Oxygene therapy duration|Mechanical ventilatory support duration	General and Teaching Hospital Celje	All	19 Years and older   (Adult, Older Adult)	Phase 4	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SBCebromhexinCovid-19	April 10, 2020	June 30, 2020	July 31, 2020	April 21, 2020		April 21, 2020	SB Celje, Celje, Slovenia		https://ClinicalTrials.gov/show/NCT04355026
175	NCT04526717	Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection		Not yet recruiting	No Results Available	Covid19	Drug: MPT0B640	MTD|Viral load|Time to clinical improvement	Joseah Bio	All	18 Years and older   (Adult, Older Adult)	Phase 1	15	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JO201901-02	December 2020	December 2021	December 2021	August 26, 2020		August 26, 2020			https://ClinicalTrials.gov/show/NCT04526717
176	NCT04353336	Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment		Recruiting	No Results Available	COVID-19|Coronavirus Infection	Drug: Chloroquine or Hydroxychloroquine	Number of patients with cure or death	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	chloroquine covid	March 23, 2020	September 23, 2020	December 23, 2020	April 20, 2020		August 5, 2020	Tanta University, Assiut University, Ainshams University, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04353336
177	NCT04466540	Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)	COALITION-V	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo	Hospitalization|Uncontrolled asthma after ≥ 5 days of starting study medication|Pneumonia|Otitis media|Fever resolution time|Time to improve respiratory symptoms|Hospitalization in the Intensive Care Unit|Need for Orotracheal Intubation|Mechanical Ventilation Time|Mortality	Hospital Alemão Oswaldo Cruz|EMS S/A|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Moinhos de Vento|Brazilian Research In Intensive Care Network	All	18 Years and older   (Adult, Older Adult)	Phase 4	1300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	30415320.8.1001.0070	May 12, 2020	August 30, 2020	December 30, 2020	July 10, 2020		July 10, 2020	Centro de Pesquisas Clínicas Dr. Marco Mota HCOR, Maceió, Alagoas, Brazil|Hospital e Clínica São Roque, Ipiaú, Bahia, Brazil|Clínica Otorhinus, Salvador, Bahia, Brazil|Hospital da Bahia, Salvador, Bahia, Brazil|Hospital Santa Izabel, Salvador, Bahia, Brazil|Instituto Cárdio Pulmonar da Bahia, Salvador, Bahia, Brazil|Hospital SAMUR, Vitória Da Conquista, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, Ceará, Brazil|Unimed Sul Capixaba, Cachoeiro De Itapemirim, Espírito Santo, Brazil|Hospital das Clínicas Universidade Federal de Goiás, Goiânia, Goiás, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Agerais, Brazil|Hospital Júlia Kubitschek, Belo Horizonte, Minas Gerais, Brazil|Instituto da Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Casa de Caridade de Carangola, Carangola, Minas Gerais, Brazil|Hospital Maternidade e Pronto Socorro Santa Lucia, Poços De Caldas, Minas Gerais, Brazil|Hospital da Unimed, São João Del Rei, Minas Gerais, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, Minas Gerais, Brazil|Hospital de Clínicas da Universidade Federal do Triangulo Mineiro, Uberaba, Minas Gerais, Brazil|Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil|Hospital do Rocio, Campo Largo, Paraná, Brazil|Clínica Clinilive, Maringá, Paraná, Brazil|Hospital Universitário Regional de Maringá, Maringá, Paraná, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco, Brazil|SECRETARIA MUNICIPAL DE SAÚDE DE SAIRÉ (Unidade Mista Olília Mendonça Souto Maior), Sairé, Pernambuco, Brazil|Complexo Hospitalar de Niterói, Niterói, Rio De Janeiro, Brazil|Hospital Unimed Volta Redonda, Volta Redonda, Rio De Janeiro, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Porto Alegre (ISCMPA), Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil|CEPEM Centro de Pesquisa de Medicina Tropical de Rondônia, Porto Velho, Rondônia, Brazil|Irmandade de Misericórdia Do Hospital Da Santa Casa de Monte Alto, Monte alto, Salto Alto, Brazil|Maestri e Kormann Consultoria Medico Cientifica, Blumenau, Santa Catarina, Brazil|Imigrantes Hospital e Maternidade, Brusque, Santa Catarina, Brazil|Hospital São José, Criciúma, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Santa Casa de Araras, Araras, São Paulo, Brazil|Hospital de Amor, Barretos, São Paulo, Brazil|Santa Casa de Misericórdia de Barretos, Barretos, São Paulo, Brazil|Alphacor Cardiologia Clinica E Diagnóstica LTDA, Barueri, São Paulo, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, São Paulo, Brazil|Hospital de Cordeirópolis, Cordeirópolis, São Paulo, Brazil|Centro de Combate ao Coronavírus de Itapevi, Itapevi, São Paulo, Brazil|Dux Medicina, Jundiaí, São Paulo, Brazil|Hospital Carlos Fenando Malzoni, Matão, São Paulo, Brazil|Centro de Atendimento Para O Enfrentamento A Covid-19 Da Prefeitura Municipal de Monte Altoprefeitura de Monte Alto, Monte alto, São Paulo, Brazil|Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Hospital Casa de Saúde de Santos, Santos, São Paulo, Brazil|Kaiser Clínica e Hospital Dia, São José Do Rio Preto, São Paulo, Brazil|Hospital Policlin, São José Dos Campos, São Paulo, Brazil|Hospital Regional de São José dos Campos, São José Dos Campos, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|ESF Dr. João Paccola Primo, Lençois Paulista, Brazil|Cardioclinica da Ilha do Governador, Rio De Janeiro, Brazil|International Research Center - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital do Coração, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital Leforte, São Paulo, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Samaritano, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Hospital São Camilo Pompéia, São Paulo, Brazil|Hospital São Paulo - UNIFESP, São Paulo, Brazil|Hospital Sírio-Libanês, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04466540
178	NCT04387786	Dornase Alfa Administered to Patients With COVID-19 (DACOVID)	DACOVID	Active, not recruiting	No Results Available	COVID-19|Mechanical Ventilation	Drug: Dornase Alfa	Number of participants discharged from the intensive care unit (ICU)|Number of participants who survived COVID-19|Mean change in FiO2	Feinstein Institute for Medical Research|Cold Spring Harbor Laboratory|Northwell Health	All	18 Years to 85 Years   (Adult, Older Adult)		5	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	216	March 31, 2020	April 24, 2020	July 2020	May 14, 2020		May 14, 2020	Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States		https://ClinicalTrials.gov/show/NCT04387786
179	NCT04456153	Atovaquone for Treatment of COVID-19		Recruiting	No Results Available	COVID-19	Drug: Experimental Group|Drug: Placebo Group	Viral Load	University of Texas Southwestern Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	STU-2020-0707	July 22, 2020	December 2020	March 2021	July 2, 2020		July 30, 2020	University of Texas Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT04456153
180	NCT04542876	Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection		Completed	No Results Available	Covid19	Drug: Guduchi Ghan Vati	Virologic clearance|Hospital Stay|Clinically relevant adverse effects|Laboratory tests	Aarogyam UK|Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	46	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AYU/DSSR/03	May 1, 2020	July 31, 2020	August 18, 2020	September 9, 2020		September 9, 2020	Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India		https://ClinicalTrials.gov/show/NCT04542876
181	NCT04339426	Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection		Recruiting	No Results Available	Covid19	Drug: Atovaquone/Azithromycin	Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity	HonorHealth Research Institute	All	18 Years to 95 Years   (Adult, Older Adult)	Phase 2	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HRI-COVID-19-Anti-Malarial-001	April 20, 2020	October 2020	April 2021	April 9, 2020		June 9, 2020	HonorHealth, Scottsdale, Arizona, United States		https://ClinicalTrials.gov/show/NCT04339426
182	NCT04437693	Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients	HCQ-COVID19	Not yet recruiting	No Results Available	COVID 19	Drug: Hydroxychloroquine	Prevention of SARS-CoV-2 infection|Presence of any adverse effects related to HCQ|Incidence of COVID-19 related symptoms	Hamad Medical Corporation	All	18 Years to 60 Years   (Adult)	Phase 2|Phase 3	500	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	MRC-02-20-442	August 31, 2020	August 30, 2021	December 31, 2021	June 18, 2020		August 11, 2020			https://ClinicalTrials.gov/show/NCT04437693
183	NCT04331665	Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia		Not yet recruiting	No Results Available	COVID-19|Pneumonia	Drug: Ruxolitinib	Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay	University Health Network, Toronto	All	12 Years and older   (Child, Adult, Older Adult)	Not Applicable	64	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U-DEPLOY: RUX-COVID|20-5315	April 20, 2020	October 30, 2020	January 31, 2021	April 2, 2020		April 13, 2020	Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04331665
184	NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19		Completed	No Results Available	COVID-19	Drug: Sarilumab|Drug: Placebo	Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)|Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level	Regeneron Pharmaceuticals|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1912	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	6R88-COV-2040	March 18, 2020	July 24, 2020	September 2, 2020	March 19, 2020		October 1, 2020	Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04315298
185	NCT04527224	Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia		Not yet recruiting	No Results Available	Covid19	Drug: AstroStem-V	Treatment related adverse events|Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|Oxygenation index (PaO2 / FiO2 ratio)|Mortality rate|Ventilator treatment status|Improvement of pneumonia|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test|Duration of total hospitalization and intensive care unit stay (days)	Nature Cell Co. Ltd.	All	19 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	10	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASVP1N2A-US	December 1, 2020	October 1, 2021	April 1, 2022	August 26, 2020		September 11, 2020			https://ClinicalTrials.gov/show/NCT04527224
186	NCT04389671	The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19		Not yet recruiting	No Results Available	COVID-19|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)	Drug: Lucinactant	Oxygenation index (OI) area under the curve (AUC)0-12|FiO2|PaO2|Oxygenation from pulse oximetry (SpO2)|P/F ratio|Ventilation Index (VI)|Lung compliance	Windtree Therapeutics	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	02-CL-2001a	October 2020	March 2021	April 2021	May 15, 2020		October 8, 2020	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04389671
187	NCT04377620	Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)		Recruiting	No Results Available	COVID-19	Drug: Placebo|Drug: Ruxolitinib	Proportion of participants who have died due to any cause|Number of Ventilator free days|Number of ICU free days|Oxygen free days|Vasopressor free days|Hospital free days|Improvement in the COVID-19 ordinal scale|Change in SOFA Score|Number of treatment-related adverse events	Incyte Corporation	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	500	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	INCB 18424-369	May 24, 2020	September 29, 2020	September 29, 2020	May 6, 2020		June 16, 2020	Georgetown University Hospital, Washington, District of Columbia, United States|Tampa General Hospital, Tampa, Florida, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Clinic Inc., Burlington, Massachusetts, United States|UMass MMC - University Campus, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Jefferson Hospital, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04377620
188	NCT04384731	Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19	Caards-1	Recruiting	No Results Available	COVID-19|ARDS, Human	Drug: poractant alfa	Evolution of the PaO2 / FiO2 ratio between the measurements taken before (t0) and one hour after the end of the invasive procedure (H1).|Oxygenation : PaO2 / FiO2 ratio.|Oxygenation : area under the PaO2 / FiO2 curve.|Oxygenation : area under the SpO2 curve.|Evolution of thoraco-pulmonary compliance (mL / mbar) between before and one hour after the procedure.|Overall survival rate|Mortality rate at discharge from the intensive care unit.|Mortality rate at discharge from the hospital.|Number of ventilator-free days|Number of prone position sessions.|Time between inclusion and the last prone position session.	Dr Christophe LENCLUD|Versailles Hospital	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	P20/06	May 29, 2020	November 30, 2020	January 30, 2021	May 12, 2020		July 28, 2020	CH Francois Quesnay, Mantes la Jolie, France		https://ClinicalTrials.gov/show/NCT04384731
189	NCT04363372	A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19		Recruiting	No Results Available	COVID-19	Drug: MRx-4DP0004|Drug: Placebo	Change in mean clinical status score in each treatment arm|Number of adverse events in each treatment arm|Number of patients with an improvement in clinical status score in each treatment arm|Number of patients with a deterioration in clinical status score in each treatment arm|Number of patients with at least 95% oxygen saturation on room air in each treatment arm|Time to patients with at least 95% oxygen saturation on room air in each treatment arm|Number of patients with an improvement in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients with an deterioration in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients requiring Continuous Positive Airway Pressure in each treatment arm|Number of patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to patients requiring Continuous Positive Airway Pressure in each treatment arm|Time to patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to discharge in each treatment arm|Number of deaths in each treatment arm	4D pharma plc	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MRx-4DP0004-II-001	June 2020	August 2020	September 2020	April 27, 2020		July 1, 2020	University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom		https://ClinicalTrials.gov/show/NCT04363372
190	NCT04418128	Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia		Not yet recruiting	No Results Available	Corona Virus Infection|COVID-19	Drug: Nafamostat Mesylate	Proportion of patients with clinical improvement|Time to clinical improvement (TTCI)|Clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of ≤ 2 and maintained for 24 hours|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Incidence of new non-invasive ventilation or high flow oxygen use|Duration of new supplement oxygen use|Incidence of new supplement oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mortality at day 28|Time (days) from treatment initiation to death|Proportions of patients with a negative nasopharyngeal swab and sputum sample for SARS-CoV-2 quantitative RT-PCR|Viral load change (log10 viral load) of nasopharyngeal swab and sputum sample for SARS-CoV-2 quantitative RT-PCR|Adverse events that occurred during treatment	Gyeongsang National University Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	84	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-04-012	June 10, 2020	March 30, 2021	April 30, 2021	June 5, 2020		June 9, 2020			https://ClinicalTrials.gov/show/NCT04418128
191	NCT04412018	An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19		Recruiting	No Results Available	COVID-19|Inflammatory Response	Drug: Icosapent ethyl	Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit|Change in D-dimer levels from the randomization visit (Day 1) to the Day 14 visit|Change in erythrocyte sedimentation rate from the randomization visit (Day 1) to the Day 14 visit|Change in complete blood count from the randomization visit (Day 1) to the Day 14 visit|Change in differential count from the randomization visit (Day 1) to the Day 14 visit|Change in serum albumin levels from the randomization visit (Day 1) to the Day 14 visit|Change in neutrophil-to-lymphocyte ratio (NLR) from the randomization visit (Day 1) to the Day 14 visit|Change in systemic immune-inflammation index from the randomization visit (Day 1) to the Day 14 visit	Canadian Medical and Surgical Knowledge Translation Research Group|Amarin Corporation|HLS Therapeutics, Inc	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00043601	June 4, 2020	December 2020	December 2020	June 2, 2020		September 11, 2020	North York Diagnostic and Cardiology Clinic, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04412018
192	NCT04474340	COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients		Recruiting	No Results Available	Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia|Pneumonia, Viral	Drug: COVID-19 Convalscent Plasma	Time to clinical improvement|All cause mortality	Ministry of Health, Kuwait	All	15 Years to 85 Years   (Child, Adult, Older Adult)	Phase 1	300	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MOHKuwait	May 21, 2020	September 30, 2020	December 30, 2020	July 16, 2020		July 21, 2020	Ministry Of Health, Kuwait, Kuwait		https://ClinicalTrials.gov/show/NCT04474340
193	NCT04370288	Clinical Application of Methylene Blue for Treatment of Covid-19 Patients	Covid-19	Recruiting	No Results Available	Covid-19	Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)	Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count	Mashhad University of Medical Sciences	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IR.MUMS.REC.1399.122	April 19, 2020	September 20, 2020	September 21, 2020	April 30, 2020		May 4, 2020	Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04370288
194	NCT04475120	Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients		Completed	No Results Available	Covid19	Drug: liposomal lactoferrin	Rate of viral clearance Time to viral clearance|Time to clinical improvement	University of Rome Tor Vergata	All	20 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4220	April 15, 2020	July 2, 2020	July 2, 2020	July 17, 2020		July 17, 2020	University of Rome Tor Vergata, Rome, Italy		https://ClinicalTrials.gov/show/NCT04475120
195	NCT04485429	Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19	Drug: Methylprednisolone|Drug: Heparin	Rate of invasive mechanical ventilation|Severity assessment by ordinal severity scale|Severity assessment by SOFA score|Length of hospital stay|Length of stay in intensive care|Death rate	D'Or Institute for Research and Education	All	18 Years and older   (Adult, Older Adult)	Phase 3	268	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	31180820600005249	July 20, 2020	December 31, 2020	December 31, 2020	July 24, 2020		July 24, 2020	D'Or Institute for Research and Education, Rio de Janeiro, Brazil		https://ClinicalTrials.gov/show/NCT04485429
196	NCT04452474	Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).		Not yet recruiting	No Results Available	COVID-19	Drug: Olokizumab 64 mg|Drug: Placebo	Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category|Subjects' clinical status distribution based on 5-point clinical status scale during the study|28-day case fatality rates	R-Pharm|Cromos Pharma, LLC|Covance	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2|Phase 3	376	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CL04041080	June 30, 2020	November 16, 2020	January 29, 2021	June 30, 2020		June 30, 2020	George Washington University Medical Center, Washington, District of Columbia, United States|Center For Haptitis C/ Atlanta Medical Center, Atlanta, Georgia, United States|PMG Research of DuPage Medical Group, Downers Grove, Illinois, United States|Northwest Indiana Center for Clinical Research, Portage, Indiana, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|PMG Research, Inc., Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04452474
197	NCT04377997	Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19		Not yet recruiting	No Results Available	Cardiovascular Diseases|COVID-19	Drug: Enoxaparin	Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.|Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.	Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dartmouth-Hitchcock Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020P001136	May 15, 2020	January 1, 2021	January 1, 2022	May 7, 2020		May 7, 2020			https://ClinicalTrials.gov/show/NCT04377997
198	NCT04382755	Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure	ZILU-COV	Recruiting	No Results Available	COVID-19	Drug: Zilucoplan®|Drug: Placebo	Mean change in oxygenation|Median change in oxygenation|number of AE's (Adverse Events)|number of SAE's (Serious Adverse Events)|mean change in 6-point ordinal scale change|Time since randomization until improvement in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence of fever (defined as 37.1°C or more) for more than 48h without antipyretic|Number of days with fever|Mean change in CRP levels between day 1 and day 6|Mean change in CRP levels between day 1 and day 15 (or discharge whichever comes first)|Mean change in ferritin levels between day 1 and day 6|Mean change in ferritin levels between day 1 and day 15 (or discharge, whichever comes first)|Incidence of AE's|Incidence of SAE's|Incidence of SUSAR's (Suspected Unexpected Serious Adverse Reaction)|Incidence of SAR's (Serious Adverse Reaction)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change of SOFA score between day 1 and day 6 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 15 or on discharge, whichever is first)|Percentage of patients reporting each severity rating on a 6-point ordinal scale at randomization, day 6 and 15 (or discharge, whichever comes first) and day 28 (phone call)|6-point Ordinal Scale at 6 and 15 days (or discharge whichever comes first) and day 28 (phone call), in relation to serum D-dimers and complement C5a levels at randomization|Incidence of nosocomial bacterial or invasive fungal infection for 28 days (phone call) after enrolment in trial|Time since randomization until first use of high-flow oxygen devices in non-ventilated patients|Time since randomization until first use of non-invasive mechanical ventilation in non-ventilated patients|Time since randomization until first use of invasive mechanical ventilation in non-ventilated patients|Number of ventilator-free days|Duration of invasive and non-invasive mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial on invasive or non-invasive mechanical ventilation for less than 24h prior to or after randomization|Time since randomization to progression to ARDS (Acute Respiratory Distress Syndrome)|Time to progression to ARDS in ventilated patients according to D-dimers at randomization|Time to progression to ARDS in ventilated patients according to complement C5a at randomization|All-cause mortality rate (excluding group that entered during ventilation)|All-cause mortality rate (including group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities at follow up|Incidence of lung fibrosis on chest CT scan at follow up|All cause mortality for the entire study population	University Hospital, Ghent|UCB Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 2	81	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZILU-COV	May 22, 2020	May 2021	September 2021	May 11, 2020		July 9, 2020	OLVZ Aalst, Aalst, Belgium|AZ Sint Jan Brugge, Brugge, Belgium|Erasmus University Hospital, Brussels, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jan Yperman Ziekenhuis Ieper, Ieper, Belgium|University Hospital Liège, Liège, Belgium|AZ Delta, Roeselare, Belgium|AZ Vesalius, Tongeren, Belgium		https://ClinicalTrials.gov/show/NCT04382755
199	NCT04351243	A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)		Recruiting	No Results Available	COVID-19	Drug: Gimsilumab|Drug: Placebo	Incidence of mortality|Incidence of subjects who are alive and not on mechanical ventilation|Number of ventilator-free days|Time to hospital discharge	Kinevant Sciences GmbH|Roivant Sciences, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	270	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	KIN-1901-2001	April 12, 2020	October 2020	March 2021	April 17, 2020		September 4, 2020	Banner University Medical Center, Phoenix, Arizona, United States|HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States|Banner University Medical Center, Tucson, Arizona, United States|UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Miami Cancer institute, Miami, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Botsford General Hospital, Farmington Hills, Michigan, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott & White All Saints Medical Center, Fort Worth, Texas, United States|Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|Baylor Scott & White Medical Center, Irving, Texas, United States|Baylor Scott & White Medical Center, Plano, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States		https://ClinicalTrials.gov/show/NCT04351243
200	NCT04359277	A Randomized Trial of Anticoagulation Strategies in COVID-19		Terminated	No Results Available	COVID-19	Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation	Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock|Score on WHO Ordinal Scale|Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI))|Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Cardiac injury|Hypercoagulability|Disseminated Intravascular Coagulation (DIC) Score|Length of Hospital Stay	NYU Langone Health	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	77	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	s20-00479	April 21, 2020	September 20, 2020	September 20, 2020	April 24, 2020		October 7, 2020	NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04359277
201	NCT04351763	Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms	ReCOVery-SIRIO	Recruiting	No Results Available	COVID-19	Drug: Amiodarone|Drug: Verapamil	Clinical improvement|Mean change in the 7-point ordinal scale|Mortality|Time to resolution of fever|Clinical improvement or fever resolution|Tachyarrhythmias|Mortality or tachyarrhythmias|Time to clinical improvement from admission using the 7-point ordinal scale|Change in NEWS2 score|Duration of hospitalization|PO2/FIO2	Nicolaus Copernicus University	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2|Phase 3	804	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NCU-COVID19	April 27, 2020	March 2, 2021	April 10, 2021	April 17, 2020		April 17, 2020	Nicolaus Copernicus University, Bydgoszcz, Poland		https://ClinicalTrials.gov/show/NCT04351763
202	NCT04340544	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease	COMIHY	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo	Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days	University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	2700	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COMIHY	April 22, 2020	November 30, 2021	September 30, 2022	April 9, 2020		May 11, 2020	Institute for Tropical Medicine, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT04340544
203	NCT04415151	Tofacitinib for Treatment of Moderate COVID-19	I-TOMIC	Recruiting	No Results Available	COVID-19	Drug: Tofacitinib 10 mg|Drug: Placebo	Disease Severity|Clinical improvement|Time to recovery|Time to clinical improvement|Clinical status|Mortality|Mechanical Ventilatory Support|Mechanical Ventilatory Support Duration|Freedom from mechanical ventilation|Adverse events|Additional intervention|Viral titer	Yale University	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2000027848	July 29, 2020	March 31, 2021	March 31, 2021	June 4, 2020		October 8, 2020	Yale New Haven Health System, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04415151
204	NCT04509999	Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection		Not yet recruiting	No Results Available	COVID-19	Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo	Proportion x 100 = percent of patients with improved COVID-19 symptoms	University of Florida	Male	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IRB202001669-A|OCR38162	September 2020	September 2022	September 2022	August 12, 2020		August 21, 2020			https://ClinicalTrials.gov/show/NCT04509999
205	NCT04458298	A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients	PRANA	Recruiting	No Results Available	COVID-19	Drug: OP-101|Drug: Placebo	Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0|Time to Improvement (2 points) in Clinical Status Assessment Using the World Health Organization 7-Point Ordinal Scale (WHO 7OS)|Time to Resolution of Fever for at least 48 hours Without Antipyretics for Patients with Documented Fever (>=37.2 degree celsius [oral], or >=37.8 degree celsius [rectal], or >=38.0 degree celsius [tympanic])|Time to Improvement in Oxygenation for at least 48 hours|Change from Baseline in the World Health Organization (WHO)-7 Point Ordinal Scale|Time to Discharge from Clinic or Hospital or to National Early Warning Score 2 (NEWS2) of <=2 and maintained for 24 hours|Percentage of Patients Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital/Clinic or Day 30|Number of Days of Resting Respiratory Rate of more than 24 breath/min|Number of Days with Hypoxemia|Number of Days of Supplemental Oxygen use|Number of Ventilator-free Days|Number of Days in Intensive Care Unit (ICU)|Number of Days of Hospitalization for Survivors|Number of Participants with all cause deaths|Percent change from baseline in Proinflammatory Cytokines|Incidence of Drug-related Serious Adverse Events (SAEs)	Orpheris, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	OP-101-004	July 1, 2020	October 10, 2020	November 10, 2020	July 7, 2020		August 31, 2020	Research Site, Loma Linda, California, United States|Research site, Fort Lauderdale, Florida, United States|Research Site, Atlanta, Georgia, United States|Research site, Baltimore, Maryland, United States|Research Site, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04458298
206	NCT04507282	Eosinophil and Anticoagulation in COVID-19 Patients		Completed	No Results Available	COVID-19	Drug: LMWH	subprophylactic anticogulation level	Bursa Postgraduate Hospital	All	18 Years and older   (Adult, Older Adult)		80	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Bursa Postgraduate Hospital	May 15, 2020	July 1, 2020	July 15, 2020	August 11, 2020		August 18, 2020	Bursa Yüksek İhtisas Hastanesi, Yıldırım, Turkey		https://ClinicalTrials.gov/show/NCT04507282
207	NCT04443725	Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir|Drug: Standard of care treatment	Virological cure	Cairo University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CUKA-003	July 2020	October 2020	December 2020	June 23, 2020		June 25, 2020			https://ClinicalTrials.gov/show/NCT04443725
208	NCT04575610	IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)		Not yet recruiting	No Results Available	COVID-19	Drug: PF-06650833|Drug: Placebo	All-cause mortality at Day 29|Disease Severity (8 point scale)|Mortality|P/F ratio|Change of the SOFA score.|Duration (days) of mechanical ventilation|Ventilator free days.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Yale University|Pfizer	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	68	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2000028042	October 10, 2020	March 31, 2021	March 31, 2021	October 5, 2020		October 5, 2020	Yale New Haven Hospital, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04575610
209	NCT04345276	Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection		Completed	No Results Available	COVID-19	Drug: Danoprevir+Ritonavir	Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event	Huoshenshan Hospital|Ascletis Pharmaceuticals Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASC-CTP-HS-01	March 18, 2020	April 15, 2020	April 15, 2020	April 14, 2020		June 2, 2020	Huoshenshan Hostipal, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04345276
210	NCT04545541	Nebulised Heparin in Patients With Severe COVID-19	CHARTER-MT	Not yet recruiting	No Results Available	Covid19|Respiratory Failure	Drug: Nebulised unfractionated heparin (UFH)	Alive and Ventilator Free Score	Australian National University	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	202	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CHARTER meta-trial	October 2020	April 2022	June 2022	September 11, 2020		September 11, 2020			https://ClinicalTrials.gov/show/NCT04545541
211	NCT04291729	Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection		Completed	No Results Available	COVID-19	Drug: Ganovo+ritonavir+/-Interferon nebulization	Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event	The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	11	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASC-CTP-NC-01	February 17, 2020	March 19, 2020	March 19, 2020	March 2, 2020		April 13, 2020	The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China		https://ClinicalTrials.gov/show/NCT04291729
212	NCT04366050	Ramipril for the Treatment of COVID-19	RAMIC	Enrolling by invitation	No Results Available	COVID-19	Drug: Ramipril 2.5 MG Oral Capsule|Drug: Placebo oral capsule	Composite of mortality or need for ICU admission or ventilator use	University of California, San Diego|Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 2	560	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	RAMIC Trial	May 11, 2020	May 2021	May 2021	April 28, 2020		July 8, 2020	University of California, San Diego, La Jolla, California, United States		https://ClinicalTrials.gov/show/NCT04366050
213	NCT04341675	Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia	SCOPE	Recruiting	No Results Available	COVID-19	Drug: Sirolimus|Drug: Placebo	Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies	University of Cincinnati	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-0337	April 24, 2020	July 2020	September 2020	April 10, 2020		May 20, 2020	Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04341675
214	NCT04394416	Trial of Imatinib for Hospitalized Adults With COVID-19		Recruiting	No Results Available	COVID-19	Drug: Imatinib|Drug: Placebo oral tablet	The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events	University of Maryland, Baltimore	All	18 Years and older   (Adult, Older Adult)	Phase 3	204	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2038GCCC	June 2, 2020	June 1, 2022	June 1, 2023	May 19, 2020		June 4, 2020	University of Maryland Medical Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04394416
215	NCT04361643	Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial	GETAFE	Not yet recruiting	No Results Available	COVID-19	Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo	Clinical improvement|Immune-inflammatory improvement|Mortality	Hospital Universitario Getafe	All	60 Years and older   (Adult, Older Adult)	Phase 4	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID19-EC01	October 27, 2020	August 31, 2021	December 31, 2021	April 24, 2020		July 31, 2020	Hospital Universitario de Getafe, Getafe, Spain		https://ClinicalTrials.gov/show/NCT04361643
216	NCT04455243	Inflammatory Regulation Effect of NAC on COVID-19 Treatment	INFECT-19	Not yet recruiting	No Results Available	COVID-19	Drug: N-Acetyl cysteine|Drug: Placebo	Time to Recovery	Dr. Tariq Alhawassi|King Saud University	All	18 Years and older   (Adult, Older Adult)	Phase 3	1180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	E-20-4934	August 1, 2020	August 30, 2021	August 30, 2021	July 2, 2020		July 21, 2020			https://ClinicalTrials.gov/show/NCT04455243
217	NCT04438837	Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers		Not yet recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)|Post-Exposure Prophylaxis	Drug: Hydroxychloroquine	Clinical COVID-19|Confirmed COVID-19|Time to virological recovery|Time to symptoms onset|Development of pneumonia|Development of severe disease|Need for hospitalization or ICU|Adverse events|Mortality|Time to de-isolation	Rambam Health Care Campus	All	18 Years and older   (Adult, Older Adult)	Not Applicable	582	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	0193-20-RMB CTIL	July 2020	June 2022	June 2022	June 19, 2020		July 23, 2020	Rambam Health Care Campus, Haifa, Israel		https://ClinicalTrials.gov/show/NCT04438837
218	NCT04541979	Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19		Recruiting	No Results Available	COVID-19	Drug: aerosolized DNase|Drug: NaCl	Time to cessation of oxygen therapy DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with COVID-19 and respiratory dysfunction.|28-day mortality|Number of Days alive and without ventilator treatment|Number of Days alive and without high flow nasal oxygen treatment (Optiflow)|Number of Days alive and free of stay in the ICU|Number of Days alive and outside hospital|Number of Days alive and free of a new episode and with oxygen saturation ≤93% after primary endpoint has been met|Number of Days alive and without need of supplemental oxygen|Number of patients with adverse reactions	Region Skane	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	NETSC-19	June 4, 2020	November 1, 2020	December 1, 2020	September 9, 2020		September 9, 2020	Lund ED, Lund, Sweden		https://ClinicalTrials.gov/show/NCT04541979
219	NCT04421027	A Study of Baricitinib (LY3009104) in Participants With COVID-19	COV-BARRIER	Recruiting	No Results Available	COVID-19	Drug: Baricitinib|Drug: Placebo	Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])|Percentage of Participants with at Least 1-Point Improvement on NIAID-OS or Live Discharge from Hospital|Number of Ventilator-Free Days|Time to Recovery|Overall Improvement on the NIAID-OS|Duration of Hospitalization|Percentage of Participants with a Change in Oxygen Saturation from <94% to ≥94% from Baseline|Mortality|Duration of Stay in the Intensive Care Unit (ICU) in Days|Time to Clinical Deterioration (one-category increase on the NIAID-OS)|Time to Resolution of Fever, in Participants with Fever at Baseline|Mean Change from Baseline on the National Early Warning Score (NEWS)|Time to Definitive Extubation|Time to Independence from Non-Invasive Mechanical Ventilation|Time to Independence from Oxygen Therapy in Days|Number of Days with Supplemental Oxygen Use|Number of Days of Resting Respiratory Rate <24 Breaths per Minute	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 3	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	17830|I4V-MC-KHAA|2020-001517-21	June 12, 2020	December 5, 2020	December 5, 2020	June 9, 2020		October 6, 2020	Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Valleywise Health, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|White Oak Medical Center, Adventist Healthcare, Silver Spring, Maryland, United States|South Shore Hospital, Weymouth, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Renown Regional Med. Center, Reno, Nevada, United States|SUNY Downstate, Brooklyn, New York, United States|East Carolina University, Greenville, North Carolina, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States|Swedish Medical Center, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Hospital Z.G.A.D "Evita Pueblo", Berazategui, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Caba, Buenos Aires, Argentina|Fundacion Sanatorio Guemes, Caba, Buenos Aires, Argentina|Casa Hospital San Juan de Dios, Ramos Mejía, Buenos Aires, Argentina|Hospital Interzonal General de Agudos "Eva Peron", San Martin, Buenos Aires, Argentina|Centros de Investigaciones Cli-nicas. Clinica Viedma, Viedma, Rio Negro, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Hospital San Roque, Cordoba, Argentina|Hospital Sao Jose de Doencas Infecciosas - HSJ - Secretaria de Saude de Fortaleza, Fortaleza, Ceara, Brazil|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro Hospitalar de Reabilitacao Ana Carolina Moura Xavier, Curitiba, Parana, Brazil|CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva, Curitiba, Paraná, Brazil|CPCLIN, Natal, Rio Grande Do Norte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Carlos Fernando Malzoni Matao, Matao, Sao Paulo, Brazil|Pesquisare, Santo Andre, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo André, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, São Paulo, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, São Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|CECIP - Centro de Estudos do Interior Paulista, Jaù, São Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda, São Bernardo do Campo, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiencia, São Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica, São Paulo, Brazil|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Ospedale SS Annunziata, Chieti Scalo, Chieti, Italy|INMI Lazzaro Spallanzani, Roma, Rome, Italy|Ospedale Luigi Sacco, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Nuovo Ospedale di Prato S. Stefano, Prato, Italy|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Edogawa Medicare Hospital, Edogawa-ku, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|Hospital General Agustín O'Horán, Yucatan, Merida, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo León, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran- Medicina Critica, Federal District, Mexico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|GCM Medical Group, PSC- Hato Rey, San Juan, Puerto Rico|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|The Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Barnet Hospital, Barnet, Herts, United Kingdom|St. George's University Hospitals NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04421027
220	NCT04412772	A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS	ARCHITECTS	Recruiting	No Results Available	COVID-19	Drug: Tocilizumab|Drug: Placebo	Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation	Queen's Medical Centre	All	18 Years to 95 Years   (Adult, Older Adult)	Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	RA-2020-019	June 1, 2020	December 31, 2021	December 31, 2021	June 2, 2020		June 2, 2020	Queen's Medical Center, Honolulu, Hawaii, United States		https://ClinicalTrials.gov/show/NCT04412772
221	NCT04334382	Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19	HyAzOUT	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days	Intermountain Health Care, Inc.|University of Utah|Utah Department of Health	All	45 Years and older   (Adult, Older Adult)	Phase 3	1550	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1051360	April 2, 2020	December 31, 2020	December 31, 2021	April 6, 2020		April 9, 2020	Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04334382
222	NCT04393311	Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients		Not yet recruiting	No Results Available	COVID-19	Drug: Ulinastatin|Drug: Placebo	Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation	Stanford University	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	56639	November 2020	May 2021	May 2021	May 19, 2020		September 30, 2020	Stanford University, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04393311
223	NCT04500132	To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia		Recruiting	No Results Available	COVID-19	Drug: EC-18|Drug: Placebo EC-18	Rate of transition to ARDS	Enzychem Lifesciences Corporation	All	19 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	EC-18-C201	May 28, 2020	August 2021	May 2022	August 5, 2020		August 6, 2020	Chungbuk National University Hospital, Cheongju-si, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04500132
224	NCT04362189	Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: HB-adMSC|Drug: Placebo	Interleukin-6|C Reactive protein|Oxygenation|TNF alpha|IL-10|Return to room air (RTRA)|EKG qt interval|Leukocyte differential|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+/CD8+ ratio|Myoglobin|Troponin|Creatinine kinase MB|Serum ferritin|Adverse events|7-point ordinal scale|D-dimer|Chest X-ray|CT scan|PCR test for SARS-CoV-2	Hope Biosciences|Advanced Diagnostics Healthcare|Hope Biosciences Stem Cell Research Foundation|United Memorial Medical Center	All	Child, Adult, Older Adult	Phase 2	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Allogeneic Treatment COVID-19	June 30, 2020	October 31, 2020	October 31, 2020	April 24, 2020		August 12, 2020	River Oaks Hospital and Clinics, Houston, Texas, United States|United Memorial Medical Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04362189
225	NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19	APN01-COVID-19	Recruiting	No Results Available	COVID-19	Drug: RhACE2 APN01|Drug: Physiological saline solution	All Cause-death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death	Apeiron Biologics	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	APN01-01-COVID19	April 30, 2020	December 2020	December 2020	April 6, 2020		October 6, 2020	Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany|Regional State Budgetary Educational Institution "Clinical Hospital № 5, Barnaul", Barnaul, Russian Federation|State Healthcare Institution "State Clinical Hspital № 15 named after O.M. Filatov", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "City Clinical Hospital №52 of Health Department of Moscow", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow", Moscow, Russian Federation|Saint Petersburg SBHI City Hospital 38 named after N A Semashko, Pushkin, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "Ryazan State Medical University named after I.P. Pavlov" HD RF, Ryazan, Russian Federation|Alexandrovskaya Hospital, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint-Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education " Saratov State Medical University named after V.I. Razumovsky" HD RF, Saratov, Russian Federation|Regional State Budgetary Healthcare Institution "Clinical Hospital №1", Smolensk, Russian Federation|State budgetary institution of Healthcare of Tver region "Regional clinical hospital", Tver, Russian Federation|Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems "Healthy Ageing", Yaroslavl, Russian Federation|Cambridge University Hospitals NHS Trust/University of Cambridge, Cambridge, United Kingdom		https://ClinicalTrials.gov/show/NCT04335136
226	NCT04358549	Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: Favipiravir + Standard of Care|Drug: Standard of Care	Time to viral clearance|Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15|Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)|Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)|Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin|Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC	Fujifilm Pharmaceuticals U.S.A., Inc.	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FAVI-COV-US201	April 17, 2020	October 1, 2020	November 1, 2020	April 24, 2020		September 9, 2020	HonorHealth, Scottsdale, Arizona, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Boston Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Memorial Health Care, Worcester, Massachusetts, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Houston Methodist Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04358549
227	NCT04370236	XPro1595 for the Treatment of Pulmonary Complications From COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: XPro1595|Drug: Placebo	Proportion of participants with disease progression from randomization to 28 days post-randomization|Proportion of participants with all-cause mortality|Proportion of participants who transfer to ICU level care by Day 28 (ICU level care is defined as a hospital setting where patient to nurse ratio is < 4);|Proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by Day 28;|Proportion of participants with evidence of new CHF or new MI requiring medical intervention by Day 28;|Proportion of participants with a new onset embolus or thrombus by Day 28;|Proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by Day 28;|Proportion of participants with an increase in the WHO Ordinal Scale of Clinical Improvement score at any time during the study;|Length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;|Change from baseline in inflammation markers over time.	Inmune Bio, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	366	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	XPro1595-COVID-19	July 2020	February 2021	February 2021	April 30, 2020		June 2, 2020			https://ClinicalTrials.gov/show/NCT04370236
228	NCT04359511	Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia	CORTICOVIDHUGO	Not yet recruiting	No Results Available	COVID-19	Drug: Prednisone|Drug: Hydrocortisone	Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.|Proportion of patients free of oxygen at day 14 and 28|Proportion of patients discharged alive from hospital at day 14 and 28|Time to discharge for patients alive|Proportion of patients that were hospitalized to ICU or who died at day 14 and 28|14 and 28 day mortality rate|The time until weaning from oxygen therapy|The proportion of patients with clinical degradation of at least 1 point on the ordinal scale to 7 categories on D14 and D28	University Hospital, Tours	All	18 Years and older   (Adult, Older Adult)	Phase 3	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CORTI-COVID-19-HUGO|DR200136	June 2020	December 2020	December 2020	April 24, 2020		June 4, 2020			https://ClinicalTrials.gov/show/NCT04359511
229	NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	COVIDOSE	Completed	No Results Available	COVID-19	Drug: Tocilizumab	Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline	University of Chicago	All	18 Years and older   (Adult, Older Adult)	Phase 2	32	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-0515	April 4, 2020	June 5, 2020	June 5, 2020	April 2, 2020		August 3, 2020	University of Chicago Medicine, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04331795
230	NCT04521322	Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease	CARR-COV-02	Recruiting	No Results Available	Covid19	Drug: Iota-Carrageenan	diagnose of COVID19 disease|Progression to a more severe disease state, defined as need for oxygen therapy.|lasting of disease|Incidence of COVID-19 disease onset in the first week after treatment	Ariel Dogliotti|Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno	All	18 Years and older   (Adult, Older Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	CEMIC	July 24, 2020	October 30, 2020	November 30, 2020	August 20, 2020		August 21, 2020	centro de educación médica e investigaciones clinicas (CEMIC), Buenos Aires, Capital Federal, Argentina		https://ClinicalTrials.gov/show/NCT04521322
231	NCT04494724	Clazakizumab vs. Placebo - COVID-19 Infection		Recruiting	No Results Available	COVID-19 Infection	Drug: Clazakizumab|Drug: Placebo	Primary Endpoint|Requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO)|Infusion-related reactions during 24 hours from the time of infusion|Patient survival at 28 days|Patient survival at 60 days|Requirement for open-label clazakizumab|Time in the intensive care unit (ICU)|Time in the hospital|Time to mechanical ventilation|Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14|Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28|Change in Radiologic Assessment of Lung Edema (RALE) at day 14|Change in Radiologic Assessment of Lung Edema (RALE) at day 28	The Methodist Hospital System	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Pro00025969	July 13, 2020	December 31, 2020	July 31, 2021	July 31, 2020		July 31, 2020	Houston Methodist Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04494724
232	NCT04429867	Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease		Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo	Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.|Hospital length of stay|30-Day Mortality|Resolution of Symptoms|Incidence of QTc >500ms after initiation of therapy|Incidence of discontinuation of therapy	WellStar Health System	All	18 Years and older   (Adult, Older Adult)	Phase 4	700	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	1604885	May 7, 2020	December 7, 2020	December 7, 2020	June 12, 2020		June 16, 2020	Wellstar Kennestone Hospital, Marietta, Georgia, United States		https://ClinicalTrials.gov/show/NCT04429867
233	NCT04344444	Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease	RCT	Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	Most severe outcome	LCMC Health	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 3	600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID 2020-001	April 13, 2020	April 10, 2021	December 10, 2021	April 14, 2020		August 24, 2020	University Medical Center New Orleans, New Orleans, Louisiana, United States		https://ClinicalTrials.gov/show/NCT04344444
234	NCT04405843	Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19		Recruiting	No Results Available	COVID-19	Drug: Ivermectin Oral Product|Drug: Placebo	Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention	Centro de Estudios en Infectogía Pediatrica	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ScDi823	July 14, 2020	November 2020	December 14, 2020	May 28, 2020		September 2, 2020	Centro de Estudios en Infectología Pediátrica, Cali, Valle, Colombia		https://ClinicalTrials.gov/show/NCT04405843
235	NCT04425772	A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）		Not yet recruiting	No Results Available	COVID-19	Drug: FNC+Standard of Care|Drug: FNC dummy tablet+Standard of Care	Change (reduction) in viral load from baseline|proportion of subjects change from mild or moderate type to severe type|proportion of subjects change from severe type to critical type|novel coronavirus nucleic acid conversion rate|Novel coronavirus nucleic acid negative conversion time|The time and proportion of improvement in pulmonary imaging|Time and proportion of temperature return to normal|time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.)|time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms|Changes of blood oxygen detection index|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of adverse events	HeNan Sincere Biotech Co., Ltd	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	342	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FNC-Hope4	June 12, 2020	August 12, 2020	August 12, 2020	June 11, 2020		June 11, 2020			https://ClinicalTrials.gov/show/NCT04425772
236	NCT04554433	New Treatment for COVID-19 Using Ethanol Vapor Inhalation .		Not yet recruiting	No Results Available	Covid-19|Drug Effect	Drug: Ethanol with Asprin	Disinfection of COVID-19 in human respiratory tract .|Improvement of general condition of mechanically ventilated patients confirmed COVID-19 positive ..	Mansoura University	All	20 Years to 60 Years   (Adult)	Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20.08.79	October 1, 2020	October 1, 2021	June 1, 2022	September 18, 2020		September 21, 2020			https://ClinicalTrials.gov/show/NCT04554433
237	NCT04307693	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)		Terminated	No Results Available	COVID-19	Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate	Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine	Asan Medical Center	All	16 Years to 99 Years   (Child, Adult, Older Adult)	Phase 2	65	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S2020-0472-0001	March 11, 2020	April 30, 2020	April 30, 2020	March 13, 2020		May 27, 2020	Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04307693
238	NCT04397562	A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19	CORONA	Active, not recruiting	No Results Available	COVID-19	Drug: Levilimab|Drug: Placebo	Mortality rate|7-point Ordinal Scale|Duration of hospital stay|Rate of subjects required ICU stay|Duration of ICU Stay|Rate of subjects with COVID-19 progression to critical (respiratory failure required invasive ventilation or septic shock or multiple organ failures|Rate of subjects requiring the rescue therapy|Duration of oxygen supplementation|Rate of subjects requiring the invasive ventilation|Duration of invasive ventilation	Biocad	All	18 Years and older   (Adult, Older Adult)	Phase 3	204	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BCD-089-4	April 29, 2020	April 2021	April 2021	May 21, 2020		June 11, 2020	State Budgetary Healthcare Institution Kaluga region "Kaluga Regional Clinical Hospital", Kaluga, Russian Federation|State Budget Institution of the Republic of Dagestan "Republican Clinical Hospital", Machačkala, Russian Federation|A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation|City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow, Russian Federation|City Clinical Hospital No.52, Moscow, Russian Federation|City Clinical Hospital № 15 named. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department, Moscow, Russian Federation|Federal State Budgetary Institution "Central Clinical Hospital with Clinic", Office of the President of the Russian Federation, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Railway clinical hospital named after N.A. Semashko, Moscow, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation|North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "North Ossetian State Medical Academy" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation		https://ClinicalTrials.gov/show/NCT04397562
239	NCT04364763	A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)		Recruiting	No Results Available	COVID-19	Drug: RBT-9 (90 mg)|Drug: 0.9% sodium chloride (normal saline)	Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale|Time to first occurrence of death from any cause or new/worsened organ dysfunction|All-cause survival|Oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio|Fever incidence|Acute kidney injury (AKI) incidence|New or worsening congestive heart failure (HF)|Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit (ICU) status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status	Renibus Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	252	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	REN-005	August 5, 2020	June 30, 2021	December 31, 2021	April 28, 2020		September 28, 2020	New Smyrna Beach, FL, New Smyrna Beach, Florida, United States|Fort Worth, TX, Fort Worth, Texas, United States|Houston, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04364763
240	NCT04411628	A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19		Completed	No Results Available	COVID-19	Drug: LY3819253|Drug: Placebo	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253|Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load	Eli Lilly and Company|AbCellera Biologics Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	24	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	17823|J2W-MC-PYAA	May 28, 2020	August 26, 2020	August 26, 2020	June 2, 2020		September 22, 2020	Cedars Sinai Medical Center, Los Angeles, California, United States|Veterans Affairs Medical Center San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Alexandria Center for Life - NYC/ NYCEDC, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Unified Research Enterprise Brody School of Medicine at ECU, Greenville, North Carolina, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04411628
241	NCT04331834	Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic	PrEP_COVID	Suspended	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebos	Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank	Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital Plató|Hospital de Granollers	All	18 Years and older   (Adult, Older Adult)	Phase 3	440	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PrEP_COVID	April 3, 2020	October 3, 2020	October 30, 2020	April 2, 2020		July 15, 2020	ISGlobal, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04331834
242	NCT04313023	The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2		Recruiting	No Results Available	COVID-19	Drug: PUL-042 Inhalation Solution|Drug: Placebo	Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality	Pulmotect, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PUL-042-501	June 9, 2020	October 2020	November 2020	March 18, 2020		September 4, 2020	University of California Irvine, Orange, California, United States|Premier Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04313023
243	NCT04501952	Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting		Recruiting	No Results Available	COVID-19	Drug: RDV|Drug: Placebo to Match RDV	Composite Endpoint Measuring Proportion of Participants Hospitalized or Death From Any Cause by Day 14.|Proportion of Participants Experiencing Treatment-Emergent Adverse Events|All-cause Mortality at Day 28|Rate of Hospitalization by Day 28|Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7|Time to Resolution of COVID-19-Related Symptoms|Proportion of Participants Progressing to Requiring Oxygen Supplementation by Day 28	Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	1230	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GS-US-540-9012|2020-003510-12	September 18, 2020	December 2020	January 2021	August 6, 2020		October 2, 2020	Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast, Vero Beach, Florida, United States|Triple O Research Institute PA, West Palm Beach, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Arizona Clinical Trials, Bethesda, Maryland, United States|Be Well Medical Center, Berkley, Michigan, United States|Memorial Hospital of Gulfport, Gulfport, Mississippi, United States|Rosedale Infectious Diseases, Huntersville, North Carolina, United States|The Crofoot Research Center, Inc, Houston, Texas, United States|Intermountain Healthcare, Murray, Utah, United States		https://ClinicalTrials.gov/show/NCT04501952
244	NCT04292899	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)		Completed	No Results Available	COVID-19	Drug: Remdesivir|Drug: Standard of Care	The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events	Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	4891	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GS-US-540-5773|2020-000841-15	March 6, 2020	April 9, 2020	June 30, 2020	March 3, 2020		July 27, 2020	Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT04292899
245	NCT04385264	#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19	#StayHome	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Mannitol	Proportion of poor outcomes (in index cases)|Secondary household attack rate (in household contacts)|Subjective disease severity (in index cases)|Rate of acute respiratory distress syndrome (in index cases)|Severity of radiological lung pathology (in index cases)|Objective disease severity (in index cases)|Safety: Unintended toxic HCQ accumulation (in index cases)|Safety: Adverse events (in index cases)|Social distancing knowledge, attitudes and practices amongst index cases and household contacts	Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Unisante	May 12, 2020	August 2020	October 2020	May 12, 2020		May 12, 2020	Unisanté, Lausanne, Vaud, Switzerland		https://ClinicalTrials.gov/show/NCT04385264
246	NCT04539262	Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation		Recruiting	No Results Available	COVID-19	Drug: Remdesivir (RDV)|Drug: Placebo	Time-weighted Average Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation|Proportion of Participants Progressing From Early Stage Coronavirus Disease 2019 (COVID-19) to Hospitalization or Death by Day 14|Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and its Metabolites (GS-441524 and GS-704277)|PK Parameter: AUClast of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: CLss/F of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: t1/2 of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Vz/F of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Cmax of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Tmax of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Clast of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Tlast of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: AUCtau of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: λz of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Ctau of RDV and its Metabolites (GS-441524 and GS-704277)|Change in SARS-CoV-2 Viral Load From Baseline to Day 4|Change in SARS-CoV-2 Viral Load From Baseline to Day 7|Change in SARS-CoV-2 Viral Load From Baseline to Day 14|Time to Negative SARS-CoV-2 Polymerase Chain Reaction (PCR)	Gilead Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	282	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GS-US-553-9020	September 14, 2020	October 2020	December 2020	September 4, 2020		October 8, 2020	The Institute for Liver Health, Mesa, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Franco Felizarta, MD, Bakersfield, California, United States|Western Clinical Research, Placentia, California, United States|Westchester Research Center at Westchester General Hospital, Miami, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Triple O Research Institute, PA, West Palm Beach, Florida, United States|STAT Research, Vandalia, Ohio, United States|Baylor Research Institute, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT04539262
247	NCT04312997	The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection		Recruiting	No Results Available	COVID-19	Drug: PUL-042 Inhalation Solution|Drug: Placebo	Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality	Pulmotect, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PUL-042-502	June 16, 2020	October 2020	December 2020	March 18, 2020		September 4, 2020	University of California Irvine, Orange, California, United States|Premeir Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|DBC Research Corp., Tamarac, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04312997
248	NCT04377711	A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Ciclesonide|Drug: Placebo	Percentage of patients hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30|Time to hospital admission or death|Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM/PM assessments)|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30|Safety will be assessed based on adverse events.	Covis Pharma S.à.r.l.	All	12 Years to 100 Years   (Child, Adult, Older Adult)	Phase 3	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ALV-020-001	June 8, 2020	September 1, 2020	December 1, 2020	May 6, 2020		June 11, 2020	University of Buffalo, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT04377711
249	NCT04348409	Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19		Recruiting	No Results Available	COVID-19	Drug: Nitazoxanide Tablets|Drug: Placebo	Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation	Azidus Brasil|Farmoquimica S.A.|Hospital Vera Cruz|Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil|Centro de Genomas - UNIFESP|Emilio Ribas Institute of Infectious Diseases	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NITFQM0320OR	May 25, 2020	July 31, 2020	July 31, 2020	April 16, 2020		June 9, 2020	Hospital Vera Cruz, Campinas, São Paulo, Brazil|Centro de Genomas, São Paulo, Brazil|Hospital Emílio Ribas, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04348409
250	NCT04540926	Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia		Not yet recruiting	No Results Available	COVID 19 Pneumonia	Drug: Cyclosporin A	Number of days to clinical improvement until hospital discharge or death.	Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	200	Other	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	135.2020	September 2020	September 2020	September 30, 2020	September 7, 2020		September 7, 2020	Jose Luis Jl Galvez-Romero, Puebla, Mexico		https://ClinicalTrials.gov/show/NCT04540926
251	NCT04360551	Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Telmisartan 40mg|Drug: Placebo	Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers	University of Hawaii	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	H051	July 1, 2020	June 30, 2021	June 30, 2021	April 24, 2020		August 3, 2020	University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States		https://ClinicalTrials.gov/show/NCT04360551
252	NCT04470297	Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19		Not yet recruiting	No Results Available	Covid19|Lung Injury	Drug: Ramelteon 8mg	Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0]|Clinical worsening to critical COVID-19 illness|Duration of supplemental oxygen therapy|Duration of mechanical ventilation (if applicable)|Duration of hospitalisation|Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR|C-reactive protein (CRP) level's reduction|Incidence of New Onset Lymphopenia|Direct bilirubin level's reduction|Side Effects	Associação Fundo de Incentivo à Pesquisa	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MELCOV2020	September 2020	November 2020	March 2021	July 14, 2020		July 24, 2020			https://ClinicalTrials.gov/show/NCT04470297
253	NCT04348435	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19		Enrolling by invitation	No Results Available	COVID-19	Drug: HB-adMSCs|Drug: Placebos	Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9	Hope Biosciences|Hope Biosciences Stem Cell Research Foundation	All	Child, Adult, Older Adult	Phase 2	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	Allogeneic COVID-19 Protection	May 14, 2020	December 31, 2020	April 30, 2021	April 16, 2020		July 14, 2020	Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States		https://ClinicalTrials.gov/show/NCT04348435
254	NCT04329572	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19		Suspended	No Results Available	COVID-19	Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets	Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days	Azidus Brasil	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	400	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIAPRE0320OR	April 23, 2020	May 31, 2020	June 30, 2020	April 1, 2020		April 22, 2020	Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04329572
255	NCT04292730	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment		Completed	No Results Available	COVID-19	Drug: Remdesivir|Drug: Standard of Care	The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events	Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	1113	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GS-US-540-5774|2020-000842-32	March 15, 2020	April 29, 2020	June 26, 2020	March 3, 2020		July 27, 2020	Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT04292730
256	NCT04445935	Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial		Recruiting	No Results Available	Anticoagulation in COVID-19 ARDS	Drug: Bivalirudin Injection|Drug: Standard treatment	P/F ratio|Kidney function	Hamad Medical Corporation	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	MRC-05-082	June 28, 2020	September 28, 2020	March 28, 2021	June 24, 2020		June 24, 2020	Hamad Medical Corporation, Doha, Qatar		https://ClinicalTrials.gov/show/NCT04445935
257	NCT04344756	Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort	CORIMMUNO-COAG	Not yet recruiting	No Results Available	COVID19 Pneumonia	Drug: Tinzaparin or unfractionated heparin	Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale ≤5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	808	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200389-6	April 20, 2020	July 31, 2020	September 30, 2020	April 14, 2020		April 15, 2020	Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France|réanimation hôpital Cochin, Paris, France|Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France		https://ClinicalTrials.gov/show/NCT04344756
258	NCT04463264	Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: Nitazoxanide|Drug: Placebo	Eradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th.|Comparative decrease of the viral load|Clinical improvement|Pneumonia patients meeting severity criteria.|Number of days with fever	Laboratorios Roemmers S.A.I.C.F.	All	18 Years to 59 Years   (Adult)	Phase 2|Phase 3	135	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	NTZ-COVID ARG1	June 26, 2020	November 15, 2020	December 26, 2020	July 9, 2020		October 8, 2020	Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina		https://ClinicalTrials.gov/show/NCT04463264
259	NCT04347278	Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry	RegCOVID19	Recruiting	No Results Available	SARS-CoV-2	Drug: Patients with the treatment agains COVID19	Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.	Instituto de Investigación Marqués de Valdecilla|Hospital Universitario Marqués de Valdecilla|Hospital Universitario de Canarias|Hospital San Pedro de Alcántara	All	1 Year to 100 Years   (Child, Adult, Older Adult)		1000	Other	Observational	Observational Model: Other|Time Perspective: Other	IDI-REM-2020-1	April 22, 2020	October 15, 2020	January 1, 2021	April 15, 2020		June 2, 2020	Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain		https://ClinicalTrials.gov/show/NCT04347278
260	NCT04349631	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19		Enrolling by invitation	No Results Available	COVID-19	Drug: HB-adMSCs	Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9	Hope Biosciences	All	Child, Adult, Older Adult	Phase 2	56	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Protection Against COVID-19	April 22, 2020	December 31, 2020	December 31, 2020	April 16, 2020		July 13, 2020	Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States		https://ClinicalTrials.gov/show/NCT04349631
261	NCT04344782	Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort	CORIMMUNO-BEVA	Not yet recruiting	No Results Available	COVID19 Pneumonia	Drug: Bevacizumab Injection	Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	130	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200389-7	April 15, 2020	September 30, 2020	November 30, 2020	April 14, 2020		April 17, 2020			https://ClinicalTrials.gov/show/NCT04344782
262	NCT04484493	Corticosteroid Nasal Spray in COVID-19 Anosmia		Completed	No Results Available	Covid19|Anosmia	Drug: mometasone furoate nasal spray	improvement of olfaction	Benha University	All	18 Years and older   (Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RC 4-7-2020	August 8, 2020	September 3, 2020	September 6, 2020	July 23, 2020		September 9, 2020	Benha University Hospital, Faculty of Medicine, Banhā, Qalubia, Egypt		https://ClinicalTrials.gov/show/NCT04484493
263	NCT04435795	Inhaled Ciclesonide for Outpatients With COVID19		Not yet recruiting	No Results Available	COVID 19	Drug: Ciclesonide	Improvement in dyspnea at day 7|Hospitalization at day 14|Oxygen Use|Mortality|Clinical status|Anxiety|Sleep Disturbance|Exercise capacity	McGill University Health Centre/Research Institute of the McGill University Health Centre	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	454	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2021-6696	June 25, 2020	February 25, 2021	March 25, 2021	June 17, 2020		June 17, 2020			https://ClinicalTrials.gov/show/NCT04435795
264	NCT04379479	Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)	FUTURE-T	Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2 Infection	Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral	Change in the score of the "Contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by COVID-19"|Clinical deterioration|Duration of the clinical status	National Polytechnic Institute, Mexico	All	18 Years and older   (Adult, Older Adult)	Phase 2	562	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IC-20-001|SH-001-2020	May 2020	August 2020	December 2020	May 7, 2020		May 7, 2020	Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT04379479
265	NCT04346615	Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen		Recruiting	No Results Available	COVID-19 Infection	Drug: Zavegepant (BHV-3500)|Drug: Placebo	To compare the efficacy of zavegepant (BHV-3500) to placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a six-point rating scale at Day 15. .|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 29.|Proportion of subjects who have a 6-point severity rating of 2 or 3, or use any ventilation or high-flow nasal cannula as procedures, on any day through Day 29.|Proportion of subjects admitted into an ICU on any day through Day 29 from AE eCRFs.|Proportion of subjects who have a 6-point severity rating of 3, 4, 5, or 6, are alive, and do not use invasive mechanical ventilation as a procedure at Day 15. The analogous definition is applied to Day 29.|Proportion of subjects who have a 6-point severity rating of 4, 5 or 6, or use a low- or high-flow nasal, are alive, and do not use any ventilation at Day 15. The analogous definition is applied to Day 29.|Difference between treatment groups in the mean 6-point severity rating at Day 29|Number of days from baseline to the first day through Day 29 with any 6-point severity rating greater than baseline.|Number of days from baseline to the first of any 2 consecutive days through Day 29 with all SpO2/FiO2 ratios > 400 on both days.|Number of days from baseline to the first day through Day 29 with ≥ 1-point decrease in any NEWS2 score from baseline.|Number of days from baseline to the first day through Day 29 with all NEWS2 scores < 2 on that day.|Mean change from baseline in NEWS2 score at Days 15 and 29 for subjects who are alive at these time points|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 15.|Proportion of subjects who are discharged from the hospital, have a 6-point severity rating of 6 on any day after discharge, and use supplemental oxygen on any day after discharge.|Mean number of days with respiratory rate > 24 breaths/minute through Day 29 for subjects who are alive at Day 29 and do not use invasive mechanical ventilation.|Mean number of days with supplemental oxygen use through Day 29 for subjects who are alive at Day 29. A day in which any 6-point severity rating is 2, 3, or 4, or supplemental oxygen is used as a procedure counts.|Number of days from baseline to the first day through Day 29 on which any SpO2 ≥ 90%, any 6-point severity rating is 5 or 6, and no supplemental oxygen is used as a procedure.|Mean number of ventilator-free days through Day 29 for subjects who are alive at Day 29.|Mean SOFA total scores at ICU admission and Day 29 (if still in ICU), from SOFA and AE eCRFs.|Mean number of days of hospitalization through Day 29 for subjects who are alive on Day 29. All days on study on or before hospitalization discharge are days of hospitalization, from 6-point severity rating scale eCRFs|Number of days from baseline to the first of any 2 consecutive days through Day 29 in which all temperatures show lack of fever on both days and no antipyretics are used on either day.|Number of subjects with deaths, SAEs, severe AEs, and Grade 3 or 4 laboratory test abnormalities at any time on study.|Number and percentage of subjects with severe or life-threatening bacterial, invasive fungal, or opportunistic infections at any time through Day 29 from AE/SAE eCRFs.|Number and percentage of subjects with intranasal administration reactions at any time through Day 29 from AE/SAE eCRFs.|Proportion of subjects with ≥ 50% reduction in eGFR from baseline at any time on study from laboratory test eCRFs.	Biohaven Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BHV3500-203	April 25, 2020	April 2021	April 2021	April 15, 2020		September 25, 2020	Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Roper Hospital, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT04346615
266	NCT04448119	Control of COVID-19 Outbreaks in Long Term Care		Recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Favipiravir|Drug: Favipiravir Placebo	Control of Outbreak|Mortality (Residents)|COVID-19 Infection (Residents)|COVID-19 Infection (Staff)|Hospitalization (Residents)|Medication Discontinuation (Residents)|Medication Discontinuation (Staff)|COVID-19 in new LTCH Units (a)|COVID-19 in new LTCH Units (b)|COVID-19 in new LTCH Units (c)	Appili Therapeutics Inc.|MOUNT SINAI HOSPITAL|Applied Health Research Centre|Sunnybrook Health Sciences Centre|University Health Network, Toronto|University of Toronto	All	65 Years and older   (Older Adult)	Phase 2	760	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CONTROL-COVID-Favipiravir-1	September 2020	March 2021	March 2021	June 25, 2020		September 14, 2020	Mount Sinai Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04448119
267	NCT04379310	Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)	Covid-19	Completed	No Results Available	Covid-19	Drug: ACE Inhibitors and Calcium Channel Blockers	extend of lung involvement|oxygen saturation on admission	Nisantasi University	All	18 Years to 99 Years   (Adult, Older Adult)		54	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	20200504441	May 1, 2020	May 5, 2020	May 8, 2020	May 7, 2020		June 5, 2020	Vital Hospital, Bahcelievler, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04379310
268	NCT04363866	A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)		Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Hydroxychloroquine|Drug: Placebo	Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale|Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5|Toxicity of Study Drug Assessed by Incidence of Adverse Events	Oregon Health and Science University|OHSU Knight Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	STUDY00021303	May 2020	December 2020	June 2021	April 27, 2020		April 27, 2020	Oregon Health and Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT04363866
269	NCT04427098	Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients	INHIXACOV19	Recruiting	No Results Available	COVID-19	Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin	To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.|To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.|To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	300	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001308-40	May 22, 2020	October 30, 2020	October 30, 2020	June 11, 2020		June 17, 2020	Policlinico S. Orsola Malpighi Dipartimento Malattie Infettive, Bologna, Emilia Romagna, Italy|Azienda Ospedaliero-Universitaria di Parma Anestesia e Rianimazione Dipartimento di Medicina e Chirurgia, Parma, Emilia Romagna, Italy|I.R.C.C.S. "Casa Sollievo della Sofferenza", San Giovanni Rotondo (FG) UOVD Emostasi e trombosi- Poliambulatorio Giovanni Paolo II Viale Padre Pio n.7 San Giovanni Rotondo (FG), San Giovanni Rotondo, Foggia, Italy|Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy|Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy|Azienda Ospedaliero-Universitaria "Policlinico - V. Emanuele", Catania Anestesia e Rianimazione UO Malattie Infettive, Catania, Italy|ASST Cremona Unità Operativa di Chirurgia Vascolare Dipartimento di Medicina di Laboratorio e di Radiologia- Centro Emostasi e Trombosi, Cremona, Italy|Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy|Ospedale Carlo Poma di Mantova MALATTIE INFETTIVE Padiglione 37 Str. Lago Paiolo, 10, 46100 Mantova, Mantova, Italy|AZIENDA OSPEDALIERA Regionale S CARLO POTENZA Struttura Complessa Interaziendale "Malattie Infettive", Matera, Italy|Ospedale San Raffaele Unità Funzionale dell'Unità Operativa di Malattie Infettive Osp. San Raffaele, Milano, Italy|Ospedale Amedeo di Savoia Torino Università di Torino Malattie Infettive, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona UOC Malattie Infettive e Tropicali, Verona, Italy	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04427098/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04427098
270	NCT04381858	Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin	Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization	Centenario Hospital Miguel Hidalgo	All	16 Years to 90 Years   (Child, Adult, Older Adult)	Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	2020-A-10	May 6, 2020	August 30, 2020	September 30, 2020	May 11, 2020		May 12, 2020	Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico		https://ClinicalTrials.gov/show/NCT04381858
271	NCT04509973	Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia	COVIDSTEROID2	Recruiting	No Results Available	Covid19|Hypoxia	Drug: Dexamethasone	Days alive without life support at day 28|Number of participants with one or more serious adverse reactions|All-cause mortality at day 28|All-cause mortality at day 90|Days alive without life support at day 90|Days alive and out of hospital at day 90|All-cause mortality at day 180|Health-related quality of life at day 180	Scandinavian Critical Care Trials Group|Copenhagen Trial Unit, Center for Clinical Intervention Research|Centre for Research in Intensive Care (CRIC)|Aarhus University Hospital|Aalborg University Hospital|Rigshospitalet, Denmark|The George Institute for Global Health, Australia	All	18 Years and older   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RH-ITA-009|2020-003363-25|2020-07-16|H-20051056	August 27, 2020	September 17, 2021	February 17, 2022	August 12, 2020		September 1, 2020	Dept. of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark., Aalborg, Denmark|Dept. of Intensive care, Aarhus University Hospital, Aarhus, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Neuroanaesthesiology, Copenhagen, Denmark|Dept. of Thoracic Anaesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Gentofte Hospital, Hellerup, Denmark|Dept. of Anaesthesia and Intensive Care, Herlev Hospital, Herlev, Denmark|Dept. of Anaesthesia, Regional Hospital West Jutland, Herning, Herning, Denmark|Dept. of Intensive Care, Nordsjællands Hospital - Hillerød, Denmark., Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Dept. of Anaesthesia and Intensive Care, Lillebaelt Hospital, Kolding, Denmark|Dept. of Intensive Care, Køge University Hospital, Køge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Roskilde, Roskilde, Denmark|Dept. of Anaesthesia, Slagelse Hospital, Slagelse, Denmark|Dept. of Anaesthesia and Intensive Care, Viborg Hospital, Viborg, Denmark|Jawahar Lal Nehru Medical Collega, AMU, Aligarh, India|Apollo Hospital, Chennai, India|Amrita Institute of Medical Sciences, Kochi, India|Bombay Hospital & Medical Research Centre, Mumbai, India|K. J. Somaiya Super Specialty Hospital, Mumbai, India|P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India|S L Raheja Fortis Hospital, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Wockhardt hospitals, Mumbai, India|Indraprastha Apollo Hospital, New Delhi, India|Max Super Specialty Hospital, Saket, New Delhi, India|Symbiosis University Hospital and Research Centre, Pune, India|Vishwaraj Hospital, Pune, India|Rajendra Institute of Medical Sciences, Ranchi, India|Gotri General Hospital, Vadodara, India|Christian Medical College Vellore, Vellore, India|Dept. of Anaesthesia and Intensive Care, Sahlgranska Universitetssjukhuset, Göteborg, Sweden|Dept. of Infectious Diseases, Sahlgranska Universitetssjukhuset, Göteborg, Sweden|Dept. of Anaesthesia and Intensive Care, Universitetssjukhuset i Linköping, Linköping, Sweden|Dept. of Anaesthesia and Intensive Care, Skånes Universitetssjukhus (SUS) Malmö, Malmö, Sweden|Dept. of Infectious Diseases, Skånes Universitetssjukhus (SUS) Malmö, Malmö, Sweden|Dept. of Anaesthesia and Intensive Care, Vrinnevisjukhuset, Norrköping, Norrköping, Sweden|Dept. of Anaesthesia and Intensive Care, Capio St Görans Sjukhus, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Dept. of Cardiology, Södersjukhuset, Stockholm, Sweden|Dept. of Infectious Diseases, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Infectious Diseases, Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Dept. of Infectious Diseases, Södersjukhuset, Stockholm, Sweden|Dept. of Internal Medicine, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Internal Medicine, Södersjukhuset, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden|Dept. of Intensive Care Medicine, Bern University Hospital (Inselspital), Bern, Switzerland		https://ClinicalTrials.gov/show/NCT04509973
272	NCT04541485	To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)		Not yet recruiting	No Results Available	COVID-19 Patients	Drug: DWRX2003|Drug: Placebo	Incidence of Treatment-Emergent Adverse Events|Time to SARS-CoV-2 eradication (days) by Nasopharyngeal specimen|Rate of SARS-CoV-2 eradication by Nasopharyngeal specimen	Daewoong Pharmaceutical Co. LTD.	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	DW_DWJ1516101_Phillipphines	October 6, 2020	October 20, 2020	January 29, 2021	September 9, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04541485
273	NCT04320615	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia	COVACTA	Completed	No Results Available	COVID-19 Pneumonia	Drug: Tocilizumab (TCZ)|Drug: Placebo	Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Time to Recovery|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 3	450	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	WA42380|2020-001154-22	April 3, 2020	June 24, 2020	July 28, 2020	March 25, 2020		September 25, 2020	University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom		https://ClinicalTrials.gov/show/NCT04320615
274	NCT04542447	To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.		Recruiting	No Results Available	Covid19	Drug: Nuvastatic	To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA)|IL-6 reduction|Serum c-reactive protein (CRP)|IgG|Hb|Total leucocyte count|F2-Isoprostane|Improvement in ARDS associated clinical symptoms cause	Natureceuticals Sdn Bhd	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	10	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BIAG-CSP-037	September 1, 2020	September 30, 2020	September 30, 2020	September 9, 2020		September 10, 2020	Navin Hospital, Ghaziabad, Uttar Pradesh, India		https://ClinicalTrials.gov/show/NCT04542447
275	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia		Active, not recruiting	No Results Available	COVID-19 Pneumonia	Drug: Placebo|Drug: Tocilizumab	Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or "Ready for Discharge" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)	Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	379	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ML42528	May 14, 2020	August 18, 2020	September 19, 2020	May 1, 2020		August 21, 2020	Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|El Centro Regional Medical Center, El Centro, California, United States|Harper University Hospital, Fountain Valley, California, United States|eStudySite, La Mesa, California, United States|Highland Hospital Oakland, Oakland, California, United States|St. Joseph'S Hospital, Orange, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Miami Veterans Administration Healthcare System - NAVREF, Miami, Florida, United States|University of Miami Pulmonary, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St. Lukes Boise Medical Center, Boise, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Ochsner Clinic, New Orleans, Louisiana, United States|LSU-Shreveport, Shreveport, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Optum Health Care, Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|NYC Health and Hospitals Queens, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Novant Health Presbyterian Medical Center (Presbyterian Hospital), Charlotte, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Novant Health Rowan Medical Center, Salisbury, North Carolina, United States|Novant Health Foryth Medical Center, Winston-Salem, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|JPS Health Network, Fort Worth, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|McAllen Medical Center, McAllen, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Sentara Medical Group, Virginia Beach, Virginia, United States|Hospital Unversitario Walter Cantidio, Fortaleza, CE, Brazil|Hospital Agamenon Magalhães, Recife, PE, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Centro Multidisciplinar de Estudos Clínicos CEMEC FMABC, Sao Bernardo Do Campo, SP, Brazil|BR Trials - Pesquisa Clínica, Sao Paulo, SP, Brazil|Escola Paulista de Medicina Da Universidade Federal de São Paulo - EPMUNIFESP, Sao Paulo, SP, Brazil|Hospital Heliópolis, Sao Paulo, SP, Brazil|Aga Khan University Hospital, Nairobi, Kenya|Organismo Publico Descentralizado Hospital Juarez de Mexico, Ciudad De México, Mexico|Hospital General de Culiacan, Culiacan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Hospital Militar Central, Jesus Maria, Peru|Hospital Nacional Sergio E. Bernales, Lima, Peru|Hospital Nacional Arzobispo Loayza; Oncology, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Nacional Hipolito; Unanue, Lima, Peru|Hospital Maria Auxiliadora, Lima, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|University of the Free State, Bloemfontein, South Africa|George Provincial Hospital, George, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Milpark Hospital, Parktown West, South Africa|University of Stellenbosch; Respiratory Research, Parow, South Africa|Phoenix Pharma, Port Elizabeth, South Africa		https://ClinicalTrials.gov/show/NCT04372186
276	NCT04375735	London's Exogenous Surfactant Study for COVID19	LESSCOVID	Not yet recruiting	No Results Available	ARDS, Human|COVID-19	Drug: Bovine Lipid Extract Surfactant	Adverse events (patient) - Decrease in oxygenation|Adverse events (patient) - Decrease in hemodynamics|Adverse event (healthcare worker) - Circuit breach|Adverse event (healthcare worker) - COVID-19 symptoms|Change in oxygenation|Change in Lung compliance|Ventilated days|Length of ICU stay|Length of hospital stay|Mortality|G-CSF levels (serum inflammatory biomarker)|GM-CSF levels (serum inflammatory biomarker)|IFN gamma levels (serum inflammatory biomarker)|IL-1 beta levels (serum inflammatory biomarker)|IL-4 levels (serum inflammatory biomarker)|IL-6 levels (serum inflammatory biomarker)|IL-10 levels (serum inflammatory biomarker)|I levels (serum inflammatory biomarker)|MCP-1 levels (serum inflammatory biomarker)|TNF alpha levels (serum inflammatory biomarker)	Lawson Health Research Institute|London Health Sciences Centre	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9890	July 1, 2020	January 1, 2021	July 1, 2021	May 5, 2020		June 11, 2020			https://ClinicalTrials.gov/show/NCT04375735
277	NCT04377308	Fluoxetine to Reduce Intubation and Death After COVID19 Infection		Recruiting	No Results Available	COVID-19|Cytokine Storm	Drug: Fluoxetine	Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale	University of Toledo Health Science Campus	All	18 Years and older   (Adult, Older Adult)	Phase 4	2000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FRIDA COVID19	May 1, 2020	April 20, 2021	October 20, 2021	May 6, 2020		May 6, 2020	University of Toledo, Toledo, Ohio, United States		https://ClinicalTrials.gov/show/NCT04377308
278	NCT04329650	Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19	Drug: Siltuximab|Drug: Methylprednisolone	Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.	Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SILCOR-COVID-19	April 15, 2020	May 20, 2020	May 20, 2020	April 1, 2020		April 17, 2020	Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain		https://ClinicalTrials.gov/show/NCT04329650
279	NCT04417257	Study of LAU-7b for the Treatment of COVID-19 Disease in Adults	RESOLUTION	Recruiting	No Results Available	COVID-19 Disease	Drug: LAU-7b|Drug: Placebo oral capsule	Health status of the patient on the 7-point ordinal scale (World Health Organization) compared to placebo|The safety of LAU-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo|Rate of COVID-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo|Rate of COVID-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo|Rate of COVID-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo|Rate of COVID-19 disease-related death, depicted by a change from baseline in the ordinal scale score to category 7|Health status of the patient on the 7-point ordinal scale (World Health Organization), compared to placebo|Mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo|Time to an improvement of one category on the ordinal scale patient health status, compared to placebo|Time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo|Time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo|Time to death, defined here as a tim to reach category 7 on the ordinal scale patient health status, censored to Day 29 if it happens later than Day 29, compared to placebo|Duration of hospitalization (days) within the study period Days 1-29, compared to placebo|Time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo|The change from baseline in the score obtained on the EQ-5D-5L quality-of-life survey	Laurent Pharmaceuticals Inc.	All	45 Years and older   (Adult, Older Adult)	Phase 2	240	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	LAU-20-01	June 29, 2020	December 15, 2020	January 15, 2021	June 4, 2020		September 7, 2020	Wayne State University, Harper University Hospital, Detroit, Michigan, United States|St-Paul's Hospital, Vancouver, British Columbia, Canada|Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi, Chicoutimi, Quebec, Canada|CIUSSSS de l'Est-de-l'Ile-de-Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CISSS Ds Laurentides, Saint-Jérôme, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04417257
280	NCT04348500	Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease		Active, not recruiting	No Results Available	COVID19	Drug: Clazakizumab	Evaluate the safety of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay|Reduced need for ventilation	Cedars-Sinai Medical Center	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	17	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	00000644	April 24, 2020	December 31, 2020	March 31, 2021	April 16, 2020		October 2, 2020	Cedars-Sinai Medical Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04348500
281	NCT04331470	Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19		Recruiting	No Results Available	COVID-19	Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine	Clear chest CT-scan|PCR test|Physical statues of patient	Fasa University of Medical Sciences	All	15 Years to 100 Years   (Child, Adult, Older Adult)	Phase 2|Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	97548	April 4, 2020	April 20, 2020	May 20, 2020	April 2, 2020		April 13, 2020	Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04331470
282	NCT04273529	The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia		Not yet recruiting	No Results Available	COVID-19 Thalidomide	Drug: thalidomide|Drug: placebo	Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence	First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20200214-COVID-19-M-T	February 20, 2020	May 30, 2020	June 30, 2020	February 18, 2020		February 21, 2020			https://ClinicalTrials.gov/show/NCT04273529
283	NCT04273581	The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19		Not yet recruiting	No Results Available	COVID-19 Thalidomide	Drug: placebo|Drug: Thalidomide	Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment	First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20200214-COVID-19-S-T	February 18, 2020	April 30, 2020	May 30, 2020	February 18, 2020		February 21, 2020			https://ClinicalTrials.gov/show/NCT04273581
284	NCT04344951	Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial	HOPE	Recruiting	No Results Available	Pneumonia, Viral|Covid-19	Drug: UNIKINON (Chloroquine phosphate) 200mg tablets	50% reduction in symptom score for patients with lower respiratory tract infection|Lack of progression for patients with upper respiratory tract infection|Comparison of the primary endpoint with respective patients not receiving the treatment|Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.|Frequency of AEs and SAEs	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|Athens General Hospital Hippokrateio|Athens General Hospital of Thoracic Diseases SOTIRIA|General Hospital of Athens Sismanoglio|Divine Providence Hospital Pammakaristos|AHEPA University Hospital|University General Hospital of Ioannina|Corfu General Hospital Agia Irini	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	60	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	UNIKINON-01/HOPE	April 6, 2020	April 1, 2021	April 30, 2021	April 14, 2020		June 2, 2020	Divine Providence Hospital "Pammakaristos", Athens, Greece|Athens General Hospital "Hippokrateio", Athens, Greece|Athens General Hospital of Thoracic Diseases "SOTIRIA", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases "SOTIRIA", 3rd University Pathology Clinic, Athens, Greece|Corfu General Hospital Agia Irini, Corfu, Greece|University General Hospital of Ioannina, Ioánnina, Greece|General Hospital of Athens "Sismanoglio", Maroúsi, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloníki, Greece		https://ClinicalTrials.gov/show/NCT04344951
285	NCT04374032	Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection		Active, not recruiting	No Results Available	COVID-19 Infection	Drug: metenkefalin + tridecactide|Drug: The standard of care	Time to onset of change in the patient's clinical condition|Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE|Length of in-hospital stay|Survival rate|Intubation rate|Proinflammatory markers levels	Bosnalijek D.D	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EN-COVCS-01	May 1, 2020	October 31, 2020	December 31, 2020	May 5, 2020		October 2, 2020	Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Hospital Travnik, Travnik, Bosnia and Herzegovina|Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina		https://ClinicalTrials.gov/show/NCT04374032
286	NCT04554979	COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience		Completed	No Results Available	Covid19|Diarrhea	Drug: Hydroxychloroquine Pill	COVID-19 disease spectrum and duration|GIT manifestations among COVID-19 patients|Non-communicable disease and COVID-19|Seasonal change and COVID-19|Possible region specific classification for COVID-19 disease	Cairo University	All	18 Years and older   (Adult, Older Adult)		199	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	1004	June 1, 2020	July 15, 2020	July 15, 2020	September 18, 2020		September 22, 2020	Faculty of Medicine Cairo University, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04554979
287	NCT04328441	Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine	BCG-CORONA	Active, not recruiting	No Results Available	COVID-19	Drug: BCG Vaccine|Drug: Placebo	Health Care Workers absenteeism|the cumulative incidence of documented COVID-19|the cumulative incidence of Hospital Admission due to documented COVID-19|the number of days of unplanned absenteeism, because of documented COVID-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented COVID-19|the cumulative incidence of Intensive Care Admission due to documented COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (≥38 gr C)|the cumulative incidence of self-reported fever (≥38 gr C)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of Intensive Care Admission for any reason|the cumulative incidence of Hospital Admission for any reason|the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period	UMC Utrecht|Radboud University	All	18 Years and older   (Adult, Older Adult)	Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	NL73249.041.20	March 25, 2020	March 31, 2021	April 30, 2021	March 31, 2020		August 19, 2020	Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04328441/SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04328441
288	NCT04261517	Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19		Completed	No Results Available	Pneumonia, Pneumocystis|Coronavirus|COVID-19	Drug: Hydroxychloroquine	The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2	Shanghai Public Health Clinical Center	All	18 Years and older   (Adult, Older Adult)	Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HC-COVID-19	February 6, 2020	February 25, 2020	February 25, 2020	February 7, 2020		April 13, 2020	Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04261517
289	NCT04315896	Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)	HYDRA	Active, not recruiting	No Results Available	COVID-19|Severe Acute Respiratory Syndrome	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction	National Institute of Respiratory Diseases, Mexico|Sanofi	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HidroxycloroquinaCOVID19	April 14, 2020	July 1, 2020	August 15, 2020	March 20, 2020		July 27, 2020	Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico		https://ClinicalTrials.gov/show/NCT04315896
290	NCT04411680	Study of Sargramostim in Patients With COVID-19	iLeukPulm	Recruiting	No Results Available	COVID-19|Sars-CoV2	Drug: Sargramostim|Drug: Standard of care	Change in oxygenation parameter of P(A-a)O2 gradient by Day 6|Percent of patients who have been intubated by Day 14|Change in ordinal scale|All cause 28-day mortality|Number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions (ADRs)	Partner Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PTX-001-002	August 18, 2020	November 2020	March 2021	June 2, 2020		October 7, 2020	St. Joseph Hospital of Orange, Orange, California, United States|Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04411680
291	NCT04342221	Hydroxychloroquine for COVID-19	COV-HCQ	Recruiting	No Results Available	COVID-19, Hydroxychloroquine Sulfate	Drug: Hydroxychloroquine Sulfate|Drug: Placebo	Effect of HCQ on in vivo viral clearance	University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	220	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COV-HCQ|2020-001224-33	March 29, 2020	March 2021	February 2022	April 10, 2020		July 2, 2020	Zollernalb Klinikum Balingen, Balingen, Germany|Klinikum Darmstadt, Darmstadt, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum am Steinenberg, Reutlingen, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Institute for Tropical Medicine, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT04342221
292	NCT04528667	Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19		Not yet recruiting	No Results Available	Covid19	Drug: STI-5656|Drug: Placebo	Proportion of subjects discharged from hospital|Incidence of adverse events (safety)|Time to hospital admission, treatment, and discharge|Number of days hospitalized|Change in clinical status as assessed using a 0-8 ordinal scale|Change in RT-PCR test results|Change in C-reactive protein levels|AUC of STI-5656 (PK)|Cmax of STI-5656 (PK)|t½ of STI-5656 (PK)|Change in cytokine levels|Tmax of STI-5656 (PK)	Sorrento Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BTK-COV-202BR	September 2020	May 2021	May 2021	August 27, 2020		August 27, 2020			https://ClinicalTrials.gov/show/NCT04528667
293	NCT04411667	Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection		Recruiting	No Results Available	Sars-CoV2	Drug: Octagam	Mechanical Ventilation|Oxygen Therapy|Length of Stay	George Sakoulas, MD|Octapharma|Sharp HealthCare	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-IVIG|2004902	April 28, 2020	November 1, 2020	November 30, 2020	June 2, 2020		June 2, 2020	Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hospital, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT04411667
294	NCT04398004	Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early	ACHIEVE	Recruiting	No Results Available	COVID-19|Virus Diseases|Corona Virus Infection	Drug: Clarithromycin	Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8	Hellenic Institute for the Study of Sepsis	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ACHIEVE|2020-001882-36	May 6, 2020	May 6, 2022	May 6, 2022	May 21, 2020		May 26, 2020	COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus "Tzaneio", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece		https://ClinicalTrials.gov/show/NCT04398004
295	NCT04445285	Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure	DAMPENCOVID	Recruiting	No Results Available	Covid19	Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride	Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function	Jon Simmons|University of South Alabama	All	18 Years and older   (Adult, Older Adult)	Phase 2	44	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	USAH 1002 000	April 28, 2020	November 30, 2020	February 28, 2021	June 24, 2020		August 21, 2020	University of South Alabama, Mobile, Alabama, United States		https://ClinicalTrials.gov/show/NCT04445285
296	NCT04476953	COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation		Enrolling by invitation	No Results Available	COVID-19	Drug: Placebo|Drug: Fisetin	Serious Adverse Events|Change in oxygenation status|COVID-19 Severity Category	Mayo Clinic	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-003936	August 3, 2020	July 2021	July 2021	July 20, 2020		August 13, 2020	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04476953
297	NCT04424901	Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19	TOLD	Recruiting	No Results Available	COVID-19 Pneumonia|Vascular Complications	Drug: Dipyridamole	Coagulation system|Viral Detection	UConn Health	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-192-2.F	May 3, 2020	May 1, 2021	May 30, 2021	June 11, 2020		June 11, 2020	UConn Health, Farmington, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04424901
298	NCT04527562	Colchicine in Moderate Symptomatic COVID-19 Patients	COLCOVIDBD	Recruiting	No Results Available	Covid19	Drug: Colchicine|Drug: Placebo	Time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a Seven-category ordinal scale.|Length of hospital stay|Number of participant requiring increased amount of supplemental oxygen|Number of participants requiring mechanical ventilation|Number of participants who die	Dhaka Medical College	All	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	U1111-1255-3541	July 14, 2020	December 2020	December 2020	August 26, 2020		August 28, 2020	Dhaka Medical College Hospital, Dhaka-1000, Bangladesh		https://ClinicalTrials.gov/show/NCT04527562
299	NCT04517188	Halodine Nasal Antiseptic in Patients With COVID-19		Not yet recruiting	No Results Available	SARS-CoV-2 Infection	Drug: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP	Nasopharyngeal SARS-CoV-2 Viral Load	Halodine LLC	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	HDN-N02-COV24A	October 15, 2020	February 15, 2021	February 15, 2021	August 18, 2020		September 4, 2020			https://ClinicalTrials.gov/show/NCT04517188
300	NCT04382651	Study of Efficacy and Safety of MAS825 in Patients With COVID-19	MAS-COVID	Recruiting	No Results Available	COVID-19 Pneumonia, Impaired Respiratory Function	Drug: MAS825|Drug: Matching placebo	APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time	Novartis Pharmaceuticals|Novartis	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CMAS825F12201	June 11, 2020	October 2, 2020	January 26, 2021	May 11, 2020		August 14, 2020	Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04382651
301	NCT04523090	Catalysing the Containment of COVID-19	C3-RCT	Recruiting	No Results Available	Covid19	Drug: Nitazoxanide|Drug: Placebo	Time specific disease severity|Progression to severe disease|Need for respiratory support (high flow nasal oxygen, non-invasive ventilation, or intubation) in those admitted to hospital because of disease progression.|In-hospital and 30- and 60-day all-cause mortality. available).|Time-specific viral load as measured by RT-PCR using NP swabs and sputum (where available).|Cough aerosol sampling positivity	University of Cape Town|Medical Research Council, South Africa|Aurum Institute|National Institutes of Health (NIH)|Texas Tech University Health Sciences Center|University of KwaZulu|Perinatal HIV Research Unit of the University of the Witswatersrand	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 2|Phase 3	960	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	C3-RCT	August 27, 2020	April 2021	August 2021	August 21, 2020		September 1, 2020	University of Cape Town, Cape Town, Western Cape, South Africa		https://ClinicalTrials.gov/show/NCT04523090
302	NCT04491994	Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression	COVID-19	Completed	Has Results	Covid19|Progression	Drug: HCQ	Number of Participants With Progression|Viral Clearance	UNICEF|Pak Emirates Military Hospital Rawalpindi, Pakistan	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	540	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sultan Mehmood Kamran 2	April 10, 2020	May 31, 2020	May 31, 2020	July 30, 2020	August 21, 2020	August 21, 2020	Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04491994/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04491994
303	NCT04530474	Outpatient Use of Ivermectin in COVID-19		Not yet recruiting	No Results Available	Covid19	Drug: Ivermectin Pill|Drug: Placebo	Clinical Improvement	Temple University	All	18 Years and older   (Adult, Older Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	1285242	October 1, 2020	June 30, 2021	December 31, 2021	August 28, 2020		August 28, 2020	Temple University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04530474
304	NCT04343144	Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.	CORIMUNO-NIVO	Not yet recruiting	No Results Available	COVID19- Infection With SARS-CoV-2 Virus	Drug: Nivolumab Injection	Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|World Health Organisation (WHO) progression scale	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	92	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200389-5	April 15, 2020	July 31, 2020	September 30, 2020	April 13, 2020		April 14, 2020	Pneumologie hôpital Tenon, Paris, France		https://ClinicalTrials.gov/show/NCT04343144
305	NCT04346797	CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort	CORIMUNO19-ECU	Recruiting	No Results Available	SARS-CoV-2|COVID19	Drug: Eculizumab	Survival without needs of intubation at day 14|Change in organ failure at day 3|Intubation free survival at day 14|WHO progression scale at days 4, 7 and 14|Survival at 14, 28 and 90 days|Time to discharge|Time to oxygen supply independency|Time to negative viral excretion|Incidence of secondary infections|Vasopressor-free survival|Ventilator-free survival|28-day ventilator-free days|Incidence of dialysis|PaO2/FiO2 ratio|Rate of respiratory acidosis at day 4|Time to ICU discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-4	April 16, 2020	September 30, 2020	December 31, 2020	April 15, 2020		April 27, 2020	Saint Louis, Paris, Ile De France, France|Réanimation médicale, Paris, France|saint Louis, Paris, France		https://ClinicalTrials.gov/show/NCT04346797
306	NCT04359654	Nebulised Dornase Alfa for Treatment of COVID-19	COVASE	Not yet recruiting	No Results Available	COVID19|Hypoxia	Drug: Dornase Alfa Inhalation Solution [Pulmozyme]	Measuring the change in inflammation|Number of patients that are alive at 28 days|Amount of days that patient requires oxygen|Average oxygenation index|Days patient admitted to hospital|Percentage of patients that need mechanical ventilation	University College, London	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	132333	May 1, 2020	August 1, 2020	November 1, 2020	April 24, 2020		April 30, 2020	University College London Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04359654
307	NCT04361903	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection	RESPIRE	Not yet recruiting	No Results Available	Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Ruxolitinib Oral Tablet	Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19|Improvement of respiratory performance - Arterial Blood Gas Analisys - pH|Improvement of respiratory performance - Arterial Blood Gas Analisys - pO2|Improvement of respiratory performance - Arterial Blood Gas Analisys - pCO2|Improvement of respiratory performance - ratio values|Evaluation of known adverse events related to the use of the drug - D-Dimer|Evaluation of known adverse events related to the use of the drug - fibrinogen|Evaluation of known adverse events related to the use of the drug - transaminases|Evaluation of known adverse events related to the use of the drug - aPTT|Evaluation of known adverse events related to the use of the drug - INR|Evaluation of known adverse events related to the use of the drug - glycemia|Evaluation of known adverse events related to the use of the drug - creatinine|Evaluation of known adverse events related to the use of the drug - Leucocytes count|Evaluation of known adverse events related to the use of the drug - Leucocytes formula|Evaluation of the epidemiological parameters: Chest CT|Evaluation of the epidemiological parameters: Eco Chest|Evaluation of the epidemiological parameters: CHEST X-ray|Monitoring of Serum levels of cytokines before and every 48 h from start to to end of treatment|Monitoring incidence of treatment Emergent Adverse Events of ruxolitinib therapy	Azienda USL Toscana Nord Ovest|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|Azienda Ospedaliera Universitaria Senese|Azienda Ospedaliero, Universitaria Pisana	All	18 Years and older   (Adult, Older Adult)		13	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	2020.COVID-19.RUXO106	April 25, 2020	May 24, 2020	May 31, 2020	April 24, 2020		April 24, 2020			https://ClinicalTrials.gov/show/NCT04361903
308	NCT04332107	Azithromycin for COVID-19 Treatment in Outpatients Nationwide	ACTION	Recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Azithromycin|Drug: Placebos	Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)|Death	Thomas M. Lietman|Bill and Melinda Gates Foundation|Pfizer|Stanford University|University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Phase 3	2271	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20-30504	May 22, 2020	September 30, 2020	September 30, 2021	April 2, 2020		July 14, 2020	University of California San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04332107
309	NCT04338074	TXA and Corona Virus 2019 (COVID19) in Outpatients	TCOutpatient	Recruiting	No Results Available	COVID-19	Drug: Tranexamic acid tablets|Drug: Placebo oral tablet	Hospitalization	University of Alabama at Birmingham	All	19 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TXACOVID1	June 1, 2020	December 15, 2020	December 31, 2020	April 8, 2020		June 12, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04338074
310	NCT04425707	Ivermectin In Treatment of COVID 19 Patients		Recruiting	No Results Available	Covid19	Drug: Ivermectin	to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.	Ministry of Health and Population, Egypt	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-2020/3	June 9, 2020	July 1, 2020	September 1, 2020	June 11, 2020		June 11, 2020	isolation and referal hospitals for COVID 19 patients, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04425707
311	NCT04500418	Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients		Recruiting	No Results Available	Covid19	Drug: Cenicriviroc (CVC)|Drug: Placebo	Subject´s Responder status (score on the 7-point ordinal scale on Day 15)|Evaluation of change in clinical condition based on the 7-point ordinal scale|Evaluation of change in clinical condition based on the 7-point ordinal scale and Responder Status|Hospital resource utilization comparison	Charite University, Berlin, Germany|Allergan	All	18 Years and older   (Adult, Older Adult)	Phase 2	183	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CVC for COVID-19|2020-001493-29	August 25, 2020	September 30, 2021	September 30, 2021	August 5, 2020		August 26, 2020	Medical Department of Hepatology and Gastroenterology, Charité University Medicine, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany		https://ClinicalTrials.gov/show/NCT04500418
312	NCT04347174	A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients		Recruiting	No Results Available	COVID-19	Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19	Sequential Organ Failure Assessment (SOFA) scores|7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|All-cause mortality|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death	Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CRSC20004	April 30, 2020	June 30, 2020	July 30, 2020	April 15, 2020		June 11, 2020	All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India		https://ClinicalTrials.gov/show/NCT04347174
313	NCT04511650	A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)	RESCUE	Recruiting	No Results Available	COVID-19|Acute Respiratory Distress Syndrome	Drug: Razuprotafib Subcutaneous Solution|Drug: Placebo Subcutaneous Solution	Number of participants with any serious adverse event from baseline to Day 7|Number of participants with any serious adverse event from baseline to Day 28|Number of participants with any treatment emergent adverse event from baseline to Day 7|Number of participants with any treatment emergent adverse event from baseline to Day 28|Proportion of subjects alive and free of respiratory failure at Day 7|Proportion of subjects alive and free of respiratory failure at Day 28|Length hospitalized and free of respiratory failure from baseline to Day 7|Length hospitalized and free of respiratory failure from baseline to Day 28|Length of hospitalization from baseline to Day 7|Length of hospitalization from baseline to Day 28|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|All-cause mortality at Day 7|All-cause mortality at Day 28|Length of ICU stay from baseline to Day 28|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 7|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 28|Time to return to prehospitalization oxygen requirement|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 7|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 28|Change in PaO2:FiO2 ratio from baseline to Day 7|Change in PaO2:FiO2 ratio from baseline to Day 28	Aerpio Therapeutics|Medical Technology Enterprise Consortium (MTEC)	All	18 Years and older   (Adult, Older Adult)	Phase 2	180	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AKB-9778-CI-6001	September 2020	February 2021	February 2021	August 13, 2020		September 28, 2020	University of California- Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Cincinnati, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04511650
314	NCT04409522	Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients		Recruiting	No Results Available	COVID-19	Drug: Melatonin|Drug: The usual treatment	Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route	Mohammad Sadegh Bagheri Baghdasht|Baqiyatallah Medical Sciences University	All	16 Years to 100 Years   (Child, Adult, Older Adult)	Not Applicable	55	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IR.BMSU.REC.1399.039	May 12, 2020	June 5, 2020	September 25, 2020	June 1, 2020		June 1, 2020	Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04409522
315	NCT04420741	Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure	COMBAT-COVID	Recruiting	No Results Available	COVID-19|Respiratory Failure	Drug: Iloprost|Drug: Isotonic saline	Mechanical ventilation free days|28 and 90-day mortality|Modified Sequential Organ Failure Assessment (SOFA)|Vasopressor free days|Renal replacement free days|Serious adverse reactions (SARs)|Serious adverse events (SAEs)	Pär Johansson|Rigshospitalet, Denmark	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COMBAT-COVID-19|2020-001296-33	June 15, 2020	May 31, 2021	May 31, 2021	June 9, 2020		July 13, 2020	Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark|Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre, Denmark		https://ClinicalTrials.gov/show/NCT04420741
316	NCT04500067	Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment		Recruiting	No Results Available	Covid19|Pneumonia	Drug: IVIG	Period duration (in days) to clinical improvement|O2 saturation (SPO2 percentage), with self-breathing|Respiratory movements rate (amount per minute), with self-breathing|Body temperature without antipyretics use|Lymphocyte count|Time from the onset of the disease to discharge, in days|Duration of the need for ventilatory support, in days|Duration of the need for intensive care, in days|Duration of need for oxygenation in days (SPO2 ≤ 93% with self-breathing)|The C-reactive protein (CRP) level|The tumor necrozis factor alpha (TNF-α) level|The interleukin-1β (IL-1β) level|The interleukin-6 (IL-6) level|The D-dimer level|The Complement (C3 component) level|The Circulating immune complexes level|The ferritin level|The procalcitonin level|IgG subtypes|Survival assessment for a 28-day follow-up period since the onset of severe pneumonia	Biopharma Plasma LLC	All	18 Years and older   (Adult, Older Adult)	Phase 3	76	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-BV-BP	May 7, 2020	September 30, 2020	September 30, 2020	August 5, 2020		August 5, 2020	Site 08 - "Central City Clinical Hospital of Ivano-Frankivsk City Council", Ivano-Frankivs'k, Ivano-Frankivs'k Region, Ukraine|Site 02 - "Bila Tserkva City Hospital №3", Bila Tserkva, Kyiv Region, Ukraine|Site 03 - "Lviv Regional Infectious Diseases Clinical Hospital", Lviv, Lviv Region, Ukraine|Site 04 - "City Clinical Infectious Diseases Hospital", Odesa, Odesa, Odesa Region, Ukraine|Site 07 - "Ternopil City Municipal Ambulance Hospital", Ternopil', Ternopil' Region, Ukraine|Site 06 - "Vinnytsia City Clinical Hospital №1", Vinnitsia, Vinnitsia Region, Ukraine|Site 09 - "Volyn Regional Clinical Hospital", Luts'k, Volyn Region, Ukraine|Site 01 - "Kyiv City Clinical Hospital №17", Kyiv, Ukraine|Site 05 - "Kyiv City Clinical Hospital №4", Kyiv, Ukraine		https://ClinicalTrials.gov/show/NCT04500067
317	NCT04573153	Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine + Metabolic cofactor supplementation|Drug: Hydroxychloroquine + Sorbitol	The evaluation of clinical efficacy of the combination of metabolic cofactor supplementation and hydroxychloroquine|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Chest Tomography|ECG Measurement|Change of complete blood count from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in creatinine levels from baseline|Changes in D-dimer levels from baseline|Changes in ferritin levels from baseline|Changes in triglycerides levels from baseline|Changes in LDH levels from baseline	ScandiBio Therapeutics AB|Istanbul Medipol University Hospital|Istanbul Umraniye Training and Research Hospital|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Dr. Lutfi Kirdar Kartal Training and Research Hospital|Bagcilar Training and Research Hospital|Kanuni Sultan Suleyman Training and Research Hospital|Alanya Alaaddin Keykubat University Alanya Training and Research Hospital|Canakkale 18 Mart University Health Research and Application Hospital|Monitor CRO	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	400	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19-MCS	September 21, 2020	January 31, 2021	March 31, 2021	October 2, 2020		October 6, 2020	University of Health Sciences Istanbul Ümraniye Training and Research Hospital, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04573153
318	NCT04449965	Povidone-Iodine Rinses in the Management of COVID-19		Not yet recruiting	No Results Available	Covid19	Drug: Povidone-iodine|Drug: Placebo	Change in SARS-CoV-2 positivity in the saliva|Change in the SAR-CoV-2 viral load in the saliva|Change in Wisconsin Upper Respiratory Symptom Survey (WURSS-44)|Change Sino nasal Outcome Test (SNOT-22)|Change in clinical condition	St. Paul's Hospital, Canada	All	19 Years and older   (Adult, Older Adult)	Early Phase 1	81	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Betadine COVID-19	July 1, 2020	November 1, 2020	December 1, 2020	June 29, 2020		June 29, 2020			https://ClinicalTrials.gov/show/NCT04449965
319	NCT04522466	Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients	PREAVIS	Terminated	No Results Available	Sars-CoV2	Drug: Hydroxychloroquine (HCQ)	Pharmacokinetics of hydroxychloroquine (HCQ)|Correlation between hydroxychloroquine (HCQ) concentration and cardiac toxicity (QT interval)|Correlation between Pharmacokinetic (concentration) and pharmacodynamic (viral load) of hydroxychloroquine (HCQ)|Pharmacokinetic model	Centre Hospitalier Universitaire de Saint Etienne|CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang	All	18 Years and older   (Adult, Older Adult)	Phase 3	7	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20CH065|2020-001281-11	April 3, 2020	May 28, 2020	May 28, 2020	August 21, 2020		September 7, 2020	Groupement Hospitalier des Portes de Province, Montélimar, France|Centre Hospitalier de Roanne, Roanne, France|CHU Saint-Etienne, Saint-Étienne, France|Clinique Mutualiste, Saint-Étienne, France		https://ClinicalTrials.gov/show/NCT04522466
320	NCT04338958	Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation	RuxCoFlam	Recruiting	No Results Available	Covid-19	Drug: Ruxolitinib	overall response rate in reversal of hyperinflammation	University of Jena	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RuxCoFlam	April 22, 2020	January 31, 2021	August 31, 2021	April 8, 2020		September 10, 2020	Universitätsmedizin Göttingen - Klinik für Hämatologie und Onkologie, Göttingen, Germany|University Hospital Jena, Jena, Germany|Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany		https://ClinicalTrials.gov/show/NCT04338958
321	NCT04521296	Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo		Not yet recruiting	No Results Available	Mild to Moderate COVID-19	Drug: DWJ1248|Drug: Placebo	Time to SARS-CoV-2 eradication|Rate of SARS-CoV-2 eradication|Time to clinical improvement of subjective symptoms	Daewoong Pharmaceutical Co. LTD.	All	19 Years and older   (Adult, Older Adult)	Phase 2	90	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	DW_DWJ1248201	August 2020	December 2020	December 2020	August 20, 2020		August 20, 2020			https://ClinicalTrials.gov/show/NCT04521296
322	NCT04252664	A Trial of Remdesivir in Adults With Mild and Moderate COVID-19		Suspended	No Results Available	COVID-19|SARS-CoV-2	Drug: Remdesivir|Drug: Remdesivir placebo	Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events	Capital Medical University|Chinese Academy of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 3	308	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAP-China remdesivir 1	February 12, 2020	April 10, 2020	April 27, 2020	February 5, 2020		April 15, 2020	Jin Yin-tan hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04252664
323	NCT04358614	Baricitinib Therapy in COVID-19		Completed	No Results Available	COVID|Pneumonia	Drug: Baricitinib 4 MG Oral Tablet	To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.|To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.|ICU admission rate|Discharge rate.	Fabrizio Cantini|Hospital of Prato	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	12	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HPrato-4	March 16, 2020	April 5, 2020	April 7, 2020	April 24, 2020		April 24, 2020	Fabrizio Cantini, Prato, Tuscany, Italy		https://ClinicalTrials.gov/show/NCT04358614
324	NCT04349241	Efficacy and Safety of Favipiravir in Management of COVID-19	FAV-001	Completed	No Results Available	Coronavirus Disease (COVID-19)	Drug: favipiravir|Drug: Standard of care therapy	Viral clearance|Clinical improvement|Radiological Improvement	Ain Shams University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FMASU P14 / 2020	April 18, 2020	June 1, 2020	June 20, 2020	April 16, 2020		June 25, 2020	Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt		https://ClinicalTrials.gov/show/NCT04349241
325	NCT04343092	Efficacy of Ivermectin as Add on Therapy in COVID19 Patients		Completed	No Results Available	COVID 19	Drug: Ivermectin (IVM)	Number of cured patients|Mean time to cure of the covid 19 patients	University of Baghdad	All	18 Years and older   (Adult, Older Adult)	Phase 1	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PRO20040001	April 18, 2020	May 31, 2020	June 1, 2020	April 13, 2020		June 5, 2020	General Directorate of Medical City, Bagdad, Baghdad, Iraq		https://ClinicalTrials.gov/show/NCT04343092
326	NCT03891420	A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19		Recruiting	No Results Available	COVID-19|Yellow Fever	Drug: Galidesivir|Drug: Placebo	number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (YFV) titer (Group A)|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)|mortality	BioCryst Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years and older   (Adult, Older Adult)	Phase 1	132	Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BCX4430-108|272201300017C-18-0-1|DMID18-0022	April 9, 2020	May 31, 2021	May 31, 2021	March 27, 2019		July 23, 2020	Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil|Hospital Sao Vicente de Paulo-PPDS, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Foundation Regional Faculty of Medicine of São José do Rio Preto, São José Do Rio Preto, SP, Brazil|Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT03891420
327	NCT04555096	A Trial of GC4419 in Patients With Critical Illness Due to COVID-19		Recruiting	No Results Available	Covid19|SARS-CoV-2 Infection	Drug: GC4419|Drug: Placebo	28 day all-cause mortality	Galera Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COV-4419-201	September 9, 2020	November 2021	December 2021	September 18, 2020		September 22, 2020	Mercy Research, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04555096
328	NCT04394208	Silymarin in COVID-19 Pneumonia	SCOPE	Recruiting	No Results Available	COVID-19|Viral Pneumonia Human Coronavirus	Drug: Silymarin|Drug: Placebo	Time to clinical improvement|Clinical outcome|Duration of Mechanical Ventilation|Hospitalization|Virologic Response|Adverse events	Cairo University	All	18 Years and older   (Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	CairoU COVID-19 Study Group	August 16, 2020	January 30, 2021	February 28, 2021	May 19, 2020		August 18, 2020	Cairo University, Giza, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04394208
329	NCT04333472	Piclidenoson for Treatment of COVID-19		Not yet recruiting	No Results Available	COVID-19|Coronavirus Infection	Drug: Piclidenoson|Drug: Placebo	Proportion of subjects alive and free of respiratory failure|Proportion of subjects discharged home alive|Treatment-emergent adverse events (AEs)|Clinical status|Time to improvement|Incidence of mechanical ventilation|Ventilator-free days|Incidence of Intensive Care Unit (ICU) admission|Duration of ICU stay|Time to hospital discharge|Duration of need for supplemental oxygen|Time to virus negativity|SARS-CoV-2 viral load|AEs leading to withdrawal|Treatment-emergent serious AEs (SAEs)|Treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ECGs)|Incidence of meeting safety-related stopping rules|Pharmacokinetics of piclidenoson in this patient population|Serum cytokine levels	Can-Fite BioPharma|Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CF101-241COVID-19	October 6, 2020	March 6, 2021	July 6, 2021	April 3, 2020		September 29, 2020	Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah tikva, Israel		https://ClinicalTrials.gov/show/NCT04333472
330	NCT04446065	Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers	HERD	Not yet recruiting	No Results Available	COVID-19|SARS-CoV2	Drug: Previfenon®|Drug: Placebo	Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR|Rate of positive cases for IgM and IgG anti-SARS-CoV-2|Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test|Hospitalization due to any acute respiratory infection|Event of upper and lower airway respiratory infection	MELISA Institute Genomics & Proteomics Research SpA|Universidad Austral	All	25 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	524	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	MEL109042020	September 30, 2020	September 30, 2021	October 30, 2021	June 24, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04446065
331	NCT04497987	A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff	BLAZE-2	Recruiting	No Results Available	COVID-19|SARS-CoV2	Drug: LY3819253|Drug: Placebo	Percentage of Participants with SARS-CoV-2 Infection|Percentage of Participants with Moderate or Worse Severity COVID-19|Percentage of Participants with Mild or Worse Severity COVID-19|Percentage of Participants Who are Hospitalized due to COVID-19|Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Percentage of Participants Who Die Due to COVID-19	Eli Lilly and Company|National Institute of Allergy and Infectious Diseases (NIAID)|AbCellera Biologics Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	2400	Industry|NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	18063|J2X-MC-PYAD|CoVPN #3501	August 2, 2020	March 8, 2021	June 29, 2021	August 4, 2020		October 2, 2020	Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States|Care Access Research, Phoenix, Arizona, United States|Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States|Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Belmont Village Lincoln Park, Lincoln Park, Illinois, United States|Family Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Care Access Rch Lake Charles, Lake Charles, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States|Care Access, Boston, Massachusetts, United States|St. Paul IDA-CARe, Saint Paul, Minnesota, United States|Care Access, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Hospital & Medical Center, Omaha, Nebraska, United States|Care Access Research - Bronx, Bronx, New York, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Donahoe Manor, Bedford, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04497987
332	NCT04364802	COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients	PIIPPI	Recruiting	No Results Available	COVID-19|SARS-CoV 2	Drug: Povidone-Iodine Nasal Spray and Gargle	Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort	Alexandra Kejner|University of Kentucky	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	250	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	58748	April 29, 2020	May 2021	May 2021	April 28, 2020		May 14, 2020	University of Kentucky, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT04364802
333	NCT04487990	CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19		Recruiting	No Results Available	Acute Kidney Injury|Covid19	Drug: unfractionated Heparin	Clotted dialyzers|Time-free of clotting|Number of dialyzers used|Pressure variation|Urea sieving|Downtime of dialysis	University of Sao Paulo General Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U1111-1252-0194|33351120.0.0000.0068	June 29, 2020	December 2020	July 2021	July 27, 2020		July 27, 2020	University of São Paulo General Hospital, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT04487990
334	NCT04420299	Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19		Recruiting	No Results Available	Covid-19	Drug: Bemiparin	Proportion of patients that worsen|Mortality from any cause at day 28|Proportion of subjects that requires admission to the ICU|Proportion of subjects requiring non-invasive mechanical ventilation|Proportion of subjects requiring invasive mechanical ventilation.|Proportion of subjects with some organ failure|Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline|Proportion of subjects with pathological angioTAC|Proportion of subjects with improvement in chest radiography|Proportion and median hospital discharge between patients in both groups.|Titration score|Ferritin score|D-dimer modification score|Adverse events (total and serious).|Related adverse events (total and serious).|Clinically relevant major and non major hemorrhages.	Fundación de investigación HM|Syntax for Science, S.L	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BEMICOVID-19|2020-001548-24	June 4, 2020	March 31, 2021	March 31, 2021	June 9, 2020		June 11, 2020	Hospital Universitario HM Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04420299
335	NCT04341116	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	Coronavirus Disease 2019 COVID-19	Drug: TJ003234|Drug: Placebo	Proportion (%) of subjects experiencing deterioration in clinical status|Treatment Emergent Adverse Events|Clinical status|Improvement in clinical status|Sequential Organ Failure Assessment (SOFA) score|Change from baseline in PaO2/ FiO2|Length of time to normalization of oxygen saturation|Change from baseline in percentage of subjects requiring mechanical ventilation|Change from baseline in Glucocorticoid use|Mortality rate from any cause|Length of hospitalization|Change from baseline in D-dimer|Serum concentration of TJ003234|Incidence and titer of anti-drug antibodies (ADA)	I-Mab Biopharma Co. Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	144	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TJ003234COV201	April 11, 2020	September 2020	September 2020	April 10, 2020		July 14, 2020	Georgetown University Hospital, Washington, District of Columbia, United States|The GW Medical Faculty Associates, Washington, District of Columbia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univeristy Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04341116
336	NCT04487886	Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)	DAMPEN-CI	Not yet recruiting	No Results Available	COVID-19	Drug: Duvelisib|Drug: Placebo	Number of Participants Requiring Mechanical Ventilation or Dying|Days to Recovery|Duration of Hospitalization|Incidence of Death|Proportion of Participants Transferred to ICU|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Incidence of Grade III-V Adverse Events|Incidence of Secondary Bacterial or Viral Infections|Change in Th1 T Cell Frequency|Change in Th17 T Cell Frequency|Change in Interleukin-2 (IL-2)|Change in Interleukin-2 receptor (IL-2R)|Change in Interleukin-6 (IL-6)|Change in Interleukin-7 (IL-7)|Change in Interleukin-8 (IL-8)|Change in Interleukin-10 (IL-10)|Change in Interferon gamma-induced Protein 10 (IP-10)|Change in Macrophage Inflammatory Protein 1alpha (MIP-1a)|Change in Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Granulocyte Colony-stimulating Factor (G-CSF)|Change in Tumor Necrosis Factor (TNF)-alpha|Change in Vasoactive Intestinal Peptide (VIP)|Change in Gene Expression Profile of Regulatory T Cells (Tregs)|Change in Gene Expression Profile of cluster of differentiation 8 (CD8)+Interferon Gamma (IFNg)+ Granulocyte-macrophage colony-stimulating factor (GM-CSF)+|Change in Gene Expression Profile of CD8+ T cell immunoglobulin and mucin domain-containing protein 3 (Tim3)+ Programmed cell death protein 1 (PD-1)+|Change in Gene Expression Profile of cluster of differentiation 14 (CD14)+ cluster of differentiation (CD16)+ monocytes|Change in SARS-CoV-2 Viremia|Change in Immunoglobulin G (IgG) Antibodies|Change in Immunoglobulin M (IgM) Antibodies|Overall Survival	Emory University|Verastem, Inc.|University of Pennsylvania	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	STUDY00000701	August 2020	February 2022	February 2022	July 27, 2020		July 28, 2020	Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT04487886
337	NCT04360876	Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial		Not yet recruiting	No Results Available	COVID-19|ARDS	Drug: Dexamethasone injection|Drug: Placebos	Ventilator Free Days (VFD) at Day 28|Clinical Status at day 14 as measured by World Health Organization (WHO) 7-point ordinal scale.|Clinical Status at day 28 as measured by WHO 7-point ordinal scale|In-Hospital Mortality at day 28|In-Hospital Mortality at day 90|Time to Mortality to day 28|ICU-free days to day 28|Hospital Length of Stay among survivors to day 90|Severity of ARDS to day 10|Days to resolution of fever|Change in C-Reactive Protein (CRP) level from baseline to day 10|Vasopressor-free days to day 28|Renal replacement-free days to day 28|Duration of mechanical ventilation to day 28|Oxygenation-free days to day 28|Incidence of New Mechanical Ventilation to day 28|Change in sequential organ failure assessment (SOFA) score from baseline to day 10|In-hospital adverse events to day 28|Discontinuation of study drug infusion	University of Colorado, Denver	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	20-0811	September 1, 2020	December 31, 2020	January 30, 2021	April 24, 2020		July 14, 2020			https://ClinicalTrials.gov/show/NCT04360876
338	NCT04389801	Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection		Not yet recruiting	No Results Available	Covid 19	Drug: Desferal 500 MG Injection	Mortality rate|Duration of severe symptoms	Hesham Al-Inany|Cairo University	All	Child, Adult, Older Adult	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	0012	June 1, 2020	September 30, 2020	December 31, 2020	May 15, 2020		May 15, 2020			https://ClinicalTrials.gov/show/NCT04389801
339	NCT04567576	Predictive Factors for COVID-19 in Rheumatology		Not yet recruiting	No Results Available	Rheumatic Diseases|Covid19	Drug: Disease-modifying antirheumatic drugs (DMARDs)	Clinical behavior of the disease // COVID-19|Mortality	Fundación Santa Fe de Bogota	All	18 Years to 100 Years   (Adult, Older Adult)		150	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	FPColCOVIDReuma2020	October 2020	May 2021	October 31, 2021	September 28, 2020		September 28, 2020			https://ClinicalTrials.gov/show/NCT04567576
340	NCT04357444	Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	LILIADE-COVID	Not yet recruiting	No Results Available	COVID 19	Drug: 1: ILT101|Drug: 2: Placebo Comparator	The PaO2/FiO2 ratio at D11|Changes in Tregs between Baseline and Day 7 (expressed in %)|Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time (in days) from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Use of antibiotics for respiratory (proved or suspected) infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.	Assistance Publique - Hôpitaux de Paris|Iltoo Pharma	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	APHP200406|2020-001571-32	June 2020	July 2020	August 2020	April 22, 2020		June 9, 2020	Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France		https://ClinicalTrials.gov/show/NCT04357444
341	NCT04523181	Phase 2 Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild to Moderate COVID-19 Hospitalized Patients		Not yet recruiting	No Results Available	Covid-19	Drug: Antroquinonol|Drug: Placebo	recover ratio|Time to 2-point improvement|Duration of hospitalization|Time to virological clearance	Golden Biotechnology Corporation	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	174	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	GHCovid-2-001	September 21, 2020	December 31, 2020	March 31, 2021	August 21, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04523181
342	NCT04529499	Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients		Recruiting	No Results Available	Covid19	Drug: AVIGAN|Drug: Placebo Comparator	Primary Efficacy Endpoint: Time to resolution of hypoxia (Stage I)|Time to alleviation of symptoms (Stage I)|Percentage of patients with score of 0 = absent or mild = 1 (Stage I)|Time to improvement in each of the symptoms (Stage I)|Percentage of patients reporting a 'clinical relapse' (Stage I)|Time to negative conversion of detectable SARS-CoV 2 (Stage I)|Percentage of patients showing negative conversion of detectable SARS-CoV 2 (Stage I)|Changes over time in patient's clinical status on the 10-point ordinal scale of clinical status (Stage I)|Changes over time in patient's clinical status on the 8-point ordinal scale of clinical status (Stage I)|Changes over time in findings on chest X-ray (Stage I)|Changes over time in the National Early Warning Score-2 (Stage I)|Percentage of patients requiring ICU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Time (no. of days) from randomization to ICU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Duration (no. of days) the patient requires CU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Percentage of Patients dying (all cause and due to COVID-19) (Stage I)|Percentage of 'clinical relapse' (Stage I + Stage II)|Incidence of treatment emergent adverse events (Stage I + Stage II)	Dr. Reddy's Laboratories Limited	All	21 Years to 80 Years   (Adult, Older Adult)	Phase 3	780	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CVD-04-CD-001	August 20, 2020	December 31, 2020	January 31, 2021	August 27, 2020		September 18, 2020	Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait|Mishref Field Hospital (Mishref), Kuwait City, Kuwait		https://ClinicalTrials.gov/show/NCT04529499
343	NCT04489446	Sildenafil in COVID-19		Recruiting	No Results Available	Covid19|SARS-COV2 Infection	Drug: Sildenafil|Drug: Placebo	Arterial Oxygenation|Alveolo-arterial gradient|Intensive care unit admission|Noninvasive Mechanical Ventilation or Requirement of High-Flow Nasal Cannula|Invasive mechanical ventilation|Survival	Universidad Nacional Andres Bello|Hospital Naval Almirante Nef, Viña del Mar, Chile	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	UNAB-003	August 2020	December 2020	March 2021	July 28, 2020		August 17, 2020	Hospital Naval Almirante Nef, Viña Del Mar, Valparaiso, Chile		https://ClinicalTrials.gov/show/NCT04489446
344	NCT04575584	Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)		Not yet recruiting	No Results Available	Coronavirus Disease (COVID-19)	Drug: Molnupiravir|Drug: Placebo	Time-to-sustained recovery|Percentage of participants with an adverse event (AE)|Percentage of participants who discontinued study intervention due to an AE|Percentage of participants with all-cause mortality|Pulmonary score on a scale|Pulmonary+ score on a scale|National Early Warning Score on a scale|WHO 11-point outcomes score on a scale	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	4482-001|2020-003367-26|MK-4482-001	October 19, 2020	April 15, 2021	October 18, 2021	October 5, 2020		October 5, 2020			https://ClinicalTrials.gov/show/NCT04575584
345	NCT04575597	Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)		Not yet recruiting	No Results Available	Coronavirus Disease (COVID-19)	Drug: Molnupiravir|Drug: Placebo	Percentage of participants who are hospitalized and/or die|Percentage of participants with an adverse event (AE)|Percentage of participants who discontinued study intervention due to an AE|Time to improvement or resolution of targeted COVID-19 signs/symptoms|Time to progression of targeted COVID-19 signs/symptoms|WHO 11-point outcomes score on a scale	Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1450	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	4482-002|2020-003368-24|MK-4482-002	October 19, 2020	April 11, 2021	October 14, 2021	October 5, 2020		October 5, 2020			https://ClinicalTrials.gov/show/NCT04575597
346	NCT04402866	TD-0903 for ALI Associated With COVID-19		Recruiting	No Results Available	Acute Lung Injury (ALI) Associated With COVID-19|Lung Inflammation Associated With COVID-19	Drug: TD-0903|Drug: Placebo	Part 2: SaO2/FiO2 ratio|Part 2: Ventilator-free Days (VFDs)|Part 2: Intensive Care Unit Free Days (ICU-free)|Part 2: AUC in SaO2/FiO2 ratio|Part 2: SaO2/FiO2 ratio > 315|Part 2: Subjects Discharged|Part 2: Hospital Discharge|Part 2: Mortality Rate|Part 2: Modified Borg Dyspnea Score|Part 2: Clinical Status Scale|Part 2: Vital Status|Part 2: Subjects alive and free of ventilatory support	Theravance Biopharma	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	159	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	0188|2020-001807-18	June 24, 2020	October 2020	October 2020	May 27, 2020		September 25, 2020	Theravance Biopharma Investigational Site, Chisinau, Moldova, Republic of|Theravance Biopharma Investigational Site, Bucharest, Romania|Theravance Biopharma Investigational Site, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT04402866
347	NCT04513184	Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19		Recruiting	No Results Available	Covid19	Drug: IV Dexamethasone|Drug: Nasal Dexamethasone	Time of clinical improvement|Time-to-death from all causes|Time free from mechanical ventilation|Viral load|Length of hospital stay	Edda Sciutto Conde|Hospital General de México Dr. Eduardo Liceaga|Instituto Nacional de Cardiologia Ignacio Chavez|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|Universidad Nacional Autonoma de Mexico	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	DI/20/407/04/36	August 2020	November 30, 2020	December 31, 2020	August 14, 2020		August 21, 2020	Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Cdmx, Mexico|Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Cdmx, Mexico|El Instituto Nacional de Neurologia Y Neurocirugia Manuel Velasco Suarez, Mexico City, Cdmx, Mexico		https://ClinicalTrials.gov/show/NCT04513184
348	NCT04342897	A Study of LY3127804 in Participants With COVID-19		Active, not recruiting	No Results Available	COVID-19|Pneumonia	Drug: LY3127804|Drug: Placebo	Number of Ventilator Free Days|Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment|Percentage of Participants who are Alive and Respiratory Failure Free|Mortality|Length of Hospitalization|Number of Participants with any Serious Adverse Event (SAE)|Number of Participants with any Treatment Emergent Adverse Event (TEAE)	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 2	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	17824|I7W-MC-UDAA	April 20, 2020	November 30, 2020	November 30, 2020	April 13, 2020		October 7, 2020	Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Banner Univ Med Ctr Tucson, Tucson, Arizona, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Nuvance Danbury Hospital, Danbury, Connecticut, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Henry Ford Hospital Detroit, Detroit, Michigan, United States|Allina Hospital Network, Minneapolis, Minnesota, United States|State University of New York Hospital, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04342897
349	NCT04333732	CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION	CROWN CORONA	Recruiting	No Results Available	COVID 19	Drug: MR or M-M-R II ® vaccine|Drug: Placebo	Symptomatic COVID-19|Severity of COVID-19 over the study period|Effectiveness of preventing/reducing SARS-CoV-2 infection	Washington University School of Medicine|COVID -19 Therapeutics Accelerator	All	18 Years and older   (Adult, Older Adult)	Phase 3	30000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	202004099|INV-017499	September 4, 2020	August 2021	August 2021	April 3, 2020		September 9, 2020	Washington University School of Medicine, Saint Louis, Missouri, United States|Unity Health Toronto, Toronto, Ontario, Canada|University of Ghana Medical Centre, Accra, Greater Accra Region, Ghana|St James's Hospital, Dublin, Leinster, Ireland|Radboud University Medical Center, Nijmegen, Netherlands|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Infectious Diseases Institute Kampala, Uganda, Kampala, Uganda|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia|University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe		https://ClinicalTrials.gov/show/NCT04333732
350	NCT04558463	The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19		Recruiting	No Results Available	Covid19	Drug: Favipiravir|Drug: Oseltamivir 75mg	Clinical radiologic changes|Percentage of RT-PCR test convertion|Adverse event|Hospital length of stay (LOS)|Case Fatality Rate (CFR)	Indonesia University	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-04-0455	April 16, 2020	September 30, 2020	October 30, 2020	September 22, 2020		September 22, 2020	Cipto Mangunkusumo National Referral Hospital, Jakarta, DKI Jakarta, Indonesia		https://ClinicalTrials.gov/show/NCT04558463
351	NCT04358588	Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19		No longer available	No Results Available	Coronavirus Infection|COVID-19|Pneumonia, Viral	Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System		Bellerophon	All	18 Years to 95 Years   (Adult, Older Adult)			Industry	Expanded Access:Intermediate-size Population		PULSE-EAP-001				April 24, 2020		June 12, 2020			https://ClinicalTrials.gov/show/NCT04358588
352	NCT04392713	Efficacy of Ivermectin in COVID-19		Recruiting	No Results Available	COVID	Drug: Ivermectin 6 MG Oral Tablet (2 tablets)	Negative PCR|Need for mechanical ventilation	Combined Military Hospital, Pakistan	All	15 Years to 65 Years   (Child, Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IVE-COV	April 15, 2020	July 2020	July 2020	May 19, 2020		May 19, 2020	Combined Military Hospital Lahore, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04392713
353	NCT04395105	Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial		Recruiting	No Results Available	Respiratory Distress Syndrome, Adult|Covid-19	Drug: Dexamethasone (high dose)	Ventilator-free days at 28 days|28-days mortality|Frequency of nosocomila infections|Viral shedding|Serum C-reactive Protein variation|SOFA variation|Use of prone position|Delirium|Muscle weakness|90-day mortality	Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno	All	18 Years and older   (Adult, Older Adult)	Phase 3	284	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1264	May 21, 2020	December 31, 2020	January 31, 2021	May 20, 2020		July 20, 2020	CEMIC (Centro de Educación Médica e Investigaciones Clínicas), Ciudad Autonoma de Buenos Aires, Argentina|Sanatorio Sagrado Corazon, Ciudad Autonoma de Buenos Aires, Argentina|Clínica Bazterrica, Ciudad Autónoma de Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04395105
354	NCT04445311	Ivermectin in Treatment of COVID-19		Recruiting	No Results Available	COVID	Drug: Ivermectin	time to be symptoms free|hospitalization|Mechanical ventilation|length of stay|mortality	Zagazig University	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZU-IRB#6151/31-5-2020	May 31, 2020	July 30, 2020	August 15, 2020	June 24, 2020		June 24, 2020	Waheed Shouman, Zagazig, Sharkia, Egypt		https://ClinicalTrials.gov/show/NCT04445311
355	NCT04510402	Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects		Not yet recruiting	No Results Available	Covid19|Povidone Iodine Adverse Reaction	Drug: Povidine iodine nasal swabs	Number of participants with treatment-related adverse events as assessed by self reporting, metabolic and endocrine metrics|Number of participants with dose dependent side effects determined by self reporting diaries, thyroid and metabolic testing	Brigham and Women's Hospital|3M	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 1|Phase 2	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2020p002323	August 2020	February 2021	April 2021	August 12, 2020		August 12, 2020			https://ClinicalTrials.gov/show/NCT04510402
356	NCT04345848	Preventing COVID-19 Complications With Low- and High-dose Anticoagulation	COVID-HEP	Recruiting	No Results Available	COVID|Sars-CoV2	Drug: Enoxaparin	Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration	University Hospital, Geneva	All	18 Years and older   (Adult, Older Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2020-00794	April 28, 2020	March 31, 2021	March 31, 2021	April 15, 2020		September 22, 2020	Geneva University Hospitals, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Locarno, Locarno, Switzerland|Hôpital du Valais, Sion, Switzerland		https://ClinicalTrials.gov/show/NCT04345848
357	NCT04542434	Niclosamide in COVID-19		Not yet recruiting	No Results Available	Covid19	Drug: Niclosamide Oral Tablet|Drug: Placebo	Mortality|TEAE|SAEs|Safety laboratory|Blood pressure|fecal RNA virus clearance|Body temperature|Heart rate|SaO2|ECG	First Wave Bio, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	148	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FW-COV-003	November 1, 2020	May 1, 2021	May 1, 2021	September 9, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04542434
358	NCT04350736	First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19		Completed	No Results Available	Acute Lung Injury (ALI) Associated With COVID-19|Inflammatory Lung Conditions Associated With COVID-19	Drug: TD-0903|Drug: Placebo	Safety and Tolerability of SAD of TD-0903: Adverse Events|Safety and Tolerability of MAD of TD-0903: Adverse Events|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax	Theravance Biopharma	All	18 Years to 50 Years   (Adult)	Phase 1	54	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	0183|2020-000577-24	April 23, 2020	June 24, 2020	June 24, 2020	April 17, 2020		September 2, 2020	Theravance Biopharma Investigational Site, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT04350736
359	NCT04570449	Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)		Not yet recruiting	No Results Available	Covid19	Drug: Fluoxetine|Drug: Placebo	Rate of hospitalization|Physical symptoms assessed through daily checklist|Rate of intubation|Rate of death|Depressive symptoms assessed weekly|Post traumatic stress disorder symptoms assessed weekly|Anxiety symptoms assessed weekly|Suicidality assessed daily	Milton S. Hershey Medical Center	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	00015598	September 2020	September 2021	October 2021	September 30, 2020		September 30, 2020	Milton S. Hershey Medical Center Clinical Research Center, Hershey, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04570449
360	NCT04422561	Prophylactic Ivermectin in COVID-19 Contacts		Completed	Has Results	COVID	Drug: Ivermectin Tablets	Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID	Zagazig University	All	16 Years to 70 Years   (Child, Adult, Older Adult)	Phase 2|Phase 3	340	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ZU-IRB#6150/31-5-2020	May 31, 2020	July 14, 2020	July 27, 2020	June 9, 2020	August 27, 2020	August 27, 2020	Zagazig University, Zagazig, Sharkia, Egypt	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04422561
361	NCT04354155	COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial		Recruiting	No Results Available	Infection Viral|Thromboses, Venous|COVID-19	Drug: Enoxaparin Prefilled Syringe [Lovenox]	Safety of in-hospital thromboprophylaxis|Median twice-daily enoxaparin dose	Neil Goldenberg|Johns Hopkins All Children's Hospital	All	up to 18 Years   (Child, Adult)	Phase 2	38	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COVAC-TP	June 2, 2020	September 2022	October 15, 2022	April 21, 2020		July 27, 2020	Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States		https://ClinicalTrials.gov/show/NCT04354155
362	NCT04392427	New Antiviral Drugs for Treatment of COVID-19		Not yet recruiting	No Results Available	COVID|Drug Effect	Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :	negative test result for COVID-19	Mansoura University	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	20.05.69	October 2020	May 2022	May 2022	May 18, 2020		September 3, 2020	Mansoura University, Mansoura, Select A State Or Province, Egypt		https://ClinicalTrials.gov/show/NCT04392427
363	NCT04356508	COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1		Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2|2019-nCoV|Pneumonia, Viral	Drug: Nivolumab	Viral clearance kinetics|Treatment-related adverse events of nivolumab (Intervention arm only)|Lymphocyte kinetics|Cytokine kinetics|Length of inpatient stay due to COVID-19	Dr Gerry Gin Wai Kwok|The University of Hong Kong|Queen Mary Hospital, Hong Kong	All	18 Years and older   (Adult, Older Adult)	Phase 2	15	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW20213	April 14, 2020	June 30, 2020	August 31, 2021	April 22, 2020		April 22, 2020			https://ClinicalTrials.gov/show/NCT04356508
364	NCT04405271	TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)		Not yet recruiting	No Results Available	Healthcare Workers|COVID-19|SARS-CoV 2	Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo	COVID-19 incident cases|Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology|Severity of symptomatic COVID-19|Respiratory symptom duration in days|Relation between treatments and symptoms duration|Time course of specific IgM/IgG seroconversion	Hospital Italiano de Buenos Aires|Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)	All	18 Years and older   (Adult, Older Adult)	Phase 3	1378	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	5616	July 31, 2020	November 15, 2020	November 15, 2020	May 28, 2020		July 28, 2020	Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina		https://ClinicalTrials.gov/show/NCT04405271
365	NCT04575038	CRISIS2: A Phase 2 Study Assessing the Safety and Antiviral Activity of Brequinar in Non-hospitalized Patients With COVID-19	CRISIS2	Not yet recruiting	No Results Available	COVID-19 Infection	Drug: Brequinar|Drug: Placebo	SARS-CoV-2 viral load|Rates of AEs and SAEs including laboratory assessments|Viral shedding duration|Hospital Admission	Clear Creek Bio, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CCB-CRISIS-02	October 15, 2020	January 31, 2021	February 28, 2021	October 5, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04575038
366	NCT04347980	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	DHYSCO	Recruiting	No Results Available	Respiratory Distress Syndrome, Adult|COVID-19	Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine	Day-28 mortality|Ventilator-free days|Intensive Care Unit mortality|Day-60 mortality|Nosocomial pneumonia|Bacteremia	Centre Chirurgical Marie Lannelongue	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	122	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2037815010	April 2020	June 2020	August 2020	April 15, 2020		April 17, 2020	Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France		https://ClinicalTrials.gov/show/NCT04347980
367	NCT04422678	The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia		Not yet recruiting	No Results Available	COVID-19	Drug: Imatinib Mesylate|Drug: Standard of Care	Primary endpoint: Disease Progression|Improvement in Hypoxic Index|Hospital Length of Stay|Days on invasive mechanical ventilation|Inflammatory Markers|Viral clearance|Radiological assessment|Safety of Imatinib	Alexandria University|Science, Technology & Innovation Funding Authority (STIFA), Egypt	All	18 Years and older   (Adult, Older Adult)	Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Alex CCM 2020/5	June 2020	September 2020	October 2020	June 9, 2020		June 9, 2020			https://ClinicalTrials.gov/show/NCT04422678
368	NCT04459676	Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19|Pneumonia	Drug: Standard of Care (SOC) + ANG-3777|Drug: Standard Of Care (SOC) + Placebo	Proportion of patients alive, without the need for mechanical ventilation and free of the need for RRT (on an ongoing basis) at Day 28	Angion Biomedica Corp|CTI Clinical Trial and Consulting Services	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ANG3777-ALI-201	July 31, 2020	October 2020	October 2020	July 7, 2020		August 4, 2020	UPCLIN - Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP), Ribeirão Preto, Brazil|Hospital Guilherme Alvaro, Santos, Brazil|Escola Paulista de Medicina (Universidade Federal de São Paulo), São Paulo, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, Brazil|Hospital Heliópolis-SP, São Paulo, Brazil|Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04459676
369	NCT04533347	A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease		Not yet recruiting	No Results Available	COVID 19 Disease	Drug: Tafenoquine Oral Tablet|Drug: Placebo	Proportion of patients with clinical recovery of COVID-19 symptoms on Day 12 [± 1 day]|Proportion of patients with negative SARS-CoV-2 RT-PCR on Day 12 [± 1 day]|Hospitalization rates due to COVID-19 symptoms (excluding admittance only for administrative or observations purposes)|Number of COVID-19-related medical follow up visits [Doctor's office or emergency room (ER) visit]|Proportion of patients with COVID-19 symptoms at Day 12 by individual symptoms	60 Degrees Pharmaceuticals LLC|Peachtree BioResearch Solutions Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	275	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TQ 2020_06	October 2020	January 2021	February 2021	August 31, 2020		August 31, 2020			https://ClinicalTrials.gov/show/NCT04533347
370	NCT04363853	Tocilizumab Treatment in Patients With COVID-19		Recruiting	No Results Available	Sars-CoV2	Drug: Tocilizumab	Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography	Instituto Nacional de Cancerologia de Mexico|Roche Pharma AG	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INF-3343-20-22-1	June 1, 2020	June 1, 2021	August 1, 2021	April 27, 2020		June 17, 2020	National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico		https://ClinicalTrials.gov/show/NCT04363853
371	NCT04381364	Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)	HALT	Recruiting	No Results Available	Covid-19|Pneumonia, Viral|Sars-CoV2	Drug: Ciclesonide Inhalation Aerosol	Duration of received supplemental oxygen therapy|Invasive mechanical ventilation or all-cause death (key secondary outcome)|All cause death|Invasive mechanical ventilation|Remaining dyspnea symptoms	Ola Blennow, MD, PhD|Karolinska University Hospital|Danderyd Hospital|Centrallasarettet Västerås|St Goran's Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	446	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-02183	May 29, 2020	December 1, 2020	December 31, 2020	May 8, 2020		August 24, 2020	Danderyd Hospital, Danderyd, Sweden|Capio S:t Görans Hospital, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Visby Hospital, Visby, Sweden|Västmanland County Hospital Västerås, Västerås, Sweden|Örebro University Hospital, Örebro, Sweden		https://ClinicalTrials.gov/show/NCT04381364
372	NCT04445246	Inhaled Iloprost for Suspected COVID-19 Respiratory Failure	ILOCOVID	Recruiting	No Results Available	COVID-19|ARDS, Human|Hypoxemic Respiratory Failure	Drug: Inhaled ILOPROST	change in oxygenation parameters|Rates of endotracheal intubation|Invasive ventilation duration|ICU length of stay|Hospital Length of stay|Rates of proning therapy|Rates of ECMO cannulation|Mortality	Hamad Medical Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MRC-05-026	May 23, 2020	May 31, 2021	May 31, 2021	June 24, 2020		June 24, 2020	Hamad Medical Corporation, Doha, Qatar		https://ClinicalTrials.gov/show/NCT04445246
373	NCT04535791	Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers	COVID-19	Recruiting	No Results Available	Covid19|Vitamin D	Drug: Cholecalciferol	Number of Participants with COVID-19|Number of Participants with hospitalization for COVID-19|Serum concentration of 25 (OH) vitamin D	Coordinación de Investigación en Salud, Mexico|Hospital Infantil de Mexico Federico Gomez	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 3	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	R-2020-785-090	July 15, 2020	May 2021	July 2021	September 2, 2020		September 2, 2020	Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico		https://ClinicalTrials.gov/show/NCT04535791
374	NCT04445467	An Adaptive Clinical Trial of Antivirals for COVID-19 Infection	VIRCO	Recruiting	No Results Available	COVID	Drug: Favipiravir	Time to virological cure|Safety|Clinical improvement|Clinical symptoms|Biomarkers	Bayside Health	All	18 Years and older   (Adult, Older Adult)	Phase 2	190	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	66223	August 1, 2020	November 2020	November 2020	June 24, 2020		August 19, 2020	Alfred Health, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT04445467
375	NCT04512079	FREEDOM COVID-19 Anticoagulation Strategy	FREEDOM COVID	Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Enoxaparin|Drug: Apixaban	Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism	Valentin Fuster|Icahn School of Medicine at Mount Sinai	All	18 Years and older   (Adult, Older Adult)	Phase 4	3600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 20-2115	September 2020	March 2021	June 2021	August 13, 2020		August 14, 2020	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04512079
376	NCT04459247	Short Term, High Dose Vitamin D Supplementation for COVID-19	SHADE	Active, not recruiting	No Results Available	COVID	Drug: Vit D	Virus negativity|Inflammatory Marker|Inflammatory Marker 2	Postgraduate Institute of Medical Education and Research	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	121/20	June 15, 2020	August 30, 2020	September 10, 2020	July 7, 2020		August 27, 2020	Deptt of Endocrinology, Chandigarh, India		https://ClinicalTrials.gov/show/NCT04459247
377	NCT04542408	Hamburg Edoxaban for Anticoagulation in COVID-19 Study	HERO-19	Not yet recruiting	No Results Available	Covid19	Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Drug: Low dose Low molecular weight heparin or Placebo	Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism|All-cause mortality|Mortality related to venous thromboembolism|Mortality related to arterial thromboembolism|Rate of venous and/ or arterial thromboembolism|Rate and length of mechanical ventilation|Length of initial stay at ICU after application of IMP|Rehospitalisation|Rate and length of renal replacement therapy|Cardiac arrest/ CPR	Universitätsklinikum Hamburg-Eppendorf	All	18 Years and older   (Adult, Older Adult)	Phase 3	172	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HERO-19	September 1, 2020	May 31, 2021	September 30, 2021	September 9, 2020		September 9, 2020	Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Marienkrankenhaus, Hamburg, Germany|Universitärsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hanover, Germany|Krankenhaus Köln-Merheim, Köln, Germany|TU München Klinikum rechts der Isar, München, Germany|Universitätsklinikum Münster, Münster, Germany		https://ClinicalTrials.gov/show/NCT04542408
378	NCT04483830	Suloexide in the Treatment of Early Stages of COVID-19	SulES-COVID	Completed	No Results Available	Covid19	Drug: Sulodexide|Drug: Placebo	hospital care|days of hospital care|days of need suplemental oxigen|serum level of d-dimmer|serum level of creatinine|thromboembolic event|need for mechanical ventilation	Clinedem|Alfasigma S.p.A.	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	243	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Clidm/Vas/2020-05-01	June 5, 2020	August 6, 2020	September 7, 2020	July 23, 2020		September 9, 2020	Clinedem, San Luis Rio Colorado, Sonora, Mexico		https://ClinicalTrials.gov/show/NCT04483830
379	NCT04345653	Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers		Active, not recruiting	No Results Available	COVID19	Drug: Hydroxychloroquine Sulfate (HCQ)	Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation	Hackensack Meridian Health	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	44	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Pro2020-0356	April 14, 2020	June 5, 2020	April 8, 2021	April 14, 2020		June 9, 2020	Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04345653
380	NCT04529525	Ivermectin to Prevent Hospitalizations in COVID-19	IVERCORCOVID19	Recruiting	No Results Available	Covid19	Drug: Ivermectin|Drug: Placebo	Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm|Time to hospitalization|Percentage of Use of invasive mechanical ventilation support in each arm|Time to invasive mechanical ventilation support|Percentage of dialysis in each arm|All-cause mortality|Negative of the swab at 3±1 days and 12±2 days after entering the study|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])	Instituto de Cardiología de Corrientes	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IVERCORCOVID19MSPICC	August 19, 2020	December 31, 2020	January 31, 2021	August 27, 2020		September 15, 2020	Ministry of Public Health of the Province of Corrientes, Corrientes, Argentina		https://ClinicalTrials.gov/show/NCT04529525
381	NCT04472611	Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial	COLSTAT	Not yet recruiting	No Results Available	SARS-CoV-2	Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin	COVID 19 Severity	Yale University	All	18 Years and older   (Adult, Older Adult)	Phase 3	466	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000027950	August 1, 2020	August 1, 2021	August 1, 2022	July 15, 2020		July 31, 2020	Yale New Haven Hosptial System, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04472611
382	NCT04539795	COVID-19 Phase Ib Study of Safety and Tolerability of Alvelestat	COSTA	Not yet recruiting	No Results Available	Covid19	Drug: Alvelestat|Drug: Placebo	Numbers and % of subjects who experience at least 1 treatment-emergent adverse event|Mortality rate|Adverse events of special interest|Effect of alvelestat on blood pharmacodynamic biomarkers of inflammation	University of Alabama at Birmingham|Mereo BioPharma	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	15	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB-300005845	October 1, 2020	September 30, 2021	September 30, 2021	September 7, 2020		September 7, 2020	UAB Lung Health Center, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04539795
383	NCT04536363	Cri Analog PG1 Effectiveness and Safety in Covid-19	PGE1-COVID19	Not yet recruiting	No Results Available	Covid19	Drug: Analogs, Prostaglandin E1|Drug: Standard therapeutic protocol	Mortality|Hypoxemia Resolution|Days from admission to intensive care unit and administration of ANALOG PGE1|ICU stay|Days with high flow oxygen|Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG|Evolution time of the disease	Alonso Vera Torres|Fundación Santa Fe de Bogota	All	18 Years and older   (Adult, Older Adult)	Phase 2	284	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CEIS-2020-089	October 1, 2020	December 1, 2020	March 1, 2021	September 2, 2020		September 2, 2020			https://ClinicalTrials.gov/show/NCT04536363
384	NCT04371952	DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)	DYNAMIC	Not yet recruiting	No Results Available	COVID19	Drug: Doxycycline|Drug: Placebo	Percentage of Patients with Clinical Respiratory Aggravation|Percentage of patients hospitalized|Percentage of patients requiring ventilatory assistance|Positive SARS-CoV-2 PCR Test|Duration of symptoms|Duration of hospitalization|Hospitalization intensive care or reanimation|Duration of mechanical ventilatory assistance|Percentage of deaths related to SARS-CoV-2|AE / SAE in both arms	Nantes University Hospital	All	46 Years and older   (Adult, Older Adult)	Phase 3	330	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	RC20_0191	June 1, 2020	December 1, 2020	December 1, 2020	May 1, 2020		May 18, 2020	CHU Avicenne - APHP, Bobigny, France|CHU Bordeaux, Bordeaux, France|CHU Caen, Caen, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Nantes, Nantes, France		https://ClinicalTrials.gov/show/NCT04371952
385	NCT04389840	Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure		Recruiting	No Results Available	COVID-19|Acute Lung Injury|SARS-CoV-2	Drug: Dociparastat sodium|Drug: Placebo	Proportion of participants who are alive and free of invasive mechanical ventilation|All-cause mortality	Chimerix	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	524	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CMX-DS-004	June 3, 2020	February 2021	March 2021	May 15, 2020		October 2, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States|Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States|Our Lady of the Lake, Baton Rouge, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Texas Health Harris Methodist Hospital Fort Worth, Dallas, Texas, United States|Sentara Clinical Trials, Norfolk, Virginia, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04389840
386	NCT04393051	Baricitinib Compared to Standard Therapy in Patients With COVID-19	BARICIVID-19	Not yet recruiting	No Results Available	Covid-19|SARS-CoV 2|SARS Pneumonia	Drug: Baricitinib Oral Tablet	Need of invasive mechanical ventilation|Mortality|Time to invasive mechanical ventilation|Time to independence from non-invasive mechanical ventilation|Time to independence from oxygen therapy|Time to improvement in oxygenation for at least 48 hours|Length of hospital stay|Length of ICU stay|Instrumental response|Proportion of adverse events	Azienda Ospedaliero, Universitaria Pisana	All	18 Years and older   (Adult, Older Adult)	Phase 2	126	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BARICIVID-19	May 20, 2020	June 30, 2020	July 30, 2020	May 19, 2020		May 20, 2020	Azienda Ospedaliero Universitaria Pisana, Pisa, Italy		https://ClinicalTrials.gov/show/NCT04393051
387	NCT04549922	Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19	ASKCOV	Not yet recruiting	No Results Available	Covid19	Drug: ISIS 721744|Drug: Normal Saline	Days alive without respiratory support (any supplemental oxygen) after 15 days (DAFOR15)|SOFA - Sequential Organ Failure Assessment Score up to 15 days after randomization|Need for mechanical ventilation|Duration of mechanical ventilation	Hospital do Coracao|Ionis Pharmaceuticals, Inc.|Hospital Moinhos de Vento	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	90	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ASKCOV_Trial	October 2020	February 2021	December 2021	September 15, 2020		September 15, 2020			https://ClinicalTrials.gov/show/NCT04549922
388	NCT04469114	Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia		Recruiting	No Results Available	Covid19	Drug: Tofacitinib 10 mg|Drug: Placebo	Death or respiratory failure ate Day 28|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of disease severity at Day 14|Status of alive and not on mechanical ventilation or ECMO at Day 14 and 28 NIAID ordinal scale of disease severity at Day 14|Status of requiring supplemental oxygen at Day 28|Status of being alive and not hospitalized at Day 14 and 28|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of disease severity at Day 14 NIAID ordinal scale of disease severity at Day 28|Number of patients with cure|Number of patients at the ICU or on ventilatory support at Day 28|Number of days free from mechanical ventilation at 28 days|Number of days in hospital|Number of days in ICU	Hospital Israelita Albert Einstein|Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 2	260	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	34810620.0.1001.0071	September 16, 2020	December 7, 2020	January 31, 2021	July 13, 2020		September 23, 2020	Hospital Israelita Albert Einstein, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04469114
389	NCT04516915	IMU-838 and Oseltamivir in the Treatment of COVID-19	IONIC	Recruiting	No Results Available	Covid 19	Drug: IMU-838|Drug: Oseltamivir	To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) vs. Oseltamivir alone in adult subjects with COVID-19|To evaluate safety (number of adverse events) and tolerability (laboratory abnormalities) of IMU 838 + Oseltamivir vs. Oseltamivir alone in adult subjects with COVID-19.|To determine the effects of IONIC Intervention on improvement of at least two points in clinical status scale (from 0 to 8; with 8 being no evidence of clinical infection and 8 being death)|To assess the effects of IONIC Intervention vs. Oseltamivir on the need for invasive ventilation, renal replacement therapy or ECMO|To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay|To assess the effects of IONIC Intervention vs. Oseltamivir on the time from treatment initiation to death	University Hospitals Coventry and Warwickshire NHS Trust|Immunic AG|University of Warwick|MODEPHARMA	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RA486120	June 15, 2020	May 2021	July 2021	August 18, 2020		August 21, 2020	University Hospital Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom		https://ClinicalTrials.gov/show/NCT04516915
390	NCT04505774	Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)		Recruiting	No Results Available	Covid19	Drug: theraputic heparin|Drug: prophylactic heparin	21 Day Organ Support (respiratory or vasopressor) Free Days|Key Platform Secondary Thrombotic Endpoint|Other Platform Secondary Endpoints of Morbidity and Hospitalization|All cause mortality	Matthew Neal MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Phase 4	2000	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACTIV-4 ACUTE	September 4, 2020	March 2021	December 2021	August 10, 2020		October 1, 2020	NYU Langone, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04505774
391	NCT04317040	CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment	SAC-COVID	Active, not recruiting	No Results Available	Covid19	Drug: CD24Fc|Drug: Placebo	Improvement of COVID-19 disease status|Proportion of patients who died or had respiratory failure.|Disease progression of COVID-19|All cause of death|Proportion of clinical relapse|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of high flow oxygen therapy|Absolute lymphocyte count|Change of D-dimers	OncoImmune, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	241	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CD24Fc-007|20200674	April 8, 2020	October 31, 2020	December 2020	March 20, 2020		September 25, 2020	Baptist Health Research Institute, Jacksonville, Florida, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Texas at Houston, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04317040
392	NCT04570501	Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients		Not yet recruiting	No Results Available	Covid19	Drug: Angiotensin-(1-7)|Drug: Placebo	Time to recovery|Incidence of mortality at Day 29|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29	Stanford University	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	58189	November 2020	May 2021	May 2021	September 30, 2020		September 30, 2020	Stanford University, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04570501
393	NCT04382924	Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease		Recruiting	No Results Available	COVID	Drug: NP-120 (Ifenprodil)	Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients|NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients|Rate of mechanical ventilation in IP versus control group patients|Duration of mechanical ventilation (if applicable) in IP versus control group patients|Duration of supplemental oxygen in IP versus control group patients|Time to return to room pressure (SpO2 > 94%) on room air|Duration in ICU (if applicable) in IP versus control group patients|Rate of Mortality in IP versus control group patients|Duration of hospitalization in IP versus control group patients|Time to discharge in IP versus control group patients|Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients	Algernon Pharmaceuticals|Novotech (Australia)	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	682	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AGN120-3	August 5, 2020	January 2022	February 2022	May 11, 2020		September 9, 2020	Westchester Research Center, Miami, Florida, United States|Affinity Health - Loretto Hospital, Chicago, Illinois, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Promedica Health: Toledo Hospital and BayPark Hospital, Toledo, Ohio, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Makati Medical Center, Manila, Philippines|Philippine General Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|National Institute of Infectious Diseases, Bucharest, Romania		https://ClinicalTrials.gov/show/NCT04382924
394	NCT04350320	Trial to Study the Benefit of Colchicine in Patients With COVID-19	COL-COVID	Recruiting	No Results Available	COVID19	Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.	Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	All	18 Years and older   (Adult, Older Adult)	Phase 3	102	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IMIB-COLVID-2020-03	April 30, 2020	October 20, 2020	November 20, 2020	April 17, 2020		May 5, 2020	Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain		https://ClinicalTrials.gov/show/NCT04350320
395	NCT04493359	Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19	SWITCH-COVID	Recruiting	No Results Available	Covid19|Angiotensin II Receptor Antagonist Adverse Reaction	Drug: Renin-angiotensin system inhibitors	Need for ICU or mortality|High sensitivity troponin levels and covid-19 severity|ACE-2 activity and disease severity|ACE-2 activity with different Renin-angiotensin system inhibitors|Blood control and acute renal failure	University of Sao Paulo	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	33575220.9.0000.0068	July 25, 2020	February 14, 2022	February 14, 2022	July 30, 2020		July 31, 2020	Instituto do Coração - Incor HCFMUSP, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT04493359
396	NCT04537806	A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19		Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome|COVID-19	Drug: Brexanolone|Drug: Placebo	Percentage of Participants Who are Alive and Free of Respiratory Failure at Day 28|Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)|All-cause Mortality Through Day 28	Sage Therapeutics	All	18 Years and older   (Adult, Older Adult)	Phase 3	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	547-ARD-301	November 2020	October 2021	October 2021	September 3, 2020		September 3, 2020			https://ClinicalTrials.gov/show/NCT04537806
397	NCT04334460	Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects		Recruiting	No Results Available	Sars-CoV2	Drug: BLD-2660	Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)	Blade Therapeutics|Clinipace Worldwide	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	B-2660-204	May 4, 2020	September 2020	October 2020	April 6, 2020		September 3, 2020	Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Brandon, Florida, United States|Blade Research Site, Fort Pierce, Florida, United States|Blade Research Site, Panama City, Florida, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Idaho Falls, Idaho, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Ames, Iowa, United States|Blade Research Site, Lexington, Kentucky, United States|Blade Research Site, Louisville, Kentucky, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Farmington Hills, Michigan, United States|Blade Research Site, Omaha, Nebraska, United States|Blade Research Site, Ridgewood, New Jersey, United States|Blade Research Site, Charleston, North Carolina, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Blade Research Site, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Blade Research Site, Dallas, Texas, United States|Blade Research Site, Spokane, Washington, United States|Blade Research Site, Campinas, Sao Paulo, Brazil|Blade Research Site, Bahia, Brazil|Blade Research Site, Belo Horizonte, Brazil|Blade Research Site, Botucatu, Brazil|Blade Research Site, Porto Velho, Brazil|Blade Research Site, Ribeirão Preto, Brazil|Blade Research Site, São José Do Rio Preto, Brazil|Blade Research Site, Vitória, Brazil		https://ClinicalTrials.gov/show/NCT04334460
398	NCT04318444	Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)		Recruiting	No Results Available	COVID-19|Corona Virus Infection	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Number of participants with symptomatic, lab-confirmed COVID-19.	Columbia University	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	AAAS9676	March 29, 2020	March 2021	March 2022	March 24, 2020		April 27, 2020	Columbia University Irving Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04318444
399	NCT04402203	Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh		Recruiting	No Results Available	COVID-19|Favipiravir (Favipira)	Drug: Favipiravir|Drug: Only Standard Treatment	Number of participants negative by RT-PCR for the virus at 4-10 days after initiation of therapy.|Number of participants with lung condition change assessed with X-ray.|Number of participants with clinical recovery|Number of participants with adverse effects of drug.|Number of participants requiring ICU admission|Number of death	Bangladesh Medical Research Council (BMRC)	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2|Phase 3	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	29318042020	May 2020	July 2020	July 2020	May 26, 2020		May 26, 2020	Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4), Dhaka, Bangladesh		https://ClinicalTrials.gov/show/NCT04402203
400	NCT04435717	Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)	COVITOZ-01	Recruiting	No Results Available	Covid19	Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)	Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.|Progression of pneumonia|PaO2/FiO2|cause mortality to 28 days after started treatment|Length of hospital stay|patients requiring Intensive Care Unit admission|evolution of inflammatory parameters IL12|evolution of inflammatory parameters IL-10, IL-1, IL-6, IL-17 and IFN-gamma|evolution of inflammatory parameters Procalcitonin (PCT),|evolution of inflammatory parameters C-reactive protein (PCR),|evolution of inflammatory parameters D-dimer|evolution of inflammatory parameters and ferritin|pharmacokinetics of tocilizumab Cmin|pharmacokinetics of tocilizumab Cmax|pharmacokinetics of tocilizumab Cmedia|pharmacokinetics of tocilizumab Tmax|pharmacokinetics of tocilizumab AUC|Adverse event|Adverse event to cause the treatment interruption.|Adverse event Abnormalities in laboratory	Hospital Universitario Ramon y Cajal	All	18 Years and older   (Adult, Older Adult)	Phase 2	78	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVITOZ-01	May 4, 2020	August 4, 2020	August 4, 2020	June 17, 2020		June 17, 2020	Hospital Universitario Ramón y Cajal, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04435717
401	NCT04467840	Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19|Lung Infection	Drug: Opaganib|Drug: Placebo	Intubation and mechanical ventilation|WHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0|Time to intubation and mechanical ventilation|Time to low oxygen flow via nasal cannula|Supplemental oxygen requirement|Total daily oxygen requirement|Time to negative swabs for SARS-CoV-2|Negative swabs for SARS-CoV-2 at day 14|Fever|Mortality	RedHill Biopharma Limited	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	270	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ABC-201	August 21, 2020	January 2021	February 2021	July 13, 2020		October 6, 2020	ABC-201 Site 702, Ashdod, Israel|ABC-201 Site 701, Jerusalem, Israel|ABC-201 Site 703, Safed, Israel|ABC-201 Site 501, Mexico City, Mexico|ABC-201 Site 110, Barnaul, Russian Federation|ABC-201 Site 122, Kirovsk, Russian Federation|ABC-201 Site 101, Moscow, Russian Federation|ABC-201 Site 120, Murmansk, Russian Federation|ABC-201 Site 103, Ryazan, Russian Federation|ABC-201 Site 114, Ryazan, Russian Federation|ABC-201 Site 102, Smolensk, Russian Federation|ABC-201 Site 109, St Petersburg, Russian Federation|ABC-201 Site 111, St Petersburg, Russian Federation|ABC-201 Site 104, Tver, Russian Federation|ABC-201 Site 118, Volgograd, Russian Federation|ABC-201 Site 112, Yaroslavl, Russian Federation		https://ClinicalTrials.gov/show/NCT04467840
402	NCT04363502	Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection		Recruiting	No Results Available	Covid19	Drug: Clazakizumab|Drug: Placebo	Change in C-reactive protein (CRP) level	Johns Hopkins University	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IRB00247932	May 7, 2020	December 2020	December 2020	April 27, 2020		August 19, 2020	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04363502
403	NCT04403269	NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE	GERONIMO 19	Recruiting	No Results Available	Sars-CoV2	Drug: IgIV	Mortality|Total number of days of full hospitalization|Duration of oxygen therapy|Ferritin level in the blood|CRP level in the blood|LDH level in the blood|Lymphocyte level in the blood|PNN level in the blood|platelet level in the blood|WHO performance index|WHOQOL-OLD questionnaire|Lung function by pulmonary computed tomography|Lung function by EFR|Readmission Rates	Versailles Hospital	All	75 Years and older   (Older Adult)	Phase 2	35	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P20/07 GERONIMO 19	May 5, 2020	May 5, 2021	May 5, 2021	May 27, 2020		May 27, 2020	Centre Hospitalier de Versailles, Le Chesnay, France		https://ClinicalTrials.gov/show/NCT04403269
404	NCT04435314	Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19		Not yet recruiting	No Results Available	covid19	Drug: Nitazoxanide|Drug: Placebo	The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|Incidence of Treatment-Emergent Adverse Events|The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|The proportion of subjects with asymptomatic laboratory-confirmed COVID identified after the start of treatment and before the end of the study|Treatment adherence|Disease complication|Incidence of subjects that underwent unscheduled visit	Azidus Brasil|Farmoquimica S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	NITFQM0620OR	June 2020	August 2020	August 2020	June 17, 2020		June 17, 2020			https://ClinicalTrials.gov/show/NCT04435314
405	NCT04482621	Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial	DART	Recruiting	No Results Available	COVID-19	Drug: Decitabine|Other: Placebo Saline	Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more	Johns Hopkins University	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IRB00247544	September 14, 2020	May 2021	July 2021	July 22, 2020		September 25, 2020	Johns Hopkins University, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04482621
406	NCT04318015	Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)	PHYDRA	Recruiting	No Results Available	COVID-19|Severe Acute Respiratory Syndrome	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel	National Institute of Respiratory Diseases, Mexico|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 3	400	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	ProfilaxisCOVID	April 14, 2020	December 31, 2020	March 31, 2021	March 23, 2020		April 17, 2020	Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico		https://ClinicalTrials.gov/show/NCT04318015
407	NCT04341038	Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury	TACROVID	Recruiting	No Results Available	COVID-19|Lung Injury	Drug: Tacrolimus|Drug: Methylprednisolone	Time to reach clinical stability|Time to reach an afebrile state for 48 hours.|Time to reach PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300|Time to reach FR ≤ 24 rpm for 48 hours|Time to normalization of D-dimer (<250 ug / L)|Time until PCR normalization (<5mg / L).|Time until normalization of ferritin (<400ug / L)|Study the impact of immunosuppressive treatment on viral load using quantitative PCR|Time until hospital discharge|Need for ventilatory support devices|Duration that it is necessary to maintain ventilatory support.|COVID-19 mortality|all-cause mortality|Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.	Hospital Universitari de Bellvitge|Institut d'Investigació Biomèdica de Bellvitge	All	18 Years and older   (Adult, Older Adult)	Phase 3	84	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	TACRO-BELL-COVID|2020-001445-39	April 1, 2020	June 1, 2020	July 1, 2020	April 10, 2020		April 10, 2020	Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04341038
408	NCT04551768	Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19		Not yet recruiting	No Results Available	COVID19	Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole	Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.	Bausch Health Americas, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BHC-RIB-5401-GL	November 2020	April 2021	April 2021	September 16, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04551768
409	NCT04441398	Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients		Not yet recruiting	No Results Available	covid19	Drug: Nitazoxanide|Drug: Placebo	Change in signs and symptoms scale|Incidence of Treatment-Emergent Adverse Events|The proportion of subjects hospitalized after start of treatment and before the end of the study|The proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study|Duration of symptoms|Rate of mortality within 21-days	Azidus Brasil|Farmoquimica S.A.	All	50 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NITFQM0720OR	July 2020	September 2020	September 2020	June 22, 2020		June 22, 2020			https://ClinicalTrials.gov/show/NCT04441398
410	NCT04423861	Efficacy and Safety of Nitazoxanide 600 mg TID for the Treatment of Hospitalized Patients With COVID-19		Not yet recruiting	No Results Available	covid19	Drug: Nitazoxanide|Drug: Placebo	Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation	Azidus Brasil|Farmoquimica S.A.|Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NITFQM0520OR	July 2020	August 2020	August 2020	June 9, 2020		June 9, 2020			https://ClinicalTrials.gov/show/NCT04423861
411	NCT04356677	Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19		Not yet recruiting	No Results Available	COVID19	Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole	Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.	Bausch Health Americas, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BHC-RIB-5401-HC	November 2020	April 2021	April 2021	April 22, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04356677
412	NCT04407689	InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort	ILIAD-7-FR	Recruiting	No Results Available	COVID-19|Lymphocytopenia	Drug: Interleukin-7|Drug: Placebo	Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|"clinical improvement" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared tp placebo arm|length of hospitalization compared to placebo arm|length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo arm|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm	Revimmune|University Hospital, Limoges|Amarex Clinical Research	All	25 Years to 80 Years   (Adult, Older Adult)	Phase 2	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CLI107 COVID FR (ILIAD-7-FR)	June 8, 2020	October 30, 2020	December 30, 2020	May 29, 2020		June 22, 2020	University Hospital of Limoges, Limoges, France|Hôpital Edouard Herriot, Lyon, France		https://ClinicalTrials.gov/show/NCT04407689
413	NCT04379076	InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort	ILIAD-7-UK	Recruiting	No Results Available	COVID-19|Lymphocytopenia	Drug: Interleukin-7|Drug: Placebos	Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve|To obtain "clinical improvement" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|determine if CYT107 will lead to a significant decline of SARS-CoV-2 viral load through day 30 or HD|To compare the effect of CYT107 versus placebo on the frequency of secondary infections through day 45|To compare the effect of CYT107 versus placebo on the length of hospitalization|To compare the effect of CYT107 versus placebo on the length of stay in ICU|To compare the effect of CYT107 versus placebo on readmissions to ICU|To compare the effect of CYT107 versus placebo on organ support free days|To compare the effect of CYT107 versus placebo on the frequency of re-hospitalization through day 45|To assess the impact of CYT107 on all-cause mortality through day 45|To determine the effect of CYT107 on CD4+ and CD8+ T cell counts|To track and evaluate other known biomarkers of inflammation: Ferritin|To track and evaluate other known biomarkers of inflammation: CRP|To track and evaluate other known biomarkers of inflammation: D-dimer|Evaluation of physiological status through NEWS2 score	Revimmune|Amarex Clinical Research	All	25 Years to 80 Years   (Adult, Older Adult)	Phase 2	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CLI107 COVID UK (ILIAD-7-UK)	May 14, 2020	October 30, 2020	December 30, 2020	May 7, 2020		May 15, 2020	Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04379076
414	NCT04577378	Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	Isotretinoin	Not yet recruiting	No Results Available	Covid19	Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)	lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferons|All cause mortality rate|Serum level of viral RNA|Ventilation free days|ICU free days	Kafrelsheikh University	All	15 Years to 80 Years   (Child, Adult, Older Adult)	Phase 2	45	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Isotretinoin	October 20, 2020	November 20, 2020	November 20, 2020	October 6, 2020		October 6, 2020	Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt		https://ClinicalTrials.gov/show/NCT04577378
415	NCT04551898	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)		Not yet recruiting	No Results Available	Covid19	Drug: BGB-DXP593|Drug: Placebo	Change from baseline to Day 8 in SARS-CoV-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples|Time-weighted average change in viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Change from baseline to Day 15 in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Number of participants requiring hospitalization due to worsened COVID-19|Time to resolution of all COVID-19-related symptoms|All-cause mortality rate at Day 29|Number of participants experiencing Adverse Events (AEs)|Number of participants experiencing Serious Adverse Events (SAEs)	BeiGene	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BGB-DXP593-102	October 30, 2020	December 31, 2020	February 28, 2021	September 16, 2020		September 16, 2020			https://ClinicalTrials.gov/show/NCT04551898
416	NCT04454307	Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients		Not yet recruiting	No Results Available	COVID-19	Drug: Tramadol|Other: Standard care delivered in the isolation hospitals.	Number of COVID-19 PCR negative cases	Tanta University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1|Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	TRAM/COVID19	July 2020	August 2020	October 2020	July 1, 2020		July 2, 2020			https://ClinicalTrials.gov/show/NCT04454307
417	NCT04429334	Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation		Not yet recruiting	No Results Available	COVID19	Drug: nangibotide|Drug: placebo	Adverse Events|Mortality	Inotrem	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MOT-C-204	August 2020	March 2021	March 2021	June 12, 2020		July 28, 2020	Réanimation Médicale, Hôpital Central, Nancy, France		https://ClinicalTrials.gov/show/NCT04429334
418	NCT04551781	Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis		Completed	No Results Available	Covid19	Drug: 20 Mg Prednisone for 14 days|Drug: control	improved	South Valley University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	450	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	SVU-MED-CHT019420861	April 1, 2020	July 30, 2020	July 30, 2020	September 16, 2020		September 16, 2020	south-Vally University faculty of medicine, Qena, Kena, Egypt		https://ClinicalTrials.gov/show/NCT04551781
419	NCT04348474	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19		Suspended	No Results Available	Covid-19	Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets	Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity	Azidus Brasil	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	200	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIAPRE0420OR	April 20, 2020	June 30, 2020	July 31, 2020	April 16, 2020		April 22, 2020	Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04348474
420	NCT04336904	Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: Favipiravir|Other: Placebo	Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality	Giuliano Rizzardini|ASST Fatebenefratelli Sacco	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	HS216C17-PHASE III	March 25, 2020	July 2020	July 2020	April 7, 2020		April 8, 2020	Asst Fatebenefratelli Sacco, Milano, Italy		https://ClinicalTrials.gov/show/NCT04336904
421	NCT04390061	TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia	TOFACoV-2	Not yet recruiting	No Results Available	Pneumonitis, Interstitial|COVID-19	Drug: Tofacitinib|Drug: Hydroxychloroquine	Prevention of severe Respiratory Failure requiring mechanical ventilation|Prevention of need of ICU admission|Prevention of COVID-19 related Deaths|Identification of predictors of outcome|Incidence of Treatment-Emergent Adverse Events	Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord|Ospedale Civile Santo Spirito, Pescara|Università Magna Grecia, Catanzaro|ASST Papa Giovanni XXIII, Bergamo|Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma|ASST Cremona, Cremona|Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano|Ospedale di Circolo e Fondazione Macchi, Varese	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	116	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-002035-30	June 2020	September 2020	October 2020	May 15, 2020		May 15, 2020			https://ClinicalTrials.gov/show/NCT04390061
422	NCT04481685	A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	Covid19	Drug: ATI-450|Drug: Placebo	Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1β|Change in serum cytokine Tumor Necrosis Factor (TNF-α)	University of Kansas Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	IIT-2020-ATI-450-COVID-19	July 20, 2020	July 2021	July 2022	July 22, 2020		August 21, 2020	The University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT04481685
423	NCT04575558	HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19	HOPE_BRAZIL	Withdrawn	No Results Available	Sars-CoV2	Drug: Hydroxychloroquine and Azithromycin	Clinical deterioration rate|Mortality and cause of death|Incidence and type of Adverse Events (EAs)|Incidence and type of Serious Adverse Events (SAE)|Discontinuation rate or temporary suspension of treatment|Descriptive radiologic changes on chest CT scans	Latin American Cooperative Oncology Group|Oncoclínicas	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	LACOG 0220	June 30, 2020	September 1, 2020	October 30, 2020	October 5, 2020		October 5, 2020	Núcleo de Oncologia da Bahia - NOB, Salvador, BA, Brazil|Oncoclínicas BH, Belo Horizonte, MG, Brazil|Centro Oncológico do Triângulo - COT, Uberlândia, MG, Brazil|Multihemo, Recife, PE, Brazil|Oncoclinicas RJ, Rio De Janeiro, RJ, Brazil|Centro de Pesquisa em Oncologia PUCRS, Porto Alegre, RS, Brazil|Centro Paulista de Oncologia, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT04575558
424	NCT04362137	Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)	RUXCOVID	Recruiting	No Results Available	Cytokine Storm (Covid-19)	Drug: Ruxolitinib|Drug: Placebo	Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care|Clinical status|Percentage of patients with at least two-point improvement from baseline in clinical status|Percentage of patients with at least one-point improvement from baseline in clinical status|Percentage of patients with at least one-point deterioration from baseline in clinical status|Time to improvement in clinical status|Mean change from baseline in the clinical status|Mortality rate|Proportion of patients requiring mechanical ventilation|Duration of hospitalization|Time to discharge or to a NEWS2 score of ≤2|Change from baseline in NEWS2 score|Change from baseline in SpO2/FiO2 ratio.|Proportion of patients with no oxygen therapy	Novartis Pharmaceuticals|Incyte Corporation|Novartis	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	402	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CINC424J12301|INCB 18424-368|2020-001662-11	May 2, 2020	October 16, 2020	October 19, 2020	April 24, 2020		October 6, 2020	Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Butte, Montana, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Flushing, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sorocaba, SP, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Colombes Cedex, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT04362137
425	NCT04569227	Prevention of COVID-19 Infection to Severe Pneumonia or ARDS		Not yet recruiting	No Results Available	Covid19 Pneumonia	Drug: EC-18|Drug: Placebo	Proportion of patients alive and free of respiratory failure through at Day 28|Probability of progression of mild pneumonia patients to severe pneumonia or ARDS within 28 days|Assessment of all-cause mortality|Respiratory failure defined based on resource utilization requiring at least 1 of the following:|Proportion of patients alive and free of invasive mechanical ventilation at a pre-specified timepoint|Proportion of patients alive and discharged from the hospital at a pre-specified timepoint|Lengths of ICU stay|Lengths of alive and respiratory failure-free days|Proportion of patients with objective measures of improvement (returning to room air) at time points (days 7, 14, and 28)|Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)	Enzychem Lifesciences Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	EC-18-204	October 6, 2020	September 2021	November 2021	September 29, 2020		September 29, 2020			https://ClinicalTrials.gov/show/NCT04569227
426	NCT04350086	Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection	PRODEX	Withdrawn	No Results Available	COVID-19 Infection|Sars-cov-2|Respiratory Failure|Palliative Situation	Drug: Treatment with Dexmedetomidine	Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.|Overall survival of patients on Dexmedetomidine|Daily analgesic effect of Dexmedetomidine|Other sedative pharmacological agents|Average dosage required for Dexmedetomidine to achieve mild to moderate sedation	University Hospital, Limoges	All	18 Years and older   (Adult, Older Adult)	Phase 4	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	87RI20_0011 (PRODEX)	April 20, 2020	November 20, 2020	November 20, 2020	April 16, 2020		September 2, 2020	University Hospital, Limoges, France		https://ClinicalTrials.gov/show/NCT04350086
427	NCT04442178	InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )	ILIAD-7-US-I	Not yet recruiting	No Results Available	COVID-19|Lymphocytopenia	Drug: CYT107|Drug: Placebo	Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|"clinical improvement" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|Length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo a|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm	Revimmune|Washington University School of Medicine|Amarex Clinical Research	All	25 Years to 80 Years   (Adult, Older Adult)	Phase 2	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ILIAD-7 COVID US INFECTIOUS	June 30, 2020	November 30, 2020	December 31, 2020	June 22, 2020		June 22, 2020			https://ClinicalTrials.gov/show/NCT04442178
428	NCT04426201	InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O )	ILIAD-7-US-O	Not yet recruiting	No Results Available	COVID-19|Lymphocytopenia	Drug: CYT107|Drug: Placebo	Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|"clinical improvement" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo arm|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm	Revimmune|Memorial Sloan Kettering Cancer Center|Amarex Clinical Research	All	25 Years to 80 Years   (Adult, Older Adult)	Phase 2	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ILIAD-7 COVID US ONCO	June 22, 2020	November 30, 2020	December 31, 2020	June 11, 2020		June 11, 2020			https://ClinicalTrials.gov/show/NCT04426201
429	NCT04350580	Polyvalent Immunoglobulin in COVID-19 Related ARds	ICAR	Recruiting	No Results Available	Acute Respiratory Distress Syndrome|COVID-19	Drug: Human immunoglobulin|Drug: Placebo	Ventilator-free days|Mortality|Sequential Organ Failure Assessment Score|P/F ratio|Lung compliance|Radiological score|Biological efficacy endpoints - C-reactive protein|Biological efficacy endpoints - Procalcitonin|Immunological profile|Number of patients using other treatments for COVID-19 related ARDS|Occurrence of deep vein thrombosis or pulmonary embolism|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Kidney Disease: Improving Global Outcomes (KDIGO) score and need for dialysis|Occurrence of adverse event related to immunoglobulins|Occurrence of critical illness neuromyopathy|Occurrence of ventilator-acquired pneumonia	Centre Hospitalier St Anne|Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences|Laboratoire français de Fractionnement et de Biotechnologies	All	18 Years and older   (Adult, Older Adult)	Phase 3	138	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	D20-P013|2020-001570-30	April 11, 2020	April 2021	June 2021	April 17, 2020		September 22, 2020	CHU Sud Amiens, Amiens, France|CHU Angers, Angers, France|Service de réanimation polyvalente, rond point de Girac, Angoulême, France|CH Aulnay, Aulnay-sous-Bois, France|Centre hospitalier de Béthune, Beuvry, France|Hopital Avicenne, Bobigny, France|CH Chalons en champagne, Chalons en champagne, France|CH-Nord-Ardennes, Charleville-Mézières, France|Hopital d'instruction des armées Percy, Clamart, France|Centre Hospitalier de Dieppe, Dieppe, France|Hôpital Raymond Poincaré, Garches, France|CHU de Grenoble, Grenoble, France|Grand hopital de l'est Francilien - site de Jossigny, Jossigny, France|Hopital Robert Boulin, Libourne, France|Pôle de Médecine intensive/réanimation Hôpital Salengro, CHRU de Lille, Lille, France|Groupement Hospitalier Edouar Herriot, Lyon, France|Hôpital de la Croix Rousse Novembre 2019, Lyon, France|Hopital Jacques Cartier, Massy, France|Hopital Jacques Monod, Montivilliers, France|Service de Médecine Intensive-Réanimation, CHU, Nantes, France|CHR Orléans, Orléans, France|Centre Hospitalier Sainte-Anne, Paris, France|CHU Lariboisiere, Paris, France|CHU Pitié Salpétriere Service de réanimation chirurgicale, Paris, France|CHU Saint Antoine, Paris, France|Fondation ophtalmologique Rotschild, Paris, France|Hôpital Paris Saint-Joseph, Paris, France|Hôpital Pitié Salpêtrière, Paris, France|Institut Mutualiste Montsouris, Paris, France|CHU Robert Débré, Reims, France|CH Poissy, Saint-Germain-en-Laye, France|Groupe hospitalier Saint Vincent, Strasbourg, France|Hôpital de Hautepierre, Strasbourg, France|Hopital de Tarbes, Tarbes, France|Hôpital Nord Franche-Comté, Trévenans, France|CH Valenciennes, Valenciennes, France|Chu Nancy - Brabois, Vandœuvre-lès-Nancy, France|Hopital de Vannes, Vannes, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, Étampes, France		https://ClinicalTrials.gov/show/NCT04350580
430	NCT04415060	SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival	SAVE-ICU	Recruiting	No Results Available	Covid19	Drug: Isoflurane Inhalant Product|Drug: Sevoflurane inhalant product	Hospital Mortality|Ventilator-Free Days|ICU-Free Days|Participant Quality of Life at 3 and 12 months after discharge|Median Daily Oxygenation|Adjunctive ARDS therapies|Hospital-Free Days|Disability|Cost Utility Analysis|Cost Effectiveness Analysis	Sunnybrook Health Sciences Centre	All	18 Years and older   (Adult, Older Adult)	Phase 3	752	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2149	June 15, 2020	June 15, 2023	June 15, 2023	June 4, 2020		September 2, 2020	University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Universite de Sherbrooke, Sherbrooke, Quebec, Canada|University Health Network - Toronto Western Hopsital, Toronto, Canada		https://ClinicalTrials.gov/show/NCT04415060
431	NCT04366323	Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19		Recruiting	No Results Available	Sars-CoV2	Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS	Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate	Andalusian Network for Design and Translation of Advanced Therapies	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	26	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AdiQure/COVID-19	April 27, 2020	October 2021	October 2021	April 28, 2020		June 5, 2020	Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT04366323
432	NCT04453501	Anti Infective Agents Impact in COVID-19 Pneumonia	AZITHROVID	Completed	No Results Available	COVID|Pneumonia, Viral	Drug: favorable outcome	Favorable outcome|Risk factors 1|Risk factors 2|Interest of anti-infective agents	Centre d'Investigation Clinique et Technologique 805	All	18 Years and older   (Adult, Older Adult)		132	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	AZITHROVID|INDS	March 2, 2020	April 25, 2020	April 25, 2020	July 1, 2020		July 1, 2020	Benjamin Davido, Garches, France		https://ClinicalTrials.gov/show/NCT04453501
433	NCT04510662	Telmisartan in Respiratory Failure Due to COVID-19	STAR-COVID	Recruiting	No Results Available	COVID-19|Respiratory Insufficiency|Telmisartan|Respiratory Distress Syndrome, Adult	Drug: Telmisartan	Death|Mechanical ventilation|Occurrence of acute kidney injury|Incidence of hypotension|Incidence of hypotension requiring vasopressors|Incidence of Sepsis|Hospital length of stay	Abraham Edgar Gracia-Ramos|National Polytechnic Institute, Mexico|Hospital Regional de Alta Especialidad de Zumpango	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CI/HRAEZ2020/05	August 2020	March 2021	April 2021	August 12, 2020		August 12, 2020	Hospital Regional de Alta Especialidad de Zumpango, Zumpango, Estado De Mexico, Mexico		https://ClinicalTrials.gov/show/NCT04510662
434	NCT04578158	Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Remdesivir|Dietary Supplement: Quercetin Phytosome	Survival time|Length of stay in hospital|Days of mechanical ventilation|Blood parameters according to the protocol described above|Blood gas analysis|Radiological imaging|PaO2|Heart rate|Respiratory rate|Quality of life questionnaire|Number and dose of other drugs used	Liaquat University of Medical & Health Sciences|University of Milano Bicocca|University of Pavia|Dow University of Health Sciences|University of Oxford	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	LUMHS/REC/894	October 26, 2020	February 25, 2021	April 25, 2021	October 7, 2020		October 7, 2020	Liaquat University Hospital, Jāmshoro, Sindh, Pakistan		https://ClinicalTrials.gov/show/NCT04578158
435	NCT04477083	Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19		Active, not recruiting	No Results Available	Covid19|Hydroxychloroquine Adverse Reaction	Drug: inhalable hydroxychloroquine (HCQ)|Drug: supportive and symptomatic treatment	Time to clinical recovery defined as 3 days afebrile with improved cough and other clinical signs|Time to achieve viral clearance state determined by two successive negative PCR results for two oropharyngeal swabs separated by 48 hours.|Incidence of Treatment-Emergent Adverse Events	Mansoura University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	inhalable HCQ	July 15, 2020	August 15, 2020	August 15, 2020	July 20, 2020		July 20, 2020	Mansoura University Hospital, Mansoura, Outside U.S./Canada, Egypt		https://ClinicalTrials.gov/show/NCT04477083
436	NCT04528771	S-Nitrosylation Therapy of COVID-19		Not yet recruiting	No Results Available	SARS-CoV2 Infection|Covid19	Drug: SNO|Drug: Nitrogen gas	Length of Hospital Stay|Number of Ventilator Days|Length of Intensive Care|All-Cause Mortality|Treatment Emergent Adverse Events|Time to Respiratory Status Improvement|Clinical Status|Respiratory Clinical Status	Robert Schilz|Case Western Reserve University|University Hospitals Cleveland Medical Center	All	18 Years to 89 Years   (Adult, Older Adult)	Phase 1	21	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY20200453	October 31, 2020	March 31, 2021	April 30, 2021	August 27, 2020		August 27, 2020	University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04528771
437	NCT04378244	CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19	CORONA	Not yet recruiting	No Results Available	COVID-19|Cytokine Storm|Acute Respiratory Distress Syndrome	Drug: DeltaRex-G	Maximum Tolerated Dose|Survival|Hospital Stay|Ventilator Therapy|Intensive Care Unit Stay|Cytokine Pattern	Aveni Foundation	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 1|Phase 2	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AF20-203	November 12, 2020	November 12, 2021	March 12, 2022	May 7, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04378244
438	NCT04342663	A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection	STOP COVID	Active, not recruiting	No Results Available	COVID 19|Coronavirus	Drug: Fluvoxamine|Drug: Placebo	Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	Phase 2	152	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	202004023	April 10, 2020	August 20, 2020	October 1, 2020	April 13, 2020		September 1, 2020	BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04342663
439	NCT04371640	Sirolimus in COVID-19 Phase 1	SirCO-1	Recruiting	No Results Available	SARS-CoV-2|Covid-19	Drug: Sirolimus 1 MG/ML|Drug: Placebo	Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse events	Walter K. Kraft|Thomas Jefferson University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	15680	May 2020	July 2020	August 2020	May 1, 2020		May 7, 2020	Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04371640
440	NCT04359329	Estrogen Patch for COVID-19 Symptoms		Recruiting	No Results Available	COVID	Drug: Estradiol patch	Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death	Sharon Nachman|Stony Brook University	All	18 Years and older   (Adult, Older Adult)	Phase 2	110	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SBU-EstrogenPatch-COVID19	April 20, 2020	November 15, 2020	November 15, 2020	April 24, 2020		April 24, 2020	Stony Brook University Hospital, Stony Brook, New York, United States		https://ClinicalTrials.gov/show/NCT04359329
441	NCT04561063	COVID-19 Prophylaxis South Africa (COVER HCW)	COVER	Not yet recruiting	No Results Available	Covid19|SARS-CoV Infection	Drug: Nitazoxanide|Drug: Sofosbuvir/Daclatasvir	Number of SARS-CoV-2 infections|Duration of symptoms|Maximum score on WHO Ordinal Scale|Time to onset of SARS-CoV-2 infection|Number of symptomatic SARS-CoV-2 infections|Number of asymptomatic SARS-CoV-2 infections|Peak score on modified Flu PRO	University of Witwatersrand, South Africa	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	1950	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	EZ-SS-025	December 2020	July 2021	July 2021	September 23, 2020		September 28, 2020	Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa|Sunnyside Office Park, Johannesburg, Gauteng, South Africa		https://ClinicalTrials.gov/show/NCT04561063
442	NCT04382053	Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia		Recruiting	No Results Available	COVID 19 Pneumonia, Impaired Respiratory Function	Drug: DFV890|Drug: Standard of Care (SoC)	APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier)|Serum C-reactive protein (CRP) levels|Clinical status over time|Proportion of participants not requiring mechanical ventilation for survival.|Proportion of participants with at least one-point improvement from baseline in clinical status	Novartis Pharmaceuticals|Novartis	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDFV890D12201|2020-001870-32	May 27, 2020	December 21, 2020	December 21, 2020	May 11, 2020		October 5, 2020	Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Heidelberg, Baden-Württemberg, Germany|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Surat, Gujrat, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, San Martin de Porres, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04382053
443	NCT04527211	Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel	IveprofCovid19	Not yet recruiting	No Results Available	Covid19|Healthcare Worker Patient Transmission	Drug: Ivermectin	Clinical development of covid-19 disease during the intervention period|Seroconversion|Hospitalization requirement|Intensive Care Unit Requirement|Safety of the intervention	Javeriana University	All	18 Years and older   (Adult, Older Adult)	Phase 3	550	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	Epi1JaveCali	September 7, 2020	November 30, 2020	December 16, 2020	August 26, 2020		August 26, 2020	Pontificia Universidad Javeriana, Cali, Valle Del Cauca, Colombia		https://ClinicalTrials.gov/show/NCT04527211
444	NCT04530409	Timing of Corticosteroids in COVID-19		Recruiting	No Results Available	Covid19|Corticosteroids	Drug: Early-Dexamethasone|Drug: Late-Dexamethasone	Percentage of cases that will need hospitalization|Percentage of cases that deteriorate to acute respiratory distress syndrome|Percentage of cases with increased d-dimer|Time to recovery of diarrhea|Percentage reduction in CRP|Percentage reduction in LDH|Percentage reduction in ALT|Percentage reduction in Ferritin|Time to recovery of lymphopenia|Time to recovery of cough|Time to recovery of fever|Time to recovery of myalgia|Time to recovery of anosmia|Time to recovery of dyspnea	ClinAmygate	All	18 Years and older   (Adult, Older Adult)	Phase 4	450	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PR0012	August 26, 2020	October 1, 2020	November 1, 2020	August 28, 2020		September 15, 2020	Asalam, Maadi, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04530409
445	NCT04485130	DISulfiram for COvid-19 (DISCO) Trial	DISCO	Not yet recruiting	No Results Available	Covid19	Drug: Disulfiram|Drug: Placebo	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8)|Virologic impact of 3 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Immunologic impact of 3 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).	University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DSF151837	September 1, 2020	June 1, 2021	September 1, 2021	July 24, 2020		July 24, 2020	San Francisco General Hospital, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04485130
446	NCT04405921	Hydroxychloroquine, Azithromycin in the Treatment of Covid-19	PACTT	Not yet recruiting	No Results Available	SARS-CoV-2 Pneumonia|COVID-19	Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG	Clinical recovery at day-14, from the start of treatment.|Viral Clearance via RT-PCR at day 5- 7-10 and day 14	Centre Hôpital Universitaire Farhat Hached	All	18 Years and older   (Adult, Older Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	PACTT	July 2020	December 2020	March 2021	May 28, 2020		June 19, 2020	University Hospital Farhat Hached, Sousse, Tunisia		https://ClinicalTrials.gov/show/NCT04405921
447	NCT04568863	Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19	MELCOVID	Recruiting	No Results Available	COVID-19|SARS-CoV 2|Coronavirus Infection	Drug: Melatonin intravenous|Drug: Placebo intravenous	Mortality	Pharmamel S.L.|Hospital Universitario La Paz|Instituto de Investigación Hospital Universitario La Paz	All	18 Years and older   (Adult, Older Adult)	Phase 2	18	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PHM-2020-001	June 20, 2020	October 30, 2020	November 30, 2020	September 29, 2020		September 29, 2020	Hospital Universitario La Paz, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04568863
448	NCT04494646	BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)		Recruiting	No Results Available	Covid19	Drug: Bardoxolone methyl|Drug: Placebo	Incidence of Serious Adverse Events in Phase 2|Proportion of participants who have recovered in Phase 3|Average number of renal replacement therapy (RRT)-free days|Average number of mechanical ventilation-free days|Incidence of All-Cause Mortality|Proportion of participants who experienced deterioration from baseline	NYU Langone Health|Reata Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	440	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	20-00591	September 8, 2020	January 30, 2021	February 28, 2021	July 31, 2020		October 2, 2020	NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04494646
449	NCT04362813	Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia	CAN-COVID	Recruiting	No Results Available	Pneumonia and Cytokine Release Syndrome (Covid-19)	Drug: Canakinumab|Drug: Placebo	Number of patients with clinical response|COVID-19-related death rate during the 4-week period after study treatment|Ratio to baseline in the C-reactive protein (CRP)|Ratio to baseline in the serum ferritin|Ratio to baseline in the D-dimer|Number of participants with Adverse Event (AE), serious adverse events (SAE), clinically significant changes in laboratory measures, and vital signs	Novartis Pharmaceuticals|Novartis	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	450	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CACZ885D2310|2020-001370-30	April 30, 2020	September 22, 2020	December 22, 2020	April 27, 2020		October 1, 2020	Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, West Reading, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Lyon cedex 04, Rhone, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Prien A Chiemsee, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Reggio Emilia, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04362813
450	NCT04388709	Interferon Lambda Therapy for COVID-19		Not yet recruiting	No Results Available	SARS-CoV-2	Drug: Peginterferon Lambda-1A	Number of participants with resolution of hypoxia|Number of adverse events.|Days with fever|Time to resolution of fever|Rate of progression to requiring critical care|Overall survival|Time to discharge	Icahn School of Medicine at Mount Sinai|Eiger BioPharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 2	66	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 20-0820	September 2020	May 2021	May 2021	May 14, 2020		June 16, 2020	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04388709
451	NCT04474483	Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19	COVID-19	Not yet recruiting	No Results Available	COVID-19	Drug: Melatonin|Other: Placebo (Methylcellulose) capsule	Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality	State University of New York at Buffalo	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	UBMELCOVID19	August 11, 2020	August 10, 2021	August 10, 2021	July 16, 2020		July 16, 2020	University at Buffalo, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT04474483
452	NCT04495816	COVID-19 Anosmia Study		Recruiting	No Results Available	Anosmia|Covid19	Drug: Omega-3 Fatty Acid Supplement|Drug: Placebo/Control	Brief Smell Identification Test (BSIT)|Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)|Sinonasal Outcomes Test (SNOT-22)	Icahn School of Medicine at Mount Sinai	Female	18 Years and older   (Adult, Older Adult)	Phase 2	126	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GCO 20-1132	July 15, 2020	April 2021	June 2021	August 3, 2020		August 4, 2020	Mount Sinai Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04495816
453	NCT04342689	The Role of Resistant Starch in COVID-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch	Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score	Yale University|University of Michigan|University of Minnesota	All	19 Years and older   (Adult, Older Adult)	Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2000027887	June 3, 2020	June 1, 2021	June 1, 2021	April 13, 2020		June 17, 2020	Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04342689
454	NCT04570397	Ravulizumab and COVID-19		Not yet recruiting	No Results Available	Covid19|Thrombotic Microangiopathies|Acute Kidney Injury	Drug: Ravulizumab	Assess the efficacy of ravulizumab to ameliorate SARS-CoV-2 (COVID-19)-induced acute kidney injury manifesting as thrombotic microangiopathy.|Evaluation of pharmacokinetics of ravulizumab in participants with COVID-19	Brigham and Women's Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	32	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	092420	November 2020	May 2021	November 2021	September 30, 2020		September 30, 2020	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04570397
455	NCT04469491	Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study	COV-NI	Not yet recruiting	No Results Available	COVID-19|INTERFERON|NEBULIZATION	Drug: inhaled type I interferon|Drug: WFI water nebulization	oxygen requirement score at day 0|oxygen requirement score at day 15|Variation oxygen requirement score between day 0 and day15	Centre Hospitalier Universitaire, Amiens	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PI2020_843_0041	July 2020	March 2021	March 2021	July 14, 2020		July 14, 2020	CHU Amiens, Amiens, France		https://ClinicalTrials.gov/show/NCT04469491
456	NCT04472728	Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients	COVA	Recruiting	No Results Available	Covid-19|SARS-CoV2	Drug: BIO101|Drug: Placebo	End-of-Part 1 interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.|For part-2 sample size interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.|For the final analysis: Proportion of subjects with all cause mortality or respiratory failure.|Interim analysis; indication of activity of BIO101: Oxygen saturation by pulse oximetry (SpO2) SpO2 / Fraction of inspired oxygen (FiO2) ratio|Interim analysis; indication of activity of BIO101: Inflammatory markers|Interim analysis; indication of activity of BIO101: Renin Angiotensin System biomarkers|Key secondary endpoint for final analysis: Proportion of participants with positive or negative events|Additional secondary endpoints for final analysis: Respiratory function|Additional secondary endpoints for final analysis:proportion of patients who experienced positive event|Additional secondary endpoints for final analysis:proportion of patients who experienced negative events|Additional secondary endpoint for final analysis: The National Early Warning Score 2 (NewS2):|Additional secondary endpoint for final analysis: Population Pharmacokinetics study (pop-PK)|Additional secondary endpoint : Population Pharmacokinetics study (pop-PK)|Secondary endpoint: Population Pharmacokinetics study (pop-PK)	Biophytis	All	55 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	310	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BIO101-CL05	June 16, 2020	July 2021	September 2021	July 15, 2020		September 2, 2020	Barnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches, Louisiana, United States|AZ-Sint Maarten, Mechelen, Belgium|CHU CLU Namur (Saint-Elisabeth) Place Louise Godin, Namur, Belgium|Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar, São Paulo, Brazil|Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital, Paris, Paris Cedex 13, France|Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, Paris, France		https://ClinicalTrials.gov/show/NCT04472728
457	NCT04467151	Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: anti-SARS-CoV-2 plasma|Other: Placebo	Disease progression measured by WHO scale|Comparison of maximum WHO score per group|Comparison of decrease of median and maximum WHO score per group|Comparison of time to clinical improvement per group|Comparison of time to reach score of "6" or greater on the WHO scale	Kashif Khan|University of Southern California	All	18 Years and older   (Adult, Older Adult)	Phase 2	96	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HS-20-00516	August 2020	October 2021	December 2021	July 10, 2020		July 24, 2020			https://ClinicalTrials.gov/show/NCT04467151
458	NCT04391101	Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)		Not yet recruiting	No Results Available	SARS-Cov-2	Drug: Convalescent plasma	Intrahospital mortality from any cause|Length of hospital stay|Free time for ventilatory support on day 60|Overall survival at day 60 since hospitalization|Cumulative incidence of adverse events: transfusion reactions (fever, flare), TRALI (transfusion-associated lung injury), TACO (transfusion-related circulatory overload), transfusion- related infections	Hospital San Vicente Fundación|Clínica León XIII|Grupo de Inmunodeficiencias primarias Universidad de Antioquia|Clínica Universitaria Bolivariana|Hospital Pablo Tobón Uribe|Clínica Rosario El Tesoro|Clínica Las Américas|Clínica Cardiovid	All	18 Years and older   (Adult, Older Adult)	Phase 3	231	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	002	June 2020	June 2021	December 2021	May 18, 2020		May 20, 2020	Hospital San Vicente Fundacion, Medellín, Antioquia, Colombia		https://ClinicalTrials.gov/show/NCT04391101
459	NCT04409327	Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes		Recruiting	No Results Available	COVID19	Drug: RTB101|Drug: Placebo	The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die|The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection|Mortality rate in subjects who develop laboratory-confirmed COVID19|Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2|Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19|Safety and tolerability will be assessed by report of AE/SAEs	Restorbio Inc.	All	65 Years and older   (Older Adult)	Phase 3	550	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	RTB101-210	July 11, 2020	September 2020	October 2020	June 1, 2020		July 31, 2020	Nursing Home, Middletown, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT04409327
460	NCT04458948	Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients		Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	Duration of viral shedding|Evaluation of Fatality Rate|Evaluation of Clinical Response|Evaluation of Length of Hospital Stay	University of New Mexico	All	18 Years and older   (Adult, Older Adult)	Phase 2	10000	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-156	March 24, 2020	March 24, 2021	March 24, 2025	July 7, 2020		July 7, 2020	University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04458948/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04458948
461	NCT04488575	Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection		Recruiting	No Results Available	Covid19	Drug: EDP1815|Drug: Placebo	Change from baseline to the lowest S/F oxygen ratio|Change in S/F Ratio|Percentage change in S/F Ratio|Percentage of participants at each level on the WHO OSCI score|Percentage of participants with shifts from each level of the WHO OSCI score at baseline|Percentage of participants remaining at their baseline score on the WHO OSCI (or lower)|Percentage of participants reporting each level of the WHO OSCI score at their worst post-baseline day|The time in days spent at each participant's worst reported WHO OSCI score (excluding death).|Intubation and mechanical-ventilation free survival|Overall survival|Number of days requiring oxygen therapy|Number of days with pyrexia|Maximum daily temperature|SpO2 level|Time to discharge|Time to oxygen saturation (SpO2) ≥94%|Time to recovery|Number of participants experiencing AEs by seriousness and relationship to treatment|Incidence of clinically significant abnormal lab parameters	Evelo Biosciences, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EDP1815-205	August 26, 2020	December 21, 2020	December 21, 2020	July 28, 2020		September 16, 2020	Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04488575
462	NCT04405102	COVID-19 Ozanimod Intervention Study	COZI	Recruiting	No Results Available	COVID-19	Drug: Ozanimod|Other: Standard of care	Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale|The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%|Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use|Rate of intubation|Ventilator-free days at day 28|Rate of ICU admission/length of stay/mortality|Severity index measurement	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Celgene|Bristol-Myers Squibb	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	48	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-3474	September 16, 2020	January 1, 2023	January 1, 2024	May 28, 2020		September 30, 2020	Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada		https://ClinicalTrials.gov/show/NCT04405102
463	NCT04530578	Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19	NEBUHEPA	Recruiting	No Results Available	Covid19|Pneumonia	Drug: Heparin sodium|Drug: Enoxaparin	Percentage of patients requirement mechanical ventilation|Percentage of patients with PaO2 to Fi02 ratio > 300|Lengths of hospital-stay|Mortality rate	Clinica San Camilo, Argentina	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSanCamilo	June 1, 2020	October 30, 2020	June 1, 2021	August 28, 2020		August 31, 2020	Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04530578
464	NCT04412252	Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy		Withdrawn	No Results Available	COVID-19	Drug: Tofacitinib|Other: Placebo	Clinical status using ordinal scale|Status of alive and not using mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Status of discharged or not requiring supplemental oxygen|Mortality	Pfizer	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	A3921377	July 6, 2020	September 16, 2020	October 18, 2020	June 2, 2020		July 31, 2020	Hartford Hospital (HH), Hartford, Connecticut, United States|University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04412252
465	NCT04468646	To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients		Recruiting	No Results Available	Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus	Drug: NK-1R antagonist	Time to improvement on a 7-point ordinal scale as compared to baseline|total in-hospital days and the total duration|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours	Prof. Dr. Fridoon Jawad Ahmad|University of Lahore|bahria international hospital|University of Health Sciences Lahore	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	UniversityHSL-NK1R	June 15, 2020	July 15, 2020	August 30, 2020	July 13, 2020		July 13, 2020	Bahria International Hospital, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04468646
466	NCT04381052	Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection		Not yet recruiting	No Results Available	COVID-19	Drug: Clazakizumab|Other: Placebo	Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative Incidence of Intubation|Time to Extubation|Length of Intensive Care Unit (ICU) stay|Number of Patients who Present a Decrease in C-reactive protein (CRP)|Number of Patients with Acute Kidney Injury (AKI)|Number of Patients with a Need for Renal Replacement Therapy (RRT)|Duration of Renal Replacement Therapy (RRT)|Patient Survival|Number of Patients with Hemodialysis|Number of Patients with Continuous Renal Replacement Therapies (CRRT)|Number of Patients with Peritoneal Dialysis	Columbia University|NYU Langone Health|CSL Behring	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	AAAT0142	May 2020	August 1, 2020	August 1, 2020	May 8, 2020		May 8, 2020	Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04381052
467	NCT04348383	Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.	DEFACOVID	Recruiting	No Results Available	COVID19	Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days	1. Mortality rate|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IMIB-DFC-2020-02	April 8, 2020	January 15, 2021	January 15, 2021	April 16, 2020		August 13, 2020	Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain		https://ClinicalTrials.gov/show/NCT04348383
468	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)	RACONA	Not yet recruiting	No Results Available	COVID19	Drug: Nafamostat Mesilate|Drug: Placebo	Time-to-clinical improvement|Responders|Critical or dead patients|pO2/FiO2 ratio|SOFA score over time|Hospitalization|Mechanical ventilation|Mechanical ventilation duration|Cardiovascular disease	University Hospital Padova|Yokohama City University|University of Zurich	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	256	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	RACONA Nafamostat	April 2020	December 2021	December 2021	April 20, 2020		April 20, 2020			https://ClinicalTrials.gov/show/NCT04352400
469	NCT04505592	Tenecteplase in Patients With COVID-19		Recruiting	No Results Available	COVID-19|Respiratory Failure|ARDS	Drug: Tenecteplase|Drug: Placebo	Number of participants free of respiratory failure|Number of occurrences of bleeding|Number of participants with in-hospital deaths at 14 days|Number of participants with death at 28 days|Number of ventilator-free days|Number of respiratory failure-free days|Number of vasopressor-free days|Vasopressor doses at 24 hours|Vasopressor doses at 72 hours|P/F ratio at 24 hours|P/F ratio at 72 hours|Number of ICU-free days|Hospital length of stay|Number of participants with new-onset renal failure|Number of participants with need for renal replacement therapy	Hooman Poor|Genentech, Inc.|Icahn School of Medicine at Mount Sinai	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	GCO 20-1764	September 25, 2020	February 2021	April 2021	August 10, 2020		September 30, 2020	Mount Sinai Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04505592
470	NCT04499313	Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19		Recruiting	No Results Available	Covid19|ARDS	Drug: Dexamethasone|Drug: Methylprednisolone	Mortality rate (In hospital)|Clinical improvement|Ventilator free days|Changes in Oxygen level	Chattogram General Hospital|Health Science Center of Xi'an Jiaotong University	All	20 Years to 80 Years   (Adult, Older Adult)	Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10000753	August 2, 2020	November 15, 2020	November 30, 2020	August 5, 2020		August 18, 2020	Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh		https://ClinicalTrials.gov/show/NCT04499313
471	NCT04360824	Covid-19 Associated Coagulopathy		Recruiting	No Results Available	COVID 19 Associated Coagulopathy	Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis	Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions	University of Iowa	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 4	170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202004235	May 6, 2020	April 16, 2021	April 16, 2021	April 24, 2020		June 19, 2020	University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04360824
472	NCT04357782	Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation	AVoCaDO	Active, not recruiting	No Results Available	COVID-19|Hypoxia	Drug: L-ascorbic acid	Incidence of adverse events|Incidence of serious adverse reactions|Incidence of adverse reactions|Ventilator-free days|ICU-free days|Hospital-free days|All-cause mortality|Change in S/F ratio during HDIVC infusion|C-reactive protein (CRP)|Lactate dehydrogenase (LDH)|D-dimer|Lymphocyte count|Neutrophil to Lymphocyte ratio (NLR)|Serum Ferritin	Hunter Holmes Mcguire Veteran Affairs Medical Center|McGuire Research Institute	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 1|Phase 2	20	U.S. Fed|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Davis 001	April 16, 2020	September 18, 2020	October 15, 2020	April 22, 2020		September 18, 2020	Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT04357782
473	NCT04487574	A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19		Recruiting	No Results Available	SARS-CoV-2 Infection	Drug: XC221|Drug: Placebo	Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration.|Time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row.|Patient rate with clinical improvement by day 2-28. Presence of all of the following factors during 48 hours in a row.|Patient rate with a negative test result for SARS-CoV-2 by Day 7±1, 15±1, 21 ±1 and 28 ± 1.|Duration of hospitalization.|Patient rate transferred to the intensive care unit (ICU) during hospitalization.|Duration of ICU stay.|Patient rate with ARDS during hospitalization.|Presence of a fatal outcome.|Patient rate requiring oxygen therapy by Day 2-28.|Patient rate requiring high-flow oxygen therapy by Day 2-28.|Patient rate requiring non-invasive ventilation by Day 2-28.|Patient rate requiring invasive ventilation by Day 2-28.|Patient rate requiring extracorporeal membrane oxygenation (EMO) by Day 2-28.|The total duration of oxygen therapy by the last day of hospitalization.|The total duration of high-flow oxygen therapy by the last day of hospitalization.|The total duration of non-invasive ventilation by the last day of hospitalization.|The total duration of invasive ventilation of lungs by the last day of hospitalization.|The total duration of EMO by the last day of hospitalization.|Patient rate with Sp02 > 95% by Day 2-28.|Average alteration of Sp02 by Day 2-28 from baseline.|Average time to reach SpO2 ≥ 95%.|Patient rate with RR < 22 / min by Day 2-28.|Average alteration in RR by Day 2-28 from baseline.|Average time to reach RR ≤ 22 / min.|Patient rate with body temperature < 37.5°C by Day 2-28.|Average alteration in body temperature by Day 2-28 from baseline.|Average time until the patient reaches a body temperature of ≤37.5°C.|Patient rate with CT-1 according to CT data by Day 2-28.|Average alteration in CT data by 1 point in terms of severity (CT-1, CT-2, CT-3, CT-4) by Day 7, 10, 15, 18, 21 and 28 compared to the baseline value.|Average time to reach CT-1 according to CT data.|Patient rate with a score < 2 according to the Daytime and Nighttime Cough Scale by Day 2-28.|Mean change in Daytime and Nighttime Cough scores by Day 2-28 from baseline.|Average time to reach < 2 points when assessed according to the Daytime and Nighttime Cough Scale.|Patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28.|Average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28 from baseline.|Average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale.|Patient rate with a transition decrease to category 3 or lower according to the WHO scale by Day 2-13 and Day 15-28.|Mean WHO grade change by Day 2-28 from baseline.|Average time to reach the 3rd category or below according to the WHO scale.|Patient rate with a NEWS score < 2 by Day 2-28.|Average change in NEWS score by Day 2-28 from baseline.|Average time to reach a NEWS score ≤ 2.	RSV Therapeutics LLC	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	XC221-03-02-2020	July 25, 2020	December 2020	December 2020	July 27, 2020		September 25, 2020	Regional State Budgetary Institution of Healthcare "City Hospital No. 5, Barnaul", Barnaul, Altai Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow Region "Zhukovskaya City Clinical Hospital", Zhukovskiy, Moscow Region, Russian Federation|Municipal Budgetary Institution of Healthcare "Central City Hospital of Novoshakhtinsk", Novoshakhtinsk, Rostov Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow "City Clinical Hospital No. 15 of the Moscow Department of Healthcare", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University), Department of Faculty Therapy No. 2, Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow "City Clinical Hospital No. 52 of the Moscow Department of Healthcare", Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow "City Clinical Hospital No. 40 of the Moscow Department of Healthcare", Moscow, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare "City Multidisciplinary Hospital", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare "City Hospital No. 40 of Kurortny District", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare "City Hospital No. 15", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital" (4th Cardiology Department), Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital", Saint Petersburg, Russian Federation|Regional State Budgetary Institution of Healthcare "Medical-Sanitary Unit No. 2", Tomsk, Russian Federation		https://ClinicalTrials.gov/show/NCT04487574
474	NCT04350450	Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore		Withdrawn	No Results Available	COVID|Coronavirus|COVID-19	Drug: Hydroxychloroquine	Time to resolution of symptoms|Number of days from onset of illness to symptom resolution|Number of days to return to work|Rate of hospital admission in treated and untreated healthcare workers|Adverse effect of HCQ during treatment	Montefiore Medical Center	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-11445	April 2020	August 2020	August 2020	April 17, 2020		May 27, 2020	Montefiore Medical Center, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT04350450
475	NCT04449588	Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS		Recruiting	No Results Available	COVID-19 Pneumonia	Drug: BDB-001 Injection|Other: Conventional treatment	Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline|28-day all-cause mortality rate|Percentage of subjects achieving recovery in SpO2|Mean change of PaO2/FiO2|Mechanical ventilation time|Time of oxygen therapy|Lymphocyte count|Change in inflammation indicators (CRP or IL-6) from baseline|Improvement in body temperature|Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Improvement at Day3, 7, 11 & Day14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Time to get categories 1 to 4 in the 8-points ordinal scale|Time to attain an improvement of 1 point on the ordinal scale	Staidson (Beijing) Biopharmaceuticals Co., Ltd|Beijing Defengrui Biotechnology Co. Ltd	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	368	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STS-BDB001-04	July 23, 2020	August 7, 2021	August 7, 2022	June 29, 2020		July 27, 2020	Southwest Hospital Chongqing, Chongqing, Chongqing, China|RSUP Persahabatan(Persahabatan General Hospital), East Jakarta, Jakarta, Indonesia|RSUD Pasar Minggu(Pasar Minggu General Hospital), South Jakarta, Jakarta, Indonesia|RSUD Cengkareng(Cengkareng General Hospital), West Jakrata, Jakrata, Indonesia		https://ClinicalTrials.gov/show/NCT04449588
476	NCT04405999	Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease		Completed	No Results Available	Increased Risk of SARS-CoV-2 Infection	Drug: Bromhexine Hydrochloride	Polymerase chain reaction (PCR)|Time to symptoms|Time to positive PCR|Number of cases|Case severity|Drug tolerance	Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	05-20-02-С	May 14, 2020	August 9, 2020	August 31, 2020	May 28, 2020		September 3, 2020	Almazov National Medical Research Centre, Saint Petersburg, Russian Federation		https://ClinicalTrials.gov/show/NCT04405999
477	NCT04374071	Early Short Course Corticosteroids in COVID-19		Completed	No Results Available	COVID|Pneumonia, Viral	Drug: Methylprednisolone	Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).	Henry Ford Health System	All	18 Years and older   (Adult, Older Adult)		250	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	HFH IRB # 13739	March 12, 2020	March 27, 2020	April 30, 2020	May 5, 2020		May 5, 2020	Henry Ford Hospital, Detroit, Michigan, United States		https://ClinicalTrials.gov/show/NCT04374071
478	NCT04552483	Effects of Early Use of Nitazoxanide in Patients With COVID-19		Completed	No Results Available	Covid19|Coronavirus	Drug: Nitazoxanide|Drug: Placebo	Days with fever|Days with cough|Days with asthenia|SARS-COV-2 viral load - absolute number|SARS-COV-2 viral load - percentage|Hospital admission rate - absolute number|Hospital admission rate - percentage|Serum Interleukin-6|Serum Interleukin-1-beta|Serum Interleukin-8|Serum tumor necrosis factor (TNF)-alfa|Serum interferon-gamma|Serum monocyte chemoattractant protein (MCP)-1|Complete blood count|C-reactive protein - absolute number|C-reactive protein - percentage	Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil|National Research Council, Brazil|ATCGen|Complexo Hospitalar Municipal de São Caetano do Sul|Hospital de Transplante Doutor Euryclides de Jesus Zerbini|Secretaria Municipal de Saúde de Bauru|Santa Casa de Misericórdia de Sorocaba|Secretaria Municipal de Saúde de Guarulhos|Hospital e Maternidade Therezinha de Jesus|Secretaria de Estado de Saúde do Distrito Federal	All	18 Years and older   (Adult, Older Adult)	Phase 2	396	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SARITA-2|RBR-4nr86m|32258920.0.1001.5257	June 8, 2020	August 20, 2020	September 5, 2020	September 17, 2020		September 17, 2020	Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil		https://ClinicalTrials.gov/show/NCT04552483
479	NCT04365257	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)	PREVENT	Recruiting	No Results Available	COVID-19	Drug: Prazosin|Other: Standard of care	Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma	Johns Hopkins University|Fast Grants	All	45 Years to 85 Years   (Adult, Older Adult)	Phase 2	220	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00246659|COV2001	May 13, 2020	December 2020	December 2020	April 28, 2020		May 15, 2020	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04365257
480	NCT04354714	Ruxolitinib to Combat COVID-19		Withdrawn	No Results Available	COVID-19	Drug: Ruxolitinib|Procedure: Peripheral blood draw	Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0|Proportion of participants with detectable virus	Washington University School of Medicine|Incyte Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	04-13-20-DiPersio	June 30, 2020	July 31, 2021	December 31, 2021	April 21, 2020		May 21, 2020			https://ClinicalTrials.gov/show/NCT04354714
481	NCT04416048	Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19	COVID-PREVENT	Not yet recruiting	No Results Available	COVID-19	Drug: Rivaroxaban|Other: Standard Of Care (SOC)	Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation|Development of disseminated intravascular coagulation (DIC) according to the ISTH criteria|Number of days requiring invasive ventilation|Number of days requiring non-invasive ventilation|Improvement on a seven-category ordinal scale recommended by the WHO as clinical improvement scale for patients with respiratory infections	Charite University, Berlin, Germany|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|Bayer	All	18 Years and older   (Adult, Older Adult)	Phase 3	400	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COVID-PREVENT|2020-002282-33	August 1, 2020	April 30, 2021	May 30, 2021	June 4, 2020		July 16, 2020	Kardiologie und Angiologie I Universitätsherzzentrum Freiburg, Freiburg, Baden-Württemberg, Germany|Clinic for Gastroenterology, Infectology and Poisoning Universitäsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Cardiology and Pneumology Clinic Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Bayern, Germany|Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich, Munich, Bayern, Germany|Cardiology, Pneumology and Intensive Care Clinic, München Klinik Neuperlach, München, Bayern, Germany|Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken, Hennigsdorf, Brandenburg, Germany|Clinic for Cardiology, Angiology und Nephrology Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Hessen, Germany|Clinic and Polyclinic Internal Medicine Universitätsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|Cardiology and Pneumology Clinic Universitätsmedizin Göttingen, Göttingen, Niedersachsen, Germany|Clinic for Cardiology and Intensive Care - Klinikum Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|Medical Clinic I. Marien Hospital, Universitätsklinikum der Ruhr Universität Bochum, Herne, Herne, Nordrhein-Westfalen, Germany|Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universitätsklinikum Wupperthal, Wuppertal, Nordrhein-Westfalen, Germany|Center for Cardiology, University Medicine Mainz, Mainz, Rheinland-Pfalz, Germany|Clinic for Vascular Medicine, Städtisches Krankenhaus Dresden, Dresden, Sachsen, Germany|Medical Clinic I. Universitätsklinikum Carl Gustav Carus, Dresden, Dresden, Sachsen, Germany|Cardiology, Pneumology and Intensive Care Clinic Helios Klinikum Pirna, Dresden, Pirna, Sachsen, Germany|Medical Clinic II, University Clinic Schleswig-Holstein - Campus Lübeck, Lübeck, Schleswig-Holstein, Germany|Department of Pneumology and Infectology Charité University Medicine Berlin, Campus Mitte, Berlin, Germany|Internal Medicine II, Cardiology, Sana Klinikum, Lichtenberg. Berlin, Berlin, Germany|Medical Clinic II. St. Joseph Hospital Berlin, Berlin, Germany|Department of Cardiology Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany|Internal Medicine, Hospital Bethel Berlin in Lichterfelde, Berlin, Germany|Internal Medicine/Cardiology department Unfallkrankenhaus Berlin, Berlin, Germany|Department of Cardiology Charité University Medicine Berlin, Campus Virchow, Berlin, Germany|Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin, Berlin, Germany|Intensive Care and Cardiology, Hospital Havelhöhe, Berlin, Germany|Internal Medicine Deparment Hospital Waldfriede, Berlin, Berlin, Germany		https://ClinicalTrials.gov/show/NCT04416048
482	NCT04435184	Crizanlizumab for Treating COVID-19 Vasculopathy	CRITICAL	Recruiting	No Results Available	COVID-19	Drug: Crizanlizumab|Other: 0.9% saline	Soluble P-selectin level|D-dimer level|VWF level|CRP level|Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials|Time to hospital discharge|Safety of Crizanlizumab as assessed by adverse events	Johns Hopkins University|Novartis|Socar Research SA|Brigham and Women's Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00249874	July 9, 2020	October 1, 2020	October 1, 2020	June 17, 2020		September 24, 2020	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04435184
483	NCT04441385	Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).	MARACOVID	Recruiting	No Results Available	COVID-19	Drug: Maraviroc 300 mg|Other: Standard care therapy	Proportion of patients developing severe ARDS.|All-cause mortality.|Percentage of patients requiring tracheal intubation, use of Non-invasive Ventilation NIV or High Flow Nasal Cannula (HFNC) devices during the study period|Percentage of patients who progress to severe ARDS, death or ICU admission.|Differences in Time to Clinical Improvement|Change in clinical status of subject on a 7-point ordinal scale.|Percentage of patients requiring immunosuppressive/immunomodulatory treatment as a rescue medication.|Proportion of patients developing adverse effects, serious adverse reactions, laboratory or physical examination findings, EKG abnormalities acquired during the trial, death and adverse events leading to early discontinuation of treatment.	Hospital Universitario Infanta Leonor|Hospital Clínic de Barcelona|ViiV Healthcare	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MARACOVID|2020-002011-21	June 26, 2020	November 30, 2020	December 20, 2020	June 22, 2020		July 9, 2020	Hospital Clínic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04441385
484	NCT04366739	Repurposing of Chlorpromazine in Covid-19 Treatment	reCoVery	Not yet recruiting	No Results Available	COVID-19	Drug: CHLORPROMAZINE (CPZ)|Combination Product: Standard of Care (SOC)	Time To Response (TTR)|Objective Response Rate (ORR)|All-cause mortality|Duration in days required for hospital discharge|Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours|Number of days without oxygen therapy|Incidence of oxygen use, NIV or high flow oxygen therapy|Duration in days of oxygen prescription, NIV or high flow oxygen therapy|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample|Biochemical response: serum viral load of SARS-CoV-2|Biochemical response: C-reactive protein (CRP)|Biochemical response: blood test for lymphocytes (lymphopenia)|Parenchymal involvement (chest CT)|Define the optimal dose of CPZ and its tolerance: rates of serious adverse events|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS)|Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation|Define the optimal dose of CPZ and its tolerance: biological anomalies|Define the optimal dose of CPZ and its tolerance: ECG abnormalities|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment|Define the optimal dose of CPZ and its tolerance: CPZ dose administered	Centre Hospitalier St Anne|Hôpital Cochin	All	18 Years and older   (Adult, Older Adult)	Phase 3	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	D20-P016	April 29, 2020	August 30, 2020	September 30, 2020	April 29, 2020		April 29, 2020	Centre Hospitalier Sainte-Anne, Paris, France		https://ClinicalTrials.gov/show/NCT04366739
485	NCT04348513	Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection	Thy-Support	Recruiting	No Results Available	Pulmonary Infection|Covid-19	Drug: T3 solution for injection|Drug: Placebo	Assessment of weaning from cardiorespiratory support|Assessment of hemodynamic status|Assessment of pulmonary function|Assessment of hepatic function|Assessment of renal function|Assessment of cardiac function|Assessment of cardiac injury|Assessment of the course of COVID-19 infection|Assessment of clinical outcome and safety	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|ATTIKON University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	T3inj-02/ThySupport	May 29, 2020	May 2, 2021	May 31, 2021	April 16, 2020		June 2, 2020	Attikon University General Hospital, Haidari/Athens, Greece		https://ClinicalTrials.gov/show/NCT04348513
486	NCT04540120	Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome		Recruiting	No Results Available	Covid19|Cytokine Release Syndrome	Drug: dapansutrile capsules|Drug: placebo capsules	Proportion of subjects with complete resolution of fever symptoms and shortness of breath|Cumulative incidence of SAEs|Cumulative incidence of Grade 3 and Grade 4 Adverse Events|Discontinuation or temporary suspension of participation|Changes in white cell count|Changes in hemoglobin|Changes in platelets|Changes in creatinine|Changes in glucose|Changes in total bilirubin|Changes in ALT|Changes in AST|Incidence of new infection that occurs during the study|Incidence of opportunistic infections|Complete resolution of fever symptoms and shortness of breath|Time to clinical improvement|Time to sustained absence of fever|Clinical improvement in symptoms relevant to COVID 19|Incidence of composite endpoint of hospitalization, supplemental oxygen, mechanical ventilation, or death|Clinical improvement in symptoms|Improvement in oxygenation|Change in ALT|Change in AST|Change in blood glucose|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Hemoglobin A1c (HbA1C)|Change in Lactate dehydrogenase (LDH)|Change in Lymphocyte, Absolute count|Change in Monocyte, Absolute count|Change in Neutrophils, Absolute count|Change in Eosinophil, Absolute count|Change in CRP|Change in D-Dimer|Change in Ferritin|Change in Fibrinogen|Change in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)|Change in IL-1β|Change in IL-6|Change in IL-18|Change in granulocyte colony-stimulating factor (G-CSF)|Change in interferon-γ-induced protein 10 (IP-10)|Change in C3a	Olatec Therapeutics LLC|CTI Clinical Trial and Consulting Services	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	OLT1177-10	September 25, 2020	January 2021	February 2021	September 7, 2020		September 29, 2020	MIDC, Huntsville, Alabama, United States|MIDC, Burr Ridge, Illinois, United States|MIDC, Overland Park, Kansas, United States|PanAmerican Clinical Research LLC, Brownsville, Texas, United States|J & S Studies, Inc., College Station, Texas, United States		https://ClinicalTrials.gov/show/NCT04540120
487	NCT04425252	Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19	CRISIS	Recruiting	No Results Available	COVID-19	Drug: Brequinar|Other: Standard of Care	Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration	Clear Creek Bio, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCB-CRISIS-01	June 25, 2020	March 2021	April 2021	June 11, 2020		October 2, 2020	Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida/Tampa General, Tampa, Florida, United States|Temple University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04425252
488	NCT04400799	Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19		Recruiting	No Results Available	COVID-19|Pulmonary Embolism, Deep Vein Thrombosis	Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml	hospitalizations|all-cause death|Number of cardiovascular events|any hospitalizations|Net clinical benefit|Disseminated intravascular coagulation	University of Zurich|University Hospital Inselspital, Berne|University Hospital, Geneva|Centre Hospitalier Universitaire Vaudois|University Hospital, Basel, Switzerland|Oncology Institute of Southern Switzerland|Clinica Luganese Moncucco	All	50 Years and older   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OVID Trial	June 15, 2020	March 14, 2021	April 14, 2021	May 26, 2020		July 16, 2020	University Hospital Basel, Basel, Switzerland|Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|University Hospital Bern, Bern, Switzerland|Hôpitaux Universitaires Genève, Geneva, Switzerland|Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Clinica Luganese Moncucco, Lugano, Switzerland|University hospital zurich, Zürich, Switzerland		https://ClinicalTrials.gov/show/NCT04400799
489	NCT04369742	Treating COVID-19 With Hydroxychloroquine (TEACH)		Suspended	No Results Available	COVID-19	Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate	Cumulative incidence of SAEs through day 30|Cumulative incidence of grade 3 or 4 AEs through day 30|Incidence of discontinuation of therapy (for any reason)|Severe disease progression composite outcome|Cumulative incidence of events|Hospital length of stay|Days of fever|Days of non-invasive ventilator use|Days of non-rebreather mask oxygen supplementation|Score on Cytokine Release Syndrome (CRS) Grading Scale|Percentage of subjects reporting each severity score on 8 point ordinal scale Day 1 and EOT (End of Treatment - Day 6)|Percentage of subjects with qTC prolongation at EOT|Cumulative Incidence of mortality|Cumulative Incidence of ICU admission|Cumulative Incidence of Invasive mechanical ventilation|Cumulative Incidence of ECMO|Cumulative Incidence of hypotension requiring vasopressor support|SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT|Change in Alanine Aminotransferase (ALT) levels|Change in Aspartate Aminotransferase (AST) levels|Change in Creatinine levels|Change in Glucose levels|Change in White Blood Cell (WBC) count|Change in Hemoglobin levels|Change in Platelet count|Change in total bilirubin levels|Change in Lactate Dehydrogenase (LDH) levels|Change in C-Reactive Protein (CRP) levels|Change in Interleukin 6 (IL-6) levels	NYU Langone Health|State University of New York - Downstate Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	626	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	20-00463	April 15, 2020	June 2021	June 2021	April 30, 2020		July 2, 2020	State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04369742
490	NCT04347226	Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19		Recruiting	No Results Available	Solid Tumor|Sars-CoV2|Hematological Malignancy	Drug: BMS-986253	Time to Improvement in the 7-point ordinal scale|Time to Death|Time to Intubation|Proportion of patients requiring ICU admission|Percentage Rate of Mortality at 1 month	Matthew Dallos|Bristol-Myers Squibb|Columbia University	All	18 Years and older   (Adult, Older Adult)	Phase 2	138	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAS9881	April 16, 2020	September 2021	September 2022	April 15, 2020		October 7, 2020	Columbia University Irving Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04347226
491	NCT04365517	The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients	SIDIACO	Not yet recruiting	No Results Available	Covid19|Diabetes Mellitus, Type 2|CKD	Drug: Sitagliptin	Time for clinical improvement|Clinical parameter of acute lung disease|Biochemical parameter of acute lung disease|Clinical parameters of acute lung disease|Dipeptilpeptidase 4 expression in biological samples|Cytokine-inflammatory profile|Glycemic variability	University of Milan	All	18 Years and older   (Adult, Older Adult)	Phase 3	170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sacco FBF	July 29, 2020	October 30, 2020	December 30, 2020	April 28, 2020		July 9, 2020	ASST FBF Sacco, Milan, Italy		https://ClinicalTrials.gov/show/NCT04365517
492	NCT04348461	BAttLe Against COVID-19 Using MesenchYmal Stromal Cells		Not yet recruiting	No Results Available	COVID|Respiratory Distress Syndrome	Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells	Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Instituto de Investigación Sanitaria y Biomédica de Alicante|Hospital General Universitario Gregorio Marañon|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario de Salamanca|Hospital General Universitario de Alicante|Hospital Clínico Universitario Virgen de la Arrixaca	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BALMYS-19	April 6, 2020	September 15, 2020	September 30, 2020	April 16, 2020		April 16, 2020			https://ClinicalTrials.gov/show/NCT04348461
493	NCT04326920	Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)	SARPAC	Recruiting	No Results Available	COVID-19	Drug: Sargramostim|Other: Control	Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function	University Hospital, Ghent|Flanders Institute of Biotechnology	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARPAC	March 24, 2020	October 31, 2020	December 31, 2020	March 30, 2020		April 24, 2020	AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium		https://ClinicalTrials.gov/show/NCT04326920
494	NCT04495101	Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Participants With Coronavirus Disease (COVID-19)		Recruiting	No Results Available	COVID-19	Biological: Prolastin|Drug: Standard Medical Treatment	Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants who Sustained Normalization of Temperature|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression|Mortality Through Day 29	Instituto Grifols, S.A.|Grifols Therapeutics LLC	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GC2005|2020-001953-36	July 2020	November 2020	November 2020	July 31, 2020		July 31, 2020	Hospital Germans Trias, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital Valle de Hebrón, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Príncipe de Asturias, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04495101
495	NCT04385043	Hyperimmune Plasma in Patients With COVID-19 Severe Infection	COV2-CP	Recruiting	No Results Available	COVID-19	Other: plasma hyperimmune|Drug: standard therapy	decrease in mortality|lymphocytes|PCR levels vs control|PCR levels vs before treatment|AB levels and clinical improvement|Inflammatory cytokines vs controls|Inflammatory cytokines vs before treatment	University of Catanzaro|Azienda Ospedaliera Policlinico "Mater Domini"|Azienda Sanitaria Provinciale Di Catanzaro|Annunziata Hospital, Cosenza, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli	All	18 Years to 60 Years   (Adult)	Phase 2|Phase 3	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Covid-19 convalescent plasma	May 1, 2020	October 15, 2020	May 15, 2021	May 12, 2020		May 12, 2020	Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Italy|Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy|Azienda Ospedaliera Annunziata, Cosenza, Italy|Azienda Sanitaria Provinciale, Crotone, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Sanitaria Provinciale, Vibo Valentia, Italy		https://ClinicalTrials.gov/show/NCT04385043
496	NCT04400890	Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19		Recruiting	No Results Available	COVID-19	Drug: Plant Polyphenol|Dietary Supplement: Vitamin D3	Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates	Marvin McCreary, MD|Mount Carmel Health System	All	45 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	McCreary2020	September 12, 2020	November 2020	January 2021	May 26, 2020		September 24, 2020	Mt Carmel HealthSystems, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT04400890
497	NCT04432324	Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)		Not yet recruiting	No Results Available	COVID-19	Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment	Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Absolute Value and Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression	Instituto Grifols, S.A.|Grifols Therapeutics LLC	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GC2004|2020-001696-32	June 2020	July 2020	December 2020	June 16, 2020		June 16, 2020	Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04432324
498	NCT04353284	Camostat Mesylate in COVID-19 Outpatients		Recruiting	No Results Available	COVID-19	Drug: Camostat Mesilate|Other: Placebo	Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature	Yale University	All	18 Years and older   (Adult, Older Adult)	Phase 2	114	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2000027971	June 19, 2020	May 31, 2021	May 31, 2021	April 20, 2020		September 7, 2020	Yale University, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04353284
499	NCT04392531	Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19		Recruiting	No Results Available	COVID19 Infection	Drug: Cyclosporine|Drug: Standard treatment	Severity Category|Mortality Rate|Number of Days in hospital|Number of days in ICU beds|Fio2 Needs|Adverse events rate|Change in CRP|Change in ferritin|Change in LDH|Change in CPK|Change in D Dimer|Change in IL-6|Change in KL-6|Change in Viral Load|Change specific antibodies	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FJD-COVID19-20-01	April 16, 2020	December 2020	December 2020	May 19, 2020		August 28, 2020	Complejo Hospitalario Universitario La Coruña, La Coruña, Galicia, Spain|Hospital Quiron La Coruña, La Coruña, Galicia, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital General de Villalba, Villalba, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04392531
500	NCT04257656	A Trial of Remdesivir in Adults With Severe COVID-19		Terminated	No Results Available	COVID-19|Remdesivir|SARS-CoV-2	Drug: Remdesivir|Drug: Remdesivir placebo	Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events	Capital Medical University	All	18 Years and older   (Adult, Older Adult)	Phase 3	237	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAP-China remdesivir 2	February 6, 2020	March 30, 2020	April 10, 2020	February 6, 2020		April 15, 2020	Bin Cao, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04257656
501	NCT04385095	Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection		Recruiting	No Results Available	SARS-CoV-2	Drug: SNG001|Drug: Placebo	Ordinal Scale for Clinical Improvement|Progression to pneumonia (hospital setting only)|Time to clinical improvement (hospital setting only)|National Early Warning Score 2 (NEWS2) assessment of acute-illness severity (hospital setting only)|Changes in daily breathlessness, cough and sputum scale (BCSS)|Safety and tolerability - blood pressure II. Viral load|Safety and tolerability - heart rate II. Viral load|Safety and tolerability - temperature II. Viral load|Safety and tolerability - respiratory rate II. Viral load|Safety and tolerability - oxygen saturation II. Viral load|Safety and tolerability - adverse events II. Viral load|Safety and tolerability - concomitant medications II. Viral load|Time to clinical improvement (home setting only)|Time to improvement of COVID-19 symptoms (home setting only).|Time to self-reported recovery (home setting only)|Self-reported daily rating of overall feeling of wellness (home setting only).|Quality of life measured using EQ-5D-5L (home setting only).|Virus clearance/load (if samples are available)|Blood and sputum biomarkers (if samples are available).|Contact with health services (home setting only|Consumption of antibiotics (home setting only	Synairgen Research Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2	820	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SG016	March 16, 2020	February 1, 2021	May 31, 2021	May 12, 2020		August 27, 2020	Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital,, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom|Glenfield Hospital,, Leicester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|City Campus of Nottingham University, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT04385095
502	NCT04547127	A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	COVID-19	Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical Treatment	All-Cause Mortality Rate|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Time to ICU Discharge|Duration of All Oxygen Use|Duration of Mechanical Ventilation|Absolute Value Change from Baseline in Ordinal Scale|Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale	Instituto Grifols, S.A.|Grifols Therapeutics LLC	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GC2003|2020-001299-14	April 29, 2020	December 2020	December 2020	September 14, 2020		September 14, 2020	Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Complejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital Clínico Universitario de Santiago -CHUS, Santiago, Spain		https://ClinicalTrials.gov/show/NCT04547127
503	NCT04502667	Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19	COVID-19	Recruiting	No Results Available	Covid19|Vitamin D|Children, Only	Drug: Cholecalciferol	INTERLEUKINS (IL-2,6,7,10) (pg/ml)|FERRITIN (ng/ml)|DIMER-D|Vitamin D (ng/ml)	Coordinación de Investigación en Salud, Mexico|Hospital Infantil de Mexico Federico Gomez|Hospital General de México Dr. Eduardo Liceaga	All	1 Month to 17 Years   (Child)	Phase 3	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R-2020-3603-020	July 15, 2020	February 2021	April 2021	August 6, 2020		August 6, 2020	Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico		https://ClinicalTrials.gov/show/NCT04502667
504	NCT04532554	Growth Hormone in Obese Cases With Covid-19		Withdrawn	No Results Available	Covid19	Drug: Growth Hormone|Drug: Placebo	Need for hospitalization|Time to recovery|Percentage of reduction in CRP|Percentage of reduction in LDH|Percentage of reduction in Ferritin|Time to recovery from leucopenia	ClinAmygate	All	18 Years and older   (Adult, Older Adult)	Phase 4	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PR0015	October 26, 2020	December 10, 2020	December 20, 2020	August 31, 2020		September 16, 2020	Asalam, Maadi, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04532554
505	NCT04280705	Adaptive COVID-19 Treatment Trial (ACTT)		Completed	Has Results	COVID-19	Other: Placebo|Drug: Remdesivir	Time to Recovery|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin Time (PT)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change in the Ordinal Scale|14-day Participant Mortality|29-day Participant Mortality|Time to an Improvement by at Least One Category Using an Ordinal Scale|Time to an Improvement of at Least Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First	National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	1062	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-0006	February 21, 2020	May 21, 2020	May 21, 2020	February 21, 2020	September 25, 2020	September 25, 2020	University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/ICF_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/Prot_001.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/SAP_002.pdf	https://ClinicalTrials.gov/show/NCT04280705
506	NCT04545008	Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19		Not yet recruiting	No Results Available	Covid19	Drug: Famotidine|Drug: N-Acetyl cysteine	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Rate of Hospitalization|Time to Symptom Resolution	Prisma Health-Upstate|Clemson University	All	18 Years and older   (Adult, Older Adult)	Phase 1	42	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00100394	September 2020	March 2021	August 2021	September 10, 2020		September 10, 2020			https://ClinicalTrials.gov/show/NCT04545008
507	NCT04518410	ACTIV-2: A Study for Outpatients With COVID-19		Recruiting	No Results Available	Coronavirus|Covid19	Drug: LY3819253|Drug: Placebo	Duration of COVID-19 symptoms (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2)|Cumulative incidence of death from any cause or hospitalization (Phase 3)|Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3)|Cumulative incidence of death from any cause or hospitalization (Phase 2)|Duration of COVID-19 symptoms (Phase 3)|Presence of SARS-CoV-2 RNA (Phases 2 and 3)|Level of SARS-Cov-2 RNA (Phases 2 and 3)|COVID-19 severity ranking (Phases 2 and 3)|Incidence of ≥1 worsening symptom of COVID-19 (Phases 2 and 3)|Duration of fever (Phases 2 and 3)|Time to self-report return to usual (pre-COVID-19) health (Phases 2 and 3)|Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3)|Oxygen saturation level (Phase 2)|Level of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)|Level of SARS-CoV-2 RNA from saliva (Phase 2)|Level of SARS-CoV-2 RNA from self-collected nasal swabs (Phase 2)|Level of SARS-CoV-2 RNA (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA in saliva (Phase 2)|Post-treatment level of SARS-CoV-2 RNA (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 3 (Phase 3)|Concentration of investigational agent (Phase 2 - LY3819253)|Level of anti-drug antibodies (Phase 2 - LY3819253)|AUC (Phase 2 - LY3819253)|Total body clearance (CL) (Phase 2 - LY3819253)|Elimination half-life (Phase 2 - LY3819253)|Cmax (Phase 2 - LY3819253)|Cmin (Phase 2 - LY3819253)	National Institute of Allergy and Infectious Diseases (NIAID)|Eli Lilly and Company|AIDS Clinical Trials Group	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	2000	NIH|Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	A5401/ACTIV-2|38742	August 19, 2020	November 2020	February 2021	August 19, 2020		October 8, 2020	University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States|UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100, Los Angeles, California, United States|University of California San Diego (Site 1002), 220 Dickinson Street, San Diego, California, United States|University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84, San Francisco, California, United States|Harbor UCLA (Site 1022), 1124 West Carson Street, Torrance, California, United States|University of Colorado (Site 1007), 12401 East 17th Avenue, Aurora, Colorado, United States|AGA Clinical Trials (Site 1026), 900 West 49th Street, Hialeah, Florida, United States|The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast, Atlanta, Georgia, United States|Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive, Atlanta, Georgia, United States|Northwestern University (Site 1025), 645 North Michigan Ave, Chicago, Illinois, United States|Rush University Medical Center (Site 1017), 600 Paulina St., Chicago, Illinois, United States|Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave., Chicago, Illinois, United States|University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard, Kansas City, Kansas, United States|New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904, New Orleans, Louisiana, United States|Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 1016), 55 Fruit Street, Boston, Massachusetts, United States|Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200, Saint Louis, Missouri, United States|Columbia University Irving Medical Center (Site 1019), 180 Fort Washington Avenue, New York, New York, United States|Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street, New York, New York, United States|University of Rochester (Site 1010), 601 Elmwood Ave, Rochester, New York, United States|University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor, Chapel Hill, North Carolina, United States|Case Western Reserve University (Site 1033), 2061 Cornell Road, Cleveland, Ohio, United States|Ohio State University Medical Center (Site 1020), 480 Medical Center Drive, Columbus, Ohio, United States|Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way, Ohio City, Ohio, United States|University of Pennsylvania (Site 1031), 3400 Spruce Street, Philadelphia, Pennsylvania, United States|The University of Pittsburgh (Site 1018), 3471 5th Ave., Pittsburgh, Pennsylvania, United States|Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183, Nashville, Tennessee, United States|Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive, Galveston, Texas, United States|Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street, Houston, Texas, United States|Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road, Falls Church, Virginia, United States|University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave., Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT04518410
508	NCT04446377	A Study of LAM-002A for the Prevention of Progression of COVID-19		Recruiting	No Results Available	COVID-19 Disease	Drug: Apilimod Dimesylate Capsule|Other: Placebo	Viral Load Change|Viral Load AUC|Safety and Tolerability measured in proportion of TEAEs	AI Therapeutics, Inc.|Yale University	All	18 Years and older   (Adult, Older Adult)	Phase 2	142	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	LAM-002A-CVD-CLN01	July 15, 2020	December 31, 2020	January 31, 2021	June 24, 2020		July 17, 2020	Yale University, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04446377
509	NCT04444271	Mesenchymal Stem Cell Infusion for COVID-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Mesenchymal stem cells|Other: Placebo	Overall survival|Clinical improvement|Time of COVID19 PCR negativity|Radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital	Dr. Zaineb Akram|National Institute of Blood and Marrow Transplant (NIBMT), Pakistan	All	10 Years and older   (Child, Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIBMT-MSc-COVID-2020	May 1, 2020	August 30, 2020	September 30, 2020	June 23, 2020		June 30, 2020	NIBMT, Rawalpindi, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04444271
510	NCT04463004	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation		Recruiting	No Results Available	COVID-19|Sars-CoV2|Pneumonia	Drug: Mavrilimumab|Drug: Placebos	Proportion of subjects alive and off of oxygen at day 14|Proportion of subjects alive and without respiratory failure at 28 days	Virginia Commonwealth University|Kiniksa Pharmaceuticals, Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HM20019145	September 2, 2020	August 2021	August 2021	July 9, 2020		September 10, 2020	Virginia Commonwealth University, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT04463004
511	NCT04463602	Desidustat in the Management of COVID-19 Patients		Recruiting	No Results Available	COVID-19	Drug: Desidustat|Other: Standard of Care	Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|Laboratory Assessments|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer	Cadila Healthcare Limited	All	18 Years and older   (Adult, Older Adult)	Phase 2	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DESI.20.004	July 25, 2020	December 15, 2020	January 30, 2021	July 9, 2020		August 13, 2020	Avant Sante Site 1, Monterrey, Mexico		https://ClinicalTrials.gov/show/NCT04463602
512	NCT04480398	Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients		Completed	No Results Available	Covid19|Asymptomatic Condition	Drug: Guduchi Ghan Vati	Virologic clearance|Change in the number of patients going from asymptomatic to moderately disease|Hospital Stay|Clinically relevant adverse effects	Aarogyam UK|Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University|Samta Ayurveda Prakoshtha, India	All	18 Years to 75 Years   (Adult, Older Adult)		91	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	AYU/DSSR/02	May 12, 2020	June 15, 2020	July 3, 2020	July 21, 2020		July 22, 2020	Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India		https://ClinicalTrials.gov/show/NCT04480398
513	NCT04333628	Chloroquine for Mild Symptomatic and Asymptomatic COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: chloroquine|Other: standard care	change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease	HaEmek Medical Center, Israel|T MAY BIOPHARMA LTD.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EMC 0045-20	April 2020	April 2021	December 2021	April 3, 2020		April 14, 2020			https://ClinicalTrials.gov/show/NCT04333628
514	NCT04372628	Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19	TREATNOW	Recruiting	No Results Available	COVID-19	Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo	Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29	Vanderbilt University Medical Center|AbbVie	All	18 Years and older   (Adult, Older Adult)	Phase 2	600	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	200827	June 1, 2020	December 1, 2020	May 1, 2021	May 4, 2020		September 9, 2020	University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT04372628
515	NCT04304053	Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention	HCQ4COV19	Completed	No Results Available	COVID-19	Drug: Treatment and prophylaxis|Other: Standard Public Health measures	Study 1- Clinical and virological outcome in exposed contacts|Study 1- Transmission of SARS-CoV-2 in exposed contacts|Study 2- Virological outcome in index cases|Study 2- Clinical outcome in index cases	Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut	All	18 Years and older   (Adult, Older Adult)	Phase 3	2300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	HCQ4COV19|2020-001031-27	March 18, 2020	June 15, 2020	June 15, 2020	March 11, 2020		June 30, 2020	Departament de Salut, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04304053
516	NCT04355143	Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)	COLHEART-19	Recruiting	No Results Available	COVID-19	Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians	Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality	University of California, Los Angeles	All	18 Years and older   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-000685	May 1, 2020	April 25, 2021	April 25, 2021	April 21, 2020		May 21, 2020	UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT04355143
517	NCT04494399	IFN Beta-1b and Ribavirin for Covid-19		Recruiting	No Results Available	Covid19	Drug: Interferon beta-1b|Drug: Ribavirin	Clinical symptoms alleviation|Hospitalisation|Time to negative viral load|Inflammatory changes|Mortality|Adverse events and serious adverse events	The University of Hong Kong|Hospital Authority, Hong Kong	All	18 Years and older   (Adult, Older Adult)	Phase 2	96	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW 20-513	July 29, 2020	July 1, 2022	August 1, 2022	July 31, 2020		July 31, 2020	The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04494399
518	NCT04516941	CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19	CONVINCE	Not yet recruiting	No Results Available	SARS-CoV Infection|COVID-19	Drug: Edoxaban Tablets|Drug: Colchicine Tablets	Edoxaban vs. no active treatment|Colchicine vs no active treatment|Number of patients with asymptomatic proximal deep-vein thrombosis|Number of patients with symptomatic proximal or distal deep-vein thrombosis|Number of patient with symptomatic pulmonary embolism or thrombosis|Number of patients with myocardial infarction|Number of patients with ischemic stroke|Number of patients with non-CNS systemic embolism|Number of deaths|Ventilation need	University Hospital Inselspital, Berne|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	All	18 Years and older   (Adult, Older Adult)	Phase 3	420	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CONVINCE Version 1.0 12052020	October 1, 2020	October 1, 2021	December 31, 2021	August 18, 2020		August 18, 2020	Bern University Hospital, Bern, Switzerland|Ospedale regionale Lugano, Lugano, Switzerland		https://ClinicalTrials.gov/show/NCT04516941
519	NCT04335071	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	CORON-ACT	Recruiting	No Results Available	SARS-CoV-2 Infection	Drug: Tocilizumab (TCZ)|Drug: Placebo	Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)	University Hospital Inselspital, Berne|Roche Pharma AG	All	30 Years to 80 Years   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-00691|2020DR2044	April 26, 2020	October 2020	October 2020	April 6, 2020		April 28, 2020	University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04335071
520	NCT04434118	Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients		Enrolling by invitation	No Results Available	Rheumatoid Arthritis|COVID	Drug: Traditional antirheumatic drugs	The risk of COVID-19 infection among RA patients|The incidence of hospitalization for Covid-19 patients.	Sadat City University	All	18 Years to 60 Years   (Adult)		600	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	IRB: RC-5-2020	March 20, 2020	December 30, 2020	December 30, 2020	June 16, 2020		October 6, 2020	Faculty of Medicine, Shibīn Al Kawm, Egypt		https://ClinicalTrials.gov/show/NCT04434118
521	NCT04396106	Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: AT-527|Other: Placebo	Proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.|Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|Time to clinical recovery|Proportions (active vs. placebo) of subjects with respiratory failure or death	Atea Pharmaceuticals, Inc.	All	45 Years to 80 Years   (Adult, Older Adult)	Phase 2	190	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	AT-03A-001	May 26, 2020	December 2020	January 2021	May 20, 2020		September 17, 2020	Atea Study Site, Scottsdale, Arizona, United States|Atea Study Site, Los Angeles, California, United States|Atea Study Site, Sacramento, California, United States|Atea Study Site, Washington, District of Columbia, United States|Atea Study Site, Orlando, Florida, United States|Atea Study Site, Atlanta, Georgia, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Boston, Massachusetts, United States|Atea Study Site, Butte, Montana, United States|Atea Study Site, Bronx, New York, United States|Atea Study Site, New York, New York, United States|Atea Study Site, Charlotte, North Carolina, United States|Atea Study Site, Cincinnati, Ohio, United States|Atea Study Site, Columbus, Ohio, United States|Atea Study Site, Charleston, South Carolina, United States|Atea Study Site, Columbia, South Carolina, United States|Atea Study Site, Houston, Texas, United States|Atea Study Site, Tacoma, Washington, United States|Atea Study Site, Brussels, Belgium|Atea Study Site, Belo Horizonte, Brazil|Atea Study Site, Brasília, Brazil|Atea Study Site, Campo Largo, Brazil|Atea Study Site, Porto Alegre, Brazil|Atea Study Site, São Paulo, Brazil|Atea Study Site, Chisinau, Moldova, Republic of|Atea Study Site, Bucharest, Romania|Atea Study Site, Bloemfontein, South Africa|Atea Study Site, Cape Town, South Africa|Atea Study Site, Stellenbosch, South Africa|Atea Study Site, Worcester, South Africa|Atea Study Site, Brovary, Ukraine|Atea Study Site, Kyiv, Ukraine		https://ClinicalTrials.gov/show/NCT04396106
522	NCT04494984	A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.		Recruiting	No Results Available	Covid19	Drug: INM005|Drug: Placebo	Clinical changes in COVID-19 symptoms|Pharmacokinetics evaluation of INM005|Time to progression of disease|Disease progression|Discharge|Intensive care unit (ICU) hospitalization|Mechanical ventilation assistance (MVA)|Mortality|Changes in viral load	Inmunova S.A.	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2|Phase 3	242	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CT-INM005-01	July 27, 2020	October 2020	November 2020	July 31, 2020		August 4, 2020	Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Muñiz, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Pirovano, Ciudad Autonoma de Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04494984
523	NCT04497649	Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients		Recruiting	No Results Available	Covid19	Drug: Sofosbuvir|Drug: Daclatasvir	Number of patients with improvement or mortality	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Tanta sofosbuvir covid	July 1, 2020	October 1, 2020	October 10, 2020	August 4, 2020		September 15, 2020	Cairo and Tanta Universitities, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04497649
524	NCT04504877	Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19	BONSAI	Recruiting	No Results Available	Covid19|Burn Out|Post Traumatic Stress Disorder	Drug: Cannabidiol	aMBI-HSS: Abbreviated Maslach Burnout Inventory - Human Services Survey|Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)|Brief measure for assessing generalized anxiety disorder: The GAD-7|PHQ-9: Patient´s Health Questionnaire-9|Change in proinflammatory cytokine concentration|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	University of Sao Paulo	All	24 Years to 60 Years   (Adult)	Phase 2|Phase 3	102	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	BONSAI Study	June 16, 2020	September 30, 2020	September 30, 2020	August 7, 2020		August 11, 2020	Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, SP, Brazil		https://ClinicalTrials.gov/show/NCT04504877
525	NCT04360759	Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19	CQOTE	Withdrawn	No Results Available	Covid-19|HIV	Drug: Chloroquine or hydroxychloroquine	Event-free survival at 28 days post-randomization between experimental group and standard of care group|Incidence of serious adverse events|Incidence of adverse events of special interest related to investigational product at time of hospitalisation|Premature discontinuation of treatment|Time from treatment initiation to death, ARDS (PF/SF ratio < 300), or mechanical ventilation|Proportion with moderate and severe ARDS|Duration of hospitalisation and ICU stay in survivors|Incidence of Covid-19 in household contacts	University of Cape Town	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIV-COVID-19 CQOTE	May 1, 2020	May 30, 2021	June 30, 2021	April 24, 2020		August 18, 2020	Khayelitsha Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa		https://ClinicalTrials.gov/show/NCT04360759
526	NCT04397718	Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization	HITCH	Recruiting	No Results Available	COVID-19	Drug: Degarelix|Other: Saline	A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.|Time to clinical improvement|Inpatient mortality|Duration of hospitalization|Duration of intubation for mechanical ventilation.|Time to normalization of temperature.|Maximum severity of COVID19 illness.|A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.	VA Office of Research and Development	Male	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	198	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	COVID19-8900-15	July 6, 2020	December 6, 2020	December 6, 2020	May 21, 2020		September 4, 2020	VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04397718
527	NCT04386447	Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19	OsCOVID19	Not yet recruiting	No Results Available	Covid-19|Corona Virus Infection|SARS-CoV 2	Drug: Oxytocin|Drug: Standard of Care	Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization	Azienda Ospedaliero-Universitaria di Parma|University of Parma	All	18 Years and older   (Adult, Older Adult)	Phase 2	145	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OsCOVID19	September 1, 2020	October 31, 2020	December 31, 2020	May 13, 2020		July 1, 2020	CNRS, Lyon, France|Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy|Ospedale San Francesco, Nuoro, Italy		https://ClinicalTrials.gov/show/NCT04386447
528	NCT04331899	Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19	COVID-Lambda	Active, not recruiting	No Results Available	COVID-19	Drug: Peginterferon Lambda-1a|Other: Placebo	Duration of Viral shedding of SARS-CoV-2 by qRT-PCR|Sars-CoV-2 viral load|Area under the curve of SARS-COV-2 viral load|Time to alleviation of all symptoms Time to alleviation of all symptoms|Number of participants requiring emergency department visits or hospitalizations within 28 days of initiation of treatment	Stanford University	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	55619	April 24, 2020	August 14, 2020	May 2021	April 2, 2020		September 28, 2020	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04331899
529	NCT04323631	Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death		Withdrawn	No Results Available	COVID-19	Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine	Number patients developing severe infection or death	Rambam Health Care Campus|Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	0	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0154-20-RMB	April 30, 2020	April 30, 2020	April 30, 2020	March 26, 2020		June 30, 2020			https://ClinicalTrials.gov/show/NCT04323631
530	NCT04338126	Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients	TCInpatient	Not yet recruiting	No Results Available	COVID19	Drug: Tranexamic acid|Drug: Placebo oral tablet	Admission to Intensive Care Unit	University of Alabama at Birmingham	All	19 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TXACOVID2	September 30, 2020	December 15, 2020	December 31, 2020	April 8, 2020		June 11, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04338126
531	NCT04412304	Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients		Completed	No Results Available	Covid-19|Thromboembolic Events|Bleeding	Drug: Dose of Tinzaparin or Dalteparin	28-days ICU mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission.	Karolinska Institutet	All	Child, Adult, Older Adult		166	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	Anticoagulant therapy Covid-19	March 6, 2020	April 30, 2020	May 28, 2020	June 2, 2020		June 22, 2020	South General Hospital, Stockholm, Stockholms Län, Sweden		https://ClinicalTrials.gov/show/NCT04412304
532	NCT04353518	Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo	Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)|Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale	Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India	All	18 Years and older   (Adult, Older Adult)	Phase 3	4000	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CRSC20005	April 30, 2020	March 30, 2021	May 30, 2021	April 20, 2020		April 22, 2020			https://ClinicalTrials.gov/show/NCT04353518
533	NCT04567810	Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)		Recruiting	No Results Available	Covid19	Drug: anti-SARS-CoV-2 IgY|Drug: Placebo	Number of participants with treatment-related adverse events|Number of Participants With Vital Sign Findings Reported as TEAEs|Number of Participants With Clinically Significant Findings in Physical Examinations|Number of Participants With Clinically Significant Changes From Baseline in ECG Data|Number of participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters|Number of Participants with Presence of Serum anti-SARS-CoV-2 IgY	Stanford University	All	18 Years to 45 Years   (Adult)	Phase 1	48	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	CVR001	September 18, 2020	December 2020	December 2020	September 29, 2020		September 30, 2020	Linear Clinical Research - Harry Perkins Research Institute, Nedlands, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT04567810
534	NCT04460183	A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19		Recruiting	No Results Available	COVID-19	Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care	Proportion of participants who progress to level >4 of modified WHO ordinal scale due to COVID-19 by Day 14|Change in room air oxygen saturation (SpO2) from baseline over time|Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time|Change from baseline on the modified WHO ordinal scale at each visit up to Day 28|Time to improvement to a lower level (<4) of modified WHO ordinal scale|Time to progression to a higher level (>4) of modified WHO ordinal scale|Number of participants with adverse events and serious adverse events	Thirty Respiratory Limited	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RESP301-002	July 29, 2020	January 27, 2021	April 23, 2021	July 7, 2020		September 3, 2020	Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, United Kingdom|Royal Preston Hospital, Preston, United Kingdom		https://ClinicalTrials.gov/show/NCT04460183
535	NCT04348305	Hydrocortisone for COVID-19 and Severe Hypoxia	COVID STEROID	Active, not recruiting	No Results Available	Covid-19|Hypoxia	Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL	Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year	Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RH-ITA-008|2020-001395-15	April 17, 2020	September 10, 2020	June 8, 2021	April 16, 2020		September 7, 2020	Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Rigshospitalet, Copenhagen, Denmark|Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark|North Zealand Hospital, Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Køge Hospital, Køge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Slagelse Hospital, Slagelse, Denmark|Viborg Hospital, Viborg, Denmark		https://ClinicalTrials.gov/show/NCT04348305
536	NCT04362111	Early Treatment of Cytokine Storm Syndrome in Covid-19		Recruiting	No Results Available	Cytokine Storm|COVID-19	Drug: Anakinra|Drug: Normal saline	Percentage of patients discharged from the hospital alive and without the need for mechanical ventilation.|Percentage of subjects with 25% change (decrease) in cytokine storm markers at 48 hours|Percentage of subjects without increase in oxygen requirement and no increase in oxygen delivery/respiratory support measures after 48 hours.|Average time in days to achieve sustained ≥93% oxygen saturation without oxygen/respiratory support|Percentage of subjects with resolution of laboratory markers of Cytokine Storm syndrome|Percentage of subjects who develop bacterial or fungal or non-Covid-19 viral infection|Percentage of subjects who develop neutralizing antibody to Covid-19	University of Alabama at Birmingham	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Chatham-Cytokine Covid-19	July 29, 2020	January 2021	March 2021	April 24, 2020		September 11, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04362111
537	NCT04532294	Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants		Recruiting	No Results Available	Covid19	Drug: BGB DXP593|Drug: Placebo	Number of participants experiencing Treatment Emergent Adverse Events (TEAEs)|Number of participants experiencing Serious Adverse Events (SAEs)|Maximum observed plasma concentration (Cmax) of BGB-DXP593|Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUCt) of BGB-DXP593|AUC from time zero to infinity (AUCinf) of BGB-DXP593|AUC from time zero to Day 29 (AUC0-29) of BGB-DXP593|Time to maximum observed plasma concentration (tmax) of BGB-DXP593|Terminal half life (t1/2) of BGB-DXP593|Clearance (CL) of BGB-DXP593|Volume of distribution (Vz) of BGB-DXP593|Immunogenic response to BGB-DXP593 as assessed by the Detection of antidrug antibodies (ADA)	BeiGene	All	18 Years to 60 Years   (Adult)	Phase 1	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	BGB-DXP593-101	September 8, 2020	October 15, 2020	December 31, 2020	August 31, 2020		September 15, 2020	Q Pharm Pty Limited, Herston, Queensland, Australia		https://ClinicalTrials.gov/show/NCT04532294
538	NCT04496245	Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85	COVIDRASP	Recruiting	No Results Available	Respiratory Viral Infection|Covid19	Drug: Broncho-Vaxom®	Acute Respiratory Infection necessitating workforce removal|Time to ARI necessitating workforce removal.|The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal|The proportion of HCW with documented Cov infection.|Time to Lower respiratory infection (LRI) necessitating workforce removal.|The proportion of Health Care Workers contracting a LRI necessitating workforce removal|The proportion of HCW with documented Cov LRI.	The University of Queensland|Griffith University|The Prince Charles Hospital|Princess Alexandra Hospital, Brisbane, Australia|Telethon Kids Institute|Queensland Children's Hospital, Brisbane, Australia	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	BV-2020/19	August 24, 2020	June 30, 2021	June 30, 2021	August 3, 2020		September 4, 2020	The Prince Charles Hospital, Brisbane, Queensland, Australia|The Princess Alexandra Hospital, Brisbane, Queensland, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04496245/ICF_000.pdf|"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04496245/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT04496245
539	NCT04411602	Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD		Recruiting	No Results Available	Severe Acute Respiratory Syndrome|COVID	Drug: SARS-CoV-2 plasma	Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.|Ventilatory free days|Patient mortality (including death from any cause)	Ascension South East Michigan	All	18 Years and older   (Adult, Older Adult)	Phase 1	90	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1589349	April 7, 2020	December 31, 2020	December 31, 2020	June 2, 2020		June 2, 2020	Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States		https://ClinicalTrials.gov/show/NCT04411602
540	NCT04435522	Maraviroc in Patients With Moderate and Severe COVID-19		Recruiting	No Results Available	COVID	Drug: Maraviroc	Rate of Completion|Clinical improvement at Day 7|Change in Chitinase 3-like 1(Chi3l1) (ng/mL)|Change in Interleukin-6 (IL-6) (pg/mL)|Change in CCL5 (RANTES) (ng/mL)|Mortality|Time to Discharge|Days on mechanical ventilation	Rhode Island Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 1	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1611471-1	September 21, 2020	December 31, 2020	January 2021	June 17, 2020		September 25, 2020	Rhode Island Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT04435522
541	NCT04377503	Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19		Not yet recruiting	No Results Available	Cytokine Release Syndrome|Covid-19	Drug: Tocilizumab 180 MG/ML|Drug: Methylprednisolone Sodium Succinate	Patient clinical status 15 days after randomization|Improving oxygenation|Thorax CT improvement|ICU length of stay|Duration of mechanical ventilation|Incidence of acute kidney (AKI) with necessity of renal replacement therapy	Hospital Sao Domingos	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	covid-19 hsd	May 2020	August 2020	November 2020	May 6, 2020		May 6, 2020			https://ClinicalTrials.gov/show/NCT04377503
542	NCT04411446	Cholecalciferol to Improve the Outcomes of COVID-19 Patients	CARED	Recruiting	No Results Available	COVID	Drug: Vitamin D|Drug: Placebo	Respiratory SOFA.|Need of a high dose of oxygen or mechanical ventilation.|Change in oxygen saturation.|Oxygen desaturation.|Change in Quick SOFA score.|Myocardial infarction.|Stroke.|Acute kidney injury.|Pulmonary thromboembolism.|Combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.|Admission to ICU.|Invasive Mechanical Ventilation.|Hospital Length of Stay.|ICU length of stay.|Death	Vitamin D Study Group|Ag Nac Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación	All	18 Years and older   (Adult, Older Adult)	Phase 4	1265	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	001	August 12, 2020	December 15, 2020	December 28, 2020	June 2, 2020		August 14, 2020	Hospital de Alta Complejidad en Red El Cruce, Florencio Varela, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04411446
543	NCT04510194	MET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19		Not yet recruiting	No Results Available	Covid19|SARS-CoV Infection	Drug: Metformin|Drug: Placebo	Rate of Death due to COVID-19|Rate of Hospitalization due to COVID-19|Rate of Emergency Department Utilization|Rate of Urgent Care Utilization|Incidence of Possible COVID-19 Symptoms|Incidence of all-cause study medicine discontinuation|Disease Severity Rating|Dyspnea Assessment (PROMIS survey)|Global Health Survey (PROMIS survey)|Seroconversion of SARS-Cov2 Antibodies OR SARS-Cov2 PCR Positivity (Prevention Cohort Only)	University of Minnesota	All	30 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	1522	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Metformin	September 2020	September 2021	September 2021	August 12, 2020		August 25, 2020			https://ClinicalTrials.gov/show/NCT04510194
544	NCT04479202	The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19	BOIFIM	Completed	No Results Available	Berberine|COVID-19	Drug: Berberine|Drug: Montmorrillonite	Changes in diarrhea frequency and Bristol Stool Scale|IL-6 (ng/ml)|IL-10（ng/ml）|IL-1β (ng/ml)|TNF-α (pg/ml)|leukocyte count (10^9/l)|c reactive protein (mg/l)|procalcitonin (ng/ml)	Chinese Medical Association	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	76	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	Berberine treats COVID-19|XJ2020005101	February 8, 2020	April 18, 2020	April 23, 2020	July 21, 2020		July 21, 2020	Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT04479202
545	NCT04480424	Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)		Recruiting	No Results Available	COVID-19	Biological: GAMUNEX-C|Drug: Standard Medical Treatment	All-Cause Mortality Rate Through Day 29|Time to Actual ICU Discharge|Duration of Mechanical Ventilation|Time to Actual Hospital Discharge|Duration of Any Oxygen Use|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale|Overall Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Number of Participants who Develop ARDS Distributed by Severity|Change from Baseline in Sequential Organ Failure Assessment (SOFA) Score|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours	Grifols Therapeutics LLC	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GC2007	September 17, 2020	December 2020	February 2021	July 21, 2020		September 23, 2020	CHI Health, Omaha, Nebraska, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|MultiCare Deaconness Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT04480424
546	NCT04537299	COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes	COVID-FIS	Not yet recruiting	No Results Available	Covid19|SARS-CoV Infection	Drug: Fisetin|Drug: Placebo	Change in COVID-19 Severity	Mayo Clinic|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Phase 2	150	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-008867|1R01AG072301-01	December 2020	December 2023	December 2023	September 3, 2020		September 3, 2020	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04537299
547	NCT04402944	Pulmozyme to Improve COVID-19 ARDS Outcomes		Not yet recruiting	No Results Available	COVID	Drug: Pulmozyme|Drug: Placebo	Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality.	Boston Children's Hospital|Brigham and Women's Hospital	All	3 Years and older   (Child, Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	P00035140	June 18, 2020	May 31, 2021	December 31, 2021	May 27, 2020		June 12, 2020			https://ClinicalTrials.gov/show/NCT04402944
548	NCT04343963	Pyridostigmine in Severe SARS-CoV-2 Infection	PISCO	Recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Pyridostigmine Bromide|Drug: Placebo	Critical condition or death|IL-6	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	436	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Inf-3323	April 4, 2020	September 30, 2020	April 30, 2021	April 14, 2020		July 7, 2020	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico		https://ClinicalTrials.gov/show/NCT04343963
549	NCT04522830	A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19	BTL-TML-COVID	Recruiting	No Results Available	SARS-CoV-2 Infection	Drug: BTL-TML-COVID|Drug: Placebo	Mean duration and severity of disease|Number of participants with treatment related adverse events	Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.|Curavit Clinical Research	All	60 Years and older   (Adult, Older Adult)	Phase 2	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-04-0311	July 30, 2020	October 5, 2020	October 30, 2020	August 21, 2020		August 27, 2020	Intermountain Clinical Reserach, Draper, Utah, United States		https://ClinicalTrials.gov/show/NCT04522830
550	NCT04401527	Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite		Withdrawn	No Results Available	COVID-19|Acute Respiratory Distress Syndrome|Acute Respiratory Failure	Drug: Sodium Nitrite|Drug: Normal Saline	Survival with Unassisted Breathing|Survival without Mechanical Ventilation|Survival without Intensive Care|Survival without Hospitalization|Survival without ECMO|Survival	Hope Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SN02-01	July 22, 2020	August 15, 2020	August 15, 2020	May 26, 2020		September 15, 2020	Participating Research Facility, Tampa, Florida, United States|Participating Research Facility, Fort Worth, Texas, United States		https://ClinicalTrials.gov/show/NCT04401527
551	NCT04335032	EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)		Not yet recruiting	No Results Available	SARS-CoV-2	Drug: Eicosapentaenoic acid gastro-resistant capsules	Evaluation of EPA-FFA efficacy compared to standard of care|Increase in oxygen saturation|PaO2/FiO2 >300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction	S.L.A. Pharma AG	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	240	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EPA-COV-001	April 13, 2020	July 13, 2020	July 31, 2020	April 6, 2020		April 24, 2020			https://ClinicalTrials.gov/show/NCT04335032
552	NCT04565392	Study of Famotidine With Vitamins C and D for Pandemic Coronavirus	CDFCOV19	Not yet recruiting	No Results Available	Covid19	Drug: Famotidine 20 MG	Negative outcome|Positive response|Relapse|tolerability of ascorbic acid|Unexpected serious adverse event	drpykessupplements.com	All	18 Years and older   (Adult, Older Adult)	Phase 4	216	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pykonsult 201	December 1, 2020	June 30, 2021	July 31, 2021	September 25, 2020		September 25, 2020	Pykonsult headquarters, New Fairfield, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04565392
553	NCT04460105	Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Lanadelumab|Other: Placebo	Number of Participants with Treatment emergent adverse events (TEAEs)|Pharmacokinetic (PK) Plasma Concentrations of Lanadelumab|Percentage Change from Baseline in Plasma Kallikrein Activity (pKal)|Percentage Change from Baseline in Cleaved High Molecular Weight Kininogen (cHMWK)|Percentage Change from Baseline in Functional C1-Inhibitor (C1-INH)	Shire|Takeda Development Center Americas, Inc.|Takeda	All	18 Years and older   (Adult, Older Adult)	Phase 1	24	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TAK-743-1002	October 31, 2020	January 27, 2021	January 27, 2021	July 7, 2020		October 2, 2020	Cardiology Associates Research Company, Daytona Beach, Florida, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04460105
554	NCT04378920	A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715)	LEAF-4L6715	Recruiting	No Results Available	COVID19|Acute Respiratory Distress Syndrome	Drug: LEAF-4L6715|Drug: LEAF-4L7520	proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio|proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg|all cause mortality	Institut de Cancerologie Strasbourg Europe|LEAF	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	180	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-003|2020-001393-30|2020-A00900-39	April 14, 2020	December 31, 2020	December 31, 2020	May 7, 2020		September 4, 2020	Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, France		https://ClinicalTrials.gov/show/NCT04378920
555	NCT04244591	Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure		Completed	No Results Available	COVID-19 Infections	Drug: methylprednisolone therapy|Other: Standard care	Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality	Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Glucocorticoid COVID-19	January 26, 2020	April 13, 2020	April 13, 2020	January 28, 2020		June 16, 2020	Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04244591
556	NCT04410562	Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy	COVID-Preg	Recruiting	No Results Available	Pregnancy Related|COVID|Covid-19	Drug: Hydroxychloroquine|Drug: Placebo	Number of PCR confirmed cases among pregnant women|Incidence of COVID-19 disease during pregnancy|Incidence of COVID-19-related admissions|Incidence of all-cause admissions|Incidence of all-cause outpatient attendances|Mean duration of symptoms-signs of COVID-19|Frequency and severity of adverse events|Incidence of preeclampsia|Incidence of gestational diabetes|Incidence of SARS-CoV-2 infections during pregnancy|Prevalence of intrauterine growth restriction|Maternal mortality rate|Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.|Proportion of neonates with clinical signs/symptoms of COVID-19|Prevalence of low birth weight (<10th centile according to local standards)|Prevalence of preterm birth (<37 weeks of gestational age)|Prevalence of embryo and foetal losses (miscarriages and stillbirths)|Frequency of congenital malformations|Proportion of adverse perinatal outcome|Neonatal morbidity|Neonatal mortality rate	Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|University Hospital of Torrejon|Fundación de investigación HM	Female	Child, Adult, Older Adult	Phase 3	714	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-001587-29	May 13, 2020	May 13, 2021	August 1, 2021	June 1, 2020		June 1, 2020	Hospital Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Clínic Maternity, Barcelona, Catalunya, Spain|University hospital of Torrejón, Madrid, Spain|HM Puerta del Sur, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04410562
557	NCT04436458	Niclosamide In Moderate COVID-19		Not yet recruiting	No Results Available	COVID	Drug: Niclosamide Oral Tablet|Drug: Placebo	The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group	First Wave Bio, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FW-COV-002	December 2020	April 2021	April 2021	June 18, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04436458
558	NCT04460651	PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial	PREPARE-IT	Not yet recruiting	No Results Available	COVID19	Drug: Icosapent ethyl (IPE)|Drug: Placebo	Percentage of SARS-CoV-2 positive subjects|Highest mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group.|Highest mean WHO score up to day 60 for the active treatment group as compared to placebo among subjects with a positive test received at any moment during the study after the first visit|Total cholesterol, LDL, HDL, triglycerides (mg/dL) at baseline and at day 60|Ultrasensitive C-reactive Protein (mg/dL) at baseline and at day 60|Difference in hospital length of stay between groups|Difference in duration of mechanical ventilation in both groups|Rate of hospital admissions due to SARS (Severe Acute Respiratory Syndrome) in patients who were negative for SARS CoV-2 upon admission|Mean highest WHO descriptive score in active treatment versus placebo groups up to day 60 among hospitalized patients (WHO grades 3 or more) without serum evidence / PCR detecting SARS-CoV-2 infection|Rate of total events, non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), up to day 60	Estudios Clínicos Latino América|Amarin Pharma Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	1500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	PREPARE-IT. Version 1.2	July 2020	December 2020	December 2020	July 7, 2020		July 7, 2020			https://ClinicalTrials.gov/show/NCT04460651
559	NCT04345523	Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients	ConPlas-19	Recruiting	No Results Available	COVID-19	Other: Blood and derivatives.|Drug: Standard of Care	Category Changes in Ordinal Scale|Time to category 5, 6 or 7 of the ordinal scale|Mortality of any cause at 15 days|Mortality of any cause at 29 days|Oxygenation free days|Ventilator free days|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load	Cristina Avendaño Solá|Puerta de Hierro University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	278	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ConPlas-19	April 3, 2020	July 2020	July 2020	April 14, 2020		April 15, 2020	Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04345523
560	NCT04351295	Efficacy of Faviprevir in COVID-19 Treatment		Recruiting	No Results Available	COVID	Drug: Favipiravir|Drug: Placebos	Number of patients with mortality or need for mechanical ventilation	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	faviprevir covid	April 20, 2020	December 1, 2020	December 1, 2020	April 17, 2020		September 29, 2020	Tanta University, Ainshams University, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04351295
561	NCT04349371	Saved From COVID-19		Recruiting	No Results Available	COVID	Drug: Chloroquine|Drug: Placebo oral tablet	Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance	Columbia University	All	18 Years and older   (Adult, Older Adult)	Phase 2	350	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	AAAS9992	April 2020	April 2021	April 2021	April 16, 2020		April 21, 2020	Columbia University Irving Medical Center/NYP, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04349371
562	NCT04408235	High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy	COVID-19 HD	Not yet recruiting	No Results Available	COVID|Pneumonia, Viral|Coagulation Disorder	Drug: Enoxaparin	Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:|Any of the following events occurring within the hospital stay|Mortality at 30 days	Azienda Ospedaliero-Universitaria di Modena	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	EudraCT N°: 2020-001972-13	June 2020	June 2021	June 2021	May 29, 2020		May 29, 2020	Azienda Ospedaliero-Universitaria, Modena, Italy		https://ClinicalTrials.gov/show/NCT04408235
563	NCT04374552	Asymptomatic COVID-19 Trial	ACT	Not yet recruiting	No Results Available	SARS-CoV-2 Infection	Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo	The primary outcome is the rate of decline in viral load over the 10 days after randomization	Rutgers, The State University of New Jersey	All	20 Years and older   (Adult, Older Adult)	Phase 2	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Pro2020000872	May 5, 2020	November 2020	April 2021	May 5, 2020		May 5, 2020	Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04374552
564	NCT04358809	Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill		Not yet recruiting	No Results Available	COVID-19	Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo	Number of patients with increased disease severity|Incidence of adverse events and serious adverse events (Safety)|Number of COVID-19 patients discharged from hospital|Number of COVID-19 patients transfer to ICU|Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale|Number of of symptom free patients	Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India	All	18 Years and older   (Adult, Older Adult)	Phase 3	480	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CRSC20006	April 30, 2020	February 28, 2021	April 30, 2021	April 24, 2020		April 24, 2020			https://ClinicalTrials.gov/show/NCT04358809
565	NCT04542213	Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19	Covid19DPP4i	Recruiting	No Results Available	Hyperglycemia|Covid19	Drug: Linagliptin tablet|Drug: Insulin	Glucose levels|Number of patients who achieve metabolic control|Number of patients who die or need mechanical ventilation|C reactive protein levels	Hospital Regional de Alta Especialidad del Bajio	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	28	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CEI-22-2020	August 1, 2020	September 30, 2020	September 30, 2020	September 9, 2020		September 9, 2020	Hospital Regional de Alta Especialidad del Bajìo, Leòn, Guanajuato, Mexico	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04542213/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04542213
566	NCT04473170	Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19	SENTAD-COVID	Completed	No Results Available	Coronavirus Disease 2019 (COVID-19)	Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care	Adverse reactions incidence.|Rate of mortality within 28-days.|Time to clinical improvement on a seven-category ordinal scale.|Assessment of the immune response profile.|Assessment of acute-phase serum markers.	Abu Dhabi Stem Cells Center	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	146	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CT.001.1.0.SENTAD-COVID	April 4, 2020	May 20, 2020	July 14, 2020	July 16, 2020		July 16, 2020	Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates		https://ClinicalTrials.gov/show/NCT04473170
567	NCT04401293	Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients		Recruiting	No Results Available	Sars-CoV2|COVID	Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin	Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.|Major bleeding|Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4|Sepsis-induced coagulopathy (SIC) score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization	Northwell Health	All	18 Years and older   (Adult, Older Adult)	Phase 3	308	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	20-0340	April 26, 2020	October 22, 2020	April 26, 2021	May 26, 2020		June 9, 2020	Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States		https://ClinicalTrials.gov/show/NCT04401293
568	NCT04425460	A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19		Not yet recruiting	No Results Available	COVID-19	Drug: Favipiravir|Other: Placebo	Time from randomization to clinical recovery|Negativity in RT-PCR nucleic acid test|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Incidence of deterioration/aggravation of pneumonia|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy or non-invasive ventilation|ICU admission rate within 28 days of randomization|All-cause mortality within 28 days of randomization.	Zhejiang Hisun Pharmaceutical Co. Ltd.|Opera CRO, a TIGERMED Group Company	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	256	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	HS216C17(MRCT)	June 2020	August 2020	September 2020	June 11, 2020		June 11, 2020	The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Shangcheng District, China|Peking University First Hospital, Beijing, Xicheng District, China|Department of Internal Medicine Pneumology and infectious diseases Neukölln Clinic, Berlin, Germany|Medical clinic and polyclinic IV Hospital of the University of Munich, München, Germany|Infectious Diseases Hospital Cluj-Napoca, Cluj-Napoca, Cluj, Romania|National Institute of Infectious Diseases "Prof.Dr.Matei Bals", Bucharest, Ilfov, Romania|"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timisoara, Timis, Romania|"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania|Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania|Emergency County Hospital "Pius Brinzeu"Timisoara, Timişoara, Timis, Romania		https://ClinicalTrials.gov/show/NCT04425460
569	NCT04375397	Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury	iNSPIRE	Recruiting	No Results Available	CoronaVirus Induced Disease-2019 (COVID-19)	Drug: Ibrutinib|Drug: Placebo	Percentage of Participants Alive and Without Respiratory Failure|Change in the World Health Organization (WHO)-8 Point Ordinal Scale From Baseline|Median Reduction in Days Spent on Supplemental Oxygen|All-Cause Mortality|Percentage of Participants Experiencing Respiratory Failure or Death|Mechanical Ventilation-Free Survival|Days on Mechanical Ventilation|Duration of hospitalization|Time to Discharge|Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio|Oxygenation Index|Number of Participants With Adverse Events|Number of Participants With Abnormal Laboratory Findings	AbbVie|Janssen Research & Development, LLC|Pharmacyclics LLC (An AbbVie Company)	All	18 Years and older   (Adult, Older Adult)	Phase 2	46	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	M20-310	June 6, 2020	March 19, 2021	April 16, 2021	May 5, 2020		September 7, 2020	Desert Regional Medical Center /ID# 224276, Palm Springs, California, United States|Stanford Univ School Medicine /ID# 221954, Stanford, California, United States|Medstar Washington Hospital Center /ID# 221886, Washington, District of Columbia, United States|GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States|Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States|University of Miami /ID# 223227, Miami, Florida, United States|Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States|Brigham & Women's Hospital /ID# 221847, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 222994, Boston, Massachusetts, United States|University of Tennessee Health Care System /ID# 223472, Memphis, Tennessee, United States|Houston Methodist Hospital /ID# 224057, Houston, Texas, United States|Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04375397
570	NCT04407507	Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms	SILVERBULLET	Not yet recruiting	No Results Available	COVID-19	Drug: Ivermectin|Drug: Placebo	Participants with a disease control status defined as no disease progression to severe.	Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.	All	18 Years and older   (Adult, Older Adult)	Phase 2	66	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	SARS-COV-IverMX-01	June 2020	August 2020	October 2020	May 29, 2020		May 29, 2020			https://ClinicalTrials.gov/show/NCT04407507
571	NCT04392232	A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection		Recruiting	No Results Available	Coronavirus|COVID-19|Convalescent Plasma	Drug: Convalescent Plasma	Survival Rate	TriHealth Inc.	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-045	May 5, 2020	December 31, 2020	December 31, 2020	May 18, 2020		May 20, 2020	Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04392232
572	NCT04382066	Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19	APLICOV-PC	Recruiting	No Results Available	COVID-19	Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day	Frequency of occurrence of Neutropenia ≥ grade 3|Frequency of occurrence of Thrombocytopenia ≥ grade 3|Frequency of occurrence of Anemia ≥ grade 3|Frequency of occurrence of Lymphopenia ≥ grade 3|Frequency of occurrence of CPK increase ≥ grade 3|Frequency of occurrence of Increase ALT and / or AST ≥ grade 3|Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3|Frequency of occurrence of Neurotoxicity ≥ grade 3|Frequency of occurrence of QT-QTc interval extension ≥ grade 3|Frequency of occurrence of Other adverse events ≥ grade 3|Percentage of patients in whom treatment cannot be completed.|Percentage of patients with adverse events.|Percentage of patients with serious adverse events.|Percentage of patients with ECG abnormalities.|Change in the viral load of SARS-CoV-2|Time to negative PCR test for COVID-19|Mortality|Percentage of patients requiring invasive mechanical ventilation and / or ICU admission|Percentage of patients requiring non-invasive mechanical ventilation|Percentage of patients requiring oxygen therapy	PharmaMar|Apices Soluciones S.L.	All	18 Years and older   (Adult, Older Adult)	Phase 1	27	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APL-D-002-20|2020-001993-31	May 12, 2020	November 2020	November 2020	May 11, 2020		August 28, 2020	Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital Universitario de Getafe, Getafe, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hosptial Quironsalud Madrid, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04382066
573	NCT04449380	Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients	INTERCOP	Not yet recruiting	No Results Available	COVID-19 Virus Infection	Drug: Interferon-ß-1a|Combination Product: Standard of Care (SOC)	Time to negative conversion of SARS-CoV-2 nasopharyngeal swab|Improvement in clinical severity score (a)|Improvement in clinical severity score (b)|Incidence of new oxygen use, non-invasive ventilation, or high flow oxygen devices during the trial|Oxygenation free days in the first 28 days|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial|Number of patients transferred to Intensive Care Unit (ICU)|Mortality rate|Changes from baseline in pulmonary computed tomography (CT) imaging severity score|Duration of hospital stay expressed in days|Viral load measured on plasma with RT-PCR	IRCCS San Raffaele	All	18 Years and older   (Adult, Older Adult)	Phase 2	126	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INTERCOP	September 2020	April 2021	June 2021	June 26, 2020		July 29, 2020	IRCCS Ospedale San Raffaele, Milano, Italy		https://ClinicalTrials.gov/show/NCT04449380
574	NCT04354389	DAS181 for STOP COVID-19		Withdrawn	No Results Available	COVID-19	Drug: DAS181|Drug: Placebo	Percent of subjects return to room air (RTRA)|Percent of subjects who have recovered|Improved COVID-19 Clinical Classification|Return To Room Air (RTRA)|Percent of subjects who achieve clinical stability|SARS-CoV-2 RNA undetectable|Clinical Deterioration|Percent of subjects discharged|Death (all cause)	Ansun Biopharma, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	DAS181-2-08|2020-003192-17	July 25, 2020	September 30, 2020	November 30, 2020	April 21, 2020		August 11, 2020	Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy		https://ClinicalTrials.gov/show/NCT04354389
575	NCT04447534	Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19		Recruiting	No Results Available	COVID	Drug: Chloroquine|Drug: zinc	Number of patients with improvement or mortality	Tanta University	All	18 Years and older   (Adult, Older Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	tanta zinc chloroquine	June 23, 2020	October 1, 2020	October 1, 2020	June 25, 2020		August 17, 2020	Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04447534
576	NCT04407273	STATIN THERAPY AND COVID-19 INFECTION	STACOV	Active, not recruiting	No Results Available	COVID|Statin|Cardiovascular Diseases	Drug: observational	SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy	Institut Investigacio Sanitaria Pere Virgili	All	18 Years and older   (Adult, Older Adult)		1200	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	106/2020	May 14, 2020	August 20, 2020	December 30, 2020	May 29, 2020		September 17, 2020	Facultat de Medicina i Ciències de la Salut de Reus, Reus, Tarragona, Spain	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04407273/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04407273
577	NCT04498936	Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19		Recruiting	No Results Available	COVID	Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide	Change of PCR from positive to negative|Clinical improvement|Adverse events	Assiut University|Helwan University	All	12 Years to 65 Years   (Child, Adult, Older Adult)	Phase 4	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19 treatment	July 15, 2020	October 30, 2020	December 30, 2020	August 5, 2020		August 5, 2020	15th May Hospital, Helwan, Cairo, Egypt|Assiut University Hospital, Assiut, Egypt		https://ClinicalTrials.gov/show/NCT04498936
578	NCT04413838	Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection	NIVISCO	Not yet recruiting	No Results Available	Obesity, COVID-19 Infection	Drug: NIVOLUMAB|Other: Routine standard of care	Patient's clinical state|Readmission|Mortality|Oxygen flow needs|Requirement of oxygen|Discharge from hospital|Adverse events|Presence of nasopharyngeal SARS-CoV-2|nasopharyngeal SARS-CoV-2 viral charge|Number of total Lymphocytes T|Number of CD3+ Lymphocytes T(lymphocyte subpopulation of CD3+ T cells)|Number of CD4+ Lymphocytes T(lymphocyte subpopulation of CD4+ T cells)|Number of CD8+ Lymphocytes T(lymphocyte subpopulation of CD8+ T cells)|Interleukin 6 (IL-6)|Interleukin 10 (IL-10)|Tumor Necrosis Factor alpha (TNFα )|Interferon gamma (IFNγ)|Type I Interferon (type I IFN)|Tim3 expression|PD1 expression|PD-L1 expression|Human Leukocyte Antigen - DR isotype gene expression (HLA-DR expression)|Production of IFNγ by lymphocytes T|Production of granzyme B by lymphocytesT|Lipopolysaccharides (LPS)|LBP(LPS-Binding Protein)|sCD14|High Density Lipoproteins|Apolipoprotein	Hospices Civils de Lyon	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	69HCL20_0478	June 15, 2020	June 15, 2021	September 15, 2021	June 4, 2020		June 4, 2020	Hôpital Lyon Sud Service Endocrinologie, Diabète et Nutrition, Pierre-Bénite, France		https://ClinicalTrials.gov/show/NCT04413838
579	NCT04508439	Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection		Recruiting	No Results Available	Covid19|Pneumonia|Coagulation Disorder|Pulmonary Embolism	Drug: Enoxaparin	low molecular weight heparin (enoxaparin) and ventilatory support time|thrombotic complications and Rivaroxaban|low molecular weight heparin (enoxaparin) and length of hospital stay|low molecular weight heparin (enoxaparin) and mortality rate	Hospital Regional de Alta especialidad de Ixtapaluca	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	130	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	NR-CEI-HRAEI-19-2020	June 20, 2020	August 30, 2020	December 30, 2020	August 11, 2020		August 11, 2020	Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico City, Ixtapaluca, Mexico		https://ClinicalTrials.gov/show/NCT04508439
580	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19		Active, not recruiting	No Results Available	SARS-CoV 2	Drug: Tocilizumab|Drug: Placebos	The primary endpoint is the time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation|Time from investigational medication (or placebo) to at least one point worsening on clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline|Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline	Massachusetts General Hospital|Genentech, Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	243	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2020P001159	April 20, 2020	October 1, 2020	October 1, 2020	April 22, 2020		August 24, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04356937
581	NCT04482712	Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS	RAPA-CARDS	Not yet recruiting	No Results Available	Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Respiratory Failure|Sars-CoV2	Drug: Rapamycin|Drug: Placebo	Survival rate|Change in Clinical Status assessed by the World Health Organization (WHO) scale|Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale	The University of Texas Health Science Center at San Antonio|Claude D. Pepper Older Americans Independence Center	All	60 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	HSC20200489H	October 2020	October 2021	October 2022	July 22, 2020		July 22, 2020	University Hospital System, San Antonio, Texas, United States|Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT04482712
582	NCT04419025	Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease		Recruiting	No Results Available	COVID|Sars-CoV2|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|Oxidative Stress	Drug: N-acetylcysteine	Decrease in Respiratory Rate|Hospital length of stay (LOS)|Need for mechanical ventilation|Length of time intubated|Need for hospitalization|Recovery disposition	Cambridge Health Alliance	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHA-IRB-1139/05/20	September 23, 2020	January 31, 2021	May 31, 2021	June 5, 2020		September 25, 2020	CHA Cambridge Hospital, Cambridge, Massachusetts, United States|CHA Everett Hospital, Everett, Massachusetts, United States|CHA Respiratory Clinic, Somerville, Massachusetts, United States|CHA Somerville campus, Somerville, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04419025
583	NCT04361032	Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia	TRONCHER	Not yet recruiting	No Results Available	COVID19|Intensive Care Unit	Drug: Tocilizumab Injection|Drug: Deferoxamine	the mortality rate	Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	260	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ECC2020-06	September 4, 2020	September 4, 2020	October 4, 2020	April 24, 2020		August 27, 2020	Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia		https://ClinicalTrials.gov/show/NCT04361032
584	NCT04382781	Immunosupressive Treatment in COVID-19 Patients	SAM-COVID	Recruiting	No Results Available	COVID-19 Infection	Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins	Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale	Spanish Network for Research in Infectious Diseases|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	FIS-INM-2020-03	May 2020	May 2020	May 2020	May 11, 2020		May 12, 2020	Hospital Virgen Macarena, Sevilla, Spain	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04382781/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04382781
585	NCT04364009	Anakinra for COVID-19 Respiratory Symptoms	ANACONDA	Recruiting	No Results Available	COVID-19 Infection|ANAKINRA Treatment|Optimized Standard of Care (oSOC)	Drug: Anakinra plus oSOC|Drug: oSOC	Treatment success|OMS progression scale (on a 7 point ordinal scale)|Overall survival|Time to ICU admission|Time to ventilatory support|Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28|Change in inflammatory parameter|Hospital length of stay|ICU parameter|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Predictors of efficacy of Anakinra	University Hospital, Tours|INSERM CIC-P 1415, University Hospital Center of Tours|Swedish Orphan Biovitrum (SOBI)	All	18 Years and older   (Adult, Older Adult)	Phase 3	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANACONDA-COVID-19|2020-001734-36|DR200111	April 27, 2020	September 10, 2021	September 24, 2021	April 27, 2020		September 22, 2020	CHRU de TOURS, Tours, France		https://ClinicalTrials.gov/show/NCT04364009
586	NCT04323761	Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)		No longer available	No Results Available	SARS-CoV2 Infection	Drug: Remdesivir		Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)			Industry	Expanded Access:Treatment IND/Protocol		GS-US-540-5821|2020-001453-49				March 27, 2020		October 7, 2020	University of Alabama- Birmingham, Birmingham, Alabama, United States|Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|Community Regional Medical Centers (CRMC), Fresno, California, United States|St. Jude Medical Center, Fullerton, California, United States|Scripps Memorial Hospital La Jolla, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|Scripps Mercy Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, Medical Center (Parnassus Campus), San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo Medical Center, San Mateo, California, United States|Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Health, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States|Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Swedish Hospital, Chicago, Illinois, United States|Mercy Hospital & Medical Center, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States|Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States|Riverview Health, Noblesville, Indiana, United States|Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|CalvertHealth Medical Center, Prince Frederick, Maryland, United States|University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Charlton Memorial Hospital, Fall River, Massachusetts, United States|Lawrence General Hospital, Lawrence, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Health Care Corporation, Flint, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States|Clara Maass Medical Center, Belleville, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Trinitas Regional Medical Center, Elizabeth, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Ocean Medical Center, Oakhurst, New Jersey, United States|Bayshore Medical Center, Red Bank, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|Virtua Health Voorhees Campus, Voorhees, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Mount Sinai Queens, Astoria, New York, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|Southside Hospital, Bay Shore, New York, United States|Lincoln Medical Center, Bronx, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Montefiore Medical Center, Weiler Campus, Bronx, New York, United States|Montefiore Health System Moses Medical Center, Bronx, New York, United States|The Brooklyn Hospital Center, Brooklyn, New York, United States|Kingsbrook Jewish Medical Center, Brooklyn, New York, United States|University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States|Woodhull Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|New York Harbor VA Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Interfaith Medical Center, Brooklyn, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Brooklyn, Brooklyn, New York, United States|New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States|Kaleida Health System, Buffalo, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|New York Presbyterian- Queens, Flushing, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|NYU Langone Health, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States|NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States|New York City Health + Hospitals / Harlem, New York, New York, United States|New York Presbyterian Lower Manhattan Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States|Samaritan Hospital, Troy, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University College of Medicine, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Francis Hospital, Tulsa, Oklahoma, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|St. Francis Hospital, Greenville, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Texas Department of Criminal Justice Hospital (Hospital Galveston)/University of Texas Medical Branch, Galveston, Texas, United States|HCA Houston Healthcare West, Houston, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|Methodist Mansfield Medical Center, Mansfield, Texas, United States|Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Gold Coast Hospital, Southport, Australia|Landeskrankenhaus Graz West, Graz, Austria|Universitätsklinik für Innere Medizin II, Innsbruck, Austria|Kepler Universitätsklinikum, Linz, Austria|Medical University and General Hospital Vienna, Vienna, Austria|Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Hôpital Civil Marie Curie, Lodelinsart, Belgium|William Osler Health System, Brampton, Ontario, Canada|The Ottowa Hospital, Ottawa, Ontario, Canada|Nicosia General Hospital, Nicosia, Cyprus|Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Bulovce, Praha 8 - Liben, Czechia|Rigshospitalet, Copenhagen, Denmark|Põhja-Eesti Regionaalhaigla, Tallinn, Estonia|Vilnius University, Tartu, Estonia|Hopital Avicenne, Bobigny, France|Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France|Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hôpital Raymond Poincaré, Garches, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hôpital Charles-Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitatsklinikum, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany|Klinikum Würzburg Mitte, Würzburg, Germany|University General Hospital of Patras Panagia I Voithia, Patra, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece|Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary|Landspítali, Reykjavik, Iceland|Kerry University Hospital, Tralee, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Hasharon Hospital, Petah Tikva, Israel|Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera dei Colli, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Italy|Azienda Ospedaliero Universitaria, Turin, Italy|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Vilnius University, Vilnius, Lithuania|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland|Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland|Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal|Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal|Centro Hospitalar Universitário De São João, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania|Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania|Clinical hospital for infectious disease, Timisoara, Romania|Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia|Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia|Univerzitetni Klinicni Center Maribor, Maribor, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT04323761
587	NCT04540406	NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes		Not yet recruiting	No Results Available	Suspected or Confirmed COVID-19	Drug: NBT-NM108|Other: Usual Care Only	Gut Microbiota Composition|Outcome of COVID-19 related illnesses|Proportion of participants who are "alive and not admitted to the hospital"|Proportion of participants who have complete resolution of all objective symptoms|Proportion of participants who have complete resolution of subjective symptoms|Illness severity based on the categorization from FDA COVID-19 Guidance Document|Illness severity based the Ordinal Scale for Clinical Improvement from the World Health Organization|Body temperature (F)|Oxygen saturation SpO2 level|Pulse rate per minute|Respiratory rate per minute|Fasting blood glucose (mg/dl)	Notitia Biotechnologies Company|University of South Florida|Rutgers University	All	18 Years to 69 Years   (Adult, Older Adult)	Phase 2	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NBTNM10810012020	October 1, 2020	March 1, 2021	March 1, 2021	September 7, 2020		September 15, 2020	University of South Florida Morsani College of Medicine, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT04540406
588	NCT04410354	Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19		Recruiting	No Results Available	COVID-19	Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir	Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen	ViralClear Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	VC-02-01	June 16, 2020	November 2020	December 2020	June 1, 2020		October 7, 2020	Mayo Clinic in Arizona, Phoenix, Arizona, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Atlantic Health System / Overlook Medical Center, Summit, New Jersey, United States|St. David's South Austin Medical Center, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|HCA Houston Healthcare Medical Center, Houston, Texas, United States|HCA Houston Healthcare Mainland, Texas City, Texas, United States		https://ClinicalTrials.gov/show/NCT04410354
589	NCT04341207	Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients	ONCOVID	Recruiting	No Results Available	Cancer & COVID 19	Drug: Hydroxychloroquine|Drug: Azithromycin	Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin	Gustave Roussy, Cancer Campus, Grand Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	1000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001250-21|2020/3078	April 3, 2020	April 2022	April 2022	April 10, 2020		April 10, 2020	Gustave Roussy, Villejuif, Val De Marne, France		https://ClinicalTrials.gov/show/NCT04341207
590	NCT04401150	Lessening Organ Dysfunction With VITamin C - COVID-19	LOVIT-COVID	Recruiting	No Results Available	Vitamin C|COVID-19|Hospitalized Patients	Drug: Vitamin C|Drug: Control	Death or persistent organ dysfunction|Number of intensive care unit-free days|Persistent organ dysfunction-free days in ICU|Number of patients deceased at 6 months|Health related quality of life in 6-month survivors|Organ function|Global tissue dysoxia|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia	Université de Sherbrooke|Lotte & John Hecht Memorial Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 3	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MP-31-2021-3741	August 14, 2020	November 2021	January 2022	May 26, 2020		August 18, 2020	Research Center of the CHUS, Sherbrooke, Quebec, Canada|Research Centre of the CHUS, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04401150
591	NCT04373824	Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study		Recruiting	No Results Available	COVID	Drug: Ivermectin	effect of Ivermectin on eradication of virus.	Max Healthcare Insititute Limited	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MHC-COVID-19- INV- ACT-BHR	April 25, 2020	July 25, 2020	July 25, 2020	May 4, 2020		May 4, 2020	Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India		https://ClinicalTrials.gov/show/NCT04373824
592	NCT04359953	Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19	COVID-Aging	Recruiting	No Results Available	COVID-19 Infection	Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan	Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants	University Hospital, Strasbourg, France	All	60 Years and older   (Adult, Older Adult)	Phase 3	1600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7747	April 25, 2020	June 1, 2021	June 1, 2021	April 24, 2020		July 27, 2020	CHU de Strasbourg, Strasbourg, France		https://ClinicalTrials.gov/show/NCT04359953
593	NCT04404361	PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer		Recruiting	No Results Available	COVID	Drug: Pacritinib|Drug: Placebo	Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization	CTI BioPharma	All	18 Years and older   (Adult, Older Adult)	Phase 3	358	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PAC319	May 22, 2020	July 31, 2021	October 31, 2021	May 27, 2020		August 28, 2020	Grady Memorial Hospital, Atlanta, Georgia, United States|St. Vincent Medical Group, Inc, Indianapolis, Indiana, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Ascension Providence Hospital - Novi Campus, Novi, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Overlook Medical Center, Morristown, New Jersey, United States|Chilton Medical Center, Pompton Plains, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT04404361
594	NCT04390217	LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia		Not yet recruiting	No Results Available	COVID-19|Coronavirus Disease 2019|Covid19|COVID-19 Pneumonia	Drug: LB1148|Drug: Placebo	Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure.|Clinical status at fixed time points|Duration of hospital stay|Measurement of the number and proportion of patients requiring admission to the intensive care unit (ICU) during hospitalization|Duration of ICU stay|Invasive mechanical ventilation requirements|Duration of invasive mechanical ventilation|All-cause 28-day mortality|Safety and tolerability of LB1148	Leading BioSciences, Inc	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	LBS-COVID19-201	October 31, 2020	December 31, 2020	March 31, 2021	May 15, 2020		September 2, 2020			https://ClinicalTrials.gov/show/NCT04390217
595	NCT04527354	Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia		Recruiting	No Results Available	SARS-CoV-2 Infection|Fibrosis Lung	Drug: Treamid|Drug: Placebo	Rate of clinically significant change in FVC and/or DLCO at Week 4 relative to the baseline value|Change in distance covered for 6 minutes (6MWD) at Weeks 2 and 4 from the baseline value (based on 6-minute walk test)|Change in the score of the Borg scale at Weeks 2 and 4 from the baseline value (based on the 6-minute walk test)|Change in forced expiratory volume for the first second (FEV1) according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in FEV1/FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in DLCO according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|Change in Total Lung Capacity (TLC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|Change in Functional Residual Capacity (FRC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|The rate of reduction in the lung damage degree based on the computed tomography (CT) at Week 4 relative to the baseline value|Change in mMRC Dyspnea Score in Week 1, Week 2, Week 3, and Week 4 from the baseline value|Change in the overall score of the KBILD Questionnaire at Week 2 and Week 4 relative to the baseline value	PHARMENTERPRISES LLC	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	COVID-TRE-03	September 8, 2020	November 2020	November 2020	August 26, 2020		October 1, 2020	State Federal-Funded Educational Institution of Higher Professional Training "Kazan State Medical University" of the Ministry of Health Care and Social Development of the Russian Federation, Kazan, Russian Federation|Federal State-Funded Research Institution "Research Institute of Complex Cardiovascular Diseases", Kemerovo, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training "Kemerovo State Medical University" of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russian Federation|SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation|State Federal-Funded Institution of Health Care of the city of Moscow "City Clinical Hospital named after M.E. Zhadkevich of the Moscow City Health Department", Moscow, Russian Federation|Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI "City Hospital № 62", branch 5, Moscow, Russian Federation|State Budgetary Institution of Healthcare "Leningrad region Clinical Hospital", Saint Petersburg, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Healthcare of the Russian Federation, Saratov, Russian Federation|State Federal-Funded Institution of Health Care "Republican Clinical Hospital named after G.G. Kuvatov", Ufa, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training "Bashkir State Medical University" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training "Volgograd State Medical University" of the Ministry of Healthcare of the Russian Federation, Volgograd, Russian Federation|State autonomous healthcare institution of Yaroslavl Region "Сlinical hospital for emergency medical care n. a. N.V. Solovyov", Yaroslavl, Russian Federation		https://ClinicalTrials.gov/show/NCT04527354
596	NCT04350671	Interferon Beta 1a in Hospitalized COVID-19 Patients	IB1aIC	Enrolling by invitation	No Results Available	COVID-19	Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine	Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events	Shahid Beheshti University of Medical Sciences	All	50 Years and older   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Interferon Beta 1a in COVID-19	April 15, 2020	April 20, 2020	April 24, 2020	April 17, 2020		April 20, 2020	Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04350671
597	NCT04397510	Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury		Enrolling by invitation	No Results Available	Covid-19|ARDS, Human|Acute Lung Injury	Drug: Heparin|Drug: 0.9% Sodium-chloride	Mean daily PaO2 to FiO2 ratio|Duration of mechanical ventilation|ICU length of stay|Mortality Rate|Incidence of adverse drug events	Frederick Health	All	18 Years and older   (Adult, Older Adult)	Phase 4	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FHHep518	June 1, 2020	December 31, 2020	December 31, 2020	May 21, 2020		August 18, 2020	Frederick Health Hospital, Frederick, Maryland, United States		https://ClinicalTrials.gov/show/NCT04397510
598	NCT04459286	The Nitazoxanide Plus Atazanavir for COVID-19 Study	NACOVID	Not yet recruiting	No Results Available	Covid-19	Drug: Nitazoxanide and atazanavir/ritonavir|Other: Standard of Care	Time to clinical improvement|Time to SARS-CoV-2 negativity|Difference in SARS-CoV-2 AUC|Time to symptoms resolution|Clinical status as assessed with the seven-category ordinal scale on days 7 and 14|Duration of hospitalization in survivors|Day 28 mortality|Time from treatment initiation to death|Proportion with viral RNA detection over time	Obafemi Awolowo University|University of Liverpool|African Centre of Excellence for Genomics of Infectious Diseases|Infectious Disease Hospital Olodo|Obafemi Awolowo University Teaching Hospitals Complex|Osun State Ministry of Health	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	98	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NACOVID2020	September 21, 2020	January 21, 2021	March 21, 2021	July 7, 2020		September 2, 2020	Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria|State Specialist Hospital Asubiaro, Osogbo, Osun State, Nigeria|Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria		https://ClinicalTrials.gov/show/NCT04459286
599	NCT04479644	Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198		Recruiting	No Results Available	COVID-19	Drug: BRII-198|Drug: Placebo	Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-198	Brii Biosciences Limited|TSB Therapeutics (Beijing) CO.LTD	All	18 Years to 49 Years   (Adult)	Phase 1	12	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BRII-198-001	July 13, 2020	March 2021	March 2021	July 21, 2020		July 21, 2020	Investigative Site, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04479644
600	NCT04479631	Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196		Recruiting	No Results Available	COVID-19	Drug: BRII-196|Drug: Placebo	Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-196	Brii Biosciences Limited|TSB Therapeutics (Beijing) CO.LTD	All	18 Years to 49 Years   (Adult)	Phase 1	12	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BRII-196-001	July 12, 2020	March 2021	March 2021	July 21, 2020		July 21, 2020	Investigative Site, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04479631
601	NCT04331600	Chloroquine as Antiviral Treatment in Coronavirus Infection 2020		Recruiting	No Results Available	COVID-19	Drug: Chloroquine phosphate|Other: Telemedicine	COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications	Wroclaw Medical University	All	18 Years and older   (Adult, Older Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WROCLAW CORONA STUDY 2020	April 16, 2020	September 30, 2020	December 31, 2020	April 2, 2020		May 22, 2020	Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland		https://ClinicalTrials.gov/show/NCT04331600
602	NCT04390022	Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial	SAINT	Active, not recruiting	No Results Available	Covid-19|Coronavirus Infection|SARS-CoV-2 Infection	Drug: Ivermectin|Drug: Placebo	Proportion of patients with a positive SARS-CoV-2 PCR|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel	Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health	All	18 Years to 59 Years   (Adult)	Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SAINT	July 31, 2020	November 30, 2020	December 30, 2020	May 15, 2020		September 23, 2020	Clinica Universidad de Navarra, Pamplona, Navarra, Spain		https://ClinicalTrials.gov/show/NCT04390022
603	NCT04334265	Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019		Recruiting	No Results Available	COVID-19	Drug: Anluohuaxian	Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung	Peking University First Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	750	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020 research 110	April 1, 2020	June 1, 2020	December 1, 2020	April 6, 2020		April 24, 2020	The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04334265
604	NCT04333589	Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive		Recruiting	No Results Available	COVID-19	Drug: Favipiravir	Viral nucleic acid test negative conversion rate|Clinical cure rate	Peking University First Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020 research 112	April 1, 2020	June 1, 2020	September 15, 2020	April 3, 2020		April 24, 2020	The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04333589
605	NCT04501783	Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: Favipiravir|Drug: Standard of care (SOC)|Drug: standard concomitant therapy	Time to clinical improvement|Time to viral clearance|Rate of clinical improvement at separate time points|Rate of viral clearance at separate time points|Time to body temperature normalization|Rate of resolution of lung changes on CT|Rate of adverse drug reactions (ADR) and serious ADR|Rate of severe ADR|Rate therapy termination due to ADR	R-Pharm	All	18 Years to 60 Years   (Adult)	Phase 3	168	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TL-FVP-t-01	May 20, 2020	July 29, 2020	August 2020	August 6, 2020		August 6, 2020	Medical center LLC "Neuroprofi", Korolev, Russian Federation|Federal budgetary institution of science "Central Research Institute of Epidemiology" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare, Moscow, Russian Federation|Medical centers JSC "Medsi Group of Companies", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "City Clinical Hospital №57 of the Moscow City Healthcare Department", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "Infectious Diseases Clinical Hospital №1 of the Moscow City Healthcare Department", Moscow, Russian Federation|Medical center LLC "Medical Center Eco-safety", Saint Petersburg, Russian Federation|St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District", Saint Petersburg, Russian Federation|Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1", Voronezh, Russian Federation|State Budgetary Healthcare Institution of the Moscow Region "Zhukovskaya City Clinical Hospital"., Zhukovskiy, Russian Federation		https://ClinicalTrials.gov/show/NCT04501783
606	NCT04445389	Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults		Recruiting	No Results Available	SARS-CoV-2	Drug: GX-19|Drug: Saline	Incidence of solicited adverse events|Incidence of unsolicited adverse events|Incidence of serious adverse events|Geometric mean titer (GMT) of antigen-specific binding antibody titers|Percentage of subjects who seroconverted after vaccination|Geometric mean titer (GMT) of neutralizing antibody level|Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers	Genexine, Inc.	All	18 Years to 50 Years   (Adult)	Phase 1|Phase 2	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	GX-19-HV-001	June 17, 2020	March 17, 2021	June 17, 2022	June 24, 2020		July 28, 2020	Severance hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04445389
607	NCT04351919	Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)	COVID+PA	Withdrawn	No Results Available	Patients With COVID19	Drug: Hydroxychloroquine|Drug: Azithromycin	improvment or healing of clinical signs|Evolution of clinical signs	Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ECC2020-04	May 5, 2020	July 15, 2020	July 15, 2020	April 17, 2020		August 28, 2020	Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia		https://ClinicalTrials.gov/show/NCT04351919
608	NCT04357457	Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia	AIRVM-COVID	Recruiting	No Results Available	Covid 19|Hypoxemic Respiratory Failure	Drug: Almitrine|Drug: Placebo	Rate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatment	Assistance Publique - Hôpitaux de Paris	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	212	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	APHP200461|2020-001909-22	September 3, 2020	December 2020	December 2020	April 22, 2020		September 23, 2020	Hospital Pitié-Salpêtrière, Paris, France		https://ClinicalTrials.gov/show/NCT04357457
609	NCT04355429	Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)	CAPTOCOVID	Not yet recruiting	No Results Available	Pneumonia|Coronavirus Infection|COVID-19	Drug: captopril 25mg	Efficacy of captopril nebulization addition to standard of care compared to standard of care.	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	230	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200410	May 5, 2020	July 2020	August 2020	April 21, 2020		April 28, 2020	CH Victor Dupuy- Argenteuil, Argenteuil, France|Hôpital Avicenne,, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Antoine Béclère, Clamart, France|CH de Compiègne-Noyon, Compiègne, France|Groupe hospitalier Sud Ile de France, Melun, France|Hôpital de la Pitié- Salpêtrière, Paris, France|Hôpital Tenon, Paris, France|CHRU de Tours, Hôpital Bretonneau, Tours, France|Hôpital de Tours, Tours, France		https://ClinicalTrials.gov/show/NCT04355429
610	NCT04405570	A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19		Recruiting	No Results Available	SARS-CoV 2	Drug: EIDD-2801|Drug: Placebo (PBO)	Virologic Efficacy|Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach|Number of Participants With any Adverse Events (AEs), Grade 2 or higher as Assessed by Kaplan Meier Approach	Ridgeback Biotherapeutics, LP	All	18 Years and older   (Adult, Older Adult)	Phase 2	108	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	EIDD-2801-2003	June 16, 2020	October 15, 2020	November 15, 2020	May 28, 2020		October 7, 2020	Valley Clinical Trials, Inc., Northridge, California, United States|FOMAT Medical Research, Oxnard, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Care United Research, LLC, Forney, Texas, United States		https://ClinicalTrials.gov/show/NCT04405570
611	NCT04403685	Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers	TOCIBRAS	Terminated	No Results Available	COVID|SARS Pneumonia|Cytokine Release Syndrome	Drug: Tocilizumab	Evaluation of clinical status|All-cause mortality|Hospital Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events	Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute|Federal University of São Paulo	All	18 Years and older   (Adult, Older Adult)	Phase 3	129	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOCIBRAS	May 8, 2020	July 8, 2020	July 21, 2020	May 27, 2020		August 26, 2020	UNIFESP, São Paulo, Sao Paulo, Brazil|HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil|HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil|HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil|HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil|HSL - Hospital Sírio Libanês, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04403685
612	NCT04435015	The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications		Not yet recruiting	No Results Available	Coagulopathy|Cardiovascular Complication|COVID-19	Drug: Camostat Mesylate|Drug: Microcrystalline Cellulose, NF	Percent change in plasma D-Dimer|Overall Safety and adverse event|Change in plasma Fibrinogen levels|Change in plasma troponin|New onset cardiomyopathy|Duration of intubation|Length of stay in the intensive care unit|Time to discharge from hospital|Occurrence of major adverse cardiovascular events	Yale University|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2000028279	August 1, 2020	December 30, 2020	July 30, 2021	June 17, 2020		June 18, 2020			https://ClinicalTrials.gov/show/NCT04435015
613	NCT04372017	Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection		Active, not recruiting	No Results Available	COVID-19|SARS-CoV 2	Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D	Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.|Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.	Sanford Health	All	18 Years and older   (Adult, Older Adult)	Phase 3	1	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	PEPCOH	May 14, 2020	June 4, 2020	June 4, 2021	May 1, 2020		June 9, 2020	Sanford Health, Sioux Falls, South Dakota, United States		https://ClinicalTrials.gov/show/NCT04372017
614	NCT04369365	A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic		Recruiting	No Results Available	COVID	Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo	Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections|Number of severe COVID-19 cases|Severity of COVID-19 cases|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of viral and bacterial infections|Number of participants with azithromycin-resistant bacterial strains in nasal swabs test	Prof. Dr. Matthias Preusser|Medical University of Vienna	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	OnCoVID-19 Trial	April 27, 2020	August 27, 2020	December 27, 2020	April 30, 2020		May 1, 2020	AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria		https://ClinicalTrials.gov/show/NCT04369365
615	NCT04492514	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation		Recruiting	No Results Available	COVID 19|SARS-CoV 2|Pneumonia	Drug: Mavrilimumab|Drug: Placebo	Primary Outcome Measure:|Secondary Outcome Measures:	Kristin Hudock|Kiniksa Pharmaceuticals, Ltd.|University of Cincinnati	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IND 149353	May 20, 2020	May 31, 2021	May 31, 2021	July 30, 2020		July 30, 2020	University of Cincinnati, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04492514
616	NCT04408183	GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel		Recruiting	No Results Available	SARS-CoV 2|Infection	Drug: GLS-1200|Drug: Placebo	Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0|Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group|Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome.	GeneOne Life Science, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	225	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	T2R-002	June 1, 2020	September 2020	November 2020	May 29, 2020		June 4, 2020	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04408183
617	NCT04563208	Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19	DuACT	Not yet recruiting	No Results Available	Covid19|SARS-CoV Infection	Drug: Placebo|Drug: DuACT	Rate of decline in viral load|Time to resolution of viral load|Comparison of proportion of subjects who are asymptomatic and symptomatic|Change in modified NEWS-2|Proportion of subjects with treatment emergent adverse events	University of Witwatersrand, South Africa	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	DUACT-101	December 2020	February 2021	March 2021	September 24, 2020		September 28, 2020	Sunnyside Office Park, Johannesburg, Gauteng, South Africa		https://ClinicalTrials.gov/show/NCT04563208
618	NCT04516564	A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects		Recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)	Drug: AK119|Drug: Placebo	Incidence of treatment-emergent AEs|Maximum serum concentration (Cmax) of AK119|Area under the concentration-time curve (AUC) of serum concentration of AK119|Percentage of subjects who develop detectable anti-drug antibodies (ADAs)	Akesobio Australia Pty Ltd|Akeso	All	18 Years to 55 Years   (Adult)	Phase 1	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other	AK119-101	September 2020	March 2021	April 2021	August 18, 2020		September 21, 2020	Christchurch Clinical Studies Trust, Christchurch, New Zealand		https://ClinicalTrials.gov/show/NCT04516564
619	NCT04414241	Hydroxychloroquine to Prevent SARS-CoV-2 Infection		Not yet recruiting	No Results Available	SARS-CoV-2	Drug: Hydroxychloroquine	Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2|Safety: Proportion of participants with grade 3 or more adverse events|Tolerability: Proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events	Universidad Peruana Cayetano Heredia	All	18 Years and older   (Adult, Older Adult)	Phase 3	320	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	202087|20923	June 2020	September 2020	October 2020	June 4, 2020		June 4, 2020	Centro Médico Naval "Cirujano Mayor Santiago Távara", Callao, Peru|Hospital Nacional Hipólito Unanue, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Cayetano Heredia, Lima, Peru		https://ClinicalTrials.gov/show/NCT04414241
620	NCT04372602	Duvelisib to Combat COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo	Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0	Washington University School of Medicine|Verastem, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	28	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	202007009	September 30, 2020	October 31, 2021	March 31, 2022	May 4, 2020		September 10, 2020	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04372602
621	NCT04463420	Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19		Recruiting	No Results Available	COVID-19	Drug: PHR160 Spray|Drug: Placebo|Drug: Standard treatment	Dyspnea|long of hospitalization|Radiological Treatment Response|Mortality|Allergic drug|Laboratory Treatment Response|O2 saturation without supplemental oxygen|drug reactions Adverse	Baqiyatallah Medical Sciences University	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	224	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IR.BMSU.REC.1399.176	August 15, 2020	November 15, 2020	December 15, 2020	July 9, 2020		August 18, 2020	Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04463420
622	NCT04399980	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation		Active, not recruiting	No Results Available	COVID 19|SARS-CoV 2|Pneumonia	Drug: Mavrilimumab|Drug: Placebos	Proportion of subjects alive and off of oxygen at day 14|Proportion of subjects alive at 28 days|Proportion of subjects alive and without respiratory failure at 28 days	The Cleveland Clinic|Kiniksa Pharmaceuticals, Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IND 149324|IRB 20-523	May 20, 2020	May 31, 2021	May 31, 2021	May 22, 2020		October 6, 2020	Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic Health System, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04399980
623	NCT04391127	Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection		Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo	Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization	Centenario Hospital Miguel Hidalgo	All	16 Years to 90 Years   (Child, Adult, Older Adult)	Phase 3	108	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	2020-A-09	May 4, 2020	August 30, 2020	September 30, 2020	May 18, 2020		September 4, 2020	Jose Manuel Arreola Guerra, Aguascalientes, Mexico		https://ClinicalTrials.gov/show/NCT04391127
624	NCT04347889	Preventing COVID-19 in Healthcare Workers With HCQ: A RCT		Not yet recruiting	No Results Available	Covid-19	Drug: Hydroxychloroquine|Other: Vitamin C	COVID-19 Seroconversion rate|Admission for Covid-19	Stony Brook University	All	18 Years and older   (Adult, Older Adult)	Phase 2	1212	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	IRB2020-00222	April 20, 2020	December 30, 2020	December 30, 2020	April 15, 2020		April 17, 2020			https://ClinicalTrials.gov/show/NCT04347889
625	NCT04330690	Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial	CATCO	Recruiting	No Results Available	COVID-19	Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir	Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)	Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	2900	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2114	March 18, 2020	March 18, 2022	May 18, 2022	April 1, 2020		September 25, 2020	Peter Lougheed Centre, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Misericordia Community Hospital, Edmonton, Alberta, Canada|University of Alberta Hopsital, Edmonton, Alberta, Canada|Grey Nuns Community Hospital, Edmonton, Alberta, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|Richmond Hospital, Richmond, British Columbia, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|Island Health - Nanaimo Regional General Hospital, Victoria, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Saint John's, Newfoundland and Labrador, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|William Osler Health System - Brampton Civic Hospital, Brampton, Ontario, Canada|William Osler Health System - Etobicoke General Hospital, Etobicoke, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St.Joseph's Health Care, London, Ontario, Canada|University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada|Trillium Health Partners-Credit Valley Hospital, Mississauga, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Hôpital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health Toronto - St. Joseph's Health Centre, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04330690
626	NCT04352465	Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients		Not yet recruiting	No Results Available	COVID-19	Drug: Methotrexate	Change in clinical conditions|Change of Clinical symptoms - respiratory rate|Hypoxia|Changes of blood oxygen|Inflammatory parameters|Evolution of Acute Respiratory Syndrome|Hospital discharge|ICU discharge|Rate of mortality	Azidus Brasil|InCor Heart Institute|Hospital Santa Marcelina|PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	42	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LDE-MTX_COVID19	May 1, 2020	June 30, 2020	November 30, 2020	April 20, 2020		April 29, 2020	Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04352465
627	NCT04382586	Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants		Recruiting	No Results Available	COVID-19 Pulmonary Complications|COVID-19	Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo	Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale	BeiGene	All	18 Years and older   (Adult, Older Adult)	Phase 2	52	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BGB-3111-219	July 6, 2020	April 2021	April 2021	May 11, 2020		October 7, 2020	Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System, Inc. / Chilton Medical Center, Pompton Plains, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Instituto Dor de Pesquisa E Ensino, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04382586
628	NCT04347954	PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)		Recruiting	No Results Available	COVID-19	Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%	Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)	Stanford University	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	45	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IRB-56134	August 15, 2020	December 2020	January 2021	April 15, 2020		September 21, 2020	Stanford Health Care, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04347954
629	NCT04530604	Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)		Not yet recruiting	No Results Available	COVID|Sars-CoV2|COVID-19|Acute Respiratory Distress Syndrome	Drug: Defibrotide	Number of major hemorrhagic complications within 14 days of initiation of treatment|Overall survival|Ventilator free survival|Number of ventilator free days within 14 days of study entry|The time to improvement in oxygenation|Mean change in the WHO COVID-19 Ordinal Scale during therapy	Gregory Yanik|Jazz Pharmaceuticals|University of Michigan	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HUM00182089	September 2020	July 2021	July 2021	August 28, 2020		August 28, 2020	University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04530604
630	NCT04344236	Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19		Recruiting	No Results Available	COVID-19	Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse	Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient	NYU Langone Health	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	s20-00444	April 9, 2020	May 1, 2020	May 9, 2020	April 14, 2020		April 14, 2020	NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04344236
631	NCT04480593	The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.	Bee-Covid	Completed	No Results Available	Covid19	Drug: Brazilian Green Propolis Extract (EPP-AF)|Other: Standard care	Composite clinical outcome with oxygen therapy dependency time or hospitalization time|Percentage of participants with adverse events during the use of propolis|Rate and severity of acute kidney injury during the study|Renal replacement therapy.|Rate of need for vasopressor use|Need for intensive care unit (ICU)|Intensive care unit (ICU) readmission|Invasive oxygenation time|Variation of plasma c-reactive protein	D'Or Institute for Research and Education|Hospital Sao Rafael	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	31099320.6.0000.0048	June 2, 2020	August 30, 2020	August 30, 2020	July 21, 2020		September 30, 2020	Hospital Sao Rafael, Salvador, BA, Brazil		https://ClinicalTrials.gov/show/NCT04480593
632	NCT04273646	Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19		Not yet recruiting	No Results Available	2019 Novel Coronavirus Pneumonia|COVID-19	Biological: UC-MSCs|Drug: Placebo	Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio	Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202001	April 20, 2020	June 30, 2020	February 15, 2022	February 18, 2020		April 14, 2020	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04273646
633	NCT04527471	Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19		Recruiting	No Results Available	Coronavirus Infection|Covid-19|SARS-CoV-2	Drug: Ensifentrine Dose 1|Drug: Placebo pMDI	Proportion of patients with recovery|Time to recovery|Proportion of patients with improvement (from Day 1) of one category using the 7-point ordinal scale|Proportion of patients with improvement (from Day 1) of two categories using the 7-point ordinal scale|Mortality rate|Proportion of patients alive and not in respiratory failure|Proportion of patients needing re-hospitalization|Duration of hospitalization from Day 1|Mean change from baseline in 7-point ordinal scale|Total time on supplemental oxygen|Incidence of new non-invasive ventilation or high flow oxygen use|Duration of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Duration of new oxygen use|Incidence of new mechanical ventilator use|Duration of new mechanical ventilator use|Proportion of patients receiving invasive mechanical ventilation or ECMO	Verona Pharma Inc|Verona Pharma plc	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	45	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RPL554-COV-201	August 28, 2020	December 2020	March 2021	August 26, 2020		September 1, 2020	The University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04527471
634	NCT04427501	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness	BLAZE-1	Recruiting	No Results Available	COVID-19	Drug: LY3819253|Drug: LY3832479|Drug: Placebo	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load|Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold|Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death	Eli Lilly and Company|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2	800	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	17947|J2W-MC-PYAB	June 17, 2020	September 20, 2020	January 15, 2021	June 11, 2020		September 18, 2020	Arizona Clin Trials-Mesa, Mesa, Arizona, United States|Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Surprise, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|Orange Grove Banner Clinic, Tucson, Arizona, United States|Arizona Clin Trials-Tucson, Tucson, Arizona, United States|Smart Cures Clin Research, Anaheim, California, United States|VCT-Covina, Covina, California, United States|VCT-Covina, Covina, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|University of CA, Irvine, Orange, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|IACT Health - VHC, Columbus, Georgia, United States|Northwestern University, Chicago, Illinois, United States|J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|CAR d/b/a CT of SWLA, LLC, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Care Access Research - Bronx, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OH State Univ College of Med, Columbus, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Ascension St. John Tulsa OK, Tulsa, Oklahoma, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Central Texas Clinical Rch, Austin, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Centex-Houston, Houston, Texas, United States|Centex-Wesfield, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States		https://ClinicalTrials.gov/show/NCT04427501
635	NCT04569877	GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia	GI-COVID	Recruiting	No Results Available	Severe Acute Respiratory Syndrome (SARS) Pneumonia|COVID-19 Pneumonia	Drug: Molgramostim nebuliser solution|Other: Placebo nebuliser solution	Mechanical ventilation|Clinical status of subject at day 15 and day 29 (on a 7-point ordinal scale):|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Oxygen supply|Clinical parameter: temperature|Clinical parameter: blood pressure|Clinical parameter: heart beat|Clinical parameter: respiratory rate|Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)|Laboratory: C-reactive protein test|Laboratory: ferritin|Laboratory: Interleukin-6|Laboratory: procalcitonin|Bacterial pneumonia|Vaso-active drugs|Mortality|GM-CSF	University of Giessen	All	18 Years and older   (Adult, Older Adult)	Phase 2	238	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	KKS-279|2020-001654-21	September 24, 2020	December 25, 2022	December 25, 2022	September 30, 2020		October 2, 2020	Prof. Dr. Susanne Herold, PhD, Gießen, Germany		https://ClinicalTrials.gov/show/NCT04569877
636	NCT04332094	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	TOCOVID	Recruiting	No Results Available	COVID-19	Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin	In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III	All	18 Years and older   (Adult, Older Adult)	Phase 2	276	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIBSP-COV-2020-23	April 2, 2020	September 2020	October 2020	April 2, 2020		April 7, 2020	Hospital de la Santa Creu i Sant Pau, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04332094
637	NCT04327505	Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19	COVID-19-HBO	Recruiting	No Results Available	SARS (Severe Acute Respiratory Syndrome)|Cytokine Storm|ARDS, Human|COVID-19|Sars-CoV2|Acute Respiratory Failure	Drug: Hyperbaric oxygen	ICU admission|30-day mortality|Time-to-intubation|Time-to-ICU|Inflammatory response|Overall survival	Karolinska Institutet|Karolinska Trial Alliance|University of California, San Diego|Blekinge County Council Hospital|JK Biostatistics AB|The Swedish Research Council	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19-HBO|2020-001349-37|K-1199/2020	June 3, 2020	December 31, 2021	December 31, 2022	March 31, 2020		June 5, 2020	Bergmannsheil und Kinderklinik Buer GmbH, Gelsenkirchen, Germany|Krankenhaus St. Joesf, Regensburg, Germany|Blekingesjukhuset, Karlskrona, Blekinge, Sweden		https://ClinicalTrials.gov/show/NCT04327505
638	NCT04408456	Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19	PEP-CQ	Completed	No Results Available	CoVID-19	Drug: HCQ|Other: Standard therapy	Incidence confirmed case of COVID-19|Incidence of probable case of COVID-19|Incidence of adverse drug reaction (ADR)	Postgraduate Institute of Medical Education and Research	All	18 Years and older   (Adult, Older Adult)	Phase 3	325	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	IEC-04/2020-1624	March 1, 2020	July 31, 2020	July 31, 2020	May 29, 2020		August 4, 2020	Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India		https://ClinicalTrials.gov/show/NCT04408456
639	NCT04516759	AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19	ARCADIA	Recruiting	No Results Available	Covid19	Drug: AZD1656|Other: Placebo	Clinical Improvement by Day 14|*Title: Clinical Improvement at Day 7, 14 and 21|Glycaemic Control|Occurrence of Adverse Events|Occurrence of Serious Adverse Events|Duration of Hospitalisation|Time to Intubation/ Mechanical Intervention|Mortality Rate	St George Street Capital	All	18 Years and older   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SGS.1656.201|2020-002211-21	August 12, 2020	December 2020	December 2020	August 18, 2020		September 28, 2020	Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|Croydon Health Services NHS Trust, Croydon, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, United Kingdom|Medway NHS Foundation Trust, Gillingham, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|Penine Acute Hospitals NHS Trust, Salford, United Kingdom|Sheffield Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Somerset NHS Foundation Trust, Taunton, United Kingdom|Walsall Healthcare NHS Trust, Walsall, United Kingdom		https://ClinicalTrials.gov/show/NCT04516759
640	NCT04363060	Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit	AziA	Not yet recruiting	No Results Available	COVID-19 Pneumonia	Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate	Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion	Nantes University Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	104	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RC20_0168	April 30, 2020	July 30, 2020	July 30, 2020	April 27, 2020		April 29, 2020	Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France		https://ClinicalTrials.gov/show/NCT04363060
641	NCT04573322	Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects		Recruiting	No Results Available	SARS-CoV-2 (Covid19)	Drug: Trans Sodium Crocetinate|Drug: Normal saline	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Time to recovery through Day 28|WHO Ordinal Severity Scale|WHO Ordinal Severity Scale - Time to Improvement|WHO Ordinal Severity Scale - Change from Baseline|National Early Warning Score (NEWS)|National Early Warning Score (NEWS) - Change from Baseline|Mechanical Ventilation|Mechanical Ventilation - Duration|Hospitalization|Oxygenation|Oxygenation - New Oxygen Use|Oxygenation - Advanced Therapies|Oxygenation - Time to Return to Baseline|Oxygenation - Pulse Oximetry|Oxygenation - ABG Measurements|Mortality	Diffusion Pharmaceuticals Inc	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	224	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	100-303	September 10, 2020	November 14, 2021	December 14, 2021	October 2, 2020		October 2, 2020	National Institute of Infectious Diseases- Prof. Dr. Matei Balş, Bucharest, Romania		https://ClinicalTrials.gov/show/NCT04573322
642	NCT04519424	CSL324 in COVID-19		Not yet recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)	Biological: CSL324|Drug: Placebo	Proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation|Proportion of deaths from all causes|Proportion of subjects intubated|Median length of stay in hospital|Number and proportion of subjects with at least a 2-point improvement in the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale|Number and proportion of subjects within each of the categories of the NIAID ordinal scale|Proportion of subjects using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP)|Proportion of subjects using high-flow nasal cannula (HFNC)|Proportion of subjects using extracorporeal membrane oxygenation (ECMO)|Maximum Change in Sequential Organ Failure Assessment (SOFA) score|Change in SOFA score and in individual components of the SOFA score|Number and proportion of subjects experiencing adverse events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects experiencing adverse events of special interest (AESIs)|Presence of anti-CSL324 antibodies|Maximum concentration (Cmax) of CSL324|Time to reach maximum concentration (Tmax) of CSL324|Area under the concentration-time curve (AUC0-last) of CSL324|Trough concentration (Ctrough) of CSL324	CSL Behring	All	18 Years and older   (Adult, Older Adult)	Phase 2	124	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CSL324_COVID-19	September 2020	April 2021	May 2021	August 19, 2020		September 30, 2020	Memorial Health University Medical Center, Savannah, Georgia, United States		https://ClinicalTrials.gov/show/NCT04519424
643	NCT04539275	COVID-19 (VA CURES-1)	VA CURES-1	Not yet recruiting	No Results Available	COVID-19	Drug: Convalescent Plasma|Other: Masked Saline Placebo	Proportion of participants developing acute hypoxemic respiratory failure or all-cause death|Time (in days) to recovery|Time (in days) to death or respiratory failure|Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm|Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm|Subject 28-day all-cause mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Participant's clinical status by ordinal scale|Mean change in the ordinal scale|Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first|Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29|Duration of hospitalization|Number of hospitalizations related to COVID-19|Cumulative incidence of Serious Adverse Events (SAEs)|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Incidence of discontinuation or temporary suspension of study product administrations (for any reason)|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in total bilirubin|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in prothrombin time (PT)	VA Office of Research and Development	All	18 Years and older   (Adult, Older Adult)	Phase 3	702	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	COVID19-8900-22	October 19, 2020	March 14, 2022	June 30, 2022	September 4, 2020		October 7, 2020	Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Southeast Louisiana Veterans Health Care System, New Orleans, LA, New Orleans, Louisiana, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States|VA Southern Nevada Healthcare System, North Las Vegas, NV, Las Vegas, Nevada, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04539275
644	NCT04365231	Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial	HASCOPT	Not yet recruiting	No Results Available	COVID19	Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients	Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit	Hospital St. Joseph, Marseille, France	Female	18 Years and older   (Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HASCOPT2020	April 2020	June 2020	January 2021	April 28, 2020		April 28, 2020	Hopital Saint Joseph, Marseille, Paca, France		https://ClinicalTrials.gov/show/NCT04365231
645	NCT04576728	Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19	ESsCOVID	Recruiting	No Results Available	Covid19	Drug: Trimodulin|Other: Placebo (human albumin 1%)	Clinical detoriation rate|28-day all-cause mortality rate|Clinical deterioration rate|28-days all-cause mortality rate on day 29|Time to clinical deterioration|Time to Mortality|Proportion of subjects in each of the 9-categories of the ordinal scale|Time to clinical improvement|Proportion of subjects with score ≤2|Days on IMV|Days without oxygen supply|Time to discontinuation from any form of oxygen supply|Proportion of subjects without any form of oxygen supply|Hospital-free-days|SARS-CoV-2 status|Adverse events (AEs), treatment-emergent AEs (TEAEs), AEs of special interest, infusional TEAEs|TEAEs|SAEs|Dose modifications|Time to recovery|Change over time in ECG parameters|Change over time in vital signs	Biotest	All	18 Years and older   (Adult, Older Adult)	Phase 2	164	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	998	October 6, 2020	March 2021	March 2021	October 6, 2020		October 8, 2020	Hospital Clinic, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04576728
646	NCT04545060	VIR-7831 for the Early Treatment of COVID-19 in Outpatients	COMET-ICE	Recruiting	No Results Available	Covid19	Biological: VIR-7831|Drug: Placebo	Proportion of participants who have progression of COVID-19 through Day 29|Occurence of of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESI)|Incidence and titers (if applicable) of serum ADA to VIR-7831|Cmax|Clast|Tmax|Tlast|AUCinf|AUClast|%AUCextrap|t1/2|Vz|Vss|CL|Proportion of participants who have progression of COVID-19 as defined by hospitalization >24 hrs or death at Day 8, Day 15, or Day 22|Proportion of participants who progress to develop severe and/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22, or Day 29|Severity and duration of participant-reported symptoms of COVID-19 related illness using the FLU-PRO patient-reported outcome instrument|Detection of SARS-CoV-2 in nasal secretions by PCR at baseline and during follow-up period through Day 29|29-day, 60-day, and 90-day all-cause mortality	Vir Biotechnology, Inc.|GlaxoSmithKline	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1360	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	VIR-7831-5001|GSK Study 214367	August 27, 2020	January 2021	July 2021	September 10, 2020		September 10, 2020	Investigative Site, Anniston, Alabama, United States|Investigative Site, Pembroke Pines, Florida, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Houston, Texas, United States|Investigative Site, McAllen, Texas, United States		https://ClinicalTrials.gov/show/NCT04545060
647	NCT04561219	Nitazoxanide Therapy for Patients With COVID-19 Pneumonia		Active, not recruiting	No Results Available	Covid19|Corona Virus Infection|Pneumonia, Viral	Drug: Nitazoxanide|Drug: Placebo	Orotracheal intubation rate|Mechanical ventilation free days|Hospitalisation days|ICU days|Intranasal oxygen support days|Mortality rate|Days with fever|Days with cough|Days with dyspnea|Radiologic findings|Cardiologic findings|C-reactive protein - absolute number|C-reactive protein serum levels|Lactate dehydrogenase (LDH) serum levels|Troponin serum levels|Electrolytes serum levels|Glucose serum levels|Renal function|Coagulogram|Liver function panel|Ferritin|D-dimer|Blood cell count|Inflammatory mediators	Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil|National Research Council, Brazil|Financiadora de Estudos e Projetos|ATCGen|Hospital Central da Aeronáutica, Rio de Janeiro|Hospital da Força Aérea do Galeão|Hospital Naval Marcilio Dias|Hospital Universitario Pedro Ernesto|Hospital de Força Aérea de São Paulo|Hospital das Clínicas Luzia de Pinho Melo|Complexo Hospitalar Municipal de São Caetano do Sul|Hospital Municipal de Barueri Dr Francisco Moran|Hospital Regional de Sorocaba Dr Adib Domingos Jatene|Hospital Geral de São Mateus Dr Manoel Bifulco|Santa Casa de Misericórdia de Belo Horizonte|Mater Dei Hospital, Brazil|Hospital Eduardo de Menezes|Hospital das Clínicas da Universidade Federal de Pernambuco|Hospital das Forças Armadas, Brazil|Hospital Regional da Asa Norte, Brazil|Complexo Hospitalar do Trabalhador de Curitiba|Hospital Estadual de Doenças Tropicais Dr Anuar Auad|Hospital Geral de Fortaleza	All	18 Years and older   (Adult, Older Adult)	Phase 2	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SARITA-1|RBR-88bs9x|30662420.0.1001.0008	April 19, 2020	October 2, 2020	October 2, 2020	September 23, 2020		September 25, 2020	Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil		https://ClinicalTrials.gov/show/NCT04561219
648	NCT04438980	Glucocorticoids in COVID-19 (CORTIVID)	CORTIVID	Recruiting	No Results Available	Covid-19 Pneumonia	Drug: Methylprednisolone|Other: Placebo	Proportion of patients developing treatment failure|Mortality at day 28|Proportion of patients requiring ICU admission|Proportion of patients requiring rescue-therapy with tocilizumab|Length of hospital stay|Proportion of severe adverse events|Proportion of bacterial, fungal or opportunistic infections|Evolution of inflammatory biomarkers related to COVID-19|Proportion of SARS-CoV-2 clearance.	Fundacion Miguel Servet|Complejo Hospitalario de Navarra|Hospital Sant Joan Despí Moisès Broggi	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	72	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CORTIVID	May 15, 2020	December 2020	February 2021	June 19, 2020		June 22, 2020	Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain		https://ClinicalTrials.gov/show/NCT04438980
649	NCT04371406	Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients	MG-COVID	Not yet recruiting	No Results Available	Covid-19	Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc	Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14	Assistance Publique - Hôpitaux de Paris	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	2770	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200447|2020-001702-35	May 2, 2020	August 2, 2020	September 2, 2020	May 1, 2020		May 1, 2020			https://ClinicalTrials.gov/show/NCT04371406
650	NCT04351152	Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19		Recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19) Pneumonia	Biological: Lenzilumab|Drug: Standard of Care	Time to Recovery|Incidence of Invasive Mechanical Ventilation and/or Death|Incidence of severe acute respiratory distress syndrome (ARDS)|Duration of Intensive Care Unit (ICU) Stay|Ventilator-free Days|Duration of Hospitalization|Time to Improvement in 1 or 2 Categories using 8-point Ordinal Scale|Time to Death|Number of Subjects Alive and Off Oxygen|Percentage of Participants Experiencing Adverse Events|Percentage of Participants Experiencing Serious Adverse Events|Proportion of Subjects Discharged from Hospital|All-cause Mortality and Proportion of Subjects Alive|Time to improvement in oxygenation for > 48 hours|Incidence of Non-invasive Ventilation (or Use of High-flow Oxygen Device)|Time to Clinical Improvement, Defined as NEWS2 < 2 Maintained for 24 Hours|Change from Baseline to Day 28 in Clinical status Based on the 8-point Ordinal Scale|Duration of Time on Low-flow or High-flow Supplemental Oxygen	Humanigen, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	HGEN003-06	April 30, 2020	September 2020	September 2020	April 17, 2020		August 5, 2020	Mayo Clinic, Phoenix, Arizona, United States|University of Southern California (USC) Medical Center, Los Angeles, California, United States|USC - Los Angeles County Medical Center, Los Angeles, California, United States|Baptist Medical Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Atrium Health, Charlotte, North Carolina, United States|St. David's Healthcare, Austin, Texas, United States|St. David's North Austin Medical Center, Austin, Texas, United States|Texas Health, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT04351152
651	NCT04327206	BCG Vaccination to Protect Healthcare Workers Against COVID-19	BRACE	Recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)|Respiratory Illness|Corona Virus Infection|COVID-19	Drug: BCG Vaccine|Drug: 0.9%NaCl	COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Fever or respiratory illness|Episodes of fever or respiratory illness|Work absenteeism due to fever or respiratory illness|Bed confinement due to fever or respiratory illness|Symptom duration of fever or respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with fever or respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers	Murdoch Childrens Research Institute|Royal Children's Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	10078	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	62586|U1111-1256-4104	March 30, 2020	June 30, 2021	March 30, 2022	March 31, 2020		August 20, 2020	St Vincent's Hospital, Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Noord West Ziekenhuis, Alkmaar, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|St Antonius Hospital, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|University hospital in Utrecht (UMCU), Utrecht, Netherlands|University Hospital German Trias I Pujol, Badalona, Barcelona, Spain|Mutua Terrassa Univeristy Hospital, Terrassa, Barcelona, Spain|University Hospital Cruces, Barakaldo, Bizkaia, Spain|Marqués de Valdecilla University Hospital, Santander, Spain|University Hospital Virgen Macarena, Sevilla, Spain|Lozano Blesa University Hospital, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT04327206
652	NCT04336332	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19		Recruiting	No Results Available	SARS-CoV-2|COVID-19	Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate	Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood	Rutgers, The State University of New Jersey	All	18 Years and older   (Adult, Older Adult)	Phase 2	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	002011|Pro2020000712	April 1, 2020	April 30, 2021	April 30, 2021	April 7, 2020		May 8, 2020	Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04336332
653	NCT04345406	Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19		Not yet recruiting	No Results Available	COVID	Drug: ACEIs|Drug: Conventional treatment	number of patients with virological cure	Tanta University	All	Child, Adult, Older Adult	Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACEIS COVID 19	April 15, 2020	December 1, 2029	December 1, 2029	April 14, 2020		April 14, 2020	Tanta University, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04345406
654	NCT04357808	Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)	SARCOVID	Recruiting	No Results Available	Covid-19	Drug: Sarilumab|Other: Standar of care	Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation	Maria del Rosario Garcia de Vicuña Pinedo|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARCOVID|2020-001634-36	April 13, 2020	December 2020	December 2020	April 22, 2020		August 4, 2020	Hospital Universitario de la Princesa, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04357808
655	NCT04568421	Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection	SAR-COVID	Recruiting	No Results Available	Rheumatic Diseases	Drug: Immunosuppressive Agents	Mortality|Hospitalization|SARS-CoV-2 infection presentation|Admission at the intensive care unit|Invasive mechanical ventilation|COVID-19 Complications|Recovery rate	Sociedad Argentina de Reumatologia	All	18 Years to 100 Years   (Adult, Older Adult)		3000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	01	August 18, 2020	December 31, 2021	December 31, 2021	September 29, 2020		September 29, 2020	Sociedad Argentina de Reumatología, Ciudad Autónoma de Buenos Aires, Caba, Argentina	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04568421/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04568421
656	NCT04359290	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	RuXoCoil	Recruiting	No Results Available	ARDS, Human|COVID	Drug: Ruxolitinib administration	Overall survival|Assessment of the duration of ventilation support|cytokine storm|time on ICU|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)|pulmonary function assessed by a CT scan|overall survival	Philipps University Marburg Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KKS-278	July 1, 2020	December 2020	July 2021	April 24, 2020		August 17, 2020	Andreas Neubauer, Marburg, Germany		https://ClinicalTrials.gov/show/NCT04359290
657	NCT04407130	Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.		Enrolling by invitation	No Results Available	COVID-19 Patients	Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo	Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >88% despite oxygenation|Number of days on oxygen support|Chest X-ray improvement|Duration of hospitalization|All causes of mortality	International Centre for Diarrhoeal Disease Research, Bangladesh	All	40 Years to 65 Years   (Adult, Older Adult)	Phase 2	72	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PR-20039	June 16, 2020	July 2020	July 2020	May 29, 2020		June 26, 2020	Icddr,B, Dhaka, Bangladesh		https://ClinicalTrials.gov/show/NCT04407130
658	NCT04445623	Prasugrel in Severe COVID-19 Pneumonia	PARTISAN	Not yet recruiting	No Results Available	COVID19|Thrombosis	Drug: Prasugrel Hydrochloride 10 MG Oral Tablet|Drug: Placebo	P/F ratio at day 7|Daily P/F ratio|Daily need for oxygen supply|Need for ICU|Death|MOF|Discharge|Clinical progression of the disease SOFA score|Clinical progression of the disease APACHE II|Venous thrombosis/ pulmonary embolism/thrombosis|Need for CT imaging|Daily Temperature|Daily blood pressure|Daily total blood count Hemoglobin|Daily total blood count Red Blood Cells|Daily total blood count Leukocytes|Daily total blood count Platelets|Daily indices of organ damage Liver|Indices of inflammation C-reactive protein|Indices of haemostasis PT|Daily progression at imaging (chest-X-ray)|Major bleeding|Total bleeding|Unexpected clinical or laboratory findings|Indices of inflammation D-dimer|Indices of inflammation Fibrinogen|Indices of inflammation IL-6|Indices of inflammation IL-1|Daily indices of organ damage kidney|Daily indices of organ damage heart|Haemostasis aPTT|Haemostasis VASP PRI|Haemostasis platelet-leukocytes aggregates	Azienda Ospedaliera Universitaria Integrata Verona|University of Milan	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	128	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	MGI-COVID-19-prasugrel	July 2020	October 2020	January 2021	June 24, 2020		June 26, 2020	Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy		https://ClinicalTrials.gov/show/NCT04445623
659	NCT04326790	The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention	GRECCO-19	Recruiting	No Results Available	Corona Virus Disease 19 (Covid 19)	Drug: Colchicine|Drug: Standard treatment	Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee|Maximal concentration of cardiac troponin	National and Kapodistrian University of Athens	All	18 Years and older   (Adult, Older Adult)	Phase 2	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	906295542	April 3, 2020	August 31, 2020	September 30, 2020	March 30, 2020		May 8, 2020	AHEPA Hospital, Thessaloniki, Gibraltar		https://ClinicalTrials.gov/show/NCT04326790
660	NCT04382040	A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19		Recruiting	No Results Available	COVID-19|Corona Virus Infection|SARS-CoV 2|Coronavirus|Coronavirus Infection	Drug: ArtemiC|Drug: Placebo	Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours in comparison to routine treatment|Percentage of participants with definite or probable drug related adverse events|Time to negative COVID-19 PCR|Proportion of participants with normalization of fever and oxygen saturation through day 14 since onset of symptoms|COVID-19 related survival|Incidence and duration of mechanical ventilation|Incidence of Intensive Care Init (ICU) stay|Duration of ICU stay|Duration of time on supplemental oxygen	MGC Pharmaceuticals d.o.o	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MGC-006	May 8, 2020	November 2020	January 2021	May 11, 2020		October 1, 2020	Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India|Hillel Yaffe Medical Center, Hadera, Haifa, Israel|Nazareth Hospital EMMS, Nazareth, North, Israel|Rambam Health Care Campus, Haifa, Israel		https://ClinicalTrials.gov/show/NCT04382040
661	NCT04339712	Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	ESCAPE	Recruiting	No Results Available	COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection	Drug: Anakinra|Drug: Tocilizumab	Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function	Hellenic Institute for the Study of Sepsis	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ESCAPE|2020-001039-29	April 2, 2020	April 1, 2022	April 1, 2022	April 9, 2020		April 22, 2020	2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, "Latsio", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, "Koutlimbaneio & Triantafylleio" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT04339712
662	NCT04409262	A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia	REMDACTA	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo	Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or "Ready for Hospital Ward") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use	Hoffmann-La Roche|Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	450	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	WA42511|2020-002275-34	June 16, 2020	December 1, 2020	December 1, 2020	June 1, 2020		September 10, 2020	Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St. John's Health Center, Santa Monica, California, United States|Stanford University, Stanford, California, United States|Yale University School of Medicine; HIV Clinical Trials Program, New Haven, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St Luke's Health System; Rheumatology Research, Boise, Idaho, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Medical Center, Novi, Michigan, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|Cone Health Medical Group, Greensboro, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Providence Saint Vincent's Medical Center, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health-Midlands, Columbia, South Carolina, United States|The Liver Institute at Methodist Dallas, Arlington, Texas, United States|Baylor Scott and White Medical Center - College Station, College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Medical Center - Irving, Irving, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, AM, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, Sao Bernardo Do Campo, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil|Medsi Clinic, Moscow, Adygeja, Russian Federation|Clinical Infectious Diseases Hospital #1; Chair of Infectious Disease and Epidemiology, Moskva, Moskovskaja Oblast, Russian Federation|City Clinical Hospital #15, Moscow, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|Pokrovsky City Hosptial, St Petersburg, Russian Federation|Medical Military Academy n.a S.M.Kirov, St.Petersburg, Russian Federation		https://ClinicalTrials.gov/show/NCT04409262
663	NCT04380376	Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia	MICOV	Recruiting	No Results Available	COVID-19|Viral Pneumonia	Drug: Melphalan|Other: Standard of care	The changes of COVID Ordinal Outcomes Scale|Percentage of the patients with Clinical Recovery|The changes of the Borg's scale|CRP level|Lymphocyte count|D-dimer|IL-6|Percentage of patients without artificial lung ventilation	Federal State Budgetary Institution, Pulmonology Scientific Research Institute|Medsi Clinic #1, Moscow|Moscow State University of Medicine and Dentistry	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	PSRI05-20	April 30, 2020	October 30, 2020	October 30, 2020	May 8, 2020		May 12, 2020	Kirill Zykov, Moscow, Russian Federation|Clinical hospital, Moscow, Russian Federation		https://ClinicalTrials.gov/show/NCT04380376
664	NCT04416334	PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS	COLCHI-COVID	Recruiting	No Results Available	SARS-CoV-2 Infection (COVID-19)	Drug: Colchicine plus symptomatic treatment (paracetamol)|Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)	Number of participants who die due to COVID-19 infection|Number of participants who require hospitalization due to COVID-19 infection	Instituto de Investigación Marqués de Valdecilla|Gerencia de atención primaria área 1|Gerencia de atención primaria área 2|Gerencia Atencion Primaria Area 3|Gerencia de atención primaria área 4	All	70 Years and older   (Older Adult)	Phase 3	1028	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COLCHICOVID	May 25, 2020	September 25, 2020	December 31, 2020	June 4, 2020		June 11, 2020	Atención primaria (Área 2), Laredo, Cantabria, Spain|Gerencia de atención primaria (Área 3), Reinosa, Cantabria, Spain|Atencion primaria (AREA 1), Santander, Cantabria, Spain|Gerencia de atención primaria (área 4), Torrelavega, Cantabria, Spain		https://ClinicalTrials.gov/show/NCT04416334
665	NCT04328961	Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)		Active, not recruiting	No Results Available	COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2	Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid	Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion	University of Washington|Bill and Melinda Gates Foundation	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	829	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	STUDY00009750|INV-016204	March 31, 2020	September 30, 2020	October 31, 2020	April 1, 2020		September 7, 2020	University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04328961
666	NCT04363827	Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)	PROTECT	Recruiting	No Results Available	COVID19|Hydroxychloroquine|Prophylaxis|Treatment|SARS-CoV-2	Drug: Hydroxychloroquine	the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.|the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.|The proportion of subjects with positive swabs in Group 1 within 1 month from randomization in both arms|The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization|The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.|The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population|Absolute and relative frequencies of Serious Adverse Events|Variation in Quality of Life scores in different time points	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|University of Bologna	All	18 Years and older   (Adult, Older Adult)	Phase 2	2300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRST100.47	May 14, 2020	September 2020	March 2021	April 27, 2020		June 2, 2020	Irst Irccs, Meldola, FC, Italy		https://ClinicalTrials.gov/show/NCT04363827
667	NCT04425733	MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)		Withdrawn	No Results Available	Coronavirus Disease 2019 (COVID-19)|Pneumonia|Hypoxemia	Drug: MK-5475|Drug: Placebo	Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)|Change From Baseline to Day 1 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)|Change From Baseline to Day 2 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)|Change From Baseline to Day 3 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)|Change From Baseline to Day 4 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)|Change From Baseline to Day 5 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)|Change From Baseline to Day 6 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)|Change From Baseline to Day 7 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)	Merck Sharp & Dohme Corp.	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	5475-009|2020-002062-14|MK-5475-009	July 7, 2020	November 10, 2020	November 10, 2020	June 11, 2020		August 14, 2020			https://ClinicalTrials.gov/show/NCT04425733
668	NCT04335305	Checkpoint Blockade in COVID-19 Pandemic	COPERNICO	Recruiting	No Results Available	COVID-19|Pneumonia, Viral	Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)	Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)	MedSIR	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MedOPP376	April 9, 2020	December 31, 2020	June 30, 2021	April 6, 2020		October 7, 2020	Hospital Quirónsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain		https://ClinicalTrials.gov/show/NCT04335305
669	NCT04338828	Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED	NO COV-ED	Recruiting	No Results Available	COVID19	Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen	Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality	Massachusetts General Hospital|Department of Anesthesia, MGH	All	18 Years and older   (Adult, Older Adult)	Phase 2	260	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2019P00XXXX	April 18, 2020	April 2021	April 2022	April 8, 2020		May 20, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04338828
670	NCT04285190	The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19		Withdrawn	No Results Available	Coronavirus Disease 2019|Novel Coronavirus Pneumonia	Drug: T89	The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment	Tasly Pharmaceuticals, Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T89-NCP-01	February 26, 2020	April 15, 2020	April 20, 2020	February 26, 2020		June 16, 2020			https://ClinicalTrials.gov/show/NCT04285190
671	NCT04517162	Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients		Recruiting	No Results Available	Covid19|Cytokine Storm|Regulation of Inflammatory Response|Pulmonary Fibrosis	Drug: Collagen-Polyvinylpyrrolidone	Clinical primary Outcome measure|Immunological secondary outcome measure	Janette Furuzawa Carballeda|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRE-3412-20-21-1	August 19, 2020	February 19, 2021	June 19, 2021	August 18, 2020		September 3, 2020	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Cdmx, Mexico		https://ClinicalTrials.gov/show/NCT04517162
672	NCT04409483	Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger	TRASCOV	Withdrawn	No Results Available	Covid-19	Drug: Lopinavir-Ritonavir Drug Combination|Combination Product: Standard Care	Hospitalization or death|All-cause mortality|Time to hospitalization|Length of hospitalization|Admission to intensive care|Adverse events|Serious adverse events	Epicentre|Université Abdou Moumouni|Centre de Recherche Médicale et Sanitaire|Ministry of Public Health, Republic of Niger	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Trascov	June 1, 2020	December 31, 2020	December 31, 2021	June 1, 2020		June 29, 2020			https://ClinicalTrials.gov/show/NCT04409483
673	NCT04384380	Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19		Completed	No Results Available	Coronavirus Infection	Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]	Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Taoyuan General Hospital|Center for Drug Evaluation, Taiwan|Centers for Disease Control, Taiwan|Taiwan Food and Drug Administration|National Health Research Institutes, Taiwan	All	20 Years to 79 Years   (Adult, Older Adult)	Not Applicable	33	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TYGH109014	April 1, 2020	May 31, 2020	May 31, 2020	May 12, 2020		August 4, 2020	Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04384380/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT04384380
674	NCT04374461	A Study of N-acetylcysteine in Patients With COVID-19 Infection		Recruiting	No Results Available	Covid-19	Drug: N-acetylcysteine|Other: Peripheral Blood	Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement	Memorial Sloan Kettering Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	84	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-168	May 1, 2020	May 2021	May 2021	May 5, 2020		October 2, 2020	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04374461
675	NCT04537585	COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7	Tomeka	Not yet recruiting	No Results Available	Covid19	Combination Product: Tomeka®|Drug: "Vernonia amygdalina"	Number of participants with treatment-TOMEKA® usage|Change From Baseline in herbs Vernonia amygdalina usage	Guyguy K Tshima, MD|Centre Médical de Kinshasa (CMK)|University of Kinshasa	All	15 Years to 65 Years   (Child, Adult, Older Adult)	Not Applicable	2000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	TOMEKA	November 2020	November 2022	December 2022	September 3, 2020		September 3, 2020	Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the		https://ClinicalTrials.gov/show/NCT04537585
676	NCT04480138	Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)		Recruiting	No Results Available	Covid19	Drug: Pegylated Interferon-α2b|Other: Standard of Care	Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer|Interferon gamma|Ferritin|TNF alpha|Interleukin 1-β	Cadila Healthcare Limited	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PEGI.20.003	August 11, 2020	December 15, 2020	January 30, 2021	July 21, 2020		August 13, 2020	Avant Sante Site 1, Monterrey, Mexico		https://ClinicalTrials.gov/show/NCT04480138
677	NCT04435587	Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection	IDRA-COVID19	Not yet recruiting	No Results Available	Asymptomatic Infections|SARS-CoV2 Infection	Drug: Ivermectin Pill|Drug: Combined ART/hydroxychloroquine	Adverse event rates|Efficacy for shortening duration of SAR-CoV2 detection by PCR|Antibody detection rates	Mahidol University	All	18 Years and older   (Adult, Older Adult)	Phase 4	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	323/2563 (IRB3)	July 2020	June 2021	November 2021	June 17, 2020		June 23, 2020	Siriraj Hospital, Bangkok Noi, Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT04435587
678	NCT04357366	suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	SAVE	Recruiting	No Results Available	COVID-19|Virus Diseases|Corona Virus Infection|Lower Respiratory Tract Infection Viral	Drug: Anakinra|Drug: trimethoprim/sulfamethoxazole	The ratio of patients who will not develop serious respiratory failure (SRF)|Comparison of the rate of patients who will not develop serious respiratory failure (SRF) until day 14 with historical comparators from Hellenic Sepsis Study Group Database|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14|Change of SOFA score in enrolled subjects between days 1 and 7|Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14|Change of cytokine production between days 1 and 7|Change of plasma inflammatory mediators levels between days 1 and 7|Rate of Mortality	Hellenic Institute for the Study of Sepsis	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	SAVE|2020-001466-11	April 15, 2020	April 15, 2022	April 15, 2022	April 22, 2020		September 28, 2020	COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|1st Department of InternalMedicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|1st University Departmentof Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseasesof Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|Department of Internal Medicine, General Hospital of Katerini, Kateríni, Greece|Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece		https://ClinicalTrials.gov/show/NCT04357366
679	NCT04374487	Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications		Active, not recruiting	No Results Available	COVID 19	Drug: Convalescent Plasma|Other: Standard Care Therapy	The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor use	Max Healthcare Insititute Limited	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MHC-COVID-19-CP	May 9, 2020	August 9, 2021	August 9, 2021	May 5, 2020		July 22, 2020	Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India		https://ClinicalTrials.gov/show/NCT04374487
680	NCT04558021	A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19	NICLONEX	Recruiting	No Results Available	Covid19	Drug: Niclosamide suspension|Other: Placebo	Physician's judgment on clinical recovery from the time of admission|Clinical improvement in NEWS2|Improvement in serum biomarkers|Requirement for indotracheal intubation|Occurrence of Macrophage Activation Syndrome(MAS)|Occurrence of Coagulopathy	Imuneks Farma ilac San. Tic. A.S.	All	18 Years and older   (Adult, Older Adult)	Phase 3	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	NOV2020/01930	September 28, 2020	December 30, 2020	January 7, 2021	September 22, 2020		September 22, 2020	Akdeniz Üniversitesi Tıp Fakültesi Hastanesi, Antalya, Turkey|Antalya Eğitim ve Araştırma Hastanesi, Antalya, Turkey|Gaziantep Üniversitesi Tıp Fakültesi Hastanesi, Gaziantep, Turkey|Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi, Istanbul, Turkey|Dokuz Eylül Üniversitesi Hastanesi, İzmir, Turkey|İzmir SBÜ Tepecik Eğitim ve Araştırma Hastanesi, İzmir, Turkey|SBÜ Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi, İzmir, Turkey|İzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi, İzmir, Turkey		https://ClinicalTrials.gov/show/NCT04558021
681	NCT04558125	Low-Dose Tenecteplase in Covid-19		Active, not recruiting	No Results Available	Pulmonary Embolism|COVID	Drug: TNKase	Percent improvement in shock index (HR/SBP) 6 hours after the TNK/placebo bolus.|1. Clinical status at 24 hours after administration of TNK / placebo based upon 7-point scale.	Cedars-Sinai Medical Center	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	45	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ML42522	September 8, 2020	December 31, 2021	June 30, 2022	September 22, 2020		September 22, 2020	Cedars-Sinai Medical Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04558125
682	NCT04440007	Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19	SOC	Not yet recruiting	No Results Available	Covid-19	Drug: Abivertinib|Other: Standard of Care	Proportion of subjects alive and free of respiratory failure at Day 14|Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)|Proportion of subjects alive and free of respiratory failure at Day 28|Change in clinical status|Discharge from ICU|Time to respiratory failure or death	Sorrento Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STI-5656-2001	August 2020	January 2021	March 2021	June 19, 2020		June 25, 2020			https://ClinicalTrials.gov/show/NCT04440007
683	NCT04412057	Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury		Recruiting	No Results Available	COVID-19 Pneumonia|Acute Lung Injury|ARDS	Drug: CERC-002|Drug: Placebo	Proportion of patient alive and free of respiratory failure|Proportion of subjects who are alive	Aevi Genomic Medicine, LLC, a Cerecor company|Cerecor Inc	All	18 Years and older   (Adult, Older Adult)	Phase 2	82	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CERC-002-CVID-201	June 9, 2020	October 2020	November 2020	June 2, 2020		October 1, 2020	Hoag Memorial Hospital, Newport Beach, California, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Parkview Research Center, Fort Wayne, Indiana, United States|MedPharmics, LLC, Metairie, Louisiana, United States|LSUHSC - Shreveport, Shreveport, Louisiana, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|AnMed Health Medical Center, Anderson, South Carolina, United States|Lowcountry Infectious Diseases, P.A., Charleston, South Carolina, United States|BRCR Global Texas, McAllen, Texas, United States		https://ClinicalTrials.gov/show/NCT04412057
684	NCT04560205	Tocilizumab in COVID-19 Lahore General Hospital	TC19LGH	Recruiting	No Results Available	SARS-CoV Infection	Drug: Tocilizumab	Clinical response after administration|Clinical response to treatment|Duration of hospitalization|Clinical outcome of the treatment|Supplemental Oxygen Requirement from Baseline	Lahore General Hospital	All	15 Years to 80 Years   (Child, Adult, Older Adult)	Phase 1	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LGH001	May 1, 2020	October 30, 2020	October 30, 2020	September 23, 2020		September 23, 2020	Lahore General Hospital, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04560205
685	NCT04311697	Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure	COVID-AIV	Recruiting	No Results Available	Critical COVID-19 With Respiratory Failure|Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection|Acute Lung Injury	Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care	Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days|Days free of Respiratory Failure	NeuroRx, Inc.|Lavin Consulting, LLC|International Business Machines (IBM)	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	144	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID-AIV	May 15, 2020	August 2020	September 2020	March 17, 2020		August 31, 2020	University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Houston Methodist Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04311697
686	NCT04354441	Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women	HyPreC	Withdrawn	No Results Available	COVID-19|SARS-CoV-2|Pregnant Women|Hydroxychloroquine	Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet	COVID-19-related hospital admissions|Symptoms related to COVID-19 infection|Adverse Events|Maternal outcomes|Newborn outcomes	Sir Mortimer B. Davis - Jewish General Hospital	Female	18 Years to 50 Years   (Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	1, March 30, 2020	May 2020	May 2020	May 2020	April 21, 2020		June 25, 2020			https://ClinicalTrials.gov/show/NCT04354441
687	NCT04492475	Adaptive COVID-19 Treatment Trial 3 (ACTT-3)		Recruiting	No Results Available	COVID-19	Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir	Time to recovery|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in hemoglobin|Change from baseline in international normalized ratio (INR)|Change from baseline in platelets|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of invasive mechanical ventilation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of non invasive ventilation/high flow oxygen use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Time to recovery for participants not on mechanical ventilation (baseline ordinal score of 4, 5, or 6)	National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	1038	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-0006 ACTT-3	August 4, 2020	November 1, 2023	November 1, 2023	July 30, 2020		October 8, 2020	University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04492475
688	NCT04344457	Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19	COVID-19	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product	Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement	Perseverance Research Center, LLC|Athena Medical Group	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	80	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIZ-PRC-COVID-19	April 16, 2020	June 20, 2020	September 30, 2020	April 14, 2020		July 1, 2020	Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States		https://ClinicalTrials.gov/show/NCT04344457
689	NCT04519125	Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia		Not yet recruiting	No Results Available	Severe Acute Respiratory Syndrome Coronavirus 2|COVID-19	Drug: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Other: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)	SARS-CoV-2 infection|Serious and non-serious adverse events|Discontinuation of using TDF/FTC for any reason|Adherence to TDF/FTC|Severity of SARS-CoV-2 infection	Hospital Universitario San Ignacio|Pontificia Universidad Javeriana|Hospital Universitario Nacional de Colombia|Hospital de la Samaritana, Sede Bogotá y Sede Zipaquirá|Hospital Universitario San Jorge, Pereira.|Fundación Universitaria Autónoma de Las Américas|Universidad Tecnológica de Pereira|Colsanitas	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2|Phase 3	950	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	2020 /143|77389	August 30, 2020	December 31, 2020	April 1, 2021	August 19, 2020		August 19, 2020		"Study Protocol, Statistical Analysis Plan, and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/25/NCT04519125/Prot_SAP_ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04519125
690	NCT04530617	Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients		Not yet recruiting	No Results Available	Covid19|Diabetes|Hypertension|Obesity	Drug: Camostat Mesilate|Drug: Artemisia Annua Leaf	Rate of hospitalizations and oxygen use	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Instituto Nacional de Cardiologia Ignacio Chavez|Hospital General de Mexico|Hospital General Dr. Manuel Gea González	All	18 Years and older   (Adult, Older Adult)	Phase 2	360	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	3421	September 2020	January 2021	February 2021	August 28, 2020		September 3, 2020			https://ClinicalTrials.gov/show/NCT04530617
691	NCT04399356	Niclosamide for Mild to Moderate COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring	Change in respiratory viral clearance (by PCR)|Fecal viral clearance (by PCR)|Reduction (change) in respiratory viral shedding (by PCR)|Reduction (change) in GI viral shedding (by PCR)|Progression to severe COVID-19 Disease|Time to resolution of a fever	Tufts Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	STUDY00000605	October 12, 2020	January 1, 2021	February 12, 2021	May 22, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04399356
692	NCT04352933	PROLIFIC ChemoprophylaxisTrial (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine	Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm	Cambridge University Hospitals NHS Foundation Trust	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PROLIFIC2020 (A095583)	May 11, 2020	October 31, 2020	April 2021	April 20, 2020		May 13, 2020	Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom		https://ClinicalTrials.gov/show/NCT04352933
693	NCT04475588	Efficacy and Safety of Itolizumab in COVID-19 Complications		Completed	No Results Available	Acute Respiratory Distress Syndrome|Cytokine Release Syndrome|Covid19	Drug: Itolizumab IV infusion|Drug: Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy	One-month mortality rate between the two arms|Biomarkers (IL-6, TNF-a, IL1, IL17, etc…)|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Radiological response|Duration of hospitalization|Remission of respiratory symptoms	Biocon Limited	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ITOLI-C19-02-I-00	May 1, 2020	July 8, 2020	July 8, 2020	July 17, 2020		July 17, 2020	Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai, India|Seth GS Medical College and KEM Hospital, Mumbai, India|MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi, India|All India Institute Of Medical Sciences, New Delhi, India		https://ClinicalTrials.gov/show/NCT04475588
694	NCT04363203	VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)	VA-REACH	Suspended	No Results Available	SARS-CoV-2|COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet	Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization	Salomeh Keyhani MD|San Francisco VA Health Care System	All	216 Months and older   (Adult, Older Adult)	Phase 3	300	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20-30517	April 30, 2020	March 2021	August 2021	April 27, 2020		June 22, 2020	San Francisco VA, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04363203
695	NCT04409509	Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)	Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo	The incidence of tracheal intubation or death prior to tracheal intubation|Proportion of subjects with death from all causes|Proportion of subjects intubated|Number and proportion of subjects with ≥ 2-point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale|Number and proportion of subjects within each of the categories of the NIAID|Proportion of subjects requiring continuous positive airway pressure (CPAP)|Proportion of subjects requiring bilevel positive airway pressure (BiPAP)|Proportion of subjects requiring high-flow nasal cannula (HFNC)|Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO)|Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score|Change from Baseline in SOFA score and in the individual components of SOFA score|Length of hospital stay|Number and proportion of subjects experiencing Adverse Events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects with adverse events of special interest (AESIs)|Number and proportion of subjects with CSL312 induced anti-CSL312 antibodies|Maximum plasma concentration (Cmax) of CSL312|Time to maximum plasma concentration (Tmax) of CSL312|Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last) of CSL312|Terminal half-life (T1/2) of CSL312	CSL Behring	All	18 Years and older   (Adult, Older Adult)	Phase 2	124	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CSL312_COVID-19	July 1, 2020	December 2020	December 2020	June 1, 2020		September 30, 2020	Nova Clinical Research, LLC, Bradenton, Florida, United States|Theia Clinical Research, LLC, Saint Petersburg, Florida, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Inspira Health Center Vineland, Vineland, New Jersey, United States|Sisters of Charity Hospital/ St. Joseph's Campus, Buffalo, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Monument Health Clinical Research, Rapid City, South Dakota, United States|PharmaTex Research, Amarillo, Texas, United States|UT Health Science Center, McGovern Medical School, Houston, Texas, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States		https://ClinicalTrials.gov/show/NCT04409509
696	NCT04473053	Rapid Experimental Medicine for COVID-19	DEFINE	Recruiting	No Results Available	COVID-19	Drug: Nafamostat Mesilate|Drug: TD139|Other: Standard care	The safety of the candidate therapies in COVID-19 patients by measuring physiological changes in the circulatory and respiratory system.|The safety of the candidate therapies in COVID-19 patients by recording the number of treatment related adverse events.|Measuring the PK of the proposed trial treatments in COVID-19 patients.|Measure a change in the expression of key coagulation biomarkers in the blood of COVID-19 patients during and after treatment period.|Measure a change in the expression of key cytokines in the blood of COVID-19 patients during and after treatment period.|To evaluate the improvement or deteroriation of patients in each treatment arm.|To evaluate the number of oxygen-free days.|To evaluate incidence of any form of new ventilation use.|To evaluate ventilator-free days|Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2/FiO2)|To evaluate SARS-CoV-2 viral load.|To evaluate time to discharge|To evaluate the use of renal dialysis or haemofiltration for each treatment arm.	University of Edinburgh|University of Oxford|Latus Therapeutics	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	AC20063	July 3, 2020	July 3, 2021	December 3, 2021	July 16, 2020		August 21, 2020	NHS Lothian, Edinburgh, United Kingdom		https://ClinicalTrials.gov/show/NCT04473053
697	NCT04483973	SPI-1005 Treatment in Severe COVID-19 Patients		Not yet recruiting	No Results Available	Covid19|Coronavirus|Coronavirus Infection|Corona Virus Infection	Drug: Ebselen|Drug: Placebo	Number of participants with treatment-related adverse events|WHO Ordinal Scale|Degree of supplemental oxygen|Peripheral Oxygen Saturation (SpO2)	Sound Pharmaceuticals, Incorporated	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SPI-1005-292	August 2020	December 2020	December 2020	July 23, 2020		July 23, 2020			https://ClinicalTrials.gov/show/NCT04483973
698	NCT04332380	Convalescent Plasma for Patients With COVID-19: A Pilot Study	CP-COVID-19	Completed	No Results Available	Coronavirus|Coronavirus Infection	Drug: Plasma	Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality	Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud	All	18 Years to 60 Years   (Adult)	Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABN011-1	May 1, 2020	July 28, 2020	July 28, 2020	April 2, 2020		August 17, 2020	Universidad del Rosario, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04332380
699	NCT04484025	SPI-1005 Treatment in Moderate COVID-19 Patients		Not yet recruiting	No Results Available	Covid19|Corona Virus Infection|Coronavirus|Coronavirus Infection	Drug: Ebselen|Drug: Placebo	Number of participants with treatment-related adverse events|WHO Ordinal Scale|Degree of supplemental oxygen|Peripheral Oxygen Saturation (SpO2)	Sound Pharmaceuticals, Incorporated	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SPI-1005-291	August 2020	December 2020	December 2020	July 23, 2020		July 23, 2020			https://ClinicalTrials.gov/show/NCT04484025
700	NCT04303507	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting	COPCOV	Recruiting	No Results Available	COVID19|Coronavirus|Acute Respiratory Illnesses	Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo	Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses	University of Oxford	All	16 Years and older   (Child, Adult, Older Adult)	Not Applicable	40000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	VIR20001	April 29, 2020	April 2021	April 2021	March 11, 2020		October 2, 2020	RSUPN Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia|Istituto Sacro Cuore Don Calabria, Negrar, Negrar Di Valpolicella VR, Italy|Mahosot hospital, Vientiane, Lao People's Democratic Republic|The Aga Khan University Hospital, Karachi, Pakistan|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|University Hospitals Of Morecambe Bay NHS Foundation Trust, Kendal, Cumbria, United Kingdom|Torbay and South Devon NHS Foundation Trust, Torquay, Devon, United Kingdom|The Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom|West Hertfordshire Hospitals NHS Trust, Watford, Hertfordshire, United Kingdom|Lewisham and Greenwich NHS Trust, Woolwich, London, United Kingdom|Sherwood Forest Hospitals NHS Foundation Trust, Sutton In Ashfield, Nottinghamshire, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT04303507
701	NCT04345419	Remdesivir vs Chloroquine in Covid 19		Recruiting	No Results Available	COVID	Drug: Chloroquine or hydroxychloroquine|Drug: Remdesivir	Number of patients with improvement or mortality	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	COVID 19 treatment	June 16, 2020	December 2029	December 2029	April 14, 2020		August 18, 2020	Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04345419
702	NCT04547140	Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)		Not yet recruiting	No Results Available	COVID-19	Biological: Liquid Alpha1-Proteinase Inhibitor (Human)|Drug: Placebo|Drug: Standard Medical Treatment	Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression	Grifols Therapeutics LLC	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GC2006	September 2020	April 2021	September 2021	September 14, 2020		September 14, 2020			https://ClinicalTrials.gov/show/NCT04547140
703	NCT04412668	Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19		Recruiting	No Results Available	SARS-CoV-2 (COVID-19) Severe Pneumonia	Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo	Incidence of treatment-emergent adverse events (TEAEs)|Time to normalization of oxygen saturation (SpO2) (>93% on room air sustained for at least 24 hours)|Duration of supplemental oxygen (O2) requirement|Number of days with fever (temperature >100.4ºF [38.0ºC])|Time to normalization of temperature (≤100.4ºF [38.0ºC])|Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60|Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score	aTyr Pharma, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ATYR1923-C-003	June 12, 2020	October 31, 2020	October 31, 2020	June 2, 2020		October 7, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States|aTyr Investigative Site, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|University of Iowa, Iowa City, Iowa, United States|aTyr Investigative Site, Vineland, New Jersey, United States|aTyr Investigative Site, Toledo, Ohio, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Manati Medical Center, Manatí, Puerto Rico		https://ClinicalTrials.gov/show/NCT04412668
704	NCT04401579	Adaptive COVID-19 Treatment Trial 2 (ACTT-2)		Active, not recruiting	No Results Available	COVID-19	Other: Placebo|Drug: Remdesivir|Drug: Baricitinib	Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Change from baseline in C-reactive protein (CRP)|Change from baseline in d-dimer concentration	National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	1034	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-0006 ACTT-2	May 8, 2020	August 1, 2023	August 1, 2023	May 26, 2020		August 13, 2020	University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Hospital Clinico San Carlos - Enfermedades Infecciosas, Madrid, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, City Of London, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04401579
705	NCT04379271	A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: IMU-838|Other: Placebo	Proportion of patients without any need* for INV until end-of-study (EoS)|Duration of ICU treatment until EoS|28-day all-cause mortality|Time to clinical improvement|Duration of hospitalization|Proportion of patients both for all patients and surviving patients free of renal-replacement therapy (RRT)* until EoS|Proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)* until EoS|Proportion of patients free of INV until Days 6 and 14*|Proportion of patients free of RRT until Days 6 and 14*|Proportion of patients free ECMO until Days 6 and 14*|Proportion of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28|Proportion of patients with clinical recovery: Axillary temperature ≤36.6 ℃, or oral temperature ≤37.2 ℃, or rectal or tympanic temperature ≤37.8 ℃;|Proportion of patients with clinical recovery: Respiratory frequency ≤24 times/min without oxygen inhalation; and|Proportion of patients with clinical recovery: Oxygen saturation ≥98% without oxygen inhalation|Proportion of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first|Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Duration of INV|Duration of ECMO|Duration of RRT|Duration of auxiliary oxygen therapy (including all types of oxygen therapy)|Duration of hospitalization for survivors|The rate of ICU* admission on Days 6, 14, and 28|Hospital-free days|Time from IMP treatment initiation to death|Time to first prescription of INV|Time to first prescription of RRT|Time to first prescription of ECMO|Time to first prescription of INV, RRT, and ECMO|Time to ICU admission|Cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until Day 14)|Time to clinical recovery|Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28|Correlation of trough levels (quartiles) to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Adverse events (AEs) and serious AEs|Vital signs: height|Vital signs: weight|Vital signs: body temperature (ºC)|Vital signs: pulse rates,|Vital signs: systolic and diastolic blood pressures|Clinical laboratory parameters: blood chemistry|Clinical laboratory parameters: hematology|Clinical laboratory parameters: urinalysis|12-lead electrocardiogram: heart rate|12-lead electrocardiogram: PQ-interval|12-lead electrocardiogram: QRS-interval|12-lead electrocardiogram: QT interval|12-lead electrocardiogram: the heart rate-corrected QTc interval (according to Bazett's formula)|Temperature|D-dimer|Lactate dehydrogenase (LDH)|C-reactive protein|Troponin I|Procalcitonin|Correlation of disease markers to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Decrease of SARS-CoV-2 viral load|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load|Qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative SARS-CoV-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)|Rate of conversion to a negative SARS-CoV-2 (qualitative) test on Days 6, 14 and 28|Time to conversion to a negative SARS-CoV-2 (qualitative) test|Interleukin (IL)-17|Interleukin (IL)-1ß|Interleukin (IL)-6|interferon gamma (IFNγ)|tumor necrosis factor alpha|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: • Time to appearance of IgA and/or IgG antibodies|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: • Proportion of patients with IgA and/or IgG antibodies on Days 6, 14, and 28	Immunic AG|FGK Clinical Research GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	230	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	P2-IMU-838-COV	June 11, 2020	September 2020	October 2020	May 7, 2020		July 1, 2020	Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria|UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria|University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany|Clinic of the Hannover Medical School, Pneumology Clinic, Hannover, Germany		https://ClinicalTrials.gov/show/NCT04379271
706	NCT04360122	Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19		Not yet recruiting	No Results Available	Coronavirus Disease (COVID-19)	Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine	Decrease the incidence of COVID-19 infection or its severity	Ain Shams University	All	18 Years and older   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	FMASU P20a/ 2020	May 20, 2020	November 1, 2020	December 1, 2020	April 24, 2020		May 5, 2020	Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt		https://ClinicalTrials.gov/show/NCT04360122
707	NCT04537663	Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults	BCG-PRIME	Recruiting	No Results Available	Respiratory Tract Infections|Covid19	Drug: Bacille Calmette-Guérin (BCG)|Drug: Placebo	The trial has an adaptive primary endpoint. Based on predefined objective and quantitative criteria the primary endpoint will be either a clinically relevant respiratory tract infection, or COVID-19.|Cumulative incidence of SARS-CoV-2 infection (irrespective the presence of symptoms)|Cumulative incidence of asymptomatic, mild/moderate, and severe (requiring hospitalization) SARS-CoV-2 infection.|Influenza infection|An acute respiratory tract infection|Medically attended acute respiratory tract infection|Acute respiratory tract infection related hospital admission|Pneumonia diagnosed by a GP or medical specialist|Functioning in daily activities|Serious adverse events and adverse events.|Major cardiovascular events|All cause 6-month mortality|History of falls|Quality of life using the EQ5D quality of life instrument|Activities in daily living	UMC Utrecht	All	60 Years and older   (Adult, Older Adult)	Phase 4	5200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	BCG-PRIME	August 25, 2020	November 2020	April 2021	September 3, 2020		September 3, 2020	Meander Medical Center, Amersfoort, Netherlands|Amsterdam University Medical Center, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Amphia hospital, Breda, Netherlands|Hagahospital, Den Haag, Netherlands|Catharina hospital, Eindhoven, Netherlands|Zuyderland Hospital, Geleen, Netherlands|Martini hospital, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|St. Antonius hospital, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Ikazia Hospital, Rotterdam, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Bernhoven hospital, Uden, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT04537663
708	NCT04358081	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease		Completed	No Results Available	Covid-19	Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo	Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 3	20	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CJWT629A12301	May 1, 2020	July 27, 2020	July 27, 2020	April 22, 2020		October 1, 2020	Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04358081
709	NCT04373044	Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19		Recruiting	No Results Available	Symptomatic COVID-19 Infection Laboratory-Confirmed	Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration	Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events	University of Southern California|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	144	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	0S-20-3|NCI-2020-02685|P30CA014089	May 1, 2020	May 1, 2021	May 1, 2022	May 4, 2020		June 2, 2020	Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04373044
710	NCT04391179	Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19	DICER	Recruiting	No Results Available	COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection	Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet	Change in D-dimer|Global composite rank score	University of Michigan	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	HUM00179783	May 31, 2020	December 2020	December 2020	May 18, 2020		July 31, 2020	North Shore UniversityHealth, Evanston, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04391179
711	NCT04355676	Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19		Not yet recruiting	No Results Available	Coronavirus Infection	Drug: Selinexor	Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged From Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Number of Participants with Adverse Events (AE)	Karyopharm Therapeutics Inc	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XPORT-CoV-1002	April 30, 2020	August 30, 2020	August 30, 2020	April 21, 2020		April 21, 2020			https://ClinicalTrials.gov/show/NCT04355676
712	NCT04410159	Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients	GARGLES	Completed	Has Results	COVID-19	Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water	Number of Participants With Early Viral Clearance|Number of Participants With Negative RT-PCR Results|Number of Patients That Progress to More Severe Disease|Number of Patients With Abnormal Radiological Findings|Number of Patients With Abnormal Laboratory Findings	Universiti Sains Islam Malaysia|Universiti Kebangsaan Malaysia Medical Centre	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	USIMalaysia	June 22, 2020	June 29, 2020	July 6, 2020	June 1, 2020	July 21, 2020	July 21, 2020	Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia	"Study Protocol, Statistical Analysis Plan, and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/59/NCT04410159/Prot_SAP_ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04410159
713	NCT04486313	Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19		Recruiting	No Results Available	COVID-19	Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex	Reducing the Time to Sustained Response|Reducing the Rate of Progression	Romark Laboratories L.C.	All	12 Years to 120 Years   (Child, Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	RM08-3008	August 13, 2020	December 30, 2020	December 30, 2020	July 24, 2020		September 29, 2020	Invesclinic US LLC, Fort Lauderdale, Florida, United States|RH Medical Urgent Care, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT04486313
714	NCT04362332	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19	ARCHAIC	Terminated	No Results Available	COVID-19	Drug: Chloroquine Sulfate|Drug: Hydroxychloroquine|Other: Standard supportive care	Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.|Side effects	UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development	All	18 Years to 110 Years   (Adult, Older Adult)	Phase 4	25	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL73529.041.20 versie 3	April 14, 2020	June 8, 2020	June 8, 2020	April 24, 2020		June 19, 2020	UMCU, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT04362332
715	NCT04328480	The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.	COLCOVID	Recruiting	No Results Available	COVID-19	Drug: Colchicine|Other: Local standard of care	All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.	Estudios Clínicos Latino América|Population Health Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 3	2500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COLCOVID version1.2	April 17, 2020	June 30, 2020	August 30, 2020	March 31, 2020		April 30, 2020	Sanatorio Parque, Rosario, Santa Fe, Argentina		https://ClinicalTrials.gov/show/NCT04328480
716	NCT04466280	Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Mucodentol|Device: Personal protective equipment	PCR test|Laboratory Treatment Response|drug reactions Adverse|Allergic drug|Radiological Treatment Response	Baqiyatallah Medical Sciences University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	IR.BMSU.REC.1399.086	July 15, 2020	November 15, 2020	December 15, 2020	July 10, 2020		July 10, 2020	Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04466280
717	NCT04343989	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection		Recruiting	No Results Available	COVID-19	Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo	Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient Survival	NYU Langone Health	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	s20-00392	March 31, 2020	July 1, 2020	July 1, 2020	April 14, 2020		May 6, 2020	New York University School of Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04343989
718	NCT04357028	Measles Vaccine in HCW	MV-COVID19	Recruiting	No Results Available	Covid19	Drug: Measles-Mumps-Rubella Vaccine|Drug: Placebos	COVID-19 disease incidence|SARS-CoV-2 pneumonia|Critical care admission duration with SARS-CoV-2|Oxygen therapy with SARS-CoV-2	Kasr El Aini Hospital	All	18 Years to 50 Years   (Adult)	Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	N-30-2020	July 13, 2020	October 1, 2020	November 1, 2020	April 22, 2020		July 16, 2020	Cairo University Hospital, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04357028
719	NCT04380519	Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)		Completed	No Results Available	COVID-19	Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo	Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19	R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2|Phase 3	372	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CL04041078	April 23, 2020	July 10, 2020	July 24, 2020	May 8, 2020		September 29, 2020	Federal State Budget Institution "National Medical Surgery Center named after N.I. Pirogov" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution "City Clinical Hospital № 15 named after O.M. Filatov" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution "Federal Center for Cerebrovascular Pathology and Stroke" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution "National Medicine Research Center on Cardiology" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare "City Clinical Hospital #52", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare "Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare", Moscow, Russian Federation|State Budget Healthcare Institution "City Clinical Hospital #40", Moscow City Healthcare Department, "Communarca" Division, Moscow, Russian Federation|АО "State Company "Medsi" based on Clinical Hospital №1", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare "Clinical infectious diseases hospital named after S.P. Botkin", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare "City Hospital №40", Saint Petersburg, Russian Federation		https://ClinicalTrials.gov/show/NCT04380519
720	NCT04433988	Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients		Not yet recruiting	No Results Available	COVID	Drug: Pentoxifylline|Drug: Placebo	Primary Outcome|Respiratory infection|Serious Adverse Events	Sadat City University	All	18 Years to 60 Years   (Adult)	Phase 1|Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	RC-6-2020	December 13, 2020	December 30, 2020	December 30, 2020	June 16, 2020		October 6, 2020	Faculty of Medicine, Shibīn Al Kawm, Egypt		https://ClinicalTrials.gov/show/NCT04433988
721	NCT04346329	Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19	Chloroquine UN	Not yet recruiting	No Results Available	COVID	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Adverse effects|Immune-score|COVID-19 prevention|Clinical response	Universidad Nacional de Colombia|Fundación Salud de los Andes	All	18 Years and older   (Adult, Older Adult)	Phase 3	86	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention	UNAL-COVID-CP	April 20, 2020	June 1, 2020	October 1, 2020	April 15, 2020		April 15, 2020	Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04346329
722	NCT04354259	Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19	ILIAD	Recruiting	No Results Available	Sars-CoV2|Covid-19	Drug: Peginterferon Lambda-1A|Other: placebo	Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint)|Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint)|Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint)|Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)|Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1)|Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2)|Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3)|Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4)|Cohort A (Ambulatory) - Swab negative at day 3 (Virologic/Immunological Outcome #1)|Cohort A (Ambulatory) - Time RNA negativity (Virologic/Immunological Outcome #2)|Cohort A (Ambulatory) - Proportion viremic (Virologic/Immunological Outcome #3)|Cohort A (Ambulatory) - Proportion with antibodies (Virologic/Immunological Outcome #4)|Cohort A (Ambulatory) - Correlation with interferon lambda 4 genotype (Virologic/Immunological Outcome #5)|Cohort A (Ambulatory) - Symptoms in household contacts (Transmission Outcome #1)|Cohort A (Ambulatory) - COVID-19 in household contacts (Transmission Outcome #2)|Cohort B (Hospitalized) - ICU admission (Clinical Outcome #1)|Cohort B (Hospitalized) - Need for intubation (Clinical Outcome #2)|Cohort B (Hospitalized) - Length of hospital stay (Clinical Outcome #3)|Cohort B (Hospitalized) - Change in respiratory symptom score (Clinical Outcome #4)|Cohort B (Hospitalized) - Readmission to hospital (Clinical Outcome #5)|Cohort B (Hospitalized) - All-cause mortality (Clinical Outcome #6)|Cohort B (Hospitalized) - COVID-19-related mortality (Clinical Outcome #7)|Cohort B (Hospitalized) - Adverse (AEs) and Serious Adverse Events (SAEs) (Clinical Outcome #8)|Cohort B (Hospitalized) - Dose reduction or dose omission (Clinical Outcome #9)|Cohort B (Hospitalized) - Proportion negative swab. (Virologic/Immunological Outcome #1)|Cohort B (Hospitalized) - Proportion negative by day 14 (Virologic/Immunological Outcome) #2)|Cohort B (Hospitalized) - Time to negativity by rectal swab (Virologic/Immunological Outcome #3)|Cohort B (Hospitalized) - Correlation with interferon lambda 4 (IFNL4) genotype (Virologic/Immunological Outcome #4)|Cohort B (Hospitalized) - Proportion with Antibody (Virologic/Immunological Outcome #6)|Cohort B (Hospitalized) - Proportion with viremia (Virologic/Immunological Outcome #7)	University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	Phase 2	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	JF-4-2020	May 13, 2020	August 1, 2020	November 30, 2020	April 21, 2020		May 18, 2020	Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04354259
723	NCT04366271	Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19	MESCEL-COVID19	Recruiting	No Results Available	COVID	Biological: Mesenchymal cells|Drug: Standard of care	Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events	Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 2	106	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MESCEL-COVID19|2020-001450-22	May 7, 2020	July 31, 2020	May 31, 2021	April 28, 2020		May 11, 2020	Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04366271
724	NCT04565249	Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19		Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome|SARS-CoV-2	Drug: PLN-74809|Drug: Placebo	Number of participants with treatment-related adverse events and laboratory abnormalities, assessed by CTCAE V5.0|Assessment of PLN-74809 plasma concentrations	Pliant Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PLN-74809-ARDS-204	September 21, 2020	August 31, 2021	October 31, 2021	September 25, 2020		September 25, 2020			https://ClinicalTrials.gov/show/NCT04565249
725	NCT04438850	COVidIVERmectin: Ivermectin for Treatment of Covid-19	COVER	Recruiting	No Results Available	Covid19	Drug: Ivermectin|Other: Placebo	SADR|Viral load|Trend viral load|Clinical resolution|Viral clearance|Virological clearance|hospitalization rate|Severity score	IRCCS Sacro Cuore Don Calabria di Negrar|Istituto Di Ricerche Farmacologiche Mario Negri	All	18 Years and older   (Adult, Older Adult)	Phase 2	102	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	cover_1	July 31, 2020	August 2020	October 2020	June 19, 2020		August 13, 2020	IRCCS Sacro Cuore Don Calabria hospital, Negrar, Verona, Italy|Policlinico S. Orsola, Bologna, Italy|Ospedale Luigi Sacco, Milan, Italy|Ospedale di Rovereto, Rovereto, Italy|Ospedale Amedeo di Savoia, Turin, Italy|Hospital Clinic/ISGlobal, Barcelona, Spain|Hospital La Paz-Carlos III, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04438850
726	NCT04352946	HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial	HERO	Not yet recruiting	No Results Available	Prophylaxis|COVID-19|Health Care Worker|Hydroxychloroquine	Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet	Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost	GeoSentinel Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 3	374	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	GFICOVID-19-1	April 24, 2020	June 24, 2020	August 24, 2020	April 20, 2020		April 22, 2020	The New York Center for Travel and Tropical Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04352946
727	NCT04366115	Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS	AVM0703	Not yet recruiting	No Results Available	Covid19|Acute Respiratory Distress Syndrome	Drug: AVM0703|Drug: Placebo|Drug: hydrocortisone	Dose-Limiting Toxicities|28 day all-cause mortality will be a primary end point for Phase 1 and 2	AVM Biotechnology LLC|Medpace, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	8	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AVM0703-101	November 2020	June 2022	June 2023	April 28, 2020		September 18, 2020			https://ClinicalTrials.gov/show/NCT04366115
728	NCT04344288	Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection	CORTI-Covid	Recruiting	No Results Available	Viral Pneumonia Human Coronavirus|COVID-19	Drug: Prednisone|Other: Control group	Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths	Hospices Civils de Lyon	All	18 Years and older   (Adult, Older Adult)	Phase 2	304	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	69HCL20_0321|2020-001553-48	April 21, 2020	November 2020	November 2020	April 14, 2020		June 11, 2020	Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Groupement Hospitalier Nord, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital St Joseph Saint Luc, Lyon, France|Hôpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|CHU St Etienne, Saint-Étienne, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France|CHG Vienne, Vienne, France|Médipôle, Villeurbanne, France|Clinique des Portes du Sud, Vénissieux, France|CH Annecy-Genevois, Épagny, France		https://ClinicalTrials.gov/show/NCT04344288
729	NCT04386070	Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19	PROTECT-Surg	Not yet recruiting	No Results Available	Pulmonary Complications in Surgical Patients|COVID|Severe Acute Respiratory Syndrome	Drug: Lopinavir-Ritonavir|Drug: Hydroxychloroquine	Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death|Rate of Pneumonia|Rate of ARDs|Death rate|Rate of unexpected ventilation|COVID-19 pulmonary complications|Overall SARS-CoV-2 infected rate|Duration of hospital stay|Pulmonary function	University of Birmingham|Christian Medical College and Hospital, Ludhiana, India|Tamale Teaching Hospital, Ghana.|University of Lagos, Nigeria|Kigali University Teaching Hospital|Hospital Español Veracruz|Université d'Abomey-Calavi|University of Witwatersrand, South Africa|University of Edinburgh|Istituto Clinico Humanitas|University of Cape Town	All	16 Years and older   (Child, Adult, Older Adult)	Phase 3	6400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	RG_20-029 COVID-19|2020-001448-24	May 15, 2020	May 14, 2021	May 14, 2026	May 13, 2020		May 13, 2020			https://ClinicalTrials.gov/show/NCT04386070
730	NCT04335786	Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease		Recruiting	No Results Available	Acute Respiratory Distress Syndrome|SARS-CoV-2|COVID|COVID-19|Severe Acute Respiratory Syndrome	Drug: Valsartan (Diovan)|Drug: Placebo oral tablet	first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury	Radboud University	All	18 Years and older   (Adult, Older Adult)	Phase 4	651	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NL73547.091.20|2020-001320-34	April 17, 2020	December 2020	December 2021	April 6, 2020		June 9, 2020	Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Erasmus MC, Rotterdam, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands		https://ClinicalTrials.gov/show/NCT04335786
731	NCT04286503	The Clinical Study of Carrimycin on Treatment Patients With COVID-19		Not yet recruiting	No Results Available	Novel Coronavirus Infectious Disease (COVID-19)	Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment	Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment	Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	520	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BeijingYouan Hospital	February 23, 2020	February 28, 2021	February 28, 2021	February 27, 2020		February 27, 2020		"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04286503
732	NCT04374565	Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia		Active, not recruiting	No Results Available	Corona Virus Infection|SARS-CoV 2|SARS Pneumonia|Pneumonia	Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma	Transfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (ECMO)|Hospital length of stay (LOS)|ICU LOS|Grade 3 or 4 Adverse Events (AEs)	University of Virginia	All	18 Years and older   (Adult, Older Adult)	Phase 2	29	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200114	May 5, 2020	April 5, 2021	April 5, 2021	May 5, 2020		August 21, 2020	University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT04374565
733	NCT04339816	Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial	AZIQUINE-ICU	Recruiting	No Results Available	COVID-19|Respiratory Failure	Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo	Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90	Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic	All	18 Years and older   (Adult, Older Adult)	Phase 3	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	AZIQUINE-ICU-25032020|2020-001456-18	May 13, 2020	December 31, 2021	June 30, 2022	April 9, 2020		June 4, 2020	František Duška, Praha, Česká Republika, Czechia		https://ClinicalTrials.gov/show/NCT04339816
734	NCT04359862	Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection	SEVO-COVID19	Recruiting	No Results Available	Acute Respiratory Distress Syndrome|COVID19 Infection	Drug: Sevoflurane|Drug: Propofol	PaO2/FiO2|TNFα|IL-1b|IL-6|IL-8|Mortality	Fundación para la Investigación del Hospital Clínico de Valencia	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 4	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SEVO-COVID19	April 16, 2020	August 16, 2020	September 16, 2020	April 24, 2020		April 29, 2020	Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain		https://ClinicalTrials.gov/show/NCT04359862
735	NCT04536350	Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS		Not yet recruiting	No Results Available	Covid19|Corona Virus Infection|ARDS|Aviptadil	Drug: Aviptadil 67μg|Drug: Placebo 0.9% NaCl solution	time to clinical improvement|Frequency of mechanical ventilation|Time requiring oxygen supplementation|Slope in SaO2|Slope in FiO2|Slope in C-reactive Protein|Neutrophile ratio|lymphocyte ratio|Interleukine 6 level|Procalcitonin level|Frequency of Multi organ dysfunction Syndrome (MODS)	Prof. Dr. Jörg Leuppi|Cantonal Hosptal, Baselland	All	18 Years and older   (Adult, Older Adult)	Phase 1	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Aviptadil Trial	September 2020	December 2021	March 2022	September 2, 2020		September 7, 2020	Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St.Gallen, St.Gallen, Switzerland		https://ClinicalTrials.gov/show/NCT04536350
736	NCT04501978	ACTIV-3: Therapeutics for Inpatients With COVID-19	TICO	Recruiting	No Results Available	Covid19	Drug: LY3819253|Drug: Placebo|Drug: Remdesivir	Pulmonary ordinal outcome (Stage 1)|Pulmonary+ ordinal outcome (Stage 1)|Time from randomization to sustained recovery (Stage 2)|All-cause mortality|Composite of time to sustained recovery and mortality|Days alive outside short-term acute care hospital|Pulmonary ordinal outcome|Pulmonary+ ordinal outcome|Change in New Early Warning (NEW) Score|Incidence of clinical organ failure|Composite of death or serious clinical COVID-19 related events|Composite of cardiovascular events and thromboembolic events|Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death|Incidence of infusion reactions|Composite of SAEs or death|Change in SARS-CoV-2 neutralizing antibody levels|Change in overall titers of antibodies|Change in neutralizing antibody levels	National Institute of Allergy and Infectious Diseases (NIAID)|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)|University of Copenhagen|Medical Research Council|Kirby Institute|Washington D.C. Veterans Affairs Medical Center|AIDS Clinical Trials Group|National Heart, Lung, and Blood Institute (NHLBI)|US Department of Veterans Affairs|Prevention and Early Treatment of Acute Lung Injury (PETAL)|Cardiothoracic Surgical Trials Network (CTSN)	All	18 Years and older   (Adult, Older Adult)	Phase 3	10000	NIH|Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	014 / ACTIV-3	August 4, 2020	July 2021	July 2021	August 6, 2020		October 6, 2020	Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States|Community Regional Medical Center (Site 203-005), 2823 Fresno Street, Fresno, California, United States|Keck Hospital of USC (Site 301-020), 1500 San Pablo Street, Los Angeles, California, United States|Mount Zion Hospital, UCSF Medical Center (Site 203-007), 1600 Divisadero St., San Francisco, California, United States|San Francisco VA Healthcare System (Site 074-002), 4150 Clement St., San Francisco, California, United States|Moffitt-Long Hospital, UCSF Medical Center (Site 203-001), 505 Parnassus Ave., San Francisco, California, United States|Stanford University Hospital & Cinics (Site 203-003), 300 Pasteur Dr., Stanford, California, United States|University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue, Aurora, Colorado, United States|Denver Public Health (Site 017-004), 605 Bannock St., MC2600 (Infectious Disease Clinic), Denver, Colorado, United States|MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW, Washington, District of Columbia, United States|Bay Pines VA Healthcare System (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104, Bay Pines, Florida, United States|Miami VA Healthcare System (Site 074-003), 1201 NW 16 Street, Miami, Florida, United States|The Emory Clinic (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE, Atlanta, Georgia, United States|University of Kentucky Hospital (Site 210-004), 1000 South Limestone St., Lexington, Kentucky, United States|Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway, New Orleans, Louisiana, United States|University of Maryland (Site 301-019), 22 South Greene Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 202-002), 55 Fruit Street, Boston, Massachusetts, United States|Baystate Medical Center (Site 201-001), 759 Chestnut Street, Springfield, Massachusetts, United States|University of Michigan (Site 205-001), 1500 East Medical Center Drive, Ann Arbor, Michigan, United States|Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd., Detroit, Michigan, United States|Hennepin Healthcare (Site 027-001), 701 Park Avenue, Minneapolis, Minnesota, United States|University of Mississippi Medical Center (Site 202-005), 2500 North State Street, Jackson, Mississippi, United States|Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive, Lebanon, New Hampshire, United States|Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road, Bronx, New York, United States|Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street, Bronx, New York, United States|Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation (Site 207-001), 9410 Carnegie Avenue, L15, Cleveland, Ohio, United States|Cleveland Clinic Foundation (Site 207-005), 9500 Euclid Avenue, Cleveland, Ohio, United States|Cleveland Clinic Foundation (Site 207-006), 9500 Euclid Avenue, Cleveland, Ohio, United States|Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd., Portland, Oregon, United States|Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive, Nashville, Tennessee, United States|UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor, Dallas, Texas, United States|Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave., Dallas, Texas, United States|Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd., Houston, Texas, United States|Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street, Murray, Utah, United States|University of Utah Health (Site 211-002), 419 Wakara Way, Suite 207, Salt Lake City, Utah, United States|University of Virginia (Site 301-021), 1215 Lee Street, Charlottesville, Virginia, United States|Harborview Medical Center (Site 208-001), 325 9th Avenue, Seattle, Washington, United States|University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street, Seattle, Washington, United States|WVU Medicine (Site 301-023), One Medical Center Drive, Morgantown, West Virginia, United States|Aalborg University Hospital (Site 625-005), Hobrovej 18, Aalborg, Denmark|Department of Infectious Diseases (Site 625-002), Aarhus University Hospital, Skejby, Palle Juul-Hensens Boulevard 99, Aarhus N, Denmark|Righospitalet (Site 625-006), Blegdamsvej 9,, Copenhagen Ø, Denmark|Herlev Hospital (Site 625-012), Medicinsk Afdeling, Herlev Ringvej 75, Herlev, Denmark|Nordsjællands Hospital (Site 625-009), Dyrehavevej 29, Hillerød, Denmark|Hvidovre Hospital (Site 625-001), Department of Infectious Diseases, Kettegård allé 30, Hvidovre, Denmark|Medicinsk Afdeling (Site 625-011), Kolding Sygehus, Sygehusvej 24, Kolding, Denmark|Odense Universitetshospital (Site 625-004), Infektionsmedicinsk Forskningsenhed,J.B. Winsløwsgade 4, Odense, Denmark|Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04501978
737	NCT04347512	EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA	TEACHCOVID	Withdrawn	No Results Available	Sars-CoV-2, Community-Acquired Pneumonia,COVID-19	Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm	Rate of patients reaching a significant hypoxemia, in each arms.	University Hospital, Strasbourg, France	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7783	June 2, 2020	June 2, 2020	June 2, 2020	April 15, 2020		June 4, 2020			https://ClinicalTrials.gov/show/NCT04347512
738	NCT04416399	STerOids in COVID-19 Study	STOIC	Recruiting	No Results Available	Coronavirus Infection	Drug: Budesonide dry powder inhaler	Emergency department attendance of hospitalisation related to COVID-19|Body temperature|Blood oxygen saturation level|Symptoms as assessed by common cold questionnaire|Symptoms as assessed by FluPro questionnaire|Nasal/throat swab SARS-CoV-2 viral load	University of Oxford	All	18 Years and older   (Adult, Older Adult)	Phase 2	478	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STOIC study	July 16, 2020	November 15, 2020	December 30, 2020	June 4, 2020		July 24, 2020	Oxford Respiratory Trials Unit, Oxford, Oxfordshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04416399
739	NCT04353180	Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)	Isotretinoin	Not yet recruiting	No Results Available	COVID19	Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment	lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Frequency of adverse events and severe adverse events|Angiotensin II (Ang II) changes over time|Sequential organ failure assessment score(SOFA score) over time|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Thrombin time (TT)	Kafrelsheikh University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Proposed by Mahmoud Elkazzaz	September 2020	October 2020	November 2020	April 20, 2020		September 10, 2020	Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04353180
740	NCT04447469	Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation		Recruiting	No Results Available	COVID	Drug: mavrilimumab|Other: Placebo	Cohort 1: Proportion of Participants Alive and Without Respiratory Failure at Day 15|Cohort 2: Mortality Rate at Day 15|Cohort 1: Time to Return to Room Air by Day 15|Cohort 1: Time to 2-point Clinical Improvement by Day 15|Cohort 1: Mortality Rate at Day 29|Cohort 1: Time to 1-Point Clinical Improvement by Day 15|Cohort 2: Mortality Rate at Day 29|Cohort 2: Proportion of Participants Alive and Without Respiratory Failure at Day 15|Cohorts 1 and 2: Proportion of Participants Alive and Without Respiratory Failure At Day 29|Cohorts 1 and 2: Time to Return to Room Air by Day 29|Cohort 2: Time to 2-point Clinical Improvement by Day 15|Cohorts 1 and 2: Time to 1-point Clinical Improvement by Day 29|Cohorts 1 and 2: Time to 2-point Clinical Improvement by Day 29|Cohort 1: Respiratory Failure-Free Survival by Day 15|Cohort 1: Respiratory Failure-Free Survival by Day 29|Cohort 1: Proportion of Participants Who Return to Room Air by Day 15|Cohorts 1 and 2: Proportion of Participants Who Return to Room Air by Day 29|Cohort 1: Mortality Rate at Day 15|Cohorts 1 and 2: Overall Survival by Day 29|Cohorts 1 and 2: Clinical Status Over Time|Cohorts 1 and 2: Number of Days Alive and Out of Hospital Through Day 90	Kiniksa Pharmaceuticals, Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	573	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	KPL-301-C203	July 27, 2020	February 2021	April 2021	June 25, 2020		October 8, 2020	UCLA Medical Center, Los Angeles, California, United States|Sharp Health Care, San Diego, California, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Allina Health System, Minneapolis, Minnesota, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Mercy Hospital, Springfield, Missouri, United States|University of Texas Health Sciences, Houston, Texas, United States|UPECLIN - Unidade de Pesquisa Clínica, Botucatu, Brazil|IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará, Fortaleza, Brazil|Hospital Bruno Born, Lajeado, Brazil|Centro de Pesquisas Clínicas, Natal, Brazil|Hospital Cardio Pulmonar, Salvador, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Clinica Las Condes, Santiago, Chile|Hospital Essalud Alberto Sabogal Sologuren, Bellavista, Peru|Hospital Arzobispo Loayza, Lima Cercado, Peru|Hospital Nacional Cayetano Heredia, San Martín De Porres, Peru|IATROS International, Bloemfontein, South Africa|Limpopo Clinical Research Initiative, Rustenburg, South Africa		https://ClinicalTrials.gov/show/NCT04447469
741	NCT04412291	A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study		Recruiting	No Results Available	Covid-19	Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment	Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from admission using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to change in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever|Number of days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of days of hospitalization in survivors|Number of deaths due to any cause	Karolinska University Hospital|Karolinska Institutet	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001748-24	June 11, 2020	August 2020	February 2021	June 2, 2020		June 26, 2020	Karolinska University Hospital, Huddinge, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT04412291
742	NCT04575064	An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY		Active, not recruiting	No Results Available	SARS-CoV-2 Infection|COVID-19|Moderate and Severe COVID-19	Other: Standard of Care (SoC)|Drug: Remdesivir	Improvement of clinical status on the ordinal 7-point severity-scale at day 15.|Time to an improvement of one category from admission using the 7-point ordinal scale|Mortality: 28 days mortality; in-house mortality|Hospital stay: Duration of hospital stay due to COVID-19|Oxygen: Need of, time to first receiving and duration of oxygen|Intensive care: Need of, time to first receiving and duration of intensive care|Mechanical ventilation: Need of, time to first receiving and duration of mechanical ventilation|ECMO: Need of, time to first receiving and duration for extracorporeal membrane oxygenation|Superinfections, assessed with pathogen testing|Kidney failure|Myocardial failure|Multiple organ failure	Professor Dr. Bernd Mühlbauer|Dept. of Statistics and Medical Biometry, University of Bremen|INSERM (Institut national de la santé et de la recherche médicale), Paris, France|World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland|Klinikum Bremen-Mitte, gGmbH	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WHO-SOLIDARITY-GERMANY|2020-001549-38	June 29, 2020	March 2022	November 2022	October 5, 2020		October 5, 2020	Gesundheit Nord gGmbH, Bremen, Germany|Universitätsklinikum Gießen, Gießen, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Technische Universität München (TUM), München, Germany		https://ClinicalTrials.gov/show/NCT04575064
743	NCT04551911	Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19		Not yet recruiting	No Results Available	Covid19|Coronavirus|SARS-CoV-2 Infection	Drug: Rayaldee 30Mcg Extended-Release (ER) Capsule|Drug: Placebo	Severity and duration of disease as evidenced by COVID-19 symptoms using the FLU-PRO© questionnaire.|Concentration of serum total 25-hydroxyvitamin D maintained at or above 50 ng/mL.	OPKO Health, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	160	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CTAP101-CL-2014	September 2020	February 2021	April 2021	September 16, 2020		September 21, 2020			https://ClinicalTrials.gov/show/NCT04551911
744	NCT04429854	Donated Antibodies Working Against nCoV	DAWN-Plasma	Recruiting	No Results Available	COVID-19	Biological: Convalescent Plasma|Drug: Standard of care	Patients requiring mechanical ventilation or death|Clinical status of subject at day 15 and day 30 (on a 10-point "WHO progression" ordinal scale)	Universitaire Ziekenhuizen Leuven|Federal Knowledge Centre (KCE)	All	18 Years and older   (Adult, Older Adult)	Phase 2	483	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S63992	May 2, 2020	November 2, 2021	November 2, 2021	June 12, 2020		June 12, 2020	ZNA, Antwerpen, Belgium|Institut Bordet, Brussel, Belgium|UMC Sint-Pieter, Brussel, Belgium|CHU Brugmann, Brussel, Belgium|Erasmus Ziekenhuis, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St Luc, Brussel, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC Liège Mont Légia, Liège, Belgium|CHR Citadelle Liège, Liège, Belgium|CHU Liège Sart-Tilman, Liège, Belgium|CHR Jolimont Mons-Hainaut, Mons, Belgium|AZ Delta, Roeselare, Belgium		https://ClinicalTrials.gov/show/NCT04429854
745	NCT04356833	Nebulised Rt-PA for ARDS Due to COVID-19	PACA	Recruiting	No Results Available	COVID	Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)	treatment efficacy - Percentage change in PaO2/FiO2 ratio|Safety as measured by bleeds|Safety as measured by other (non-bleed related) adverse events|Safety as measured by fibrinogen levels|Absolute change in PaO2/FiO2 ratio|Changes in respiratory compliance|Clinical status as determined by a 7 point ordinal scale|Sequential Organ Failure Assessment (SOFA) score|Follow up period - oxygen free days|Follow up period - ventilator free days|Follow up period - intensive care stay|New oxygen via ventilation use - incidence|New oxygen via ventilation use - duration|Incidence of new mechanical ventilation use|Duration of new mechanical ventilation use|In hospital mortality	University College, London	All	16 Years to 70 Years   (Child, Adult, Older Adult)	Phase 2	24	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	132151	April 22, 2020	January 14, 2021	January 14, 2021	April 22, 2020		April 30, 2020	The Royal Free Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04356833
746	NCT04559113	Methylprednisolone in COVID-19 Patients (Methyl19LGH)	Methyl19LGH	Recruiting	No Results Available	SARS-CoV Infection|SARS (Severe Acute Respiratory Syndrome)	Drug: Methylprednisolone Injectable Product	Clinical response after administration|Clinical response to treatment|Duration of hospitalization	Lahore General Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LGH005	May 1, 2020	October 30, 2020	October 30, 2020	September 22, 2020		September 22, 2020	Muhammad Irfan Malik, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04559113
747	NCT04504734	Bucillamine in Treatment of Patients With COVID-19		Enrolling by invitation	No Results Available	Covid19	Drug: Bucillamine|Drug: Placebo	Efficacy: Frequency of hospitalization or death|Safety: Changes in adverse events from baseline to end of study	Revive Therapeutics, Ltd.	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	1000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RT-003	September 30, 2020	February 1, 2021	May 1, 2021	August 7, 2020		October 1, 2020	Research Site, Los Angeles, California, United States|Research Site, Modesto, California, United States|Research Stite, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04504734
748	NCT04351516	Test and Treat COVID 65plus+	COVID65plus	Recruiting	No Results Available	SARS-CoV 2|COVID-19	Drug: Hydroxychloroquine|Other: Placebo	● Rate of hospitalization or death at day 7 after study inclusion	University Hospital Tuebingen	All	65 Years and older   (Older Adult)	Phase 2|Phase 3	350	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID65plus|2020-001482-37	April 21, 2020	December 31, 2020	May 1, 2021	April 17, 2020		May 27, 2020	Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany		https://ClinicalTrials.gov/show/NCT04351516
749	NCT03944447	Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19	OMNI-Can	Recruiting	No Results Available	Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus	Drug: Cannabis, Medical	Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms|Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events	OMNI Medical Services, LLC|OMNI Medical Services Inc	All	7 Years and older   (Child, Adult, Older Adult)	Phase 2	200000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00033337	December 1, 2018	December 31, 2025	December 31, 2025	May 9, 2019		August 28, 2020	OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States		https://ClinicalTrials.gov/show/NCT03944447
750	NCT04330144	Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)		Not yet recruiting	No Results Available	Contact Person From COVID-19 Confirmed Patient	Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)	The rate of COVID-19	Gangnam Severance Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	2486	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	3-2020-0036	April 1, 2020	March 30, 2021	March 30, 2022	April 1, 2020		April 1, 2020			https://ClinicalTrials.gov/show/NCT04330144
751	NCT04458363	Convalescent Plasma in Pediatric COVID-19		Recruiting	No Results Available	COVID	Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies	Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer	Emory University	All	up to 22 Years   (Child, Adult)	Early Phase 1	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000789	July 2020	June 2022	June 2022	July 7, 2020		July 7, 2020	Children's Healthcare of Atlanta, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT04458363
752	NCT04389580	Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	Combination	Not yet recruiting	No Results Available	COVID-19	Drug: Drug: Isotretinoin plus Tamoxifen|Drug: Aerosolized Isotretinoin plus Tamoxifen	lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap	Kafrelsheikh University	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	160	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COV-19 Treatment This is	June 2020	August 2020	September 2020	May 15, 2020		June 4, 2020			https://ClinicalTrials.gov/show/NCT04389580
753	NCT04334148	Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine	HERO-HCQ	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events	Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University	All	18 Years and older   (Adult, Older Adult)	Phase 3	2000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	Pro00105274	April 22, 2020	October 2020	October 2020	April 6, 2020		August 25, 2020	Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of Florida Health Central Florida, Leesburg, Florida, United States|University of Miami Florida, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|Columbia University, Irving Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04334148
754	NCT04295551	Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)		Not yet recruiting	No Results Available	COVID-19	Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment	Clinical recovery time	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QF-XYP1990-1	March 14, 2020	July 14, 2020	April 14, 2021	March 4, 2020		March 4, 2020			https://ClinicalTrials.gov/show/NCT04295551
755	NCT04410328	Aggrenox To Treat Acute Covid-19	ATTAC-19	Not yet recruiting	No Results Available	Covid19	Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Other: Standard of care	Covid (Coronavirus Disease-19) Ordinal Scale|Mortality|Supplemental Oxygen|Invasive-ventilator|ICU stay|Hospital stay|Inflammatory markers|Thromboembolic complications|COVID ordinal scale	Rutgers, The State University of New Jersey|Boehringer Ingelheim	All	19 Years and older   (Adult, Older Adult)	Phase 3	132	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro2020001469	October 1, 2020	March 15, 2021	December 15, 2021	June 1, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04410328
756	NCT04322565	Colchicine Counteracting Inflammation in COVID-19 Pneumonia	ColCOVID-19	Recruiting	No Results Available	Coronavirus Infections|Pneumonia, Viral	Drug: Colchicine	Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical ventilhation|Hospitalization|Time from treatment initiation to death|Time to Negativization COVID 19|Fever	Azienda Ospedaliero-Universitaria di Parma	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	310	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ColCOVID-19	April 20, 2020	December 20, 2020	December 21, 2020	March 26, 2020		July 10, 2020	Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy		https://ClinicalTrials.gov/show/NCT04322565
757	NCT04466241	Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial	INTENSE-COV	Not yet recruiting	No Results Available	COVID-19|COVID-19 Drug Treatment|Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Drug: Telmisartan 40Mg Oral Tablet|Drug: Atorvastatin 20 Mg Oral Tablet	Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11|Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28|Kinetics of SARS-CoV-2 viral load|Death rate at Day 11 and Day 28|All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28|Time to hospital discharge|Duration of oxygen supplementation|Prevalence of grade III or IV adverse events|Residual concentration of lopinavir, telmisartan and atorvastatin|Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes)|Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2)|Proportion of patients with good results according to HIV status|Number of contact cases infected by COVID-19 at Day 28	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Université de Bordeaux|PACCI Program	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	294	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANRS COV01 INTENSE COV	September 10, 2020	November 20, 2020	December 20, 2020	July 10, 2020		September 10, 2020	Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire		https://ClinicalTrials.gov/show/NCT04466241
758	NCT04531748	Selective Estrogen Modulation and Melatonin in Early COVID-19	SENTINEL	Not yet recruiting	No Results Available	Covid19	Drug: Toremifene|Drug: Melatonin|Other: Placebo	Peak increase in COVID-19 Sign and Symptom score|Nadir Oxygen Saturation|Peak Heart Rate|Time to COVID-19 Sign and Symptom score resolution|Time to WHO 7-point ordinal scale score of 3 or higher	Reena Mehra, MD|The Cleveland Clinic	All	18 Years and older   (Adult, Older Adult)	Phase 2	390	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20-842	September 2020	September 2021	September 2021	August 28, 2020		August 28, 2020			https://ClinicalTrials.gov/show/NCT04531748
759	NCT04534803	BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)		Not yet recruiting	No Results Available	Covid19	Drug: BCG Vaccine|Other: Placebo	To assess the efficacy of BCG vaccination compared to placebo in reducing severe Covid-19 disease among elderly residents of skilled nursing facilities.|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases), continued|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of episodes)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of days)	Harvard Medical School|Texas Medical Research Associates, L.L.C.	All	70 Years and older   (Older Adult)	Phase 3	2100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	IRB20-1243	September 2020	September 30, 2021	November 30, 2021	September 1, 2020		September 21, 2020			https://ClinicalTrials.gov/show/NCT04534803
760	NCT04363450	Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)	HCQPreP	Recruiting	No Results Available	COVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|Hydroxychloroquine	Drug: Hydroxychloroquine|Drug: Placebo	Incidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infection	Louisiana State University Health Sciences Center in New Orleans|Lafayette General Health|University of Louisiana at Lafayette	All	18 Years and older   (Adult, Older Adult)	Phase 3	1700	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	LSU NO HSC IRB 20-050	April 27, 2020	March 31, 2021	June 1, 2021	April 27, 2020		September 2, 2020	Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States		https://ClinicalTrials.gov/show/NCT04363450
761	NCT04343248	Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)		Recruiting	No Results Available	COVID-19|Viral Respiratory Illnesses	Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex	Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI	Romark Laboratories L.C.	All	55 Years to 120 Years   (Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	RM08-3006	May 12, 2020	December 31, 2020	December 31, 2020	April 13, 2020		September 18, 2020	The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04343248
762	NCT04492358	Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center		Not yet recruiting	No Results Available	Covid19	Drug: Colchicine|Drug: Prednisone tablet|Drug: standard of care	Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19|Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment|Percentage of patients who stop medication due to adverse events.|Severity of symptoms by COVID-19 in the two treatment arms	Maria Joyera Rodríguez|Fundacion Clinic per a la Recerca Biomédica	All	65 Years and older   (Older Adult)	Phase 2|Phase 3	144	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-002462-14	September 2020	October 2021	October 2021	July 30, 2020		July 30, 2020			https://ClinicalTrials.gov/show/NCT04492358
763	NCT04569825	Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease		Recruiting	No Results Available	Clinical Trial	Drug: Ophtamesone	Recovery rate of anosmia and shorten recovery time	University Of Anbar	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	1148	August 1, 2020	September 30, 2020	October 15, 2020	September 30, 2020		September 30, 2020	Raid Muhmid Al-Ani, Ramadi, Anbar, Iraq		https://ClinicalTrials.gov/show/NCT04569825
764	NCT04359680	Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection		Recruiting	No Results Available	COVID-19|Viral Respiratory Illnesses	Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex	The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.|The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.	Romark Laboratories L.C.	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	RM08-3007	May 13, 2020	December 31, 2020	December 31, 2020	April 24, 2020		September 4, 2020	HealthStar Research LLC, Hot Springs, Arkansas, United States|So Cal Clinical Research, Huntington Beach, California, United States|Long Beach Clinical Trials, LLC, Long Beach, California, United States|Meris Clinical Research, Brandon, Florida, United States|Invesclinica US LLC, Fort Lauderdale, Florida, United States|The Chappel Group Research, Kissimmee, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|DMI Research, Pinellas Park, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States|Chicago Medical Research Institute, Inc., Chicago, Illinois, United States|Quad Clinical Research, Chicago, Illinois, United States|Chicago Medical Research, LLC, Hazel Crest, Illinois, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Beacom Family Health Connection, Fremont, Nebraska, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|RH Medical Urgent Care Professional PLLC, Bronx, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|The New York Center for Travel and Tropical Medicine, New York, New York, United States|Centex Studies, Inc., Houston, Texas, United States|SMS Clinical Research LLC, Mesquite, Texas, United States|LinQ Research LLC, Pearland, Texas, United States|Rio Grande Valley Clinical Research Institute, Pharr, Texas, United States|BFHC Research, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT04359680
765	NCT04371978	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19		Recruiting	No Results Available	COVID 19|Coronavirus|Diabetes Mellitus, Type 2|Diabetes Mellitus|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System Diseases|Dipeptidyl-Peptidase IV Inhibitors|Linagliptin|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Hypoglycemic Agents|Respiratory Tract Diseases|Incretins|Hormones	Drug: Linagliptin 5 MG	Time to clinical change|Percent of serious adverse events and premature discontinuation of treatment.|Percent of patients with clinical improvement.|Length of hospitalization.|All-cause mortality.|Percent of supplemental oxygen use.|Supplemental oxygen-free days.|Percent of mechanical ventilation use.|Ventilator-free days.|Percent of ICU admissions.|ICU-free days.|Percent of 50% decrease in C-reactive protein (CRP) levels|Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.	Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0303-20-RMC	October 1, 2020	June 30, 2021	September 30, 2021	May 1, 2020		October 2, 2020	Rabin Medical Center, Petah tikva, Israel		https://ClinicalTrials.gov/show/NCT04371978
766	NCT04390139	Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19	COVIDMES	Recruiting	No Results Available	COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome	Drug: XCEL-UMC-BETA|Other: Placebo	All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin	Banc de Sang i Teixits	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BST-COVID-01	May 13, 2020	October 2020	December 2020	May 15, 2020		May 15, 2020	Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04390139
767	NCT04551755	Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19		Not yet recruiting	No Results Available	Covid19	Drug: Ivermectin and Doxycycline|Other: Placebo	Time to outcome measure of fever (<100.40F)and cough|Negative RT-PCR test on day 5 of treatment	Bangladesh Medical Research Council (BMRC)	All	18 Years and older   (Adult, Older Adult)	Phase 2	188	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	31211062020	September 2020	November 2020	December 2020	September 16, 2020		September 16, 2020			https://ClinicalTrials.gov/show/NCT04551755
768	NCT04370015	Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.		Not yet recruiting	No Results Available	SARS-CoV-2|Healthcare Workers	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period|Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment|Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR|Clinical disease severity in confirmed SARS-CoV-2 participants|Incidence of any acute respiratory infection	Services Institute of Medical Sciences, Pakistan	All	18 Years to 60 Years   (Adult)	Not Applicable	374	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	16082019	May 15, 2020	June 30, 2020	October 15, 2020	April 30, 2020		May 6, 2020			https://ClinicalTrials.gov/show/NCT04370015
769	NCT04359537	Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19	CHEER	Recruiting	No Results Available	COVID 19	Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo	COVID-19-free survival in experimental arms compared to placebo|Incidence of confirmed SARS-COV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related adverse events	Shaheed Zulfiqar Ali Bhutto Medical University	All	18 Years to 60 Years   (Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	F.1-1/2015/ERB/SZABMU/549	May 1, 2020	August 25, 2020	September 25, 2020	April 24, 2020		May 19, 2020	Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan		https://ClinicalTrials.gov/show/NCT04359537
770	NCT04468971	REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia	RESOLVE	Recruiting	No Results Available	COVID19|ARDS	Biological: CK0802|Drug: Placebo	Regimen related ≥ grade 3 toxicity within 48 hours of first infusion|28-day treatment success, defined as S28|Time to extubation|Oxygenation improvement|Ventilator free days|Organ failure free days|ICU free days|All-cause mortality	Cellenkos, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	45	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CK0802.501.1	September 29, 2020	September 30, 2021	September 30, 2021	July 13, 2020		October 1, 2020	Johns Hopkins Hospital, Baltimore, Maryland, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Baylor College of Medicine, St Luke's Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04468971
771	NCT04397497	Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)	COMBAT-19	Not yet recruiting	No Results Available	Covid-19|Acute Respiratory Failure|ARDS, Human|Sars-CoV2|Viral Pneumonia	Drug: Mavrilimumab|Drug: Placebo	Reduction in the dependency on oxygen supplementation|Proportion of responders (using the WHO 7-point ordinal scale)|Time to response (using the WHO 7-point ordinal scale)|Proportion of improving patients (using the WHO 7-point ordinal scale)|Time to resolution of fever|Reduction in case fatality|Proportion of patient requiring mechanical ventilation/deaths|Change in biochemical markers|Median changes in the National Early Warning Score 2 (NEWS2)|Time to clinical improvement as evaluated with the National Early Warning Score 2 (NEWS2)|Variations in radiological findings|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Ospedale San Raffaele	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COMBAT-19	May 22, 2020	September 22, 2020	November 22, 2020	May 21, 2020		May 26, 2020	IRCCS Policlinico San Donato, San Donato, MI, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Istituto Ortopedico Galeazzi, Milano, Italy		https://ClinicalTrials.gov/show/NCT04397497
772	NCT04355364	Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE)	COVIDORNASE	Recruiting	No Results Available	COVID-19|Acute Respiratory Distress Syndrome	Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure	Efficacy of intratracheal administration: occurrence of at least one grade improvement	Fondation Ophtalmologique Adolphe de Rothschild|University Hospital, Strasbourg, France|Centre Hospitalier Régional Metz-Thionville	All	18 Years and older   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	CGE_2020_9	April 21, 2020	August 21, 2020	August 21, 2020	April 21, 2020		June 1, 2020	Hôpital Fondation A. de Rotschhild, Paris, France		https://ClinicalTrials.gov/show/NCT04355364
773	NCT04565379	Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients		Recruiting	No Results Available	COVID19 Pneumonia	Drug: NuSepin® 0.1 mg|Drug: NuSepin® 0.2 mg|Drug: Placebo	Difference in Time to Clinical Improvement (TTCI) between the 2 treatments and the placebo group (in days)|Percentage of patients with CRP < 10 mg/L or < 30% decreases from baseline|Clinical Status assessed by the six-category ordinal scale at fixed time points|Time to complete clinical remission OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All-cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Length of ICU stay (days)|Number of incidence of treatment emergent adverse events (TEAEs) in 3 treatment groups	Shaperon	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Shaperon001|2020-003107-34	September 25, 2020	November 30, 2020	November 30, 2020	September 25, 2020		September 30, 2020	"Leon Daniello" Clinical Hospital of Pneumophtisiology Cluj-Napoca Pneumology Clinic, Cluj-Napoca, Romania|Clinical Hospital for Infectious Diseases and Pneumophtisiology "Victor Babes", Craiova Infectious Diseases Clinic for Adults, Craiova, Romania|"Sf. Parascheva" Infectious Diseases Clinical Hospital Iasi Infectious Diseases Department, Iaşi, Romania|"Sf. Ioan cel Nou" Suceava County Emergency Hospital Infectious Diseases Department, Suceava, Romania		https://ClinicalTrials.gov/show/NCT04565379
774	NCT04510233	Ivermectin Nasal Spray for COVID19 Patients		Not yet recruiting	No Results Available	Covid19	Drug: Ivermectin nasal|Drug: Ivermectin oral|Other: standard care	PCR of SARS-Cov2 RNA	Tanta University	All	18 Years to 60 Years   (Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IvrInh	September 2020	October 2020	December 2020	August 12, 2020		August 12, 2020			https://ClinicalTrials.gov/show/NCT04510233
775	NCT04395456	A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)	SAVE	Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)	Drug: AMY-101|Other: WFI 5% glucose	The proportion of patients who are alive, without evidence of ARDS (i.e. PaO2/FIO2 >300 mm Hg), who do not require any oxygen support (in room air).|The proportion of patients assigned to each category, of a six-category ordinal scale.|Proportion of patients surviving|Proportion of respiratory failure-free survival|Cumulative incidence of resolution of ARDS (defined as PaO2/FiO2 ≥200 in room air)|Cumulative incidence of freedom from oxygen requirement|Proportion of patients requiring invasive mechanical ventilation due to worsening of ARDS|Proportion of patients requiring non-invasive mechanical ventilation (NIV) due to worsening of ARDS|Proportion of patients developing thrombotic microangiopathies|Changes in PaO2 and PaO2/FIO2|Changes in quick Sequential Organ Failure Assessment Score (qSOFA: respiratory rate, systolic blood pressure, Glasgow Coma Scale (GCS)|Changes in maximal and minimal cardiovascular parameters: Respiratory rate|Changes in maximal and minimal cardiovascular parameters: Heart Rate|Changes in levels of biomarkers of inflammation (CBC, CRP, Ferritin, Procalcitonin, D-dimers, LDH)|Length of stay in ICU|Cumulative incidence of discharge from hospital|Number of adverse events|Changes in levels of anti-drug antibodies|Changes in levels of biomarkers of complement activity: C3, C3a, C5a, sC5b-9|Changes in levels of biomarkers of cytokine release syndrome: IL-1, IL-6, IL-12|Changes in levels of Club Cell protein CC16 (biomarker of lung damage )|Changes in levels of AMY-101 plasma level	Amyndas Pharmaceuticals S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 2	144	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	AMY-101_SAVE	July 2020	January 2021	March 2021	May 20, 2020		May 20, 2020			https://ClinicalTrials.gov/show/NCT04395456
776	NCT04510038	Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury	COLHEART-19	Not yet recruiting	No Results Available	Covid19|Myocardial Injury	Drug: Colchicine|Other: Covid-19 Standard of Care	All Cause Mortality|Mechanical Ventilation|Mechanical Circulatory Support|Time to Deterioration|Adverse Events|Troponin|Delta|BNP|Changes in C Reactive Protein|LOS|Re-Hospitalization|Changes in D Dimer	Miami Cardiac and Vascular Institute|University of California, Los Angeles	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2|Phase 3	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	152247	September 1, 2020	September 1, 2021	January 1, 2022	August 12, 2020		August 12, 2020			https://ClinicalTrials.gov/show/NCT04510038
777	NCT04332042	TOFAcitinib in SARS-CoV2 Pneumonia		Not yet recruiting	No Results Available	SARS-COv2 Related Interstitial Pneumonia	Drug: Tofacitinib	need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events	Università Politecnica delle Marche	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOFACoV	April 10, 2020	June 20, 2020	July 10, 2020	April 2, 2020		April 2, 2020	Ospedali Riuniti di Ancona, Ancona, Marche, Italy		https://ClinicalTrials.gov/show/NCT04332042
778	NCT04346628	Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19		Enrolling by invitation	No Results Available	Sars-CoV2|COVID-19	Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment	Time until cessation of oral shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load|Count of participants with clinical worsening of COVID-19 disease|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Count of participant with absence of development of any symptoms|Cmax of favipiravir|Cmin of favipiravir	Stanford University	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	56032	July 12, 2020	July 2021	July 2021	April 15, 2020		October 2, 2020	Stanford University, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04346628
779	NCT04434144	A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh		Completed	No Results Available	Ivermectin|Hydroxychloroquine|COVID19	Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin	Number of participants with "treatment success" determine by a negative RT PCR for COVID19.|Number of participants with "adverse effects" determined by the existence of the pharmacological side effects of the particular drug during treatment.	Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar	All	16 Years to 80 Years   (Child, Adult, Older Adult)		116	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	10000918	May 2, 2020	June 5, 2020	June 5, 2020	June 16, 2020		June 16, 2020	Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh		https://ClinicalTrials.gov/show/NCT04434144
780	NCT04425382	Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar	DOLCI	Recruiting	No Results Available	Coronavirus|COVID|Pneumonia	Drug: Darunavir/Cobicistat|Drug: Lopinavir/Ritonavir	Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)|Percentage of Virological Clearance|Percentage of Clinical Deterioration|Incidence of Adverse Events|Length of Hospital Stay|All-cause Mortality	Hamad Medical Corporation	All	18 Years and older   (Adult, Older Adult)		200	Industry	Observational	Observational Model: Other|Time Perspective: Retrospective	MRC-05-069	March 1, 2020	July 2020	September 2020	June 11, 2020		June 11, 2020	Hamad Medical Corporation, Doha, Qatar		https://ClinicalTrials.gov/show/NCT04425382
781	NCT04483960	Australasian COVID-19 Trial (ASCOT)	ASCOT	Recruiting	No Results Available	SARS-CoV-2 Infection (COVID-19)	Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Biological: Convalescent plasma	Proportion of participants alive and not having required new intensive respiratory support (invasive or non-invasive ventilation) or vasopressors/inotropic support in the 28 days after randomisation.|World Health Organization (WHO) 7-point outcome scale (clinician assessed)|Mortality|Time to death|Length of hospital stay|Receipt of invasive or non-invasive ventilation|Length of receipt of invasive or non-invasive ventilation|Length of intensive care unit (ICU) stay|Presence of chest infiltrates on chest x-ray (CXR) or CT|Time to defervescence from randomisation|Biomarker levels|Antibiotic use|Adverse Events|Serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death in hospital|Acute Kidney Injury (AKI)|Thrombotic events|Viral clearance	University of Melbourne|The Peter Doherty Institute for Infection and Immunity|Australasian Society for Infectious Diseases	All	18 Years and older   (Adult, Older Adult)	Phase 3	2400	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ERM 62646	July 21, 2020	June 12, 2021	June 12, 2022	July 23, 2020		July 23, 2020	Calvary Public Bruce Hospital, Bruce, Australian Capital Territory, Australia|The Canberra Hospital, Canberra, Australian Capital Territory, Australia|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|The Sutherland Hospital, Caringbah, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Griffith Base Hospital, Griffith, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Lismore Base Hospital, Lismore, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Cairns Hospital, Cairns, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mackay Base Hospital, Mackay, Queensland, Australia|Logan Hospital, Meadowbrook, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Mater, South Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Townsville University Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Ballarat Health Services, Ballarat Central, Victoria, Australia|St John of God Ballarat Hospital, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital - Penninsula Health, Frankston, Victoria, Australia|Peninsula Private Hospital, Frankston, Victoria, Australia|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Latrobe Regional Hospital, Traralgon, Victoria, Australia|Northeast Health Wangaratta, Wangaratta, Victoria, Australia|West Gippsland Hospital, Warragul, Victoria, Australia|Albury Wodonga Health, Wodonga, Victoria, Australia|Rockingham General Hospital, Cooloongup, Western Australia, Australia|Joondalup Health Campus, Joondalup, Western Australia, Australia|St John of God Midland Public and Private Hospitals, Midland, Western Australia, Australia|Armadale Health Service, Mount Nasura, Western Australia, Australia|Fiona Stanley Hospita, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Knox Private Hospital, Wantirna, Australia		https://ClinicalTrials.gov/show/NCT04483960
782	NCT04438694	Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection	CP IN COVID19	Recruiting	No Results Available	COVID19	Biological: Convalescent Plasma|Drug: Standard of Care	Duration of hospitalization/Recovery status	Cairo University	All	21 Years to 70 Years   (Adult, Older Adult)	Phase 1|Phase 2	67	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N39-2020	June 1, 2020	May 31, 2021	December 31, 2021	June 19, 2020		September 29, 2020	Cairo University Hospital, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04438694
783	NCT04438629	Evaluation of Immune Response in COVID-19 Patients	IMMUNOVID	Recruiting	No Results Available	Allergy and Immunology|Infection Viral	Drug: COVID-19 treatment	COVID-19 associated immune disorder|COVID-19 associated inflammation|Oxygenation|Diagnostic of COVID disease composite|Changes at the cytokine pattern|Changes at circulating immune cell composition|Intensive Care Unit Admission|Length of hospital stay|Clinical Status|Mortality	Azienda Ospedaliera Universitaria Integrata Verona	All	18 Years to 90 Years   (Adult, Older Adult)		80	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IMMUNOVID 2590CESC	March 26, 2020	June 10, 2020	November 26, 2020	June 19, 2020		June 22, 2020	Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy		https://ClinicalTrials.gov/show/NCT04438629
784	NCT04332991	Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease	ORCHID	Completed	No Results Available	Coronavirus|Acute Respiratory Infection|SARS-CoV Infection	Drug: Hydroxychloroquine|Drug: Placebo	COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28	Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)	All	18 Years and older   (Adult, Older Adult)	Phase 3	479	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PETAL 05 Orchid	April 2, 2020	June 19, 2020	July 23, 2020	April 3, 2020		September 2, 2020	University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04332991
785	NCT04444700	A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic	RAPID-BRAZIL	Recruiting	No Results Available	COVID|Coronavirus Infection|Severe Acute Respiratory Syndrome|Thromboembolism, Venous|Anticoagulants and Bleeding Disorders	Drug: Therapeutic anticoagulation	Composite main outcome|All-cause death|Composite outcome of ICU admission or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia	University of Sao Paulo General Hospital|St. Michael's Hospital, Toronto|University of Vermont Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 3	462	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAAE: 33109220.7.0000.0068	July 4, 2020	November 30, 2020	December 31, 2020	June 23, 2020		August 19, 2020	Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT04444700
786	NCT04398290	iNOPulse for COVID-19	NO-COVER	Withdrawn	No Results Available	COVID-19|Hypoxemia|Hypoxemic Respiratory Failure	Drug: Inhaled nitric oxide (iNO)|Drug: Nitrogen gas|Drug: Oxygen gas	Incidence of treatment emergent adverse events|Incidence of adverse events|Incidence of methemoglobinemia|Number of participants with progression of respiratory failure|Time until resolution of hypoxemia|Incidence of mortality|Duration of hospitalization	Roger Alvarez|Bellerophon Therapeutics|University of Miami	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20200449	December 1, 2020	June 1, 2021	July 15, 2021	May 21, 2020		August 19, 2020	University of Miami Hospitals & Clinics, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT04398290
787	NCT04578236	Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)		Not yet recruiting	No Results Available	Covid19	Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Drug: Drug: Standard treatment Standard treatment	lung injury score|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Time to first negative SARS-CoV-2 PCR in NP swap|All cause mortality rate|Ventilation free days|ICU free days	Kafrelsheikh University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	360	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARS	November 2020	December 2020	January 2021	October 7, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04578236
788	NCT04387240	Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19		Not yet recruiting	No Results Available	Covid 19 Positive|Corona Virus Infection	Drug: Artemisinin / Artesunate|Other: placebo	length of stay in hospital|number of ICU admission|resolution of symptoms	Princess Nourah Bint Abdulrahman University	All	18 Years to 60 Years   (Adult)	Phase 2	22	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	20-0192	December 2020	April 2021	April 2021	May 13, 2020		September 17, 2020	Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04387240
789	NCT04341870	Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO	CORIMUNO-VIRO	Suspended	No Results Available	COVID19|SARS-CoV-2 Infection	Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine	Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines	Assistance Publique - Hôpitaux de Paris	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	27	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-3	April 11, 2020	May 8, 2020	August 2020	April 10, 2020		May 6, 2020	AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France		https://ClinicalTrials.gov/show/NCT04341870
790	NCT04343001	Coronavirus Response - Active Support for Hospitalised Covid-19 Patients	CRASH-19	Not yet recruiting	No Results Available	Covid-19	Drug: Aspirin|Drug: Losartan|Drug: Simvastatin	Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge	London School of Hygiene and Tropical Medicine	All	40 Years and older   (Adult, Older Adult)	Phase 3	10000	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-KEP-420	October 2020	April 2021	August 2021	April 13, 2020		August 19, 2020	University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan		https://ClinicalTrials.gov/show/NCT04343001
791	NCT04511923	Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury	CHARTER-Irl	Not yet recruiting	No Results Available	Covid19|ARDS, Human|Lung Injury, Acute|Ventilation Perfusion Mismatch	Drug: Nebulised heparin	D-dimer profile|Frequenccy of Severe Adverse Outcomes|Oxygenation Index|Indices of Inflammation|Ratios of Indices of Inflammation|Indices of Coagulation|Quasi-Static Lung Compliance|Time to separation from invasive ventilation|Number treated with neuromuscular blockers|Number treated with Prone positioning|Number treated with extra-corporeal membrane oxygenation|Number requiring Tracheostomy|Time to separation from invasive ventilation among survivors|Discharge to ward|Discharge to ward in survivors|Patient Survival|Number of patients residing at home or in a community setting at day 60|Number of surviving patients residing at home or in a community	University College Hospital Galway	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NUIG-2020-003	September 2020	September 2021	January 2022	August 13, 2020		August 13, 2020	Galway University Hospital, Galway, Ireland		https://ClinicalTrials.gov/show/NCT04511923
792	NCT04298060	DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)	STOP-Flu	Not yet recruiting	No Results Available	Influenza Infection|SAD-RV Infection and COVID-19	Drug: DAS181|Drug: Placebo	Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement	Ansun Biopharma, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	280	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	DAS181-2-07	July 2020	March 2021	September 2022	March 6, 2020		July 9, 2020	Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China		https://ClinicalTrials.gov/show/NCT04298060
793	NCT04344600	Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection	PROTECT	Recruiting	No Results Available	Sars-CoV2	Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline	Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples	Johns Hopkins University|Eiger BioPharmaceuticals	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	164	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	IRB00248163	May 29, 2020	June 2021	December 2021	April 14, 2020		August 20, 2020	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04344600
794	NCT04341480	The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19		Active, not recruiting	No Results Available	Gynecological Cancer	Drug: Chemotherapy	SARS-CoV-2 infection|Tumor response|Safety and tolerability of chemotherapy as measured by the Common Terminology|Quality of Life (QOL) measures using Functional Assessment of Cancer Therapy (FACT- ovarian cancer)	Tongji Hospital	Female	18 Years to 80 Years   (Adult, Older Adult)		305	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-TJ-COVID-19	July 1, 2020	December 10, 2020	January 10, 2021	April 10, 2020		October 8, 2020	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04341480
795	NCT04350281	Double Therapy With IFN-beta 1b and Hydroxychloroquine		Completed	No Results Available	COVID	Drug: Interferon Beta-1B|Drug: Hydroxychloroquine	Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes	The University of Hong Kong	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW 20-211	April 9, 2020	July 1, 2020	July 7, 2020	April 17, 2020		July 28, 2020	The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04350281
796	NCT04402957	LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)		Not yet recruiting	No Results Available	COVID|Severe Acute Respiratory Syndrome|Sars-CoV2|Acute Kidney Injury	Drug: LSALT peptide|Drug: Placebo	Development of Acute Respiratory Distress Syndrome (ARDS) and Other Organ Injuries|Ventilation-free days|Time on nasal cannula or oxygen masks|28 day mortality - all cause and attributable|ICU and hospitalization length of stay (days)|SARS-CoV2 testing|Need and duration for extracorporeal membrane oxygenation (ECMO)|Vasopressor free days|Radiographic pulmonary assessments|Change in modified Medical Research Council (mMRC) dyspnea and Sequential Organ Failure Assessment (SOFA) scores|Incidence of non-lung disorders|Measures of liver dysfunction|Measures of kidney dysfunction|Measures of cardiac dysfunction|Measures of coagulopathies|Changes in immunogenic responses|Healthcare outcomes|Molecular changes in pro-inflammatory pathways|Pharmacokinetics of LSALT peptide	Arch Biopartners Inc.	All	45 Years to 80 Years   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AB002	July 1, 2020	December 31, 2020	June 30, 2021	May 27, 2020		June 16, 2020			https://ClinicalTrials.gov/show/NCT04402957
797	NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19		Active, not recruiting	No Results Available	Coronavirus Disease 2019	Drug: Placebos|Drug: Leronlimab (700mg)	Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|Time to clinical resolution (TTCR)|Change from baseline in National Early Warning Score 2 (NEWS2)|Change from baseline in pulse oxygen saturation (SpO2)|Change from baseline in the patient's health status on a 7-category ordinal scale|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity	CytoDyn, Inc.	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	86	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CD10_COVID-19	April 1, 2020	July 21, 2020	August 31, 2020	April 13, 2020		August 20, 2020	University of California, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|White Plains Hospital, White Plains, New York, United States|Novant Health, Charlotte, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT04343651
798	NCT04353271	Trial of Hydroxychloroquine In Covid-19 Kinetics	THICK	Terminated	No Results Available	Covid 19|Corona Virus Infection	Drug: Hydroxychloroquine|Other: Placebo	Percentage of virus free subjects|Disease severity|Incidence of hospitalization|Incidence of Death|Incidence of confirmed SARS-CoV-2 Detection|Incidence of all-cause study medication discontinuation or withdrawal|Immunity to Covid-19	University of South Alabama	All	19 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	58	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	[1582736-1]	April 17, 2020	July 8, 2020	July 8, 2020	April 20, 2020		August 20, 2020	University of South Alabama, Mobile, Alabama, United States		https://ClinicalTrials.gov/show/NCT04353271
799	NCT04252274	Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19	DC-COVID-19	Recruiting	No Results Available	Pneumonia, Pneumocystis|Coronavirus	Drug: Darunavir and Cobicistat	The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2	Shanghai Public Health Clinical Center	All	Child, Adult, Older Adult	Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DC-COVID-19	January 30, 2020	August 31, 2020	December 31, 2020	February 5, 2020		April 13, 2020	Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04252274
800	NCT04453839	RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)	SAMICARE	Available	No Results Available	Critical COVID-19 With Respiratory Failure	Drug: RLF-100 (aviptadil)		NeuroRx, Inc.|Cavendish Impact Foundation	All	12 Years to 100 Years   (Child, Adult, Older Adult)			Industry|Other	Expanded Access:Intermediate-size Population		RLF-100_EA-1				July 1, 2020		July 29, 2020	University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Houston Methodist Hospital, Houston, Texas, United States	"Study Protocol and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04453839/Prot_ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04453839
801	NCT04305457	Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19	NoCovid	Active, not recruiting	No Results Available	Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome	Drug: Nitric Oxide	Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery	Massachusetts General Hospital|University of Alabama at Birmingham	All	18 Years and older   (Adult, Older Adult)	Phase 2	67	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NOgas mildCOVID-19	March 21, 2020	April 1, 2021	April 1, 2022	March 12, 2020		August 31, 2020	Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04305457
802	NCT04374149	Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS		Active, not recruiting	No Results Available	Cytokine Release Syndrome|COVID19	Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib	Overall Response Rate	Prisma Health-Upstate	All	12 Years to 80 Years   (Child, Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PHU COVID-19-001	April 30, 2020	September 25, 2020	December 1, 2020	May 5, 2020		September 16, 2020	Prisma Health, Greenville, South Carolina, United States		https://ClinicalTrials.gov/show/NCT04374149
803	NCT04535856	Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients	DW-MSC	Not yet recruiting	No Results Available	Covid19|Corona Virus Infection|SAR	Drug: allogeneic mesenchymal stem cell|Other: Placebo	Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change	Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD.	All	19 Years and older   (Adult, Older Adult)	Phase 1	9	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DW_DWP710101	September 11, 2020	October 30, 2020	December 31, 2020	September 2, 2020		September 4, 2020	Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia		https://ClinicalTrials.gov/show/NCT04535856
804	NCT04366908	Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome	COVIDIOL	Not yet recruiting	No Results Available	SARS-CoV 2|COVID19|SARS (Severe Acute Respiratory Syndrome)|Cytokine Release Syndrome|Cytokine Storm	Drug: BAT + Calcifediol|Drug: BAT	Admission to Intensive Care Unit|Death|Time from onset of symptoms to discharge of patients in conventional hospitalization|ICU - Time until admission|ICU - Time mechanical ventilation is removed|Evaluation of the inflammatory markers related with the disease|Vitamin D metabolites|Evolution in SatO2|Evolution in the Sat O2/FiO2 ratio.|Evolution in the degree of dyspnea|Evolution of the improvement of radiological findings by simple radiology|Incidence of adverse events|Appearance of hemorrhagic or thrombotic phenomena	Maimónides Biomedical Research Institute of Córdoba|Junta de Andalucía - Consejería de Salud y Familias|Dynamic Solutions|FAES Farma	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	1008	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVIDIOL	April 28, 2020	July 28, 2020	August 28, 2020	April 29, 2020		April 30, 2020			https://ClinicalTrials.gov/show/NCT04366908
805	NCT04534725	COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;	C-SMART	Not yet recruiting	No Results Available	Cancer|Covid19|Respiratory Viral Infection	Drug: Interferon alfa|Drug: Selinexor|Drug: Lenzilumab	Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)|incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing|incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .|incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records|time to clinical improvement or discharge from hospital assessed using medical records|ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool|ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records|ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records|ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale|ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records|ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR|ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records|ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records|ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.|ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records|ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.|ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.|ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.|ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records|ARM 3: Time to clinical improvement assessed using medical records.|ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 3: change to clinical condition assessed with Karnofsky Performance score|ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale|ARM 3: Time to all-cause mortality|ARM 3:Duration of hospitalisation assessed using medical records|ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.|ARM 3: Duration of oxygen supplementation (days). assessed using medical records.|ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)|ARM 3: Safety and tolerability of selinexor using relevant medical records|ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records|ARM 4: Incidence of all cause death by day 28 and 60|ARM 4: Time to all-cause mortality|ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 4: Incidence of ARDS assessed using medical records|ARM 4: incidence of HLH. assessed using medical records|ARM 4: Duration of hospitalisation. assessed using hospital medical records.|ARM 4: Proportion discharged from hospital. assessed using medical records|ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records|ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records|ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.|ARM 4: Incidence and duration of ICU admission. assessed using medical records|ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records|ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.|ARM 4: incidence of non-invasive ventilation. assessed using medical records|ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.|ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records|ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records|ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records|ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.	Peter MacCallum Cancer Centre, Australia	All	18 Years and older   (Adult, Older Adult)	Phase 3	2282	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Peter Mac ID 20/135	September 2020	September 2021	December 2021	September 1, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04534725
806	NCT04347239	Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	Coronavirus Disease 2019	Drug: Placebos|Drug: Leronlimab (700mg)	All-cause mortality at Day 28|All-cause mortality at Day 14|Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)|Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)|Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.	CytoDyn, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CD12_COVID-19	April 15, 2020	December 31, 2020	April 1, 2021	April 15, 2020		August 31, 2020	St. Jude Medical Center, Fullerton, California, United States|UCLA, Los Angeles, California, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Barnabas, Livingston, New Jersey, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Novant Health, Winston-Salem, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04347239
807	NCT04521400	the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19		Not yet recruiting	No Results Available	Covid19	Drug: High dose Interferon-beta 1a|Drug: Lopinavir/Ritonavir|Drug: Low dose Interferon-beta 1a	Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events	Shahid Beheshti University of Medical Sciences	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Interferon in COVID	August 20, 2020	September 4, 2020	September 11, 2020	August 20, 2020		August 20, 2020			https://ClinicalTrials.gov/show/NCT04521400
808	NCT04320277	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	BARI-COVID	Not yet recruiting	No Results Available	Pharmacological Action	Drug: Baricitinib	The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.	Hospital of Prato	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	200	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HPrato-3	May 16, 2020	June 30, 2020	July 30, 2020	March 24, 2020		April 22, 2020	Fabrizio Cantini, Prato, Tuscany, Italy		https://ClinicalTrials.gov/show/NCT04320277
809	NCT04355962	Sevoflurane in COVID-19 ARDS (SevCov)		Recruiting	No Results Available	ARDS, Human|Coronavirus	Drug: Sevoflurane|Drug: Intravenous drug	Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28|Length of stay ICU|Plasma Inflammatory markers|Length of stay at hospital|Sex-related differences in complications	University of Zurich|Kantonsspital Münsterlingen|Triemli Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	2020-00719	April 23, 2020	March 31, 2021	March 31, 2021	April 21, 2020		September 11, 2020	Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Stadtspital Triemli, Zurich, Switzerland|University Hospital Zuirch, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04355962
810	NCT04387760	Favipiravir vs Hydroxychloroquine in COVID -19		Recruiting	No Results Available	SARS-CoV 2|COVID-19	Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients	Primary outcome measure will be time to viral clearance|Requirement of Escalation of Respiratory Support|Adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as RBS <3.9 mmol/L))|Requirement of ICU Admission|Mortality rate|Serum lactate measurement|Serum Ferritin measurement|Serum D Dimer measurement|Ratio of Lymphocyte to Neutrophil, measurement|Discharge and Length of Hospital Stay|Readmission Rate|Daily Sequential Organ Failure Assessment (SOFA) score|Daily National Early Warning Score (NEWS) 2 score|Clinical improvement|QT prolongation|Cardiac arrythmia (fatal and non fatal)	Royal College of Surgeons in Ireland - Medical University of Bahrain|Ebrahim Khalil Kanoo Community Medical Center|Hereditary blood Disorder Centre - Salmaniya Medical Complex|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali|Jidhafs COVID-19 Centre|Sitra FICU	All	21 Years and older   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	40 / 07-May-2020	August 11, 2020	April 14, 2021	May 14, 2021	May 14, 2020		August 18, 2020	Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain		https://ClinicalTrials.gov/show/NCT04387760
811	NCT04321096	The Impact of Camostat Mesilate on COVID-19 Infection	CamoCO-19	Recruiting	No Results Available	Corona Virus Infection	Drug: Camostat Mesilate|Drug: Placebo oral tablet	Cohort 1: Days to clinical improvement from study enrolment|Cohort 2: Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Cohort 1: Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Cohort 1: Day 30 mortality|Cohort 1: Change in NEW(2) score from baseline to day 30|Cohort 1: Admission to ICU|Cohort 1: Use of invasive mechanical ventilation or ECMO|Cohort 1: Duration of supplemental oxygen (days)|Cohort 1+2: Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30|Cohort 2: Number participant-reported secondary infection of housemates|Cohort 2: Time to hospital admission related to COVID-19 infection	University of Aarhus	All	18 Years to 110 Years   (Adult, Older Adult)	Phase 1|Phase 2	580	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-001200-42	April 4, 2020	December 31, 2020	May 1, 2021	March 25, 2020		April 30, 2020	Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark		https://ClinicalTrials.gov/show/NCT04321096
812	NCT04456439	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)		Available	No Results Available	Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)	Biological: Remestemcel-L|Drug: Hydrocortisone|Drug: Diphenhydramine		Mesoblast International Sàrl|Mesoblast, Ltd.	All	2 Months to 17 Years   (Child)			Industry	Expanded Access:Intermediate-size Population		MSB-MSC-MISC001				July 2, 2020		July 2, 2020			https://ClinicalTrials.gov/show/NCT04456439
813	NCT04342156	Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19	SHARP COVID-19	Withdrawn	No Results Available	Coronavirus Infection|Hydroxychloroquine Adverse Reaction	Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab	positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.|Positive serology at day 28.|Symptoms of COVID-19.	Tan Tock Seng Hospital|National Center for Infectious Diseases|Singapore Clinical Research Institute|Singapore Eye Research Institute|Saw Swee Hock School of Public Health|Duke-NUS Graduate Medical School|Netherlands: Ministry of Health, Welfare and Sports	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2020/00402	April 2020	August 2020	October 2020	April 10, 2020		October 7, 2020			https://ClinicalTrials.gov/show/NCT04342156
814	NCT04473261	Efficacy of Iodine Complex Against COVID-19 Patients	I-COVID-PK	Recruiting	No Results Available	Covid19|SARS-CoV-2|Corona Virus Infection	Drug: Iodine Complex|Drug: Placebo	qRT-PCR|Severity of Symptoms	Sohaib Ashraf|MTI Medical Private Limited, Pakistan|Sheikh Zayed Federal Postgraduate Medical Institute	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SZMC/IRB/Internal/216/2020	July 14, 2020	September 15, 2020	September 30, 2020	July 16, 2020		July 16, 2020	Shaikh Zayed Hospital, Lahore, Pakistan		https://ClinicalTrials.gov/show/NCT04473261
815	NCT04524663	Oral Camostat Compared With Standard Supportive Care in Mild COVID-19 Patients	COPS-2002	Not yet recruiting	No Results Available	Covid19	Drug: Camostat Mesilate|Drug: Placebo|Other: Standard of Care Treatment	Time until cessation of shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load (Nucleic Acid)|Clinical worsening of COVID-19 disease in symptomatic patients|Development of antibodies to SARS-CoV-2|Time until cessation of symptoms	Stanford University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	56029	October 2020	April 2021	April 2021	August 24, 2020		September 21, 2020	Stanford University, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04524663
816	NCT04328272	Effectiveness of Hydroxychloroquine in Covid-19 Patients	Covid	Not yet recruiting	No Results Available	COVID19	Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets	National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers	Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad	All	18 Years to 50 Years   (Adult)	Phase 3	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Ath/ct101/22/3	March 28, 2020	May 28, 2020	June 28, 2020	March 31, 2020		April 2, 2020	Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan		https://ClinicalTrials.gov/show/NCT04328272
817	NCT04338906	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	CLOCC	Not yet recruiting	No Results Available	COVID	Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine	Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality	Heinrich-Heine University, Duesseldorf|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany	All	18 Years and older   (Adult, Older Adult)	Phase 4	334	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CLOCC-2020	June 1, 2020	June 1, 2021	December 31, 2021	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338906
818	NCT04396067	Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	Antibodies	Not yet recruiting	No Results Available	COVID-19	Drug: Aerosolized 13 cis retinoic acid|Drug: Aerosolized All trans retinoic acid|Other: Placebo	lung injury score|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|d-dimers|Absolute lymphocyte counts|The immune correlates of protection against future exposure to SARS-CoV-2|Immunological profile|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Occurrence of adverse event related to immunoglobulins|IgG, IgA and IgM against COVID-19|ACE2 expression in patients with COVID-19 infection|All cause mortality rate [|Ventilation free days|ICU free days	Kafrelsheikh University|Damietta University	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	360	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19	October 2020	October 2020	December 2020	May 20, 2020		September 15, 2020			https://ClinicalTrials.gov/show/NCT04396067
819	NCT04365582	OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome	OUTCOV	Suspended	No Results Available	COVID	Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab	Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events	Groupe Hospitalier Paris Saint Joseph	All	50 Years and older   (Adult, Older Adult)	Phase 3	640	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OUTCOV	May 7, 2020	December 7, 2020	February 7, 2021	April 28, 2020		September 29, 2020	Hôpital Privé d'Antony, Antony, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France		https://ClinicalTrials.gov/show/NCT04365582
820	NCT04366245	Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection		Recruiting	No Results Available	SARS-CoV 2	Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection	Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization or an increase of 2 points or more from the basal level|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients requiring treatment.|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.	Andalusian Network for Design and Translation of Advanced Therapies	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	72	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PC/COVID-19	April 23, 2020	December 2021	December 2021	April 28, 2020		June 11, 2020	Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital U. Puerto Real, Puerto Real, Cádiz, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital U. Torrecárdenas, Almería, Spain|Hospital U. Puerta del Mar, Cádiz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital Regional U. de Málaga, Málaga, Spain|Hospital U. Virgen de la Victoria, Málaga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital U. Nuestra Señora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT04366245
821	NCT04408326	Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	ACES	Recruiting	No Results Available	COVID|Acute Respiratory Distress Syndrome	Drug: Angiotensin II|Drug: Interleukin-1 receptor antagonist	Proportions of patients with mean arterial pressure ≥ 65 mmHg or an increase of mean arterial pressure ≥10 mmHg at 3 hours|Noradrenaline dose|Sequential Organ Failure Assessment (SOFA) score|RRT-free days|RRT discontinuation|Serum creatinine|PaO2/FiO2 ratio|Mortality|Adverse events|Change in serum C-reactive protein|Change in serum ferritin	Guy's and St Thomas' NHS Foundation Trust|Australian and New Zealand Intensive Care Research Centre|Monash University|Royal Surrey County Hospital NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	283005	June 1, 2020	May 1, 2021	May 1, 2021	May 29, 2020		June 5, 2020	Guy's & St Thomas' Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04408326
822	NCT04355052	Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus	COSTA	Recruiting	No Results Available	COVID - 19	Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin	clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death	Sheba Medical Center	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 3	250	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7092-20-SMC	April 11, 2020	October 11, 2020	December 11, 2020	April 21, 2020		April 21, 2020	Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel		https://ClinicalTrials.gov/show/NCT04355052
823	NCT04332666	Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial	ATCO	Not yet recruiting	No Results Available	Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2	Drug: Angiotensin 1-7|Drug: Placebos	ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings	Erasme University Hospital|Fonds Erasme pour la Recherche Médicale	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	P2020/201	September 30, 2020	December 30, 2020	June 15, 2021	April 3, 2020		August 19, 2020			https://ClinicalTrials.gov/show/NCT04332666
824	NCT04400929	Using GM-CSF as a Host Directed Therapeutic Against COVID-19		Recruiting	No Results Available	COVID|Sars-CoV2|ARDS, Human	Drug: Sargramostim|Other: Normal Saline 0.9%	Measuring oxygenation	Singapore General Hospital	All	21 Years to 80 Years   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SH-Leuk-01	June 2, 2020	June 2021	June 2022	May 26, 2020		July 7, 2020	Singapore General Hospital, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04400929
825	NCT04327401	COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III	CoDEX	Terminated	No Results Available	Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome	Drug: Dexamethasone	Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score	Hospital Sirio-Libanes|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 3	299	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAAE: 30227020.5.1001.0008	April 13, 2020	July 22, 2020	July 22, 2020	March 31, 2020		August 7, 2020	Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04327401/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04327401
826	NCT04330495	Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection		Not yet recruiting	No Results Available	COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors	Drug: Hidroxicloroquina|Drug: Control group	Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events	Instituto de Investigación Marqués de Valdecilla	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	EnCOVID-HidroxiCLOROQUINA	April 6, 2020	November 6, 2020	November 6, 2020	April 1, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04330495
827	NCT04366232	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)	JAKINKOV	Not yet recruiting	No Results Available	Covid-19	Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care	Biological criteria|Duration of oxygen therapy (days)|Number of intensive care units admissions|Number of days in intensive care units|Mortality rate|Total number of days in hospital|Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score)|Number of bacterial and/or fungal sepsis	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|Hopital d'instruction des Armees Sainte-Anne|Assistance Publique Hopitaux De Marseille	All	18 Years and older   (Adult, Older Adult)	Phase 2	54	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-CHITS-003|2020-001963-10	June 2020	August 31, 2020	August 31, 2020	April 28, 2020		June 9, 2020	AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France|Hôpital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France		https://ClinicalTrials.gov/show/NCT04366232
828	NCT04358406	Rhu-pGSN for Severe Covid-19 Pneumonia		Recruiting	No Results Available	Sars-CoV2	Drug: Recombinant human plasma gelsolin (Rhu-pGSN)|Other: Placebo	Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis|Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)|Efficacy: Daily change in the WHO 9-point severity score|Efficacy: All cause mortality rate at Days 28 and 90|Efficacy: Proportion of subjects alive without the ongoing use of vasopressors, ongoing intubation/mechanical ventilation, ongoing residence in an intensive care unit (ICU), new ongoing need for dialysis/renal replacement therapy|Efficacy: Proportion of subjects discharged to home or immediate prior residence|Efficacy: Length of stay (LOS) of surviving subjects in the hospital and in ICU|Efficacy: Proportion of subjects readmitted to the hospital|Safety and Tolerability: Proportion of subjects with adverse events (AEs)|Safety and Tolerability: Proportion of subjects with new or worsening clinically significant laboratory abnormalities|Immunogenicity: Proportion of subjects with rhu-pGSN antibodies|Pharmacokinetics: Maximum concentration (C max) of added rhu-pGSN|Pharmacokinetics: Time to maximum concentration (T max) of added rhu-pGSN|Pharmacokinetics: Half-life (T 1/2) of added rhu-pGSN|Pharmacokinetics: Area under the curve from time 0 to 8 hours (AUC 0-8) of added rhu-pGSN|Pharmacokinetics: Area under the curve from time 0 to infinity (AUC 0-inf) of added rhu-pGSN	BioAegis Therapeutics Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BTI-202	July 30, 2020	October 30, 2020	October 30, 2020	April 24, 2020		July 31, 2020	Sant Joan de Reus SAM University Hospital, Reus, Spain		https://ClinicalTrials.gov/show/NCT04358406
829	NCT04353128	Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.	MeCOVID	Recruiting	No Results Available	Covid19|SARS-CoV 2|Coronavirus Infection	Drug: Melatonin 2mg|Drug: Placebo oral tablet	SARS-CoV 2 infection rate	Instituto de Investigación Hospital Universitario La Paz	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2|Phase 3	450	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	MeCOVID	April 20, 2020	October 2020	December 2020	April 20, 2020		June 16, 2020	Hospital Universitario La Paz, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04353128
830	NCT04275414	Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia	BEST-CP	Completed	No Results Available	Coronavirus Infections	Drug: Bevacizumab Injection	Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Rate of improvement of oxygen-support status|The change of areas of pulmonary lesions shown on chest radiological imaging (chest CT or X-ray)|Blood lymphocyte counts|Level of CRP|Level of hs-CRP|All-cause mortality|Discharge rate	Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	27	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QLEmer20200214	February 15, 2020	April 5, 2020	May 2, 2020	February 19, 2020		September 14, 2020	Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy		https://ClinicalTrials.gov/show/NCT04275414
831	NCT04560231	Remdesivir in COVID-19 Lahore General Hospital	RC19LGH	Recruiting	No Results Available	SARS-CoV Infection	Drug: Remdesivir	Clinical response after administration|Clinical response to treatment|Duration of hospitalization|Supplemental Oxygen Requirement from Baseline	Lahore General Hospital	All	15 Years to 80 Years   (Child, Adult, Older Adult)	Early Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LGH003	June 1, 2020	November 30, 2020	November 30, 2020	September 23, 2020		September 25, 2020	Muhammad Irfan Malik, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04560231
832	NCT04332835	Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study	CP-COVID-19	Recruiting	No Results Available	Coronavirus|Coronavirus Infection	Drug: Plasma|Drug: Standard Therapy	Change in Viral Load|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality	Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2|Phase 3	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	ABN011-2	August 8, 2020	October 31, 2020	October 31, 2020	April 3, 2020		September 2, 2020	Universidad del Rosario, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04332835
833	NCT04403555	Ivermectin and Doxycycine in COVID-19 Treatment		Recruiting	No Results Available	COVID	Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine	The number of patients with improvement or mortality	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	tanta combo covid treatment	June 1, 2020	December 1, 2030	December 3, 2030	May 27, 2020		August 4, 2020	Sherief Abd-Elsalam, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04403555
834	NCT04535167	First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.		Recruiting	No Results Available	Viral Disease	Drug: PF-07304814|Drug: Placebo	Frequency of treatment-emergent adverse events (TEAEs)|Number of participants who withdraw due to treatment-emergent adverse events (TEAEs)|Frequency of treatment-emergent adverse events (TEAEs), causally related to study intervention|Frequency of treatment-emergent serious adverse events|Frequency of treatment-emergent infusion site reactions|Magnitude of abnormal hematologic laboratory findings|Frequency of abnormal chemistry values|Frequency of abnormal hematologic laboratory findings|Magnitude of abnormal urinalysis findings|Change from baseline in PR values|Change from baseline in RR values|Change from baseline in QTc values|Change from baseline in QTcF values|Change from baseline in QRS values|Change from baseline in pulse rate measurements|Change from baseline in temperature values|Change from baseline in respiratory rate values|Change from baseline in systolic blood pressure|Change from baseline in diastolic blood pressure|Change from baseline in pulse oximetry/SpO2 measurement|Change in concentration at 24 hours (C24[end of infusion]) of PF-07304814 and PF-00835231|Change in concentration, dose normalised, at 24 hours (C24 (dn) [end of infusion]) of PF-07304814 and PF-00835231|Change in concentration at 120 hours (C120[end of infusion]) of PF-07304814 and PF-00835231|Change in maximum observed concentration (Cmax) of PF-07304814 and PF-00835231|Change in maximum observed concentration, dose normalised (Cmax [dn]) of PF-07304814 and PF-00835231|Change in concentration at steady state (Css) of PF-07304814 and PF-00835231|Change in concentration at steady state, dose normalised (Css [dn]) of PF-07304814 and PF-00835231|Change in terminal half life (t1/2) of PF-07304814 and PF-00835231|Change in clearance (CL) of PF-07304814|Change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity (AUCinf) of PF-07304814 and PF-00835231|Change in area-under-the-curve plasma concentration from 0 to last quantifiable concentration (AUClast) of PF-07304814 and PF-00835231|Change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity, dose normalised (AUCinf [dn]) of PF-07304814 and PF-00835231|Change in steady state volume of distribution (Vss) of PF-00835231|Cumulative amount of unchanged drug excreted into urine (Ae)|Percent of dose excreted as unchanged drug (Ae%) over dosing period	Pfizer	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	56	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	C4611001|2020-003905-73	September 9, 2020	March 21, 2021	March 21, 2021	September 1, 2020		October 5, 2020	El Camino Health, Mountain View, California, United States|Palo Alto Medical Foundation, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UC Davis Health Investigational Drug Pharmacy, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Iowa, Iowa City, Iowa, United States|Multicare Health System-Tacoma General Hospital, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT04535167
835	NCT04331054	Protective Role of Inhaled Steroids for Covid-19 Infection	INHASCO	Recruiting	No Results Available	Covid-19 Infection|Hospitalization in Respiratory Disease Department	Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice	Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.	Assistance Publique - Hôpitaux de Paris	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	436	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P 200394|2020-001306-35	April 13, 2020	January 13, 2022	January 13, 2022	April 2, 2020		September 15, 2020	Hôpital Bichat - Service de Pneumologie, Paris, France		https://ClinicalTrials.gov/show/NCT04331054
836	NCT04445506	Short Term Corticosteroids in SARS-CoV2 Patients		Completed	No Results Available	Corticosteroids|Covid19|SARS-CoV 2|Steroids|Dexamethasone	Drug: Dexamethasone	Effect on transfers to ICU and escalation of care needing mechanical ventilation|Effect on length of stay|Change in CRP levels	The Miriam Hospital	All	18 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	20-027	April 1, 2020	May 31, 2020	May 31, 2020	June 24, 2020		June 24, 2020	The Miriam Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT04445506
837	NCT04361461	Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)		Withdrawn	No Results Available	Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease	Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin	Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation	Apsen Farmaceutica S.A.|Federal University of São Paulo	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APS001/2020	April 30, 2020	November 4, 2020	November 4, 2020	April 24, 2020		July 1, 2020	Apsen Farmacêutica S.A., São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04361461
838	NCT04433546	Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).	VANGARD	Recruiting	No Results Available	Acute Respiratory Distress Syndrome|Coronavirus|Hypoxic Respiratory Failure|Hypoxemic Respiratory Failure|Respiratory Complication|Respiratory Insufficiency|Cardiac Dysfunction|Pneumonia|Pulmonary Edema|Pulmonary Inflammation|Respiratory Failure|Cytokine Storm|COVID 19|SARS-CoV-2|Cardiac Event|Cardiac Complication|Cardiac Failure|Cardiac Infarct	Drug: Pemziviptadil (PB1046)|Drug: Low Dose (10 mg) Control	Days alive and free of respiratory failure from initiation of pemziviptadil (PB1046)|Time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge)|Development of ARDS (PaO2:FiO2 ratio < 300 mm Hg) during hospitalization|All-cause mortality|Reduction in hospital resource utilization defined as a composite of:total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy|Time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first.|Change from baseline in cardiac marker high sensitivity troponin I (hsTnI)|Change from baseline in cardiac marker NT-proBNP|Change from baseline in TNF alpha|Change from baseline in IL-1|Change from baseline in IL-6|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by clinical adverse events (AEs) and their relationship to PB1046|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by vital signs and their relationship to PB1046|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by laboratory results and their relationship to PB1046|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by electrocardiogram (ECG) abnormalities and their relationship to PB1046|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by incidence of anti-drug antibodies and their relationship to PB1046	PhaseBio Pharmaceuticals Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PB1046-PT-CL-0007	July 15, 2020	December 18, 2020	December 18, 2020	June 16, 2020		October 6, 2020	Baptist Health Research Institute, Jacksonville, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Adventist Healthcare White Oak Medical Center, Silver Spring, Maryland, United States		https://ClinicalTrials.gov/show/NCT04433546
839	NCT04478071	Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	Acute Respiratory Distress Syndrome|Coronavirus Infection	Drug: vadadustat|Drug: placebo	Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale|Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale	The University of Texas Health Science Center, Houston|Akebia Therapeutics Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HSC-MS-20-0395	August 22, 2020	August 1, 2022	August 1, 2022	July 20, 2020		September 10, 2020	The University of Texas Health Science Center at Houston, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04478071
840	NCT04402970	Dornase Alfa for ARDS in Patients With SARS-CoV-2	DORNASESARS2	Recruiting	No Results Available	SARS-CoV 2|ARDS	Drug: Dornase Alfa Inhalation Solution	Improvement in PaO2/FiO2|Change in static lung compliance|Duration of mechanical ventilation|Length of ICU stay|Length of hospitalization|Secondary bacterial infections|Mortality	University of Missouri-Columbia	All	18 Years and older   (Adult, Older Adult)	Phase 3	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2022206	June 19, 2020	May 31, 2021	May 31, 2022	May 27, 2020		June 26, 2020	University of Missouri Hospital and Clinics, Columbia, Missouri, United States		https://ClinicalTrials.gov/show/NCT04402970
841	NCT04410510	P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19		Recruiting	No Results Available	COVID|Coronavirus Infection|SARS-CoV 2|COVID19	Drug: P2Et (Caesalpinia spinosa extract)|Other: Placebo	Evaluate the efficacy of P2Et in reducing the length of hospital stay of patients with clinical suspicion or confirmed case of COVID-19|Efficacy of P2Et in reducing the time to clinically significant improvement in patients with clinical suspicion or confirmed case of COVID-19|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 14 days of treatment|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 28 days of treatment|Efficacy of P2Et in reducing the proportion of hospitalized patients with clinical suspicion or confirmed case of COVID-19 who require admission to the ICU due to worsening clinical symptoms.|Efficacy of P2Et in reducing the proportion of patients with clinical suspicion or confirmed case of COVID-19 who die from the disease.|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of the P2Et in patients with COVID-19	Hospital Universitario San Ignacio|Pontificia Universidad Javeriana	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care	CS002-COVID19	September 30, 2020	December 2020	June 2021	June 1, 2020		October 2, 2020	Hospital Universitario San Ignacio, Bogotá, Colombia		https://ClinicalTrials.gov/show/NCT04410510
842	NCT04351347	The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment		Recruiting	No Results Available	COVID	Drug: Ivermectin|Drug: Nitazoxanide with ivermectin|Drug: Ivermectin wth chloroquine	Number of patients with improvement or died	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ivermecin covid	June 16, 2020	December 1, 2030	December 1, 2030	April 17, 2020		August 4, 2020	Tanta University, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04351347
843	NCT04356495	Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)	COVERAGE	Recruiting	No Results Available	Corona Virus Infection|Sars-CoV2	Dietary Supplement: Vitamins|Drug: Telmisartan	Proportion of participants with an occurrence of hospitalization|Death|Proportion of hospitalizations, overall and by cause, in each group|Death and causes of death|Proportion of intensive care hospitalizations, overall and by cause, in each group|Proportion of participants with negative nasopharyngeal SARS-CoV-2 RT-PCR|Proportion of participants with a loss of autonomy evaluated by the ADL and IADL scale|Haematological markers evolution|Biochemical markers evolution|Inflammatory markers evolution|Immunological markers evolution|Adverse events|Adverse reactions|Plasma concentration|Acceptability of the treatment	University Hospital, Bordeaux|University of Bordeaux	All	60 Years and older   (Adult, Older Adult)	Phase 3	338	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHUBX 2020/12	July 29, 2020	December 31, 2020	January 28, 2021	April 22, 2020		October 7, 2020	CH de Bastia, Bastia, France|Bordeaux university Hospital, Bordeaux, France|CHU de Dijon-Bourgogne, Dijon, France|CHRU de Nancy, Nancy, France|CHU de Toulouse, Toulouse, France		https://ClinicalTrials.gov/show/NCT04356495
844	NCT04399746	Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19	IvAzCol	Recruiting	No Results Available	COVID	Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol	Viral clearance|Symptoms duration|SpO2|SpO2/FiO2	Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IvAzCol	March 15, 2020	May 20, 2020	June 10, 2020	May 22, 2020		May 22, 2020	Outpatient treatment, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT04399746
845	NCT04321174	COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir	CORIPREV-LR	Recruiting	No Results Available	Coronavirus Infections|Post-exposure Prophylaxis	Drug: Lopinavir/ritonavir	Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life	Darrell Tan|St. Michael's Hospital, Toronto	All	18 Months and older   (Child, Adult, Older Adult)	Phase 3	1220	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	CORIPREV-1	April 17, 2020	March 31, 2021	March 31, 2022	March 25, 2020		April 21, 2020	St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04321174
846	NCT04405739	The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)		Recruiting	No Results Available	SARS-CoV 2	Drug: EIDD-2801|Drug: Placebo (PB0)	Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801|Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS|Number of Participants With any Adverse Events(AEs) as assessed by DAIDS	Ridgeback Biotherapeutics, LP	All	18 Years and older   (Adult, Older Adult)	Phase 2	89	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	EIDD-2801-2004	June 16, 2020	October 28, 2020	November 25, 2020	May 28, 2020		October 7, 2020	Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Howard County General Hospital, Columbia, Maryland, United States		https://ClinicalTrials.gov/show/NCT04405739
847	NCT04447404	DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury		Recruiting	No Results Available	SARS-CoV 2	Drug: DUR-928|Drug: Placebo	Composite endpoint of alive and free of organ failure|Occurrence of serious adverse events following treatment|Alive at days 28 and 60|Alive and out of ICU|Alive and out of hospital	Durect	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	C928-020	September 21, 2020	September 2021	October 2021	June 25, 2020		September 30, 2020	Site 02, Chicago, Illinois, United States|Site 01, Detroit, Michigan, United States|Site 03, Newark, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04447404
848	NCT04477993	Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19	RUXO-COVID	Recruiting	No Results Available	Severe Acute Respiratory Syndrome Coronavirus 2|SARS-CoV2	Drug: Janus Kinase Inhibitor (ruxolitinib)|Other: Placebo	A composite outcome of death or ICU admission or mechanical ventilation at day 14.|A composite outcome of death or ICU admission or mechanical ventilation at day 28|Time to treatment failure|Overall survival at days 14 and 28|Cumulative incidence of ICU admission rate at days 14 and 28|Cumulative incidence of mechanical ventilation at days 14 and 28|Duration of hospital stay|Duration of ICU stay|Duration of mechanical ventilation|Duration of non-invasive ventilation|Secondary hemophagocytic syndrome rate|Cumulative incidence nosocomial infection rate at days 14 and 28|Incidence of discontinuation of oxygen supplementation at days 14 and 28|Rate of grade 1-2 and 3-5 emerging adverse events at day 28|Cumulative dose of methylprednisolone at days 14 and 28|Change in PaO2/FiO2 ratio from baseline to days 14 and 28|Change in interleukin 6 levels [pg/mL] from baseline to days 14 and 28|Change in d-dimer levels [ng/mL] from baseline to days 14 and 28|Change in fibrinogen levels [mg/dL] from baseline to days 14 and 28|Change in ferritin levels [ng/mL] from baseline to days 14 and 28|Change in C reactive protein levels [mg/L] from baseline to days 14 and 28|Change in alanine aminotransferase [U/L] from baseline to days 14 and 28|Change in aspartate aminotransferase [U/L] from baseline to days 14 and 28|Change in creatinine levels [mg/dL] from baseline to days 14 and 28|Change in glucose levels [mg/dL] from baseline to days 14 and 28|Change in hemoglobin levels [g/dL] from baseline to days 14 and 28|Change in platelet count [x10ˆ3/mmˆ3] from baseline to days 14 and 28|Change in absolute neutrophil count [x10ˆ3/mmˆ3] from baseline to days 14 and 28|Change in absolute neutrophil count [/mmˆ3] from baseline to days 14 and 28|Change in absolute lymphocyte count [/mmˆ3] from baseline to days 14 and 28|Change in prothrombin time ratio from baseline to days 14 and 28|Change in partial thromboplastin time ratio from baseline to days 14 and 28|Change in bilirubin [mg/dl] from baseline to days 14 and 28|Change in lactate dehydrogenase [U/L] from baseline to days 14 and 28|Change in CPK-MB [ng/mL] from baseline to days 14 and 28|Change in troponin [ng/mL] from baseline to days 14 and 28|Change in von Willebrand factor antigen level (VWF:Ag) [%] from baseline to days 14 and 28|Change in von Willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28|Change in ADAMTS-13 [%] from baseline to days 14 and 28|Change in von Willebrand multimeters from baseline to days 14 and 28|Change in plasminogen activator inhibitor-1 levels [ng/mL] from baseline to days 14 and 28|Change in E-selectin levels [ng/mL] from baseline to days 14 and 28|Change in P-selectin levels [ng/mL] from baseline to days 14 and 28|Change in endothelin [fmol/mL] from baseline to days 14 and 28|Change in circulating microparticles from baseline to days 14 and 28|Change in thromboelastography from baseline to days 14 and 28	Vanderson Geraldo Rocha|University of Sao Paulo General Hospital	All	18 Years to 95 Years   (Adult, Older Adult)	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	32894720.3.0000.0068	July 17, 2020	February 17, 2021	December 31, 2021	July 20, 2020		July 20, 2020	Hospital das Clínicas, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04477993
849	NCT04344184	Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)		Not yet recruiting	No Results Available	COVID-19|Lung Injury, Acute	Drug: L-ascorbic acid|Other: Placebo	Number of ventilator-free days|All-cause-mortality|Acute-inflammation-free days|Organ-failure-free days	Virginia Commonwealth University	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HM20018977	October 2020	May 2021	May 2021	April 14, 2020		July 22, 2020	Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT04344184
850	NCT04346446	Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients		Completed	No Results Available	COVID	Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma	Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.	Institute of Liver and Biliary Sciences, India	All	18 Years and older   (Adult, Older Adult)	Phase 2	29	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ILBS-COVID-02	April 20, 2020	May 30, 2020	May 30, 2020	April 15, 2020		June 12, 2020	Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India		https://ClinicalTrials.gov/show/NCT04346446
851	NCT04254874	A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoV	Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization	Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ20200131	February 1, 2020	June 1, 2020	July 1, 2020	February 5, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04254874
852	NCT04379492	A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19		Withdrawn	No Results Available	COVID-19|COVID19|Sars-CoV2|SARS-Cov-2	Drug: Hydroxychloroquine|Other: Placebo	Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)|Number of participants requiring mechanical ventilation for respiratory failure	Memorial Sloan Kettering Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-187	May 5, 2020	September 25, 2020	September 25, 2020	May 7, 2020		September 30, 2020	Memorial Sloan - Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04379492
853	NCT04400019	Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	PREVICHARM	Not yet recruiting	No Results Available	Sars-CoV2|Coronavirus Infection|Prevention & Control|Nursing Home|Hydroxychloroquine	Drug: Hydroxychloroquine Only Product in Oral Dose Form	Number of secondary cases of SARS-CoV2 infection among residents at six days|Number of secondary cases of SARS-CoV2 infection among residents at 14 days|Number of secondary cases of SARS-CoV2 infection among residents at 28 days|SARS-CoV-2 infection in nursing home staff who provide direct care at six days|SARS-CoV-2 infection in nursing home staff who provide direct care at 14 days|SARS-CoV-2 infection in nursing home staff who provide direct care at 28 days|Mortality|Compliance with treatment|Symptoms of SARS-CoV-2 infection at six days|Symptoms of SARS-CoV-2 infection at 14 days|Symptoms of SARS-CoV-2 infection at 28 days|Hospitalization|Adverse events at six days|Adverse events at 14 days|Adverse events at 28 days	University of Malaga|Instituto de Investigacion Biomedica de Malaga|Carlos III Health Institute	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1930	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	COV20/00565	September 2020	December 15, 2020	April 1, 2021	May 22, 2020		September 29, 2020			https://ClinicalTrials.gov/show/NCT04400019
854	NCT04334629	LIBERATE Trial in COVID-19	LIBERATE	Recruiting	No Results Available	Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection	Drug: Ibuprofen	Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days	King's College London|Guy's & St Thomas NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Phase 4	230	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	282009	May 26, 2020	September 25, 2020	May 25, 2021	April 6, 2020		May 28, 2020	Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04334629
855	NCT04341935	Effects of DPP4 Inhibition on COVID-19		Not yet recruiting	No Results Available	Coronavirus Infection|Type 2 Diabetes	Drug: Linagliptin|Drug: Insulin regimen	Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures	University of Miami	All	18 Years and older   (Adult, Older Adult)	Phase 4	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20200384	January 30, 2021	June 30, 2021	December 30, 2021	April 10, 2020		October 7, 2020	University of Miami, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT04341935
856	NCT04414631	Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19		Recruiting	No Results Available	Coronavirus Infections	Drug: Conestat alfa	Disease severity|Time to clinical improvement|Proportion of participants alive and not having required invasive or non-invasive ventilation|Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg)	University Hospital, Basel, Switzerland|Pharming Technologies B.V.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-01252; me20Osthoff3	August 6, 2020	June 2021	July 2021	June 4, 2020		August 11, 2020	University Hospital Basel, Division of Internal Medicine, Basel, Switzerland		https://ClinicalTrials.gov/show/NCT04414631
857	NCT04329195	ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic	ACORES-2	Recruiting	No Results Available	History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection	Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy	Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge	Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitié-Salpêtrière	All	18 Years and older   (Adult, Older Adult)	Phase 3	554	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200409	April 9, 2020	May 9, 2020	August 9, 2020	April 1, 2020		June 4, 2020	Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France		https://ClinicalTrials.gov/show/NCT04329195
858	NCT04365309	Protective Effect of Aspirin on COVID-19 Patients	PEAC	Enrolling by invitation	No Results Available	Novel Coronavirus Pneumonia|Aspirin|Treatment	Drug: Aspirin 100mg	clinical recovery time (TTCR)|the time of SARS-CoV2 overcasting	Xijing Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	128	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Xi jingH	February 10, 2020	April 2020	June 2020	April 28, 2020		April 28, 2020	Cai Yue, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT04365309
859	NCT04421664	Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)		Terminated	No Results Available	Corona Virus Infection|SARS-CoV Infection|Coronavirus	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Ordinal Scale of COVID19 Disease Severity at 14 days|Incidence of Hospitalization|Incidence of COVID-19 related Death|Incidence of all-cause Death|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Overall change in disease severity over 14 days among those who are symptomatic at baseline	McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta|University of British Columbia|McMaster University|Lawson Health Research Institute|Eastern Health|University of Minnesota	All	18 Years and older   (Adult, Older Adult)	Phase 3	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-6549	March 25, 2020	August 17, 2020	August 17, 2020	June 9, 2020		September 22, 2020	University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Eastern Health, Saint John's, Newfoundland and Labrador, Canada|McMaster University, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04421664
860	NCT04382768	Inhaled Ibuprofen to Treat COVID-19	CórdobaTrail	Recruiting	No Results Available	Coronavirus Infection|Respiratory Disease|SARS (Disease)	Drug: Inhaled Hypertonic ibuprofen	Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen.|Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen.|Chage in length of Hospital stay|Chage in duration of ventilation|Chage in length of Critical Care stay|Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28.|Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28.|Time from first dose to conversion to normal or mild pneumonia|Antibiotic requirement|Glucocorticoids requirement|Incidence of adverse event|Incidence of serious adverse event|Number of deaths from any cause at 28 days|Lymphocyte count	Química Luar SRL|National Council of Scientific and Technical Research, Argentina|Centro de Excelencia en Productos y Procesos Córdoba	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DNL000004	May 1, 2020	January 2021	January 2021	May 11, 2020		June 11, 2020	Centro de Excelencia en Productos y Procesos Córdoba, Córdoba, Argentina		https://ClinicalTrials.gov/show/NCT04382768
861	NCT04380935	Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome		Recruiting	No Results Available	COVID|Acute Respiratory Distress Syndrome	Biological: Convalescent plasma|Drug: Standard of care	All-cause mortality|Length of stay in intensive care unit|Duration of mechanical ventilation|Body temperature (degree in Celsius)|The Sequential Organ Failure Assessment (SOFA) Score|PAO2/FIO2 ratio|C-Reactive Protein (CRP) in mg/L|D-Dimer in ng/mL|Procalcitonin in ng/mL|Interleukin 6 (IL-6) in pg/mL|Allergic/ anaphylaxis transfusion reaction|Hemolytic transfusion reaction|Transfusion Related Acute Lung Injury|Transfusion associated Circulatory Overload	Indonesia University|Dr Cipto Mangunkusumo General Hospital|Fakultas Kedokteran Universitas Indonesia	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	convalescent plasma RSCM-FKUI	May 18, 2020	October 31, 2020	October 31, 2020	May 8, 2020		August 18, 2020	Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia|St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia|Ciputra Hospital CitraRaya, Jakarta, DKI Jakarta, Indonesia		https://ClinicalTrials.gov/show/NCT04380935
862	NCT04342169	University of Utah COVID-19 Hydrochloroquine Trial		Recruiting	No Results Available	Coronavirus Infection|Coronavirus|Infectious Disease	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition	University of Utah	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB_00131893	April 4, 2020	April 2022	April 2023	April 10, 2020		August 20, 2020	University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04342169
863	NCT04390464	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)	TACTIC-R	Recruiting	No Results Available	COVID19	Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care	Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All cause mortality at day 28|Time to clinical improvement	Cambridge University Hospitals NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Phase 4	1167	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TACTIC-R	May 8, 2020	May 7, 2021	May 1, 2022	May 15, 2020		May 18, 2020	Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04390464
864	NCT04312243	NO Prevention of COVID-19 for Healthcare Providers	NOpreventCOVID	Recruiting	No Results Available	Coronavirus Infections|Healthcare Associated Infection	Drug: Inhaled nitric oxide gas	COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test	Massachusetts General Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	470	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	NOpreCOVID-19	April 7, 2020	April 7, 2021	April 7, 2022	March 18, 2020		June 16, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04312243
865	NCT04365153	Canakinumab in Covid-19 Cardiac Injury (The Three C Study)		Active, not recruiting	No Results Available	COVID-19|SARS-CoV 2	Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos	Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first.|Mortality at day 28	The Cleveland Clinic|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 2	45	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IND 149328	April 24, 2020	December 31, 2020	December 31, 2020	April 28, 2020		September 3, 2020	Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04365153
866	NCT04406389	Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)	IMPACT	Recruiting	No Results Available	COVID-19	Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban	30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events	Weill Medical College of Cornell University	All	18 Years and older   (Adult, Older Adult)	Phase 4	186	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-04021936	October 2020	December 2020	June 2021	May 28, 2020		September 28, 2020	Weill Cornell Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04406389
867	NCT04347382	Honey & Nigella Sativa Trial Against COVID-19	HNS-COVID-PK	Completed	No Results Available	Coronavirus Infection|Sars-CoV2	Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos	Days required to get a positive COVID-19 PCR to negative|HRCT/ X-ray findings of disease progression|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Oxygen Saturation at room air|Incidence of viral myocarditis|Incidence of Acute respiratory Distress Syndrome	Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute	All	18 Years and older   (Adult, Older Adult)	Phase 3	313	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SZMC/IRB/Internal/0026/2020|IRB/2020/658/SIMS	April 30, 2020	August 30, 2020	August 30, 2020	April 15, 2020		October 7, 2020	Federal Post-Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Punjab, Pakistan|Services Institute of Medical Sciences, Services Hospital, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04347382
868	NCT04357730	Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection		Recruiting	No Results Available	Severe Acute Respiratory Syndrome|Respiratory Failure|Acute Respiratory Distress Syndrome	Drug: Alteplase 50 MG [Activase]|Drug: Alteplase 100 MG [Activase]	PaO2/FiO2 improvement from pre-to-post intervention|Achievement of PaO2/FiO2 ≥ 200 or 50% increase in PaO2/FiO2|National Early Warning Score 2 (NEWS2)|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale|48 hour in-hospital mortality|14 days in-hospital mortality|28 days in-hospital mortality|ICU-free days|In-hospital coagulation-related event-free (arterial and venous) days|Ventilator-free days|Successful extubation|Successful weaning from paralysis|Survival to discharge	Denver Health and Hospital Authority|Genentech, Inc.|University of Colorado, Denver|National Jewish Health|Beth Israel Deaconess Medical Center|Long Island Jewish Medical Center|Scripps Health|St. Mary's Medical Center|University of Miami|Ben Taub Hospital|Methodist Dallas Medical Center	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-0880	May 14, 2020	September 2020	November 2020	April 22, 2020		September 14, 2020	Denver Health Medical Center, Denver, Colorado, United States		https://ClinicalTrials.gov/show/NCT04357730
869	NCT04263402	The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia		Recruiting	No Results Available	2019-nCoV Severe Pneumonia	Drug: Methylprednisolone	Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ20200201	February 1, 2020	June 1, 2020	July 1, 2020	February 10, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04263402
870	NCT04357613	IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.	IMAGE-19	Not yet recruiting	No Results Available	SARS Virus	Drug: Experimental drug	To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.|To evaluate the feasibility of imatinib therapy.|To evaluate safety of imatinib therapy|To evaluate the clinical evolution|To evaluate the progression rate to severe COVID-19 disease|To evaluate mortality|To evaluate viral load|To evaluate plasmatic levels of imatinib	Versailles Hospital	All	70 Years and older   (Older Adult)	Phase 2	99	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P20/05_IMAGE19	September 1, 2020	December 1, 2020	December 1, 2021	April 22, 2020		August 7, 2020	CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France		https://ClinicalTrials.gov/show/NCT04357613
871	NCT04453371	Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)	AtTAC	Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome	Drug: Tissue plasminogen activator|Drug: Ringer solution	P/F (PaO2/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV.|Ventilator-free time (days free from MV) for 28 days of observation.	Negovsky Reanimatology Research Institute|Demikhov Municipal Clinical Hospital 68	All	18 Years and older   (Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	tPA-2020	October 15, 2020	January 15, 2021	February 15, 2021	July 1, 2020		September 16, 2020			https://ClinicalTrials.gov/show/NCT04453371
872	NCT04429555	Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS		Not yet recruiting	No Results Available	Pneumonia, Viral	Drug: Ibudilast|Drug: Placebo	Proportion of subjects free from respiratory failure|Mean change from baseline in clinical status using the NIAID 8-point ordinal scale at Day 7|Percentage of patients with improvement in clinical status|Change in cytokine levels from baseline|Adverse event Incidence, severity, relationship to study drug, and study discontinuations|Changes in laboratory values from baseline|Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 14|Mean change from baseline in clinical status|Incidence of mechanical ventilation or intubation|Intensive care unit admission|Plasma concentrations of Ibudilast|All cause mortality	MediciNova	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MN-166-COVID-19-201	September 2020	June 30, 2021	December 1, 2021	June 12, 2020		September 2, 2020			https://ClinicalTrials.gov/show/NCT04429555
873	NCT04394377	Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial	ACTION	Recruiting	No Results Available	Coronavirus Infection	Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d	Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.|Incidence of Venous thromboembolism|Incidence of acute myocardial infarction|Incidence of stroke|Number of days using oxygen therapy|Peak of troponin|Peak of D-dimer|Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria	Brazilian Clinical Research Institute|Hospital Israelita Albert Einstein|Hospital do Coracao|Hospital Sirio-Libanes|Hospital Moinhos de Vento|Hospital Alemão Oswaldo Cruz|Beneficência Portuguesa de São Paulo|Brazilian Research In Intensive Care Network	All	18 Years and older   (Adult, Older Adult)	Phase 4	600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	002/2020	June 21, 2020	December 2020	December 2020	May 19, 2020		October 6, 2020	Centro de Estudos Clínicos do Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Instituto de Ensino e Pesquisa do Hospital da Bahia, Salvador, Bahia, Brazil|Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel, Salvador, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Centro de Ensino e Aperfeiçoamento em Pesquisa - CEAP, Serra, Espirito Santo, Brazil|Centro de Pesquisas Cardiológicas de Goiânia do Hospital das Clínicas (UFG), Goiânia, Goiás, Brazil|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Hospital Universitário da Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Agamenon Magalhães, Recife, Pernambuco, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - Unesp, Botucatu, São Paulo, Brazil|Praxis Pesquisa Médica, Santo André, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil|BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil|Hcor - Hospital do Coração, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Samaritano Paulista, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Hospital São Paulo, São Paulo, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil|Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04394377
874	NCT04415073	A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19		Suspended	No Results Available	Coronavirus|COVID|ARDS|Cytokine Storm|Cytokine Release Syndrome	Drug: SNDX-6352|Drug: Placebo	Proportion of subjects alive and free of respiratory failure|Secondary clinical improvement outcomes|Time to clinical improvement (TTCI)|To evaluate improvement in oxygenation in hospitalized adults with respiratory signs and symptoms secondary to COVID 19 treated with axatilimab|To evaluate changes in biomarkers following treatment with axatilimab|To evaluate the safety and tolerability of axatilimab in the same population|Ventilation outcomes|To evaluate antiviral effect of axatilimab in hospitalized adults with recently diagnosed SARS CoV-2 infection|To characterize exposure to axatilimab	Syndax Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 2	186	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	SNDX-6352-0505	May 30, 2020	November 15, 2020	November 15, 2020	June 4, 2020		August 11, 2020	HonorHealth, Scottsdale, Arizona, United States|Montefiore Medical Center, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT04415073
875	NCT04406246	Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide		Recruiting	No Results Available	Coronavirus Infection	Drug: Nitazoxanide 500Mg Oral Tablet	Health workers that require hospitalization	Materno-Perinatal Hospital of the State of Mexico|Laboratorios Liomont	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	150	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-04-682	May 21, 2020	December 31, 2020	December 31, 2020	May 28, 2020		May 28, 2020	Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico		https://ClinicalTrials.gov/show/NCT04406246
876	NCT04425863	IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19		Active, not recruiting	No Results Available	Severe Acute Respiratory Syndrome|Ventilation Pneumonitis	Drug: Ivermectin 5 MG/ML	Illness development|Reduction of need ICU admission|Reduction of mortality rate|Optimyzing doses of drugs used in the clinical trial|Adverse effects	Eurnekian Public Hospital	All	5 Years and older   (Child, Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IDEA	May 1, 2020	August 10, 2020	August 10, 2020	June 11, 2020		August 11, 2020	Hospital Eurnekian, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04425863
877	NCT04371107	Proactive Care of Ambulatory COVID19 Patients	AMBU-COVID	Not yet recruiting	No Results Available	Covid19|Azithromycin|Ambulatory	Other: consultation|Drug: Azithromycin	Length of symptom duration (in days) with azithromycin treatment	Centre Hospitalier Universitaire, Amiens	All	18 Years and older   (Adult, Older Adult)	Phase 3	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PI2020_843_0039	April 29, 2020	June 2020	July 2020	May 1, 2020		May 6, 2020	CHU Amiens, Amiens, France		https://ClinicalTrials.gov/show/NCT04371107
878	NCT04452799	Hesperidin and Diosmin for Treatment of COVID-19		Not yet recruiting	No Results Available	Coronavirus Infection	Drug: Hesperidin and Diosmin mixture	PCR test|respiratory rate|patients PaO2|serum IL1β|serum TNF-α|Mortality rate	Tanta University	All	18 Years to 65 Years   (Adult, Older Adult)	Early Phase 1	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	1111	July 1, 2020	October 1, 2020	October 30, 2020	June 30, 2020		June 30, 2020			https://ClinicalTrials.gov/show/NCT04452799
879	NCT04290871	Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.	NOSARSCOVID	Withdrawn	No Results Available	Coronavirus|SARS (Severe Acute Respiratory Syndrome)	Drug: Nitric Oxide Gas	SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air	Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	NO-SARS-COVID-19	March 23, 2020	March 1, 2021	March 1, 2022	March 2, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04290871
880	NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals	ELEVATE	Enrolling by invitation	No Results Available	Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents	Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG	Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.|Polymerase chain reaction assay (PCR) negative at day 30.|Polymerase chain reaction assay (PCR) negative at day 60.	Instituto Nacional de Rehabilitacion	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	25/20	May 11, 2020	July 20, 2020	August 20, 2020	April 9, 2020		May 13, 2020	National Institute of Rehabilitation, Mexico City, Cdmx, Mexico		https://ClinicalTrials.gov/show/NCT04340349
881	NCT04492891	Cyclosporine For The Treatment Of Covid-19(+)		Not yet recruiting	No Results Available	SARS (Disease)	Drug: Cyclosporine	WHO COVID-19 clinical severity scale	Bryan Burt, MD|Brigham and Women's Hospital|Baylor College of Medicine	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-48163	August 20, 2020	August 20, 2025	August 20, 2025	July 30, 2020		July 30, 2020			https://ClinicalTrials.gov/show/NCT04492891
882	NCT04424134	BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization	BISCUIT	Recruiting	No Results Available	COVID 19	Drug: Bromhexine and Spironolactone|Drug: Base therapy	Change from baseline in clinical assessment score COVID 19 (CAS COVID 19)|- Combine endpoint -|C-reactive protein|D-dimer|EuroQol Group. EQ-5D™|EuroQol Group. EQ VAS|HADS|Hospital length of stay	Lomonosov Moscow State University Medical Research and Educational Center	All	18 Years and older   (Adult, Older Adult)	Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	MSU160520	May 16, 2020	July 18, 2020	August 23, 2020	June 9, 2020		June 9, 2020	Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation		https://ClinicalTrials.gov/show/NCT04424134
883	NCT04315480	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis		Active, not recruiting	No Results Available	SARS Pneumonia	Drug: Tocilizumab	arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death	Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	38	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOCICOV-1	March 12, 2020	April 9, 2020	May 2020	March 19, 2020		April 13, 2020	Università Politecnica delle Marche, Ancona, AN, Italy	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT04315480
884	NCT04433078	RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM	STORM	Recruiting	No Results Available	Cytokine Storm|SARS-CoV-2	Drug: Doxycycline|Drug: Placebo	Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death|NP SARS-CoV-2 PCR|SARS-CoV-2 Serum Quantitative Viral Load|SARS-CoV-2 IgM/IgG Antibodies|White Blood Cell Count (WBC)|Absolute Lymphocyte Count (ALC)|C-Reactive Protein (CRP)|N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP)|High Sensitivity Troponin I (hsTnT)|Tumor Necrosis Factor Alpha (TNF-a)|IL-1|IL-1B|IL-6	Temple University	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	The STORM Trial	June 22, 2020	January 2021	July 2021	June 16, 2020		June 24, 2020	Temple University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04433078
885	NCT04451239	Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis		Not yet recruiting	No Results Available	Keratonjunctivitis	Drug: topical steroids and cyclosporin-A	Symptom improvement|Signs improvement	Ameera Gamal Abdelhameed|Ministry of Health, Kuwait|Mansoura University	All	Child, Adult, Older Adult	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19 keratoconjunctivitis	June 30, 2020	July 2020	July 2020	June 30, 2020		June 30, 2020	Farawanyia hospital, Kuwait, Farawanyia, Kuwait		https://ClinicalTrials.gov/show/NCT04451239
886	NCT04476992	Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement	NICOR	Active, not recruiting	No Results Available	Hypoxemia|Pneumonia, Viral|Coronavirus Infection	Drug: Nitric Oxide-Sessions|Drug: Nitric Oxide-Continuous and Sessions	Change in Methemoglobin level at 48 hours|Change in Methemoglobin level at 96 hours|Improvement in oxygenation between the groups at 48 hours or at discharge if before 48 hours|Improvement in oxygenation between the groups at 96 hours or at discharge if before 96 hours|Rate of positive RT-PCR for SARS-CoV-2 between groups in 5 days, discharge, and 28 days|Time to clinical recovery among groups, defined as time to interruption of oxygen administration for 24 hours or discharge|Reduction in the inflammatory markers among groups|Rate of Acute Kidney Disease (AKI) between groups during hospitalization|Difference in Katz score between groups	Federal State Budgetary Scientific Institution, Research Institute of Cardiology|Siberian State Medical University	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	8322/1	July 24, 2020	July 17, 2021	September 17, 2021	July 20, 2020		September 15, 2020	Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation		https://ClinicalTrials.gov/show/NCT04476992
887	NCT04399798	Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial	BREATH	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: Baricitinib	Response to treatment: absence of moderate to severe oxygenation impairment (Berlin criteria)|Response to treatment: survival|To quantify the rate of each of: moderate or severe oxygenation impairment within 8 days|To quantify the rate of each of: moderate or severe oxygenation impairment within 15 days|Mortality|Peripheral capillary oxygen saturation (SpO2)|Partial pressure of oxygen/fraction inspired oxygen (PaO2/FiO2)|To assess the rate of patients admitted to the intensive care unit|To measure the length of hospital stay|28-day mortality|To quantify the rate of re-admission within 28 days|To quantify the cumulative incidence and severity of adverse events|Interleukin (IL)-1; IL-2; IL-10; IL-6; IL-8; IL-17; IL-2 receptor levels;|TNFalpha; vascular endothelial growth factor (VEGF); interferon gamma (IFNgamma) levels|Viral load analyses	IRCCS Policlinico S. Matteo	All	18 Years to 74 Years   (Adult, Older Adult)	Phase 2	13	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001185-11	May 15, 2020	September 15, 2020	November 15, 2020	May 22, 2020		May 22, 2020			https://ClinicalTrials.gov/show/NCT04399798
888	NCT04497519	Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers		Recruiting	No Results Available	Covid19	Drug: inhaled hydroxychloroquine	Local tolerability|Pharmacokinetic parameter	University Medical Center Groningen	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CARRIED-01	September 15, 2020	October 15, 2020	November 15, 2020	August 4, 2020		August 4, 2020	University Medical Center Groningen, Groningen, Netherlands		https://ClinicalTrials.gov/show/NCT04497519
889	NCT04490239	Intranasal Heparin Tolerability Study		Not yet recruiting	No Results Available	Covid19	Drug: Intranasal heparin sodium (porcine)	activated partial thromboplastin time (aPTT), acute phase|activated partial thromboplastin time (aPTT), chronic phase|platelet count, acute phase|platelet count, chronic phase|Number of incidents of epistaxis, acute phase|Number of incidents of epistaxis, chronic phase|Other adverse effects, acute phase|Other adverse effects, chronic phase	Joshua Sharp|University of Mississippi, Oxford	All	18 Years to 65 Years   (Adult, Older Adult)	Early Phase 1	6	Other	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Intranasal Heparin	August 2020	September 2020	September 2020	July 29, 2020		July 29, 2020	The University of Mississippi National Center for Natural Products Research, University, Mississippi, United States		https://ClinicalTrials.gov/show/NCT04490239
890	NCT04542226	Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19		Active, not recruiting	No Results Available	Infections, Coronavirus	Drug: Polyoxidonium	Clinical status of the patient (according to 7-point ordinal scale)|Clinical status of the patient (according to Ordinal scale)|Clinical status of the patient (according to NEWS scale)|Oxygen saturation|Hospitlization duration|Mortality|Incidence of serious adverse events|Incidence of adverse events|Incidence of discontinuation of drug administration	NPO Petrovax	All	18 Years and older   (Adult, Older Adult)		81	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	Covid_v_1.0	March 31, 2020	July 15, 2020	October 2020	September 9, 2020		October 6, 2020	"Ambulance hospital" of the Ministry of Health of Chuvashia, Cheboksary, Chuvashia, Russian Federation		https://ClinicalTrials.gov/show/NCT04542226
891	NCT04359095	Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia		Recruiting	No Results Available	COVID-19	Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment	Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection	Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Clinica Santa maria del Lago	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	76968	August 18, 2020	November 30, 2020	February 28, 2021	April 24, 2020		September 30, 2020	Clinica santa Maria del lago, Bogota, DC, Colombia|Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia		https://ClinicalTrials.gov/show/NCT04359095
892	NCT04328012	COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2	COVIDMED	Recruiting	No Results Available	SARS-CoV-2 Infection	Drug: lopinavir/ritonavir|Drug: Losartan|Drug: Placebos	National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival	Bassett Healthcare|Reid Health|Goshen Health System	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	4000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	1581969	April 6, 2020	January 1, 2021	April 1, 2021	March 31, 2020		August 20, 2020	Bassett Medical Center, Cooperstown, New York, United States		https://ClinicalTrials.gov/show/NCT04328012
893	NCT04334967	Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care		Suspended	No Results Available	COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus	Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C	Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality	Providence Health & Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute	All	45 Years and older   (Adult, Older Adult)	Phase 4	13	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2020000186	March 30, 2020	May 27, 2021	May 27, 2022	April 6, 2020		September 15, 2020	Portland Providence Medical Center, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT04334967
894	NCT04293887	Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients		Not yet recruiting	No Results Available	COVID-19|Recombinant Human Interferon α1β	Drug: Recombinant human interferon α1β	The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	328	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Zhaojp	March 1, 2020	May 30, 2020	June 30, 2020	March 3, 2020		March 3, 2020			https://ClinicalTrials.gov/show/NCT04293887
895	NCT04343768	An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	COVIFERON	Completed	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B	Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization	Shahid Beheshti University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Different Interferons in COVID	April 9, 2020	April 27, 2020	April 27, 2020	April 13, 2020		May 5, 2020	Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04343768
896	NCT04326725	Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia		Active, not recruiting	No Results Available	Pneumonitis|Coronavirus Infection	Drug: Plaquenil 200Mg Tablet	Protection against COVID-19	Istinye University	All	20 Years to 90 Years   (Adult, Older Adult)		80	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	2020-2/1	March 20, 2020	July 1, 2020	September 1, 2020	March 30, 2020		July 28, 2020	Istinye University Medical School, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04326725
897	NCT04349228	Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals	COVID_2Pro	Withdrawn	No Results Available	COVID19|Sars-CoV2|Hydroxychloroquine|Prophylaxis|Healthcare Worker	Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet	Symptomatic COVID(+) infection rate	Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	ECC2020-03	April 28, 2020	July 15, 2020	July 15, 2020	April 16, 2020		August 28, 2020	Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Tunis, Tunisia		https://ClinicalTrials.gov/show/NCT04349228
898	NCT04357860	Clinical Trial of Sarilumab in Adults With COVID-19	SARICOR	Not yet recruiting	No Results Available	SARS-CoV 2|SARS	Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment	Ventilation requirements|Crude mortality|Time to clinical improvement|Time until improvement in oxygenation|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients having negative COVID-19 CRP at each visit|Mean of serum cytokine levels|Adverse events related to medication and its administration|Incidence in the appearance of serious bacterial, fungal or opportunistic infections|Incidence of perforation of the gastrointestinal tract|Leukocyte and neutrophil count|Hemoglobin levels|Platelet count|Levels of creatinemia|Bilirubin levels|ALT and AST levels	Maimónides Biomedical Research Institute of Córdoba|Consejería de Salud y Familias - Junta de Andalucía|Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARICOR	April 27, 2020	July 27, 2020	July 27, 2020	April 22, 2020		April 27, 2020	Hospital Universitario Reina Sofía, Córdoba, Spain		https://ClinicalTrials.gov/show/NCT04357860
899	NCT04466670	Hemostasis in COVID-19: an Adaptive Clinical Trial		Recruiting	No Results Available	COVID-19	Drug: unfractionated Heparin|Drug: Unfractionated heparin nebulized|Drug: acetylsalicylic acid|Drug: Enoxaparin	Hospital discharge - alive / death|Length of mechanical ventilation free days|Length of renal replacement therapy free days|Number of documented venous thromboembolism or arterial thrombosis	University of Sao Paulo General Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	310	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	33788820.9.0000.0068	July 8, 2020	December 30, 2020	April 30, 2021	July 10, 2020		July 10, 2020	Vanderson Rocha, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04466670
900	NCT04338698	Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT	PROTECT	Recruiting	No Results Available	COVID 19	Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin	Laboratory Result|Clinical Outcome	Shehnoor Azhar|University of Health Sciences Lahore	All	18 Years and older   (Adult, Older Adult)	Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	12(06)/2016-Coord	April 22, 2020	September 1, 2020	November 30, 2020	April 8, 2020		July 15, 2020	Faislabad Medical University, Faisalābad, Pakistan|Gujranwala Medical College, Gujrānwāla, Pakistan|Nawaz Sharif Medical College, Gujrāt, Pakistan|Szabmu-Pims, Islamabad, Pakistan|Akram Medical Complex, Lahore, Pakistan|Fatima Jinnah Medical University, Lahore, Pakistan|King Edward Medical University-Mayo Hospital, Lahore, Pakistan|Lahore General Hospital, Lahore, Pakistan|Khyber Teaching Hospital, Peshawar, Pakistan|Rawalpindi Medical University, Rawalpindi, Pakistan|Sargodha Medical College, Sargodha, Pakistan		https://ClinicalTrials.gov/show/NCT04338698
901	NCT04371393	MSCs in COVID-19 ARDS		Recruiting	No Results Available	Mesenchymal Stromal Cells|Remestemcel-L|Acute Respiratory Distress Syndrome|COVID	Biological: Remestemcel-L|Drug: Placebo	Number of all-cause mortality|Number of days alive off mechanical ventilatory support|Number of adverse events|Number of participants alive at day 7|Number of participants alive at day 14|Number of participants alive at day 60|Number of participants alive at day 90|Number of participants with resolution and/or improvement of ARDS|Change from baseline of the severity of ARDS|Length of stay|Clinical Improvement Scale|Change in serum hs-CRP concentration|Change in IL-6 inflammatory marker level|Change in IL-8 inflammatory marker level|Change in TNF-alpha inflammatory marker level	Icahn School of Medicine at Mount Sinai|Mesoblast, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	300	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	GCO 08-1078-0014	April 30, 2020	April 2021	April 2022	May 1, 2020		October 6, 2020	Dignity Health, Gilbert, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Lutheran Hospital, Fort Wayne, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|New York University Langone Health, New York, New York, United States|Mount Sinai Health, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor, Smith & White, Plano, Texas, United States|University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT04371393
902	NCT04358627	Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients	COVID-DEX	Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome|Inflammation|Dexmedetomidine|Cytokine Storm|Delirium, Emergence	Drug: Dexmedetomidine Injectable Product	Mechanical ventilation|Duration of mechanical ventilation|Delirium on recovery from sedation	Hospital Clinic of Barcelona	All	18 Years to 99 Years   (Adult, Older Adult)		80	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	SPEC-M|SPEC-M COVID-19	April 15, 2020	May 30, 2020	June 30, 2020	April 24, 2020		April 24, 2020			https://ClinicalTrials.gov/show/NCT04358627
903	NCT04367883	Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection		Recruiting	No Results Available	COVID19|Influenza Vaccination|ACE Inhibitors|ARB	Drug: ACE inhibitor|Drug: ARB	hospital output|hospital stay	Consorci Sanitari de Terrassa|Jordi Gol i Gurina Foundation|Institut Català de la Salut	All	Child, Adult, Older Adult		2574	Other	Observational	Observational Model: Other|Time Perspective: Other	02-20-161-021	March 1, 2020	September 30, 2020	August 31, 2023	April 29, 2020		August 21, 2020	Hospital de Terrassa, Terrassa, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04367883
904	NCT04328285	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	COVIDAXIS	Active, not recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets	Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)	Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur	All	18 Years and older   (Adult, Older Adult)	Phase 3	1200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	20PH061|2020-001188-96	April 14, 2020	November 30, 2020	November 30, 2020	March 31, 2020		June 23, 2020	CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France		https://ClinicalTrials.gov/show/NCT04328285
905	NCT04443868	Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection		Not yet recruiting	No Results Available	SARS-CoV Infection	Drug: Nitric Oxide-Releasing Drug	To Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity|To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection|To Measure the efficacy of NONI in prevention of progression of COVID-19|To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19|To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19|To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection	Sanotize Research and Development corp.	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID-IND-02	January 2021	April 2021	July 2021	June 23, 2020		October 8, 2020			https://ClinicalTrials.gov/show/NCT04443868
906	NCT04342650	Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection	CloroCOVID19II	Completed	No Results Available	COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial	Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet	Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	All	18 Years and older   (Adult, Older Adult)	Phase 2	152	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAAE: 30504220.5.0000.0005	April 8, 2020	May 14, 2020	June 8, 2020	April 13, 2020		July 7, 2020	Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil		https://ClinicalTrials.gov/show/NCT04342650
907	NCT04530136	Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19		Not yet recruiting	No Results Available	Confirmed Coronavirus Disease	Drug: Ruconest	Disease Severity on the 7-Point WHO Ordinal Scale|Clinical improvement|Invasive or non-invasive ventilation|Acute Lung Injury	Pharming Technologies B.V.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	C1 6201	September 15, 2020	March 15, 2021	March 31, 2021	August 28, 2020		September 1, 2020			https://ClinicalTrials.gov/show/NCT04530136
908	NCT04498273	COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-79		Not yet recruiting	No Results Available	COVID-19	Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo	Primary	Frank C Sciurba|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh	All	40 Years to 79 Years   (Adult, Older Adult)	Phase 3	7000	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	ACTIV4-Outpatient	August 2020	January 2021	March 2021	August 4, 2020		August 4, 2020			https://ClinicalTrials.gov/show/NCT04498273
909	NCT04439071	A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)	FITE19	Recruiting	No Results Available	Pneumonia|COVID-19|Coronavirus	Drug: PTC299|Other: SOC|Drug: Placebo	Time from Randomization to Respiratory Improvement|Percentage of Participants Requiring Invasive Ventilation|Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline|Time from Randomization to Defervescence|Time from Randomization to Respiratory Rate ≤ 24 Breaths per Minute on Room Air|Time from Randomization to Cough Reported as Mild or Absent|Time from Randomization to Dyspnea Reported as Mild or Absent|Reduction of Immune Responses|Reduction in Viral Load|Duration of Hospitalization|Number of Fatalities|Number of Participants with Treatment-Emergent Adverse Events (TEAEs)	PTC Therapeutics	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	380	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PTC299-VIR-015-COV19|2020-001872-13	July 9, 2020	January 30, 2021	January 30, 2021	June 19, 2020		August 13, 2020	University of California, Irvine, Orange, California, United States|Augusta University, Augusta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Salisbury VA Medical Center, Salisbury, North Carolina, United States|University Hospitals Cleveland, Cleveland, Ohio, United States|Columbia VA Health Care System, Columbia, South Carolina, United States|Monash Medical Centre, Clayton, Victoria, Australia|Hospital Vera Cruz, Belo Horizonte, MG, Brazil|Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, SP, Brazil|Hospital Guilherme Alvaro, Santos, SP, Brazil|Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brazil|Escola Paulista de Medicina (UNIFESP), São Paulo, SP, Brazil|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04439071
910	NCT04341610	ASC Therapy for Patients With Severe Respiratory COVID-19	ASC COVID-19	Withdrawn	No Results Available	Respiratory Tract Diseases	Drug: Stem Cell Product	Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization	Rigshospitalet, Denmark	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EudraCT number: 2020-001330-36	April 20, 2020	January 30, 2021	April 30, 2021	April 10, 2020		May 27, 2020	2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT04341610
911	NCT04329923	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	PATCH	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet	Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events	Ravi Amaravadi, MD|University of Pennsylvania	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	842838	April 9, 2020	April 1, 2021	December 1, 2021	April 1, 2020		April 28, 2020	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04329923
912	NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	CORIMUNO-SARI	Active, not recruiting	No Results Available	Corona Virus Infection	Drug: Sarilumab	Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	239	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-2	March 27, 2020	March 27, 2021	December 31, 2021	March 27, 2020		April 15, 2020	Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France		https://ClinicalTrials.gov/show/NCT04324073
913	NCT04579393	Fostamatinib for Hospitalized Adults With COVID-19		Recruiting	No Results Available	Coronavirus Disease 2019	Drug: Placebo|Drug: fostamatinib	Cumulative Incidence of SAEs|Number of days in the ICU|Change in CRP, IL-6, d-dimer, ferritin, fibrinogen, absolute lymphocyte count, absolute neutrophil count, and platelet count from baseline|Ordinal scale|Days of hospitalization|Time to recovery|Number of days free of mechanical ventilation [entire hospitalization cohort 1]|Number of days on oxygen|Change in SOFA score from baseline|Days free of renal failure|Clinically relevant deep vein thrombosis|Relative change in PaO2/FiO2 or SpO2/FiO2 ratio	National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	10000110|000110-H	October 12, 2020	December 15, 2020	December 15, 2020	October 8, 2020		October 8, 2020	National Institutes of Health Clinical Center, Bethesda, Maryland, United States|INOVA Health Systems, Falls Church, Virginia, United States		https://ClinicalTrials.gov/show/NCT04579393
914	NCT04559074	Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic		Not yet recruiting	No Results Available	Hypertension	Drug: Amlodipine	Reductions in blood pressure in participants with primary hypertension and inadequate BP control by up-titration of amlodipine in 1-2 mg increments.|Mean change in daily DBP|Difference between mean changes of blood pressure|Collect data on tolerability / side effects	Queen Mary University of London|Closed Loop Medicine Ltd|Innovate UK	All	18 Years and older   (Adult, Older Adult)	Phase 4	1000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	283209	September 30, 2020	April 30, 2021	July 31, 2021	September 22, 2020		September 22, 2020			https://ClinicalTrials.gov/show/NCT04559074
915	NCT04457609	Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients		Recruiting	No Results Available	COVID|Pulmonary Infection|Sars-CoV2	Drug: Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells	Clinical improvement: Presence of dyspnea|Clinical improvement: presence of sputum|Clinical improvement: fever|Clinical improvement: ventilation status|Clinical improvement: blood pressure|Clinical improvement: heart rate|Clinical improvement: respiratory rate|Clinical improvement: oxygen saturation|General laboratory outcome from leukocyte level|General laboratory outcome from lymphocytes level|General laboratory outcome from blood pH|General laboratory outcome from blood level of CO2|General laboratory outcome from blood base excess level|General laboratory outcome from blood oxygen partial pressure|General laboratory outcome from blood level of HCO3|General laboratory outcome from blood level of O2 saturation|General laboratory outcome from level of CRP|General laboratory outcome from level of SGOT/SGPT (AST/ALT)|General laboratory outcome from the level of ureum/creatinine level|General laboratory outcome from the level of eGFR|General laboratory outcome from the level of sodium|General laboratory outcome from the level of potassium|General laboratory outcome from the level of chloride|Changes in procalcitonin level|General laboratory outcome from albumin level|General laboratory outcome from total bilirubin level|Changes in D-Dimer level|Changes in fibrinogen level|Cardiac changes from troponin level|Cardiac changes from NT proBNP level|Changes in Leukemia Inhibiting Factor|Changes in level of IL-6|Changes in level of IL-10|Changes in level of vascular endothelial growth factor (VEGF)|Changes in level of ferritin|Changes in level of CXCR3|Changes in level of CD4|Changes in level of CD8|Changes in level of CD56|Radiologic Improvement from Chest X-Ray/CT Scan	Indonesia University	All	18 Years to 95 Years   (Adult, Older Adult)	Phase 1	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ISMMSCCOVID19	July 2020	August 2020	September 2020	July 7, 2020		July 7, 2020	Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia|Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia|Universitas Indonesia Hospital, Depok, West Java, Indonesia		https://ClinicalTrials.gov/show/NCT04457609
916	NCT04345861	Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)	COVIDOC	Terminated	No Results Available	Coronavirus Infection|Pneumonia, Viral	Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin	Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images	University Hospital, Montpellier	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	7	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	RECHMPL20_168	April 11, 2020	June 8, 2020	June 8, 2020	April 15, 2020		June 11, 2020	Montpellier University hospital, Montpellier, France		https://ClinicalTrials.gov/show/NCT04345861
917	NCT04370782	Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting		Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline	Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms	St. Francis Hospital, New York	All	30 Years and older   (Adult, Older Adult)	Phase 4	750	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-21	April 28, 2020	September 30, 2020	December 31, 2020	May 1, 2020		May 18, 2020	St Francis Hospital, Roslyn, New York, United States		https://ClinicalTrials.gov/show/NCT04370782
918	NCT04510493	Canakinumab in Patients With COVID-19 and Type 2 Diabetes	CanCovDia	Recruiting	No Results Available	Coronavirus Infection|Diabetes Mellitus, Type 2	Drug: Canakinumab|Drug: Placebo	unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint)|Time to clinical improvement|Death rate|Admission to intensive care unit (ICU)|Secondary worsening of disease|Prolonged hospital stay|Change in ratio to baseline in the glycated hemoglobin|Change in ratio to baseline in the fasting glucose|Change in ratio to baseline in the fasting insulin|Change in ratio to baseline in the fasting c-peptide|Ratio to baseline in the C-reactive protein (CRP)|Change in ratio to baseline in the D-dimer|Change in ratio to baseline in the Natriuretic peptide (NTproBNP)|Change in ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)|Type of antidiabetic treatment at Day 29|Number of antidiabetic treatment at Day 29|Type of antidiabetic treatment at three months|Number of antidiabetic treatment at three months	University Hospital, Basel, Switzerland|Novartis|Swiss National Science Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 3	116	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2020-02008; me20Donath2	October 2020	September 2023	September 2023	August 12, 2020		October 8, 2020	University Medical Clinic Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|University Hospital Geneva, Geneva, Switzerland|University Hospital Lausanne, Lausanne, Switzerland|Cantonal Hospital Lucerne, Luzern, Switzerland|Cantonal Hospital St Gallen, St. Gallen, Switzerland|University Hospital Zürich, Zürich, Switzerland		https://ClinicalTrials.gov/show/NCT04510493
919	NCT04453384	Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia	POLYCOR	Recruiting	No Results Available	SARS Virus	Drug: XAV-19|Drug: Placebo	Phase 2a: XAV-19 antibody titers|Phase 2a: Adverse events of XAV-19|Phase 2b: Time to weaning of supplemental oxygen.|Phase 2a: Pharmacokinetic analysis|Phase 2a: Antibody titer between the two groups|Phase 2a: Supplemental oxygen|Phase 2a: Evaluation of Transfer to intensive care|Phase 2a: Normalization of Fever|Phase 2a: Biomarkers|Phase 2a: Hospital length of stay|Phase 2b: National Early Warning Score (NEWS)|Phase 2b: clinical status|Phase 2b: Time to improvement|Phase 2b: fever normalization|Phase 2b: Oxygen therapy|Phase 2b: oxygen requirement|Phase 2b: Time to weaning|Phase 2b: Ventilation|Phase 2b: Hospital length of stay|Phase 2b: mortality|Phase 2b: safety	Nantes University Hospital|BPIfrance|Xenothera SAS	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	368	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RC20_0230	September 1, 2020	November 2020	December 2021	July 1, 2020		September 16, 2020	CHU Angers, Angers, France|Hospices Civils Lyon, Lyon, France|CHU Nantes, Nantes, France|Hôpital Saint Antoine, Paris, France		https://ClinicalTrials.gov/show/NCT04453384
920	NCT04376788	Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19	COVID-19	Recruiting	No Results Available	COVID-19	Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML	improvement of condition|change in organs function with PFS and OS	Ain Shams University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	15	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FMASU P22/2020	May 20, 2020	July 1, 2020	September 1, 2020	May 6, 2020		July 9, 2020	Ain Shams University, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04376788
921	NCT04460443	Sofosbuvir With and Without Ribavirin in Treatment of COVID 19		Recruiting	No Results Available	COVID	Drug: sofosbuvir|Drug: Ribavirin|Drug: Daclatasvir	Number of patients with response to treatment	Tanta University	All	Child, Adult, Older Adult	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	sofosbuvir	August 1, 2020	August 1, 2021	August 31, 2021	July 7, 2020		August 4, 2020	Sherief Abd-Elsalam, Tanta, Egypt		https://ClinicalTrials.gov/show/NCT04460443
922	NCT04273763	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)		Active, not recruiting	No Results Available	Novel Coronavirus Pneumonia|2019-nCoV	Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray	Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality	Second Affiliated Hospital of Wenzhou Medical University|Wanbangde Pharmaceutical Group Co., LTD	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	18	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019NCP1.0	February 16, 2020	May 10, 2020	June 1, 2020	February 18, 2020		May 1, 2020	The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04273763
923	NCT04447235	Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection	TITAN	Recruiting	No Results Available	Cancer|COVID|Coronavirus Infection	Drug: Placebo|Drug: Ivermectin|Drug: Losartan	Incidence of severe complications due COVID-19 infection|Incidence of Severe Acute Respiratory Syndrome|Adverse events|Overall survival	Instituto do Cancer do Estado de São Paulo	All	18 Years and older   (Adult, Older Adult)	Phase 2	176	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	NP 1677/20	July 23, 2020	December 2020	February 2021	June 25, 2020		July 29, 2020	Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04447235
924	NCT04395508	An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic		Available	No Results Available	HER2-positive Breast Cancer	Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)		Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)			Industry	Expanded Access:Treatment IND/Protocol		AL42478				May 20, 2020		October 1, 2020	UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Univ School of Med; Oncology, Stanford, California, United States|MedStar Washington Hosp Center, Washington, District of Columbia, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04395508
925	NCT04428021	Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure	PLACO-COVID	Not yet recruiting	No Results Available	COVID-19	Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP)	30-days survival|Ventilator free survival|6-months survival|Incidence of complications|Days in intensive care units (ICU)|Positivity for Immunoglobulin G to SARS-Cov-2|Clearance of viral load|Sequential Organ Failure Assessment (SOFA) score|Any variation from Standard Therapy Protocol	Azienda Ospedaliera Città della Salute e della Scienza di Torino	All	18 Years and older   (Adult, Older Adult)	Phase 2	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	CS3/33	June 15, 2020	June 15, 2021	December 15, 2021	June 11, 2020		June 11, 2020			https://ClinicalTrials.gov/show/NCT04428021
926	NCT04393792	SINUS WASH Pilot Study in Adults Testing Positive for COVID-19		Recruiting	No Results Available	Coronavirus Infection	Drug: Povidone-Iodine|Drug: Normal saline	Change in viral load in the oral and nasopharyngeal cavity|Symptom severity in primary participants and co-residents	Hampshire Hospitals NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Phase 1	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SPON-AK-0420|2020-001721-31	May 2020	August 2020	August 2020	May 19, 2020		May 19, 2020	Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04393792
927	NCT04345614	A Study of Auxora in Patients With Severe COVID-19 Pneumonia		Recruiting	No Results Available	Pneumonia	Drug: Auxora|Drug: Placebo	Number of days from the Start of the First Infusion of Study Drug (SFISD) to recovery|Proportion of patients requiring invasive mechanical ventilation or dying|Proportion of patients requiring invasive mechanical ventilation|Differences in outcomes as measured by an 8-point ordinal scale|Proportion of patients who have died at day 30 (mortality)|Number of days in the hospital|Number of days in the Intensive Care Unit (ICU)|Incidence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)|CM4620-IE serum concentration	CalciMedica, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CM4620-204	April 8, 2020	March 2021	April 2021	April 14, 2020		October 5, 2020	Long Beach Memorial, Long Beach, California, United States|Baton Rouge General, Baton Rouge, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|John Peter Smith Hospital, Fort Worth, Texas, United States|Ben Taub (Baylor), Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital San Cristobal, Ponce, Puerto Rico		https://ClinicalTrials.gov/show/NCT04345614
928	NCT04475991	Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults	COMVIVIR	Not yet recruiting	No Results Available	COVID-19	Drug: Maraviroc + Currently used therapy|Procedure: Curently used therapy for COVID-19 non-critical patients|Drug: Favipiravir + Currently used therapy|Drug: Maraviroc+Favipiravir+CT	Patients free of mechanical ventilation or death|Time of clinical improvement|Rate of change in phosphorilated CCR5|Rate of change in peripheral blood levels of proinflammatory cytokines and chemokynes|Change in the trafficking and activation pattern of peripheral leukocytes	Hospital General de México Dr. Eduardo Liceaga|CCINSHAE. Secretaría de Salud. México|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Centro de Investigación en. Enfermedades Infecciosas, Mexico	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DI/20/407/04/38	August 2020	December 2020	January 2021	July 17, 2020		September 2, 2020	Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Cdmx, Mexico		https://ClinicalTrials.gov/show/NCT04475991
929	NCT04386616	A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia	COVASTIL	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo	Time to Recovery, Defined as the Time to a Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First)|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Hospital Discharge or "Ready for Discharge"|Duration of Supplemental Oxygen|Percentage of Participants Alive and Free of Respiratory Failure|Clinical Status, Assessed Using a 7-Category Ordinal Scale|Incidence of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Ventilator-Free Days|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)|Mortality Rate at Days 14 and 28|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of ≤2 Maintained for 24 hours|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Change from Baseline in Respiratory Rate|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Oxygen Saturation|Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)|Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)|Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters|Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters|Serum Concentration of UTTR1147A at Specified Timepoints|Serum Concentration of MSTT1041A at Specified Timepoints|Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study	Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GA42469|2020-002713-17	June 2, 2020	January 29, 2021	March 3, 2021	May 13, 2020		October 6, 2020	University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|eStudySite, La Mesa, California, United States|Alta Bates Summit Medical Center, Oakland, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Bay Pines VA Medical Center - NAVREF, Bay Pines, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|Northside Hospital; Peachtree Dunwoody Medical Center, Atlanta, Georgia, United States|WellStar Research Institute, Marietta, Georgia, United States|DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS, Alexandria, Louisiana, United States|MedPharmics, Metairie, Louisiana, United States|Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Lincoln Medical Mental Health Center, Bronx, New York, United States|Jacobi Medical Center; Lewis M. Fraad Department of Pediatrics, Bronx, New York, United States|Staten Island University Hospital; Department of Pharmacy, Staten Island, New York, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center; Investigational Drug Services/Regional Research, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia, Pennsylvania, United States|Parkland Health & Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility, Tacoma, Washington, United States|Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ, Rio de Janeiro, RJ, Brazil|Centro De Estudos Pesquisas em Molestias Infecciosas - CPCLIN, Natal, RN, Brazil|Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil|Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain|Hospital Clinico Universitario Valladolid, Valladolid, Spain		https://ClinicalTrials.gov/show/NCT04386616
930	NCT04373707	Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19	COVI-DOSE	Recruiting	No Results Available	COVID|Thrombosis|Pulmonary Embolism|Deep Vein Thrombosis	Drug: Enoxaparin	Venous thromboembolism|Major bleeding|Major Bleeding and Clinically Relevant Non-Major Bleeding|Net Clinical Benefit|Venous Thromboembolism at other sites|Arterial Thrombosis|All-Cause Mortality|Factors associated with the risk of venous thromboembolism	Central Hospital, Nancy, France|Ministry of Health, France|Grand Est Region|University Hospital of Saint-Etienne	All	18 Years and older   (Adult, Older Adult)	Phase 4	602	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	2020-001709-21	May 13, 2020	September 2020	October 2020	May 4, 2020		June 23, 2020	Amiens Academic Hospital, Amiens, France|Besançon Academic Hospital, Besançon, France|Brest Academic Hospital, Brest, France|Civil Hospital, Colmar, France|Dijon Academic Hospital, Dijon, France|Marseille Academic Hospital, Marseille, France|Metz-Thionville Regional Hospital, Metz, France|Montpellier Academic Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy Academic Hospital, Nancy, France|George Pompidou European Hospital, Paris, France|St Etienne Academic Hospital, Saint-Étienne, France|Strasbourg Academic Hospital, Strasbourg, France|Toulouse Academic Hospital, Toulouse, France		https://ClinicalTrials.gov/show/NCT04373707
931	NCT04381377	Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19		Recruiting	No Results Available	Infections, Coronavirus	Drug: azoximer bromide|Other: Placebo	Clinical status of the patient (according to 7-point ordinal scale)|NEWS|Oxygenation|Mechanical Ventilation|Mortality	NPO Petrovax	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	394	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PО-COV-III-20	April 29, 2020	April 2021	April 2021	May 8, 2020		May 8, 2020	Regional state budgetary institution of public health "City hospital No. 5 of Barnaul", Barnaul, Russian Federation|Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation|The state healthcare institution of the city of Moscow "City Clinical Hospital No. 15 named after OM Filatov" in "Moscow City Department of Health", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "City Clinical Hospital No. 24 of the Moscow Department of Healthcare", Moscow, Russian Federation|State budgetary institution "Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "City Clinical Hospital No. 40 of the Moscow Department of Healthcare", Moscow, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region "Infectious clinical hospital No. 2 of Nizhny Novgorod", Nizhny Novgorod, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "Orenburg State Medical University" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov, Saint Petersburg, Russian Federation|State budgetary health institution of the Vladimir region "Regional Clinical Hospital", Vladimir, Russian Federation|Yaroslavl State Medical University of Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation		https://ClinicalTrials.gov/show/NCT04381377
932	NCT04330638	Treatment of COVID-19 Patients With Anti-interleukin Drugs	COV-AID	Recruiting	No Results Available	COVID-19	Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab	Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients, according to the adapted Berlin criteria|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate	University Hospital, Ghent|Belgium Health Care Knowledge Centre	All	18 Years and older   (Adult, Older Adult)	Phase 3	342	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COV-AID	April 3, 2020	September 2020	December 2020	April 1, 2020		July 9, 2020	AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium		https://ClinicalTrials.gov/show/NCT04330638
933	NCT04412395	Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease	COVID-19_LF	Not yet recruiting	No Results Available	Corona Virus Infection|Middle East Respiratory Syndrome (MERS)|Acute Respiratory Distress Syndrome|Coronavirus Infection|COVID-19|SARS-CoV 2	Dietary Supplement: Lactoferrin (Apolactoferrin)|Drug: Placebo of excipient(s) will be administered	Survival rate.|Rate of disease remission.|The number of patients with PCR negative results.|Mean change in the disease severity (clinical assessment).|Mean change in blood pressure.|Mean change in heart beats.|Mean change in body temperature.|Mean change in body respiratory rate.|Mean change in oxygen saturation.|Mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen (PF ratio).|Mean change in complete blood picture (CBC).|Mean change in C reactive protein (CRP).|Mean change in erythrocyte sedimentation rate (ESR).|Mean change in D-dimer.|Mean change in ferritin.|Mean change in liver Albumin.|Mean change in total and direct Bilirubin.|Mean change in prothrombin time (PT) and partial thromboplastin time (PTT ).|Mean change in aspartate aminotransferase (AST).|Mean change in Alanine Aminotransferase (ALT).|Mean change in Blood Urea Nitrogen (BUN).|Mean change in Serum Creatinine.|Mean change in Serum Creatinine clearance.|Mean change in Glomerular filtration rate (GFR ).|The mean change in serum interleukin-1 (IL-1).|The mean change in serum interleukin-6 (IL-6).|The mean change in serum interleukin-10 (IL-10).|The mean change in serum tumor necrosis factor-alpha (TNF alpha).|Mean changes in immunoglobulin G (IgG).|Mean changes in immunoglobulin M (IgM).|The mean change in PCR viral load.|Mean change in lung CT manifestation.|Nature and severity of Adverse Events.|Time for lung recovery.|The number of missed drug doses among each treatment group.	National Research Center, Egypt|Egyptian Military Medical Services	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	516	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID-19_LF	June 1, 2020	August 31, 2020	September 30, 2020	June 2, 2020		June 2, 2020	National Research Center, Egypt (Clinical and Molecular Pharmacology), Cairo, Giza, Egypt|Clinmax CRO (Clinical Research Organization), Cairo, Egypt|Clinical Trial Unit National Research Center, Cairo, Egypt|Egyptian Military Medical Services (Hospitals), Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04412395
934	NCT04264858	Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients		Not yet recruiting	No Results Available	2019-nCoV|Immunoglobulin of Cured Patients	Drug: Immunoglobulin of cured patients|Drug: γ-Globulin	Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality	Wuhan Union Hospital, China	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WuhanUH-2019 nCoV-Ig	March 17, 2020	April 30, 2020	May 31, 2020	February 11, 2020		March 17, 2020	Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04264858
935	NCT04368351	Bacteriotherapy in the Treatment of COVID-19	BACT-ovid	Active, not recruiting	No Results Available	COVID|Pneumonia|Diarrhea	Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine	delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital	University of Roma La Sapienza	All	18 Years and older   (Adult, Older Adult)		70	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	DPHID-UniRoma05	March 1, 2020	June 30, 2020	July 31, 2020	April 29, 2020		May 4, 2020	Department of Public Heath and Infectious Diseases. University of Rome "Sapienza" (Italy), Rome, Italy		https://ClinicalTrials.gov/show/NCT04368351
936	NCT04336748	HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers		Not yet recruiting	No Results Available	Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis	Drug: Hydroxychloroquine	Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave	Medical University of Vienna	All	18 Years and older   (Adult, Older Adult)	Phase 3	440	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	HCQ prophylaxis for COVID19	April 2020	July 2020	August 2020	April 7, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04336748
937	NCT04310228	Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019		Recruiting	No Results Available	COVID-19	Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab	Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time	Peking University First Hospital	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020YFC0844100	March 8, 2020	May 2020	May 2020	March 17, 2020		April 10, 2020	Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04310228
938	NCT04372082	Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19	HYdILIC	Not yet recruiting	No Results Available	Sars-CoV2	Other: Standard of care (SOC)|Drug: Hydroxychloroquine|Drug: Association of diltiazem and niclosamide	death|clinical worsening (composite criteria)|Assisted-ventilation and/or hospitalization (composite criteria)|National Early Warning Score (NEWS)|cumulative incidence of hospitalizations|cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)|Mortality|cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;|adverse drug reactions	University Hospital, Lille|I-site University Lille North Europe	All	18 Years and older   (Adult, Older Adult)	Phase 3	480	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	2020_40|2020-002188-72	May 2020	May 2023	May 2023	May 1, 2020		May 1, 2020			https://ClinicalTrials.gov/show/NCT04372082
939	NCT04335552	Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection		Terminated	No Results Available	SARS-CoV-2	Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin	World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events	Duke University	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	11	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO00105339	April 17, 2020	June 17, 2020	June 26, 2020	April 6, 2020		July 31, 2020	Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04335552
940	NCT04455958	Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year		Not yet recruiting	No Results Available	Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed	Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration	Severity of symptoms|Clinical benefit rate of lopinavir/ritonavir|Time to symptom progression|Time to improvement of participants|Time to hospital admission for those who develop severe of critical symptoms|Intensive care unit (ICU) admission: yes or no|Receiving ventilator support: yes or no|Overall survival	OHSU Knight Cancer Institute|Oregon Health and Science University	All	18 Years and older   (Adult, Older Adult)	Phase 2	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	STUDY00021444|NCI-2020-02877	November 1, 2020	November 1, 2021	November 1, 2021	July 2, 2020		September 18, 2020	OHSU Knight Cancer Institute, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT04455958
941	NCT04528888	Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection	STAUNCH-19	Not yet recruiting	No Results Available	Covid19|SARS-CoV Infection|Pneumonia, Viral|Coagulopathy	Drug: Enoxaparin|Drug: Methylprednisolone|Drug: unfractionated heparin	All-cause mortality at day 28|All-cause mortality at ICU discharge|All-cause mortality at hospital discharge|Need of rescue administration of high-dose steroids or immune-modulatory drugs|New organ dysfunction during ICU stay|Grade of organ dysfunction during ICU stay|ICU free days at day 28|Occurrence of new infections|Ventilation free days at day 28|Vasopressors free-days at day 28|Switch from non-invasive to invasive mechanical ventilation|Delay from start of non-invasive ventilation to switch to invasive ventilation|Occurrence of protocol related adverse events|Occurrence of venous thromboembolism, stroke or myocardial infarction|Occurrence of major bleeding (safety end point)|Occurrence of clinically relevant non-major bleeding (safety end point)	Massimo Girardis|University of Modena and Reggio Emilia	All	18 Years and older   (Adult, Older Adult)	Phase 3	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Staunch-19-1.1-26-04-20	September 1, 2020	June 30, 2021	July 30, 2021	August 27, 2020		August 27, 2020			https://ClinicalTrials.gov/show/NCT04528888
942	NCT04363840	The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations	LEAD COVID-19	Not yet recruiting	No Results Available	COVID|Vitamin D Deficiency|Coagulopathy|Disseminated Intravascular Coagulation	Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D	Hospitalization	Louisiana State University Health Sciences Center in New Orleans	All	18 Years and older   (Adult, Older Adult)	Phase 2	1080	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-063	May 2020	December 2020	December 2020	April 27, 2020		April 27, 2020			https://ClinicalTrials.gov/show/NCT04363840
943	NCT04383730	Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)	ISCA	Recruiting	No Results Available	Critically Illness|Sedation|Invasive Mechanical Ventilation|Acute Respiratory Distress Syndrome	Drug: Intravenous sedation|Drug: Inhaled sedation	Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event|All-cause mortality|Ventilator-free days|ICU-free days|Duration of invasive mechanical ventilation|Duration of controlled mechanical ventilation|Physiological measures of lung function|Development of complications|Duration of vasopressor use|Duration of renal replacement therapy|Duration (in days) of any adjuvant therapies|Duration of continuous neuromuscular blockade|Type of sedation practices|Duration of sedation practices|Modalities of sedation practices	University Hospital, Clermont-Ferrand|Hospital Clínico Universitario de Valencia|University of Schleswig-Holstein|Groupe Hospitalier Pitie-Salpetriere	All	18 Years and older   (Adult, Older Adult)		400	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	ISCA Study	June 26, 2020	November 30, 2020	December 31, 2020	May 12, 2020		July 7, 2020	CHU, Clermont-Ferrand, France|Centre Hospitalier, Dunkerque, France|Pitié-Salpêtrière Hospital - APHP, Paris, France|CH Privé de la Loire, Saint-Étienne, France|University Medical Center Schleswig-Holstein, Kiel, Germany|Hospital Clínico Universitario de Valencia, Valencia, Spain		https://ClinicalTrials.gov/show/NCT04383730
944	NCT04532372	Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy		Not yet recruiting	No Results Available	Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed	Other: Best Practice|Drug: Leflunomide|Drug: Placebo Administration	Incidence of toxicity, graded according to the NCI CTCAE version 5|Maximum tolerated dose (MTD) (Phase 1)|Clinical activity (Response)(Phase 2)|Time to Clinical activity (Response)|Overall Survival|Oxygen Saturation improvement|SARS-CoV-2 resolution|Hospitalization|Mechanical Ventilation required|Mechanical Ventilation duration|Vital status (alive/dead)|Vital status (cause of death)	City of Hope Medical Center|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	30	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20291|NCI-2020-05746|P30CA033572	September 18, 2020	September 18, 2022	September 18, 2022	August 31, 2020		August 31, 2020	City of Hope Medical Center, Duarte, California, United States		https://ClinicalTrials.gov/show/NCT04532372
945	NCT04349098	Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection	Coronavirus	Recruiting	No Results Available	Coronavirus Infection	Drug: Selinexor|Other: Placebo	Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE)	Karyopharm Therapeutics Inc	All	18 Years and older   (Adult, Older Adult)	Phase 2	230	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	XPORT-CoV-1001|2020-001411-25	April 17, 2020	August 31, 2020	August 31, 2020	April 16, 2020		May 8, 2020	UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom		https://ClinicalTrials.gov/show/NCT04349098
946	NCT04420247	Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19		Recruiting	No Results Available	COVID|COVID-19|SARS-CoV 2|Coronavirus|Corona Virus Infection	Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care	World Health Organization (WHO) 9-levels scale (from 0-8)|WHO 9-levels scale (from 0-8)|Mortality|Ventilation free days|Duration of mechanical ventilation|National Early Warning Score (NEWS)|ICU Lenght of Stay|Hospital Lenght of Stay|Acute Kidney Disease incidence|Percentage of patients needing Dialysis|Mean of C Reactive Protein Levels|Mean of Leucocytes Levels|Mean of Lymphocyte Levels	Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva	All	18 Years and older   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CLOROTRIAL	April 16, 2020	August 31, 2020	August 31, 2020	June 9, 2020		June 17, 2020	Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil		https://ClinicalTrials.gov/show/NCT04420247
947	NCT04467918	CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms	CANDIDATE	Recruiting	No Results Available	SARS-CoV2	Drug: Cannabidiol|Other: PLACEBO	Prevention of severe/critical stage of Covid19|Time to CoVid19 symptoms relief and number of participants with negative Clinical CoVid19 symptoms as assessed by CTCAE v5.0|Change in proinflammatory cytokine concentration|Describe the parenchymal lung damage induced by COVID-19 through a qualitative analysis with chest CT|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Time to clinical improvement with CTCAE v5.0 CoVid19 symptoms to 0|Number of participants that need hospitalisation|28-day mortality|Time to positive-to-negative saliva 2019-n-CoV RT-PCR conversion|Reduction in viral load|Brief measure for assessing generalized anxiety disorder and depression|Increment of odor detection sensitivity	University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Fundação de Amparo à Pesquisa do Estado de São Paulo	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CANDIDATE study	July 6, 2020	October 17, 2020	October 31, 2020	July 13, 2020		October 6, 2020	Serviço de Assistência Médica e Social do Pessoal do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, SP, Brazil|Unidade de Pronto Atendimento/UPA - 13 de Maio/Dr. Luis Atílio Losi Viana (UPA Covid), Ribeirão Preto, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04467918
948	NCT04373733	Early Intervention in COVID-19: Favipiravir Verses Standard Care	PIONEER	Recruiting	No Results Available	Coronavirus Infection	Drug: Favipiravir|Other: Standard of care management	Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.	Chelsea and Westminster NHS Foundation Trust|NEAT ID Foundation|FUJIFILM Toyama Chemical Co., Ltd.|Imperial College London|Universitaire Ziekenhuizen Leuven	All	18 Years and older   (Adult, Older Adult)	Phase 3	450	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CW002|2020-001449-38	May 1, 2020	March 31, 2021	March 31, 2021	May 4, 2020		July 7, 2020	Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04373733
949	NCT04513314	Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium		Not yet recruiting	No Results Available	Covid19|Hyperactive Delirium|Pneumonia, Viral	Drug: Valproate|Drug: Quetiapine|Other: Standard of Care	Change from baseline RASS score of +3 or greater|Total dose of dexmedetomidine administered|Incidence of Treatment Emergent Adverse Events	University of Miami	All	18 Years and older   (Adult, Older Adult)	Phase 4	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	20200851	November 1, 2020	November 1, 2021	November 1, 2021	August 14, 2020		September 21, 2020	Jackson Memorial Hospital, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT04513314
950	NCT04358068	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19		Completed	No Results Available	COVID-19|SARS-CoV 2	Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin	Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset	National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ACTG A5395|38720	May 1, 2020	July 7, 2020	July 7, 2020	April 22, 2020		August 3, 2020	Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04358068/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04358068
951	NCT04320238	Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff		Recruiting	No Results Available	2019 Novel Coronavirus Infection	Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1	new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect	Shanghai Jiao Tong University School of Medicine	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 3	2944	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Interferon_prophylaxis	January 21, 2020	May 2020	June 2020	March 24, 2020		March 31, 2020	Taihe Hospital, Shiyan, Hubei, China		https://ClinicalTrials.gov/show/NCT04320238
952	NCT04425031	Handling Oxygenation Targets in COVID-19	HOT-COVID	Recruiting	No Results Available	Hypoxemic Respiratory Failure|Oxygen Toxicity	Drug: Oxygen	Days alive without organ support|90-days mortality|Days alive out of the hospital|Number of patients with one or more serious adverse events|1-year mortality|Quality of life assessement using the EuroQoL EQ-5D-5L telephone interview|Cognitive function 1-year after randomisation as assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score in selected sites|Carbon monoxide diffusion capacity|A health economic analysis	Aalborg University Hospital|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research	All	18 Years and older   (Adult, Older Adult)	Phase 4	780	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	AAUH-ICU-03|2017-000632-34	August 25, 2020	December 1, 2022	March 1, 2024	June 11, 2020		September 14, 2020	Dept. of Intensive Care, Aalborg University Hospital, Aalborg, Denmark|Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Herlev Hospital, Herlev, Denmark|Dept. of Intensive Care, Hillerød Hospital, Hillerød, Denmark|Dept. of Intensive Care, Holbæk Hospital, Holbæk, Denmark|Dept. of Intensive Care, Kolding Hospital, Kolding, Denmark|Dept. of Intensive Care, Køge Hospital, Køge, Denmark|Dept. of Intensive Care, Slagelse Hospital, Slagelse, Denmark		https://ClinicalTrials.gov/show/NCT04425031
953	NCT04482595	BIO 300 Oral Suspension in Discharged COVID-19 Patients		Not yet recruiting	No Results Available	Pulmonary Fibrosis	Drug: BIO 300 Oral Suspension|Drug: Placebo	Change in DLCO|Change in 6 Minute Walk Test|Change in FVC|Change in FEV1|Change in FEV1/FVC Ratio|Change in Pulse Oximetry at Rest and During the 6MWT|Change in Pulmonary Fibrosis on CT Scan|Change in St. George's Respiratory Questionnaire (SGRQ) Scores|Change in Clinical Laboratory Values for Serum Enzymes|Change in Clinical Laboratory Values|Change in Clinical Laboratory Values for Albumin|Change in Complete Blood Counts with Differential|All-Cause Mortality|Incidence of Re-Hospitalization|Adverse Events Related to BIO 300 Oral Suspension	Humanetics Corporation|NYU Langone Health|National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years and older   (Adult, Older Adult)	Phase 2	66	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CL0105-01|272201800011C-P00005-9999-1	September 2020	June 2021	July 2022	July 22, 2020		July 23, 2020	NYU Langone Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04482595
954	NCT04365985	Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19	SINK COVID-19	Recruiting	No Results Available	COVID-19|Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections	Drug: Naltrexone|Drug: Ketamine|Other: Placebo	Progression of oxygenation needs|Renal failure|Liver failure|Cytokine Storm|Mortality|Length of hospital stay|Intensive Care Unit (ICU) admission|Intensive Care Unit (ICU) duration|Intubation|Intubation duration|Time until recovery	William Beaumont Hospitals	All	18 Years and older   (Adult, Older Adult)	Phase 2	500	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2020-097	April 29, 2020	May 2021	August 2021	April 28, 2020		July 2, 2020	William Beaumont Hospital, Royal Oak, Michigan, United States		https://ClinicalTrials.gov/show/NCT04365985
955	NCT04346147	Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	Covid-19HUF	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Hidroxicloroquine|Drug: Lopinavir/ritonavir|Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet	time to clinical improvement|Safety of treatments|Tolerability of treatments	Hospital Universitario de Fuenlabrada|Centro Nacional de Investigaciones Oncologicas CARLOS III	All	18 Years and older   (Adult, Older Adult)	Phase 2	165	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	24032020	April 13, 2020	August 2020	September 2020	April 15, 2020		May 8, 2020	Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04346147
956	NCT04479358	Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19	COVIDOSE-2	Recruiting	No Results Available	COVID-19	Drug: Tocilizumab|Other: Standard of Care	Time to Recovery|Achievement of Recovery|Overall Survival|Hospital Length of Stay|Clinical Response: Maximum Temperature (Tmax) Response|Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation|Clinical Response: Rate of Vasopressor/Inotrope Utilization|Clinical Response: Duration of Vasopressor/Inotrope Utilization|Clinical Response: Time to Vasopressor/Inotrope Utilization|Clinical Response: Duration of Increased Supplemental Oxygen from Baseline|Biochemical Response: C-reactive Protein Response Rate|Safety: Rate of Secondary Infection	University of Chicago	All	18 Years and older   (Adult, Older Adult)	Phase 2	332	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-1179	September 10, 2020	December 1, 2020	March 1, 2021	July 21, 2020		September 23, 2020	University of Chicago Medicine, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04479358
957	NCT04371523	Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers	PROVIDE	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: Apo-Hydroxychloroquine|Drug: Matched Placebo	Positive for SARS-CoV-2|Hospital admissions|Intensive care unit admissions|Intubation and mechanical ventilation|ICU length of stay|Hospital length of stay|Mortality|Incidence of adverse events	St. Joseph's Healthcare Hamilton	All	18 Years and older   (Adult, Older Adult)	Phase 3	1100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	3190	May 1, 2020	July 31, 2020	August 30, 2020	May 1, 2020		May 1, 2020	St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04371523
958	NCT04435106	Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)		Completed	No Results Available	Coronavirus Infections	Drug: Opaganib|Drug: Standard of Care	Measure the time to weaning from high-flow nasal cannula|Measure the time to breathing ambient (room) air|Measure change in lymphocyte count|Measure change in C-reactive protein	Shaare Zedek Medical Center	All	18 Years to 80 Years   (Adult, Older Adult)		23	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	0123-20- SZMC	April 3, 2020	May 1, 2020	May 15, 2020	June 17, 2020		June 17, 2020	Shaare-Zedek Medical Center, Jerusalem, Israel		https://ClinicalTrials.gov/show/NCT04435106
959	NCT04333654	Hydroxychloroquine in Outpatient Adults With COVID-19		Terminated	No Results Available	Coronavirus Infection	Drug: Hydroxychloroquine SAR321068|Drug: Placebo	Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events	Sanofi	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	8	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EFC16855|2020-001269-35|U1111-1249-6168	April 12, 2020	May 26, 2020	May 26, 2020	April 3, 2020		July 14, 2020	Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 0561001, Bruxelles, Belgium|Investigational Site Number 0561002, Lodelinsart, Belgium|Investigational Site Number 2501001, Bordeaux Cedex, France|Investigational Site Number 2501002, Paris, France|Investigational Site Number 5281001, Groningen, Netherlands|Investigational Site Number 5281002, Harderwijk, Netherlands		https://ClinicalTrials.gov/show/NCT04333654
960	NCT04312009	Losartan for Patients With COVID-19 Requiring Hospitalization		Recruiting	No Results Available	Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection	Drug: Losartan|Other: Placebo	Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15	University of Minnesota|Bill and Melinda Gates Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SURG-2020-28675|INV-017069	April 13, 2020	April 1, 2021	April 1, 2021	March 17, 2020		July 21, 2020	University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|North Memorial Health Hospital, Robbinsdale, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04312009
961	NCT04519437	Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19		Recruiting	No Results Available	Healthy|Chronic Stable Illness	Drug: REGN10933+REGN10987|Drug: Placebo	Incidence of adverse event of special interests (AESIs) that occur within 4 days of study drug administration|Concentrations of REGN10933 in serum over time|Concentrations of REGN10987 in serum over time|Proportion of participants with treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Proportion of participants who achieve or exceed target concentration in serum of REGN10933|Proportion of participants who achieve or exceed target concentration in serum of REGN10987|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987	Regeneron Pharmaceuticals	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 1	940	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R10933-10987-HV-2093	July 26, 2020	October 25, 2021	October 25, 2021	August 19, 2020		September 18, 2020	Regeneron Study Site, Tempe, Arizona, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT04519437
962	NCT04384458	Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis		Recruiting	No Results Available	Coronavirus Infections	Drug: Hydroxychloroquine|Drug: Ivermectin	Proportion of participants in whom there was a positivity for SARS-CoV-2.|Participants who developed mild, moderate, or severe forms of COVID-19.|Measurement of the QT interval.|Widening of the corrected QT interval or with changes in heart rate on the ECG.|Comparison of hematological and biochemical parameters.|Occurrence of adverse events.|Assessment of COVID-19 symptom severity.|Proportion of participants who discontinue study intervention.|Proportion of participants who required hospital care.|Proportion of participants who required mechanical ventilation.	Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	HCQ+IVM	July 20, 2020	September 10, 2020	April 2021	May 12, 2020		October 6, 2020	Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil		https://ClinicalTrials.gov/show/NCT04384458
963	NCT04311177	Losartan for Patients With COVID-19 Not Requiring Hospitalization		Recruiting	No Results Available	Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection	Drug: Losartan|Other: Placebo	Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days	University of Minnesota|The Minnesota Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 2	580	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SURG-2020-28683	April 9, 2020	April 1, 2021	April 1, 2021	March 17, 2020		June 16, 2020	Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04311177
964	NCT04393246	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms		Recruiting	No Results Available	COVID-19	Drug: EDP1815|Drug: Dapagliflozin|Drug: Ambrisentan|Other: Standard of care	Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: IL-6|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: ferritin|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: c-reactive protein (CRP)|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: D-dimer|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: neutrophil/lymphocyte ratio|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: lactate dehydrogenase (LDH)|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Time to each of the individual endpoints of the composite primary outcome measure|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All-cause mortality at day 28|Time to clinical improvement	Cambridge University Hospitals NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1407	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TACTIC-E	July 3, 2020	February 15, 2021	June 15, 2021	May 19, 2020		July 8, 2020	Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04393246
965	NCT04361474	Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity	COVIDORL	Recruiting	No Results Available	Budesonide|Olfaction Disorders|SARS-CoV-2|Anosmia	Drug: Budesonide Nasal|Other: Physiological serum	Patient with more than 2 points on the ODORATEST	Fondation Ophtalmologique Adolphe de Rothschild|Hopital Lariboisière	All	18 Years and older   (Adult, Older Adult)	Phase 3	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	MDL_2020_10	May 18, 2020	May 18, 2020	May 25, 2021	April 24, 2020		June 9, 2020	Amélie YAvchitz, Paris, France		https://ClinicalTrials.gov/show/NCT04361474
966	NCT04341493	Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19		Recruiting	No Results Available	Coronavirus Infection	Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine	Mechanical ventilation requirement	Hugo Mendieta Zeron|Materno-Perinatal Hospital of the State of Mexico	All	5 Years and older   (Child, Adult, Older Adult)	Phase 4	86	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2020-03-681	April 6, 2020	August 30, 2020	December 30, 2020	April 10, 2020		April 24, 2020	Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico		https://ClinicalTrials.gov/show/NCT04341493
967	NCT04412746	Covid-19 and Diabetes in West of Algeria	COVIDIAB-13	Recruiting	No Results Available	Coronavirus Infections|Diabetes Mellitus|Prevalence|Risk Factors|Patient Outcome Assessment|Severe Acute Respiratory Syndrome	Drug: MANAGEMENT OF COVID-19	Prevalence of diabetes among all hospitalized COVID-19|Diabetes-related factors risk	Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen|ATRSS, DGRST, Algeria	All	16 Years and older   (Child, Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVIDIAB-13	April 1, 2020	June 30, 2020	June 30, 2020	June 2, 2020		June 2, 2020	Department of Internal Medicine, Acedemic Hospital of Tlemcen, Tlemcen, Algeria		https://ClinicalTrials.gov/show/NCT04412746
968	NCT04310865	Yinhu Qingwen Granula for the Treatment of Severe CoVID-19		Suspended	No Results Available	COVID-19|Severe Pneumonia|Chinese Medicine	Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment	changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events	Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	116	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	YHQW-Severe-V2.0	November 2020	March 30, 2021	June 30, 2021	March 17, 2020		May 11, 2020	Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04310865
969	NCT04261426	The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia		Not yet recruiting	No Results Available	2019-nCoV	Drug: Intravenous Immunoglobulin|Other: Standard care	Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events	Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IVIG-001	February 10, 2020	April 30, 2020	June 30, 2020	February 7, 2020		February 7, 2020			https://ClinicalTrials.gov/show/NCT04261426
970	NCT04363437	COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19	COMBATCOVID19	Recruiting	No Results Available	Coronavirus Infection	Drug: Colchicine|Drug: Usual Care	Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula|Percentage of patients who will require mechanical ventillation|Hospital length of stay|Mortality|Maximum CRP|Maximum troponin elevation	Maimonides Medical Center	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-04-12	April 26, 2020	May 31, 2020	June 14, 2020	April 27, 2020		May 8, 2020	Maimonides Medical Center, Brooklyn, New York, United States		https://ClinicalTrials.gov/show/NCT04363437
971	NCT04344379	Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus	PREP-COVID	Suspended	No Results Available	SARS-CoV-2 Infection	Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo	To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 3	122	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	APHP200386|2020-001273-73	April 17, 2020	June 30, 2020	July 15, 2020	April 14, 2020		June 12, 2020	Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France		https://ClinicalTrials.gov/show/NCT04344379
972	NCT04327388	Sarilumab COVID-19		Completed	No Results Available	Corona Virus Infection	Drug: Sarilumab SAR153191|Drug: Placebo	Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale|Percent of patients alive at Day 29|Proportion of patients with one point improvement from baseline in clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point ordinal scale|Mean change in the 7-point ordinal scale from baseline to Days 4, 7, 15, 21, and 29 (or until discharge)|Time to resolution of fever|Time to resolution of fever and improvement in oxygenation|Days with fever|Time to change in NEWS2 from baseline|Time to NEWS2 of <2 and maintained for 24 hours|Mean change from baseline to days 4, 7, 15, 21, and 29 in NEWS2|Time-to-improvement in oxygenation|Alive off supplemental oxygen at day 29|Days of hypoxemia|Days of supplemental oxygen use|Days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Ventilator free days in the first 28 days (to day 29)|The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Proportion of patients requiring rescue medication during the 28-day period|The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Days of hospitalization among survivors|Incidence of serious adverse events|The incidence of major or opportunistic bacterial or fungal infections|The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities	Sanofi|Regeneron Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 3	420	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EFC16844|2020-001162-12	March 28, 2020	July 30, 2020	September 2, 2020	March 31, 2020		September 29, 2020	Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, São José Do Rio Preto, Brazil|Investigational Site Number 0760005, São Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational site number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid / Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04327388
973	NCT04325893	Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease	HYCOVID	Terminated	No Results Available	Coronavirus	Drug: Hydroxychloroquine|Drug: Placebo	Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older	University Hospital, Angers	All	18 Years and older   (Adult, Older Adult)	Phase 3	259	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	49RC20_0071	April 1, 2020	June 18, 2020	June 18, 2020	March 30, 2020		October 6, 2020	CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Auxerre, Auxerre, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Chalon Sur Saône, Chalon Sur Saône, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|CH Compiègne, Compiègne, France|APHP Henri Mondor, Créteil, France|CH Intercommunal Créteil, Créteil, France|CHU Dijon, Dijon, France|APHP Joffre Dupuytren, Draveil, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CH Emile Roux, Le Puy-en-Velay, France|APHP Emile ROUX, Limeil-Brevannes, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|Hôpital Européen - Marseille, Marseille, France|Hôpital Saint-Joseph, Marseille, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|GH Croix Saint Simon, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco		https://ClinicalTrials.gov/show/NCT04325893
974	NCT04508023	A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection	PREVENT-HD	Recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)	Drug: Rivaroxaban|Other: Placebo|Other: Standard of Care (SOC)	Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, All-cause Hospitalization and All-cause Mortality|Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Mortality|Time to First Occurrence of All-cause Hospitalization|Time to First Occurrence of Symptomatic VTE|Time to First Occurrence of an Emergency Room (ER) Visit|Time to First Occurrence of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Hospitalization|Percentage of Participants who are Hospitalized or Dead From Any Cause|Time to All-cause Mortality up to Day 35|Time to First Occurrence of International Society on Thrombosis and Hemostasis (ISTH) Critical Site and Fatal Bleeding|Time to First Occurrence of ISTH Major Bleeding Events|Time to First Occurrence of Clinically Relevant Non-major Bleeding	Janssen Research & Development, LLC	All	18 Years and older   (Adult, Older Adult)	Phase 3	4000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CR108849|39039039DVT3004	August 13, 2020	March 3, 2021	April 6, 2021	August 11, 2020		September 18, 2020	University of Colorado Denver, Aurora, Colorado, United States|Emory University, Atlanta, Georgia, United States|Northshore Universite Healthsystem, Evanston, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Lenox Hill Hospital -Northwell Health, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT04508023
975	NCT04251871	Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection		Recruiting	No Results Available	Pneumonia Caused by Human Coronavirus (Disorder)	Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)	The incidents of acute respiratory distress syndrome (ARDS) development|The time to fever resolution rate|Time to recovery of lung injury	Beijing 302 Hospital	All	14 Years to 80 Years   (Child, Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020001D	January 22, 2020	January 22, 2021	January 22, 2021	February 5, 2020		May 5, 2020	The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04251871
976	NCT04402060	A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19		Recruiting	No Results Available	COVID|Covid-19|Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Ards|Acute Respiratory Distress Syndrome	Drug: APL-9|Other: Vehicle Control	Cumulative incidence of treatment-emergent serious adverse events and treatment-emergent adverse events.|Hospital length of stay|Any cause of mortality|Sequential Organ Failure Assessment|Total duration of mechanical ventilation|Total duration of oxygen therapy	Apellis Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	66	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	APL9-COV-201	May 26, 2020	November 2020	November 2020	May 26, 2020		June 9, 2020	Westchester General Hospital, Miami, Florida, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Audobon Hospital, Louisville, Kentucky, United States|University at Buffalo, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT04402060
977	NCT04322123	Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)	Coalition-I	Active, not recruiting	No Results Available	Coronavirus Infections	Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin	Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days	Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS	All	18 Years and older   (Adult, Older Adult)	Phase 3	630	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Brazil COVID Coalition I Trial	April 1, 2020	August 30, 2020	August 30, 2020	March 26, 2020		June 1, 2020	Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil		https://ClinicalTrials.gov/show/NCT04322123
978	NCT04290858	Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection	NoCovid	Withdrawn	No Results Available	Coronavirus Infections|Pneumonia, Viral|Dyspnea	Drug: Nitric Oxide	Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery	Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID19 NOgas mild	March 1, 2020	March 1, 2021	February 1, 2022	March 2, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04290858
979	NCT04516837	Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)		Recruiting	No Results Available	Immune Thrombocytopenia	Drug: Eltrombopag|Drug: rhTPO	Complete response|Response|No response|Relapses|Early response|Initial response|Durable response|TOR (time to response)|DOR (duration of response)|Treatments associated adverse events|Reduction in bleeding symptoms	Peking University People's Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ITP-PKU020	August 31, 2020	August 2021	August 2022	August 18, 2020		September 1, 2020	Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04516837
980	NCT04376814	Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19		Completed	No Results Available	COVID-19|Favipiravir|Kaletra|Hydroxychloroquine|Lopinavir/Ritonavir	Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir	Mortality|long of hospitalization|Laboratory Treatment Response (Blood cell count)|Laboratory Treatment Response (CRP )|Dyspnea|Oxygen saturation without supplemental oxygen.|Oxygen therapy	Baqiyatallah Medical Sciences University	All	16 Years to 100 Years   (Child, Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IR.BMSU.REC.1399.017	March 29, 2020	April 5, 2020	May 25, 2020	May 6, 2020		June 16, 2020	Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04376814
981	NCT04469621	A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19		Active, not recruiting	No Results Available	Corona Virus Infection	Drug: SAR443122|Drug: Placebo	Relative change from baseline in CRP level|Time to 50% decrease from baseline in CRP level|Time to improvement of oxygenation|Change from baseline in SPO2/FiO2 ratio|Number of Days without need for oxygen support and alive|Numbers of Ventilator-free days and alive|Change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes|Change from baseline in marker of inflammation: neutrophil to lymphocyte ratio|Change from baseline in marker of inflammation: interleukin 6 (IL-6)|Change from baseline in D-Dimer|Incidence of Deaths|Percentage of participants receiving thrombolytic treatment|Percentage of participants receiving vasopressor treatment|Incidence of serious adverse events (SAEs), adverse events of special interest (AESI) and treatment-emergent adverse events (TEAEs) leading to treatment discontinuation|Incidence of TEAEs leading to study discontinuation (primary reason)	Sanofi	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	67	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PDY16879|2020-002104-39|U1111-1250-1185	July 17, 2020	October 2020	October 2020	July 14, 2020		October 7, 2020	Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, São José Do Rio Preto, Brazil|Investigational Site Number 0760002, São Paulo, Brazil|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Talca, Chile|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation		https://ClinicalTrials.gov/show/NCT04469621
982	NCT04337918	Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection	NOCOVID	Recruiting	No Results Available	Corona Virus Infection	Drug: NORS (Nitric Oxide Releasing Solution)	Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2	Sanotize Research and Development corp.|The Emmes Company, LLC|Keyrus Life Science	All	19 Years and older   (Adult, Older Adult)	Phase 2	200	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	COVID-CTP-01	May 8, 2020	August 31, 2020	September 30, 2020	April 8, 2020		June 25, 2020	BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche Québec, Québec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borromée, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04337918
983	NCT04486508	Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19	INSPIRATION	Recruiting	No Results Available	Covid19	Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo	Composite of incident VTE, undergoing ECMO, and all-cause mortality	Rajaie Cardiovascular Medical and Research Center|Brigham and Women's Hospital|Tehran Heart Center|Masih Daneshvari Hospital|Hazrat Rasool Hospital|Modarres Hospital|Firuzgar hospital affiliated to Iran University of Medical Sciences|Imam Khomeini Hospital|Sina Hospital, Iran|Tabriz University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 3	600	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	99060	July 30, 2020	October 25, 2020	December 6, 2020	July 24, 2020		August 4, 2020	Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04486508
984	NCT04321278	Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)		Completed	No Results Available	Coronavirus Infections|Pneumonia, Viral	Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine	Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype	Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network	All	18 Years and older   (Adult, Older Adult)	Phase 3	440	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	30155020.5.1001.0071	March 28, 2020	June 14, 2020	June 14, 2020	March 25, 2020		July 2, 2020	Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Hospital e Clínica São Roque, Ipiaú, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil|Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil|Hospital São Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Hospital Nereu Ramos, Florianópolis, SC, Brazil|Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saude Santa Marcelina, São Paulo, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital Moriah, São Paulo, SP, Brazil|Hospital Nove de Julho, São Paulo, SP, Brazil|Hospital Santa Paula, São Paulo, SP, Brazil|Hospital São Camilo Pompeia, São Paulo, SP, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04321278
985	NCT04448756	M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia	ANEMONE	Recruiting	No Results Available	Coronavirus Disease 2019	Drug: M5049|Drug: Placebo	Percentage of Participants Alive and not Requiring Supplemental Oxygenation|Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs)|Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings|Clinical Status of Participants on a 9-Point Ordinal Scale|Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours on Room Air|Percentage of Participants With All-Cause Mortality|Clinical Deterioration: Time to Intensive Care Unit (ICU) Admission|Clinical Deterioration: Time to Invasive Mechanical Ventilation|Clinical Deterioration: Time to Non-Invasive Mechanical Ventilation|Total Length of Stay in Intensive Care Unit (ICU)|Total Length of Hospitalization Stay|Percentage Change From Baseline in Inflammatory Biomarkers|Percentage Change From Baseline in Cytokine Biomarkers|Percentage of Participants With Relapse|Percentage of Participants who are Re-Hospitalized|Maximum Observed Concentration (Cmax) of M5049|Time to Reach the Maximum Observed Concentration (tmax) of M5049|Terminal Rate Constant (Lambda z) of M5049|Apparent Elimination Half-Life (t1/2) of M5049|Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t) of M5049|Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h) of M5049|Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity) of M5049|Apparent Total Body Clearance (CL/F) of M5049|Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of M5049|Dose-Normalized Maximum Observed Concentration (Cmax/Dose) of M5049|Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t/Dose) of M5049|Dose-Normalized Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h/Dose) of M5049|Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity/Dose) of M5049|Accumulation Ratio for Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose [Racc(AUC0- 12h)] of M5049|Accumulation Ratio for Maximum Observed Concentration [Racc(Cmax)] of M5049	EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	MS200569_0026|2020-002248-22	July 29, 2020	November 13, 2020	November 13, 2020	June 26, 2020		October 8, 2020	University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States|LAC-USC Medical Center, Los Angeles, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Saint Louis University - Saint Louis University Hospital, Saint Louis, Missouri, United States|Christus Spohn Hospital Corpus Christi-Memorial, Corpus Christi, Texas, United States|Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Leforte Morumbi, Sao Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital Bandeirantes / Hospital Leforte Liberdade, São Paulo, Brazil|Instituto de Infectologia Emílio Ribas, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04448756
986	NCT04344041	COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)		Recruiting	No Results Available	Coronavirus	Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU	Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology	University Hospital, Angers|Mylan Laboratories	All	65 Years and older   (Older Adult)	Phase 3	260	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001602-34	April 15, 2020	May 2021	May 2021	April 14, 2020		October 2, 2020	CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France		https://ClinicalTrials.gov/show/NCT04344041
987	NCT04395170	Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.		Not yet recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)	Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19	Admission to ICU and/or mechanical ventilation|Length of hospital stay|Neutralizing antibody (IgG) titers against COVID-19|Safety - Adverse events|Death	Lifefactors Zona Franca, SAS	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	75	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LFCOLCOVID-19-001	September 2020	December 2020	June 2021	May 20, 2020		July 10, 2020	LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia		https://ClinicalTrials.gov/show/NCT04395170
988	NCT04525820	High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study	VitCov	Not yet recruiting	No Results Available	Covid19|Vitamin D Deficiency|Corona Virus Infection|ARDS|Coronavirus|SARS-CoV Infection	Drug: Single high dose vitamin D|Drug: Placebo|Drug: Treatment as usual vitamin D	Length of hospitalization|Need of intensive care|Lenght of the Intensive Care Treatment|Overall mortality|Development of vitamin D levels|Development of sepsis	Prof. Dr. Jörg Leuppi|Cantonal Hosptal, Baselland	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-01401	September 1, 2020	May 31, 2021	June 30, 2021	August 25, 2020		August 25, 2020	Cantonal Hospital Aarau, Aarau, AG, Switzerland|Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St. Gallen, Saint Gallen, SG, Switzerland		https://ClinicalTrials.gov/show/NCT04525820
989	NCT04570384	Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness		Not yet recruiting	No Results Available	Acute Hypoxemic Respiratory Failure	Drug: L-Citrulline|Drug: Placebo	Primary Biochemical Objective to measure levels of citrulline and arginine in the Blood|The primary safety objective is a beneficial effect of intravenous L-Citrulline on hemodynamic status.|Primary Clinical Objective|Evaluate the Safety of L-Citrulline|Evaluate the effect of intravenous L-Citrulline compared to placebo as measured by the total length of all mechanical ventilation|Evaluate the Effect of IV L-Citrulline to Placebo for Hospital all cause mortality|Evaluate the Effect of IV L-Citrulline to Placebo on length of ICU and Hospital Stay|Evaluate overall difference in intubation rates|Evaluate overall duration of mechanical ventilation from consent and post-infusion	Asklepion Pharmaceuticals, LLC	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CIT-COVID19-002-01	September 28, 2020	May 28, 2021	December 28, 2021	September 30, 2020		September 30, 2020	University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States		https://ClinicalTrials.gov/show/NCT04570384
990	NCT04419623	A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer		Recruiting	No Results Available	COVID-19|Sars-CoV2|Cancer|Solid Tumor|Carcinoma|Blood Cancer	Drug: Part 1 - TL-895|Drug: Part 2 - TL-895|Drug: Part 2 - Placebo	Part 1 - Recommended dose of TL-895|Part 2 - Change in the need for artificial ventilation or death|Part 2 - Change in respiratory failure events that require invasive ventilation or death	Telios Pharma, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	146	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TL-895-202	July 9, 2020	July 2021	July 2021	June 5, 2020		September 25, 2020	University of Miami, Miami, Florida, United States|Georgia Cancer Center, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Barbara Ann Karmanos Cancer Institute - Wertz Clinic, Detroit, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States|OhioHealth - Riverside Methodist Hospital, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT04419623
991	NCT04541680	Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis	NINTECOR	Not yet recruiting	No Results Available	SARS-Cov-2 Induced Pulmonary Fibrosis	Drug: Nintedanib 150 MG [Ofev]|Other: Placebo	The primary objective is to assess whether nintedanib slows the progression of lung fibrosis in COVID-19 survivors as assessed by the decline in the forced vital capacity (FVC) over 12 months compared to placebo.|compare the rate of decline of DLCO over 12 months|compare exercise capacity at 12 months|compare high resolution CT (HRCT) lung opacities extension at 12 months|compare change in health-related quality of life|compare the evolution of dyspnea over time|compare change in Depression and anxiety over time|compare change in lung injury, pulmonary hypertension and inflammation biomarkers|pulmonary hypertension prevalence at inclusion and 12 months|association between genetic susceptibility (MUC5B polymorphism) and lung fibrosis in COVID-19 survivors|safety of nintedanib	Assistance Publique - Hôpitaux de Paris|Boehringer Ingelheim	All	18 Years to 89 Years   (Adult, Older Adult)	Phase 3	250	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	APHP200527	September 2020	March 2021	December 2021	September 9, 2020		September 9, 2020			https://ClinicalTrials.gov/show/NCT04541680
992	NCT04377646	A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers	COVID-Milit	Not yet recruiting	No Results Available	Sars-CoV2|COVID19	Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo)	SARS CoV2 infection|COVID-19 symptoms description|Adverse Events	Military Hospital of Tunis|UR17DN02 : Autoimmune Diseases Research Unit|Dacima Consulting	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 3	660	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	UR17DN02-001|TN2020-NAT-INS-38	May 4, 2020	May 24, 2020	July 31, 2020	May 6, 2020		May 6, 2020	Military Hospital of Tunis, Tunis, Tunisia		https://ClinicalTrials.gov/show/NCT04377646
993	NCT04526912	Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection	ALI	Recruiting	No Results Available	Acute Lung Injury	Drug: VIB7734|Drug: Placebo	The proportion of patients who achieve treatment success through Day 28, defined as avoidance of death and critical illness|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent fatal and life-threatening SAEs, Treatment-emergent Serious Adverse Events|Change in safety laboratory parameters	Viela Bio	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	48	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	VIB7734.P1.S2	August 28, 2020	January 2021	March 2021	August 26, 2020		September 2, 2020	Research Site, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04526912
994	NCT04353037	PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine		Recruiting	No Results Available	Coronavirus|Corona Virus Infection	Drug: Group A HCQ|Drug: Group B Control	Sub Study 1: Patients|Sub Study 2: Health Care Workers|Sub Study 1: Patients: Rate of secondary infection of co-inhabitants|Sub Study 1: Patients: Adverse Events|Sub Study 1: Patients: Negative for COVID-19|Sub Study 2:Health Care Workers:Number of shifts missed|Sub Study 2:Health Care Workers:Rate of adverse events|Sub Study 2:Health Care Workers:Rate of hospitalization	UnitedHealth Group|ProHealth Care Associates|University of Pennsylvania Perelman School of Medicine	All	50 Years to 75 Years   (Adult, Older Adult)	Phase 2	850	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	2020-0003	April 7, 2020	April 2021	June 15, 2021	April 20, 2020		April 24, 2020	ProHealth New York, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04353037
995	NCT04519385	Toclizumam Versus Dexamethasone in Severe Covid-19 Cases		Completed	No Results Available	Pneumonia, Viral	Drug: Tocilizumab|Drug: Dexamethasone	Proportion of participants with Overall Survival at 14 days|Fio2/Pao2	South Valley University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	69	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	SouthVU	March 1, 2020	July 1, 2020	August 5, 2020	August 19, 2020		August 25, 2020	Qena faculty medicine, Qinā, Egypt		https://ClinicalTrials.gov/show/NCT04519385
996	NCT04468139	The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19		Recruiting	No Results Available	Covid-19	Drug: Quercetin|Dietary Supplement: bromelain|Drug: Zinc|Drug: Vitamin C	days of stay at hospital after treatment and discharge|serum zinc before and after treatment|questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,|day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19	Ministry of Health, Saudi Arabia	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-95M	June 20, 2020	July 20, 2020	July 30, 2020	July 13, 2020		July 13, 2020	Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04468139
997	NCT04482673	Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection	VitD-COVID19	Recruiting	No Results Available	COVID-19|Vitamin D Deficiency|Respiratory Viral Infection	Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo	Change in total circulating 25(OH)D concentration|Change in total circulating 25(OH)D concentration in COVID-19 positives|Change in SARS-CoV-2 antibody titers|Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha|Respiratory symptoms|Signs and symptoms of rhino/sinusitis|NCI Dietary Intake|Charlson Comorbidity survey|Paffenberger Physical Activity Assessment|Perceived stress|Pandemic stress|NEO-Personality Inventory|GrassrootsHealth Monthly Health assessment	Medical University of South Carolina|Grassroots Health Nutrition Institute|ZRT Laboratory	All	50 Years and older   (Adult, Older Adult)	Phase 4	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	00099939	July 31, 2020	December 31, 2021	December 31, 2021	July 22, 2020		August 4, 2020	Medical University of South Carolina, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT04482673
998	NCT04392128	Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)	HYACINTHE	Withdrawn	No Results Available	COVID19|Hematologic Malignancy	Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule	Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study	Institut de Cancerologie Strasbourg Europe	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-005|2020-002002-45	September 2, 2020	September 2, 2020	September 2, 2020	May 18, 2020		September 4, 2020	Institut de Cancérologie Strasbourg Europe, Strasbourg, France		https://ClinicalTrials.gov/show/NCT04392128
999	NCT04367168	Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease	ColchiVID	Recruiting	No Results Available	COVID	Drug: Colchicine|Drug: Placebo oral tablet	Number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels|Progression to severe disease	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	174	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	337420-21-1	May 27, 2020	April 27, 2021	April 27, 2021	April 29, 2020		May 28, 2020	Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT04367168
1000	NCT04288713	Eculizumab (Soliris) in Covid-19 Infected Patients	SOLID-C19	Available	No Results Available	Coronavirus	Drug: Eculizumab		Hudson Medical	All	18 Years and older   (Adult, Older Adult)			Other	Expanded Access:Individual Patients|Treatment IND/Protocol		COVID19				February 28, 2020		March 30, 2020			https://ClinicalTrials.gov/show/NCT04288713
1001	NCT04367831	Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19	IMPROVE	Recruiting	No Results Available	COVID-19|Venous Thromboses|Arterial Thrombosis	Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose	Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU|Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events|ICU Length of Stay|Total Number of Patients with the Need for Renal Replacement Therapy in the ICU|Total Number of Patients with Major bleeding in the ICU|Hospital Length of Stay	Columbia University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	AAAS8980	May 2, 2020	November 2020	April 2021	April 29, 2020		May 19, 2020	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04367831
1002	NCT04454398	Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19		Recruiting	No Results Available	Covid-19	Biological: COVI-GUARD|Other: Standard of Care|Drug: Placebo	Incidence of adverse events (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of serious adverse events (safety)|All-cause mortality at 29 and 60 days|Incidence of dose-limiting toxicities (safety)|Incidence of laboratory abnormalities (safety)|SARS-CoV-2 viral load as assessed using various sample types|Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital|Anti-drug antibodies|Cytokine levels|AUC of COVI-GUARD (PK)|Cmax of COVI-GUARD (PK)|t½ of COVI-GUARD (PK)|Tmax of COVI-GUARD (PK)	Sorrento Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	33	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GRD-COV-101	September 17, 2020	February 2021	February 2021	July 1, 2020		October 1, 2020	Temple University Lung Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04454398
1003	NCT04520620	Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention	COV-ENOX	Withdrawn	No Results Available	Sars-CoV2	Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe|Device: Ultrasound of the lower limbs	Measure of anti-Xa activity|Analysis of hemorrhagic risk|Venous thromboembolic events|Analysis individual patient characteristics by the biomarker of Kidney function|Analysis individual patient characteristics by the biomarker of inflammation|Analysis individual patient characteristics by the biomarker of coagulation|Demographic characteristics	Centre Hospitalier Universitaire de Saint Etienne|CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang	All	18 Years and older   (Adult, Older Adult)	Phase 4	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20CH089|2020-001823-15	May 2, 2020	July 10, 2020	July 10, 2020	August 20, 2020		August 20, 2020	Groupement Hospitalier des portes de Province, Montélimar, France|Centre Hospitalier de Roanne, Roanne, France|CHU de Saint-Etienne, Saint-Étienne, France|Clinique Mutualiste, Saint-Étienne, France		https://ClinicalTrials.gov/show/NCT04520620
1004	NCT04348695	Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.	Ruxo-Sim-20	Recruiting	No Results Available	Coronavirus Infection	Drug: Ruxolitinib plus simvastatin|Other: Standard of Care	Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs	Fundación de investigación HM|Apices Soluciones S.L.	All	18 Years and older   (Adult, Older Adult)	Phase 2	94	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Ruxo-Sim-20|2020-001405-23	April 12, 2020	May 13, 2020	May 13, 2020	April 16, 2020		April 17, 2020	Hospital Universitario Madrid Sanchinarro, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04348695
1005	NCT04381988	A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy		Recruiting	No Results Available	COVID-19|Cancer	Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy	cumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or death	Memorial Sloan Kettering Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	132	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	20-176	May 7, 2020	May 2021	May 2021	May 11, 2020		May 13, 2020	Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States		https://ClinicalTrials.gov/show/NCT04381988
1006	NCT04439006	Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization		Recruiting	No Results Available	Aplastic Anemia|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Monoclonal B-Cell Lymphocytosis|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed	Other: Best Practice|Drug: Ibrutinib	Proportion of patients with diminished respiratory failure and death|Death|Time from study initiation to 48 hours fever-free|Duration of hospitalization|Time in intensive care unit (ICU)|Time to ICU admission|Number of days requiring supplemental oxygen|Total days of mechanical ventilation|Time to mechanical ventilation|Shock and need for pressure support|Incidence of any infection (viral, fungal, bacterial)|Time to clinical resolution|Incidence of grade 3 or higher adverse events|At the end of therapy (day 14)|Time to viral clearance|Survival	Jennifer Woyach|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	72	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-20135|NCI-2020-03341|P30CA016058	July 22, 2020	December 31, 2021	December 31, 2022	June 19, 2020		August 19, 2020	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT04439006
1007	NCT04255017	A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoV	Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir	Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ20200128	February 1, 2020	June 1, 2020	July 1, 2020	February 5, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04255017
1008	NCT04388826	COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111		Recruiting	No Results Available	Respiratory Distress Syndrome, Adult	Drug: Veru-111	Proportion of subjects that are alive without respiratory failure at Day 29.|WHO clinical Improvement|Normalization of Fever and Oxygen|Discharge from Hospital|Patients alive and free of respiratory failure	Veru Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	V0211901	June 18, 2020	November 30, 2020	December 18, 2020	May 14, 2020		October 6, 2020	HonorHealth, Scottsdale, Arizona, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|WC-CRCN at North Vista Hospital, Las Vegas, Nevada, United States|Inspira Medical Center, Vineland, New Jersey, United States|Memorial Hermann Memorial City Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04388826
1009	NCT04389320	Antimalarial and Covid 19 in Rheumatoid Arthritis		Completed	No Results Available	Rheumatoid Arthritis	Drug: Hydroxychloroquine	immunoglobulin mesurement	Assiut University	All	20 Years to 70 Years   (Adult, Older Adult)		60	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	covid 19 in RA	March 15, 2020	May 1, 2020	May 1, 2020	May 15, 2020		May 15, 2020	Manal Hassanien, Assiut, Yes, Egypt		https://ClinicalTrials.gov/show/NCT04389320
1010	NCT04383717	Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial		Not yet recruiting	No Results Available	Respiratory Tract Infections	Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine	COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg/dL	Cairo University	All	6 Years to 90 Years   (Child, Adult, Older Adult)	Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Levamisole and isoprinosine	May 5, 2020	August 30, 2020	October 30, 2020	May 12, 2020		May 13, 2020			https://ClinicalTrials.gov/show/NCT04383717
1011	NCT04561180	Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to DEX in Patients With COVID-19 Pneumonia		Not yet recruiting	No Results Available	Pneumonia as One of the Lung Complications Caused by SARS-CoV-2 Infection	Drug: EG-HPCP-03a|Drug: EG-HPCP-03a Placebo|Drug: Standard of Care|Drug: Dexamethasone	The proportion of patients alive and without respiratory failure	Evergreen Therapeutics, Inc.	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	96	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HPC-EG-009A-2.1	December 2020	October 2021	December 2021	September 23, 2020		September 23, 2020			https://ClinicalTrials.gov/show/NCT04561180
1012	NCT04261270	A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoV Pneumonia	Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir	Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery	Tongji Hospital	All	18 Years to 55 Years   (Adult)	Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	ASC09F-CTP-TJ-01	February 1, 2020	May 1, 2020	July 1, 2020	February 7, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04261270
1013	NCT04338802	Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19		Not yet recruiting	No Results Available	COVID-19|Nintedanib|Safety|Effect of Drugs	Drug: Nintedanib 150 MG|Other: Placebo	Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score	Huilan Zhang|Tongji Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	96	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	huilanz Zhang	April 2, 2020	May 4, 2020	August 1, 2020	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338802
1014	NCT04326426	ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection		Enrolling by invitation	No Results Available	Coronavirus Infection	Drug: Tradipitant|Drug: Placebo	Time to improvement on a 7-point ordinal scale as compared to baseline|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours	Vanda Pharmaceuticals	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	VLY-686-3501	April 13, 2020	August 1, 2020	August 31, 2020	March 30, 2020		April 20, 2020	Lenox Hill Hospital Northwell Health, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04326426
1015	NCT04268537	Immunoregulatory Therapy for 2019-nCoV		Not yet recruiting	No Results Available	2019 nCoV, PD-1	Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment	lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days	Southeast University, China	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2020YFC0841300-03	February 10, 2020	April 30, 2020	October 31, 2020	February 13, 2020		February 13, 2020			https://ClinicalTrials.gov/show/NCT04268537
1016	NCT04380961	A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19		Recruiting	No Results Available	Severe or Critical Confirmed Coronavirus Disease (COVID)-19	Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC)	Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Percentage of Participants with All-cause Mortality|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants with Related Adverse Events|Percentage of Participants with Severe or Life Threatening Bacterial, Invasive Fungal, Viral or Opportunistic Infections|Percentage of Participants with Grade 3 and 4 Neutropenia|Percentage of Participants with Grade 3 and 4 Lymphocytopenia|Percentage of Participants with Increased Alanine Aminotransferase (ALT) Greater than or equal to 3 Times Upper Limit of Normal (ULN) Combined with Increased Bilirubin > 2 Times ULN|Time to Improvement of at least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Time from Study Intervention to end of Oxygen Supplementation|Time from Study Intervention to Hospital Discharge Among the Surviving Participants|Total Length of Hospitalization|Number of Ventilation Free Days|Participant's Clinical Status at Day 7, 14, 21, 28 as Assessed by 6-Point Ordinal Clinical Recovery Scale|Total Time on Invasive Mechanical Ventilation|Percentage of Participants with a Worse Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale over Time|Percentage of Participants on Extracorporeal Membrane Oxygenation (ECMO) Over Time|Total Time on ECMO|Percentage of Alive Participants at Day 28, Week 8 and Week 16|Percentage of Alive Participants that Required Readmission at Week 8 and Week 16	Janssen Pharmaceutica N.V., Belgium	All	18 Years to 84 Years   (Adult, Older Adult)	Phase 2	270	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CR108820|CNTO136COV2001|2020-003056-32	April 24, 2020	March 15, 2021	August 6, 2021	May 8, 2020		September 2, 2020	UCSF Fresno, Fresno, California, United States|MemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|The Corporation of Mercer University, Macon, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Illinois College of Medicine at Peoria, Peoria, Illinois, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center - Infectious Disease, Newark, New Jersey, United States|SUNY Upstate Medical University, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor All Saints Medical Center at Fort Worth, Fort Worth, Texas, United States|Texas Health Research & Education Institute, Fort Worth, Texas, United States|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Instituto de infectologia Emilio Ribas, São Paulo, Brazil|Federal Siberian Scientific Clinical Center of Federal Medical-Biological Agency, Krasnoyarsk, Russian Federation|Central Scientific-Research Institute of Epidemiology, Moscow, Russian Federation|Central Clinical Hospital and Out-patient Clinic of Russian Federation, Moscow, Russian Federation|Infectious Clinical Hospital #1 Of The Moscow City Health Department, Moscow, Russian Federation|Scientific-Research Emergency Institute n.a. N.V. Sklifosovskiy, Moscow, Russian Federation|City Clinical Hospital #40, Moscow, Russian Federation|Hospital for War Veterans, St-Petersburg, Russian Federation|Clinical Infectious Diseases Hospital n. a. S.P. Botkin, St. Petersburg, Russian Federation|City Hospital# 40, St.Petersburg, Russian Federation|Ulyanovsk Central City Clinical Hospital, Ulyanovsk, Russian Federation|Karl Bremer Hospital, Bellville, South Africa|Dr Kalla, Lenasia, South Africa|Univ of Stellenbosch Respiratory Research Unit, Parow, South Africa|Into Research, Pretoria, South Africa|Mediclinic Victoria Hospital, Tongaat, South Africa|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Gral. Univ. de Elche, Elche, Spain|Hosp. Clinico San Carlos, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Gral. Univ. Valencia, Valencia, Spain		https://ClinicalTrials.gov/show/NCT04380961
1017	NCT04374942	Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?	HEROs	Enrolling by invitation	No Results Available	Pre-Exposure Prophylaxis|Coronavirus|SARS-CoV 2	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Microbiologically confirmed COVID-19 (SARS-CoV-2 infection)|Adverse events|Symptom duration of COVID-19|Days of hospitalization attributable to COVID-19|Respiratory failure requiring ventilatory support attributable to COVID-19|Mortality|Impact on work eligibility|Seropositivity|Short-term psychological impact	Megan Landes|University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	Phase 3	988	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	HEROs Protocol 1.5|ISRCTN14326006	April 30, 2020	August 27, 2020	January 30, 2022	May 5, 2020		May 8, 2020	University Health Network, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04374942
1018	NCT04279197	Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu		Recruiting	No Results Available	Pulmonary Fibrosis Due to COVID-19	Drug: Fuzheng Huayu Tablet|Drug: Vitamin C tablets|Other: Placebo|Other: respiratory function rehabilitation training	The improvement proportion of pulmonary fibrosis|Blood oxygen saturation|Clinical symptom score|Quality of Life-BREF (QOL-BREF)|Patient Health Questionnaire-9(PHQ-9)|Generalized anxiety disorder-7(GAD-7)|The 6-minute walk distance	ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People's Hospital|Tongji Hospital|Wenzhou Central Hospital|Wuhan No.1 Hospital|Wuhan Union Hospital, China|Wuhan Third Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Fzhy-ncp-2	April 23, 2020	December 2021	December 2021	February 21, 2020		September 23, 2020	Shuguang Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04279197
1019	NCT04489628	Tele-health Enabled Clinical Trial for COVID-19		Not yet recruiting	No Results Available	SARS-CoV Infection	Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring	Patients requiring admission to the hospital or experiencing death	University Hospitals Cleveland Medical Center|Northwestern University	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	110	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	STUDY20200461	August 1, 2020	August 1, 2021	August 1, 2021	July 28, 2020		July 31, 2020	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04489628
1020	NCT04323592	Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	MP-C19	Completed	Has Results	Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human	Drug: Methylprednisolone|Other: standard care	Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28|In-hospital Death Within 28 Days|Admission to Intensive Care Unit (ICU)|Endotracheal Intubation (Invasive Mechanical Ventilation)|Change in C-reactive Protein (CRP)|Number of Days Free From Mechanical Ventilation	University of Trieste	All	18 Years to 80 Years   (Adult, Older Adult)		173	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	MP-19 023_2020	March 23, 2020	May 10, 2020	May 10, 2020	March 26, 2020	June 4, 2020	June 24, 2020	Marco Confalonieri, Trieste, TS, Italy	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_003.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/SAP_004.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_006.pdf	https://ClinicalTrials.gov/show/NCT04323592
1021	NCT04306393	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	NOSARSCOVID	Recruiting	No Results Available	SARS (Severe Acute Respiratory Syndrome)|Coronavirus	Drug: Nitric Oxide Gas	Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment	Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	NO-SARS-COVID-19	March 21, 2020	March 21, 2021	March 21, 2022	March 12, 2020		July 14, 2020	University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04306393
1022	NCT04349592	Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19		Recruiting	No Results Available	Covid19	Drug: Hydroxychloroquine|Drug: Azithromycin|Other: Placebo Tablet|Other: Placebo capsules	Proportion of virologically cured (PCR-negative status) as assessed on day six|virologic cure on other study days|virologic semiquantitative analysis of changing viral load|proportion of initially symtomatic subjects with disappearance of clinical symptoms|proportion of initially asymtomatic subjects with appearance of new clinical symptoms|proportions of subjects with potentially medication- related adverse events	Hamad Medical Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	456	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MRC-05-001	April 14, 2020	August 14, 2020	August 30, 2020	April 16, 2020		July 30, 2020	Hamad Medical Corporation, Doha, Qatar		https://ClinicalTrials.gov/show/NCT04349592
1023	NCT04385186	Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19		Not yet recruiting	No Results Available	Infections, Coronavirus	Drug: Inactivated convalescent plasma|Drug: Support treatment	Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment|Clinical evolution|Clinical evolution by seven-parameter ordinal scale|Multi-organ failure progression|Change in hemoglobin concentration|Change in blood cell count|Change in serum creatinine level|Change in aspartate aminotransferase level|Change in alanin aminotransferase level|Change in bilirubin level|Change in lactate dehydrogenase level|Change in creatine kinase level|Change in creatine kinase MB level|Change in C reactive protein concentration|Change in D Dimer concentration|Change in Procalcitonin concentration|Change in IL6 level|Radiography imaging|Tomography imaging|Assessment of oxygenation|Viral Load|Antibody titer|Oxygen-free days through Day 60|Mechanical ventilation-free days through Day 28|Intensive Care Unit (ICU)-free days through Day 28|Hospital-free days through Day 60	National Blood Center Foundation, Hemolife	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	CT01	June 20, 2020	November 30, 2020	December 30, 2020	May 12, 2020		June 2, 2020	Clínica Antioquía, Medellín, Antioquía, Colombia|Clínica Sagrado Corazón, Medellín, Antioquía, Colombia|IPS Universitaria, Medellín, Antioquía, Colombia|Universidad de Antioquía, Medellín, Antioquía, Colombia|National Blood Center Foundation, Hemolife/Fundación Banco Nacional de Sangre Hemolife, Bogotá, Cundinamarca, Colombia|Clínica Rosales, Pereira, Risaralda, Colombia|Clinica Nuestra, Cali, Valle, Colombia|Clínica Corpas, Bogotá, Colombia|E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia|Clínica la Estancia, Popayán, Colombia		https://ClinicalTrials.gov/show/NCT04385186
1024	NCT04355637	Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia		Recruiting	No Results Available	Coronavirus Infection	Drug: Inhaled budesonide	Proportion of patients in both arms fulfilling the criteria for treatment failure|ICU admission|ICU refusal|Occurrence of complications|lactate dehydrogenase (LDH)|C Reactive Protein (CRP)|ferritin|D-dimer|leukocyte counts	Sara Varea|Fundacion Clinic per a la Recerca Biomédica	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 4	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TACTIC-COVID|2020-001616-18	April 21, 2020	August 31, 2020	October 18, 2020	April 21, 2020		July 23, 2020	Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04355637
1025	NCT03376854	Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS	CHILL-pilot	Recruiting	No Results Available	Respiratory Distress Syndrome, Adult|Sars-CoV2	Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care	Targeted temperature compliance|Adverse event|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel|Complete blood count with differential count and platelet count|Biomarkers|Serum electrolytes|Blood glucose|28-day ventilator-free days	University of Maryland, Baltimore	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00078506	May 1, 2018	November 30, 2020	December 31, 2020	December 19, 2017		June 16, 2020	University of Maryland Medical Center, Baltimore, Maryland, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/ICF_011.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/SAP_012.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/Prot_013.pdf	https://ClinicalTrials.gov/show/NCT03376854
1026	NCT04322786	The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?		Active, not recruiting	No Results Available	Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom	Drug: ACE inhibitor	Incidence of influenza	University College, London	All	18 Years and older   (Adult, Older Adult)		1302508	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	ISAC17_205R	January 1, 1998	May 31, 2016	March 31, 2020	March 26, 2020		March 26, 2020			https://ClinicalTrials.gov/show/NCT04322786
1027	NCT04528927	Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia	THINC	Withdrawn	No Results Available	COVID 19|Patients Hospitalized	Drug: HCQ|Drug: Azithromycin|Drug: Doxycycline|Dietary Supplement: Zinc	Evaluate the rate of patients cured at the end of the study.|Evaluate the rate of patients are pauci-symptomatic at the end of the study.|Evaluate the rate of patients with worsening clinical signs	Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ECC2020-05	May 15, 2020	July 15, 2020	July 15, 2020	August 27, 2020		August 27, 2020	Eshmoun Clinical Research Centre, Tunis, Tunisia		https://ClinicalTrials.gov/show/NCT04528927
1028	NCT04360096	Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19	AVICOVID-2	Not yet recruiting	No Results Available	SARS-CoV 2|COVID|ARDS|ALI|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Dyspnea	Drug: RLF-100 (aviptadil)|Drug: Placebo|Device: Nebulized administration of RLF-100 or Placebo	Progression to ARDS|Blood oxygenation|RDP Dsypnea Scale|Distance walked in six minutes	NeuroRx, Inc.	All	12 Years to 85 Years   (Child, Adult, Older Adult)	Phase 2|Phase 3	288	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RLF-100_002	July 1, 2020	October 1, 2020	November 30, 2020	April 24, 2020		June 29, 2020			https://ClinicalTrials.gov/show/NCT04360096
1029	NCT04374019	Novel Agents for Treatment of High-risk COVID-19 Positive Patients		Recruiting	No Results Available	COVID|Sars-CoV2	Drug: Hydroxychloroquine and Azithromycin|Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua	Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function	Susanne Arnold|University of Kentucky	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-20-COVID-01-PMC	May 1, 2020	May 2021	May 2021	May 5, 2020		July 10, 2020	University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT04374019
1030	NCT04351191	PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds	PRECISE	Recruiting	No Results Available	Sars-CoV2|Symptomatic Condition|Covid-19	Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo	RT-PCR result|Progression of symptoms|Mortality	Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Hospital, Lahore|Pakistan Kidney and Liver Institute	All	20 Years to 50 Years   (Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NBC-COVID1902	April 15, 2020	May 30, 2020	June 30, 2020	April 17, 2020		May 1, 2020	Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04351191
1031	NCT04330300	Coronavirus (COVID-19) ACEi/ARB Investigation	CORONACION	Suspended	No Results Available	Hypertension|COVID-19	Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker	Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring|All-cause mortality	National University of Ireland, Galway, Ireland	All	60 Years and older   (Adult, Older Adult)	Phase 4	2414	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	C.A. 2348	April 30, 2020	July 31, 2021	December 1, 2021	April 1, 2020		June 30, 2020	University Hospital Galway, Galway, Ireland		https://ClinicalTrials.gov/show/NCT04330300
1032	NCT04539873	Impact of Colchicine in Hospitalized Colombian Patients With COVID-19	(COLCOVID19)	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: Colchicine 0.5 MG|Combination Product: CONTROL GROUP	Number of participants who die or require transfer to Intesive care unit|Number of participants who die	Fundación Universitaria de Ciencias de la Salud|Hospital de San Jose	All	18 Years and older   (Adult, Older Adult)	Phase 3	128	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	5175	September 2020	November 2020	December 2020	September 7, 2020		September 7, 2020	Fundación Universitaria de Ciencias de La Salud, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04539873
1033	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients		Recruiting	No Results Available	SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS	Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC	In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction	Oslo University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	700	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	118684	March 28, 2020	August 2020	November 2020	March 25, 2020		April 14, 2020	Andreas Barratt-Due, Oslo, Norway		https://ClinicalTrials.gov/show/NCT04321616
1034	NCT04382846	Novel Regimens in COVID-19 Treatment		Not yet recruiting	No Results Available	COVID|Corona Virus Infection	Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin	Number of patients with virological cure	Tanta University	All	18 Years and older   (Adult, Older Adult)	Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	tanta covid treatment	May 8, 2020	December 1, 2030	December 1, 2030	May 11, 2020		May 11, 2020			https://ClinicalTrials.gov/show/NCT04382846
1035	NCT04499677	FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals	FLARE	Recruiting	No Results Available	COVID-19	Drug: Favipiravir|Drug: Lopinavir/ Ritonavir|Other: Favipiravir Placebo|Other: Lopinavir/ Ritonavir Placebo	Upper respiratory tract viral load at Day 5|Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy|Proportion of participants with undetectable stool viral load after 7 days of therapy and 14 days post-randomisation|Rate of decrease in upper respiratory tract viral load during 7 days of therapy|Duration of fever following commencement of medication|Proportion of participants with hepatotoxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants admitted to hospital with COVID-19 related illness|Proportion of participants admitted to ICU with COVID-19 related illness|Proportion of participants who have died with COVID-19 related illness|Pharmacokinetics of favipiravir as measured by Clearance (CL)|Pharmacokinetics of favipiravir as measured by Volume of distribution (V)|Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)|Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)|Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)|Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)|Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)|Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)|Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)|Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)|Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment	University College, London|LifeArc	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	132084	September 24, 2020	December 11, 2020	March 1, 2021	August 5, 2020		October 1, 2020	Royal Free Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04499677
1036	NCT04561076	Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers		Not yet recruiting	No Results Available	COVID 19	Drug: HLX70|Other: Placebo	Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0|Safety evaluation- proportion of subjects undergoing DLT events|PK parameters-Areas under the concentration-time curves|PK parameters-Maximum measured concentration|PK parameters-Time from dosing to maximum measured concentration|PK parameters-Terminal phase elimination rate constant|PK parameters-Terminal phase elimination half life|PK parameters-Clearance|PK parameters-Volume of distribution during terminal phase and at steady state|PK parameters-Mean residence time|Anti-drug antibody	Hengenix Biotech Inc|Sanyou Biopharmaceuticals(Shanghai)Co., Ltd|Shanghai ZJ Bio-Tech Co., Ltd	All	18 Years to 60 Years   (Adult)	Phase 1	24	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	HLX70-001US-255086	December 9, 2020	September 6, 2021	September 18, 2021	September 23, 2020		September 24, 2020			https://ClinicalTrials.gov/show/NCT04561076
1037	NCT04379518	Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients		Recruiting	No Results Available	Malignant Neoplasm|SARS Coronavirus 2 Infection	Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod	Incidence of adverse events (AEs)|Kinetics of viral load in nasopharyngeal swabs|Kinetics of viral load in the peripheral blood and nasopharyngeal swabs|Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood|30-day mortality|Hospitalization due to infection|Determine known mediators of antiviral immunity	Roswell Park Cancer Institute|National Cancer Institute (NCI)|AIM ImmunoTech Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	44	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	I 659920|NCI-2020-02317|P30CA016056	September 4, 2020	September 4, 2021	September 4, 2021	May 7, 2020		September 17, 2020	Roswell Park Cancer Institute, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT04379518
1038	NCT04467931	ACEI or ARB and COVID-19 Severity and Mortality in US Veterans		Active, not recruiting	No Results Available	Hypertension|COVID	Drug: ACEI/ARB|Drug: Non-ACEI/ARB|Drug: ACEI|Drug: ARB	All-Cause-Hospitalization or All-Cause Mortality|All-Cause Mortality|ICU admission|Duration of hospitalization|Mechanical ventilation|Dialysis	University of Utah|VA Salt Lake City Health Care System|University of Pennsylvania|Wake Forest University Health Sciences|University of Florida|Johns Hopkins Bloomberg School of Public Health|Boston University|Northwestern University|Edith Nourse Rogers Memorial Veterans Hospital|Columbia University|MedStar Georgetown University Hospital	All	18 Years and older   (Adult, Older Adult)		10000	Other|U.S. Fed	Observational	Observational Model: Cohort|Time Perspective: Retrospective	00132408	January 19, 2020	July 31, 2020	July 31, 2020	July 13, 2020		July 13, 2020	University of Utah, Salt Lake City, Utah, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04467931/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04467931
1039	NCT04374539	Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial	REP-COVID	Recruiting	No Results Available	Coronavirus	Biological: Plasma exchange|Drug: Standar medical treatmen	Impact of plasma exchange	Fundacion Clinic per a la Recerca Biomédica	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	116	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001722-66	April 29, 2020	May 5, 2021	August 29, 2021	May 5, 2020		July 7, 2020	Hospital Clinic i Provincial de Barcelona, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04374539
1040	NCT04460547	Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic		Not yet recruiting	No Results Available	COVID-19	Drug: Convalescent Plasma Transfusion|Drug: Hydroxychloroquine|Drug: DAS181|Drug: Ivermectin|Drug: Interferon Beta-1A	Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.	Qassim University	All	1 Year and older   (Child, Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	COAHS	July 25, 2020	August 15, 2020	September 20, 2020	July 7, 2020		July 7, 2020			https://ClinicalTrials.gov/show/NCT04460547
1041	NCT04441424	Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients		Completed	No Results Available	IMMUNOTHERAPY	Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin	Death versus survival of treated patients|The length of stay in hospitals	Alkarkh Health Directorate-Baghdad	All	18 Years and older   (Adult, Older Adult)	Not Applicable	49	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CPT-COVID-19	April 3, 2020	June 1, 2020	June 1, 2020	June 22, 2020		June 23, 2020	Akarkh Healt hdirectorate, Baghdad, Iraq	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04441424/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04441424
1042	NCT04346667	Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds	PEACE	Recruiting	No Results Available	SARS-CoV-2|Coronavirus Infection|Asymptomatic Condition|COVID-19	Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo	RT-PCR negative status|Progression of symptoms|Development of Symptoms|Adverse events	Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Institute of Medical Sciences, Pakistan|Pakistan Kidney and Liver Institute|Forman Christian College|Harvard School of Public Health	All	20 Years to 50 Years   (Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	NBC-COVID19-02	April 14, 2020	May 30, 2020	June 30, 2021	April 15, 2020		May 1, 2020	Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04346667
1043	NCT04345887	Spironolactone in Covid-19 Induced ARDS		Not yet recruiting	No Results Available	Respiratory Distress Syndrome, Adult	Drug: Spironolactone 100mg|Drug: Placebo oral tablet	p/f ratio|SOFA	Istanbul University-Cerrahpasa	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	10042020	April 21, 2020	July 21, 2020	October 21, 2020	April 15, 2020		April 15, 2020	Istanbul University-Cerrahpaşa, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04345887
1044	NCT04535700	Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19		Not yet recruiting	No Results Available	Type 2 Diabetes	Drug: Pioglitazone 30 mg|Other: standard of care	Patients treated with pioglitazone, together with conventional treatment for COVID-19 infection, who during their admission evolve towards the need to receive support with mechanical ventilation, enter the ICU and / or die.|Incidence of pioglitazone treatment-Emergent Adverse Events in patients with DM2 and symptomatic SARS-CoV-2 infection.|Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	All	18 Years and older   (Adult, Older Adult)	Phase 4	76	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ESCORPIO	September 7, 2020	March 10, 2021	April 10, 2021	September 2, 2020		September 2, 2020			https://ClinicalTrials.gov/show/NCT04535700
1045	NCT04341584	CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection	CORIMUNO-ANA	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: Anakinra	Survival without needs of ventilator utilization at day 14|WHO progression scale ≤ 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-5	April 2020	May 2020	December 31, 2020	April 10, 2020		April 14, 2020			https://ClinicalTrials.gov/show/NCT04341584
1046	NCT04333407	Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.	C-19-ACS	Recruiting	No Results Available	COVID-19	Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg	All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate	Imperial College London	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	3170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20HH5868	April 3, 2020	March 30, 2021	March 30, 2021	April 3, 2020		April 9, 2020	Charing Cross Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04333407
1047	NCT04470544	Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19	RECOVER	Recruiting	No Results Available	Severe Acute Respiratory Syndrome	Drug: Camostat Mesilate|Other: Standard of Care	Change in the proportion of patients alive and free from respiratory failure|Change in the proportion of patients alive and free of ventilator use or ECMO|Mortality Rate|Clinical Change|Adverse Events	Alan Bryce|Academic and Community Cancer Research United	All	18 Years and older   (Adult, Older Adult)	Phase 2	264	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAM20CV	July 28, 2020	September 15, 2022	September 15, 2022	July 14, 2020		September 25, 2020	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT04470544
1048	NCT04523246	Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents	NH-Shingrix	Not yet recruiting	No Results Available	Herpes Zoster|Allergy and Immunology|Corona Virus Infection	Biological: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|Drug: Normal Saline	Evidenced of active and trained innate immunity|Respiratory Disease Severity (6 month)	Barbara Carlson|Oklahoma Medical Research Foundation|University of Oklahoma	All	65 Years to 100 Years   (Older Adult)	Early Phase 1	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	OUHSC IRB#12394	September 2020	March 2021	September 2021	August 21, 2020		August 25, 2020			https://ClinicalTrials.gov/show/NCT04523246
1049	NCT04472585	Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients	SINZ-COVID-PK	Recruiting	No Results Available	Coronavirus Infection|COVID|Sars-CoV2	Drug: Nigella Sativa / Black Cumin|Drug: Ivermectin Injectable Solution|Other: Placebo|Drug: Zinc	qRT-PCR|Severity of symptoms	Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SZMC/IRB/Internal/215/2020	July 14, 2020	September 15, 2020	September 30, 2020	July 15, 2020		July 15, 2020	Shaikh Zayed Hospital, Lahore, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04472585
1050	NCT04322344	Escin in Patients With Covid-19 Infection	add-on-COV2	Recruiting	No Results Available	Coronavirus Infections	Drug: Escin|Drug: standard therapy	Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function	University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico "Mater Domini"	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	120	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	covid-19 add-on therapy	March 23, 2020	June 30, 2020	December 30, 2020	March 26, 2020		September 15, 2020	Luca Gallelli, Catanzaro, Italy		https://ClinicalTrials.gov/show/NCT04322344
1051	NCT04340557	Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection		Recruiting	No Results Available	SARS-CoV Infection	Drug: Losartan	Mechanical ventilation|ICU transfer|Oxygen therapy	Sharp HealthCare	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COVID-ARB|2003902	March 27, 2020	October 6, 2020	December 31, 2020	April 9, 2020		June 2, 2020	Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT04340557
1052	NCT04350684	Umifenovir in Hospitalized COVID-19 Patients	UAIIC	Enrolling by invitation	No Results Available	COVID-19	Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care	Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events	Shahid Beheshti University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Umifenovir in COVID-19	April 15, 2020	April 22, 2020	April 24, 2020	April 17, 2020		April 20, 2020	Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04350684
1053	NCT04260594	Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus		Not yet recruiting	No Results Available	2019-nCoV	Drug: Arbidol|Other: basic treatment	Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count	Jieming QU|Ruijin Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	380	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Abdrcspc202001	February 7, 2020	July 1, 2020	December 30, 2020	February 7, 2020		February 7, 2020			https://ClinicalTrials.gov/show/NCT04260594
1054	NCT04476979	Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19	TOCIDEX	Recruiting	No Results Available	Coronavirus Infection|SARS (Severe Acute Respiratory Syndrome)|Virus Diseases|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Respiratory Tract Infections|Respiratory Tract Disease	Drug: Tocilizumab|Drug: Dexamethasone	Survival without needs of ventilator utilization at day 14|WHO progression scale at day 7 and 14|Overall survival at 14, 28, 60 and 90 days|Cumulative incidence of discharge alive at 14 and 28 days|Survival without needs of mechanical ventilation at day 1|Cumulative incidence of oxygen supply independency at 14 and 28 days	Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-TOCIDEX|2020-001246-18	July 16, 2020	March 31, 2021	December 31, 2021	July 20, 2020		August 18, 2020	CH Andrée Rosemon, Cayenne, French Guiana		https://ClinicalTrials.gov/show/NCT04476979
1055	NCT04488081	I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients	I-SPY_COVID	Recruiting	No Results Available	COVID-19	Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast	Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality	QuantumLeap Healthcare Collaborative|University of California, San Francisco|University of Pennsylvania|University of Minnesota|Emory University|University of Alabama at Birmingham|University of California, San Diego|University of Colorado, Denver|University of Southern California|Yale University|Columbia University|Wake Forest University Health Sciences|Sanford Health|Montefiore Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I-SPY-COVID	July 31, 2020	July 24, 2022	November 1, 2022	July 27, 2020		September 29, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States		https://ClinicalTrials.gov/show/NCT04488081
1056	NCT04532931	COVID-19 Treatment in South Africa		Recruiting	No Results Available	COVID-19	Other: Standard of care (Paracetamol)|Drug: Artesunate-amodiaquine|Drug: Pyronaridine-artesunate|Drug: Favipiravir plus Nitazoxanide|Drug: Sofosbuvir/daclatasvir	Incidence of SARS-CoV-2 clearance|Time to clearance of nasal SARS-CoV-2|Median quantity of SARS-CoV-2|Proportion of days with fever after randomization|Proportion of days with respiratory symptoms after randomization|FLU-PRO© Plus|Serious adverse events|Adverse events resulting in treatment discontinuation|Adverse events considered related to the investigational products|LRTI|Maximum score on WHO Ordinal Scale for Clinical Improvement during study participation|Cumulative incidence of hospitalization|Days of hospitalization|Cumulative incidence of mortality	Shin Poong Pharmaceutical Co. Ltd.|Medicines for Malaria Venture	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	250	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SP-PA-COV-202	September 3, 2020	December 2020	January 2021	August 31, 2020		October 8, 2020	Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg, South Africa		https://ClinicalTrials.gov/show/NCT04532931
1057	NCT04431466	A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19	IFORS	Recruiting	No Results Available	Coronavirus Infection	Drug: Ivermectin|Other: Standard treatment for COVID-19	Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Viral load variation in the nasopharyngeal swab.|Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Proportion of patients with clinical improvement.	Universidade Federal de Sao Carlos	All	18 Years and older   (Adult, Older Adult)	Phase 2	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IFORS	July 1, 2020	December 1, 2020	July 1, 2021	June 16, 2020		September 2, 2020	Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil|Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04431466
1058	NCT04546581	Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC)		Not yet recruiting	No Results Available	COVID|COVID-19|SARS-CoV-2|SARS (Severe Acute Respiratory Syndrome)	Drug: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo|Drug: Remdesivir	Ordinal Outcome Scale - Day 7|All-cause mortality through Day 28|Ordinal Outcome Scale|Change in National Early Warning Score (NEWS)|Time to Worsening|Discharge Status|Days Alive Outside the Hospital|Pulmonary-only Components of the Primary Ordinal Outcome|Thrombotic Components of the Primary Ordinal Outcome|Time to recovery|Clinical Organ Dysfunction|Safety and Tolerability - Adverse Events|Safety and Tolerability - Infusion Reactions, Interruptions, or Cessation|Safety and Tolerability - Serious Adverse Events|Safety and Tolerability - Prevalence of Adverse Events|Change in Neutralizing Antibody Level	University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|The International Network for Strategic Initiatives in Global HIV Trials	All	18 Years and older   (Adult, Older Adult)	Phase 3	500	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	INSIGHT 013	September 2020	July 2021	July 2021	September 14, 2020		September 14, 2020	Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London (UCL), London, United Kingdom		https://ClinicalTrials.gov/show/NCT04546581
1059	NCT04390152	Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19		Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome	Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)	Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between "Sequential Organ Failure Assessment" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.	BioXcellerator|Clinical Somer	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BIOXSOMCOV001	September 2020	December 2020	July 2021	May 15, 2020		July 9, 2020	BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia		https://ClinicalTrials.gov/show/NCT04390152
1060	NCT04425850	USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19	IVERCAR	Active, not recruiting	No Results Available	Contagious Pleuropneumonia	Device: iota carrageenan|Drug: Ivermectin	Reduction in contagion|Secondary and or side effects	Eurnekian Public Hospital	All	5 Years and older   (Child, Adult, Older Adult)		70	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IVERCAR	June 1, 2020	August 10, 2020	August 10, 2020	June 11, 2020		August 11, 2020	Hospital Eurnekian, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04425850
1061	NCT04446429	Anti-Androgen Treatment for COVID-19		Recruiting	No Results Available	COVID-19|SARS-CoV2|Androgenetic Alopecia|Prostate Cancer|Benign Prostatic Hyperplasia|SARS (Severe Acute Respiratory Syndrome)	Drug: Dutasteride|Drug: Ivermectin|Drug: Azithromycin|Drug: Proxalutamide	COVID-19 hospitalization|COVID-19 Ordinal Outcomes Scale|Symptoms severity of COVID-19	Applied Biology, Inc.	Male	50 Years and older   (Adult, Older Adult)	Not Applicable	381	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AB-DRUG-SARS-004	July 2, 2020	December 31, 2020	January 31, 2021	June 24, 2020		July 29, 2020	Corpometria Institute, Brasilia, Brazil		https://ClinicalTrials.gov/show/NCT04446429
1062	NCT04371822	Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients	SnPPIX	Not yet recruiting	No Results Available	COVID-19	Drug: SnPP Protoporphyrin plus Sunlight exposure|Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Other: placebo	lung injury score|Serum ferritin|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap	Kafrelsheikh University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	56	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Proposed by Mahmoud Elkazz	August 2020	October 2020	November 2020	May 1, 2020		June 24, 2020	Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt		https://ClinicalTrials.gov/show/NCT04371822
1063	NCT04528329	Anosmia and / or Ageusia and Early Corticosteroid Use		Recruiting	No Results Available	Covid19|Anosmia	Drug: Early-Dexamethasone|Drug: Late dexamethazone	Time to recovery	ClinAmygate	All	18 Years and older   (Adult, Older Adult)	Phase 4	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PR0013	August 30, 2020	November 30, 2020	December 15, 2020	August 27, 2020		September 16, 2020	Asalam, Maadi, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04528329
1064	NCT04343729	Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19	MetCOVID	Active, not recruiting	No Results Available	SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia	Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution	Mortality rate at day 28|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	All	18 Years and older   (Adult, Older Adult)	Phase 2	416	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAEE: 30615920.2.0000.0005	April 18, 2020	June 16, 2020	September 2020	April 13, 2020		July 1, 2020	Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil		https://ClinicalTrials.gov/show/NCT04343729
1065	NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	CloroCOVID19	Completed	No Results Available	SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia	Drug: Chloroquine diphosphate	Mortality rate reduction of 50% by day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vinícius Guimarães de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mourão|Ludmila Abrahão Hajjar|Jorge Souza Mendonça	All	18 Years and older   (Adult, Older Adult)	Phase 2	278	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAAE: 30152620.1.0000.0005	March 23, 2020	May 7, 2020	June 7, 2020	March 26, 2020		July 7, 2020	Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil		https://ClinicalTrials.gov/show/NCT04323527
1066	NCT04354428	Treatment for COVID-19 in High-Risk Adult Outpatients		Recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]	Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]	University of Washington|Bill and Melinda Gates Foundation	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	STUDY00009878|INV-017062	April 16, 2020	December 2020	January 2021	April 21, 2020		October 8, 2020	Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States	"Study Protocol: Hydroxychloroquine and Azithromycin arms", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_002.pdf|"Study Protocol: Lopinavir-Ritonavir arm", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_003.pdf|"Informed Consent Form: Hydroxychloroquine and Azithromycin arms", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_004.pdf|"Informed Consent Form: Lopinavir-Ritonavir arm", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_005.pdf	https://ClinicalTrials.gov/show/NCT04354428
1067	NCT04403100	Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"		Recruiting	No Results Available	COVID-19|Coronavirus Infection|Virus Disease|Acute Respiratory Infection|SARS-CoV Infection	Drug: Hydroxychloroquine Sulfate Tablets|Drug: Lopinavir/ Ritonavir Oral Tablet|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Drug: Placebo	Proportion of participants who were hospitalized for progression of COVID-19 disease|Proportion of participants who died due to COVID-19 progression and/ or complications|Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization|Time to clinical improvement|Time to clinical failure|Hospitalization for any cause|Proportion of participants who died due to pulmonary complications|Proportion of participants who died due to cardiovascular complications|Proportion of participants who presented with adverse events|Time to improvement on respiratory scale symptoms|proportion of non-adherent participants to any of study drugs	Cardresearch|Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA|Cytel Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	1968	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID19_AMB_Brasil	June 3, 2020	September 3, 2020	November 28, 2020	May 27, 2020		June 9, 2020	CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil		https://ClinicalTrials.gov/show/NCT04403100
1068	NCT04278963	Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19		Suspended	No Results Available	CoVID-19|Chinese Medicine	Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment	Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events	China Academy of Chinese Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	YHQW-V3.0	February 27, 2020	January 2021	January 2021	February 20, 2020		May 11, 2020	Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China		https://ClinicalTrials.gov/show/NCT04278963
1069	NCT04334928	Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel	EPICOS	Recruiting	No Results Available	Coronavirus Infection	Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine	Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days	Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 3	4000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	PrEP COVID-19	April 15, 2020	December 31, 2020	December 31, 2020	April 6, 2020		August 25, 2020	Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Córdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital de Getafe, Getafe, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Reina Sofía, Tudela, Navarra, Spain|Hospital Arnau de Vilanova, Llíria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirón Barcelona, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Universitario de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofía, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain		https://ClinicalTrials.gov/show/NCT04334928
1070	NCT04461925	Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs		Recruiting	No Results Available	COVID-19 Pneumonia	Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Drug: Antibiotics|Drug: Hormones|Drug: Anticoagulant Therapy|Device: Оxygen therapy	Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.|Changes in length of hospital stay|Changes in mortality rate|Changes of С-reactive protein (CRP, mg/L)|Evaluation of Pneumonia Improvement|Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)|Peripheral blood count recovery time	Institute of Cell Therapy|Kyiv City Clinical Hospital # 4	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	30	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	#4/24.04.2020	May 2, 2020	May 2, 2021	December 2021	July 8, 2020		July 8, 2020	Institute of Cell Therapy, Kyiv, Ukraine		https://ClinicalTrials.gov/show/NCT04461925
1071	NCT04459702	A Study of Combination Therapies to Treat COVID-19 Infection		Not yet recruiting	No Results Available	COVID|COVID-19|Corona Virus Infection|Coronavirus Infection|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|Coronavirus-19|SARS-CoV 2|SARS Pneumonia	Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir	Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores|Efficacy of Treatment by Time to Non-Infectivity|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.|Safety of Dual Therapy as Measured by Complete Blood Count|Safety of Quadruple Therapy as Measured by Complete Blood Count|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT|Safety of Dual Therapy as Measured by Metabolic Panel ALT|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein|Safety of Dual Therapy as Measured by Treatment Related SAE|Safety of Quadruple Therapy as Measured by Treatment Related SAE	ProgenaBiome|Big Corona Ltd.	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PRG-043	July 2020	July 2021	December 2021	July 7, 2020		July 7, 2020	ProgenaBiome, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT04459702
1072	NCT04302766	Expanded Access Remdesivir (RDV; GS-5734™)		Available	No Results Available	Coronavirus Disease 2019	Drug: Remdesivir		U.S. Army Medical Research and Development Command	All	Child, Adult, Older Adult			U.S. Fed	Expanded Access:Intermediate-size Population|Treatment IND/Protocol		S-20-01				March 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04302766
1073	NCT04306705	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	TACOS	Recruiting	No Results Available	Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab	Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy	Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells	Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital	All	18 Years to 80 Years   (Adult, Older Adult)		120	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	WHTJCOVID-19	February 20, 2020	May 30, 2020	June 20, 2020	March 13, 2020		March 17, 2020	Tongji Hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04306705
1074	NCT04446104	A Preventive Treatment for Migrant Workers at High-risk of COVID-19		Completed	No Results Available	Covid-19	Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C	Incidence of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Incidence of acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Incidence of febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Incidence of adverse events and serious adverse events in control arm (Vitamin C)|Incidence of drug discontinuation due to adverse events in control arm (Vitamin C)	National University Hospital, Singapore	Male	21 Years to 60 Years   (Adult)	Phase 3	4257	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2020/00561	May 13, 2020	August 31, 2020	August 31, 2020	June 24, 2020		September 24, 2020	Tuas South Dormitory, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04446104
1075	NCT04261907	Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection		Not yet recruiting	No Results Available	2019-nCoV	Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group	The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal	First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	160	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASC09F-CTP-ZY-01	February 7, 2020	May 31, 2020	June 30, 2020	February 10, 2020		February 10, 2020			https://ClinicalTrials.gov/show/NCT04261907
1076	NCT04264533	Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia		Recruiting	No Results Available	Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated	Drug: VC|Drug: Sterile Water for Injection	Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores	ZhiYong Peng|Zhongnan Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	2020001	February 14, 2020	September 30, 2020	September 30, 2020	February 11, 2020		March 10, 2020	Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04264533
1077	NCT04336410	Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers		Active, not recruiting	No Results Available	Coronavirus Infection	Drug: INO-4800|Device: CELLECTRA® 2000	Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response	Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)	All	18 Years and older   (Adult, Older Adult)	Phase 1	120	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COVID19-001	April 3, 2020	July 2021	July 2021	April 7, 2020		September 21, 2020	Central Kentucky Research Associates, Lexington, Kentucky, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04336410
1078	NCT03331445	Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections		Recruiting	No Results Available	Respiratory Tract Infections|Corona Virus Infection	Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation	Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score	Chris Miller|Mallinckrodt|Nitric Solutions Inc.	All	19 Years and older   (Adult, Older Adult)	Phase 2	20	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NTM-CTP-01: H17-02107	October 24, 2017	December 31, 2020	March 31, 2021	November 6, 2017		September 9, 2020	Nitric Solutions-Mobile Unit, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT03331445
1079	NCT04452318	Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay		Recruiting	No Results Available	Healthy Participants	Drug: REGN10933 + REGN10987|Drug: Placebo	Proportion of participants who have a positive SARS-CoV-2 RT-qPCR (based on central lab test) and signs and symptoms (strict-term) of SARS-CoV-2 infection during the Efficacy assessment period (EAP)|Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infection (either symptomatic or asymptomatic) during the EAP|Incidence and severity of treatment-emergent adverse events (TEAEs)|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (strict term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (broad term) during the EAP|Number of days of symptomatic SARS-CoV-2 infection (strict-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Number of days of symptomatic SARS-CoV-2 infection (broad-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Time-weighted average of viral shedding (log10 copies/mL) from the first positive SARS CoV-2 RT-qPCR Nasopharyngeal (NP) swab sample (with an onset during the EAP) until the visit within the window including 22 days after the positive test during the EAP|Maximum SARS-CoV-2 RT-qPCR log10 viral copies/mL in Nasopharyngeal (NP) swab samples among individuals with ≥1 RT-qPCR positive that has an onset during the EAP|Maximum SARS-CoV-2 RT-qPCR log10 viral copies/mL in NP swab samples|Area under the curve (AUC) in viral shedding (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR NP swab sample until the first confirmed negative test, that has an onset during the EAP|Number of medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset during the EAP|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days of hospital and intensive care unit (ICU) stay in subjects hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days missed for daily responsibilities due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Concentrations of REGN10933 in serum over time and selected PK parameters|Concentrations of REGN10987 in serum over time and selected PK parameters|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933 over time|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987 over time|Incidence and severity of TEAEs in baseline seropositive participants (based on central lab test)|Incidence and severity of symptomatic SARS-CoV-2 infection|Proportion of participants who subsequently develop signs and symptoms (strict-term) of symptomatic SARS-CoV-2 infection during EAP|Proportion of participants who subsequently develop signs and symptoms (broad-term) of symptomatic SARS-CoV-2 infection during EAP|Number of days of symptomatic SARS CoV-2 infection (strict-term)|Number of days of symptomatic SARS CoV-2 infection (broad-term)|Time-weighted average change from baseline in viral shedding in NP swab samples until the visit within the window including day 23	Regeneron Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 3	2000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R10933-10987-COV-2069	July 13, 2020	June 15, 2021	August 15, 2021	June 30, 2020		October 1, 2020	Regeneron Study Site 1, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Northridge, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Eatonton, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 2, Chicago, Illinois, United States|Regeneron Study Site 3, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Gulfport, Mississippi, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Hazelwood, Missouri, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Fayetteville, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Gaffney, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Yakima, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04452318
1080	NCT04449276	A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults		Recruiting	No Results Available	Severe Acute Respiratory Syndrome|Coronavirus|SARS-CoV-2|COVID-19	Biological: CVnCoV Vaccine|Drug: Placebo	Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination|Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination|Number of Participants with Solicited Local Adverse Events|Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Local Adverse Events|Number of Participants with Solicited Systemic Adverse Events|Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Systemic Adverse Events|Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine|Number of Participants with Unsolicited Adverse Events|Intensity of Unsolicited Adverse Events Assessed by the Investigator|Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine|Number of Participants with One or More Serious Adverse events (SAEs)|Number of Participants with One or More Serious Adverse events (SAEs) Considered Related to Trial Vaccine|Number of Participants with One or More Adverse Events of Special Interest (AESIs)|Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine|Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies|Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies|Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies|Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies	CureVac AG|Coalition for Epidemic Preparedness Innovations (CEPI)	All	18 Years to 60 Years   (Adult)	Phase 1	168	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	CV-NCOV-001|2020-001286-36	June 18, 2020	August 2021	August 2021	June 26, 2020		July 1, 2020	Universitair Ziekenhuis Ghent, Ghent, Belgium|Ludwig-Maximilians-Universität München, München, Bavaria, Germany|Medical University Hannover (MHH), Hannover, Germany|University Hospital Tübingen Institut für Tropenmedizin, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT04449276
1081	NCT04461353	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers		Completed	No Results Available	Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Aerolized Hydroxychloroquine Sulfate|Other: Placebo	Incidences of treatment-emergent adverse events (TEAEs) as assessed by TGSHAAV (September 2007) or CTCAE version 5.0|Change from baseline in clinical laboratory test results for CBC with differential|Incidence of abnormal laboratory test results for CBC with differential at Screening|Incidence of abnormal laboratory test results for CBC with differential - Day 8|Changes from baseline for blood glucose|Incidence of abnormal laboratory test results for chemistry -Screening|Incidence of abnormal laboratory tests results for chemistry - Day 8|Incidence of abnormal laboratory tests results for urinalysis - Screening|Incidence of abnormal laboratory tests results for urinalysis- Day 8|Changes in vital signs from baseline (pre-dose) - respiratory rate|Changes in vital signs from baseline (pre-dose)- temperature|Changes in vital signs from baseline (pre-dose) - seated blood pressure|Changes in vital signs from baseline (pre-dose) - pulse|Changes in vital signs from baseline (pre-dose) - O2 saturation|Incidence of abnormal and physical examinations findings during Screening- general appearance|Incidence of abnormal and physical examinations findings on Day 1 - general appearance|Incidence of abnormal and physical examinations findings on Day 2- general appearance|Incidence of abnormal and physical examinations findings on Day 8- general appearance|Incidence of abnormal and physical examinations findings during Screening- neurological|Incidence of abnormal and physical examinations findings on Day 1- neurological|Incidence of abnormal and physical examinations findings on Day 2- neurological|Incidence of abnormal and physical examinations findings on Day 8- neurological|Incidence of abnormal and physical examinations findings during Screening - heart/cardiovascular|Incidence of abnormal and physical examinations findings on Day 1 - heart/cardiovascular|Incidence of abnormal and physical examinations findings on Day 2 - heart/cardiovascular|Incidence of abnormal and physical examinations findings on Day 8 - heart/cardiovascular|Incidence of abnormal and physical examinations findings during Screening - lungs|Incidence of abnormal and physical examinations findings on Day 1 - lungs|Incidence of abnormal and physical examinations findings on Day 2 - lungs|Incidence of abnormal and physical examinations findings on Day 8 - lungs|Incidence of abnormal and physical examinations findings during Screening- abdomen|Incidence of abnormal and physical examinations findings on Day 1 - abdomen|Incidence of abnormal and physical examinations findings on Day 2- abdomen|Incidence of abnormal and physical examinations findings on Day 8- abdomen|Incidence of abnormal and physical examinations findings during screening- endocrine|Incidence of abnormal and physical examinations findings on Day 1 - endocrine|Incidence of abnormal and physical examinations findings on Day 2- endocrine|Incidence of abnormal and physical examinations findings on Day 8- endocrine|Incidence of abnormal and physical examinations findings during Screening- extremities|Incidence of abnormal and physical examinations findings on Day 1- extremities|Incidence of abnormal and physical examinations findings on Day 2- extremities|Incidence of abnormal and physical examinations findings on Day 8- extremities|Incidence of abnormal and physical examinations findings during Screening- lymphatic|Incidence of abnormal and physical examinations findings on Day 1- lymphatic|Incidence of abnormal and physical examinations findings on Day 2 - lymphatic|Incidence of abnormal and physical examinations findings on Day 8- lymphatic|Incidence of abnormal and physical examinations findings during screening - skin|Incidence of abnormal and physical examinations findings on Day 1 - skin|Incidence of abnormal and physical examinations findings on Day 2 - skin|Incidence of abnormal and physical examinations findings on Day 8 - skin|Changes from baseline for pulmonary function tests (PFTs) - FEV1|Changes from baseline for pulmonary function tests (PFTs) - FVC|Changes from baseline for pulmonary function tests (PFTs) - FEV1/FVC|Changes from baseline for ECG readings - QT interval|Changes from baseline for ECG readings - QTcB Interval|Changes from baseline for ECG readings - QRS duration|Changes from baseline for ECG readings - PR interval|Changes from baseline for ECG readings - heart rate|Incidence of abnormal ECG - Screening|Incidence of abnormal ECG- Day 1|Incidence of abnormal ECG - Day 2|Incidence of abnormal ECG - Day 8|HCQ concentration in whole blood versus time profiles	Pulmoquine Therapeutics, Inc|Rockefeller University	All	18 Years and older   (Adult, Older Adult)	Phase 1	12	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PUL-01	June 25, 2020	August 17, 2020	August 17, 2020	July 8, 2020		October 8, 2020	The Rockefeller University, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04461353
1082	NCT04371601	Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019		Active, not recruiting	No Results Available	COVID-19 Pneumonia	Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells	Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin	Fuzhou General Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MSC-CoViD-2020	March 1, 2020	December 31, 2021	December 31, 2022	May 1, 2020		May 1, 2020	Fuzhou General Hospital, Fuzhou, Fujian, China		https://ClinicalTrials.gov/show/NCT04371601
1083	NCT04525079	To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects		Recruiting	No Results Available	SARS-CoV-2 Infection	Drug: CT-P59|Drug: Placebo	Primary safety outcome|To evaluate the safety of CT-P59|To evaluate the Pharmacokinetic(PK) of CT-P59	Celltrion	All	19 Years to 55 Years   (Adult)	Phase 1	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening	CT-P59 1.1|2020-003065-19	July 18, 2020	August 31, 2020	November 30, 2020	August 25, 2020		August 25, 2020	Chungnam National University Hospital, Daejeon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04525079
1084	NCT04366089	Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora	PROBIOZOVID	Recruiting	No Results Available	COVID|SARS-CoV 2|Pneumonia, Viral|Coronavirus Infection	Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine	Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin	Roberto Poscia MD, PhD|Azienda Policlinico Umberto I	All	18 Years and older   (Adult, Older Adult)	Phase 2	152	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	110/2020	March 26, 2020	October 30, 2020	December 31, 2020	April 28, 2020		April 28, 2020	Francesco Pugliese, Rome, RM, Italy		https://ClinicalTrials.gov/show/NCT04366089
1085	NCT04424056	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease	INFLAMMACOV	Not yet recruiting	No Results Available	Covid19	Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care	Ventilation free days at D28	Assistance Publique Hopitaux De Marseille	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	216	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-23	September 1, 2020	September 30, 2022	November 1, 2022	June 9, 2020		June 23, 2020	Assistance Publique Hôpitaux de Marseille, Marseille, France		https://ClinicalTrials.gov/show/NCT04424056
1086	NCT04426084	Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study		Active, not recruiting	No Results Available	COVID-19	Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins (Cardiovascular Agents)	Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT(Continuous Renal Replacement Therapy)|ECMO (Extracorporeal Membrane Oxygenation )|ICU Mortality	Karolinska Institutet	All	18 Years and older   (Adult, Older Adult)		22784	Other	Observational	Observational Model: Case-Control|Time Perspective: Other	4	March 1, 2020	May 11, 2020	December 31, 2022	June 11, 2020		June 11, 2020	Södersjukhuset, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT04426084
1087	NCT04275388	Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia		Not yet recruiting	No Results Available	2019 Novel Coronavirus Pneumonia	Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride	Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	All	up to 100 Years   (Child, Adult, Older Adult)		426	Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	QF-XYP2001-1	May 15, 2020	July 14, 2020	December 14, 2021	February 19, 2020		May 20, 2020			https://ClinicalTrials.gov/show/NCT04275388
1088	NCT04409834	Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial	COVID-PACT	Recruiting	No Results Available	COVID-19|Venous Thromboembolism|Arterial Thrombosis	Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution	Primary endpoint: Venous or arterial thrombotic events|Key secondary endpoint: Clinically evident venous or arterial thrombotic events	The TIMI Study Group	All	18 Years and older   (Adult, Older Adult)	Phase 4	750	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CCCTN/TIMI COVID-PACT	August 5, 2020	May 2021	May 2021	June 1, 2020		August 18, 2020	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04409834
1089	NCT04385836	Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)		Recruiting	No Results Available	Coronavirus	Drug: alpha one antitrypsin inhalation	clinical improvement	Ministry of Health, Saudi Arabia	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	4-0520- 076-K-02-H	June 1, 2020	September 1, 2020	September 1, 2020	May 13, 2020		May 13, 2020	Ministry of Health, Mecca, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04385836
1090	NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoVs Infection Pneumonia	Drug: Meplazumab for Injection	2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status	Tang-Du Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20200101	February 3, 2020	December 31, 2020	December 31, 2020	February 19, 2020		February 19, 2020	Tangdu Hospital, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT04275245
1091	NCT04403243	COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial	COLORIT	Recruiting	No Results Available	COVID 19	Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapy	change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline|Combine endpoint: Time to death or mechanical ventilation|C-reactive protein|D-dimer|EuroQol Group. EQ-5D™|exposure area on lung CT	Lomonosov Moscow State University Medical Research and Educational Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MSU080520	May 8, 2020	July 22, 2020	August 23, 2020	May 27, 2020		May 27, 2020	Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation		https://ClinicalTrials.gov/show/NCT04403243
1092	NCT04324463	Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial	ACTCOVID19	Recruiting	No Results Available	Coronavirus|Severe Acute Respiratory Syndrome	Drug: Colchicine|Drug: Interferon-Beta|Drug: Aspirin|Drug: Rivaroxaban	Outpatient trial - Colchicine vs. control and Aspirin vs. control|Inpatient trial - Interferon-β vs. control and Colchicine vs. control|Inpatient trial - Aspirin and rivaroxaban vs. control|Outpatient and Inpatient trials - Colchicine vs. control, Interferon-β vs. control|Outpatient and Inpatient trials - Aspirin vs. control, Aspirin and rivaroxaban vs. control	Population Health Research Institute|Bayer	All	18 Years and older   (Adult, Older Adult)	Phase 3	4000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PHRI.ACT.COVID19	April 21, 2020	December 31, 2020	June 30, 2021	March 27, 2020		October 8, 2020	Prodal Saude S/A, Salvador, BA, Brazil|Hospital das Clinicas de Vitoria (Hospital Universitario Cassiano Antonio Moraes), Vitoria, ES, Brazil|Hospital das Clinicas da Universidade Federal de Goias, Goiania, GO, Brazil|Ubermed Serviços em Saúde Eireli - Hospital São Domingos, Uberaba, MG, Brazil|Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, MG, Brazil|Hospital Universitario Julio Muller, Cuiabá, Mount, Brazil|Hospital Universitario da UFPI - Filial EBSERH, Teresina, PI, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, Brazil|Hospital Universitario Prof. Dr. Horacio Carlos Panepucci da Universidade Federal de Sao Carlos (HU-UFSCar), São Carlos, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital de Doencas Tropicais - HDT/UFT, Araguaina, TO, Brazil|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|CIUSSS de L'est-de-l'ile de Montreal, Hopital Maisonneuve-Rosemont, Montreal, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|Halton Healthcare/Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada|Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada|Toronto Western Hospital Family Health Team, Toronto, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Woodstock Hospital, Woodstock, Ontario, Canada|Estudios Clinicos Barros Luco Spa, Santiago, Region Metropolitana, Chile|Hospital El Pino, Santiago, Region Metropolitana, Chile|Biomelab SAS, Barranquilla, Atlantico, Colombia|Clinica de la Costa LTDA, Barranquilla, Atlantico, Colombia|Hospital Universidad del Norte, Barranquilla, Atlantico, Colombia|Centro de Diagnostico Cardiologico, Cartagena, Bolivar, Colombia|Clinica de Marly - Sede UniMarly, Bogota, Cundinamarca, Colombia|Fundacion Cometa, Pasto, Narino, Colombia|Fundacion Cardiomet CEQUIN, Armenia, Quindio, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Bucaramanga, Santander, Colombia|Fundacion Centro de Investigaciones Biomedicas Riescard, El Espinal, Tolima, Colombia|Clinica Internacional La Misericordia, Barranquilla, Colombia|Unicormed, Guayaquil, Guayas, Ecuador|Hospital de Especialidades Eugenio Espejo, Quito, Pichincha, Ecuador|Hospital Enrique Garces, Quito, Pichincha, Ecuador|Hospital General Docente de Calderon, Quito, Pichincha, Ecuador|Hospital General Pablo Arturo Suarez, Quito, Pichincha, Ecuador|Giza Chest Hospital, Giza, Cairo, Egypt|Al Rajhi University Hospital, Assiut, Egypt|Abbasia Chest Hospital, Cairo, Egypt|Abbasia Fever Hospital, Cairo, Egypt|National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt|Fayoum General Hospital, Fayoum, Egypt|Fayoum University Hospital, Fayoum, Egypt|CIMS Hospital, Ahmedabad, Gujarat, India|City Plus Hospital, Ahmedabad, Gujarat, India|Sanjivani Hospital, Ahmedabad, Gujarat, India|GMERS Medical College & Hospital, Vadodara, Gujarat, India|Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India|Mazumdar Shaw Medical Centre a Unit of Narayana, Bangalore, Karnataka, India|Bharathi Hospital and Research Center, Pune, Maharashtra, India|Sidhu Hospital Pvt.Ltd, Doraha, Punjab, India|Vijaya Medical & Educational Trust, Chennai, Tamil Nadu, India|SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India|AIG Hospital, Hyderabad, Telangana, India|KIMS, Hyderabad, Telangana, India|Mahavir Hospital & Research Centre, Hyderabad, Telangana, India|Jinnah Postgraduate Medical Center, Karachi, Pakistan|Tabba Heart Institute, Karachi, Pakistan|Philippine General Hospital, Manila, Metro Manila, Philippines|Altai Regional Center for Medical Prevention, Barnaul, Russian Federation|Altai Regional Hospital for War Veterans, Barnaul, Russian Federation|City Clinical Hospital No. 15 named after O.M. Filatova, Moscow, Russian Federation|National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital No. 10, Nizhny Novgorod, Russian Federation|City Clinical Hospital No. 3, Nizhny Novgorod, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|King Saud Medical City, Riyadh, Saudi Arabia|Thumbay Hospital Dubai, Al Qusais, Dubai, United Arab Emirates|Hatta Hospital, Hatta, Dubai, United Arab Emirates|Rashid Hospital, Dubai Health Authority, Umm Hurair, Dubai, United Arab Emirates		https://ClinicalTrials.gov/show/NCT04324463
1093	NCT04376684	Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease	OSCAR	Recruiting	No Results Available	Severe Acute Respiratory Syndrome	Biological: Otilimab|Biological: Placebo|Drug: Standard of care	Proportion of participants alive and free of respiratory failure at Day 28|Number of deaths due to all causes at Day 60|Time to number of deaths due to all causes up to Day 60|Proportion of participants alive and free of respiratory failure at Days 7, 14, 42 and 60|Time to recovery from respiratory failure|Proportion of participants alive and independent of supplementary oxygen at Days 7, 14, 28, 42, and 60|Time to last dependence on supplementary oxygen|Proportion of participants admitted to Intensive Care Unit (ICU)|Time to final ICU discharge|Time to final hospital discharge|Number of participants with Adverse events (AEs) and Serious adverse events (SAEs)	GlaxoSmithKline	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	214094	May 28, 2020	December 21, 2020	December 21, 2020	May 6, 2020		October 6, 2020	GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Loma Linda, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Winfield, Illinois, United States|GSK Investigational Site, Portland, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Germantown, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Doylestown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Roanoke, Virginia, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Yvoir, Belgium|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Montréal, Quebec, Canada|GSK Investigational Site, QC, Quebec, Canada|GSK Investigational Site, St-Jerome, Quebec, Canada|GSK Investigational Site, Talca, Región Del Maule, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Amiens Cedex 1, France|GSK Investigational Site, Angers Cedex 9, France|GSK Investigational Site, Argenteuil, France|GSK Investigational Site, Ars-Laquenexy, France|GSK Investigational Site, La Roche-Sur-Yon, France|GSK Investigational Site, La Tronche, France|GSK Investigational Site, Limoges Cedex, France|GSK Investigational Site, Melun, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pierre-Bénite, France|GSK Investigational Site, Strasbourg cedex, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Valenciennes Cedex, France|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, DF, Mexico|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Enschede, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Benoni, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Middelburg, Mpumalanga, South Africa|GSK Investigational Site, Panorama,, South Africa|GSK Investigational Site, Tygerberg, South Africa|GSK Investigational Site, Worcester, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Logroño, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, San Sebastián De Los Reyes/Madrid, Spain|GSK Investigational Site, Manchester, Greater Manchester, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Middlesbrough, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, United Kingdom		https://ClinicalTrials.gov/show/NCT04376684
1094	NCT04368377	Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19	PIC-19	Completed	No Results Available	Pneumonia, Viral|Corona Virus Infection|Respiratory Failure|Embolism and Thrombosis	Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux	P/F ratio|PaO2 difference|A-a O2 difference|CPAP duration|In-hospital change in intensity of the respiratory support|PaCO2 difference|HCO3- difference|Lactate difference|Hb difference|Plt difference|Adverse effects	University of Milan|Fondazione "Un Cuore per Milano" - a no profit foundation	All	18 Years and older   (Adult, Older Adult)	Phase 2	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18275/2020	April 6, 2020	April 23, 2020	April 23, 2020	April 29, 2020		April 29, 2020	L. Sacco Hospital, Milano, Lombardia, Italy		https://ClinicalTrials.gov/show/NCT04368377
1095	NCT03808922	Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study		Recruiting	No Results Available	Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19	Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL	Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)	Ansun Biopharma, Inc.	All	Child, Adult, Older Adult	Phase 3	250	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DAS181-3-01|2018-004318-16	May 23, 2019	April 30, 2021	December 28, 2021	January 18, 2019		April 17, 2020	City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan		https://ClinicalTrials.gov/show/NCT03808922
1096	NCT04322682	Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)	COVID-19	Recruiting	No Results Available	Corona Virus Infection	Drug: Colchicine|Drug: Placebo oral tablet	Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation	Montreal Heart Institute|National Heart, Lung, and Blood Institute (NHLBI)|Bill and Melinda Gates Foundation|The Government of Quebec|DACIMA Software	All	40 Years and older   (Adult, Older Adult)	Phase 3	6000	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	MHIPS-2020-001|3R01HL146206-02S1	March 23, 2020	December 2020	December 2020	March 26, 2020		September 25, 2020	Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, São Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04322682
1097	NCT04564040	A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole		Not yet recruiting	No Results Available	Mantle Cell Lymphoma|COVID-19	Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D	Part 1 and 2: Area under plasma concentration-time curve from time zero to infinity (AUCinf)|Part 1 and 2: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)|Part 1 and Part 2: Maximum observed plasma concentration (Cmax)|Part 1 and Part 2: Area under the plasma concentration-time curve from time zero to 24 hours post dose (AUC0-24)|Part 1 and 2: Time to reach maximum observed plasma concentration (tmax)|Part 1 and 2: Half-life associated with terminal slope (λz) of a semi-logarithmic concentrationtime curve (t1/2)|Part 1 and 2: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)|Part 1 and 2: Terminal elimination rate constant (λz)|Part 1 and 2: Apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (CL/F)|Part 1 and 2: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz/F)|Part 1 and 2: Metabolite to parent ratio based on AUCinf and/or AUClast (M:P[AUC])|Part 1 and 2: Metabolite to parent ratio based on Cmax (M:P[Cmax])|Number of subjects with serious and non-serious adverse events	AstraZeneca|Parexel	All	18 Years to 55 Years   (Adult)	Phase 1	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D8223C00005	October 7, 2020	November 30, 2020	November 30, 2020	September 25, 2020		September 25, 2020	Parexel International GmbH, Berlin, Germany		https://ClinicalTrials.gov/show/NCT04564040
1098	NCT04447833	Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome	ARDS-MSC-205	Recruiting	No Results Available	ARDS, Human|COVID	Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205	The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test	Uppsala University|Uppsala University Hospital	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	9	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-02238	June 17, 2020	December 30, 2020	June 30, 2025	June 25, 2020		June 25, 2020	Uppsala University Hospital, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT04447833
1099	NCT04322396	Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19	ProPAC-COVID	Recruiting	No Results Available	Virus Diseases|Infection Viral|Corona Virus Infection	Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement "LTOT")	Chronic Obstructive Pulmonary Disease Trial Network, Denmark	All	Child, Adult, Older Adult	Phase 2	226	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	KronLungesyg_COVID_19_protokol	April 6, 2020	October 31, 2020	March 31, 2021	March 26, 2020		May 11, 2020	Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark		https://ClinicalTrials.gov/show/NCT04322396
1100	NCT04410536	Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency	MOHC	Not yet recruiting	No Results Available	Migraine, Hemicrania	Drug: Symptomatic drugs|Drug: Bridge therapy|Behavioral: Mindfulness program	Drop out rates|Absence of Medication Overuse Headache (MOH)	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MOH	June 2020	December 2021	July 2022	June 1, 2020		June 1, 2020	Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit, Milano, Italy		https://ClinicalTrials.gov/show/NCT04410536
1101	NCT04570254	Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19	ANTIOX-COVID	Active, not recruiting	No Results Available	Pneumonia, Viral|Covid19|ARDS|Oxidative Stress	Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline	Death from any cause|Percentage of patients who required orotracheal intubation|Assisted mechanical ventilation|Stay in an intensive care unit|Measure lipoperoxidation in basal and post-therapy samples|Evaluation of the total antioxidant capacity|Oxidative and antioxidant stress|Effect of antioxidant therapy at the level on organ failure secondary to SARS-COV2	Unidad Temporal COVID-19 en Centro Citibanamex|Instituto Nacional de Cardiologia Ignacio Chavez|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	All	Child, Adult, Older Adult	Not Applicable	11	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	09-CEI-011-20160627	August 19, 2020	October 15, 2020	November 15, 2020	September 30, 2020		October 2, 2020	Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT04570254
1102	NCT04486521	Clinical Outcome of Anti-IL6 vs Anti-IL6 Corticosteroid Combination in Patients With SARS-CoV-2 Cytokine Release Syndrome		Recruiting	No Results Available	Critical Illness|Corona Virus Infection|Cytokine Release Syndrome	Drug: Interleukin 6 (IL6) Antagonist|Drug: Interleukin 6 (IL6) Antagonist and corticosteroids	Ventilator-Free Days|Median duration of ventilation|Median change in the PaO2/FiO2|Vasopressor-Free days|Duration of ICU Stay|Duration of Hospital Stay|Mortality Rate|Percentage of participants with adverse events [transaminitis, hyperglycemia]|Concentration of Ferritin, IL6, D dimer, fibrinogen, C-reactive protein (CRP), Lactate dehydrogenase (LDH) and absolute lymphocyte count and their correlation with the effectiveness of the treatment|Rate of superinfection (bacterial, viral, invasive fungal infections)|Time to the first COVID 19 test negative	King Faisal Specialist Hospital & Research Center|Society of Critical Care Medicine	All	14 Years and older   (Child, Adult, Older Adult)		11000	Other	Observational	Observational Model: Other|Time Perspective: Prospective	RAC # 2201053	July 22, 2020	July 22, 2021	July 22, 2021	July 24, 2020		July 24, 2020	King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04486521
1103	NCT04392219	COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers		Completed	No Results Available	Coronavirus	Drug: EIDD-2801|Drug: Placebo	Safety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1): Adverse Events|Safety and Tolerability of Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events|Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Single Ascending Dose (SAD) (Part 1): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Multiple Ascending Dose (MAD) (Part 3): Maximum observed concentration Cmax|Safety and Tolerability of Single Doses of EIDD-2801 (Part 2): Adverse Events	Ridgeback Biotherapeutics, LP	All	18 Years to 60 Years   (Adult)	Phase 1	130	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	EIDD-2801-1001|2020-001407-17	April 10, 2020	August 11, 2020	August 11, 2020	May 18, 2020		August 17, 2020	Covance Leeds Clinical Research Unit, Leeds, United Kingdom		https://ClinicalTrials.gov/show/NCT04392219
1104	NCT04524052	To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19		Not yet recruiting	No Results Available	Healthy	Drug: DWRX2003|Drug: Placebo	Incidence of Treatment-Emergent Adverse Events|pharmacokinetic changes of niclosamide from baseline in each dose group: Cmax|pharmacokinetic changes of niclosamide from baseline in each dose group: Tmax|pharmcodynamic analysis of niclosamide from baseline in each dose group and time point: CRP	Daewoong Pharmaceutical Co. LTD.	All	18 Years to 45 Years   (Adult)	Phase 1	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	DWJ1516101_India	August 2020	December 2020	December 2020	August 24, 2020		August 24, 2020			https://ClinicalTrials.gov/show/NCT04524052
1105	NCT04411433	Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19		Recruiting	No Results Available	Sars-CoV2|COVID-19	Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin	Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline	Ministry of Health, Turkey|Hacettepe University, Faculty of Medicine|Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization|Umraniye Education and Research Hospital|SB Istanbul Education and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital (Application and Research Center)|Kocaeli Derince Education and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19-FAV	May 8, 2020	July 30, 2020	July 30, 2020	June 2, 2020		June 2, 2020	Hacettepe University, School of Medicine, Ankara, Turkey		https://ClinicalTrials.gov/show/NCT04411433
1106	NCT04409873	Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)	AMPoL	Not yet recruiting	No Results Available	COVID-19|SARS-CoV 2|Severe Acute Respiratory Syndrome Coronavirus 2|Virus Disease|Coronavirus Infections|Pharyngeal Diseases	Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS mouthwash|Drug: Distilled water|Drug: Listerine Mouthwash Product	Change in SARS-Cov-2 viral load|Change in self-reported clinical symptom onset|Change in healthcare utilization and hospitalization	University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care	20-30874|R00RG2901	October 1, 2020	March 31, 2021	August 31, 2021	June 1, 2020		September 18, 2020	University Of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04409873
1107	NCT04545242	Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions	DEXA-REFINE	Not yet recruiting	No Results Available	Acute Hypoxemic Respiratory Failure	Drug: Dexamethasone	60-day mortality|Ventilator-free days	Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.	All	18 Years and older   (Adult, Older Adult)	Phase 4	980	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICI20-00062	October 7, 2020	September 30, 2023	December 30, 2023	September 10, 2020		September 17, 2020	Hospital Universitario Mutua Terrassa (ICU), Terrassa, Barcelona, Spain|Hospital General La Mancha Centro (ICU), Alcazar de San Juan, Ciudad Real, Spain|Complejo Hospitalario Universitario de Santiago (Anesthesia), Santiago De Compostela, La Coruña, Spain|Hospital General El Bierzo (ICU), Ponferrada, León, Spain|Hospital Universitario del Henares (ICU), Coslada, Madrid, Spain|Hospital Universitario de Getafe (ICU), Getafe, Madrid, Spain|Hospital Universitario Puerta de Hierro (ICU), Majadahonda, Madrid, Spain|Hospital Nuestra Señora del Prado (ICU), Talavera De La Reina, Toledo, Spain|Hospital Universitario de Cruces (Anesthesia), Barakaldo, Vizcaya, Spain|Hospital Universitario de Cruces (ICU), Barakaldo, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete (ICU), Albacete, Spain|Hospital Clinic de Barcelona (AVI), Barcelona, Spain|Hospital Clinic de Barcelona (Cardiac ICU), Barcelona, Spain|Hospital Clínic (Hepatic ICU), Barcelona, Spain|Hospital Clínic de Barcelona (Anesthesia), Barcelona, Spain|Hospital General de Ciudad Real (ICU), Ciudad Real, Spain|Hospital Virgen de la Luz (ICU), Cuenca, Spain|Hospital Universitario de A Coruña (ICU), La Coruña, Spain|Complejo Asistencial Universitario de León (ICU), León, Spain|Hospital Universitario La Princesa (ICU), Madrid, Spain|Hospital Universitario Ramón y Cajal (Anesthesia), Madrid, Spain|Hospital Clínico Universitario San Carlos (ICU), Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz (ICU), Madrid, Spain|Hospital Universitario Doce de Octubre (ICU), Madrid, Spain|Hospital Universitario La Paz (Anesthesia), Madrid, Spain|Hospital Universitario La Paz (ICU), Madrid, Spain|Hospital Universitario Virgen de Arrixaca (Anesthesia), Murcia, Spain|Hospital Universitario Virgen de Arrixaca (ICU), Murcia, Spain|Hospital Universitario Regional de Malaga Carlos Haya (ICU), Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Montecelo (Anesthesia), Pontevedra, Spain|Hospital Universitario Nuestra Señora de Candelaria (ICU), Santa Cruz De Tenerife, Spain|Hospital General de Segovia (ICU), Segovia, Spain|Hospital Clinico Universitario de Valencia (Anesthesia), Valencia, Spain|Hospital Clinico Universitario de Valencia (ICU), Valencia, Spain|Hospital Clínico Universitario de Valladolid (Anesthesia), Valladolid, Spain|Hospital Universitario Río Hortega (Anesthesia), Valladolid, Spain|Hospital Universitario Río Hortega (ICU), Valladolid, Spain|Hospital Virgen de la Concha (ICU), Zamora, Spain|Hospital Universitario Severo Ochoa (ICU), Leganés, ´Madrid, Spain		https://ClinicalTrials.gov/show/NCT04545242
1108	NCT04334512	A Study of Quintuple Therapy to Treat COVID-19 Infection	HAZDpaC	Recruiting	No Results Available	COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2	Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc	The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy	ProgenaBiome|DSCS CRO	All	18 Years and older   (Adult, Older Adult)	Phase 2	600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PRG-044	June 22, 2020	June 2021	September 2021	April 6, 2020		July 20, 2020	ProgenaBiome, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT04334512
1109	NCT04404192	PH94B in the Treatment of Adjustment Disorder With Anxiety		Not yet recruiting	No Results Available	Adjustment Disorder With Anxious Mood	Drug: PH94B	Hamilton Anxiety Scale|Sheehan Disability Scale|Adjustment Disorder New Module (ADNM)|Clinical Global Impression - Improvement rating (CGI-I)	VistaGen Therapeutics, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PH94B-CL-029	November 2020	July 2021	September 2021	May 27, 2020		May 27, 2020	The Medical Research Network, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04404192
1110	NCT04331808	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	CORIMUNO-TOC	Active, not recruiting	No Results Available	Corona Virus Infection	Drug: Tocilizumab	Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	228	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-1	March 30, 2020	March 31, 2021	December 31, 2021	April 2, 2020		April 28, 2020	APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Pitié Salpêtrière, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France		https://ClinicalTrials.gov/show/NCT04331808
1111	NCT04452565	NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection	NATADEX	Recruiting	No Results Available	Coronavirus Infection|Severe Acute Respiratory Infection|Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Drug: NA-831|Combination Product: NA-831 and Atazanavir|Combination Product: NA-831and Dexamethasone|Combination Product: Atazanavir and Dexamethasone	1. Time (Hours) to recovery|Time fever resolution	NeuroActiva, Inc.	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	525	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	NATADEX	October 15, 2020	December 31, 2020	February 15, 2021	June 30, 2020		September 7, 2020	Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Institute-Testing Site, Sacramento, California, United States|Coronavirus Research Institute-Testing Site, San Diego, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Fort Lauderdale, Florida, United States|Coronavirus Research Institute-Testing Site, Tampa, Florida, United States|Coronavirus Research Institute- Testing Site, Chicago, Illinois, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site, Baltimore, Maryland, United States|Coronavirus Research Institute-Testing Site, Bethesda, Maryland, United States|Coronavirus Research Institute-Testing Site, Boston, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Worcester, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Ann Arbor, Michigan, United States|Coronavirus Research Institute-Testing Site, Detroit, Michigan, United States|Coronavirus Research Institute-Testing Site, Newark, New Jersey, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|Coronavirus Research Institute-Testing Site, New York, New York, United States|Coronavirus Research Institute- Testing Site, Rochester, New York, United States|Coronavirus Research Institute-Testing Site, Durham, North Carolina, United States|Coronavirus Research Institute-Testing Site, Philadelphia, Pennsylvania, United States|Coronavirus Research Institute- Testing Site, Fort Sam Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Galveston, Texas, United States|Coronavirus Research Institute-Testing Site, Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Kirkland, Washington, United States|Coronavirus Research Institute-Testing Site, Seattle, Washington, United States|Coronavirus Research Institute-Testing Site, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT04452565
1112	NCT04435028	Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy		Completed	No Results Available	Breast Cancer|Iron Chelation	Drug: Ketotifen 1 MG	prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines	Horus University	Female	30 Years to 60 Years   (Adult)		111	Other	Observational	Observational Model: Other|Time Perspective: Prospective	1890-1-2019	January 14, 2019	August 13, 2019	August 13, 2019	June 17, 2020		June 17, 2020	Horus University, Damietta, Damiete Governonate, Egypt		https://ClinicalTrials.gov/show/NCT04435028
1113	NCT04148430	A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy		Recruiting	No Results Available	B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma	Drug: Anakinra	Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities|Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation	Memorial Sloan Kettering Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-168	October 30, 2019	October 2022	October 2022	November 1, 2019		August 24, 2020	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04148430
1114	NCT03648372	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)		Recruiting	No Results Available	Neoplasms|Lymphoma|Hematologic Neoplasms|Coronavirus Disease	Drug: TAK-981|Drug: Standard of care	Dose Escalation and Cancer Treatment Expansions: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Dose Limiting Toxicities (DLTs)|Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More Serious Adverse Events (SAEs)|Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Greater Than or Equal to (>=) Grade 3 TEAEs|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Laboratory Values|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Vital Sign Measurements|Dose Escalation and Cancer Treatment Expansions: Number of Participants who Experience Cytokine Release Syndrome CRS)|COVID-19 Expansion: Number of Participants With >=2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples|Dose Escalation and Cancer Treatment Expansions, Cmax: Maximum Observed Plasma Concentration for TAK-981|Dose Escalation and Cancer Treatment Expansions, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981|Dose Escalation and Cancer Treatment Expansions, AUCt: Area Under the Plasma Concentration-time Curve from Time 0 to Time t Over the Dosing Interval for TAK-981|Dose Escalation and Cancer Treatment Expansions, AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981|Dose Escalation and Cancer Treatment Expansions, Terminal Disposition Phase Half-life (t1/2z) for TAK-981|Dose Escalation and Cancer Treatment Expansions, Total Clearance After Intravenous Administration (CL) for TAK-981|Dose Escalation and Cancer Treatment Expansions, Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981|Dose Escalation and Cancer Treatment Expansions: Overall Response Rate (ORR)|Dose Escalation and Cancer Treatment Expansions: Duration of Response (DOR)|Dose Escalation and Cancer Treatment Expansions: Disease Control Rate (DCR)|Dose Escalation and Cancer Treatment Expansions: Progression-free Survival (PFS)|Dose Escalation and Cancer Treatment Expansions: Time to Response (TTR)|Dose Escalation and Cancer Treatment Expansions: Percentage of Participants at Each Dose Level Demonstrating Adduct Formation in Post-dose Skin or Tumor Biopsies|Dose Escalation and Cancer Treatment Expansions: Percent Change in Small Ubiquitin-like Modifier (SUMO) 2/3 Signal With Pre and Post-dose Skin or Tumor Biopsies at Each Dose Level|COVID-19 Expansion: Number of Participants Reporting one or More TEAEs|COVID-19 Expansion: Number of Participants Based on Severity of TEAEs|COVID-19 Expansion: Number of Participants Based on Duration of TEAEs|COVID-19 Expansion: Number of Participants who Experience CRS|COVID-19 Expansion: Change from Baseline in National Early Warning Score (NEWS)|COVID-19 Expansion: Percentage of Participants Reporting Each Hospitalization Severity Rating|COVID-19 Expansion: Change From Baseline in SARS-CoV-2 Viral Load in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Percentage of Participants Requiring Oxygen Supplementation; Assisted or Positive Pressure Non-invasive Ventilation; and Invasive Ventilation, on Days 3, 5, 8, 11, 15, and 30|COVID-19 Expansion: Percentage of Participants That met Intensive Care Unit (ICU) Criteria|COVID-19 Expansion: Duration of Hospitalization|COVID-19 Expansion: Time to Viral Ribonucleic Acid (RNA) Negativity in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Time to Discharge or to a NEWS of Less Than or Equal to (<=) 3 and Maintained for 24 Hours|COVID-19 Expansion: Number of Deaths in Hospital due to any Cause in First 30 Days and in 90 Days	Millennium Pharmaceuticals, Inc.|Takeda	All	18 Years and older   (Adult, Older Adult)	Phase 1	80	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TAK-981-1002|U1111-1214-4537	October 1, 2018	February 16, 2021	October 6, 2021	August 27, 2018		October 5, 2020	University of California San Diego Moores Cancer Center, La Jolla, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03648372
1115	NCT04553705	Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)		Recruiting	No Results Available	Covid19|Immunodeficiency	Drug: Omega 3/Nigella Sativa Oil|Drug: Omega 3/Nigella Sativa Oil/Indian Costus|Drug: Omega 3/Nigella Sativa Oil/Quinine pills|Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule|Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Drug: Active Comparator	Clinical improvement|Recovery rate from positive to negative swaps|Fever to normal temperature in days|Remission of lung inflammation in CT or X-ray|Length of hospitalization|(PCR levels) polymerase chain reaction assay levels|Respiratory indexes|C-reactive protein mg/L|Serum Ferritin ng/ml|Lactic acid dehydrogenase U/L|leukocytes count μl|Lipid profile [LDL, HDL, Total cholesterol ]|total plasma antioxidant capacity	Beni-Suef University|Maternity and Children Hospital, Makkah|Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy|University of Arizona|College of Pharmacy,Department of Pharmacy Practice,University of Arizona	All	25 Years to 40 Years   (Adult)	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	TQ/Omega-3 on COVID-19|DOI: 10.31219/osf.io/u56fc	September 20, 2020	November 4, 2020	December 4, 2020	September 17, 2020		September 18, 2020	Maternity and Children hospital, Mecca, Makkah, Saudi Arabia		https://ClinicalTrials.gov/show/NCT04553705
1116	NCT04315948	Trial of Treatments for COVID-19 in Hospitalized Adults	DisCoVeRy	Recruiting	No Results Available	Corona Virus Infection	Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care	Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)	Institut National de la Santé Et de la Recherche Médicale, France	All	18 Years and older   (Adult, Older Adult)	Phase 3	3100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C20-15	March 22, 2020	March 2023	March 2023	March 20, 2020		July 22, 2020	Medizinische Universität Innsbruck, Innsbruck, Austria|Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria|Hôpital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium|Hôpital Saint Luc, Brussels, Belgium|Hôpital La Citadelle, Liège, Belgium|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|Centre Hospitalier Andrée Rosemon, Cayenne, France|APHP - hôpital Henri-Mondor, Créteil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|APHP - Hôpital Saint Antoine, Paris, France|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France|APHP - Hôpital Cochin, Paris, France|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP- Hôpital Européen Georges-Pompidou, Paris, France|APHP - Hôpital Bichat Claude Bernard, Paris, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|Centre Hospitalier Annecy Genevois, Épagny, France|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schuman, Luxembourg, Luxembourg		https://ClinicalTrials.gov/show/NCT04315948
1117	NCT04492501	Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan		Completed	No Results Available	Covid19|Cytokine Release Syndrome|Critical Illness|ARDS	Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy	survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications	UNICEF|Pak Emirates Military Hospital Rawalpindi	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	600	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sultan Mehmood Kamran 3	April 1, 2020	July 20, 2020	July 20, 2020	July 30, 2020		July 30, 2020	Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT04492501
1118	NCT04335084	A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection	HELPCOVID-19	Recruiting	No Results Available	COVID-19|Coronavirus Infection|Sars-CoV2|Corona Virus Infection|COVID|Coronavirus|Coronavirus-19|Coronavirus 19	Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc	Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events	ProgenaBiome|DSCS CRO	All	18 Years and older   (Adult, Older Adult)	Phase 2	600	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	PRG-042	June 22, 2020	June 2021	September 2021	April 6, 2020		July 20, 2020	ProgenaBiome, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT04335084
1119	NCT04574869	A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure		Not yet recruiting	No Results Available	Acute Lung Injury|ALI|COVID-19	Drug: RLS-0071|Drug: Placebo	Frequency and severity of Adverse Events, including Serious Adverse Events, by treatment group and dose level, including the frequency of premature discontinuation of study intervention due to Adverse Events.|Incidence of clinically significant changes from baseline in clinical laboratory values, ADA, autoantibody panel, vital signs, physical examination, ECG, radiography, and concomitant medications.|Number of patients with positive ADA titers after receiving a single dose (Part A) or multiple doses (Part B) of RLS-0071.|Estimates of single-dose maximum plasma concentration (Cmax) for RLS-0071.|Estimates of single-dose time to maximum plasma concentration (Tmax) for RLS-0071.|Estimates of single-dose minimum plasma concentration (Cmin) for RLS-0071.|Estimates of single-dose area under the plasma concentration-time curve (AUC) for RLS-0071.|Estimates of single-dose apparent total volume of distribution for RLS-0071.|Estimates of single-dose apparent total body clearance for RLS-0071.|Estimates of single-dose apparent first-order terminal elimination half-life for RLS-0071.|Estimates of multiple-dose maximum plasma concentration (Cmax) for RLS-0071.|Estimates of multiple-dose peak time to maximum plasma concentration (Tmax) for RLS-0071.|Estimates of multiple-dose area under the plasma concentration-time curve (AUC) for RLS-0071.|Estimates of multiple-dose average plasma drug concentration observed (Cavg) for RLS-0071.|Estimates of multiple-dose trough concentration prior to dose administration (Ctrough).|Estimates of multiple-dose apparent total volume of distribution for RLS-0071.|Estimates of multiple-dose apparent total body clearance for RLS-0071.|Estimates of multiple-dose apparent first-order terminal elimination half-life for RLS-0071.|Assessment of dose response relationship of single and multiple doses of RLS-0071 on C1q levels and the complement activity assay.|Overall survival.|Incidence of progression to respiratory failure requiring mechanical ventilation.|Incidence of transfer to the ICU.|Duration of hospitalization after treatment (days).|Incidence, severity, and duration after treatment (days) of fever (≥ 39.0°C).|Incidence, severity, and duration after treatment (days) of cough per investigator assessment of CTCAE's latest version.|Duration of requirement for supplemental oxygen after treatment (days).|PaO2/FiO2|Incidence, severity, and duration after treatment (days) of new cardiovascular events as assessed by the investigator (e.g. myocardial infarction, stroke, TIA, ischemic limb) with CTCAE's latest version.|Incidence, severity, and duration after treatment (days) of respiratory acidosis as assessed by the investigator with CTCAE's latest version.|Incidence and duration after treatment (days) of dialysis.|Levels of complement activity (eg, CH50).|Levels of C1q (free and bound to RLS-0071).	ReAlta Life Sciences, Inc.	All	18 Years to 69 Years   (Adult, Older Adult)	Phase 1	42	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	RLS-0071-102	October 2020	March 2021	July 2021	October 5, 2020		October 5, 2020	Prestige Clinical Research Center, Coral Gables, Florida, United States		https://ClinicalTrials.gov/show/NCT04574869
1120	NCT04502433	Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19)		Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome	Drug: CUROSURF® (poractant alfa)	number of ventilator-free days|Number of free days from invasive ventilation|Number of free days from non-invasive ventilation (NIV)|Change from baseline in PaO2/FiO2 ratio measured at 6 hours and 12 hours following administration of each dose in the treated group and at the similar timepoints in the control group|Change from baseline in PaO2/FiO2 ratio at additional timepoints|Length of ICU stay (days)|Mortality at Day 28|Change from baseline in ventilatory parameter (Tidal volume (TV))|Delta Sequential Organ Failure Assessment (SOFA) Score|Incidence of all the AEs, AEs related to poractant alfa (treated cohort) (ADRs), serious AEs (SAEs) and AEs leading to death|Change from baseline in blood gas analysis acid-base balance parameter (pH)|Percentage of patients with PaO2/ FiO2 improvement of >20% following administration of each dose in the treated group and at similar timepoints in the control group|Number of Extracorporeal Membrane Oxygenation (ECMO)-free days- (only for cohort 2 of patients in ECMO)|Change from baseline in FiO2|Change from baseline in ventilatory parameter (respiratory rate (RR))|Change from baseline in ventilatory parameter (dynamic compliance (Cdyn))|Change from baseline in ventilatory parameter (static compliance (Cstat))|Change from baseline in ventilatory parameter (positive end-expiratory pressure (PEEP)|Change from baseline in ventilatory parameter (peak inspiratory pressure (PIP))|Change from baseline in ventilatory parameter (plateau pressure (Pplat))|Change from baseline in blood gas analysis acid-base balance parameter (pCO2)|Change from baseline in blood gas analysis acid-base balance parameter (pO2)|Change from baseline in blood gas analysis acid-base balance parameter (HCO3)|Change from baseline in blood gas analysis acid-base balance parameter (lactate)	Chiesi Farmaceutici S.p.A.	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	85	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLI-050000-04|2020-002632-75	September 1, 2020	November 30, 2020	November 30, 2020	August 6, 2020		August 6, 2020			https://ClinicalTrials.gov/show/NCT04502433
1121	NCT04468087	Antiviral Agents Against COVID-19 Infection	REVOLUTIOn	Not yet recruiting	No Results Available	COVID-19	Drug: Atazanavir|Drug: Daclatasvir 60 mg|Drug: Sofusbuvir + Daclastavir 60 mg|Drug: Placebo Atazanavir|Drug: Placebo Daclatasvir 60 mg|Drug: Placebo Sofusbuvir + Daclatasvir 60 mg|Drug: Daclatasvir 120 mg|Drug: Sofosbuvir + Daclatasvir 120 mg|Drug: Placebo Daclatasvir 120|Drug: Placebo Sofosbuvir/Daclatasvir 120	Phase II first step: Change in area under the curve of SARS-COV 2 viral load|Phase II second step: Change in area under the curve of SARS-COV 2 viral load|Phase III: Number of free days from respiratory support	Hospital do Coracao	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2|Phase 3	1134	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	REVOLUTIOn	October 7, 2020	December 31, 2021	December 31, 2021	July 13, 2020		September 21, 2020	Hospital do Coracao, Sao Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT04468087
1122	NCT04498325	Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)		Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody (ADA)	Safe and tolerable dose of NT-I7 (Phase I only)|Percent change in absolute lymphocyte count (ALC)|Change in SARS-CoV-2 viral load|COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement|Time to resolution of COVID-19 symptoms|Incidence of treatment-emergent adverse events|Number of participants by PCR result status (positive or negative)	Washington University School of Medicine|NeoImmune Tech	All	18 Years and older   (Adult, Older Adult)	Phase 1	42	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	202009065	October 31, 2020	July 31, 2021	July 31, 2021	August 4, 2020		September 30, 2020	Saint Louis University Hospital, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04498325
1123	NCT04322773	Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure	TOCIVID	Recruiting	No Results Available	Corona Virus Disease	Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care	Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events	Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APPI2-CV-2020-01	April 5, 2020	June 1, 2021	June 1, 2021	March 26, 2020		April 7, 2020	Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark		https://ClinicalTrials.gov/show/NCT04322773
1124	NCT04414618	A Study of Opaganib in Coronavirus Disease 2019 Pneumonia	COVID-19	Recruiting	No Results Available	Coronavirus Infections	Drug: Opaganib|Drug: Placebo	Evaluation of the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (L/min) over 14 days|Evaluation of the time to 50% reduction from baseline in supplemental oxygen based on oxygen flow in L/min|Evaluation of the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14|Evaluation of the proportion of afebrile patients at Day 14|Evaluation of the time to negative swabs for SARS-CoV-2 by PCR|Evaluation of the proportion of patients with negative swabs for SARS-CoV-2 by PCR at Day 14|The percentage of patients who require intubation and mechanical ventilation by Day 14|Evaluation of the time to mechanical ventilation|Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14|Evaluation of mortality 30 days post-baseline	RedHill Biopharma Limited	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ABC-110	July 2, 2020	October 23, 2020	November 30, 2020	June 4, 2020		October 7, 2020	HonorHealth Research Institute, Scottsdale, Arizona, United States|Miami Cancer Institute, Miami, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Albany Medical Center, Albany, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Memorial Herman Southeast Hospital, Houston, Texas, United States|Memorial Hermann, Memorial City Medical Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04414618
1125	NCT04351724	Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)	ACOVACT	Recruiting	No Results Available	COVID-19	Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab	sustained improvement (>48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence of new oxygen use during the trial|duration of oxygen use during the trial|Ventilator free days until day 29|Incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|Viral load/viral clearance|Duration of Hospitalization|Mortality|Obesity - mortality|Obesity - duration of hospitalization|Obesity - ICU admission|Obesity - new oxygen use|Drug-drug interactions with lopinavir/ritonavir|Renin Angiotensin System (RAS) fingerprint	Medical University of Vienna|Kaiser Franz Josef Hospital|SMZ-Ost Donauspital|Otto Wagner Hospital|Hospital Hietzing|Wilhelminenspital Vienna|Medical University Innsbruck	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2|Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACOVACT	April 16, 2020	December 1, 2020	December 31, 2020	April 17, 2020		April 24, 2020	Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria		https://ClinicalTrials.gov/show/NCT04351724
1126	NCT04333914	Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection	IMMUNONCOVID	Suspended	No Results Available	SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor	Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab	28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)	Centre Leon Berard	All	18 Years and older   (Adult, Older Adult)	Phase 2	384	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ET20-076 - IMMUNONCOVID-20|2020-001373-70	April 15, 2020	June 2020	August 2020	April 3, 2020		June 16, 2020	Centre Léon Bérard, Lyon, Rhône, France|CHU Clermont Ferrand, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|AP-HP Hôpital Saint Antoine, Paris, France|AP-HP La Pitié Salpétrière, Paris, France|Hôpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hôpital Bichat Claude Bernard, Paris, France|GH Diaconesses Croix Saint Simon, Paris, France|Gustave Roussy, Villejuif, France		https://ClinicalTrials.gov/show/NCT04333914
1127	NCT04344730	Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia	COVIDICUS	Recruiting	No Results Available	Acute Hypoxemic Respiratory Failure|COVID-19	Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation	The time-to-death from all causes|The time to need for mechanical ventilation (MV)|The viral load in the respiratory tract|Number of patient with at least one episode of healthcare-associated infections|Number of days alive without mechanical ventilation|Measure of SOFA score|Number of days alive without renal replacement therapy|Lengths of ICU-stay|Lengths of hospital-stay|Number of patients with severe hypoxemia,|Number of patients with cardiac arrest within 1 hour after intubation	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Not Applicable	550	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	APHP200388|2020-001457-43	April 10, 2020	December 31, 2020	December 31, 2020	April 14, 2020		April 14, 2020	Hopital Bichat - Aphp, Paris, France		https://ClinicalTrials.gov/show/NCT04344730
1128	NCT04482686	Trial of Combination Therapy to Treat COVID-19 Infection		Not yet recruiting	No Results Available	COVID|Covid-19|Corona Virus Infection|Coronavirus Infection|Coronavirus-19|SARS-CoV2|SARS-CoV Infection	Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C	Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events	ProgenaBiome|Topelia Therapeutics	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	PRG-049	September 2020	March 2021	April 2021	July 22, 2020		September 21, 2020	ProgenaBiome, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT04482686
1129	NCT04395768	International ALLIANCE Study of Therapies to Prevent Progression of COVID-19		Recruiting	No Results Available	COVID19	Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12	Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support	National Institute of Integrative Medicine, Australia	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Alliance-COVID19	September 9, 2020	September 30, 2021	December 31, 2021	May 20, 2020		September 11, 2020	National Institute of Integrative Medicine, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT04395768
1130	NCT04341727	Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection	WU352	Suspended	No Results Available	Coronavirus Infection	Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate	Hours to recovery|Time fever resolution	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202003188	April 4, 2020	April 1, 2021	August 1, 2021	April 10, 2020		June 4, 2020	Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04341727
1131	NCT04549376	Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo	VEP-COV	Recruiting	No Results Available	COVID19	Drug: Povidone-Iodine 0.4% NI|Drug: Povidone-Iodine 0.5% NI|Drug: Povidone-Iodine 0.6% NI|Drug: Povidone-Iodine 0.5% NS|Drug: Povidone-Iodine 0.6% NS|Other: Placebo comparator: DW-NI|Other: Placebo comparator: DW-NS	Proportion of COVID-19 positive cases following intervention|Adverse events	Pi Research Consultancy Center, Bangladesh|Dhaka Medical College	All	15 Years to 90 Years   (Child, Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	PiRCC-1131-2020	July 1, 2020	October 20, 2020	October 30, 2020	September 15, 2020		September 15, 2020	Dhaka Medical College, Dhaka, Bangladesh		https://ClinicalTrials.gov/show/NCT04549376
1132	NCT04347031	A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19		Active, not recruiting	No Results Available	Pneumonia, Viral|Respiratory Failure	Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab	1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2	Burnasyan Federal Medical Biophysical Center	All	18 Years to 60 Years   (Adult)	Phase 2|Phase 3	320	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FL-01/20	April 8, 2020	August 1, 2020	August 1, 2020	April 15, 2020		May 27, 2020	Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation		https://ClinicalTrials.gov/show/NCT04347031
1133	NCT04505098	A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults	MITIGATE	Recruiting	No Results Available	Covid19|Atherosclerosis|Cardiovascular Diseases|Upper Respiratory Tract Infections	Drug: Icosapent ethyl	Percentage of patients with moderate or severe confirmed viral URIs|Worst clinical status due to a confirmed viral URI	Kaiser Permanente|Amarin Corporation	All	50 Years and older   (Adult, Older Adult)	Phase 4	16500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	1597940	August 7, 2020	August 7, 2021	February 28, 2023	August 10, 2020		October 2, 2020	Kaiser Permanente Northern California, Oakland, California, United States		https://ClinicalTrials.gov/show/NCT04505098
1134	NCT04328467	Pre-exposure Prophylaxis for SARS-Coronavirus-2		Active, not recruiting	No Results Available	COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome	Drug: Hydroxychloroquine|Other: Placebo	COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects	University of Minnesota	All	18 Years and older   (Adult, Older Adult)	Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY00009414	April 6, 2020	August 2020	August 2020	March 31, 2020		May 27, 2020	Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04328467
1135	NCT04476680	Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease	RAID-CoV-2	Not yet recruiting	No Results Available	SARS-CoV Infection|Vitamin D Deficiency|Covid19|Acute Respiratory Tract Infection	Dietary Supplement: Vitamin D 1000 IU|Drug: Placebo	Seroconversion|Interim analysis - seropositivity at 12 weeks|Dried Blood Spot performance|Salivary IgA performance|Prevalence of SARS-CoV-2|Change in seropositivity|Change in seroconversion rate	Royal Centre for Defence Medicine|University of Nottingham|Leeds Beckett University	All	18 Years to 30 Years   (Adult)	Not Applicable	4400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	1062MODREC20	September 1, 2020	April 28, 2021	April 28, 2021	July 20, 2020		July 20, 2020	Headingley and City campuses, Leeds Beckett University, Leeds, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04476680
1136	NCT04349410	The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol	FMTVDM	Completed	No Results Available	CoVid 19 Positive	Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum	Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status	The Camelot Foundation	All	Child, Adult, Older Adult	Phase 2|Phase 3	1800	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	FMTVDM2020	April 11, 2020	September 14, 2020	September 14, 2020	April 16, 2020		October 7, 2020	FHHI-OI-Camelot; QME, Los Angeles, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/Prot_SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT04349410
1137	NCT04326036	Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection	GARM-COVID19	Enrolling by invitation	No Results Available	Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease	Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use	Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry	Healeon Medical Inc|Robert W. Alexander, MD	All	18 Years to 90 Years   (Adult, Older Adult)	Early Phase 1	10	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GARM COVID19	March 25, 2020	November 1, 2021	December 31, 2021	March 30, 2020		March 31, 2020	Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States		https://ClinicalTrials.gov/show/NCT04326036
1138	NCT04374474	Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)		Withdrawn	No Results Available	Olfactory Disorder	Other: Olfactory retraining|Drug: corticosteroid nasal irrigation|Other: smell household Items|Other: Nasal Irrigation	Change from Baseline Snap and Sniff Threshold Test at 3 months|Change from baseline Smell Identification Test (SIT) at 3 months|Change from Baseline Snap and Sniff Threshold Test at 6 months|Change from baseline Smell Identification Test (SIT) at 6 months|Change from baseline QOD-NS at 3 months|Change from baseline SF-36 health survey at 3 months|Change from baseline QOD-NS at 6 months|Change from baseline SF-36 health survey at 6 months|Adherence to the Study Protocol|Recovery	Lawson Health Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 4	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Anosmia_CoVID 19	January 10, 2021	December 10, 2021	March 10, 2022	May 5, 2020		August 27, 2020	St. Joseph's Health Care, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04374474
1139	NCT04341441	Will Hydroxychloroquine Impede or Prevent COVID-19	WHIP COVID-19	Recruiting	No Results Available	COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2	Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment	To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.	Henry Ford Health System	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	3000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	1410401	April 7, 2020	June 30, 2020	April 30, 2021	April 10, 2020		May 7, 2020	Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT04341441
1140	NCT04381936	Randomised Evaluation of COVID-19 Therapy	RECOVERY	Recruiting	No Results Available	Severe Acute Respiratory Syndrome	Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies	All-cause mortality|Duration of hospital stay|Composite endpoint of death or need for mechanical ventilation or ECMO	University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding|NIHR Health Protection Research Unit in Emerging and Zoonotic Infections	All	Child, Adult, Older Adult	Phase 2|Phase 3	15000	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NDPHRECOVERY|2020-001113-21|ISRCTN50189673	March 19, 2020	December 2021	December 2031	May 11, 2020		September 29, 2020	Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT04381936
1141	NCT04540185	A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19	OPV-NA831	Enrolling by invitation	No Results Available	Covid19|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV Infection|SARS-CoV-2	Biological: Biological: oral polio vaccine|Biological: Comparable Placebo|Drug: NA-831|Drug: Comparable Placebo of drug|Combination Product: Combination of oral polio vaccine and NA-831|Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug	Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831|Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of OPV with or without NA-831 or Placebo regardless of evidence of prior SARS-CoV-2 Infection	NeuroActiva, Inc.|Biomed Industries, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	3600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	OPV-NA831	November 1, 2020	November 1, 2022	December 31, 2022	September 7, 2020		September 9, 2020	Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|NeuroActiva-Clinical Research Unit, Auckland, New Zealand|NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand		https://ClinicalTrials.gov/show/NCT04540185
1142	NCT04473274	GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study	GOTCHA	Recruiting	No Results Available	Coronavirus Infection|Diabetes	Drug: Pioglitazone	Adverse events outcomes without attribution|Adverse events attributable|Clinical improvement|Levels of treatment|d-Dimer|C Reactive Protein|Ferritin|Lactate dehydrogenase|A1c	Samaritan Health Services	All	18 Years and older   (Adult, Older Adult)	Phase 4	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-042	May 21, 2020	June 1, 2021	June 1, 2021	July 16, 2020		July 20, 2020	Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States		https://ClinicalTrials.gov/show/NCT04473274
1143	NCT04380818	Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19		Recruiting	No Results Available	Pneumonia, Viral	Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply	Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1	Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	106	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IPACOVID	June 5, 2020	May 4, 2021	July 1, 2021	May 8, 2020		June 18, 2020	Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04380818
1144	NCT02735707	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	REMAP-CAP	Recruiting	No Results Available	Community-acquired Pneumonia, Influenza, COVID-19	Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab|Drug: Vitamin C|Drug: Therapeutic anticoagulation|Drug: Simvastatin|Drug: Convalescent plasma|Other: Protocolised mechanical ventilation strategy	All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome	MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht	All	18 Years and older   (Adult, Older Adult)	Phase 4	7100	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584	April 11, 2016	December 2021	December 2023	April 13, 2016		July 21, 2020	University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom		https://ClinicalTrials.gov/show/NCT02735707
1145	NCT04464460	A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults		Withdrawn	No Results Available	Coronavirus Disease	Drug: TAK-671|Drug: TAK-671 Placebo	Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Markedly Abnormal Laboratory Values|Number of Participants With Markedly Abnormal Values of Vital Signs|Number of Participants With Markedly Abnormal 12-lead Electrocardiograms|Number of Participants With Adverse Events (AEs) Related to Physical Examination Findings|Ceoi: Serum Concentration at the end of Infusion for TAK-671|T1/2z: Terminal Disposition Serum Half-life for TAK-671|AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-671|AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-671|Percentage of Participants With Sustained Clinical Improvement or Live Discharge at Day 28|Percentage of Participants With Sustained Clinical Recovery|Percentage of Participants With Sustained Remission of Respiratory Symptoms|Mortality Rate|Time to Sustained Clinical Improvement or Discharge From Hospital|Time to Sustained Clinical Recovery|Percentage of Participants With Any Form of New Ventilation Use|Number of Days of New Ventilation Use|Number of Ventilation-free Days|Number of Days Free of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Time to Sustained Remission of Respiratory Symptoms|Percentage of Participants Admitted to Intensive Care Unit (ICU)|Number of Days of ICU Stay|Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score at Days 7, 14, and 28	Takeda	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TAK-671-1501|U1111-1252-9426	September 25, 2020	October 30, 2020	October 30, 2020	July 9, 2020		October 8, 2020			https://ClinicalTrials.gov/show/NCT04464460
1146	NCT04316377	Norwegian Coronavirus Disease 2019 Study	NO COVID-19	Active, not recruiting	No Results Available	Corona Virus Infection	Drug: Hydroxychloroquine Sulfate	Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status|Change in C-reactive protein concentrations|Change in alanine aminotransferase concentrations|Change in aspartate aminotransferase concentrations|Change in bilirubin concentrations|Change in estimated glomerular filtration rate|Change in cardiac troponin concentrations|Change in natriuretic peptide concentrations	University Hospital, Akershus	All	18 Years and older   (Adult, Older Adult)	Phase 4	53	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	REC 121446	March 25, 2020	May 25, 2020	March 3, 2025	March 20, 2020		June 5, 2020	Akershus University Hospital, Lørenskog, Norway		https://ClinicalTrials.gov/show/NCT04316377
1147	NCT04394182	Ultra Low Doses of Therapy With Radiation Applicated to COVID-19	ULTRA-COVID	Recruiting	No Results Available	Pneumonia, Viral|Cytokine Storm	Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab	Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity	Fundacion GenesisCare|Hospital La Milagrosa|Hospital Vithas Valencia Consuelo	All	18 Years to 120 Years   (Adult, Older Adult)	Not Applicable	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	20.4.1597-GHM	April 21, 2020	December 31, 2020	April 21, 2021	May 19, 2020		May 19, 2020	Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain		https://ClinicalTrials.gov/show/NCT04394182
1148	NCT04467086	Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation	PROACTIVE	Not yet recruiting	No Results Available	Mechanical Ventilation|Sedation|Critical Illness|COVID	Drug: Propranolol Hydrochloride	Primary sedative dose change|Sedation scores|Primary sedative dose|Total sedative daily dose change|Total opioid daily dose change|Adverse event - bradycardia|Adverse event - hypotension|Adverse event - bronchospasm|Adverse event - ECG conduction delays	Ottawa Hospital Research Institute|Hamilton Health Sciences Corporation|Toronto General Hospital|University Health Network, Toronto|The Ottawa Hospital|McMaster University|Sinai Health System	All	19 Years and older   (Adult, Older Adult)	Phase 3	108	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	776228483	September 2020	February 2021	March 2021	July 10, 2020		August 6, 2020			https://ClinicalTrials.gov/show/NCT04467086
1149	NCT04439825	Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction		Not yet recruiting	No Results Available	Mood	Drug: Botulinum Neurotoxin|Drug: Placebo	Self- perception of mood before treatment and after achieving an optimal cosmetic result as determined by the PI.|Happiness levels before treatment and after achieving an optimal cosmetic result as determined by the PI.|Measurement of the Glabellar Wrinkle Severity Scores before treatment. The onset of effect and maximum efficacy compared to previous BOTOX Cosmetic injections will also be assessed by questionnaires.	DeNova Research	All	10 Years to 75 Years   (Child, Adult, Older Adult)	Phase 1	45	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BTX-PST-COVID	July 15, 2020	September 15, 2020	October 15, 2020	June 19, 2020		July 22, 2020	DeNova Research, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04439825
1150	NCT04530448	Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization		Not yet recruiting	No Results Available	COVID|Coronavirus|Coronavirus Infection|AKI|Acute Kidney Injury	Drug: Sodium bicarbonate|Other: Standard of Care	pH|Number of Days Alive Free of Stage 2-3 AKI|Stage 2-3 AKI|Vent-Free|Hospital-Free	West Virginia University	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WVU Protocol #2005006707	September 30, 2020	January 2021	March 2021	August 28, 2020		September 17, 2020	WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States		https://ClinicalTrials.gov/show/NCT04530448
1151	NCT03852537	Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia		Recruiting	No Results Available	Pneumonia	Drug: Methylprednisolone|Other: Usual Care	Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection	Mayo Clinic	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	18-010925	December 2, 2019	July 2021	July 2022	February 25, 2019		April 22, 2020	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03852537
1152	NCT04441047	Universal Anti-Viral Vaccine for Healthy Elderly Adults	ALLOPRIME	Not yet recruiting	No Results Available	Virus Diseases	Drug: AlloStim	frequency of vaccine events|Proportion of subjects with positive T-cell response|Proportion of subjects able to suppress viral propagation	Immunovative Therapies, Ltd.|Mirror Biologics, Inc.	All	65 Years and older   (Older Adult)	Phase 1|Phase 2	40	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	MBI-001-ALLOPRIME	October 6, 2020	December 7, 2020	December 31, 2021	June 22, 2020		July 28, 2020	Medical Oncology and Hematology, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT04441047
1153	NCT04276688	Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment		Completed	No Results Available	Novel Coronavirus Infection	Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B	Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens	The University of Hong Kong|Hospital Authority, Hong Kong	All	18 Years and older   (Adult, Older Adult)	Phase 2	127	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW-20-074	February 10, 2020	March 30, 2020	March 31, 2020	February 19, 2020		April 15, 2020	University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04276688
1154	NCT03680274	Lessening Organ Dysfunction With VITamin C	LOVIT	Recruiting	No Results Available	Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus	Drug: Vitamin C|Other: Control	Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration	Université de Sherbrooke|Lotte & John Hecht Memorial Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 3	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MP-31-2019-2945	November 8, 2018	December 31, 2021	December 31, 2022	September 21, 2018		April 10, 2020	Research Center of the CHUS, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT03680274
1155	NCT04324606	A Study of a Candidate COVID-19 Vaccine (COV001)		Active, not recruiting	No Results Available	Coronavirus	Biological: ChAdOx1 nCoV-19|Biological: MenACWY|Biological: ChAdOx1 nCoV-19 full boost|Biological: ChAdOx1 nCoV-19 half boost|Biological: MenACWY boost|Drug: Paracetamol|Biological: ChAdOx1 nCoV-19 0.5mL boost	Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by hospital admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by ICU admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by COVID-19 related deaths|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19	University of Oxford	All	18 Years to 55 Years   (Adult)	Phase 1|Phase 2	1090	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	COV001	April 23, 2020	October 2021	October 2021	March 27, 2020		October 1, 2020	University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT04324606
1156	NCT04278404	Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)	POPS or POP02	Recruiting	No Results Available	Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Fibrinolysis; Hemorrhage|Attention Deficit Hyperactivity Disorder|Multisystem Inflammatory Syndrome in Children (MIS-C)|Kawasaki Disease|Coagulation Disorder|Down Syndrome	Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:	Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling	Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	up to 20 Years   (Child, Adult)		5000	Other|Industry|NIH	Observational	Observational Model: Other|Time Perspective: Prospective	Pro00103838	March 5, 2020	April 24, 2024	April 24, 2024	February 20, 2020		July 7, 2020	Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04278404
1157	NCT04308668	Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2	COVID-19 PEP	Completed	No Results Available	Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections	Drug: Hydroxychloroquine|Other: Placebo	Incidence of COVID19 Disease among those who are asymptomatic at baseline|Overall change in disease severity over 14 days among those who are symptomatic at baseline|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry	University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta	All	18 Years and older   (Adult, Older Adult)	Phase 3	1309	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MED-2020-28673	March 17, 2020	May 20, 2020	May 20, 2020	March 16, 2020		July 17, 2020	Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04308668
1158	NCT04444986	Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions		Completed	No Results Available	Bioequivalence	Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT	AUC0-tlast of favipiravir|Cmax of favipiravir|AUC0-inf of favipiravir|tmax of favipiravir	Kocak Farma|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti	Male	18 Years to 40 Years   (Adult)	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	NOV2020/01919	June 5, 2020	June 11, 2020	June 13, 2020	June 24, 2020		July 22, 2020	Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey		https://ClinicalTrials.gov/show/NCT04444986
1159	NCT04406194	Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions	Favipiravir	Completed	Has Results	Bioequivalence	Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets	AUC0-tlast of Favipiravir|Cmax of Favipiravir|AUC0-inf of Favipiravir|Tmax of Favipiravir	Atabay Kimya Sanayi Ticaret A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti	Male	20 Years to 40 Years   (Adult)	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	NOV2020/1917	May 14, 2020	May 22, 2020	June 19, 2020	May 28, 2020	August 12, 2020	August 14, 2020	Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04406194/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04406194/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04406194
1160	NCT04400682	Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions	Favipiravir	Completed	Has Results	Bioequivalence	Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets	AUC0-tlast|Favipiravir Cmax|AUC0-inf of Favipiravir|Tmax of Favipiravir	Novelfarma Ilaç San. ve Tic. Ltd. Sti.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti	Male	20 Years to 40 Years   (Adult)	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	NOV2020/1923|FARGE 367	May 28, 2020	June 5, 2020	June 18, 2020	May 22, 2020	August 11, 2020	August 11, 2020	Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04400682/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04400682/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04400682
1161	NCT04422275	Coronavirus Smell Therapy for Anosmia Recovery	Co-STAR	Not yet recruiting	No Results Available	Anosmia	Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil	University of Pennsylvania Smell Identification Test (UPSIT)|Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).|Global Rating of Smell.|Global Rating of Smell Change.	Washington University School of Medicine	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PA-18-334	June 1, 2021	June 1, 2023	December 31, 2023	June 9, 2020		June 11, 2020	Washington University, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04422275
1162	NCT04476719	The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions	Umifenovir	Active, not recruiting	No Results Available	Bioequivalence	Drug: ATAFENOVIR 200 MG KAPSUL|Drug: ARBIDOL 100 MG KAPSUL	Primary PK Endpoint|Secondary PK Endpoint	Atabay Kimya Sanayi Ticaret A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti	Male	20 Years to 40 Years   (Adult)	Phase 1	18	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	NOV2020/01918	July 9, 2020	July 22, 2020	August 20, 2020	July 20, 2020		July 20, 2020	Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey		https://ClinicalTrials.gov/show/NCT04476719
1163	NCT04407000	Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions	Favipiravir	Completed	No Results Available	Bioequivalence	Drug: Test: Favipiravir 200 mg (LOQULAR)|Drug: Reference: Favipiravir 200 mg (Avigan)	Primary PK End Points AUC0-tlast|Primary PK End Points Cmax|Secondary PK End Points AUC0-inf|Secondary PK End Points tmax	World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti	Male	20 Years to 40 Years   (Adult)	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	NOV2020/01925	June 23, 2020	July 20, 2020	August 8, 2020	May 29, 2020		August 11, 2020	Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey		https://ClinicalTrials.gov/show/NCT04407000
1164	NCT04480333	Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831	NEUROSIVIR	Recruiting	No Results Available	Covid19|Corona Virus Infection|Severe Acute Respiratory Syndrome|Severe Acute Respiratory Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Severe Acute Respiratory Syndrome of Upper Respiratory Tract|Neurodegeneration|Neuroinflammatory Response	Drug: Drug: NA-831 - 0.10 mg/kg|Drug: Placebo- 0.10 mg/kg|Drug: Drug: NA-831 - 0.20 mg/kg|Drug: Placebo- 0.20 mg/kg|Drug: Drug: GS-5734 - 1.00 mg/kg|Drug: Placebo- 1.00 mg/kg|Drug: Drug: GS-5734 - 2.00 mg/kg|Drug: Placebo- 2.00 mg/kg|Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|Combination Product: Placebo 0.10 mg + 1.00 mg/kg|Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|Combination Product: Placebo 0.20 mg + 2.00 mg/kg	Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-∞)|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment	NeuroActiva, Inc.	All	21 Years to 50 Years   (Adult)	Phase 1	45	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	NEUROSIVIR	September 15, 2020	December 31, 2020	March 31, 2021	July 21, 2020		July 21, 2020	Coronavirus Research Institute, Sunnyvale, California, United States		https://ClinicalTrials.gov/show/NCT04480333
1165	NCT03871491	Azithromycin-Prevention in Labor Use Study (A-PLUS)		Recruiting	No Results Available	Maternal Death|Maternal Infections Affecting Fetus or Newborn|Neonatal SEPSIS|Maternal Sepsis During Labor|Neonatal Death|Postpartum Sepsis	Drug: Azithromycin|Drug: Placebo	Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.|Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group|Incidence of chorioamnionitis|Incidence of endometritis|Incidence of other infections|Incidence of use of subsequent maternal antibiotic therapy|Maternal initial hospital length of stay|Incidence of maternal readmissions|Incidence of maternal admission to special care units|Incidence of maternal unscheduled visit for care|Incidence of maternal GI symptoms|Incidence of maternal death due to sepsis|Incidence of other neonatal infections (e.g. eye infection, skin infection)|Neonatal initial hospital length of stay|Incidence of neonatal readmissions|Incidence of neonatal admission to special care units|Incidence of neonatal unscheduled visit for care|Incidence of neonatal death due to sepsis|Incidence of pyloric stenosis within 42 days of delivery	NICHD Global Network for Women's and Children's Health|University of Alabama at Birmingham|University Teaching Hospital, Lusaka, Zambia|University of North Carolina, Chapel Hill|Kinshasa School of Public Health|University of Colorado, Denver|Institute of Nutrition of Central America and Panama|University of Virginia|International Centre for Diarrhoeal Disease Research, Bangladesh|Thomas Jefferson University|Columbia University|Aga Khan University|Boston University|Lata Medical Research Foundation, Nagpur|Indiana University School of Medicine|Moi Univeristy|RTI International|Bill and Melinda Gates Foundation|KLE University's Jawaharlal Nehru Medical College	Female	18 Years to 45 Years   (Adult)	Phase 3	34000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	CP Azithromycin	September 1, 2020	September 1, 2023	September 1, 2023	March 12, 2019		September 16, 2020	ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belagavi, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia		https://ClinicalTrials.gov/show/NCT03871491
1166	NCT04386876	Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions	Orvical	Active, not recruiting	No Results Available	Bioequivalence	Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Test|Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Reference	Primary PK End Points	World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti	Male	20 Years to 40 Years   (Adult)	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	NOV2020/01911|FARGE365	April 30, 2020	May 22, 2020	June 20, 2020	May 13, 2020		May 15, 2020	Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey		https://ClinicalTrials.gov/show/NCT04386876
1167	NCT03474965	Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients		Recruiting	No Results Available	Sickle Cell Disease (SCD)	Drug: Crizanlizumab	PK (AUCd15) after 1st dose|PD (AUCd15) after 1st dose|PK (AUCtau) after multiple dose|PD (AUCtau) after multiple dose|PK (Cmax) after 1st dose and multiple dose|PK pre-dose concentrations|Frequency of any adverse events (AEs) as a measure of safety and tolerability|Annualized rate Vaso Occusive Crisis (VOC) events leading to healthcare visit in clinic/ER/hospital|Annualized rate Vaso Occusive Crisis (VOC) events treated at home (based on documentation by health care provider following phone contact with the patient)|Annualized rate each subcategory of VOC event (uncomplicated pain crisis, acute chest syndrome, hepatic sequestration, splenic sequestration, priapism)|Annualized rate hospitalizations and ER visits (both overall and VOC-related)|Annualized rate days of ER/hospitalization (both overall and VOC-related)|Annualized rate of dactylitis events|Number, seriousness, severity, and causality assessments of treatement emergent adverse events and other data as considered appropiate.|Absolute change from baseline in hemoglobin|Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab|Electrocardiogram (ECGs) at relevant PK time points|Growth and sexual maturation assessments (Tanner stage)|PK pre-dose concentrations prior to each study drug dose.|Percentage P-selectin inhibition prior to dosing	Novartis Pharmaceuticals|Novartis	All	6 Months to 17 Years   (Child)	Phase 2	100	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSEG101B2201|2017-001747-12	October 1, 2018	June 5, 2023	November 20, 2024	March 23, 2018		August 14, 2020	University of Alabama 1600 7th ave, Birmingham, Alabama, United States|Phoenix Childrens Hospital CVAL489A2302, Phoenix, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|Children s National Hospital, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States|Childrens Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H Lurie Childrens Hospital of Chicago CTBM100C2407, Chicago, Illinois, United States|University of Chicago Hospital, Chicago, Illinois, United States|Childrens Hospital Boston, Boston, Massachusetts, United States|Institute for Pediatric Cancer and Blood Disorders, Hackensack, New Jersey, United States|UMDNJ, New Brunswick, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Duke University Medical Center Oncology, Durham, North Carolina, United States|East Carolina University SC, Greenville, North Carolina, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Medical Uni of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hosptial, Memphis, Tennessee, United States|Cook Childrens Medical Center Oncology, Fort Worth, Texas, United States|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Laeken, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Heidelberg, Baden Wuerttemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Vellore, India|Novartis Investigative Site, Modena, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Padova, Italy|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Aarau, Aargau, Switzerland|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03474965
